FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Steele, CB Pisu, M Richardson, C AF Steele, C. Brooke Pisu, Maria Richardson, C. TI Urban/Rural Patterns in Receipt of Treatment for Non-Small Cell Lung Cancer Among Black and White Medicare Beneficiaries, 2000-2003 SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION LA English DT Article DE cancer; treatment; rural population; health insurance ID CHEMOTHERAPY USE; RACIAL DISPARITIES; GEOGRAPHIC ACCESS; HEALTH-CARE; SURGERY; CLAIMS; POPULATION; MANAGEMENT; PROSTATE; SURVIVAL AB Background: Receipt of treatment for lung cancer varies by a number of demographic factors, including race/ethnicity and urban/rural residence. We examined urban/rural patterns in receipt of treatment for non-mall cell lung cancer (NSCLC) (ie, surgery, chemotherapy, radiation therapy) among black and white Medicare beneficiaries in Alabama. Methods: After linking Alabama State Cancer Registry data with state Medicare data, we identified 3481 cases of stages I to IV and unknown-stage NSCLC diagnosed from 2000-2002 and obtained their treatment data for 1999-2003. We used bivariate and multivariate analyses to examine racial and urban/rural differences in receipt of treatment. Significant bivariate associations were tested using chi(2) tests. Results: Among beneficiaries with resectable NSCLC (ie, stages I-IIIA), urban whites were more likely to undergo surgical resection than urban blacks (49.3% vs 33.0%, respectively), and more rural whites than rural blacks (49.8% vs 23.9%, respectively) underwent surgery. There was less variation by race and urban/rural residence in the receipt of chemotherapy and radiation therapy. After controlling for age at diagnosis, gender, stage at diagnosis, comorbidity score, and socioeconomic status, the racial disparity for surgery remained. Black beneficiaries in urban counties had 45% lower odds of undergoing surgery than urban white beneficiaries (OR, 0.55; 95% CI, 0.31-0.96), and those in rural counties had 67% lower odds of receiving this treatment than their white counterparts (OR, 0.33; 95% CI, 0.19-0.57). Conclusions: Differences in receipt of surgery exist for both urban and rural black Alabamians with NSCLC. Future studies should explore access to care and perceptions about treatment among lung Cancer patients in this state. C1 [Steele, C. Brooke] Ctr Dis Control & Prevent, Comprehens Canc Control Branch, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Pisu, Maria] Univ Alabama, Div Prevent Med, Birmingham, AL USA. [Pisu, Maria] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL USA. RP Steele, CB (reprint author), Ctr Dis Control & Prevent, Comprehens Canc Control Branch, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Mail Stop K-57,4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM cks9@cdc.gov FU Centers for Disease Control and Prevention (CDC), Atlanta, Georgia FX This study was funded by the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia. NR 47 TC 10 Z9 10 U1 3 U2 3 PU NATL MED ASSOC PI WASHINGON PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA SN 0027-9684 J9 J NATL MED ASSOC JI J. Natl. Med. Assoc. PD AUG PY 2011 VL 103 IS 8 BP 711 EP 718 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 833UV UT WOS:000295911300006 PM 22046848 ER PT J AU Marsh, JW Tulenko, MM Shutt, KA Thompson, AD Weese, JS Songer, JG Limbago, BM Harrison, LH AF Marsh, Jane W. Tulenko, Mary M. Shutt, Kathleen A. Thompson, Angela D. Weese, J. Scott Songer, J. Glenn Limbago, Brandi M. Harrison, Lee H. TI Multi-locus variable number tandem repeat analysis for investigation of the genetic association of Clostridium difficile isolates from food, food animals and humans SO ANAEROBE LA English DT Article DE MLVA; Ribotype 078; BI/NAP1; 027 Ribotype; Community-associated disease ID RESTRICTION-ENDONUCLEASE ANALYSIS; RETAIL GROUND MEAT; INCREASED SPORULATION; TOXIN PRODUCTION; STRAINS; POLYMORPHISM; INFECTION; PRODUCTS; CANADA; LOCUS AB Clostridium difficile is the primary known cause of antibiotic-associated diarrhea. Diarrheal disease in food animals due to C difficile infection has been well documented. Recently, reports of C difficile infections in patients with no known risk factors for disease have raised concern of community acquisition through food animals and food. In this study, multi-locus variable number tandem repeat analysis (MLVA) was performed on a collection of 97 C difficile isolates of human, animal and food origin belonging to either the North American pulsed-field type (NAP) 1 or NAP7/NAP8. MLVA discriminated between NAP1 and NAP7/NAP8 populations. Three clusters of food, food animal and human NAP1 isolates were highly related by MLVA. These data suggest the possibility of either laboratory contamination or widespread distribution of clonal C. difficile populations. Community-associated NAP1 isolates were unrelated to NAP1 food and food animal isolates. Two MLVA loci were absent and 1 was invariant in all NAP7/NAP8 isolates. Therefore, MLVA discrimination was not sufficient to make assessments regarding the genetic associations among food, food animal and human isolates belonging to the NAP7/NAP8 pulsovar. Rigorous epidemiologic and laboratory investigations that employ highly discriminatory genotyping methods are necessary to compare C difficile isolates from food and food animals to those from humans. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Marsh, Jane W.; Tulenko, Mary M.; Shutt, Kathleen A.; Harrison, Lee H.] Univ Pittsburgh, Sch Med, Infect Dis Epidemiol Res Unit, Pittsburgh, PA 15260 USA. [Marsh, Jane W.; Tulenko, Mary M.; Shutt, Kathleen A.; Harrison, Lee H.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Thompson, Angela D.; Limbago, Brandi M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Weese, J. Scott] Univ Guelph, Guelph, ON N1G 2W1, Canada. [Songer, J. Glenn] Iowa State Univ, Ames, IA USA. RP Marsh, JW (reprint author), Univ Pittsburgh, Sch Med, Infect Dis Epidemiol Res Unit, Pittsburgh, PA 15260 USA. EM jwmarsh@pitt.edu OI Shutt, Kathleen/0000-0003-3376-6152 FU NIAID NIH HHS [K24 AI052788] NR 25 TC 14 Z9 14 U1 0 U2 9 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1075-9964 J9 ANAEROBE JI Anaerobe PD AUG PY 2011 VL 17 IS 4 SI SI BP 156 EP 160 DI 10.1016/j.anaerobe.2011.05.015 PG 5 WC Microbiology SC Microbiology GA 824ZF UT WOS:000295240000006 PM 21669297 ER PT J AU Okoro, CA Zhao, GX Li, CY Balluz, LS AF Okoro, Catherine A. Zhao, Guixiang Li, Chaoyang Balluz, Lina S. TI Use of complementary and alternative medicine among USA adults with functional limitations: For treatment or general use? SO COMPLEMENTARY THERAPIES IN MEDICINE LA English DT Article DE Complementary medicine; Alternative medicine; Alternative therapy ID HEALTH INTERVIEW SURVEY; UNITED-STATES; OLDER-ADULTS; NATIONAL-SURVEY; PHYSICAL-DISABILITIES; INSURANCE-COVERAGE; THERAPIES; CARE; PROVIDERS; INTEGRATION AB Objectives: This study compared the use of complementary and alternative medicine (CAM) to treat health conditions with CAM use for general wellness or disease prevention among USA adults with and without functional limitations. Design: This was a cross-sectional survey. Methods: Data were obtained from the 2007 U.S. National Health Interview Survey (n=20,710). Results: Overall use of CAM treatment was higher among adults with functional limitations than among those without (61.4% versus 41.8%; p<0.001). Adults with functional limitations were more likely to use 3 of 4 CAM groupings: biologically based therapies (BBT) (47.9% versus 29.5%, p<0.001), manipulative and body-based therapies (73.7% versus 54.1%, p<0.001), and mind-body therapies (MBT) (39.3% versus 17.4%, p<0.001). Use of alternative medical systems for treatment was highly prevalent among adults (86.9% versus 80.0%, p=0.06), regardless of functional status. Adults with functional limitations were as likely to use CAM to treat the condition underlying their functioning difficulty (48.7%) as they were to treat other conditions (51.3%). Massage therapy was used most often to treat conditions that limited functional ability (53.4%). Older age was a predictor of the use of BBT for treatment, whereas younger age was a predictor of the use of MBT. Conclusions: The prevalence of CAM use for treatment of conditions is high. Public health strategies are needed to promote disclosure of CAM use to health care providers, promote increased screening for CAM use by health care providers, and promote health care interactions that facilitate communication about CAM safety and efficacy. Published by Elsevier Ltd C1 [Okoro, Catherine A.; Li, Chaoyang; Balluz, Lina S.] Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Zhao, Guixiang] Ctr Dis Control & Prevent, Off Noncommunicable Dis Injury & Environm Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adult & Community Hlth, Atlanta, GA 30333 USA. RP Okoro, CA (reprint author), Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance Program Off, Off Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd NE,M-S E-97, Atlanta, GA 30333 USA. EM COkoro@cdc.gov NR 55 TC 10 Z9 11 U1 4 U2 9 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0965-2299 J9 COMPLEMENT THER MED JI Complement. Ther. Med. PD AUG PY 2011 VL 19 IS 4 BP 208 EP 215 DI 10.1016/j.ctim.2011.06.003 PG 8 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 823ES UT WOS:000295105900005 PM 21827935 ER PT J AU Okomo-Adhiambo, M Sleeman, K Ballenger, K Nguyen, HT Mishin, VP Sheu, TG Smagala, J Li, Y Klimov, AI Gubareva, LV AF Okomo-Adhiambo, Margaret Sleeman, Katrina Ballenger, Kristina Nguyen, Ha T. Mishin, Vasiliy P. Sheu, Tiffany G. Smagala, James Li, Yan Klimov, Alexander I. Gubareva, Larisa V. TI Neuraminidase Inhibitor Susceptibility Testing in Human Influenza Viruses: A Laboratory Surveillance Perspective. (vol 2, pg 2269 2010) SO VIRUSES-BASEL LA English DT Correction C1 [Okomo-Adhiambo, Margaret; Sleeman, Katrina; Ballenger, Kristina; Nguyen, Ha T.; Mishin, Vasiliy P.; Sheu, Tiffany G.; Smagala, James; Klimov, Alexander I.; Gubareva, Larisa V.] Ctr Dis Control & Prevent, Virus Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Nguyen, Ha T.] Atlanta Res & Educ Fdn, Decatur, GA 30033 USA. [Sheu, Tiffany G.] Battelle Mem Inst, Atlanta, GA 30329 USA. [Smagala, James] Oak Ridge Inst Sci & Educ, Oak Ridge, TN 37831 USA. [Li, Yan] Publ Hlth Agcy Canada, Influenza & Resp Viruses Sect, Natl Microbiol Lab, Winnipeg, MB R3E 3R2, Canada. RP Gubareva, LV (reprint author), Ctr Dis Control & Prevent, Virus Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mailstop G16, Atlanta, GA 30333 USA. EM gfv3@cdc.gov; hhk6@cdc.gov; isx0@cdc.gov; hsn7@cdc.gov; fwc7@cdc.gov; gbq3@cdc.gov; gpa1@cdc.gov; yan.li@phac-aspc.gc.ca; axk0@cdc.gov; lgubareva@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1999-4915 J9 VIRUSES-BASEL JI Viruses-Basel PD AUG PY 2011 VL 3 IS 8 BP 1415 EP 1416 DI 10.3390/v3081415 PG 2 WC Virology SC Virology GA 824OR UT WOS:000295212100008 ER PT J AU Broder, K Haber, P Miller, E DeStefano, F Vellozzi, C AF Broder, Karen Haber, Penina Miller, Elaine DeStefano, Frank Vellozzi, Claudia TI Detecting Signals in the Vaccine Adverse Event Reporting System SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Broder, Karen; Haber, Penina; Miller, Elaine; DeStefano, Frank; Vellozzi, Claudia] Ctr Dis Control & Prevent CDC, Immunizat Safety Off, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD AUG PY 2011 VL 20 SU 1 MA 830 BP S358 EP S358 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 821AG UT WOS:000294946600794 ER PT J AU Broussard, CS Tinker, SC Gilboa, SM AF Broussard, Cheryl S. Tinker, Sarah C. Gilboa, Suzanne M. TI Prevalence of Prescription Medication Use among US Pregnant Women - NHANES, 1999-2006 SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Broussard, Cheryl S.; Tinker, Sarah C.; Gilboa, Suzanne M.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD AUG PY 2011 VL 20 SU 1 MA 98 BP S43 EP S43 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 821AG UT WOS:000294946600096 ER PT J AU Duwe, K Rasmussen, S Louik, C Colarusso, T Reefhuis, J AF Duwe, Kara Rasmussen, Sonja Louik, Carol Colarusso, Tiffany Reefhuis, Jennita TI Maternal Exposure to Venlafaxine and Risk for Birth Defects, National Birth Defects Prevention Study, 1997-2007 SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Duwe, Kara; Rasmussen, Sonja; Colarusso, Tiffany; Reefhuis, Jennita] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Louik, Carol] Slone Epidemiol Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD AUG PY 2011 VL 20 SU 1 MA 607 BP S264 EP S265 PG 2 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 821AG UT WOS:000294946600585 ER PT J AU Gilboa, SM Broussard, CS Devine, O Duwe, KN Flak, AL Boulet, SL Moore, CA Werler, MM Honein, MA AF Gilboa, Suzanne M. Broussard, Cheryl S. Devine, Owen Duwe, Kara N. Flak, Audrey L. Boulet, Sheree L. Moore, Cynthia A. Werler, Martha M. Honein, Margaret A. TI Simulation Model of Annual Spina Bifida Cases Preventable in Absence of Prenatal Valproate Use SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Gilboa, Suzanne M.; Broussard, Cheryl S.; Devine, Owen; Duwe, Kara N.; Flak, Audrey L.; Boulet, Sheree L.; Moore, Cynthia A.; Honein, Margaret A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Flak, Audrey L.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Werler, Martha M.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD AUG PY 2011 VL 20 SU 1 MA 290 BP S126 EP S126 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 821AG UT WOS:000294946600280 ER PT J AU Haber, P Moro, PL Vellozzi, C Lewis, P Yue, X Broder, K AF Haber, Penina Moro, Pedro L. Vellozzi, Claudia Lewis, Paige Yue, Xin Broder, Karen TI Safety of Live Attenuated Influenza Vaccine (LAIV) in Children 2-18 Years, Vaccine Adverse Event Reporting System (VAERS), 2005-2010 SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Haber, Penina; Moro, Pedro L.; Vellozzi, Claudia; Lewis, Paige; Yue, Xin; Broder, Karen] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD AUG PY 2011 VL 20 SU 1 MA 728 BP S316 EP S316 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 821AG UT WOS:000294946600699 ER PT J AU Iskander, J Satterthwaite, R Bang, G Rankin, J AF Iskander, John Satterthwaite, Rebecca Bang, Gail Rankin, Jocelyn TI Bibliographic Analysis of the Centers for Disease Control and Prevention (CDC) Published Articles in Pharmacoepidemiology, 2010 SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Iskander, John] Ctr Dis Control & Prevent, Off Associate Director Sci, Atlanta, GA USA. [Satterthwaite, Rebecca; Bang, Gail; Rankin, Jocelyn] Ctr Dis Control & Prevent, Publ Hlth Lib & Informat Ctr, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD AUG PY 2011 VL 20 SU 1 MA 819 BP S353 EP S353 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 821AG UT WOS:000294946600783 ER PT J AU Louik, C Reefhuis, J Margulis, AV Berard, A Cooper, W AF Louik, Carol Reefhuis, Jennita Margulis, Andrea V. Berard, Anick Cooper, William TI Challenges and Pitfalls in Studying Birth Defects as Outcomes SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Louik, Carol] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. [Reefhuis, Jennita] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Margulis, Andrea V.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Berard, Anick] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada. [Berard, Anick] Res Ctr CHU Ste Justine, Montreal, PQ, Canada. [Cooper, William] Vanderbilt Univ, Sch Med, Dept Pediat & Prevent Med, Nashville, TN 37212 USA. RI Margulis, Andrea/G-2833-2013 OI Margulis, Andrea/0000-0001-7388-6082 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD AUG PY 2011 VL 20 SU 1 MA 39 BP S18 EP S18 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 821AG UT WOS:000294946600040 ER PT J AU Moro, PL Arana, J Cano, M Lewis, P Haber, P Menschik, D Martin, D Broder, K AF Moro, Pedro L. Arana, Jorge Cano, Maria Lewis, Paige Haber, Penina Menschik, David Martin, David Broder, Karen TI Clinical Patterns of Adverse Events after High-Dose Influenza Vaccine Reported to the Vaccine Adverse Event Reporting System SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Moro, Pedro L.; Arana, Jorge; Cano, Maria; Lewis, Paige; Haber, Penina; Broder, Karen] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. [Menschik, David; Martin, David] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD AUG PY 2011 VL 20 SU 1 MA 840 BP S362 EP S362 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 821AG UT WOS:000294946600804 ER PT J AU Morris, J AF Morris, Jon TI Emerging Experience with Follow-On Biologics: Active Surveillance and Risk Management SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 Ctr Dis Control & Prevent, Atlanta, GA USA. ProSanos United BioSource Corp, Harrisburg, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD AUG PY 2011 VL 20 SU 1 MA 612 BP S267 EP S267 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 821AG UT WOS:000294946600590 ER PT J AU Peters, SL Humphrey, JR Broussard, CS AF Peters, Stacey L. Humphrey, Jasmine R. Broussard, Cheryl S. TI Environmental Scan of "Safe Medications during Pregnancy" Lists SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Peters, Stacey L.; Humphrey, Jasmine R.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Broussard, Cheryl S.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD AUG PY 2011 VL 20 SU 1 MA 133 BP S57 EP S58 PG 2 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 821AG UT WOS:000294946600129 ER PT J AU Rowhani-Rahbar, A Klein, NP Dekker, CL Edwards, KM Vellozzi, C Halsey, NA Baxter, RP AF Rowhani-Rahbar, Ali Klein, Nicola P. Dekker, Cornelia L. Edwards, Kathryn M. Vellozzi, Claudia Halsey, Neal A. Baxter, Roger P. CA CISA TI Biologically Plausible Risk Intervals To Assess Febrile Seizure Following Immunization with Influenza and Pneumococcal Conjugate Vaccines SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Rowhani-Rahbar, Ali; Klein, Nicola P.; Baxter, Roger P.] No Calif Kaiser Permanente, Vaccine Study Ctr, Oakland, CA USA. [Dekker, Cornelia L.] Stanford Univ, Sch Med, Div Pediat Infect Dis, Stanford, CA 94305 USA. [Edwards, Kathryn M.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA. [Vellozzi, Claudia] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. [Halsey, Neal A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD AUG PY 2011 VL 20 SU 1 MA 557 BP S243 EP S243 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 821AG UT WOS:000294946600539 ER PT J AU Tilson, H Roberts, SS Watts, DH Beckerman, K Dominguez, K Pikis, A Scaglia, F Baugh, B Haddad, W Peng, M Trylesinski, A AF Tilson, Hugh Roberts, Susan S. Watts, D. Heather Beckerman, Karen Dominguez, Kenneth Pikis, Andreas Scaglia, Fernando Baugh, Bryan Haddad, William Peng, Michael Trylesinski, Aldo TI The Antiretroviral Pregnancy Registry: A 20(th) Anniversary Celebration SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Tilson, Hugh] Univ N Carolina, UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Roberts, Susan S.] Univ N Carolina, Clin Res Program, Wilmington, NC 28401 USA. [Roberts, Susan S.] Kendle Int Inc, Registries & Hlth Outcomes, Wilmington, NC USA. [Watts, D. Heather] NICHD, PAMA, CRMC, NIH, Bethesda, MD USA. [Beckerman, Karen] Albert Einstein Coll Med, New Rochelle, NY USA. [Dominguez, Kenneth] Ctr Dis Control & Prevent, Atlanta, GA USA. [Pikis, Andreas] US FDA, Div Antiviral Drugs & Prod, Silver Spring, MD USA. [Scaglia, Fernando] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA. [Baugh, Bryan] Tibotec Therapeut, Clin Affairs, Titusville, NJ USA. [Haddad, William] Biogenerics Inc, Poughquag, NY USA. [Peng, Michael] Roche, Roche Biometr EpiPRO, Nutley, NJ USA. [Trylesinski, Aldo] Novartis Pharma AG, Immunol & Infect Dis, Basel, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PERIODICALS, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN, MA 02148-529 USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD AUG PY 2011 VL 20 SU 1 MA 437 BP S190 EP S191 PG 2 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 821AG UT WOS:000294946600422 ER PT J AU Tinker, SC Gibbs, C Owen, D Herring, AH Margaret, H Krista, C Martha, W Marlene, A Jennita, R AF Tinker, Sarah C. Gibbs, Cassandra Owen, Devine Herring, Amy H. Margaret, Honein Krista, Crider Martha, Werler Marlene, Anderka Jennita, Reefhuis TI Sensitivity Assessment of the Impact of Time to Maternal Interview on Interview Quality in the National Birth Defects Prevention Study SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Meeting Abstract C1 [Tinker, Sarah C.; Gibbs, Cassandra; Owen, Devine; Margaret, Honein; Krista, Crider; Jennita, Reefhuis] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Herring, Amy H.] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Martha, Werler] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. [Marlene, Anderka] Massachusetts Dept Publ Hlth, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD AUG PY 2011 VL 20 SU 1 MA 286 BP S124 EP S124 PG 1 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 821AG UT WOS:000294946600276 ER PT J AU Saito, H Iwamoto, T Ohkusu, K Otsuka, Y Akiyama, Y Sato, S Taguchi, O Sueyasu, Y Kawabe, Y Fujimoto, H Ezaki, T Butler, R AF Saito, Hajime Iwamoto, Tomotada Ohkusu, Kiyofumi Otsuka, Yoshihito Akiyama, Yasushi Sato, Shigeki Taguchi, Osamu Sueyasu, Yoshiko Kawabe, Yoshiko Fujimoto, Hisao Ezaki, Takayuki Butler, Ray TI Mycobacterium shinjukuense sp nov., a slowly growing, non-chromogenic species isolated from human clinical specimens SO INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY LA English DT Article ID TUBERCULOSIS COMPLEX; MICRODILUTION WELLS; IDENTIFICATION; HYBRIDIZATION; ASSAY AB Seven isolates of a slowly growing, non-chromogenic Mycobacterium species were obtained from sputum and bronchial lavage fluid samples from elderly patients in different regions of Japan. These isolates were distinguished from related non-tuberculous species by colony morphology, positive results for Tween hydrolysis, catalase at 68 degrees C, nitrate reductase and pyrazinamidase and negative results for semi-quantitative catalase, urease and arylsulfatase. The mycolic acid pattern obtained by HPLC revealed a single cluster of late-eluting mycolic acids similar to but different from those of Mycobacterium malmoense ATCC 29571(T). The 16S rRNA gene, 16S-23S internal transcribed spacer (ITS), rpoB and hsp65 sequences were unique in comparison with those of other mycobacteria. Comparison of 16S rRNA gene sequences showed that the isolates were most closely related to Mycobacterium tuberculosis H37Rv(T) (21 base differences in 1508 bp; 98.6 % 16S rRNA gene sequence similarity). A representative strain, GTC 2738(T), showed 91.9% rpoB sequence similarity with Mycobacterium marinum strain M, 95% hsp65 sequence similarity with Mycobacterium kansasii CIP 104589(T) and 81.1% 16S-23S ITS sequence similarity with Mycobacterium gordonae ATCC 14470(T). Phylogenetic analysis of concatenated sequences of the 16S rRNA, rpoB and hsp65 genes showed that strain GTC 2738(T) was located on a distinct clade adjacent to M. tuberculosis, M. ulcerans and M. marinum, with bootstrap values of 81 %. DNA-DNA hybridization demonstrated less than 70% reassociation with type strains of genetically related species and supported the novel species status of the isolates. On the basis of this evidence, C1 [Saito, Hajime] Hiroshima Environm & Hlth Assoc, Hlth Sci Ctr, Hiroshima, Japan. [Iwamoto, Tomotada] Kobe Inst Hlth, Dept Microbiol, Kobe, Hyogo, Japan. [Ohkusu, Kiyofumi; Ezaki, Takayuki] Gifu Univ, Grad Sch Med, Dept Microbiol Regenerat & Adv Med Sci, Gifu, Japan. [Otsuka, Yoshihito] Kameda Med Ctr, Dept Lab Med, Chiba, Japan. [Akiyama, Yasushi] Hokkaido Social Insurance Hosp, Ctr Resp Dis, Sapporo, Hokkaido, Japan. [Sato, Shigeki] Nagoya City Univ Hosp, Dept Resp Med, Nagoya, Aichi, Japan. [Taguchi, Osamu] Mie Univ, Grad Sch Med, Dept Resp & Crit Care Med, Tsu, Mie 514, Japan. [Sueyasu, Yoshiko] Chikugo City Hosp, Dept Resp Dis, Chikugo, Japan. [Kawabe, Yoshiko] Tokyo Natl Hosp, Natl Hosp Org, Dept Resp Dis, Kiyose, Japan. [Fujimoto, Hisao] Kumamoto Onjaku Hosp, Misato Town, Japan. [Butler, Ray] Ctr Dis Control & Prevent, Mycobacteriol Lab, Div TB Eliminat, Atlanta, GA USA. RP Saito, H (reprint author), Hiroshima Environm & Hlth Assoc, Hlth Sci Ctr, Hiroshima, Japan. EM hajime.saito@kanhokyo.or.jp OI Iwamoto, Tomotada/0000-0002-2650-0308 FU JSPS [20249007]; TB and Leprosy panel FX work was partly supported by grants from JSPS Grant-in-Aid for Scientific Research (A) (grant no. 20249007) and the United States-Japan Cooperative Medical Science Program (TB and Leprosy panel). NR 18 TC 5 Z9 5 U1 0 U2 3 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 1466-5026 J9 INT J SYST EVOL MICR JI Int. J. Syst. Evol. Microbiol. PD AUG PY 2011 VL 61 BP 1927 EP 1932 DI 10.1099/ijs.0.025478-0 PN 8 PG 6 WC Microbiology SC Microbiology GA 815GQ UT WOS:000294514500025 PM 20833878 ER PT J AU Olack, B Burke, H Cosmas, L Bamrah, S Dooling, K Feikin, DR Talley, LE Breiman, RF AF Olack, Beatrice Burke, Heather Cosmas, Leonard Bamrah, Sapna Dooling, Kathleen Feikin, Daniel R. Talley, Leisel E. Breiman, Robert F. TI Nutritional Status of Under-five Children Living in an Informal Urban Settlement in Nairobi, Kenya SO JOURNAL OF HEALTH POPULATION AND NUTRITION LA English DT Article DE Child nutrition; Child nutrition disorders; Child nutritional status; Cross-sectional studies; Food security; Informal settlement; Slums; Kenya ID MORTALITY; MORBIDITY AB Malnutrition in sub-Saharan Africa contributes to high rates of childhood morbidity and mortality. However, little information on the nutritional status of children is available from informal settlements. During the period of post-election violence in Kenya during December 2007-March 2008, food shortages were widespread within informal settlements in Nairobi. To investigate whether food insecurity due to post-election violence resulted in high prevalence of acute and chronic malnutrition in children, a nutritional survey was undertaken among children aged 6-59 months within two villages in Kibera, where the Kenya Medical Research Institute/Centers for Disease Control and Prevention conducts population-based surveillance for infectious disease syndromes. During 25 March-4 April 2008, a structured questionnaire was administered to caregivers of 1,310 children identified through surveillance system databases to obtain information on household demographics, food availability, and child-feeding practices. Anthropometric measurements were recorded on all participating children. Indices were reported in z-scores and compared with the World Health Organization (WHO) 2005 reference population to determine the nutritional status of children. Data were analyzed using the Anthro software of WHO and the SAS. Stunting was found in 47.0% of the children; 11.8% were underweight, and 2.6% were wasted. Severe stunting was found in 23.4% of the children; severe underweight in 3.1%, and severe wasting in 0.6%. Children aged 36-47 months had the highest prevalence (58.0%) of stunting while the highest prevalence (4.1%) of wasting was in children aged 6-11 months. Boys were more stunted than girls (p<0.01), and older children were significantly (p<0.0001) stunted compared to younger children. In the third year of life, girls were more likely than boys to be wasted (p<0.01). The high prevalence of chronic malnutrition suggests that stunting is a sustained problem within this urban informal settlement, not specifically resulting from the relatively brief political crisis. The predominance of stunting in older children indicates failure in growth and development during the first two years of life. Food programmes in Kenya have traditionally focused on rural areas and refugee camps. The findings of the study suggest that tackling childhood stunting is a high priority, and there should be fostered efforts to ensure that malnutrition-prevention strategies include the urban poor. C1 [Olack, Beatrice; Cosmas, Leonard] Ctr Dis Control & Prevent, Kenya Med Res Inst, Nairobi 00621, Kenya. [Olack, Beatrice; Burke, Heather; Cosmas, Leonard; Feikin, Daniel R.; Breiman, Robert F.] Ctr Dis Control & Prevent, Int Emerging Infect Program, Nairobi 00621, Kenya. [Bamrah, Sapna; Talley, Leisel E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dooling, Kathleen] Peel Publ Hlth Unit, Brampton, ON, Canada. RP Olack, B (reprint author), Ctr Dis Control & Prevent, Kenya Med Res Inst, POB 606 Village Market, Nairobi 00621, Kenya. EM bolack@ke.cdc.gov NR 17 TC 16 Z9 21 U1 3 U2 21 PU I C D D R B-CENTRE HEALTH POPULATION RESEARCH PI DHAKA PA MOHAKHALI, 1212 DHAKA, BANGLADESH SN 1606-0997 J9 J HEALTH POPUL NUTR JI J. Heatlh Popul. Nutr. PD AUG PY 2011 VL 29 IS 4 BP 357 EP 363 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 817IT UT WOS:000294666200008 PM 21957674 ER PT J AU Park, S Sherry, B O'Toole, T Huang, YJ AF Park, Sohyun Sherry, Bettylou O'Toole, Terrence Huang, Youjie TI Factors Associated with Low Drinking Water Intake among Adolescents: The Florida Youth Physical Activity and Nutrition Survey, 2007 SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION LA English DT Article ID BEHAVIOR SURVEY QUESTIONNAIRE; SUGAR-SWEETENED BEVERAGES; US CHILDREN; CHILDHOOD OBESITY; NATIONAL-HEALTH; UNITED-STATES; ENERGY-INTAKE; BODY-WEIGHT; CONSUMPTION; OVERWEIGHT AB There is limited information on which characteristics are associated with water intake among adolescents. This cross-sectional study examined the association between demographic, dietary, and behavioral factors and low water intake as the outcome measure. Analyses were based on the 2007 Florida Youth Physical Activity and Nutrition Survey using a representative sample of 4,292 students in grades six through eight in 86 Florida public middle schools. Multivariable logistic regression was used to calculate adjusted odds ratios (ORs) and 95% confidence intervals for factors associated with low water intake (<3 glasses water per day). About 64% of students had low water intake. Factors significantly associated with low water intake were Hispanic ethnicity and non-Hispanic other (vs non-Hispanic white; ORs 0.79 and 0.76, respectively), drinking no 100% juice, drinking it <1 time/day, and drinking it 1 to 2 times/day (vs drinking it >= 3 times/day; ORs 1.83, 1.91, and 1.32, respectively), drinking no milk and drinking <2 glasses of milk/day (vs drinking >= 2 glasses/day; ORs 1.42 and 1.41, respectively), drinking <1 soda/day (vs drinking none; OR 1.40), drinking fruit-flavored drinks/sports drinks <1 time/day and drinking it >= 1 time/day (vs drinking none; ORs 1.49 and 1.41, respectively), eating at a fast-food restaurant >= 3 days/week (vs none; OR 1.38, respectively), not participating on team sports or participating on 1 to 2 team sports in previous 12 months (vs participating on >= 3 teams; ORs 1.77 and 1.24, respectively), and consuming snack/soda while watching television/movies "sometimes" and "most/every time" (vs never; ORs 1.65 and 2.20, respectively). The strongest factor associated with low water intake was frequent consumption of snacks/sodas while watching television/movies. Although study findings should be corroborated in other states and in a nationally representative sample, they may be useful in targeting adolescents for increased water consumption. J Am Diet Assoc. 2011;111:1211-1217. C1 [Park, Sohyun; Sherry, Bettylou; O'Toole, Terrence] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Huang, Youjie] Bur Epidemiol, Florida Dept Hlth, Tallahassee, FL USA. RP Park, S (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM spark3@cdc.gov NR 36 TC 13 Z9 13 U1 0 U2 13 PU AMER DIETETIC ASSOC PI CHICAGO PA 120 S RIVERSIDE PLZ, STE 2000, CHICAGO, IL 60606-6995 USA SN 0002-8223 J9 J AM DIET ASSOC JI J. Am. Diet. Assoc. PD AUG PY 2011 VL 111 IS 8 BP 1211 EP 1217 DI 10.1016/j.jada.2011.05.006 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 812TA UT WOS:000294314600019 PM 21802569 ER PT J AU Tuot, DS Plantinga, LC Hsu, CY Jordan, R Burrows, NR Hedgeman, E Yee, J Saran, R Powe, NR AF Tuot, Delphine S. Plantinga, Laura C. Hsu, Chi-yuan Jordan, Regina Burrows, Nilka Rios Hedgeman, Elizabeth Yee, Jerry Saran, Rajiv Powe, Neil R. CA Ctr Dis Control Chronic Kidney Dis TI Chronic Kidney Disease Awareness Among Individuals with Clinical Markers of Kidney Dysfunction SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID GLOMERULAR-FILTRATION-RATE; EDUCATION-PROGRAM; AFRICAN-AMERICANS; SERUM CREATININE; NATIONAL-HEALTH; CKD; PREVALENCE; ALBUMINURIA; ASSOCIATION; GUIDELINES AB Background and objectives Awareness of chronic kidney disease (CKD) among providers and patients is low. Whether clinical cues prompt recognition of CKD is unknown. We examined whether markers of kidney disease that should trigger CKD recognition among providers are associated with higher individual CKD awareness. Design, setting, participants, & measurements CKD awareness was assessed in 1852 adults with an estimated GFR <60 ml/min per 1.73 m(2) using 1999 to 2008 National Health and Nutrition Examination Survey data. CKD awareness was a "yes" answer to "Have you ever been told you have weak or failing kidneys?" Participants were grouped by distribution of the following abnormal markers of CKD: hyperkalemia, acidosis, hyperphosphatemia, elevated blood urea nitrogen, anemia, albuminuria, and uncontrolled hypertension. Odds of CKD awareness associated with each abnormal marker and groupings of markers were estimated by multivariable logistic regression. Results Among individuals with kidney disease, only those with albuminuria had greater odds of CKD awareness (adjusted odds ratio, 4.0, P < 0.01) than those without. Odds of CKD awareness increased with each additional manifested clinical marker of CKD (adjusted odds ratio, 1.3, P = 0.05). Nonetheless, 90% of individuals with two to four markers of CKD and 84% of individuals with >= 5 markers of CKD were unaware of their disease. Conclusions Although individuals who manifest many markers of kidney dysfunction are more likely to be aware of their CKD, their CKD awareness remains low. A better understanding of mechanisms of awareness is required to facilitate earlier detection of CKD and implement therapy to minimize associated complications. Clin J Am Soc Nephrol 6: 1838-1844, 2011. doi: 10.2215/CJN.00730111 C1 [Tuot, Delphine S.; Hsu, Chi-yuan] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Tuot, Delphine S.; Plantinga, Laura C.; Hsu, Chi-yuan; Powe, Neil R.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Plantinga, Laura C.; Powe, Neil R.] San Francisco Gen Hosp, Ctr Vulnerable Populat, San Francisco, CA 94110 USA. [Jordan, Regina; Burrows, Nilka Rios] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hedgeman, Elizabeth; Saran, Rajiv] Univ Michigan, Kidney Epidemiol & Cost Ctr, Ann Arbor, MI 48109 USA. [Hedgeman, Elizabeth; Saran, Rajiv] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Yee, Jerry] Henry Ford Hosp, Div Nephrol & Hypertens, Detroit, MI 48202 USA. RP Tuot, DS (reprint author), Univ Calif San Francisco, Div Nephrol, 521 Parnassus Ave,Clin Sci Bldg C-443,Box 0532, San Francisco, CA 94143 USA. EM Delphine.tuot@ucsf.edu FU Centers for Disease Control and Prevention through the Association of American Medical Colleges [5U36CD319276]; American Kidney Fund Clinical Scientist in Nephrology Fellowship; National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD [K24DK02643] FX We thank the participants and staff of the NHANES survey. The Centers for Disease Control CKD Surveillance Team consists of members from University of California, San Francisco (Neil Powe, Laura Plantinga, Kirsten Bibbins-Domingo, Josef Coresh, Alan Go, Chi-yuan Hsu, Lesley Stevens, Deidra Crews, Vanessa Grubbs, and Delphine Tuot), University of Michigan (Rajiv Saran, Elizabeth Hedgeman, Brenda Gillespie, William Herman, Freidrich Port, Bruce Robinson, Vahakn Shahinian, Jerry Yee, and Eric Young), and Centers for Disease Control and Prevention (Desmond Williams, Nilka Rios Burrows, Mark Eberhardt, Paul Eggers, Nicole Flowers, Linda Geiss, Susan Hailpern, Regina Jordan, Juanita Mondesire, Bernice Moore, Gary Myers, Meda Pavkov, Deborah Rolka, Sharon Saydah, Anton Schoolwerth, Rodolfo Valdez, and Larry Waller). This project was supported under a cooperative agreement from the Centers for Disease Control and Prevention through the Association of American Medical Colleges, grant number 5U36CD319276, identification number MM-1143-10/10. Publication and report contents are solely the responsibility of the authors and do not necessarily represent the official views of the Association of American Medical Colleges or Centers for Disease Control. Results in this manuscript were presented in poster format at the American Society of Nephrology meeting in Denver, CO, on November 18, 2010. Dr. Toot is supported by the American Kidney Fund Clinical Scientist in Nephrology Fellowship. Dr. Powe is partially supported by grant K24DK02643 from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD. NR 28 TC 44 Z9 46 U1 0 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD AUG PY 2011 VL 6 IS 8 BP 1838 EP 1844 DI 10.2215/CJN.00730111 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 805IZ UT WOS:000293721400008 PM 21784832 ER PT J AU Jolly, SE Burrows, NR Chen, SC Li, SY Jurkovitz, CT Norris, KC Shlipak, MG AF Jolly, Stacey E. Burrows, Nilka Rios Chen, Shu-Cheng Li, Suying Jurkovitz, Claudine T. Norris, Keith C. Shlipak, Michael G. TI Racial and Ethnic Differences in Mortality among Individuals with Chronic Kidney Disease: Results from the Kidney Early Evaluation Program (KEEP) SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID STAGE RENAL-DISEASE; PERFORMANCE MEASURES PROJECT; GLOMERULAR-FILTRATION-RATE; SERUM CREATININE VALUES; UNITED-STATES; CARDIOVASCULAR-DISEASE; HEMODIALYSIS-PATIENTS; SURVIVAL ADVANTAGE; AFRICAN-AMERICANS; NATIONAL-HEALTH AB Background and objectives Chronic kidney disease (CKD) is prevalent in minority populations and racial/ethnic differences in survival are incompletely understood. Design, setting, participants, & measurements Secondary analysis of Kidney Early Evaluation Program participants from 2000 through 2008 with CKD, not on dialysis, and without previous kidney transplant was performed. Self-reported race/ethnicity was categorized into five groups: non-Hispanic white, African American, Asian, American Indian / Alaska Native, and Hispanic. CKD was defined as a urinary albumin to creatinine ratio of >= 30 mg/g among participants with an estimated GFR (eGFR) >= 60 ml /min per 1.73 m(2) or an eGFR of <60 ml/min per 1.73 m(2). The outcome was all-cause mortality. Covariates used were age, sex, obesity, diabetes, hypertension, alburninuria, baseline eGFR, heart attack, stroke, smoking, family history, education, health insurance, geographic region, and year screened. Results 19,205 participants had prevalent CKD; 55% (n = 10,560) were White, 27% (n = 5237) were African American, 9% (n = 1638) were Hispanic, 5% (n = 951) were Asian, and 4% (n = 813) were American Indian/Alaska Native. There were 1043 deaths (5.4%). African Americans had a similar risk of death compared with Whites (adjusted Hazard Ratio (AHR) 1.07, 95% CI 0.90 to 1.27). Hispanics (AHR 0.66, 95% CI 0.50 to 0.94) and Asians (AHR 0.63, 95% CI 0.41 to 0.97) had a lower mortality risk compared with Whites. In contrast, American Indians/Alaska Natives had a higher risk of death compared with Whites (AHR 1.41, 95% CI 1.08 to 1.84). Conclusions Significant differences in mortality among some minority groups were found among persons with CKD detected by community-based screening. Clin J Am Soc Nephrol 6: 1858-1865, 2011. doi: 10.2215/CJN.00500111 C1 [Jolly, Stacey E.] Cleveland Clin, Inst Med, Cleveland, OH 44195 USA. [Burrows, Nilka Rios] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Chen, Shu-Cheng; Li, Suying] Minneapolis Med Res Fdn Inc, Chron Dis Res Grp, Minneapolis, MN USA. [Jurkovitz, Claudine T.] Christiana Care Hlth Syst, Ctr Outcomes Res, Newark, DE USA. [Norris, Keith C.] Charles R Drew Univ, Dept Internal Med, Los Angeles, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Shlipak, Michael G.] VA Med Ctr, San Francisco, CA USA. RP Jolly, SE (reprint author), Cleveland Clin, Inst Med, 9500 Euclid Ave,G10, Cleveland, OH 44195 USA. EM jollys@ccf.org FU NIH Diversity Supplement [3U01HL064244-09S1]; American Heart Association; NIDDK [R01 DK 066488]; NIH [U54 RR026138, P20 MD00182]; Amgen; Abbott; Novartis; Siemens; Genentech; Genzyme; Nephroceuticals; Pfizer; Life Scan; Suplena FX Dr. Jolly's work was supported by an NIH Diversity Supplement 3U01HL064244-09S1. Dr. Shlipak's work was supported by the American Heart Association Established Investigator Award, and R01 DK 066488 from NIDDK. Dr. Norris is supported in part by the NIH Grants U54 RR026138 and P20 MD00182.; The Kidney Early Evaluation Program (KEEP) is a program of the National Kidney Foundation, Inc., and is supported by Amgen, Abbott, Novartis, Siemens, Genentech, Genzyme, Nephroceuticals, Pfizer, Life Scan, and Suplena. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 44 TC 21 Z9 21 U1 2 U2 6 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD AUG PY 2011 VL 6 IS 8 BP 1858 EP 1865 DI 10.2215/CJN.00500111 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 805IZ UT WOS:000293721400011 PM 21784835 ER PT J AU Svensson, K Hernandez-Ramirez, RU Burguete-Garcia, A Cebrian, ME Calafat, AM Needham, LL Claudio, L Lopez-Carrillo, L AF Svensson, Katherine Hernandez-Ramirez, Raul U. Burguete-Garcia, Ana Cebrian, Mariano E. Calafat, Antonia M. Needham, Larry L. Claudio, Luz Lopez-Carrillo, Lizbeth TI Phthalate exposure associated with self-reported diabetes among Mexican women SO ENVIRONMENTAL RESEARCH LA English DT Article DE Diabetes; Phthalates; Urinary metabolites; Environmental health; Mexico ID URINARY CONCENTRATIONS; TEMPORAL VARIABILITY; INSULIN-RESISTANCE; PPAR-GAMMA; METABOLITES; TESTOSTERONE; ACTIVATION; MONOESTERS; HORMONES; SAMPLES AB Background: Phthalates are ubiquitous industrial chemicals used as plasticizers in plastics made of polyvinyl chloride (PVC) to confer flexibility and durability. They are also present in products used for personal-care, industry and in medical devices. Phthalates have been associated with several adverse health effects, and recently it has been proposed that exposure to phthalates, could have an effect on metabolic homeostasis. This exploratory cross-sectional study evaluated the possible association between phthalate exposure and self-reported diabetes among adult Mexican women. Methods: As part of an on-going case-control study for breast cancer, only controls were selected, which constituted 221 healthy women matched by age (+/- 5 years) and place of residence with the cases. Women with diabetes were identified by self-report. Urinary concentrations of nine phthalate metabolites were measured by online solid phase extraction coupled to high performance liquid chromatography-isotope-dilution tandem mass spectrometry. Results: Participants with diabetes had significantly higher concentrations of di(2-ethylhexyl) pththalate (DEHP) metabolites: mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-oxohexyl) phthalate (MEOHP) and mono(2-ethy1-5-carboxypentyl) phthalate (MECPP) but lower levels of monobenzyl phthalate (MBzP) a metabolite of benzylbutyl phthalate, compared to participants without diabetes. A marginally significant positive associations with diabetes status were observed over tertiles with MEHHP (OR(T3) vs. (T1) = 266; 95% CI: 0.97-7.33: p for trend = 0.063) and MEOHP (OR(T3) vs. (T1) = 2.27; 95% CI; 0.90-5.75; P for trend = 0.079) even after adjusting for important confounders. Conclusions: The results suggest that levels of some phthalates may play a role in the genesis of diabetes. (C) 2011 Elsevier Inc. All rights reserved. C1 [Svensson, Katherine; Hernandez-Ramirez, Raul U.; Burguete-Garcia, Ana; Lopez-Carrillo, Lizbeth] Natl Inst Publ Hlth, Cuernavaca 62100, Morelos, Mexico. [Svensson, Katherine] Univ Puerto Rico, Grad Sch Publ Hlth, San Juan, PR 00936 USA. [Cebrian, Mariano E.] Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Toxicol, Mexico City, DF, Mexico. [Calafat, Antonia M.; Needham, Larry L.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Claudio, Luz] Mt Sinai Sch Med, Dept Prevent Med, Div Int Hlth, New York, NY USA. RP Lopez-Carrillo, L (reprint author), Natl Inst Publ Hlth, Univ 655, Cuernavaca 62100, Morelos, Mexico. EM lizbeth@insp.mx FU Fondo Sectorial de Investigacion en Salud y Seguridad Social [2005-C02-14373, 2009-01-111384]; Fondo Sectorial de Investigacion para la Educacion [79912]; Fogarty International Center [TW000640, D43TW000640]; National Center of Minority Health and Health Disparities [MD001452] FX The study was supported by Fondo Sectorial de Investigacion en Salud y Seguridad Social 2005-C02-14373, 2009-01-111384. Additional partial funds were obtained from: Fondo Sectorial de Investigacion para la Educacion 79912 and the ITREOH program of the Fogarty International Center (TW000640) the MIRT program of the National Center of Minority Health and Health Disparities (MD001452).; Authors gratefully acknowledge B.Sc. Veronica Lopez for the overall coordination of field work and, Manori Silva, Tao Jia, Ella Samandar and Jim Preau for their technical assistance in measuring the urinary concentrations of phthalate metabolites. The study was supported by Fondo Sectorial de Investigacion en Salud y Seguridad Social 2005-C02-14373, 2009-01-111384 Additional partial funds were obtained from Fondo Sectorial de Investigacion para la Educacion 79912. Katherine Svensson is a Mount Sinai International Exchange Program Minority Student participant. Her work was supported by grant MD001452 from the National Center on Minority Health and Health Disparities of the National Institutes of Health. Additional support for this project was provided in part by the Mount Sinai International Training Program in Environmental and Occupational Health (D43TW000640) from the Fogarty International Center. NR 39 TC 45 Z9 47 U1 8 U2 30 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 J9 ENVIRON RES JI Environ. Res. PD AUG PY 2011 VL 111 IS 6 BP 792 EP 796 DI 10.1016/j.envres.2011.05.015 PG 5 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 804RI UT WOS:000293671300009 PM 21696718 ER PT J AU Brown, MJ Sinks, TH AF Brown, Mary Jean Sinks, Thomas H. TI Hundreds of partial pipe replacements conducted in Washington DC before July 2004: Brown and Sinks respond SO ENVIRONMENTAL RESEARCH LA English DT Editorial Material DE Lead; Water lead levels; Blood lead levels AB This response to a letter to the Editor by Edwards details the lack of sufficient data for further analyses. Published by Elsevier Inc. C1 [Brown, Mary Jean; Sinks, Thomas H.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Agcy Tox Subst & Dis Registry, Atlanta, GA USA. RP Brown, MJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Agcy Tox Subst & Dis Registry, Atlanta, GA USA. EM mjb5@cdc.gov NR 2 TC 0 Z9 0 U1 1 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 J9 ENVIRON RES JI Environ. Res. PD AUG PY 2011 VL 111 IS 6 BP 889 EP 889 DI 10.1016/j.envres.2011.05.010 PG 1 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 804RI UT WOS:000293671300024 ER PT J AU Qi, M Wang, RJ Ning, CS Li, XY Zhang, LX Jian, FC Sun, YR Xiao, LH AF Qi, Meng Wang, Rongjun Ning, Changshen Li, Xiaoyu Zhang, Longxian Jian, Fuchun Sun, Yanru Xiao, Lihua TI Cryptosporidium spp. in pet birds: Genetic diversity and potential public health significance SO EXPERIMENTAL PARASITOLOGY LA English DT Article DE Pet birds; Cryptosporidium; Prevalence; SSU rRNA; China ID GEESE BRANTA-CANADENSIS; RIBOSOMAL-RNA GENE; PHYLOGENETIC ANALYSIS; FARM-ANIMALS; IDENTIFICATION; APICOMPLEXA; OOCYSTS; PREVALENCE; GENOTYPES; CAMELUS AB To characterize the prevalence and assess the zoonotic transmission burden of Cryptosporidium species/genotypes in pet birds in Henan. China, 434 fecal samples were acquired from 14 families of birds in pet shops. The overall prevalence of Cryptopsoridium was 8.1% (35/434) by the Sheather's sugar flotation technique. The Cryptosporidium-positive samples were analyzed by DNA sequence analysis of the small subunit (SSU) rRNA gene. Three Cryptosporidium species and two genotypes were identified, including C. baileyi (18/35 or 51.4%) in five red-billed leiothrixes (Leiothrix lutea), four white Java sparrows (Padda oryzivora), four common mynas (Acridotheres tristis), two zebra finches (Taeniopygia guttata), a crested Lark (Galerida cristata), a Gouldian finch (Chloebia gouldiae), and a black-billed magpie (Pica pica); Cryptosporidium meleagridis (3/35 or 8.6%) in a Bohemian waxwing (Bombycilla garrulus), a Rufous turtle dove (Streptopelia orientalis), and a fan-tailed pigeon (Columba livia); Cryptosporidium galli (5/35 or 14.3%) in four Bohemian waxwings (Bombycilla garrulus) and a silver-eared Mesia (Leiothrix argentauris); Cryptosporidium avian genotype 111 (3/35 or 8.6%) in two cockatiels (Nymphicus hollandicus) and a red-billed blue magpie (Urocissa erythrorhyncha); and Cryptosporidium avian genotype V (6/35 or 17.1%) in six cockatiels (Nymphicus hollandicus). Among the pet birds. 12 species represented new hosts for Cryptosporidum infections. The presence of C. meleagridis raises questions on potential zoonotic transmission of cryptosporidiosis from pet birds to humans. (C) 2011 Elsevier Inc. All rights reserved. C1 [Qi, Meng; Wang, Rongjun; Ning, Changshen; Li, Xiaoyu; Zhang, Longxian; Jian, Fuchun; Sun, Yanru] Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou 450002, Peoples R China. [Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Zhang, LX (reprint author), Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou 450002, Peoples R China. EM zhanglx8999@yahoo.com.cn; lxiao@cdc.gov RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 FU National Natural Science Foundation of China [30871863, 30771881, 30928019]; Key National Science and Technology Specific Projects [2008ZX10004-011]; Ministry of Education of China [20094105110003]; Henan Province Special Fund of Public Welfare [81100912300] FX This study was supported in part by the National Natural Science Foundation of China (Nos. 30871863, 30771881, and 30928019), the Key National Science and Technology Specific Projects (No. 2008ZX10004-011), Ph.D. Program Founds of the Ministry of Education of China (No. 20094105110003), and the Henan Province Special Fund of Public Welfare (No. 81100912300). NR 36 TC 28 Z9 32 U1 1 U2 17 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4894 J9 EXP PARASITOL JI Exp. Parasitol. PD AUG PY 2011 VL 128 IS 4 BP 336 EP 340 DI 10.1016/j.exppara.2011.04.003 PG 5 WC Parasitology SC Parasitology GA 804QZ UT WOS:000293670400006 PM 21557938 ER PT J AU Barr, DB Wong, LY Bravo, R Weerasekera, G Odetokun, M Restrepo, P Kim, DG Fernandez, C Whitehead, RD Perez, J Gallegos, M Williams, BL Needham, LL AF Barr, Dana Boyd Wong, Lee-Yang Bravo, Roberto Weerasekera, Gayanga Odetokun, Martins Restrepo, Paula Kim, Do-Gyun Fernandez, Carolina Whitehead, Ralph D., Jr. Perez, Jose Gallegos, Maribel Williams, Bryan L. Needham, Larry L. TI Urinary Concentrations of Dialkylphosphate Metabolites of Organophosphorus Pesticides: National Health and Nutrition Examination Survey 1999-2004 SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH LA English DT Article DE NHANES; urine; organophosphorus; pesticide; dialkylphosphate ID DIALKYL PHOSPHATE METABOLITES; CENTRAL WASHINGTON-STATE; AGRICULTURAL COMMUNITY; PRESCHOOL-CHILDREN; GENERAL-POPULATION; MASS-SPECTROMETRY; EXPOSURE; 3,5,6-TRICHLORO-2-PYRIDINOL; CHLORPYRIFOS; FAMILIES AB Organophosphorus (OP) insecticides were among the first pesticides that EPA reevaluated as part of the Food Quality Protection Act of 1996. Our goal was to assess exposure to OP insecticides in the U. S. general population over a six-year period. We analyzed 7,456 urine samples collected as part of three two-year cycles of the National Health and Nutrition Examination Survey (NHANES) from 1999-2004. We measured six dialkylphosphate metabolites of OP pesticides to assess OP pesticide exposure. In NHANES 2003-2004, dimethylthiophosphate was detected most frequently with median and 95th percentile concentrations of 2.03 and 35.3 mu g/L, respectively. Adolescents were two to three times more likely to have diethylphosphate concentrations above the 95th percentile estimate of 15.5 mu g/L than adults and senior adults. Conversely, for dimethyldithiophosphate, senior adults were 3.8 times and 1.8 times more likely to be above the 95th percentile than adults and adolescents, respectively, while adults were 2.1 times more likely to be above the 95th percentile than the adolescents. Our data indicate that the most vulnerable segments of our population-children and older adults-have higher exposures to OP pesticides than other population segments. However, according to DAP urinary metabolite data, exposures to OP pesticides have declined during the last six years at both the median and 95th percentile levels. C1 [Barr, Dana Boyd] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Wong, Lee-Yang; Bravo, Roberto; Weerasekera, Gayanga; Odetokun, Martins; Restrepo, Paula; Kim, Do-Gyun; Fernandez, Carolina; Whitehead, Ralph D., Jr.; Perez, Jose; Gallegos, Maribel; Williams, Bryan L.; Needham, Larry L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Barr, DB (reprint author), Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd, Atlanta, GA 30322 USA. EM dbbarr@emory.edu; lee-yang.wong@cdc.hhs.gov; roberto.bravo@cdc.hhs.gov; martins.odetokun@cdc.hhs.gov; paula.restrepo@cdc.hhs.gov; do-gyun.kim@cdc.hhs.gov; carolina.fernandez@cdc.hhs.gov; ralph.whitehead@cdc.hhs.gov; jose.perez@cdc.hhs.gov; maribel.gallegos@cdc.hhs.gov; blwill9@emory.edu RI Barr, Dana/E-6369-2011; Barr, Dana/E-2276-2013 NR 38 TC 34 Z9 34 U1 2 U2 8 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1660-4601 J9 INT J ENV RES PUB HE JI Int. J. Environ. Res. Public Health PD AUG PY 2011 VL 8 IS 8 BP 3063 EP 3098 DI 10.3390/ijerph8083063 PG 36 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 811WP UT WOS:000294248600001 PM 21909292 ER PT J AU Karch, D AF Karch, Debra TI Sex Differences in Suicide Incident Characteristics and Circumstances among Older Adults: Surveillance Data from the National Violent Death Reporting System-17 US States, 2007-2009 SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH LA English DT Article DE suicide by sex; older adult suicide; public health surveillance; National Violent Death Reporting System; suicide data ID DELIBERATE SELF-HARM; RISK-FACTORS; COMPLETED SUICIDE; PSYCHOLOGICAL AUTOPSY; UNITED-STATES; LIFE PROBLEMS; PEOPLE; AGE; PREVENTION; DISORDER AB Each year in the U.S. more than 7,000 adults aged 60 years and older die of suicide and as the population ages, these numbers are expected to increase. While sex is an important predictor of older adult suicide, differences between males and females are often overlooked due to low occurrence, particularly among women. The National Violent Death Reporting System (NVDRS) bridges this gap by providing detailed information on older adult suicide by sex in 17 US states (covering approximately 26% of the U. S. population). NVDRS data for 2007-2009 were used to characterize male (n = 5,004) and female (n = 1,123) suicide decedents aged 60 years and older, including incident characteristics and circumstances precipitating suicide. Stratification of NVDRS data by sex shows significant differences with regard to the presence of antidepressants (19% and 45% respectively), opiates (18%, 37%), and 14 precipitating circumstances concerning mental health, interpersonal problems, life stressors and a history of suicide attempts. No differences were found for alcohol problems, suicide/other death of family or friends, non-criminal legal problems, financial problems, or disclosure of intent to take their own life. The findings of this study demonstrate the value of using comprehensive surveillance data to understand sex-specific suicide circumstances so that opportunities for targeted prevention strategies may be considered. C1 Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30341 USA. RP Karch, D (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, 4770 Buford Highway NE,MS F-64, Atlanta, GA 30341 USA. EM DKarch@cdc.gov NR 48 TC 9 Z9 9 U1 1 U2 13 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1660-4601 J9 INT J ENV RES PUB HE JI Int. J. Environ. Res. Public Health PD AUG PY 2011 VL 8 IS 8 BP 3479 EP 3495 DI 10.3390/ijerph8083479 PG 17 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 811WP UT WOS:000294248600028 PM 21909319 ER PT J AU Hsia, J Samet, J Asma, S Nelson-Blutcher, G AF Hsia, J. Samet, J. Asma, S. Nelson-Blutcher, G. TI NICOTINE DEPENDENCE AMONG DAILY CIGARETTE SMOKERS IN 14 COUNTRIES SO JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH LA English DT Meeting Abstract C1 [Hsia, J.; Asma, S.; Nelson-Blutcher, G.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Samet, J.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0143-005X J9 J EPIDEMIOL COMMUN H JI J. Epidemiol. Community Health PD AUG PY 2011 VL 65 SU 1 BP A337 EP A337 DI 10.1136/jech.2011.142976l.47 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 807MG UT WOS:000293901801508 ER PT J AU Iser, B Macario, E Sobel, J Moura, L Malta, D AF Iser, B. Macario, E. Sobel, J. Moura, L. Malta, D. TI EVALUATION OF RISK FACTOR AND PROTECTION FOR CHRONIC NON COMMUNICABLE DISEASES MONITORING SYSTEM BY PHONE SURVEY: VIGITEL, BRAZIL 2006 TO 2008 SO JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH LA English DT Meeting Abstract C1 [Iser, B.; Sobel, J.; Moura, L.; Malta, D.] Minist Hlth MoH, Natl Coordinat Injury & Noncommunicable Dis Surv, Dept Hlth Anal, Secretariat Hlth Surveillance SVS, Brasilia, DF, Brazil. [Macario, E.] Minist Hlth, Field Epidemiol Training Program, Brasilia, DF, Brazil. CDC, Ctr Global Hlth, Atlanta, GA USA. RI Malta, Deborah/H-7880-2012 OI Malta, Deborah/0000-0002-8214-5734 NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0143-005X J9 J EPIDEMIOL COMMUN H JI J. Epidemiol. Community Health PD AUG PY 2011 VL 65 SU 1 BP A254 EP A254 DI 10.1136/jech.2011.142976i.58 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 807MG UT WOS:000293901801222 ER PT J AU Vinnard, C Winston, C Wileyto, EP MacGregor, RR Bisson, G AF Vinnard, C. Winston, C. Wileyto, E. P. MacGregor, R. R. Bisson, G. TI MULTIDRUG RESISTANT TUBERCULOUS MENINGITIS IN THE UNITED STATES, 1993-2005 SO JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH LA English DT Meeting Abstract C1 [Vinnard, C.; Wileyto, E. P.; MacGregor, R. R.; Bisson, G.] Univ Penn, Philadelphia, PA 19104 USA. [Winston, C.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0143-005X J9 J EPIDEMIOL COMMUN H JI J. Epidemiol. Community Health PD AUG PY 2011 VL 65 SU 1 BP A19 EP A19 DI 10.1136/jech.2011.142976a.46 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 807MG UT WOS:000293901800047 ER PT J AU Backer, LC AF Backer, Lorraine C. TI HARMFUL ALGAL BLOOM-RELATED ILLNESS SURVEILLANCE SYSTEM (HABISS). SO JOURNAL OF SHELLFISH RESEARCH LA English DT Meeting Abstract C1 [Backer, Lorraine C.] Ctr Dis Control & Prevent, Chamblee, GA 30341 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATL SHELLFISHERIES ASSOC PI GROTON PA C/O DR. SANDRA E. SHUMWAY, UNIV CONNECTICUT, 1080 SHENNECOSSETT RD, GROTON, CT 06340 USA SN 0730-8000 J9 J SHELLFISH RES JI J. Shellfish Res. PD AUG PY 2011 VL 30 IS 2 BP 484 EP 484 PG 1 WC Fisheries; Marine & Freshwater Biology SC Fisheries; Marine & Freshwater Biology GA 812SC UT WOS:000294312200042 ER PT J AU Kirkpatrick, B Reich, A Heil, D Fleming, LE Backer, LC AF Kirkpatrick, Barbara Reich, Andrew Heil, David Fleming, Lora E. Backer, Lorraine C. TI FLORIDA NSP EXPERIENCE: COMMERCIALLY AND RECREATIONALLY HARVESTED SHELLFISH SO JOURNAL OF SHELLFISH RESEARCH LA English DT Meeting Abstract C1 [Kirkpatrick, Barbara] Mote Marine Lab, Sarasota, FL 34236 USA. [Reich, Andrew] Florida Dept Hlth, Tallahassee, FL 32399 USA. [Heil, David] Florida Dept Agr & Consumer Serv, Tallahassee, FL 32399 USA. [Fleming, Lora E.] Univ Miami, Miami, FL 33149 USA. [Backer, Lorraine C.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATL SHELLFISHERIES ASSOC PI GROTON PA C/O DR. SANDRA E. SHUMWAY, UNIV CONNECTICUT, 1080 SHENNECOSSETT RD, GROTON, CT 06340 USA SN 0730-8000 J9 J SHELLFISH RES JI J. Shellfish Res. PD AUG PY 2011 VL 30 IS 2 BP 522 EP 522 PG 1 WC Fisheries; Marine & Freshwater Biology SC Fisheries; Marine & Freshwater Biology GA 812SC UT WOS:000294312200171 ER PT J AU Zotti, ME Williams, AM AF Zotti, Marianne E. Williams, Amy M. TI Reproductive Health Assessment After Disaster: Introduction to the RHAD Toolkit SO JOURNAL OF WOMENS HEALTH LA English DT Editorial Material ID WORLD-TRADE-CENTER; HURRICANE-KATRINA; BIRTH OUTCOMES; WOMEN; LOUISIANA; EXPOSURE; ATTACKS; IMPACT; GROWTH; FLOOD AB This article reviews associations between disaster and the reproductive health of women, describes how Hurricane Katrina influenced our understanding about postdisaster reproductive health needs, and introduces a new toolkit that can help health departments assess postdisaster health needs among women of reproductive age. C1 [Zotti, Marianne E.; Williams, Amy M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Zotti, ME (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS K-22, Atlanta, GA 30341 USA. EM drhinfo@cdc.gov NR 38 TC 3 Z9 3 U1 0 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD AUG PY 2011 VL 20 IS 8 BP 1123 EP 1127 DI 10.1089/jwh.2011.3021 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 805MQ UT WOS:000293731500001 PM 21688999 ER PT J AU Duong, LM Wilson, RJ Ajani, UA Singh, SD Eheman, CR AF Duong, Linh M. Wilson, Reda J. Ajani, Umed A. Singh, Simple D. Eheman, Christie R. TI Trends in Endometrial Cancer Incidence Rates in the United States, 1999-2006 SO JOURNAL OF WOMENS HEALTH LA English DT Article ID HORMONE REPLACEMENT THERAPY; ESTROGEN-RECEPTOR-ALPHA; POSTMENOPAUSAL WOMEN; PROGNOSTIC-FACTORS; PLUS PROGESTIN; RISK; CARCINOMA; HEALTH; CORPUS; COHORT AB Background: Risk factors for endometrial cancer, such as hormone replacement therapy (HRT) and obesity, have changed significantly in the last decade. We investigated trends in endometrial cancer histologic subtypes on a national level during 1999-2006. Methods: Data covering 88% of the U. S. population were from central cancer registries in the National Program of Cancer Registries (NPCR) and Surveillance, Epidemiology, and End Results (SEER) programs that met high-quality United States Cancer Statistics (USCS) criteria. Our analyses included females with microscopically confirmed invasive uterine cancer (n = 257,039). Age-adjusted incidence rates and trends for all invasive uterine cancers and by endometrial cancer histologic subtypes (type I and II) were assessed. Results: There were 145,922 cases of type I endometrial cancers and 15,591 cases of type II for 1999-2006. We found that type I endometrial cancers have been increasing, whereas type II endometrial cancers and all invasive uterine cancers have been relatively stable throughout the 1999-2006 period. Conclusions: During the past decade, the overall burden of uterine cancer has been stable, although there have been changes in underlying histologies (e. g., endometrial). Changes in trends for underlying histologies may be masked when reviewing trends irrespective of histologic subtypes. Our findings suggest the need to examine trends of uterine cancer by histologic subtype in order to better understand the burden of endometrial cancer in relation to these subtypes to help women at increased risk for developing more aggressive types of endometrial cancer (e. g., type II). C1 [Duong, Linh M.; Wilson, Reda J.; Ajani, Umed A.; Singh, Simple D.; Eheman, Christie R.] Ctr Dis Control & Prevent, Canc Surveillance Branch, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Duong, LM (reprint author), Ctr Dis Control & Prevent, Canc Surveillance Branch, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mail Stop K-53, Atlanta, GA 30341 USA. EM lduong@cdc.gov NR 48 TC 27 Z9 27 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD AUG PY 2011 VL 20 IS 8 BP 1157 EP 1163 DI 10.1089/jwh.2010.2529 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 805MQ UT WOS:000293731500007 PM 21682550 ER PT J AU Dietz, WH AF Dietz, William H. TI Reversing the tide of obesity SO LANCET LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Dietz, WH (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. EM wcd4@cdc.gov NR 7 TC 16 Z9 16 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD AUG-SEP PY 2011 VL 378 IS 9793 BP 744 EP 746 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 816FY UT WOS:000294585300005 PM 21872735 ER PT J AU Zurovac, D Sudoi, RK Akhwale, WS Ndiritu, M Hamer, DH Rowe, AK Snow, RW AF Zurovac, Dejan Sudoi, Raymond K. Akhwale, Willis S. Ndiritu, Moses Hamer, Davidson H. Rowe, Alexander K. Snow, Robert W. TI The effect of mobile phone text-message reminders on Kenyan health workers' adherence to malaria treatment guidelines: a cluster randomised trial SO LANCET LA English DT Article ID PLASMODIUM-FALCIPARUM MALARIA; ARTEMETHER-LUMEFANTRINE; CASE-MANAGEMENT; BEHAVIOR-CHANGE; PHARMACOKINETICS; PERFORMANCE; FACILITIES; QUALITY; UGANDA; PHARMACODYNAMICS AB Background Health workers' malaria case-management practices often differ from national guidelines. We assessed whether text-message reminders sent to health workers' mobile phones could improve and maintain their adherence to treatment guidelines for outpatient paediatric malaria in Kenya. Methods From March 6, 2009, to May 31, 2010, we did a cluster-randomised controlled trial at 107 rural health facilities in 11 districts in coastal and western Kenya. With a computer-generated sequence, health facilities were randomly allocated to either the intervention group, in which all health workers received text messages on their personal mobile phones on malaria case-management for 6 months, or the control group, in which health workers did not receive any text messages. Health workers were not masked to the intervention, although patients were unaware of whether they were in an intervention or control facility. The primary outcome was correct management with artemether-lumefantrine, defined as a dichotomous composite indicator of treatment, dispensing, and counselling tasks concordant with Kenyan national guidelines. The primary analysis was by intention to treat. The trial is registered with Current Controlled Trials, ISRCTN72328636. Findings 119 health workers received the intervention. Case-management practices were assessed for 2269 children who needed treatment (1157 in the intervention group and 1112 in the control group). Intention-to-treat analysis showed that correct artemether-lumefantrine management improved by 23.7 percentage-points (95% CI 7.6-40.0; p=0.004) immediately after intervention and by 24.5 percentage-points (8.1-41.0; p=0.003) 6 months later. Interpretation In resource-limited settings, malaria control programmes should consider use of text messaging to improve health workers' case-management practices. C1 [Zurovac, Dejan] Kenya Med Res Inst Wellcome Trust, Malaria Publ Hlth & Epidemiol Grp, Res Programme, Nairobi, Kenya. [Zurovac, Dejan; Snow, Robert W.] Univ Oxford, John Radcliffe Hosp, Ctr Trop Med, Oxford OX3 9DU, England. [Zurovac, Dejan; Hamer, Davidson H.] Boston Univ, Ctr Global Hlth & Dev, Boston, MA 02215 USA. [Akhwale, Willis S.] Minist Publ Hlth & Sanitat, Dept Dis Prevent & Control, Nairobi, Kenya. [Hamer, Davidson H.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Rowe, Alexander K.] US Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. RP Zurovac, D (reprint author), Kenya Med Res Inst Wellcome Trust, Malaria Publ Hlth & Epidemiol Grp, Res Programme, POB 43640-00100, Nairobi, Kenya. EM dzurovac@nairobi.kemri-wellcome.org RI Emchi, Karma/Q-1952-2016; OI Snow, Robert/0000-0003-3725-6088; Hamer, Davidson/0000-0002-4700-1495 FU Wellcome Trust, UK [084253]; Wellcome Trust [079080] FX We are grateful to all health workers, children, carers, and data collectors who participated in the study. We thank all members of the Kenyan Ministry of Public Health and Sanitation's Division of Malaria Control who participated in the intervention development and provided continued support. We also thank Mike English and Dayo Forster for comments on the paper. The trial was funded by the Wellcome Trust, UK through a project grant to RWS (grant number 084253), which also supported DZ. RWS is supported by the Wellcome Trust as Principal Research Fellow (grant number 079080). The paper is published with the permission of the Director of the Kenya Medical Research Institute. NR 37 TC 136 Z9 136 U1 3 U2 21 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD AUG-SEP PY 2011 VL 378 IS 9793 BP 795 EP 803 DI 10.1016/S0140-6736(11)60783-6 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 816FY UT WOS:000294585300035 PM 21820166 ER PT J AU Siddappa, NB Hemashettar, G Shanmuganathan, V Semenya, AA Sweeney, ED Paul, KS Lee, SJ Secor, WE Ruprecht, RM AF Siddappa, Nagadenahalli B. Hemashettar, Girish Shanmuganathan, Vivekanandan Semenya, Amma A. Sweeney, Elizabeth D. Paul, Katherine S. Lee, Sandra J. Secor, W. Evan Ruprecht, Ruth M. TI Schistosoma mansoni Enhances Host Susceptibility to Mucosal but Not Intravenous Challenge by R5 Clade C SHIV SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; RHESUS MACAQUES; GENITAL SCHISTOSOMIASIS; RNA LOAD; INFECTION; TRANSMISSION; HIV-1; AIDS; WOMEN AB Background: The high prevalence of HIV-1/AIDS in areas endemic for schistosomiasis and other helminthic infections has led to the hypothesis that parasites increase host susceptibility to immunodeficiency virus infection. We previously showed that rhesus macaques (RM) with active schistosomiasis were significantly more likely to become systemically infected after intrarectal (i.r.) exposure to an R5-tropic clade C simian-human immunodeficiency virus (SHIV-C) than were parasite-free controls. However, we could not address whether this was due to systemic or mucosal effects. If systemic immunoactivation resulted in increased susceptibility to SHIV-C acquisition, a similarly large difference in host susceptibility would be seen after intravenous (i.v.) SHIV-C challenge. Conversely, if increased host susceptibility was due to parasite-induced immunoactivation at the mucosal level, i.v. SHIV-C challenge would not result in significant differences between parasitized and parasite-free monkeys. Methods and Findings: We enrolled two groups of RM and infected one group with Schistosoma mansoni; the other group was left parasite-free. Both groups were challenged i.v. with decreasing doses of SHIV-C. No statistically significant differences in 50% animal infectious doses (AID(50)) or peak viremia were seen between the two groups. These data strongly contrast the earlier i.r. SHIV-C challenge (using the same virus stock) in the presence/absence of parasites, where we noted a 17-fold difference in AID(50) and one log higher peak viremia in parasitized monkeys (P<0.001 for both). The lack of significant differences after the i.v. challenge implies that the increased host susceptibility is predominantly due to parasite-mediated mucosal upregulation of virus replication and spread, rather than systemic effects. Conclusions: The major impact of schistosome-induced increased host susceptibility is at the mucosal level. Given that >90% of all new HIV-1 infections worldwide are acquired through mucosal contact, parasitic infections that inflame mucosae may play an important role in the spread of HIV-1. C1 [Siddappa, Nagadenahalli B.; Lee, Sandra J.] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA. [Siddappa, Nagadenahalli B.; Ruprecht, Ruth M.] Harvard Univ, Sch Med, Boston, MA USA. [Semenya, Amma A.; Sweeney, Elizabeth D.; Paul, Katherine S.; Secor, W. Evan] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lee, Sandra J.] Dana Farber Canc Inst, Dept Computat Biol, Boston, MA 02115 USA. RP Siddappa, NB (reprint author), Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA. EM ruth_ruprecht@dfci.harvard.edu OI Byrareddy, Siddappa /0000-0002-7423-1763 FU National Institutes of Health [R56 A1062515, PO1 AI048240] FX This study was supported by National Institutes of Health grants R56 A1062515 and PO1 AI048240. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 28 TC 15 Z9 15 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1935-2727 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD AUG PY 2011 VL 5 IS 8 AR e1270 DI 10.1371/journal.pntd.0001270 PG 6 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 814TJ UT WOS:000294479800025 PM 21829749 ER PT J AU Cherng, JM Tsai, KD Yu, YW Lin, JC AF Cherng, Jaw-Ming Tsai, Kuen-Daw Yu, Yu-Whay Lin, Jung-Chung TI Molecular Mechanisms Underlying Chemopreventive Activities of Glycyrrhizic Acid against UVB-Radiation-Induced Carcinogenesis in SKH-1 Hairless Mouse Epidermis SO RADIATION RESEARCH LA English DT Article ID CHRONIC HEPATITIS-C; INDUCED SKIN-CANCER; FACTOR-KAPPA-B; IN-VITRO; GLYCYRRHETINIC ACID; OXIDATIVE STRESS; ANTIVIRAL COMPOUNDS; RAT HEPATOCYTES; INHIBITION; MICE AB Cherng, J-M., Tsai, K-D., Yu, Y-W. and Lin, J-C. Molecular Mechanisms Underlying Chemopreventive Activities of Glycyrrhizic Acid against UVB-Radiation-Induced Carcinogenesis in SKH-1 Hairless Mouse Epidermis. Radiat. Res. 176, 177-186 (2011). Glycyrrhizic acid has been shown to possess anti-inflammation, antiviral and chemoprotective activity against tumors. We evaluated the protective effects of glycyrrhizic acid in UVB-radiation-induced skin tumor formation in SKH-1 hairless mice and the early molecular biomarkers of these effects. Mice irradiated at 180 mJ/cm(2) twice per week showed 100% tumor incidence in 20 weeks. Feeding with glycyrrhizic acid prior to UVB irradiation caused delays in tumor appearance, multiplicity and size. Feeding with glycyrrhizic acid for 2 weeks before a single UVB irradiation (180 mJ/cm(2)) resulted in significant decrease in UVB-radiation-induced thymine dimer-positive cells, expression of proliferative cell nuclear antigen (PCNA), terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-positive cells, and apoptotic sunburn cells together with an increase in p53- and p21/Cip1-positive cell populations in epidermis. Simultaneously, glycyrrhizic acid also significantly inhibited NF-kappa B, cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), and nitric oxide (NO) levels. Thus glycyrrhizic acid ameliorates UVB-radiation-induced tumorigenesis via downregulation of cell proliferation controls involving thymine dimer, PCNA, apoptosis and transcription factor NF-kappa B and of inflammatory responses involving COX-2, PGE2 and NO while upregulating of p53 and p21/Cip1 to prevent DNA damage and facilitate DNA repair. (C) 2011 by Radiation Research Society C1 [Lin, Jung-Chung] Ctr Dis Control & Prevent, Cellular Virol Unit, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Tsai, Kuen-Daw] Natl Chung Cheng Univ, Inst Mol Biol, Chiayi 621, Taiwan. [Tsai, Kuen-Daw] China Med Univ, Dept Internal Med, Yunlin 651, Taiwan. [Tsai, Kuen-Daw] Beigang Hosp, Yunlin 651, Taiwan. [Cherng, Jaw-Ming; Yu, Yu-Whay] Chung Shan Med Univ Hosp, Dept Internal Med, Taichung, Taiwan. [Cherng, Jaw-Ming; Yu, Yu-Whay] Chung Shan Med Univ, Taichung, Taiwan. RP Lin, JC (reprint author), Ctr Dis Control & Prevent, Cellular Virol Unit, Div Viral Hepatitis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM linderson1939@gmail.com FU National Science Council (NSC) of Taiwan [97-2320-B-040-033-MY3]; China Medical University Beigang Hospital; National Taiwan University Hospital (NTUH), Taiwan [098-001216] FX This work was supported in part by grants from the National Science Council (NSC) of Taiwan (97-2320-B-040-033-MY3), China Medical University Beigang Hospital, and National Taiwan University Hospital (NTUH. 098-001216), Taiwan. NR 40 TC 18 Z9 20 U1 0 U2 3 PU RADIATION RESEARCH SOC PI LAWRENCE PA 810 E TENTH STREET, LAWRENCE, KS 66044 USA SN 0033-7587 J9 RADIAT RES JI Radiat. Res. PD AUG PY 2011 VL 176 IS 2 BP 177 EP 186 DI 10.1667/RR2510.1 PG 10 WC Biology; Biophysics; Radiology, Nuclear Medicine & Medical Imaging SC Life Sciences & Biomedicine - Other Topics; Biophysics; Radiology, Nuclear Medicine & Medical Imaging GA 804VM UT WOS:000293682100004 PM 21545294 ER PT J AU Roblin, DW Smith, BD Weinbaum, CM Sabin, ME AF Roblin, Douglas W. Smith, Bryce D. Weinbaum, Cindy M. Sabin, Miriam E. TI HCV Screening Practices and Prevalence in an MCO, 2000-2007 SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID AREA SOCIOECONOMIC PATTERNS; IMMUNIZATION PRACTICES ACIP; US CANCER MORTALITY; C VIRUS-INFECTION; HEPATITIS-C; UNITED-STATES; HEPATOCELLULAR-CARCINOMA; ADVISORY-COMMITTEE; PART II; CARE AB Background/Objective: The Centers for Disease Control and Prevention recommends routine screening for the hepatitis C virus antibody (anti-HCV) among persons most likely to be infected. Little is known about anti-HCV screening and prevalence in routine practice settings. We studied anti-HCV screening rates, anti-HCV positivity, and demographic and risk factors associated with increased likelihood of anti-HCV screening or positivity in a managed care organization (MCO). Methods: This was a retrospective observational study of 17-to-74-year-old MCO enrollees from 2000 to 2007 (N = 557,056; 1,949,499 enrolle-eyears). The primary outcome measures were likelihood of anti-HCV screening and HCV positivity (both in the total population and among those screened). Independent variables were: birth cohort, gender, HCV risk factors, and socioeconomic status (SES) and race of residents' neighborhoods. Likelihood of each outcome as a function of the independent variables was estimated using logistic regression. Results: Over the 8-year period, 4.31% of the total population received anti-HCV screening; 0.22% had a positive HCV result. Among those screened, HCV positivity was 5.15%. HCV screening and positivity rates increased over time. Both likelihood of HCV screening and HCV positivity were highest (P < 0.05) among persons born during 1945-1964, males, those with HCV risk factors, and residents of neighborhoods of lower SES or with higher percentages of African Americans. Conclusions: Although HCV screening and detec-tion improved in this MCO over an 8-year period, anti-HCV screening was lower than expected. Many persons at risk for HCV remained unscreened. Strategies for improving anti-HCV screening in routine practice are recommended for patients at increased risk. (Am J Manag Care. 2011; 17(8):548-555) C1 [Roblin, Douglas W.] Kaiser Permanente, Ctr Hlth Res SE, Atlanta, GA USA. [Smith, Bryce D.; Weinbaum, Cindy M.; Sabin, Miriam E.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. RP Roblin, DW (reprint author), Kaiser Permanente Georgia, 3495 Piedmont Rd,NE,Bldg 9, Atlanta, GA 30305 USA. EM douglas.roblin@kp.org FU Centers for Disease Control and Prevention [200-2008-M-27862] FX Work on this project was funded through a grant (200-2008-M-27862) to Kaiser Permanente Georgia from the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 24 TC 33 Z9 34 U1 0 U2 3 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD AUG PY 2011 VL 17 IS 8 BP 548 EP 556 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 810WH UT WOS:000294158400007 PM 21851142 ER PT J AU Ford, ES Zhao, GX Tsai, J Li, CY AF Ford, Earl S. Zhao, Guixiang Tsai, James Li, Chaoyang TI Vitamin D and all-cause mortality among adults in USA: findings from the National Health and Nutrition Examination Survey Linked Mortality Study SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Article DE Cohort studies; health surveys; mortality; vitamin D ID SERUM 25-HYDROXYVITAMIN D; CARDIOVASCULAR-DISEASE MORTALITY; RENIN-ANGIOTENSIN SYSTEM; D SUPPLEMENTATION; D DEFICIENCY; CANCER-RISK; CALCIUM SUPPLEMENTATION; PARATHYROID-HORMONE; DIETARY REQUIREMENT; GENERAL-POPULATION AB Methods We used data from the National Health and Nutrition Examination Survey Mortality Study from 2001 to 2004 with mortality compiled through 2006. Mortality status was established through a match to the National Death Index. Results Of the 7531 participants, 347 died. Median follow-up was 3.8 years. The mean unadjusted concentrations of vitamin D were 54.1 nmol/l (21.7 ng/ml) among participants who died and 60.7 nmol/l (24.3 ng/ml) among participants who survived (P = 0.002). After adjustment for socio-demographic factors, the hazard ratios (HR) for all-cause mortality were 1.65 [95% confidence interval (CI): 95% CI: 1.13-2.40] for participants with a concentration < 50 nmol/l (< 20 ng/ml) and 1.02 (95% CI: 0.74-1.41) for participants with a concentration of 50 to < 75 nmol/l (20 to < 30 ng/ml) compared with participants who had a concentration of epsilon 75 nmol/l (epsilon 30 ng/ml). After more extensive adjustment, the HRs were 1.28 (95% CI: 0.86-1.90) and 0.91 (95% CI: 0.63-1.33), respectively. The fully adjusted HR per 10 nmol/l of vitamin D was 0.93 (95% CI: 0.86-1.01). The HRs did not vary by gender (P = 0.80) or among the three major racial or ethnic groups (P = 0.46). Conclusions Concentrations of vitamin D were weakly and inversely related to all-cause mortality in this sample of US adults. C1 [Ford, Earl S.; Zhao, Guixiang; Tsai, James; Li, Chaoyang] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS K67, Atlanta, GA 30341 USA. EM eford@cdc.gov NR 62 TC 28 Z9 29 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD AUG PY 2011 VL 40 IS 4 BP 998 EP 1005 DI 10.1093/ije/dyq264 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 810ER UT WOS:000294108700026 PM 21266455 ER PT J AU Satcher, D AF Satcher, David TI The Impact of Disparities in Health on Pandemic Preparedness SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Editorial Material ID AMERICANS C1 [Satcher, David] Morehouse Sch Med, Natl Ctr Primary Care, Satcher Hlth Leadership Inst, Atlanta, GA 30310 USA. [Satcher, David] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Satcher, D (reprint author), Morehouse Sch Med, Natl Ctr Primary Care, Satcher Hlth Leadership Inst, 720 Westview Dr SW, Atlanta, GA 30310 USA. EM dsatcher@msm.edu FU NIMHD NIH HHS [U54 MD008173] NR 8 TC 0 Z9 0 U1 0 U2 3 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD AUG PY 2011 VL 22 IS 3 SU S BP 36 EP 37 PG 2 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 809WP UT WOS:000294087700005 PM 21857135 ER PT J AU Weisz, J Lozyniak, S Lane, SD Silverman, R DeMott, K Wojtowycz, MA Aubry, RH Koumans, EH AF Weisz, Jessica Lozyniak, Sara Lane, Sandra D. Silverman, Robert DeMott, Kathy Wojtowycz, Martha A. Aubry, Richard H. Koumans, Emilia H. TI It Takes At Least Two: Male Partner Factors, Racial/Ethnic Disparity, and Chlamydia trachomatis Among Pregnant Women SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Chlamydia Trachomatis; racial/ethnic disparity; male partner factors; pregnancy; social determinants ID SEXUALLY-TRANSMITTED-DISEASES; STRUCTURAL VIOLENCE; INFECTION; HIV; PATTERNS; BEHAVIOR; THERAPY; RISK; MEN AB Chlamydia trachomatis (CT), the most prevalent sexually transmitted infection in the United States, disproportionately infects women and people of color. This study aimed to identify risk factors for racial and ethnic disparities for CT infection, re-infection, and persistent infection among pregnant women. We present a secondary analysis of births from a retrospective cohort study in Syracuse, NY from January 2000 through March 2002. African American women [OR 3.35 CI (2.29, 4.92)], Latin American women [OR 4.35 CI (2.52, 7.48)], unmarried women [OR 7.57 CI (4.38, 13.10)], and teen mothers [OR 3.87 CI (2.91, 5.16)] demonstrated statistically significant increased risk for infection. In multivariate analyses that included male partner variables, father's race/ethnicity but not the mother's race/ethnicity remained statistically associated with CT. Despite near universal rates of screening pregnant women, challenges to CT control remain and reflect barriers to testing and treatment of male partners. C1 [Lane, Sandra D.] Syracuse Univ, Dept Hlth & Wellness, Syracuse, NY USA. [Lane, Sandra D.; Silverman, Robert] SUNY Upstate Med Univ, Dept Obstet & Gynecol, Syracuse, NY USA. [DeMott, Kathy] Royal Coll Physicians, London NW1 4LE, England. [Wojtowycz, Martha A.; Aubry, Richard H.] SUNY Upstate Med Univ, Ctr Maternal & Child Hlth, Syracuse, NY USA. [Koumans, Emilia H.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. RP Lane, SD (reprint author), 426 Ostrom Ave, Syracuse, NY 13244 USA. EM jweisz@nmc.org NR 25 TC 0 Z9 0 U1 4 U2 6 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD AUG PY 2011 VL 22 IS 3 BP 871 EP 885 PG 15 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 809WS UT WOS:000294088000013 PM 21841284 ER PT J AU Dignan, M Evans, M Kratt, P Pollack, LA Pisu, M Smith, JL Prayor-Patterson, H Houston, P Watson, C Hullett, S Martin, MY AF Dignan, Mark Evans, Mary Kratt, Polly Pollack, Lori A. Pisu, Maria Smith, Judith Lee Prayor-Patterson, Heather Houston, Peter Watson, Christopher Hullett, Sandral Martin, Michelle Y. TI Recruitment of Low Income, Predominantly Minority Cancer Survivors to a Randomized Trial of the I Can Cope Cancer Education Program SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Cancer survivor; minority recruitment; clinical trial ID BREAST-CANCER; AFRICAN-AMERICAN; CLINICAL-RESEARCH; HEALTH; PARTICIPATION; RETENTION; LESSONS; AGE AB This report describes recruitment of minority cancer survivors for a randomized trial of I Can Cope, a support program of the American Cancer Society. Survivor Education and Evaluation (SURE), was designed to recruit patients, age 19 and older, with a primary cancer diagnosis. Recruitment was primarily carried out in a public hospital in Birmingham, Alabama. Of 373 patients approached, 226 were eligible for the study, 175 consented, and 140 were randomized during the 20-month recruitment period. Only 43 declined participation. This resulted in a 61.9% recruitment yield. The mean age of participants was 54.2 years (SD=10.9), 92 (65.7%) were female, and 111 (79.3%) were African American. Twenty-three different cancers were represented including breast (37.1%), colorectal (12.1%), hematologic (12.9%), and lung (7.1%). Over half (63%) had been diagnosed within 12 months. The experience of the SURE project provides evidence for optimism in recruiting racial minorities to cancer research studies. C1 [Kratt, Polly; Pisu, Maria; Houston, Peter; Martin, Michelle Y.] Univ Alabama Birmingham, Div Prevent Med, Dept Med, Birmingham, AL 35294 USA. [Dignan, Mark] Univ Kentucky, Prevent Res Ctr, Lexington, KY 40506 USA. [Evans, Mary] Univ Alabama Birmingham, Ctr Study Community Hlth, Prevent Res Ctr, Birmingham, AL 35294 USA. [Pollack, Lori A.] Ctr Dis Control & Prevent CDC, US Publ Hlth Serv, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, Atlanta, GA 30333 USA. [Prayor-Patterson, Heather] Cleveland Clin, Neurol Ctr Pain, Dept Psychiat & Psychol, Cleveland, OH USA. [Hullett, Sandral] Cooper Green Mercy Hosp, Birmingham, AL USA. [Watson, Christopher] Meharry Med Coll, Nashville, TN 37208 USA. [Smith, Judith Lee] CDC, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, Atlanta, GA 30333 USA. RP Martin, MY (reprint author), Univ Alabama Birmingham, Div Prevent Med, Dept Med, 617 Med Towers,1530 3rd Ave S, Birmingham, AL 35294 USA. EM mymartin@uab.edu FU NCCDPHP CDC HHS [U48/DP000567-1] NR 27 TC 8 Z9 8 U1 0 U2 2 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD AUG PY 2011 VL 22 IS 3 BP 912 EP 924 PG 13 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 809WS UT WOS:000294088000016 PM 21841287 ER PT J AU Lim, JR Sullivan, PS Salazar, L Spaulding, AC DiNenno, EA AF Lim, Jennifer R. Sullivan, Patrick S. Salazar, Laura Spaulding, Anne C. DiNenno, Elizabeth A. TI History of Arrest and Associated Factors among Men Who Have Sex with Men SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Article DE Black; MSM; Sexual identity; Incarceration; Risk behavior; HIV/AIDS ID AFRICAN-AMERICAN MEN; BLACK-MEN; HIV-INFECTION; SUBSTANCE USE; UNITED-STATES; COCAINE USE; CONDOM USE; WHITE MEN; RISK; BEHAVIOR AB Incarceration has been proposed to be a driving factor in the disproportionate impact of HIV in African-American communities. However, few data have been reported on disparities in criminal justice involvement by race among men who have sex with men (MSM). To describe history of arrest and associated factors among, we used data from CDC's National HIV Behavioral Surveillance system. Respondents were recruited by time-space sampling in venues frequented by MSM in 15 US cities from 2003 to 2005. Data on recent arrest (in the 12 months before the interview), risk behaviors, and demographic information were collected by face-to-face interview for MSM who did not report being HIV-positive. Six hundred seventy-nine (6.8%) of 10,030 respondents reported recent arrest. Compared with white MSM, black MSM were more likely to report recent arrest history (odds ratio (OR), 1.6; 95% confidence interval (CI), 1.3-2.1). Men who were less gay-identified (bisexual [OR, 1.5; 95% CI, 1.1-1.9] or heterosexual [OR, 2.0; 95% CI, 1.2-3.5]) were more likely to report recent arrest than homosexually identified men. In addition, men who reported arrest history were more likely to have used non-injection (OR, 3.0; 95% CI, 2.4-3.6) and injection (OR, 4.7; 95%, 3.3-6.7) drugs, exchanged sex (OR, 2.7; 95% CI, 2.1-3.4), and had a female partner (OR, 1.5; 95% CI, 1.2-2.0) in the 12 months before interview. Recent arrest was associated with insertive unprotected anal intercourse in the 12 months before interview (OR, 1.4; 95% CI, 1.2-1.7). Racial differences in arrest seen in the general US population are also present among MSM, and history of arrest was associated with high-risk sex. Future research and interventions should focus on clarifying the relationship between criminal justice involvement and sexual risk among MSM, particularly black MSM. C1 [Lim, Jennifer R.; Sullivan, Patrick S.; Salazar, Laura; Spaulding, Anne C.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [DiNenno, Elizabeth A.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Sullivan, PS (reprint author), Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. EM pssuli@sph.emory.edu OI Sullivan, Patrick/0000-0002-7728-0587 FU National Institutes of Mental Health [R01-MH85600] FX Thanks are due to Luke Shouse, David Holtgrave, and Ben Hadsock from Atlanta, GA; Liza Solomon, Colin Flynn, and Frangiscos Sifakis from Baltimore, MD; Abbie Averbach, Jennifer Coyle, and Chris Smith from Boston, MA; Carol Ciesielski and Nik Prachand from Chicago, IL; Sharon Melville, Richard Yeager, Anne Freeman, Douglas Shehan, and Douglas Kershaw from Dallas, TX; Mark Thrun and Julie Subiadur from Denver, CO; Marcia Wolverton, Jan Risser, Bernardo Useche, and Hafeez Rehman from Houston, TX; Trista Bingham, Denise Johnson, and Nina Harawa from Los Angeles, CA; Marlene LaLota, Lisa Metsch, and David Forrest from Miami and Ft. Lauderdale, FL; Chris Murrill, Beryl Koblin, and Michael Camacho from New York, NY; Helene Cross, Barbara Bolden, Sally D'Errico, and Henry Godette from Newark, NJ; Kathleen Brady from Philadelphia, PA; Assunta Ritieni, Al Velasco, and Leticia Cazares from San Diego, CA; Willi McFarland and H. Fisher Raymond from San Francisco, CA; Sandra Miranda De Leon and Yadira Rolon Colon from San Juan, PR; and Leonard Bates, Christopher Hucks-Ortiz, and Christopher Lane from Washington, DC. We are thankful also to the CDC NHBS Team-Behavioral and Clinical Surveillance Branch, Division of HIV/AIDS Prevention. Drs. Sullivan and Salazar were supported, in part, by a grant from the National Institutes of Mental Health (R01-MH85600). NR 47 TC 8 Z9 8 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1099-3460 J9 J URBAN HEALTH JI J. Urban Health PD AUG PY 2011 VL 88 IS 4 BP 677 EP 689 DI 10.1007/s11524-011-9566-5 PG 13 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 808XD UT WOS:000294014400007 PM 21448578 ER PT J AU Zapata, LB Kissin, DM Robbins, CL Finnerty, E Skipalska, H Yorick, RV Jamieson, DJ Marchbanks, PA Hillis, SD AF Zapata, Lauren B. Kissin, Dmitry M. Robbins, Cheryl L. Finnerty, Erin Skipalska, Halyna Yorick, Roman V. Jamieson, Denise J. Marchbanks, Polly A. Hillis, Susan D. TI Multi-City Assessment of Lifetime Pregnancy Involvement among Street Youth, Ukraine SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Article DE Homeless youth; Street youth; Unplanned pregnancy; Sexual behavior; Risk factors ID ADVERSE CHILDHOOD EXPERIENCES; HOMELESS YOUTH; SEXUAL HEALTH; ADOLESCENT PREGNANCY; HIV SEROPREVALENCE; RISK-FACTORS; OUTCOMES; ABUSE; INTERVENTIONS; INFANTS AB Although street youth are at increased risk of lifetime pregnancy involvement (LPI), or ever becoming or getting someone pregnant, no reports to date describe the epidemiology of LPI among systematically sampled street youth from multiple cities outside of North America. The purpose of our assessment was to describe the prevalence of and risk factors associated with LPI among street youth from three Ukrainian cities. We used modified time-location sampling to conduct a cross-sectional assessment in Odesa, Kyiv, and Donetsk that included citywide mapping of 91 public venue locations frequented by street youth, random selection of 74 sites, and interviewing all eligible and consenting street youth aged 15-24 years found at sampled sites (n = 929). Characteristics of youth and prevalence of LPI overall and by demographic, social, sexual, and substance use risk factors, were estimated separately for males and females. Adjusted odds ratios (AORs) were calculated with multivariable logistic regression and effect modification by gender was examined. Most (96.6%) eligible youth consented to participate. LPI was reported for 41.7% of females (93/223) and 23.5% of males (166/706). For females, LPI was significantly elevated and highest (> 70%) among those initiating sexual activity at a parts per thousand currency sign12 years and for those reporting lifetime anal sex and exchanging sex for goods. For males, LPI was significantly elevated and highest (> 40%) among those who reported lifetime anal sex and history of a sexually transmitted infection. Overall, risk factors associated with LPI were similar for females and males. Among the total sample (females and males combined), significant independent risk factors with AORs a parts per thousand yen2.5 included female gender, being aged 20-24 years, having five to six total adverse childhood experiences, initiating sex at age a parts per thousand currency sign12 or 13-14 years, lifetime anal sex, most recent sex act unprotected, and lifetime exchange of sex for goods. Among street youth with LPI (n = 259), the most recent LPI event was reported to be unintended by 63.3% and to have ended in abortion by 43.2%. In conclusion, our assessment documented high rates of LPI among Ukrainian street youth who, given the potential for negative outcomes and the challenges of raising a child on the streets, are in need of community-based pregnancy prevention programs and services. Promising preventive strategies are discussed, which are likely applicable to other urban populations of street-based youth as well. C1 [Zapata, Lauren B.; Kissin, Dmitry M.; Robbins, Cheryl L.; Jamieson, Denise J.; Marchbanks, Polly A.; Hillis, Susan D.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Yorick, Roman V.] HealthRight Int, St Petersburg, Russia. [Skipalska, Halyna] HealthRight Int, Kiev, Ukraine. [Finnerty, Erin] HealthRight Int, New York, NY USA. RP Zapata, LB (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM lzapata@cdc.gov OI Yorick, Roman/0000-0002-8458-2938 FU HealthRight International; Centers for Disease Control and Prevention; USAID/Ukraine; International AIDS Alliance FX Project support provided by HealthRight International, Centers for Disease Control and Prevention Global AIDS Program, USAID/Ukraine and the International AIDS Alliance. NR 44 TC 2 Z9 2 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1099-3460 J9 J URBAN HEALTH JI J. Urban Health PD AUG PY 2011 VL 88 IS 4 BP 779 EP 792 DI 10.1007/s11524-011-9596-z PG 14 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 808XD UT WOS:000294014400016 PM 21779933 ER PT J AU Jentes, ES Poumerol, G Gershman, MD Hill, DR Lemarchand, J Lewis, RF Staples, JE Tomori, O Wilder-Smith, A Monath, TP AF Jentes, Emily S. Poumerol, Gilles Gershman, Mark D. Hill, David R. Lemarchand, Johan Lewis, Rosamund F. Staples, J. Erin Tomori, Oyewale Wilder-Smith, Annelies Monath, Thomas P. CA Informal WHO Working Grp Geographi TI The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever SO LANCET INFECTIOUS DISEASES LA English DT Review ID IMMUNIZATION; PERSISTENCE; VIRUSES AB The changing epidemiology of yellow fever and continued reports of rare but serious adverse events associated with yellow fever vaccine have drawn attention to the need to revisit criteria for the designation of areas with risk for yellow fever virus activity, and to revise the vaccine recommendations for international travel. WHO convened a working group of international experts to review factors important for the transmission of yellow fever virus and country-specific yellow fever information, to establish criteria for additions to or removal from the list of countries with risk for yellow fever virus transmission, to update yellow fever risk maps, and to revise the recommendations for vaccination for international travel. This report details the recommendations made by the working group about criteria for the designation of risk and specific changes to the classification of areas with risk for transmission of yellow fever virus. C1 [Jentes, Emily S.; Gershman, Mark D.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. [Jentes, Emily S.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Lemarchand, Johan] WHO, Publ Hlth Informat & GIS, CH-1211 Geneva, Switzerland. [Lewis, Rosamund F.] WHO, Yellow Fever Initiat, Global Alert & Response Dept, CH-1211 Geneva, Switzerland. [Hill, David R.] London Sch Hyg & Trop Med, London WC1, England. [Hill, David R.] UCLH NHS Fdn Trust, Natl Travel Hlth Network & Ctr, London, England. [Staples, J. Erin] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. [Tomori, Oyewale] Redeemers Univ, Dept Biol Sci, Ikeja, Lagos State, Nigeria. [Wilder-Smith, Annelies] Natl Univ Singapore Hosp, Travellers Screening & Vaccinat Clin, Singapore 117548, Singapore. [Wilder-Smith, Annelies] Univ Heidelberg, Inst Publ Hlth, Heidelberg, Germany. RP Jentes, ES (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, 1600 Clifton Rd,MS E-03, Atlanta, GA 30333 USA. EM ejentes@cdc.gov RI Wilder-Smith, Annelies/F-8751-2015; OI Wilder-Smith, Annelies/0000-0003-0362-5375 FU yellow fever vaccination centre in England; yellow fever vaccination centre in Wales; yellow fever vaccination centre in Northern Ireland; Global Alliance for Vaccines and Immunization for the Yellow Fever Initiative; Sanofi Pasteur; Novartis; GlaxoSmithKline FX WHO provided travel support for ESJ, MDG, DRH, JES, OT, AW-S, and TPM. DRH declares that his institution (the National Travel Health Network and Centre) receives a registration fee from yellow fever vaccination centres in England, Wales, and Northern Ireland as part of a programme of registration, training, standards, and audit for yellow fever centres. RFL declares that WHO receives funding from the Global Alliance for Vaccines and Immunization for the Yellow Fever Initiative. AW-S has been sponsored to attend conferences and has received speaker's fees from Sanofi Pasteur, Novartis, and GlaxoSmithKline. TPM declares board membership, patents, and stock options for Xcellerex. GP and JL declare that they have no conflict of interests. NR 53 TC 74 Z9 74 U1 4 U2 20 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD AUG PY 2011 VL 11 IS 8 BP 622 EP 632 PG 11 WC Infectious Diseases SC Infectious Diseases GA 810BU UT WOS:000294101200019 PM 21798462 ER PT J AU Wheeler, SS Langevin, S Woods, L Carroll, BD Vickers, W Morrison, SA Chang, GJJ Reisen, WK Boyce, WM AF Wheeler, Sarah S. Langevin, Stanley Woods, Leslie Carroll, Brian D. Vickers, Winston Morrison, Scott A. Chang, Gwong-Jen J. Reisen, William K. Boyce, Walter M. TI Efficacy of Three Vaccines in Protecting Western Scrub-Jays (Aphelocoma californica) from Experimental Infection with West Nile Virus: Implications for Vaccination of Island Scrub-Jays (Aphelocoma insularis) SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Aphelocoma; Conservation; Corvid-island; Vaccination; West Nile virus ID CORVUS-BRACHYRHYNCHOS; DNA VACCINE; NEW-YORK; BIRDS; CHALLENGE; CULICIDAE; DIPTERA; ANTIBODIES; EMERGENCE; MOSQUITOS AB The devastating effect of West Nile virus (WNV) on the avifauna of North America has led zoo managers and conservationists to attempt to protect vulnerable species through vaccination. The Island Scrub-Jay (Aphelocoma insularis) is one such species, being a corvid with a highly restricted insular range. Herein, we used congeneric Western Scrub-Jays (Aphelocoma californica) to test the efficacy of three WNV vaccines in protecting jays from an experimental challenge with WNV: (1) the Fort Dodge West Nile-Innovator (R) DNA equine vaccine, (2) an experimental DNA plasmid vaccine, pCBWN, and (3) the Merial Recombitek (R) equine vaccine. Vaccine efficacy after challenge was compared with naive and nonvaccinated positive controls and a group of naturally immune jays. Overall, vaccination lowered peak viremia compared with nonvaccinated positive controls, but some WNV-related pathology persisted and the viremia was sufficient to possibly infect susceptible vector mosquitoes. The Fort Dodge West Nile-Innovator DNA equine vaccine and the pCBWN vaccine provided humoral immune priming and limited side effects. Five of the six birds vaccinated with the Merial Recombitek vaccine, including a vaccinated, non-WNV challenged control, developed extensive necrotic lesions in the pectoral muscle at the vaccine inoculation sites, which were attributed to the Merial vaccine. In light of the well-documented devastating effects of high morbidity and mortality associated with WNV infection in corvids, vaccination of Island Scrub-Jays with either the Fort Dodge West Nile-Innovator DNA vaccine or the pCBWN vaccine may increase the numbers of birds that would survive an epizootic should WNV become established on Santa Cruz Island. C1 [Vickers, Winston; Boyce, Walter M.] Univ Calif Davis, Wildlife Hlth Ctr, Sch Vet Med, Davis, CA 95616 USA. [Wheeler, Sarah S.; Langevin, Stanley; Carroll, Brian D.; Reisen, William K.] Univ Calif Davis, Ctr Vectorborne Dis, Sch Vet Med, Davis, CA 95616 USA. [Woods, Leslie] Univ Calif Davis, Calif Anim Hlth & Food Safety Lab, Davis, CA 95616 USA. [Morrison, Scott A.] Nature Conservancy, San Francisco, CA USA. [Chang, Gwong-Jen J.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Dept Hlth & Human Serv, Publ Hlth Serv, Ft Collins, CO USA. RP Boyce, WM (reprint author), Univ Calif Davis, Wildlife Hlth Ctr, Sch Vet Med, Old Davis Rd, Davis, CA 95616 USA. EM wmboyce@ucdavis.edu FU National Institutes of Allergy and Infectious Diseases, NIH [RO1-AI55607]; Nature Conservancy FX We would like to thank Karen Sverlow, Jim Koobs, and Mike Manzer, California Animal Health and Food Safety Laboratory, for assistance with histology and IHC. Funding for this research was provided, in part, by Grant RO1-AI55607 from the National Institutes of Allergy and Infectious Diseases, NIH, and The Nature Conservancy. NR 38 TC 10 Z9 11 U1 2 U2 18 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD AUG PY 2011 VL 11 IS 8 BP 1069 EP 1080 DI 10.1089/vbz.2010.0173 PG 12 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 804BT UT WOS:000293629600012 PM 21438693 ER PT J AU Edwards, KT Varela-Stokes, AS Paddock, CD Goddard, J AF Edwards, Kristine T. Varela-Stokes, Andrea S. Paddock, Christopher D. Goddard, Jerome TI Gotch Ear in a Goat: A Case Report SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE PCR; Rickettsia; Ticks; Zoonosis ID GULF-COAST TICKS; AMBLYOMMA-MACULATUM; RICKETTSIA-PARKERI; SPOTTED-FEVER; UNITED-STATES; CATTLE AB A 1-year-old castrated male Saanen goat was observed to have drooping and edema of the left ear consistent with published accounts of gotch ear in cattle associated with a tick bite. The goat's left ear was edematous from the tip of the pinna to the base of the ear. No signs of trauma or infectious processes were observed. Three engorged Gulf Coast ticks (Amblyomma maculatum) were observed attached inside the ear. Ticks were removed and the ear biopsied at tick attachment sites. The affected ear was treated topically with betadine after removal of the ticks. No other treatment was administered. The goat remained free of clinical signs and the edema of the ear resolved within 3 days after tick removal. No clinical adverse effects of the condition were evident. All three ticks were positive for spotted fever group rickettsia by polymerase chain reaction analysis and showed 100% similarity with the homologous sequence of Rickettsia parkeri. There was no immunohistochemical evidence of spotted fever group rickettsia in the ear samples, supporting the hypothesis that gotch ear is not due to rickettsial infection. This report represents the first apparent case of gotch ear in a goat. C1 [Edwards, Kristine T.; Goddard, Jerome] Mississippi State Univ, Dept Entomol & Plant Pathol, Mississippi State, MS 39762 USA. [Varela-Stokes, Andrea S.] Mississippi State Univ, Dept Basic Sci, Coll Vet Med, Mississippi State, MS 39762 USA. [Paddock, Christopher D.] Ctr Dis Control & Prevent, Pathol Branch, Atlanta, GA USA. RP Edwards, KT (reprint author), Mississippi State Univ, Dept Entomol & Plant Pathol, Mississippi State, MS 39762 USA. EM kt20@msstate.edu NR 10 TC 0 Z9 0 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD AUG PY 2011 VL 11 IS 8 BP 1217 EP 1219 DI 10.1089/vbz.2010.0204 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 804BT UT WOS:000293629600034 PM 21395411 ER PT J AU Ashley, K Wise, TJ Marlow, D Agrawal, A Cronin, JP Adams, L Ashley, E Lee, PA AF Ashley, Kevin Wise, Tamara J. Marlow, David Agrawal, Anoop Cronin, John P. Adams, Lori Ashley, Elizabeth Lee, Paul A. TI Trace beryllium determination in polyvinyl alcohol wipes by extraction and fluorescence detection: interlaboratory analysis SO ANALYTICAL METHODS LA English DT Article ID MASS SPECTROMETRY METHOD; AIR FILTER SAMPLES; AMMONIUM BIFLUORIDE; WORKPLACE AIR; PERFORMANCE; METALS AB In the occupational hygiene field, polyvinyl alcohol (PVA)-based wipe materials are used extensively for beryllium (Be) sample collection and analysis. Hence there is a need for validated methods to determine trace Be in such sampling media. In this work an interlaboratory study was carried out to evaluate the performance of an extraction and fluorescence method for determining trace Be in PVA wipes containing refractory beryllium oxide (BeO). The method entails heated extraction with dilute ammonium bifluoride (NH(4)HF(2)), followed by fluorescence measurement of extracted Be in extract aliquots after reaction with the high quantum-yield fluorophore, hydroxybenzoquinoline sulfonate (HBQS). Certified BeO-spiked PVA wipe materials were prepared at six different levels ranging from 0.030 to 5.6 mu g Be per wipe. Dry wipe materials and wipes wetted with 0.5 mL of deionized water were spiked as above. Duplicates of these materials, plus media blanks, were distributed to eight participating laboratories; spiking levels were unknown to the volunteers. Each participant was requested to carry out extraction and fluorescence measurement in accordance with an ASTM International standard test method, ASTM D7202, and to report their results in units of mu g Be per wipe sample. Interlaboratory precision, as estimated by percent relative standard deviations (RSDs), ranged between 4.5% and 16%. Estimated percent Be recoveries were 90-99% for dry wipes and between 87 and 93% for wetted wipe materials after volume correction for water content. C1 [Ashley, Kevin; Wise, Tamara J.; Marlow, David] NIOSH, US Dept HHS, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Agrawal, Anoop; Cronin, John P.; Adams, Lori; Ashley, Elizabeth] Berylliant Inc, Tucson, AZ 85712 USA. [Ashley, Elizabeth] Univ Cincinnati, Dept Chem Engn, Cincinnati, OH 45221 USA. [Lee, Paul A.] Univ Arizona, Dept Chem, Tucson, AZ 85721 USA. RP Ashley, K (reprint author), NIOSH, US Dept HHS, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,MS R-7, Cincinnati, OH 45226 USA. EM KAshley@cdc.gov FU ASTM International FX Sincere gratitude is extended to Brandy Duran (Los Alamos National Laboratory, NM, USA), Davy Rousset (Institut National de Recherche et de Securite, France), Rohit Shah (Lawrence Livermore National Laboratory, CA, USA), Tom Yoshida (Los Alamos National Laboratory, NM, USA) and Linda Youmans-McDonald (Savannah River Nuclear Solutions, SC, USA) for their participation in the interlaboratory study. Mike Goldcamp, Bob Streicher and Kenn White kindly reviewed the draft manuscript. Partial funding support for the interlaboratory study was provided by ASTM International. NR 22 TC 5 Z9 5 U1 0 U2 9 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1759-9660 J9 ANAL METHODS-UK JI Anal. Methods PD AUG PY 2011 VL 3 IS 8 BP 1906 EP 1909 DI 10.1039/c1ay05115f PG 4 WC Chemistry, Analytical; Food Science & Technology; Spectroscopy SC Chemistry; Food Science & Technology; Spectroscopy GA 802MG UT WOS:000293515000029 ER PT J AU Siddaramappa, S Challacombe, JF Petersen, JM Pillai, S Hogg, G Kuske, CR AF Siddaramappa, Shivakumara Challacombe, Jean F. Petersen, Jeannine M. Pillai, Segaran Hogg, Geoff Kuske, Cheryl R. TI Common Ancestry and Novel Genetic Traits of Francisella novicida-Like Isolates from North America and Australia as Revealed by Comparative Genomic Analyses SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID TULARENSIS SUBSPECIES TULARENSIS; LIPOPOLYSACCHARIDE O-ANTIGEN; FORMERLY YERSINIA-PHILOMIRAGIA; ESCHERICHIA-COLI; THIAMIN BIOSYNTHESIS; INOSITOL MONOPHOSPHATASE; SALMONELLA-TYPHIMURIUM; NUCLEOTIDE-SEQUENCE; BETA-GALACTOSIDASE; PLASMID PEA29 AB Francisella novicida is a close relative of Francisella tularensis, the causative agent of tularemia. The genomes of F. novicida-like clinical isolates 3523 (Australian strain) and Fx1 (Texas strain) were sequenced and compared to F. novicida strain U112 and F. tularensis strain Schu S4. The strain 3523 chromosome is 1,945,310 bp and contains 1,854 protein-coding genes. The strain Fx1 chromosome is 1,913,619 bp and contains 1,819 protein-coding genes. NUCmer analyses revealed that the genomes of strains Fx1 and U112 are mostly colinear, whereas the genome of strain 3523 has gaps, translocations, and/or inversions compared to genomes of strains Fx1 and U112. Using the genome sequence data and comparative analyses with other members of the genus Francisella, several strain-specific genes that encode putative proteins involved in RTX toxin production, polysaccharide biosynthesis/modification, thiamine biosynthesis, glucuronate utilization, and polyamine biosynthesis were identified. The RTX toxin synthesis and secretion operon of strain 3523 contains four open reading frames (ORFs) and was named rtxCABD. Based on the alignment of conserved sequences upstream of operons involved in thiamine biosynthesis from various bacteria, a putative THI box was identified in strain 3523. The glucuronate catabolism loci of strains 3523 and Fx1 contain a cluster of nine ORFs oriented in the same direction that appear to constitute an operon. Strains U112 and Schu S4 appeared to have lost the loci for RTX toxin production, thiamine biosynthesis, and glucuronate utilization as a consequence of host adaptation and reductive evolution. In conclusion, comparative analyses provided insights into the common ancestry and novel genetic traits of these strains. C1 [Siddaramappa, Shivakumara; Challacombe, Jean F.; Kuske, Cheryl R.] Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA. [Petersen, Jeannine M.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO 80521 USA. [Pillai, Segaran] Dept Homeland Secur, Chem & Biol Div, Sci & Technol Directorate, Washington, DC USA. [Hogg, Geoff] Univ Melbourne, Microbiol Diagnost Unit, Publ Hlth Lab, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia. RP Kuske, CR (reprint author), Los Alamos Natl Lab, Biosci Div, Mail Stop M888, Los Alamos, NM 87545 USA. EM kuske@lanl.gov FU United States Department of Homeland Security (Chemical and Biological Division, Science and Technology Directorate) [HSHQDC-08-X-00790]; Centers for Disease Control and Prevention FX This study was funded by the United States Department of Homeland Security (Chemical and Biological Division, Science and Technology Directorate) through an interagency agreement (grant number HSHQDC-08-X-00790) and by the Centers for Disease Control and Prevention. NR 99 TC 17 Z9 19 U1 1 U2 12 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD AUG PY 2011 VL 77 IS 15 BP 5110 EP 5122 DI 10.1128/AEM.00337-11 PG 13 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA 798PW UT WOS:000293224500006 PM 21666011 ER PT J AU Ford, ES AF Ford, Earl S. TI Uric acid and mortality from all-causes and cardiovascular disease among adults with and without diagnosed diabetes: Findings from the National Health and Nutrition Examination Survey III Linked Mortality Study SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE Cohort studies; Diabetes; Mortality; Uric acid ID CORONARY-HEART-DISEASE; PRECIS DATABASE; GLUCOSE CONTROL; METAANALYSIS; HYPERURICEMIA; MELLITUS; RISK AB Using data from the National Health and Nutrition Examination Survey III Linked Mortality Study, uric acid concentration was significantly related to mortality from all-causes ( 978 diabetic participants: hazard ratio per mg/dl, 1.14; 95% confidence interval, 1.01-1.28; 12,824 nondiabetic participants: hazard ratio, 1.06; 95% confidence interval, 1.02-1.11) but not major CVD. (C) 2011 Published by Elsevier Ireland Ltd. C1 Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS K67, Atlanta, GA 30341 USA. EM eford@cdc.gov NR 14 TC 11 Z9 11 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD AUG PY 2011 VL 93 IS 2 BP E84 EP E86 DI 10.1016/j.diabres.2011.05.012 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 806QQ UT WOS:000293825400009 PM 21636162 ER PT J AU Amarasinghe, A Kuritsky, JN Letson, GW Margolis, HS AF Amarasinghe, Ananda Kuritsky, Joel N. Letson, G. William Margolis, Harold S. TI Dengue Virus Infection in Africa SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material ID HEMORRHAGIC-FEVER; AEDES-ALBOPICTUS; RETURNED TRAVELERS; GEOGRAPHIC STRAINS; FEBRILE PATIENTS; SUSCEPTIBILITY; SEROPREVALENCE; TRANSMISSION; EPIDEMIC; OUTBREAK C1 [Amarasinghe, Ananda] Seoul Natl Univ, Pediat Dengue Vaccine Initiat, Int Vaccine Inst, Seoul 151919, South Korea. [Margolis, Harold S.] Ctr Dis Control & Prevent, San Juan, PR USA. RP Amarasinghe, A (reprint author), Seoul Natl Univ, Pediat Dengue Vaccine Initiat, Int Vaccine Inst, Res Pk,San 4-8,Bongcheon 7 Dong, Seoul 151919, South Korea. EM ana_amarasinghe@yahoo.co.uk NR 40 TC 88 Z9 89 U1 1 U2 12 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2011 VL 17 IS 8 BP 1349 EP 1354 DI 10.3201/eid1708.101515 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 804TF UT WOS:000293676200002 PM 21801609 ER PT J AU Hall, AJ Rosenthal, M Gregoricus, N Greene, SA Ferguson, J Henao, OL Vinje, J Lopman, BA Parashar, UD Widdowson, MA AF Hall, Aron J. Rosenthal, Mariana Gregoricus, Nicole Greene, Sharon A. Ferguson, Jeana Henao, Olga L. Vinje, Jan Lopman, Ben A. Parashar, Umesh D. Widdowson, Marc-Alain TI Incidence of Acute Gastroenteritis and Role of Norovirus, Georgia, USA, 2004-2005 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID INFECTIOUS INTESTINAL DISEASE; NORWALK-LIKE VIRUSES; UNITED-STATES; FOODBORNE ILLNESS; HUMAN ADENOVIRUSES; GENERAL-PRACTICE; MULTIPLEX PCR; ENGLAND; IDENTIFICATION; NETHERLANDS AB Approximately 179 million cases of acute gastroenteritis (AGE) occur annually in the United States. However, lack of routine clinical testing for viruses limits understanding of their role among persons seeking medical care. Fecal specimens submitted for routine bacterial culture through a health maintenance organization in Georgia, USA, were tested with molecular diagnostic assays for norovirus, rotavirus, astrovirus, sapovirus, and adenovirus. Incidence was estimated by using national health care utilization rates. Routine clinical diagnostics identified a pathogen in 42 (7.3%) of 572 specimens; inclusion of molecular viral testing increased pathogen detection to 15.7%. Community AGE incidence was 41,000 cases/100,000 person-years and outpatient incidence was 5,400/100,000 person-years. Norovirus was the most common pathogen, accounting for 6,500 (16%) and 640 (12%) per 100,000 person-years of community and outpatient AGE episodes, respectively. This study demonstrates that noroviruses are leading causes of AGE among persons seeking medical care. C1 [Hall, Aron J.; Rosenthal, Mariana; Gregoricus, Nicole; Greene, Sharon A.; Henao, Olga L.; Vinje, Jan; Lopman, Ben A.; Parashar, Umesh D.; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Rosenthal, Mariana] Univ Michigan, Ann Arbor, MI 48109 USA. [Ferguson, Jeana] Kaiser Permanente, Atlanta, GA USA. RP Hall, AJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A34, Atlanta, GA 30333 USA. EM ajhall@cdc.gov OI Widdowson, Marc-Alain/0000-0002-0682-6933; Vinje, Jan/0000-0002-1530-3675 FU Atlanta Research and Education Foundation; Southeastern Branch of the American Society for Microbiology FX This study was supported in part by the Atlanta Research and Education Foundation and by a Henry Aldrich Student Research Grant of the Southeastern Branch of the American Society for Microbiology. NR 30 TC 63 Z9 68 U1 0 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2011 VL 17 IS 8 BP 1381 EP 1388 DI 10.3201/eid1708.101533 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 804TF UT WOS:000293676200006 PM 21801613 ER PT J AU Vega, E Barclay, L Gregoricus, N Williams, K Lee, D Vinje, J AF Vega, Everardo Barclay, Leslie Gregoricus, Nicole Williams, Kara Lee, David Vinje, Jan TI Novel Surveillance Network for Norovirus Gastroenteritis Outbreaks, United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID NORWALK-LIKE VIRUSES; REVERSE TRANSCRIPTION-PCR; GENOGROUP-II NOROVIRUSES; MOLECULAR EPIDEMIOLOGY; LIKELIHOOD; ACCURATE; ILLNESS; EUROPE; TRENDS; REGION AB CaliciNet, the outbreak surveillance network for noroviruses in the United States, was launched in March 2009. As of January 2011, twenty state and local health laboratories had been certified to submit norovirus sequences and epidemiologic outbreak data to CaliciNet. During the network's first year, 552 outbreaks were submitted to CaliciNet, of which 78 (14%) were associated with foodborne transmission. A total of 395 (72%) outbreaks were typed as GII.4, of which 298 (75%) belonged to a new variant, GII.4 New Orleans, which first emerged in October 2009. Analysis of the complete capsid and P2 region sequences confirmed that GII.4 New Orleans is distinct from previous GII.4 variants, including GII.4 Minerva (2006b). C1 [Vega, Everardo; Barclay, Leslie; Gregoricus, Nicole; Vinje, Jan] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Williams, Kara; Lee, David] Atlanta Res & Educ Fdn, Decatur, GA USA. RP Vinje, J (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G04, Atlanta, GA 30333 USA. EM jvinje@cdc.gov OI Vinje, Jan/0000-0002-1530-3675 FU CDC Foundation FX This research was partly funded by a grant from the CDC Foundation. NR 39 TC 127 Z9 139 U1 1 U2 20 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2011 VL 17 IS 8 BP 1389 EP 1395 DI 10.3201/eid1708.101837 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 804TF UT WOS:000293676200007 PM 21801614 ER PT J AU Carr, MJ Kajon, AE Lu, XY Dunford, L O'Reilly, P Holder, P De Gascun, CF Coughlan, S Connell, J Erdman, DD Hall, WW AF Carr, Michael J. Kajon, Adriana E. Lu, Xiaoyan Dunford, Linda O'Reilly, Paul Holder, Paul De Gascun, Cillian F. Coughlan, Suzie Connell, Jeff Erdman, Dean D. Hall, William W. TI Deaths associated with Human Adenovirus-14p1 Infections, Europe, 2009-2010 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID RESPIRATORY ILLNESS; MILITARY RECRUITS; SEROTYPE 14; OUTBREAK; PNEUMONIA; DISEASE; TYPE-7; ALASKA; ADULTS; CAMP C1 [Carr, Michael J.; Dunford, Linda; O'Reilly, Paul; Holder, Paul; De Gascun, Cillian F.; Coughlan, Suzie; Connell, Jeff; Hall, William W.] Univ Coll Dublin, Natl Virus Reference Lab, Dublin 4, Ireland. [Kajon, Adriana E.] Lovelace Resp Res Inst, Albuquerque, NM USA. [Lu, Xiaoyan; Erdman, Dean D.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Carr, MJ (reprint author), Univ Coll Dublin, Natl Virus Reference Lab, Dublin 4, Ireland. EM michael.carr@ucd.ie RI Valle, Ruben/A-7512-2013 FU Global Emerging Infections Surveillance and Response System, a Division of the US Armed Forces Health Surveillance Center, through the Henry M. Jackson Foundation for the Advancement of Military Medicine FX The work of A.E.K. was funded in part by the Global Emerging Infections Surveillance and Response System, a Division of the US Armed Forces Health Surveillance Center, through the Henry M. Jackson Foundation for the Advancement of Military Medicine. NR 29 TC 27 Z9 30 U1 1 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2011 VL 17 IS 8 BP 1402 EP 1408 DI 10.3201/1708.101760 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 804TF UT WOS:000293676200009 PM 21801616 ER PT J AU Milazzo, ML Campbell, GL Fulhorst, CF AF Milazzo, Mary Louise Campbell, Grant L. Fulhorst, Charles F. TI Novel Arenavirus Infection in Humans, United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID VIRUSES FAMILY-ARENAVIRIDAE; TAMIAMI VIRUS; WOODRAT; ANTIBODIES; DIVERSITY; EXPOSURE; AMERICA; RODENTS; TEXAS AB lmmunoglobulin G against Whitewater Arroyo virus or lymphocytic choriomeningitis virus was found in 41(3.5%) of 1,185 persons in the United States who had acute central nervous system disease or undifferentiated febrile illnesses. The results of analyses of antibody titers in paired serum samples suggest that a North American Tacaribe serocomplex virus was the causative agent of the illnesses in 2 persons and that lymphocytic choriomeningitis virus was the causative agent of the illnesses in 3 other antibody-positive persons in this study. The results of this study suggest that Tacaribe serocomplex viruses native to North America, as well as lymphocytic choriomeningitis virus, are causative agents of human disease in the United States. C1 [Milazzo, Mary Louise; Fulhorst, Charles F.] Univ Texas Med Branch, Galveston, TX 77555 USA. [Campbell, Grant L.] Ctr Dis Control & Prevent, Ft Collins, CO USA. RP Fulhorst, CF (reprint author), Univ Texas Med Branch, 301 Univ Blvd, Galveston, TX 77555 USA. EM cfulhors@utmb.edu FU National Institutes of Health [AI-41435] FX Financial support for the work done by M.L.M. and C.F.F. was provided by National Institutes of Health grant AI-41435, "Ecology of emerging arenaviruses in the southwestern United States." NR 18 TC 12 Z9 12 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2011 VL 17 IS 8 BP 1417 EP 1420 DI 10.3201/eid1708.110285 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 804TF UT WOS:000293676200011 PM 21801618 ER PT J AU Lees, CH Avery, C Asherin, R Rainbow, J Danila, R Smelser, C Schmitz, A Ladd-Wilson, S Nolte, KB Nagle, K Lynfield, R AF Lees, Christine H. Avery, Catherine Asherin, Ryan Rainbow, Jean Danila, Richard Smelser, Chad Schmitz, Ann Ladd-Wilson, Stephen Nolte, Kurt B. Nagle, Kayla Lynfield, Ruth TI Pandemic (H1N1) 2009-associated Deaths Detected by Unexplained Death and Medical Examiner Surveillance SO EMERGING INFECTIOUS DISEASES LA English DT Article ID INFLUENZA-A H1N1; CRITICAL ILLNESSES; UNITED-STATES; BIOTERRORISM AB During the pandemic (H1N1) 2009 outbreak, Minnesota, New Mexico, and Oregon used several surveillance methods to detect associated deaths. Surveillance using unexplained death and medical examiner data allowed for detection of 34 (18%) pandemic (H1N1) 2009-associated deaths that were not detected by hospital-based surveillance. C1 [Lees, Christine H.; Rainbow, Jean; Danila, Richard; Nagle, Kayla; Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN 55164 USA. [Avery, Catherine; Smelser, Chad] New Mexico Dept Hlth, Santa Fe, NM USA. [Asherin, Ryan; Ladd-Wilson, Stephen] Oregon Publ Hlth Dept, Portland, OR USA. [Schmitz, Ann] Ctr Dis Control & Prevent, Atlanta, GA USA. [Nolte, Kurt B.] Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA. RP Lees, CH (reprint author), Minnesota Dept Hlth, 625 Robert St N, St Paul, MN 55164 USA. EM christine.lees@state.mn.us FU Department of Health and Human Services; CDC EIP; Public Health Emergency Preparedness (PHEP) [Minnesota EIP 3U01CI000313, PHEP 5U90TP516981, Oregon EIP 5U01CI000306, PHEP 5U90TP017007-10]; New Mexico PHEP [3U90TP616999] FX Financial support for this study was obtained from the Department of Health and Human Services, CDC EIP and Public Health Emergency Preparedness (PHEP): Minnesota EIP 3U01CI000313, PHEP 5U90TP516981, Oregon EIP 5U01CI000306, PHEP 5U90TP017007-10, and New Mexico PHEP 3U90TP616999. NR 12 TC 7 Z9 7 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2011 VL 17 IS 8 BP 1479 EP 1483 DI 10.3201/eid1708.101914 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 804TF UT WOS:000293676200021 PM 21801628 ER PT J AU Sang, R Lutomiah, J Koka, H Makio, A Chepkorir, E Ochieng, C Yalwala, S Mutisya, J Musila, L Richardson, JH Miller, BR Schnabel, D AF Sang, Rosemary Lutomiah, Joel Koka, Hellen Makio, Albina Chepkorir, Edith Ochieng, Caroline Yalwala, Santos Mutisya, James Musila, Lilian Richardson, Jason H. Miller, Barry R. Schnabel, David TI Crimean-Congo Hemorrhagic Fever Virus in Hyalommid Ticks, Northeastern Kenya SO EMERGING INFECTIOUS DISEASES LA English DT Article ID POLYMERASE CHAIN-REACTION; LIVESTOCK C1 [Sang, Rosemary] Kenya Govt Med Res Ctr, Ctr Virus Res, Nairobi 00200, Kenya. [Koka, Hellen; Makio, Albina; Ochieng, Caroline; Yalwala, Santos; Mutisya, James; Musila, Lilian; Richardson, Jason H.; Schnabel, David] USA, Med Res Unit Nairobi, Nairobi, Kenya. [Miller, Barry R.] Ctr Dis Control & Prevent, Ft Collins, CO USA. RP Sang, R (reprint author), Kenya Govt Med Res Ctr, Ctr Virus Res, POB 54626, Nairobi 00200, Kenya. EM rsang@wrp-nbo.org RI Richardson, Jason/A-9441-2011; Valle, Ruben/A-7512-2013 FU Centers for Disease Control and Prevention; Armed Forces Health and Surveillance Center, Kenya FX This work received financial support from the Global Disease Detection Program (Centers for Disease Control and Prevention) and the Armed Forces Health and Surveillance Center-Walter Reed Project, Kenya. NR 12 TC 8 Z9 9 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2011 VL 17 IS 8 BP 1502 EP 1505 DI 10.3201/eid1708.102064 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 804TF UT WOS:000293676200027 PM 21801635 ER PT J AU Vega, E Vinje, J AF Vega, Everardo Vinje, Jan TI Novel GII.12 Norovirus Strain, United States, 2009-2010 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID ACUTE GASTROENTERITIS C1 [Vega, Everardo; Vinje, Jan] Ctr Dis Control & Prevent, Natl Calicivirus Lab, Atlanta, GA 30333 USA. RP Vega, E (reprint author), Ctr Dis Control & Prevent, Natl Calicivirus Lab, 1600 Clifton Rd NE,Mailstop G04, Atlanta, GA 30333 USA. EM evega@cdc.gov OI Vinje, Jan/0000-0002-1530-3675 NR 12 TC 40 Z9 42 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2011 VL 17 IS 8 BP 1516 EP 1518 DI 10.3201/eid1708.110025 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 804TF UT WOS:000293676200031 PM 21801639 ER PT J AU Potter, P AF Potter, Polyxeni TI We are such stuff/as dreams are made of SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM PMP1@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2011 VL 17 IS 8 BP 1575 EP 1576 DI 10.3201/eid1708.AC1708 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 804TF UT WOS:000293676200054 ER PT J AU White, SS Stanko, JP Kato, K Calafat, AM Hines, EP Fenton, SE AF White, Sally S. Stanko, Jason P. Kato, Kayoko Calafat, Antonia M. Hines, Erin P. Fenton, Suzanne E. TI Gestational and Chronic Low-Dose PFOA Exposures and Mammary Gland Growth and Differentiation in Three Generations of CD-1 Mice SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE delayed development; fetal origins of adult disease; lactation; mammary gland; multigenerational; perfluorooctanoic acid (PFOA) ID PERFLUOROOCTANOIC ACID; DEVELOPMENTAL TOXICITY; CROSS-FOSTER; MOUSE; PREGNANCY; C57BL/6; SERUM AB BACKGROUND: Prenatal exposure to perfluorooctanoic acid (PFOA), a ubiquitous industrial surfactant, has been reported to delay mammary gland development in female mouse offspring (F(1)) and the treated lactating dam (P(0)) after gestational treatments at 3 and 5 mg PFOA/kg/day. OBJECTIVE: We investigated the consequences of gestational and chronic PFOA exposure on F(1) lactational function and subsequent development of F(2) offspring. METHODS: We treated P(0) dams with 0, 1, or 5 mg PFOA/kg/day on gestation days 1-17. In addition, a second group of P(0) dams treated with 0 or 1 mg/kg/day during gestation and their F(1) and F(2) offspring received continuous PFOA exposure (5 ppb) in drinking water. Resulting adult F(1) females were bred to generate F(2) offspring, whose development was monitored over post natal days (PNDs) 1-63. F(1) gland function was assessed on PND10 by timed-lactation experiments. Mammary tissue was isolated from P(0), F(1), and F(2) females throughout the study and histologically assessed for age-appropriate development. RESULTS: PFOA-exposed F(1) dams exhibited diminished lactational morphology, although F(1) maternal behavior and F(2) offspring body weights were not significantly affected by P(0) treatment. In addition to reduced gland development in F(1) females under all exposures, F(2) females with chronic low-dose drinking-water exposures exhibited visibly slowed mammary gland differentiation from weaning onward. F(2) females derived from 5 mg/kg PFOA-treated P(0) dams displayed gland morphology similar to F(2) chronic water exposure groups on PNDs 22-63. CONCLUSIONS: Gestational PFOA exposure induced delays in mammary gland development and/or lactational differentiation across three generations. Chronic, low-dose PFOA exposure in drinking water was also sufficient to alter mammary morphological development in mice, at concentrations approximating those found in contaminated human water supplies. C1 [White, Sally S.; Stanko, Jason P.; Fenton, Suzanne E.] NIEHS, Natl Toxicol Program, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA. [Kato, Kayoko; Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Hines, Erin P.] US EPA, Natl Ctr Environm Assessment, Off Res & Dev, Res Triangle Pk, NC 27711 USA. RP Fenton, SE (reprint author), POB 12233,Mail Drop E1-08, Res Triangle Pk, NC 27709 USA. EM fentonse@niehs.nih.gov OI Hines, Erin Pias/0000-0002-2458-6267 FU U.S. EPA; National Health and Environmental Effects Research Laboratory-University of North Carolina with the University of North Carolina-Chapel Hill [T829472, CR833237]; NTP [HHSN27300239] FX S.S.W. was supported by U.S. EPA, National Health and Environmental Effects Research Laboratory-University of North Carolina Toxicology Curriculum Cooperative Training Agreements (T829472 and CR833237) with the University of North Carolina-Chapel Hill, and NTP contract HHSN27300239. NR 19 TC 33 Z9 33 U1 2 U2 12 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD AUG PY 2011 VL 119 IS 8 BP 1070 EP 1076 DI 10.1289/ehp.1002741 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 801MU UT WOS:000293444300022 PM 21501981 ER PT J AU Pollack, AZ Schisterman, EF Goldman, LR Mumford, SL Albert, PS Jones, RL Wactawski-Wende, J AF Pollack, Anna Z. Schisterman, Enrique F. Goldman, Lynn R. Mumford, Sunni L. Albert, Paul S. Jones, Robert L. Wactawski-Wende, Jean TI Cadmium, Lead, and Mercury in Relation to Reproductive Hormones and Anovulation in Premenopausal Women SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE anovulation; cadmium; lead; menstrual cycle; mercury; reproductive hormones ID MARGINAL STRUCTURAL MODELS; HEAVY-METALS; MENSTRUAL CYCLES; NATIONAL-HEALTH; BREAST-CANCER; IN-VITRO; ASSOCIATION; EXPOSURE; ESTROGENICITY; EPIDEMIOLOGY AB BACKGROUND: Metals can interfere with hormonal functioning by binding at the receptor site and through indirect mechanisms; thus, they may be associated with hormonal changes in premenopausal women. OBJECTIVES: We examined the associations between cadmium, lead, and mercury, and anovulation and patterns of reproductive hormones [estradiol, progesterone, follicle-stimulating hormone (FSH), luteinizing hormone] among 252 premenopausal women 18-44 years of age who were enrolled in the BioCycle Study in Buffalo, New York. METHODS: Women were followed for up to two menstrual cycles, with serum samples collected up to eight times per cycle. Metal concentrations were determined at baseline in whole blood by inductively coupled mass spectroscopy. Marginal structural models with stabilized inverse probability weights and nonlinear mixed models with harmonic terms were used to estimate the effects of cadmium, lead, and mercury on reproductive hormone levels during the menstrual cycle and anovulation. RESULTS: Geometric mean (interquartile range) cadmium, lead, and mercury levels were 0.29 (0.19-0.43) mu g/L, 0.93 (0.68-1.20) mu g/dL, and 1.03 (0.58-2.10) mu g/L, respectively. We observed decreases in mean FSH with increasing cadmium [second vs. first tertile: -10.0%; 95% confidence interval (CI), -17.3% to -2.5%; third vs. first tertile: -8.3%; 95% CI, -16.0% to 0.1%] and increases in mean progesterone with increasing lead level (second vs. first tertile: 7.5%; 95% CI, 0.1-15.4%; third vs. first tertile: 6.8%; 95% CI, -0.8% to 14.9%). Metals were not significantly associated with anovulation. CONCLUSIONS: Our findings support the hypothesis that environmentally relevant levels of metals are associated with modest changes in reproductive hormone levels in healthy, premenopausal women. C1 [Pollack, Anna Z.; Goldman, Lynn R.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Albert, Paul S.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Biostat & Bioinformat Branch, Rockville, MD USA. [Jones, Robert L.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Wactawski-Wende, Jean] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA. [Pollack, Anna Z.; Schisterman, Enrique F.; Mumford, Sunni L.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Rockville, MD USA. RP Schisterman, EF (reprint author), 6100 Execut Blvd 7B03, Rockville, MD 20852 USA. EM schistee@mail.nih.gov RI Pollack, Anna/F-2021-2011; Goldman, Lynn/D-5372-2012; OI Pollack, Anna/0000-0002-4313-3298; Schisterman, Enrique/0000-0003-3757-641X FU Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health; Long-Range Research Initiative of the American Chemistry Council FX This research was supported partially by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, and by the Long-Range Research Initiative of the American Chemistry Council. NR 53 TC 26 Z9 27 U1 0 U2 17 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD AUG PY 2011 VL 119 IS 8 BP 1156 EP 1161 DI 10.1289/ehp.1003284 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 801MU UT WOS:000293444300035 PM 21543284 ER PT J AU Lee, SJ Mehler, L Beckman, J Diebolt-Brown, B Prado, J Lackovic, M Waltz, J Mulay, P Schwartz, A Mitchell, Y Moraga-McHaley, S Gergely, R Calvert, GM AF Lee, Soo-Jeong Mehler, Louise Beckman, John Diebolt-Brown, Brienne Prado, Joanne Lackovic, Michelle Waltz, Justin Mulay, Prakash Schwartz, Abby Mitchell, Yvette Moraga-McHaley, Stephanie Gergely, Rita Calvert, Geoffrey M. TI Acute Pesticide Illnesses Associated with Off-Target Pesticide Drift from Agricultural Applications: 11 States, 1998-2006 SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE agriculture; drift; pesticides; poisoning; surveillance ID EXPOSURE AB BACKGROUND: Pesticides are widely used in agriculture, and off-target pesticide drift exposes workers and the public to harmful chemicals. OBJECTIVE: We estimated the incidence of acute illnesses from pesticide drift from outdoor agricultural applications and characterized drift exposure and illnesses. METHODS: Data were obtained from the National Institute for Occupational Safety and Health's Sentinel Event Notification System for Occupational Risks-Pesticides program and the California Department of Pesticide Regulation. Drift included off-target movement of pesticide spray, volatiles, and contaminated dust. Acute illness cases were characterized by demographics, pesticide and application variables, health effects, and contributing factors. RESULTS: From 1998 through 2006, we identified 2,945 cases associated with agricultural pesticide drift from 11 states. Our findings indicate that 47% were exposed at work, 92% experienced low-severity illness, and 14% were children (< 15 years). The annual incidence ranged from 1.39 to 5.32 per million persons over the 9-year period. The overall incidence (in million person-years) was 114.3 for agricultural workers, 0.79 for other workers, 1.56 for nonoccupational cases, and 42.2 for residents in five agriculture-intensive counties in California. Soil applications with fumigants were responsible for the largest percentage (45%) of cases. Aerial applications accounted for 24% of cases. Common factors contributing to drift cases included weather conditions, improper seal of the fumigation site, and applicator carelessness near nontarget areas. CONCLUSIONS: Agricultural workers and residents in agricultural regions had the highest rate of pesticide poisoning from drift exposure, and soil fumigations were a major hazard, causing large drift incidents. Our findings highlight areas where interventions to reduce off-target drift could be focused. C1 [Lee, Soo-Jeong; Calvert, Geoffrey M.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Mehler, Louise] Calif Environm Protect Agcy, Sacramento, CA USA. [Beckman, John] Inst Publ Hlth, Oakland, CA USA. [Diebolt-Brown, Brienne] Texas Dept State Hlth Serv, Austin, TX USA. [Prado, Joanne] Washington State Dept Hlth, Olympia, WA USA. [Lackovic, Michelle] Louisiana Dept Hlth & Hosp, New Orleans, LA USA. [Waltz, Justin] Oregon Hlth Author, Portland, OR USA. [Mulay, Prakash] Florida Dept Hlth, Tallahassee, FL USA. [Schwartz, Abby] Michigan Dept Community Hlth, Lansing, MI USA. [Mitchell, Yvette] New York State Dept Hlth, Troy, NY USA. [Moraga-McHaley, Stephanie] New Mexico Dept Hlth, Albuquerque, NM USA. [Gergely, Rita] Iowa Dept Publ Hlth, Des Moines, IA 50319 USA. RP Calvert, GM (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,R-17, Cincinnati, OH 45226 USA. EM jac6@cdc.gov FU National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA) FX Funding support was provided by the National Institute for Occupational Safety and Health (NIOSH), U.S. Environmental Protection Agency (EPA), and the state agencies that contributed data. NR 27 TC 18 Z9 19 U1 1 U2 18 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD AUG PY 2011 VL 119 IS 8 BP 1162 EP 1169 DI 10.1289/ehp.1002843 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 801MU UT WOS:000293444300036 PM 21642048 ER PT J AU Kuempel, ED Schulte, PA Sorahan, T Caldwell, J Straif, K Ward, E AF Kuempel, Eileen D. Schulte, Paul A. Sorahan, Thomas Caldwell, Jane Straif, Kurt Ward, Elizabeth TI Carbon Black: Kuempel et al. Respond SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Letter ID LUNG INFLAMMATION; RECOMMENDATIONS; EXPOSURE; EXHAUST; RATS; MICE C1 [Kuempel, Eileen D.; Schulte, Paul A.] NIOSH, Cincinnati, OH 45226 USA. [Sorahan, Thomas] Univ Birmingham, Inst Occupat & Environm Med, Birmingham, W Midlands, England. [Caldwell, Jane] US EPA, Res Triangle Pk, NC 27711 USA. [Straif, Kurt] Int Agcy Res Canc, F-69372 Lyon, France. [Ward, Elizabeth] Amer Canc Soc Inc, Atlanta, GA USA. RP Kuempel, ED (reprint author), NIOSH, Cincinnati, OH 45226 USA. EM ekuempel@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 3 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD AUG PY 2011 VL 119 IS 8 BP A333 EP A334 DI 10.1289/ehp.1103444R PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 801MU UT WOS:000293444300009 ER PT J AU Powers, AM AF Powers, Ann M. TI Genomic evolution and phenotypic distinctions of Chikungunya viruses causing the Indian Ocean outbreak SO EXPERIMENTAL BIOLOGY AND MEDICINE LA English DT Review DE Chikungunya virus; microevolution; emerging human pathogen ID AEDES-ALBOPICTUS; GLYCOPROTEIN MUTATIONS; REUNION ISLAND; SOUTH INDIA; INFECTION; EPIDEMIC; FEVER; REEMERGENCE; TRANSMISSION; PERSISTENCE AB In our current global community with the rapid movement of products and people across and between continents, the emergence of a human pathogen can have devastating consequences. One dramatic example of this has been the emergence of Chikungunya virus (CHIKV), which causes a severe, prolonged, and debilitating arthralgic disease. This virus emerged in a large outbreak on the east coast of Africa in 2004; over the subsequent seven years, CHIKV has spread across the Indian Ocean, the Indian subcontinent, Southeast Asia and even reached Europe, leaving more than two million people affected. Because CHIKV has a small genome, currently available tools to analyze complete viral genomes have provided scientists with unique opportunities to understand the epidemiology, pathogenesis and transmission of the virus. The most commonly used application of these cutting edge tools has been to track the movement of the virus over time and space. While this is an important concept for identifying areas that remain at risk for outbreaks, these postgenomic era tools can also be applied to the highly significant tasks of understanding how viral microevolutionary changes can affect both invertebrate transmission and vertebrate virulence. Significant alterations in the patterns of CHIKV movement have already been identified using microevolutionary studies. These approaches now need to be further expanded to aid in expanding vaccine, therapeutic and control options. This review will highlight some of the most significant recent research developments obtained using these cutting edge approaches for CHIKV. C1 Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO 80521 USA. RP Powers, AM (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM APowers@cdc.gov NR 44 TC 11 Z9 11 U1 1 U2 7 PU SOC EXPERIMENTAL BIOLOGY MEDICINE PI MAYWOOD PA 195 WEST SPRING VALLEY AVE, MAYWOOD, NJ 07607-1727 USA SN 1535-3702 J9 EXP BIOL MED JI Exp. Biol. Med. PD AUG PY 2011 VL 236 IS 8 BP 909 EP 914 DI 10.1258/ebm.2011.011078 PG 6 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 807EK UT WOS:000293877200003 PM 21750019 ER PT J AU El Sherif, M Esona, MD Wang, YH Gentsch, JR Jiang, BM Glass, RI Abou Baker, S Klena, JD AF El Sherif, May Esona, Mathew D. Wang, Yuhuan Gentsch, Jon R. Jiang, Baoming Glass, Roger I. Abou Baker, Shermine Klena, John D. TI Detection of the first G6P[14] human rotavirus strain from a child with diarrhea in Egypt SO INFECTION GENETICS AND EVOLUTION LA English DT Article DE Group A rotavirus; Phylogenetic analysis; Viral reassortment; Egypt ID GROUP-A ROTAVIRUS; POLYMERASE-CHAIN-REACTION; SEROTYPE G6; PHYLOGENETIC ANALYSIS; MOLECULAR EPIDEMIOLOGY; BOVINE ROTAVIRUSES; VP7; G8; IDENTIFICATION; INDIA AB We report the first detection of a G6P[14] rotavirus strain in Egypt from the stool of a child participating in a hospital-based diarrhea surveillance study conducted throughout the year 2004. Rotavirus infection was initially detected using a rotavirus group A VP6 enzyme immunoassay; the P (VP4) and G (VP7) genotypes of the strain were identified by RT-PCR. We sequenced the VP7 gene and the VP8* portion of the VP4 gene and the strain displayed the strongest identity to the VP7 [>94% nucleotides (nt), >97% amino acids (aa)] and VP4 (>93% nt. >98% aa) sequences of PA169, a novel G6P[14] strain first isolated from a child in Italy during the winter of 1987. Additional sequencing and analysis of the other remaining structural (VP1-VP3. VP6) and non-structural (NSP1-NSP5) proteins support this animal-to-human reassortment theory. According to the full genome classification system, the G6P[14] strain (EGY3399) was assigned to G6-P[14]-I2-R2-C2-M2-A11-N2-T6-E2-H3 genotypes. The greatest similarity of EGY3399 NSP4 and NSP5 gene sequences were to those of ovine and simian origin, respectively. Coupled with other observations, our results suggest G6P[14] isolates rarely cause severe diarrhea in Egyptian children, and support other studies that indicate animal rotavirus contribute to the genetic diversity of rotavirus detected from humans through interspecies transmission and single or multiple segments reassortment. Published by Elsevier B.V. C1 [El Sherif, May; Klena, John D.] USN, Med Res Unit 3, Cairo, Egypt. [Esona, Mathew D.; Wang, Yuhuan; Gentsch, Jon R.; Jiang, Baoming; Glass, Roger I.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Abou Baker, Shermine] Minist Hlth & Populat, Gen Directorate Communicable Dis Control, Cairo, Egypt. RP El Sherif, M (reprint author), NAMRU 3,PSC 452 Box 5000, FPO, AE 09835 USA. EM may.elsherif.eg@med.navy.mil RI Valle, Ruben/A-7512-2013 FU Association of Public Health Laboratories; Centers for Disease Control and Prevention (CCID/CDC); Armed Forces Health Surveillance Center/Div. of Global Emerging Infections System Operations [847705.82000.25GB.E0018 GEIS]; Program for Appropriate Technology in Health (PATH) [NCRADA-NAMRU-3-06-2365] FX This study was conducted during a fellowship sponsored by Association of Public Health Laboratories and the Centers for Disease Control and Prevention (CCID/CDC). We thank all our colleagues at the Viral Gastroenteritis Section, Gastroenteritis and Respiratory Viruses Laboratory Branch, Division of Viral Diseases, CCID/CDC for their assistance in making this work possible. We would like to acknowledge Dr. Adel Mansour and Dr. Ibrahim Adib for their supervision of the Abu Homos hospital-based diarrhea surveillance study. We also thank Dr. George Armah, Noguchi Medical Research Institute, Accra, Ghana for his thoughtful review and critique of the manuscript.; Armed Forces Health Surveillance Center/Div. of Global Emerging Infections System Operations (Work Unit no. 847705.82000.25GB.E0018 GEIS) and Program for Appropriate Technology in Health (PATH; Work Unit no. NCRADA-NAMRU-3-06-2365). NR 51 TC 23 Z9 23 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD AUG PY 2011 VL 11 IS 6 BP 1436 EP 1442 DI 10.1016/j.meegid.2011.05.012 PG 7 WC Infectious Diseases SC Infectious Diseases GA 806JV UT WOS:000293804600035 PM 21640199 ER PT J AU Bhasin, S Pencina, M Jasuja, GK Travison, TG Coviello, A Orwoll, E Wang, PY Nielson, C Wu, F Tajar, A Labrie, F Vesper, H Zhang, AQ Ulloor, J Singh, R D'Agostino, R Vasan, RS AF Bhasin, Shalender Pencina, Michael Jasuja, Guneet Kaur Travison, Thomas G. Coviello, Andrea Orwoll, Eric Wang, Patty Y. Nielson, Carrie Wu, Frederick Tajar, Abdelouahid Labrie, Fernand Vesper, Hubert Zhang, Anqi Ulloor, Jagadish Singh, Ravinder D'Agostino, Ralph Vasan, Ramachandran S. TI Reference Ranges for Testosterone in Men Generated Using Liquid Chromatography Tandem Mass Spectrometry in a Community-Based Sample of Healthy Nonobese Young Men in the Framingham Heart Study and Applied to Three Geographically Distinct Cohorts SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID HORMONE-BINDING GLOBULIN; SYMPTOMATIC ANDROGEN DEFICIENCY; ENDOGENOUS SEX-HORMONES; MIDDLE-AGED MEN; OLDER MEN; SERUM TESTOSTERONE; PHYSICAL PERFORMANCE; ADULT MEN; STANDARDIZATION PROGRAM; REFERENCE INTERVALS AB Context: Reference ranges are essential for partitioning testosterone levels into low or normal and making the diagnosis of androgen deficiency. We established reference ranges for total testosterone (TT) and free testosterone (FT) in a community-based sample of men. Methods: TT was measured using liquid chromatography tandem mass spectrometry in nonobese healthy men, 19-40 yr old, in the Framingham Heart Study Generation 3; FT was calculated. Values below the 2.5th percentile of reference sample were deemed low. We determined the association of low TT and FT with physical dysfunction, sexual symptoms [European Male Aging Study (EMAS) only], and diabetes mellitus in three cohorts: Framingham Heart Study generations 2 and 3, EMAS, and the Osteoporotic Fractures in Men Study. Results: In a reference sample of 456 men, mean (SD), median (quartile), and 2.5th percentile values were 723.8 (221.1), 698.7 (296.5), and 348.3 ng/dl for TT and 141. 8 (45.0), 134.0 (60.0), and 70.0 pg/ml for FT, respectively. In all three samples, men with low TT and FT were more likely to have slow walking speed, difficulty climbing stairs, or frailty and diabetes than those with normal levels. In EMAS, men with low TT and FT were more likely to report sexual symptoms than men with normal levels. Men with low TT and FT were more likely to have at least one of the following: sexual symptoms (EMAS only), physical dysfunction, or diabetes. Conclusion: Reference ranges generated in a community-based sample of men provide a rational basis for categorizing testosterone levels as low or normal. Men with low TT or FT by these criteria had higher prevalence of physical dysfunction, sexual dysfunction, and diabetes. These reference limits should be validated prospectively in relation to incident outcomes and in randomized trials. (J Clin Endocrinol Metab 96: 2430-2439, 2011) C1 [Bhasin, Shalender; Travison, Thomas G.; Coviello, Andrea; Zhang, Anqi; Ulloor, Jagadish] Boston Univ, Sch Med, Sect Endocrinol Diabet & Nutr, Boston, MA 02118 USA. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Sect Preventat Med & Cardiol, Boston, MA 02118 USA. [Pencina, Michael; Travison, Thomas G.; D'Agostino, Ralph] Boston Univ, Dept Biostat, Boston, MA 02118 USA. [Pencina, Michael; Jasuja, Guneet Kaur] Boston Univ, Dept Math, Stat & Consulting Unit, Boston, MA 02215 USA. [Pencina, Michael; Jasuja, Guneet Kaur; Vasan, Ramachandran S.] NHLBI, Framingham Heart Study, Framingham, MA 01701 USA. [Orwoll, Eric; Wang, Patty Y.; Nielson, Carrie] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. [Wu, Frederick] Univ Manchester, Manchester Royal Infirm, Manchester Acad Hlth Sci Ctr, Androl Res Unit,Dev & Regenerat Biomed Res Grp, Manchester M13 9WL, Lancs, England. [Tajar, Abdelouahid] Univ Manchester, Manchester Royal Infirm, Manchester Acad Hlth Sci Ctr, Arthrit Res UK,Epidemiol Unit, Manchester M13 9WL, Lancs, England. [Labrie, Fernand] Univ Laval, Quebec City, PQ G1K 7P4, Canada. [Vesper, Hubert] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Singh, Ravinder] Mayo Clin, Dept Pathol, Rochester, MN 55905 USA. RP Bhasin, S (reprint author), Boston Univ, Sch Med, Sect Endocrinol Diabet & Nutr, 650 Albany St, Boston, MA 02118 USA. EM bhasin@bu.edu OI Orwoll, Eric/0000-0002-8520-7355; Ramachandran, Vasan/0000-0001-7357-5970 FU National Institutes of Health (NIH) [1RO1AG31206]; National Institute on Aging (NIA) [5P30AG031679]; CDC Foundation; National Heart, Lung, and Blood Institute's Framingham Heart Study [N01-HC-25195]; Commission of the European Community [QLK6-CT-2001-00258]; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Center for Research Resources; NIH Roadmap for Medical Research [U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, UL1 RR024140] FX This work was supported by primarily by National Institutes of Health (NIH) Grant 1RO1AG31206 to S.B. and R.S.V. Additional support was provided by the Boston Claude D. Pepper Older Americans Independence Center Grant 5P30AG031679 from the National Institute on Aging (NIA) and by a grant from the CDC Foundation. The Framingham Heart Study is supported by the National Heart, Lung, and Blood Institute's Framingham Heart Study contract N01-HC-25195. The EMAS is funded by the Commission of the European Communities Fifth Framework Program "Quality of Life and Management of Living Resources" Grant QLK6-CT-2001-00258. The Osteoporotic Fractures in Men (MrOS) Study is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the NIA, the National Center for Research Resources, and NIH Roadmap for Medical Research under the following grant numbers: U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, and UL1 RR024140. NR 51 TC 123 Z9 126 U1 5 U2 16 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD AUG PY 2011 VL 96 IS 8 BP 2430 EP 2439 DI 10.1210/jc.2010-3012 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 802MT UT WOS:000293516400043 PM 21697255 ER PT J AU Decker, FH AF Decker, Frederic H. TI Profit Status of Home Health Care Agencies and the Risk of Hospitalization SO POPULATION HEALTH MANAGEMENT LA English DT Article AB We examined the association of profit status and patient hospitalizations in the present-day home health care market, a market that grew substantially in the past decade, with much of that growth attributed to the entry of for-profit agencies. Data from the 2007 National Home and Hospice Care Survey were linked to the risk-adjusted agency-level measure of the percent of home health episodes of care ending in hospitalizations available from the Centers for Medicare and Medicaid Services' (CMS) Home Health Compare Web site. A linear regression model was estimated (n = 510). Control variables included other agency characteristics besides profit status, area hospital bed supply, and state dummy variables to control for state fixed effects. For-profit agencies were more likely than not-for-profit agencies to have a risk of hospitalizations greater than expected after accounting for patient characteristics and model control variables. Attributes of the CMS hospitalization measure are discussed and implications for future research described. (Population Health Management 2011; 14: 199-204) C1 Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Decker, FH (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 3435, Hyattsville, MD 20782 USA. EM FDecker@cdc.gov NR 22 TC 2 Z9 2 U1 1 U2 6 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1942-7891 J9 POPUL HEALTH MANAG JI Popul. Health Manag. PD AUG PY 2011 VL 14 IS 4 BP 199 EP 204 DI 10.1089/pop.2010.0051 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 806QO UT WOS:000293825200007 PM 21506727 ER PT J AU Li, Y Crews, JE Elam-Evans, LD Fan, AZ Zhang, XZ Elliott, AF Balluz, L AF Li, Yan Crews, John E. Elam-Evans, Laurie D. Fan, Amy Z. Zhang, Xinzhi Elliott, Amanda F. Balluz, Lina TI Visual impairment and health-related quality of life among elderly adults with age-related eye diseases SO QUALITY OF LIFE RESEARCH LA English DT Article DE Age-related eye disease; Health-related quality of life; Visual impairment ID SURVEILLANCE SYSTEM BRFSS; BLUE MOUNTAINS EYE; MACULAR DEGENERATION; CATARACT-SURGERY; LENS OPACITIES; PUBLIC-HEALTH; OLDER-ADULTS; VISION; IMPACT; POPULATION AB To examine the association between age-related eye disease (ARED), visual impairment, and health-related quality of life (HRQOL). We used data from the 2006 and 2008 Behavioral Risk Factor Surveillance System to examine self-reported visual impairment and two HRQOL domains-physical impairment (including poor general health, physical unhealthy days, activity-limitation days, and disability) and mental distress (including mental unhealthy days, life dissatisfaction, major depression, lifetime depression, and anxiety) for people aged 65 years or older, by ARED status. People with any ARED were more likely than those without to report visual impairment as well as physical impairment and mental distress. The prevalence of visual impairment (P trend < 0.001) and physical impairment (P trend < 0.001) increased with increasing number of eye diseases after controlling for all covariates. There was no significant linear trend, however, in mental distress among people with one or more eye diseases. ARED was found to be associated with visual impairment and poorer HRQOL. Increasing numbers of AREDs were associated with increased levels of visual impairment and physical impairment, but were not associated with levels of mental distress. C1 [Li, Yan; Elam-Evans, Laurie D.; Fan, Amy Z.; Balluz, Lina] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Atlanta, GA 30341 USA. [Crews, John E.; Zhang, Xinzhi; Elliott, Amanda F.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30341 USA. RP Li, Y (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, 4770 Buford Hwy NE,Mailstop E-65, Atlanta, GA 30341 USA. EM Fga7@cdc.gov NR 46 TC 12 Z9 12 U1 1 U2 9 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 J9 QUAL LIFE RES JI Qual. Life Res. PD AUG PY 2011 VL 20 IS 6 BP 845 EP 852 DI 10.1007/s11136-010-9825-z PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 800WT UT WOS:000293399100006 PM 21191655 ER PT J AU Jia, HM Zack, MM Thompson, WW AF Jia, Haomiao Zack, Matthew M. Thompson, William W. TI State Quality-Adjusted Life Expectancy for US adults from 1993 to 2008 SO QUALITY OF LIFE RESEARCH LA English DT Article DE Health-Related Quality of Life (HRQOL); Life expectancy; Quality-Adjusted Life Expectancy (QALE); Mortality; Morbidity ID UNITED-STATES; OF-LIFE; HEALTH; POPULATION; OBESITY; BURDEN; SMOKING; INDEXES; DISEASE; TRENDS AB Quality-Adjusted Life Expectancy (QALE) is a summary measure of mortality and health-related quality of life (HRQOL) across different stages of life. This study developed a method to calculate state-level QALE for U.S. adults. Population HRQOL data came from the Behavioral Risk Factor Surveillance System (BRFSS). Using age-specific deaths from the Mortality Summary File, this study constructed life tables to estimate life expectancy and QALE for all 50 States and the District of Columbia by sex and race from 1993 through 2008. From 1993 to 2008, the QALE of an U.S. adult at 18 years old had increased from 51.2 to 52.3 years. In 2006, states with the highest QALE were Hawaii (56.2), Minnesota (55.2), North Dakota (54.9), Iowa (54.7), and Nebraska (54.4), while the states with the lowest QALE were West Virginia (47.1), Mississippi (48.2), Alabama (48.5), Kentucky (48.5), and Oklahoma (49.0). Because population HRQOL values and mortality statistics are available from existing and publicly accessible data and because formulas for the calculation of QALE and its standard error are easy to incorporate in a spreadsheet, State and local Health Departments can calculate QALE as a routine surveillance measurement for tracking their population's health over time. C1 [Jia, Haomiao] Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY 10032 USA. [Jia, Haomiao] Columbia Univ, Sch Nursing, New York, NY 10032 USA. [Zack, Matthew M.; Thompson, William W.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Jia, HM (reprint author), Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, 617 W 168th St, New York, NY 10032 USA. EM hj2198@columbia.edu FU CDC [200-2009-M-32247] FX This study (HJ) is supported by a CDC contract (No. 200-2009-M-32247). NR 26 TC 17 Z9 17 U1 0 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 EI 1573-2649 J9 QUAL LIFE RES JI Qual. Life Res. PD AUG PY 2011 VL 20 IS 6 BP 853 EP 863 DI 10.1007/s11136-010-9826-y PG 11 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 800WT UT WOS:000293399100007 PM 21210226 ER PT J AU Tomashek, KM Margolis, HS AF Tomashek, Kay M. Margolis, Harold S. TI Dengue: a potential transfusion-transmitted disease SO TRANSFUSION LA English DT Editorial Material ID ILL RETURNED TRAVELERS; HEMORRHAGIC-FEVER; PUERTO-RICO; BLOOD-TRANSFUSION; UNITED-STATES; VIRUS; TRANSMISSION; EPIDEMIOLOGY; THREAT; WEST C1 [Tomashek, Kay M.; Margolis, Harold S.] Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR 00920 USA. RP Tomashek, KM (reprint author), Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, 1324 Calle Canada, San Juan, PR 00920 USA. EM kct9@cdc.gov NR 54 TC 17 Z9 17 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0041-1132 J9 TRANSFUSION JI Transfusion PD AUG PY 2011 VL 51 IS 8 BP 1654 EP 1660 DI 10.1111/j.1537-2995.2011.03269.x PG 7 WC Hematology SC Hematology GA 805QF UT WOS:000293743400003 PM 21831182 ER PT J AU Redig, PT Tully, TN Ritchie, BW Roy, AF Baudena, MA Chang, GJJ AF Redig, Patrick T. Tully, Thomas N. Ritchie, Branson W. Roy, Alma F. Baudena, M. Alexandra Chang, Gwong-Jen J. TI Effect of West Nile virus DNA-plasmid vaccination on response to live virus challenge in red-tailed hawks (Buteo jamaicensis) SO AMERICAN JOURNAL OF VETERINARY RESEARCH LA English DT Article ID NEW-YORK; INFECTION; BIRDS; OUTBREAK; PROTECTS; EFFICACY; OWLS AB Objective-To evaluate the safety and efficacy of an experimental adjuvanted DNA-plasmid vaccine against West Nile virus (WNV) in red-tailed hawks (Buteo jamaicensis). Animals-19 permanently disabled but otherwise healthy red-tailed hawks of mixed ages and both sexes without detectable serum antibodies against WNV. Procedures-Hawks were injected IM with an experimental WNV DNA-plasmid vaccine in an aluminum-phosphate adjuvant (n = 14) or with the adjuvant only (control group; 5). All birds received 2 injections at a 3-week interval. Blood samples for serologic evaluation were collected before the first injection and 4 weeks after the second injection (day 0). At day 0, hawks were injected SC with live WNV. Pre- and postchallenge blood samples were collected at intervals for 14 days for assessment of viremia and antibody determination; oropharyngeal and clonal swabs were collected for assessment of viral shedding. Results-Vaccination was not associated with morbidity or deaths. Three of the vaccinated birds seroconverted after the second vaccine injection; all other birds seroconverted following the live virus injection. Vaccinated birds had significantly less severe viremia and shorter and less-intense shedding periods, compared with the control birds. Conclusions and Clinical Relevance-Use of the WNV DNA plasmid vaccine in red-tailed hawks was safe, and vaccination attenuated but did not eliminate both the viremia and the intensity of postchallenge shedding following live virus exposure. Further research is warranted to conclusively determine the efficacy of this vaccine preparation for protection of red-tailed hawks and other avian species against WNV-induced disease. (Am J Vet Res 201172:1065-1070) C1 [Redig, Patrick T.] Univ Minnesota, Coll Vet Med, Dept Clin Sci, St Paul, MN 55108 USA. [Redig, Patrick T.] Univ Minnesota, Coll Vet Med, Raptor Ctr, St Paul, MN 55108 USA. [Tully, Thomas N.] Louisiana State Univ, Sch Vet Med, Dept Vet Clin Sci, Baton Rouge, LA 70803 USA. [Roy, Alma F.; Baudena, M. Alexandra] Louisiana State Univ, Sch Vet Med, Louisiana Anim Dis Diagnost Lab, Baton Rouge, LA 70803 USA. [Ritchie, Branson W.] Univ Georgia, Dept Small Anim Med & Surg, Coll Vet Med, Athens, GA 30602 USA. [Chang, Gwong-Jen J.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Publ Hlth Serv,US Dept Hlth & Human Serv, Ft Collins, CO 80521 USA. RP Redig, PT (reprint author), Univ Minnesota, Coll Vet Med, Dept Clin Sci, St Paul, MN 55108 USA. EM redig001@umn.edu NR 25 TC 6 Z9 7 U1 1 U2 13 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA SN 0002-9645 J9 AM J VET RES JI Am. J. Vet. Res. PD AUG PY 2011 VL 72 IS 8 BP 1065 EP 1070 PG 6 WC Veterinary Sciences SC Veterinary Sciences GA 799YC UT WOS:000293321600011 PM 21801064 ER PT J AU Wadley, VG Unverzagt, FW McGuire, LC Moy, CS Go, R Kissela, B McClure, LA Crowe, M Howard, VJ Howard, G AF Wadley, Virginia G. Unverzagt, Frederick W. McGuire, Lisa C. Moy, Claudia S. Go, Rodney Kissela, Brett McClure, Leslie A. Crowe, Michael Howard, Virginia J. Howard, George TI Incident Cognitive Impairment is Elevated in the Stroke Belt: The REGARDS Study SO ANNALS OF NEUROLOGY LA English DT Article ID CARDIOVASCULAR RISK-FACTORS; TRANSIENT ISCHEMIC ATTACK; SILENT BRAIN INFARCTS; MINI-MENTAL-STATE; RACIAL-DIFFERENCES; AFRICAN-AMERICANS; OLDER-ADULTS; POPULATION; DECLINE; MORTALITY AB Objective: To determine whether incidence of impaired cognitive screening status is higher in the southern Stroke Belt region of the United States than in the remaining United States. Methods: A national cohort of adults age >= 45 years was recruited by the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study from 2003 to 2007. Participants' global cognitive status was assessed annually by telephone with the Six-Item Screener (SIS) and every 2 years with fluency and recall tasks. Participants who reported no stroke history and who were cognitively intact at enrollment (SIS >4 of 6) were included (N = 23,913, including 56% women; 38% African Americans and 62% European Americans; 56% Stroke Belt residents and 44% from the remaining contiguous United States and the District of Columbia). Regional differences in incident cognitive impairment (SIS score <= 4) were adjusted for age, sex, race, education, and time between first and last assessments. Results: A total of 1,937 participants (8.1%) declined to an SIS score <= 4 at their most recent assessment, over a mean of 4.1 (+/- 1.6) years. Residents of the Stroke Belt had greater adjusted odds of incident cognitive impairment than non-Belt residents (odds ratio, 1.18; 95% confidence interval, 1.07-1.30). All demographic factors and time independently predicted impairment. Interpretation: Regional disparities in cognitive decline mirror regional disparities in stroke mortality, suggesting shared risk factors for these adverse outcomes. Efforts to promote cerebrovascular and cognitive health should be directed to the Stroke Belt. ANN NEUROL 2011;70:229-236 C1 [Wadley, Virginia G.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Unverzagt, Frederick W.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN USA. [McGuire, Lisa C.] Ctr Dis Control & Prevent, Healthy Aging Program, Atlanta, GA USA. [Moy, Claudia S.] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD USA. [Go, Rodney; Howard, Virginia J.] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA. [Kissela, Brett] Univ Cincinnati, Dept Neurol, Cincinnati, OH USA. [McClure, Leslie A.; Howard, George] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA. [Crowe, Michael] Univ Alabama, Dept Psychol, Birmingham, AL 35294 USA. RP Wadley, VG (reprint author), Univ Alabama, Dept Med, CH19 218T, Birmingham, AL 35294 USA. EM vwadley@uab.edu RI McClure, Leslie/P-2929-2015; OI Kissela, Brett/0000-0002-9773-4013 FU National Institute of Neurological Disorders and Stroke, NIH, Department of Health and Human Services [U01 NS041588]; Centers for Disease Control and Prevention FX This research project is supported by a cooperative agreement U01 NS041588 from the National Institute of Neurological Disorders and Stroke, NIH, Department of Health and Human Services. Additional funding was provided by the Centers for Disease Control and Prevention's Healthy Aging Program. The content is solely the responsibility of the authors and does not necessarily represent the official views and positions of the National Institute of Neurological Disorders and Stroke, the NIH, or the Centers for Disease Control and Prevention. Representatives of the funding agencies were involved in the review of the manuscript prior to submission for publication. NR 37 TC 25 Z9 25 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD AUG PY 2011 VL 70 IS 2 BP 229 EP 236 DI 10.1002/ana.22432 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 806NP UT WOS:000293815200009 PM 21618586 ER PT J AU Butz, AM Matsui, EC Breysse, P Curtin-Brosnan, J Eggleston, P Diette, G Williams, D Yuan, J Bernert, JT Rand, C AF Butz, Arlene M. Matsui, Elizabeth C. Breysse, Patrick Curtin-Brosnan, Jean Eggleston, Peyton Diette, Gregory Williams, D'Ann Yuan, Jie Bernert, John T. Rand, Cynthia TI A Randomized Trial of Air Cleaners and a Health Coach to Improve Indoor Air Quality for Inner-City Children With Asthma and Secondhand Smoke Exposure SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID ENVIRONMENTAL TOBACCO-SMOKE; CIGARETTE-SMOKE; LOW-INCOME; PARTICLE CONCENTRATIONS; CHILDHOOD ASTHMA; HOMES; COTININE; INTERVENTION; NONSMOKERS; MANAGEMENT AB Objective: To test an air cleaner and health coach intervention to reduce secondhand smoke exposure compared with air cleaners alone or no air cleaners in reducing particulate matter (PM), air nicotine, and urine cotinine concentrations and increasing symptom-free days in children with asthma residing with a smoker. Design: Randomized controlled trial, with randomization embedded in study database. Settings: The Johns Hopkins Hospital Children's Center and homes of children. Participants: Children with asthma, residing with a smoker, randomly assigned to interventions consisting of air cleaners only (n=41), air cleaners plus a health coach (n=41), or delayed air cleaner (control) (n=44). Main Outcome Measures: Changes in PM, air nicotine, and urine cotinine concentrations and symptom-free days during the 6-month study. Results: The overall follow-up rate was high (91.3%). Changes in mean fine and coarse PM (PM2.5 and PM2.5-10) concentrations (baseline to 6 months) were significantly lower in both air cleaner groups compared with the control group (mean differences for PM2.5 concentrations: control, 3.5 mu g/m(3); air cleaner only, -19.9 mu g/m(3); and air cleaner plus health coach, -16.1 mu g/m(3); P=.003; and PM2.5-10 concentrations: control, 2.4 mu g/m(3); air cleaner only, -8.7 mu g/m(3); and air cleaner plus health coach, -10.6 mu g/m(3); P=.02). No differences were noted in air nicotine or urine cotinine concentrations. The health coach provided no additional reduction in PM concentrations. Symptom-free days were significantly reduced in both air cleaner groups compared with the control group (P=.03). Conclusion: Although the use of air cleaners can result in a significant reduction in indoor PM concentrations and a significant increase in symptom-free days, it is not enough to prevent exposure to secondhand smoke. C1 [Butz, Arlene M.] Johns Hopkins Univ, Sch Med, Div Gen Pediat, Dept Pediat, Baltimore, MD 21287 USA. [Matsui, Elizabeth C.; Curtin-Brosnan, Jean; Eggleston, Peyton] Johns Hopkins Univ, Sch Med, Div Allergy & Immunol, Dept Pediat, Baltimore, MD 21287 USA. [Diette, Gregory; Rand, Cynthia] Johns Hopkins Univ, Sch Med, Dept Pulm & Crit Care, Baltimore, MD 21287 USA. [Breysse, Patrick; Williams, D'Ann; Yuan, Jie] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21287 USA. [Bernert, John T.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA USA. RP Butz, AM (reprint author), Johns Hopkins Univ, Sch Med, Div Gen Pediat, Dept Pediat, 200 N Wolfe St, Baltimore, MD 21287 USA. EM abutz@jhmi.edu FU National Institute of Environmental Health Science, National Institutes of Health [E09606]; Environmental Protection Agency [P01 R-826724]; Johns Hopkins Center for Childhood Asthma in the Urban Environment FX This study was supported by grant E09606 from the National Institute of Environmental Health Science, National Institutes of Health; by grant P01 R-826724 from the Environmental Protection Agency; and by The Johns Hopkins Center for Childhood Asthma in the Urban Environment. NR 40 TC 30 Z9 31 U1 3 U2 22 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1072-4710 EI 1538-3628 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD AUG PY 2011 VL 165 IS 8 BP 741 EP 748 PG 8 WC Pediatrics SC Pediatrics GA 800EP UT WOS:000293342900009 PM 21810636 ER PT J AU Glanz, JM Newcomer, SR Hambidge, SJ Daley, MF Narwaney, KJ Xu, S Lee, GM Baggs, J Klein, NP Nordin, JD Naleway, AL Belongia, EA Weintraub, ES AF Glanz, Jason M. Newcomer, Sophia R. Hambidge, Simon J. Daley, Matthew F. Narwaney, Komal J. Xu, Stan Lee, Grace M. Baggs, James Klein, Nicola P. Nordin, James D. Naleway, Allison L. Belongia, Edward A. Weintraub, Eric S. TI Safety of Trivalent Inactivated Influenza Vaccine in Children Aged 24 to 59 Months in the Vaccine Safety Datalink SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID IMMUNIZATION PRACTICES ACIP; ADVERSE EVENTS; YOUNG-CHILDREN; ADVISORY-COMMITTEE; UNITED-STATES; CASE SERIES; INFANTS; RECOMMENDATIONS; REACTOGENICITY; EFFICACY AB Objectives: To evaluate the safety of trivalent inactivated influenza vaccine (TIV) in children aged 24 to 59 months and to evaluate the risk of medically attended events (MAEs) in a subcohort of children who had multiple annual doses of TIV over their lifetimes. Design: Self-controlled screening study. Setting: Seven US managed care organizations from October 1, 2002, to March 31, 2006. Participants: Children aged 24 to 59 months who received at least 1 TIV dose (66 283 children and 91 692 TIV doses). Exposure: Vaccination with TIV. Main Outcome Measures: Medically attended events in inpatient and emergency department settings in one of the following risk windows: 0 to 2, 1 to 14, or 1 to 42 days after vaccination. All MAEs that met the screening criteria of incidence rate ratios (IRRs) exceeding 1.0 and P <= .05 or IRRs exceeding 2.0 and P <= .20 underwent medical record review. A secondary analysis examined the risk of MAEs in children who had multiple annual lifetime TIV doses. Results: Nine diagnoses met the screening criteria. After medical record review, gastrointestinal tract symptoms (IRR, 1.18; 95% confidence interval [CI], 1.10-1.25), gastrointestinal tract disorders (7.70; 1.11-53.52), and fever (1.71; 1.64-1.80) remained significantly associated with vaccination. None of the events seemed to be serious, and none had complications. In the secondary analysis, there was an apparent dose response for vaccine and allergic reactions in the 1- to 3-day risk window. Conclusions: There was no evidence of serious MAEs following vaccination with TIV among children aged 24 to 59 months. Further studies are warranted to evaluate the risk of MAEs in children with multiple lifetime TIV doses. C1 [Glanz, Jason M.; Newcomer, Sophia R.; Hambidge, Simon J.; Daley, Matthew F.; Narwaney, Komal J.; Xu, Stan] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80237 USA. [Glanz, Jason M.; Narwaney, Komal J.] Colorado Sch Publ Hlth, Dept Epidemiol, Denver, CO USA. [Hambidge, Simon J.] Denver Hlth, Community Hlth Serv, Denver, CO USA. [Daley, Matthew F.] Univ Colorado, Dept Pediat, Denver, CO 80202 USA. [Lee, Grace M.] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Ctr Child Hlth Care Studies, Boston, MA USA. [Lee, Grace M.] Harvard Univ, Sch Med, Boston, MA USA. [Lee, Grace M.] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA. [Baggs, James; Weintraub, Eric S.] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual & Promot, Atlanta, GA USA. [Klein, Nicola P.] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA. [Nordin, James D.] HealthPartners Res Fdn, Minneapolis, MN USA. [Naleway, Allison L.] Kaiser Permanente NW, Portland, OR USA. [Belongia, Edward A.] Marshfield Clin Res Fdn, Marshfield, WI USA. RP Glanz, JM (reprint author), Kaiser Permanente Colorado, Inst Hlth Res, POB 378066, Denver, CO 80237 USA. EM jason.m.glanz@kp.org OI Naleway, Allison/0000-0001-5747-4643; Baggs, James/0000-0003-0757-4683 FU Centers for Disease Control and Prevention [200-2002-00732] FX This study was funded through a subcontract with America's Health Insurance Plans under contract 200-2002-00732 from the Centers for Disease Control and Prevention. NR 28 TC 22 Z9 24 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD AUG PY 2011 VL 165 IS 8 BP 749 EP 755 PG 7 WC Pediatrics SC Pediatrics GA 800EP UT WOS:000293342900010 PM 21810637 ER PT J AU Wang, LY Nichols, LP Austin, SB AF Wang, Li Yan Nichols, Lauren P. Austin, S. Bryn TI The Economic Effect of Planet Health on Preventing Bulimia Nervosa SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID QUALITY-OF-LIFE; WEIGHT-CONTROL BEHAVIORS; EARLY ADOLESCENT GIRLS; EATING-DISORDERS; FOLLOW-UP; ANOREXIA-NERVOSA; SHARED RISK; OBESITY; OVERWEIGHT; COST AB Objectives: To assess the economic effect of the school-based obesity prevention program Planet Health on preventing disordered weight control behaviors and to determine the cost-effectiveness of the intervention in terms of its combined effect on prevention of obesity and disordered weight control behaviors. Design: On the basis of the intervention's short-term effect on disordered weight control behaviors prevention, we projected the number of girls who were prevented from developing bulimia nervosa by age 17 years. We further estimated medical costs saved and quality-adjusted life years gained by the intervention over 10 years. As a final step, we compared the intervention costs with the combined intervention benefits from both obesity prevention (reported previously) and prevention of disordered weight control behaviors to determine the overall cost-effectiveness of the intervention. Setting: Middle schools. Participants: A sample of 254 intervention girls aged 10 to 14 years. Intervention: The Planet Health program was implemented during the school years from 1995 to 1997 and was designed to promote healthful nutrition and physical activity among youth. Main Outcome Measures: Intervention costs, medical costs saved, quality-adjusted life years gained, and cost-effectiveness ratio. Results: An estimated 1 case of bulimia nervosa would have been prevented. As a result, an estimated $33 999 in medical costs and 0.7 quality-adjusted life years would be saved. At an intervention cost of $46 803, the combined prevention of obesity and disordered weight control behaviors would yield a net savings of $14 238 and a gain of 4.8 quality-adjusted life years. Conclusions: Primary prevention programs, such as Planet Health, warrant careful consideration by policy makers and program planners. The findings of this study provide additional argument for integrated prevention of obesity and eating disorders. C1 [Wang, Li Yan] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Nichols, Lauren P.; Austin, S. Bryn] Harvard Univ, Sch Publ Hlth, Childrens Hosp, Div Adolescent & Young Adult Med, Boston, MA 02115 USA. [Austin, S. Bryn] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. RP Wang, LY (reprint author), Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,MS K33, Atlanta, GA 30341 USA. EM lgw0@cdc.gov FU Maternal and Child Health Bureau, HRSA [T71-MC00009-17] FX Dr Austin was supported by grant T71-MC00009-17 from the Leadership Education in Adolescent Health Project, Maternal and Child Health Bureau, HRSA. NR 43 TC 12 Z9 12 U1 4 U2 12 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD AUG PY 2011 VL 165 IS 8 BP 756 EP 762 PG 7 WC Pediatrics SC Pediatrics GA 800EP UT WOS:000293342900011 PM 21810638 ER PT J AU Callahan, LF Shreffler, JH Altpeter, M Schoster, B Hootman, J Houenou, LO Martin, KR Schwartz, TA AF Callahan, Leigh F. Shreffler, Jack H. Altpeter, Mary Schoster, Britta Hootman, Jennifer Houenou, Laura O. Martin, Kathryn R. Schwartz, Todd A. TI Evaluation of Group and Self-Directed Formats of the Arthritis Foundation's Walk With Ease Program SO ARTHRITIS CARE & RESEARCH LA English DT Article ID OLDER-ADULTS; PHYSICAL-ACTIVITY; OSTEOARTHRITIS; EXERCISE; KNEE; EFFICACY; PERFORMANCE; DEPENDENCE; EDUCATION; RISK AB Objective. To evaluate the effects of a revised 6-week walking program for adults with arthritis, Walk With Ease (WWE), delivered in 2 formats, instructor-led group or self-directed. Methods. In an observational pre-post study design, 462 individuals with self-reported arthritis selected either a group format (n = 192) or a self-directed (n = 270) format. Performance and self-reported outcomes were assessed at baseline and at 6 weeks. Self-reported outcomes were assessed at 1 year. Adjusted mean outcome values for group and self-directed participants were determined using regression models, adjusting for covariates. Results. At 6 weeks, significant adjusted mean improvements (P < 0.05) were seen for nearly all self-report and performance measures in both formats. Modest to moderate effect sizes (ES) were seen for disability (ES 0.16-0.23), pain, fatigue, and stiffness (ES 0.21-0.40), and helplessness (ES 0.24-0.28). The Arthritis Self-Efficacy (ASE) pain and symptom scales had modest improvements (ES 0.09-0.21). The performance measures of strength (ES 0.29-0.35), balance (ES 0.12-0.36), and walking pace (ES 0.12-0.32) all showed modest to moderate improvements. No adverse events were reported for either format. At 1 year, both formats showed modest improvement in ASE pain, but there were 5 outcomes where self-directed participants showed significant improvement, while the group participants did not. Conclusion. The revised WWE program decreases disability and improves arthritis symptoms, self-efficacy, and perceived control, balance, strength, and walking pace in individuals with arthritis, regardless of whether they are taking a group class or doing the program as self-directed walkers. At 1 year, some benefits are maintained, particularly among the self-directed. This is a safe, easy, and inexpensive program to promote community-based physical activity. C1 [Callahan, Leigh F.] Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC 27599 USA. [Hootman, Jennifer] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Callahan, LF (reprint author), Univ N Carolina, Thurston Arthrit Res Ctr, 3300 Thurston Bldg,CB 7280, Chapel Hill, NC 27599 USA. EM leigh_callahan@med.unc.edu RI Schwartz, Todd/D-4995-2012 OI Schwartz, Todd/0000-0002-0232-2543 FU Centers for Disease Control and Prevention [MM-0975-07/07]; Association of American Medical Colleges [MM-0975-07/07] FX Supported by a cooperative agreement between the Centers for Disease Control and Prevention and the Association of American Medical Colleges (MM-0975-07/07). NR 31 TC 21 Z9 21 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD AUG PY 2011 VL 63 IS 8 BP 1098 EP 1107 DI 10.1002/acr.20490 PG 10 WC Rheumatology SC Rheumatology GA 806LD UT WOS:000293808400004 PM 21560255 ER PT J AU Klabunde, CN Cronin, KA Breen, N Waldron, WR Ambs, AH Nadel, MR AF Klabunde, Carrie N. Cronin, Kathleen A. Breen, Nancy Waldron, William R. Ambs, Anita H. Nadel, Marion R. TI Trends in Colorectal Cancer Test Use among Vulnerable Populations in the United States SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID HEALTH INTERVIEW SURVEY; MEDICARE ENROLLEES; GUIDELINES; PATTERNS; QUALITY AB Background: Evaluating trends in colorectal cancer (CRC) screening use is critical for understanding screening implementation, and whether population groups targeted for screening are receiving it, consistent with guidelines. This study examines recent national trends in CRC test use, including among vulnerable populations. Methods: We used the 2000, 2003, 2005, and 2008 National Health Interview Survey to examine national trends in CRC screening use overall and for fecal occult blood test (FOBT), sigmoidoscopy, and colonoscopy. We also assessed trends by race/ethnicity, educational attainment, income, time in the United States, and access to health care. Results: During 2000 to 2008, significant declines in FOBT and sigmoidoscopy use and significant increases in colonoscopy use and in the percentages of adults up-to-date with CRC screening occurred overall and for most population subgroups. Subgroups with consistently lower rates of colonoscopy use and being up-to-date included Hispanics; people with minimal education, low income, or no health insurance; recent immigrants; and those with no usual source of care or physician visits in the past year. Among up-to-date adults, there were few subgroup differences in the type of test by which they were up-to-date (i.e., FOBT, sigmoidoscopy, or colonoscopy). Conclusions: Although use of CRC screening and colonoscopy increased among U.S. adults, including those from vulnerable populations, 45% of adults aged 50 to 75-or nearly 35 million people-were not up-to-date with screening in 2008. Impact: Continued monitoring of CRC screening rates among population subgroups with consistently low utilization is imperative. Improvement in CRC screening rates among all population groups in the United States is still needed. Cancer Epidemiol Biomarkers Prev; 20(8); 1611-21. (C)2011 AACR. C1 [Klabunde, Carrie N.] NCI, Hlth Serv & Econ Branch, Appl Res Program, Bethesda, MD 20892 USA. [Cronin, Kathleen A.] NCI, Surveillance Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Waldron, William R.] Informat Management Serv Inc, Silver Spring, MD USA. [Nadel, Marion R.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. RP Klabunde, CN (reprint author), NCI, Hlth Serv & Econ Branch, Appl Res Program, 6130 Execut Blvd,Room 4005, Bethesda, MD 20892 USA. EM klabundC@mail.nih.gov FU Intramural NIH HHS [Z99 CA999999] NR 28 TC 106 Z9 107 U1 0 U2 8 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD AUG PY 2011 VL 20 IS 8 BP 1611 EP 1621 DI 10.1158/1055-9965.EPI-11-0220 PG 11 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 804AK UT WOS:000293625600005 PM 21653643 ER PT J AU Yard, EE Terrell, ML Hunt, DR Cameron, LL Small, CM McGeehin, MA Marcus, M AF Yard, Ellen E. Terrell, Metrecia L. Hunt, Danielle Rentz Cameron, Lorraine L. Small, Chanley M. McGeehin, Michael A. Marcus, Michele TI Incidence of thyroid disease following exposure to polybrominated biphenyls and polychlorinated biphenyls, Michigan, 1974-2006 SO CHEMOSPHERE LA English DT Article DE Brominated flame retardant; Polybrominated biphenyl; Polychlorinated biphenyl; Persistent organic pollutant; Incidence density sampling ID DEVELOPMENTAL EXPOSURE; MATERNAL EXPOSURE; PBB COHORT; PCB LEVELS; VITAMIN-A; SERUM; HORMONE; RATS; ORGANOCHLORINES; ASSOCIATION AB Thyroid hormones, which influence body metabolism and development, could be affected by persistent organic pollutants. We sought to examine the relationship between polybrominated biphenyls (PBBs) and polychlorinated biphenyls (PCBs) and thyroid disease. We employed incidence density sampling to perform a nested case control analysis of the Michigan Long-Term PBB Cohort. Cohort members (n = 3333) were exposed to PBBs through contaminated cattle feed in 1973-1974 and to PCBs through daily life. Those with detectable serum PBB and PCB concentrations at enrollment were categorized into tertiles of PBB and PCB exposure. Case-patients were cohort members answering "Yes" to "Has a health-care provider ever told you that you had a thyroid problem?" during follow-up interviews; control-patients were cohort members answering "No". We used odds ratios (OR) with 95% confidence intervals (Cl) to compare odds of thyroid disease by PBB and PCB exposure and by various risk factors. Total cumulative thyroid disease incidence after 33 years was 13.9% among women and 2.6% among men. After adjusting for body mass index, we found no statistically significant differences in odds of any type of thyroid disease among women or men with elevated PBB or PCB exposure. Compared to control-patients, women with thyroid disease had increased odds of being overweight/obese (OR = 2.82, 95% CI: 1.944.11) and developing infertility (OR = 1.71, 95% Cl: 1.08-2.69), diabetes (OR= 1.61, 95% Cl: 1.04-2.51), or arthritis (OR = 1.71, 95% Cl: 1.18-2.50) during follow-up. Additional research should explore potential associations between PBBs/PCBs and thyroid disease among children exposed in utero. Published by Elsevier Ltd. C1 [Terrell, Metrecia L.; Small, Chanley M.; Marcus, Michele] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Yard, Ellen E.; Hunt, Danielle Rentz; Marcus, Michele] Ctr Dis Control & Prevent, Hlth Studies Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Yard, Ellen E.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Cameron, Lorraine L.] Michigan Dept Community Hlth, Bur Epidemiol, Div Environm Hlth, Lansing, MI USA. [McGeehin, Michael A.] Res Triangle Inst, Atlanta, GA USA. RP Marcus, M (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. EM mmarcus@emory.edu RI Marcus, Michele/J-2746-2015; OI Terrell, Metrecia/0000-0001-9406-2226 FU NIEHS [RO1-ES08341, RO1-ES012014]; US EPA [R825300]; Centers for Disease Control and Prevention [U37/CCU500392] FX This work was supported by NIEHS (Grants RO1-ES08341 and RO1-ES012014), the US EPA (Grant R825300) and supported by the Centers for Disease Control and Prevention cooperative agreement U37/CCU500392. We thank the staff of the Michigan Department of Community Health, participants of the Michigan Long-Term PBB Study, Jessica Spencer for her medical expertise and advice, and Alden Henderson for his early work on these analyses and the medical records verification. NR 47 TC 9 Z9 9 U1 2 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0045-6535 EI 1879-1298 J9 CHEMOSPHERE JI Chemosphere PD AUG PY 2011 VL 84 IS 7 BP 863 EP 868 DI 10.1016/j.chemosphere.2011.06.020 PG 6 WC Environmental Sciences SC Environmental Sciences & Ecology GA 805JZ UT WOS:000293724000002 PM 21737118 ER PT J AU Taylor, MM Collier, MG Winscott, MM Mickey, T England, B AF Taylor, M. M. Collier, M. G. Winscott, M. M. Mickey, T. England, B. TI Reticence to prescribe: utilization of expedited partner therapy among obstetrics providers in Arizona SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE expedited partner therapy; patient-delivered partner therapy; PDPT; STD; STD treatment; chlamydia; gonorrhoea ID SEXUALLY-TRANSMITTED-DISEASES; CHLAMYDIA-TRACHOMATIS; CONTROLLED-TRIAL; UNITED-STATES; AZITHROMYCIN; INFECTIONS AB Expedited partner therapy (EPT) is the practice of providing an extra dose or prescription of antibiotic to patients diagnosed with chlamydia or gonorrhoea to deliver to their sexual partner(s). Obstetrical providers who delivered more than 20 infants in Maricopa County, Arizona, USA, during the year 2008 were surveyed by telephone regarding their use of EPT. A total of 142 eligible respondents completed the survey, representing 34% (142/421) of the delivering providers, 67 (47%) of whom reported the use of EPT in their clinics. Having received information about EPT was significantly associated with its use (67% versus 41%) (P = 0.008). The most common reasons for not using EPT included the inability to obtain allergy history in partners (24%) and concern for liability (11%). Additional education regarding the use of EPT may increase the use of this personal and public health tool among some obstetrics providers in Maricopa County; however, concerns for liability may limit broad utilization. C1 [Taylor, M. M.; Mickey, T.; England, B.] Maricopa Cty Dept Publ Hlth, STD Program, Phoenix, AZ USA. [Taylor, M. M.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA. [Taylor, M. M.; Winscott, M. M.] Arizona Dept Hlth Serv, Sexually Transmitted Dis Program, Phoenix, AZ 85007 USA. [Collier, M. G.] Univ Illinois, Coll Med Peoria, Peoria, IL USA. RP Taylor, MM (reprint author), Maricopa Dept Publ Hlth, 1645 E Roosevelt St, Phoenix, AZ 85006 USA. EM mdt7@cdc.gov NR 21 TC 8 Z9 8 U1 1 U2 2 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 0956-4624 J9 INT J STD AIDS JI Int. J. STD AIDS PD AUG PY 2011 VL 22 IS 8 BP 449 EP 452 DI 10.1258/ijsa.2011.010492 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 805HI UT WOS:000293717100005 PM 21742811 ER PT J AU Guh, A Sosa, L Hadler, JL Lobato, MN AF Guh, A. Sosa, L. Hadler, J. L. Lobato, M. N. TI Missed opportunities to prevent tuberculosis in foreign-born persons, Connecticut, 2005-2008 SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE latent tuberculosis infection; immigrants; vulnerable population ID UNITED-STATES; IMMIGRANTS; DECREASE; PROGRAM; CARE AB SETTING: Factors that influence testing for latent tuberculosis infection (LTBI) among foreign-born persons in Connecticut are not well understood. OBJECTIVE: To identify predictors for LTBI testing and challenges related to accessing health care among the foreign-born population in Connecticut. DESIGN: Foreign-born Connecticut residents with confirmed or suspected tuberculosis (TB) disease during June 2005 December 2008 were interviewed regarding health care access and immigration status. Predictors for self-reported testing for LTBI after US entry were determined. RESULTS: Of 161 foreign-born persons interviewed, 48% experienced TB disease within 5 years after arrival. One third (51/156) reported having undergone post-arrival testing for LTBI. Although those with established health care providers were more likely to have reported testing (aOR 4.49, 95%CI 1.48-13.62), only 43% of such persons were tested. Undocumented persons, the majority of whom lacked a provider (53%), were less likely than documented persons to have reported testing (aOR 0.20, 95%CI 0.06-0.67). Hispanic permanent residents (immigrants and refugees) and visitors (persons admitted temporarily) were more likely than non-Hispanics in the respective groups to have reported testing (OR 5.25, 95%CI 1.51-18.31 and OR 7.08, 95%CI 1.30-38.44, respectively). CONCLUSIONS: The self-reported rate of testing for LTBI among foreign-born persons in Connecticut with confirmed or suspected TB was low and differed significantly by ethnicity and immigration status. Strategies are needed to improve health care access for foreign-born persons and expand testing for LTBI, especially among non-Hispanic and undocumented populations. C1 [Guh, A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA. [Guh, A.; Sosa, L.; Hadler, J. L.] Connecticut Dept Publ Hlth, Hartford, CT USA. [Lobato, M. N.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30329 USA. RP Guh, A (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd NE,MS A-31, Atlanta, GA 30329 USA. EM ggt4@cdc.gov NR 31 TC 6 Z9 6 U1 0 U2 2 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD AUG PY 2011 VL 15 IS 8 BP 1044 EP 1049 DI 10.5588/ijtld.10.0518 PG 6 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 804TX UT WOS:000293678000007 PM 21740666 ER PT J AU Weinfurter, P Blumberg, HM Goldbaum, G Royce, R Pang, J Tapia, J Bethel, J Mazurek, GH Toney, S Albalak, R AF Weinfurter, P. Blumberg, H. M. Goldbaum, G. Royce, R. Pang, J. Tapia, J. Bethel, J. Mazurek, G. H. Toney, S. Albalak, R. CA TB Epidemiological Studies TI Predictors of discordant tuberculin skin test and QuantiFERON (R)-TB Gold In-Tube results in various high-risk groups SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE QuantiFERON-TB Gold In-Tube; latent tuberculosis infection; tuberculin skin test; discordance ID HIV-INFECTED INDIVIDUALS; GAMMA RELEASE ASSAY; LATENT TB INFECTION; DIAGNOSIS; ADULTS; PERFORMANCE; POPULATION AB SETTING: Persons in whom targeted testing for latent tuberculosis infection (LTBI) is recommended in Seattle, Washington; Atlanta, Georgia; and central North Carolina, United States. OBJECTIVE: To compare the performance of an interferon-gamma release assay (QuantiFERON (R)-TB Gold In-Tube [QFT-GIT]) with the tuberculin skin test (TST) among foreign-born, homeless, human immunodeficiency virus (HIV) infected and substance abuse persons tested for LTBI. DESIGN: A cross-sectional study requiring participants to have a blood test, a TST and data collected. RESULTS: Of 1653 persons, 19.5% were TST-positive and 14.0% were QFT-GIT-positive. Overall concordance was moderate (kappa 0.53; 95%CI 0.47-0.58). Compared to concordant positive results, TST+/QFT-GIT-discordance was associated with HIV infection and sex, while TST-/QFT-GIT+ discordance was associated with HIV and inversely associated with foreign birth. Compared to concordant negative results, TST-/QFT-GIT+discordance was associated with foreign birth and age years, >= 50 while TST+/QFT-GIT-discordance was associated with foreign birth, age 30-49 years, being Black and inversely associated with HIV. HIV infection was significantly associated with indeterminate QFT-GIT results. CONCLUSION: QFT-GIT may be an improvement over the TST for diagnosing LTBI in foreign-born and older persons, and may be as useful as the TST in HIV-infected persons. The sensitivity of both tests may be low in HIV-infected persons. C1 [Weinfurter, P.; Bethel, J.] WESTAT Corp, Rockville, MD 20850 USA. [Blumberg, H. M.; Tapia, J.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA. [Goldbaum, G.] Snohomish Hlth Dist, Everett, WA USA. [Royce, R.] RTI Int, Res Triangle Pk, NC USA. [Pang, J.] Seattle King Cty Dept Publ Hlth, Seattle, WA USA. [Mazurek, G. H.; Toney, S.; Albalak, R.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Weinfurter, P (reprint author), WESTAT Corp, 1650 Res Blvd, Rockville, MD 20850 USA. EM cwa1@cdc.gov RI Royce, Rachel/A-7964-2012 FU Centers for Disease Control and Prevention FX Acknowledgements The authors thank R Wallace, J M Sanchez, N Ryan, S Lea, N J Talati, A Oladele, and the Tuberculosis Epidemiological Studies Consortium and the Centers for Disease Control and Prevention, which supported this study. NR 26 TC 26 Z9 26 U1 0 U2 4 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD AUG PY 2011 VL 15 IS 8 BP 1056 EP 1061 DI 10.5588/ijtld.10.0650 PG 6 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 804TX UT WOS:000293678000009 PM 21740668 ER PT J AU Charles, LE Gu, JK Andrew, ME Violanti, JM Fekedulegn, D Burchfiel, CM AF Charles, Luenda E. Gu, Ja K. Andrew, Michael E. Violanti, John M. Fekedulegn, Desta Burchfiel, Cecil M. TI Sleep Duration and Biomarkers of Metabolic Function Among Police Officers SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID CARDIOVASCULAR-DISEASE MORBIDITY; LAW-ENFORCEMENT COHORT; BODY-MASS INDEX; LONG-SLEEP; LEPTIN LEVELS; ELEVATED GHRELIN; REDUCED LEPTIN; HEALTH; ADULTS; ASSOCIATION AB Objective: To investigate associations between sleep duration and biomarkers of metabolic function among police officers. Methods: Metabolic markers were measured using standardized methods and sleep duration was assessed from questionnaire data. Mean levels of leptin and adiponectin were assessed across five levels of sleep duration using ANCOVA and linear regression models. Results: Police officers (n = 443) who reported an average of less than 5 hours and at least 8 hours of sleep had higher levels of leptin compared to those who reported an average of 5 to 7 hours of sleep. These associations were stronger and statistically significant among women, officers with BMI of 24.9 kg/m(2) or less and smaller abdominal height (< 20 cm), and officers who primarily worked on the day shift. Conclusion: Short and long sleep duration were associated with higher leptin levels and may have implications for obesity-related conditions. C1 [Charles, Luenda E.; Gu, Ja K.; Andrew, Michael E.; Fekedulegn, Desta; Burchfiel, Cecil M.] Ctr Dis Control & Prevent, Biostat & Epidemiol Branch, Hlth Effects Lab Div, NIOSH, Morgantown, WV 26505 USA. [Violanti, John M.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Social & Prevent Med, Buffalo, NY 14260 USA. RP Charles, LE (reprint author), Ctr Dis Control & Prevent, Biostat & Epidemiol Branch, Hlth Effects Lab Div, NIOSH, MS L-4050,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM lcharles@cdc.gov RI Charles, Luenda/H-6008-2011 FU National Institute for Occupational Safety and Health (NIOSH) [200-2003-01580] FX This work was supported by the National Institute for Occupational Safety and Health (NIOSH), contract no. 200-2003-01580. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. NR 43 TC 11 Z9 11 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD AUG PY 2011 VL 53 IS 8 BP 831 EP 837 DI 10.1097/JOM.0b013e31821f5ece PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 804XE UT WOS:000293687400002 PM 21785371 ER PT J AU Kelly, KJ Wang, ML Klancnik, M Petsonk, EL AF Kelly, Kevin J. Wang, Mei Lin Klancnik, Meribeth Petsonk, Edward L. TI Prevention of IgE Sensitization to Latex in Health Care Workers After Reduction of Antigen Exposures SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID RISK-FACTORS; ALLERGY; PREVALENCE; RUBBER; ANTIBODIES; DIAGNOSIS; FEATURES; CHILDREN; PROGRAM; SKIN AB Objective: To investigate occupational latex allergy in health care workers (HCWs) before and after an intervention designed to reduce latex allergen exposure from gloves. Methods: Latex antigen concentrations in work area air ducts were measured before the intervention. Symptoms and latex sensitization were monitored annually before and after the intervention in 805 HCWs, using questionnaires and skin prick testing. Results: The prevalence of latex sensitization before the intervention correlated with air duct latex antigen measurements, for HCWs exposed to low (9/413, 2%), intermediate (23/292, 8%), and high (11/67, 16%) antigen levels, P < 0.0001. After the intervention, new latex sensitization rates declined 16-fold, and 25% of previously sensitized employees reverted to negative skin tests. Conclusion: Airborne antigen exposure is a major source of latex sensitization among HCWs. Use of powder-free latex gloves markedly reduces the risk of sensitization. C1 [Kelly, Kevin J.; Klancnik, Meribeth] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Dept Pediat Allergy Immunol, Childrens Hosp Wisconsin, Milwaukee, WI 53226 USA. [Kelly, Kevin J.; Klancnik, Meribeth] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Dept Med, Childrens Hosp Wisconsin, Milwaukee, WI 53226 USA. [Wang, Mei Lin; Petsonk, Edward L.] Ctr Dis Control & Prevent, NIOSH, Morgantown, WV USA. RP Kelly, KJ (reprint author), Dept Pediat Allergy Immunol & Med, 999 N 92nd St,C-730, Wauwatosa, WI 53226 USA. EM kjkelly@mcw.edu FU Centers for Disease Control and Prevention-National Institute for Occupational Safety and Health [U60/CCU14541] FX This study was supported by grant U60/CCU14541 from Centers for Disease Control and Prevention-National Institute for Occupational Safety and Health. NR 26 TC 18 Z9 18 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD AUG PY 2011 VL 53 IS 8 BP 934 EP 940 DI 10.1097/JOM.0b013e31822589dc PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 804XE UT WOS:000293687400016 PM 21775898 ER PT J AU Cleveland, JL Junger, ML Saraiya, M Markowitz, LE Dunne, EF Epstein, JB AF Cleveland, Jennifer L. Junger, Michele L. Saraiya, Mona Markowitz, Lauri E. Dunne, Eileen F. Epstein, Joel B. TI The connection between human papillomavirus and oropharyngeal squamous cell carcinomas in the United States Implications for dentistry SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Article DE Human papillomavirus; oropharyngeal cancer; dentistry; epidemiology; risk factors; vaccines ID ORAL HUMAN-PAPILLOMAVIRUS; NECK-CANCER; SEXUAL-BEHAVIORS; TONSILLAR CARCINOMA; NATURAL-HISTORY; RISK-FACTORS; HEAD; INFECTION; HPV; PREVALENCE AB Background. Results from studies conducted in the past several years suggest that some oropharyngeal cancers, those of the base of the tongue and the tonsils, are associated with high-risk types of human papillomavirus (HPV). In this article, the authors summarize the available evidence regarding the epidemiology of HPV-associated oropharyngeal cancers in the United States, the available HPV vaccines and the implications of these for dentistry. They also examine the differences in HPV prevalence between cancers of the oral cavity and those of the oropharynx. Types of Studies Reviewed. The authors searched PubMed, Web of Science, The Cochrane Library and the National Guideline Clearinghouse to identify English-language systematic reviews and meta-analyses focused on HPV-associated oropharyngeal squamous cell cancers published from January 2005 through May 2011. Results. Molecular and epidemiologic evidence suggest a strong etiologic association of HPV with oropharyngeal cancers. The incidence of oropharyngeal cancers in the United States has increased between 1973 and 2007, whereas that of cancers at other head and neck sites has decreased steadily. Compared with HPV-negative cancers, HPV-positive oropharyngeal cancers are associated with certain sexual behaviors, occur more often among white men and people who do not use tobacco or alcohol, and may occur in a population younger by about four years (median ages, 52-56 years). Despite often having a later stage of diagnosis, people with HPV-positive oropharyngeal cancers have a lower risk of dying or recurrence than do those with HPV-negative cancers. The effectiveness of the HPV vaccine in preventing oropharyngeal cancers is unknown. Clinical Implications. Dental health care personnel (DHCP) should be knowledgeable about the role of HPV in carcinogenesis, the association of HPV with oropharyngeal cancers and HPV vaccines, and they should be prompt in referring patients with suggestive symptoms for evaluation. DHCP can play an important role in increasing patients' knowledge about HPV and oropharyngeal cancers. C1 [Cleveland, Jennifer L.; Junger, Michele L.] Ctr Dis Control & Prevent, Div Oral Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Markowitz, Lauri E.; Dunne, Eileen F.] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Natl Ctr Hepatitis HIV AIDS Sexually Transmitted, Atlanta, GA 30341 USA. [Epstein, Joel B.] Univ Illinois, Coll Med, Ctr Canc, Chicago, IL USA. [Epstein, Joel B.] Univ Illinois, Coll Dent, Dept Oral Med & Diagnost Sci, Chicago, IL USA. [Epstein, Joel B.] Univ Illinois, Coll Med, Dept Otolaryngol Head & Neck Surg, Chicago, IL USA. RP Cleveland, JL (reprint author), Ctr Dis Control & Prevent, Div Oral Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, MS F-10,4770 Buford Highway, Atlanta, GA 30341 USA. EM JLCleveland@cdc.gov NR 88 TC 32 Z9 35 U1 1 U2 4 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD AUG PY 2011 VL 142 IS 8 BP 915 EP 924 PG 10 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 805WS UT WOS:000293761900015 PM 21804058 ER PT J AU Kapetanovic, S Wiegand, RE Dominguez, K Blumberg, D Bohannon, B Wheeling, J Rutstein, R AF Kapetanovic, Suad Wiegand, Ryan E. Dominguez, Ken Blumberg, Dean Bohannon, Beverly Wheeling, John Rutstein, Richard CA LEGACY Consortium TI Associations of Medically Documented Psychiatric Diagnoses and Risky Health Behaviors in Highly Active Antiretroviral Therapy-Experienced Perinatally HIV-Infected Youth SO AIDS PATIENT CARE AND STDS LA English DT Article ID LOGISTIC-REGRESSION ANALYSIS; PATIENT-RELATED RISKS; UNITED-STATES; ADOLESCENTS; PREVALENCE; CHILDREN; NONADHERENCE; DISORDERS; ADHERENCE; RATES AB The Longitudinal Epidemiologic Study to Gain Insight into HIV/AIDS in Children and Youth (LEGACY) study is a prospective, multisite, longitudinal cohort of U. S. HIV-infected youth. This analysis was limited to perinatally HIV-infected youth (n = 197), 13 years and older, with selected variables completely abstracted from HIV diagnosis through 2006. We evaluated relationships between ever having one or more nonsubstance related medically documented psychiatric diagnoses and three risky health behaviors (substance abuse, preadult sexual activity, and treatment adherence problems) recorded between 2001 and 2006. Logistic regression was used for all binary outcomes and participant age was included as a covariate when possible. All 197 participants included in the analysis were prescribed antiretroviral therapy during the study period; 110 (56%) were female, 100 (51%) were black non-Hispanic, and 86 (44%) were Hispanic; mean age at the last visit was 16.8 years, ranging from 13 to 24 years. One hundred forty-six (74%) participants had a history of at least one risky health behavior. There were 108 (55%) participants with at least one medically documented psychiatric diagnosis, 17 (9%) with at least one record of substance abuse, 12 (6%) with documented preadult sexual activity, and 142 (72%) participants with reported adherence problems. In the final model, a history of at least one psychiatric diagnosis was associated with having at least one of the three risky behaviors (odds ratio [OR] = 2.33, p = 0.015). There is a need for a continued close partnership between HIV specialty care providers and mental health services treating perinatally HIV-infected youth with an added focus on improving treatment adherence. C1 [Kapetanovic, Suad] NIMH, NIH, Off Clin Director, Bethesda, MD 20892 USA. [Wiegand, Ryan E.; Dominguez, Ken; Bohannon, Beverly] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Blumberg, Dean] Univ Calif Davis, Childrens Hosp, Sacramento, CA 95817 USA. [Wheeling, John] Northrop Grumman Inc, Atlanta, GA USA. [Rutstein, Richard] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. RP Kapetanovic, S (reprint author), NIMH, NIH, Off Clin Director, Bldg 10-CRC,Room 6-5340,10 Ctr Dr, Bethesda, MD 20892 USA. EM suad.kapetanovic@nih.gov FU Westat Inc. [2004-N-01211, 200-2004-09976] FX Funded through CDC Solicitation No. 2004-N-01211 and prime contract #200-2004-09976 with Westat Inc. NR 24 TC 17 Z9 17 U1 2 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD AUG PY 2011 VL 25 IS 8 BP 493 EP 501 DI 10.1089/apc.2011.0107 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 799ED UT WOS:000293265500007 PM 21745118 ER PT J AU Bulterys, PL Chao, A Dalai, SC Zink, MC Dushimimana, A Katzenstein, D Saah, AJ Bulterys, M AF Bulterys, Philip L. Chao, Ann Dalai, Sudeb C. Zink, M. Christine Dushimimana, Abel Katzenstein, David Saah, Alfred J. Bulterys, Marc TI Placental Malaria and Mother-to-Child Transmission of Human Immunodeficiency Virus-1 in Rural Rwanda SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID PLASMODIUM-FALCIPARUM MALARIA; PERINATAL TRANSMISSION; INTRAUTERINE GROWTH; PROSPECTIVE COHORT; PREGNANT-WOMEN; HIV-1; INFECTION; TYPE-1; ASSOCIATION; BUTARE AB We conducted a nested case-control study of placental malaria (PM) and mother-to-child transmission (MTCT) of human immunodeficiency virus-1 (HIV-1) within a prospective cohort of 627 mother-infant pairs followed from October 1989 until April 1994 in rural Rwanda. Sixty stored placentas were examined for PM and other placental pathology, comparing 20 HIV-infected mother-infant (perinatal transmitter) pairs, 20 HIV-uninfected pairs, and 20 HIV-infected mothers who did not transmit to their infant perinatally. Of 60 placentas examined, 45% showed evidence of PM. Placental malaria was associated with increased risk of MTCT of HIV-1 (adjusted odds ratio [aOR] = 6.3;95% confidence interval [CI] = 1.4-29.1), especially among primigravidae (aOR = 12.0; 95% CI = 1.0-150; P < 0.05). Before antiretroviral therapy or prophylaxis, PM was associated with early infant HIV infection among rural Rwandan women living in a hyper-endemic malaria region. Primigravidae, among whom malaria tends to be most severe, may be at higher risk. C1 [Bulterys, Philip L.] Univ Calif Los Angeles, David Geffen Sch Med, Caltech Med Scientist Training Program, Los Angeles, CA 90095 USA. Stanford Univ, Dept Biol, Stanford, CA 94305 USA. Johns Hopkins Univ, Natl Univ Rwanda, AIDS Res Project 1989 1994, Butare, Rwanda. [Dalai, Sudeb C.; Katzenstein, David] Stanford Univ, Sch Med, Dept Infect Dis, Stanford, CA 94305 USA. Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA. [Zink, M. Christine] Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD USA. Natl Univ Rwanda, Ctr Univ Sante Publ, Sch Med, Butare, Rwanda. Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Dushimimana, Abel] WHO, Africa Reg Off, Brazzaville, Congo. [Saah, Alfred J.] Merck Res Labs, Blue Bell, PA USA. [Chao, Ann; Bulterys, Marc] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. RP Bulterys, PL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Caltech Med Scientist Training Program, 10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM bulterys@ucla.edu; annchao@bellsouth.net; sdalai@stanford.edu; mzink1@jhmi.edu; dushimimana@yahoo.fr; davidkk@stanford.edu; alfred_saah@merck.com; zbe2@cdc.gov FU National Institute of Child Health and Human Development [HD22496, HD25785]; World AIDS Foundation [114-96024]; UCLA/Caltech; Paul and Daisy Soros Fellowships for New Americans FX Financial support: This study was supported by grants from the National Institute of Child Health and Human Development (HD22496 and HD25785) and from the World AIDS Foundation (114-96024). PLB is supported by the UCLA/Caltech Medical Scientist Training Program (MSTP) and the Paul and Daisy Soros Fellowships for New Americans. NR 33 TC 12 Z9 12 U1 2 U2 4 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD AUG PY 2011 VL 85 IS 2 BP 202 EP 206 DI 10.4269/ajtmh.2011.10-0589 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 803WN UT WOS:000293613000004 PM 21813835 ER PT J AU Moss, DM Priest, JW Boyd, A Weinkopff, T Kucerova, Z Beach, MJ Lammie, PJ AF Moss, Delynn M. Priest, Jeffrey W. Boyd, Alexis Weinkopff, Tiffany Kucerova, Zuzana Beach, Michael J. Lammie, Patrick J. TI Multiplex Bead Assay for Serum Samples from Children in Haiti Enrolled in a Drug Study for the Treatment of Lymphatic Filariasis SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID PEPSIN INHIBITOR HOMOLOG; BANCROFTIAN FILARIASIS; DIROFILARIA-IMMITIS; ANTIBODY-RESPONSES; WUCHERERIA-BANCROFTI; ALBENDAZOLE THERAPY; FOLLOW-UP; DIETHYLCARBAMAZINE; INFECTION; CYTOKINES AB A multiplex bead assay (MBA) was used to analyze serum samples collected longitudinally from children enrolled in a drug trial for treatment of filariasis in Leogane, Haiti. Recombinant antigens Bm14 and Bm33 from Brugia malayi, third polar tube protein (PTP3) from Encephalitozoon cuniculi, and merozoite surface protein-1(19) (MSP-1(19)) from Plasmodium falciparum were coupled to carboxylated polystyrene microspheres. IgG responses to PTP3 and MSP-1(19) were not affected by albendazole (ALB), diethylcarbamazine (DEC), or combination of diethylcarbamazine and albendazole (DEC/ALB). However, IgG and IgG4 responses to Bm14 and Bm33 were significantly decreased (P <0.001) by DEC and DEC/ALB treatment. Antibody responses to Bm14 and Bm33 decreased after DEC treatment (but not placebo) among children who were negative for microfilaremia and antigenemia at baseline, suggesting that these children harbored early stages of infection. The MBA is an excellent serologic technique for multiple antigens that offers substantial advantages over single-antigen based enzyme-linked immunosorbent assay in mass drug administration studies for monitoring changes in antibody levels. C1 [Moss, Delynn M.] Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30329 USA. [Moss, Delynn M.; Priest, Jeffrey W.] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. [Boyd, Alexis] NIH, Off Intramural Training & Educ, Bethesda, MD 20892 USA. [Beach, Michael J.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. RP Moss, DM (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM dmm3@cdc.gov; jip8@cdc.gov; boyda2@od.nih.gov; tiffany.weinkopff@unil.ch; zik0@cdc.gov; mjb3@cdc.gov; pjl1@cdc.gov NR 45 TC 24 Z9 24 U1 0 U2 8 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD AUG PY 2011 VL 85 IS 2 BP 229 EP 237 DI 10.4269/ajtmh.2011.11-0029 PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 803WN UT WOS:000293613000009 PM 21813840 ER PT J AU Biggs, HM Bui, DM Galloway, RL Stoddard, RA Shadomy, SV Morrissey, AB Bartlett, JA Onyango, JJ Maro, VP Kinabo, GD Saganda, W Crump, JA AF Biggs, Holly M. Bui, Duy M. Galloway, Renee L. Stoddard, Robyn A. Shadomy, Sean V. Morrissey, Anne B. Bartlett, John A. Onyango, Jecinta J. Maro, Venance P. Kinabo, Grace D. Saganda, Wilbrod Crump, John A. TI Leptospirosis among Hospitalized Febrile Patients in Northern Tanzania SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID REAL-TIME PCR; INVASIVE BACTERIAL; FUNGAL-INFECTIONS; REFERENCE VALUES; RISK-FACTORS; SEROGROUP; SEROVAR; TRINIDAD; ANIMALS; CATTLE AB We enrolled consecutive febrile admissions to two hospitals in Moshi, Tanzania. Confirmed leptospirosis was defined as a >= 4-fold increase in microscopic agglutination test (MAT) titer; probable leptospirosis as reciprocal MAT titer 800; and exposure to pathogenic leptospires as titer >= 100. Among 870 patients enrolled in the study, 453 (52.1%) had paired sera available, and 40 (8.8%) of these met the definition for confirmed leptospirosis. Of 832 patients with >= 1 serum sample available, 30 (3.6%) had probable leptospirosis and an additional 277 (33.3%) had evidence of exposure to pathogenic leptospires. Among those with leptospirosis the most common clinical diagnoses were malaria in 31 (44.3%) and pneumonia in 18 (25.7%). Leptospirosis was associated with living in a rural area (odds ratio [OR] 3.4, P <0.001). Among those with confirmed leptospirosis, the predominant reactive serogroups were Mini and Australis. Leptospirosis is a major yet underdiagnosed cause of febrile illness in northern Tanzania, where it appears to be endemic. C1 [Crump, John A.] Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Dept Med, Durham, NC 27710 USA. Duke Univ, Med Ctr, Duke Global Hlth Residency Program, Dept Med, Durham, NC 27710 USA. Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA. [Bui, Duy M.; Galloway, Renee L.; Stoddard, Robyn A.; Shadomy, Sean V.] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. Duke Univ, Duke Global Hlth Inst, Durham, NC 27710 USA. [Onyango, Jecinta J.; Maro, Venance P.; Kinabo, Grace D.] Kilimanjaro Christian Med Ctr, Moshi, Tanzania. Tumaini Univ, Kilimanjaro Christian Med Coll, Moshi, Tanzania. [Saganda, Wilbrod] Mawenzi Reg Hosp, Moshi, Tanzania. RP Crump, JA (reprint author), Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Dept Med, Box 102359, Durham, NC 27710 USA. EM holly.biggs@duke.edu; dbui@cdc.gov; zul0@cdc.gov; frd8@cdc.gov; auf4@cdc.gov; amorr1023@sbcglobal.net; john.bartlett@duke.edu; jeccy_onyango@yahoo.com; ven-maro@yahoo.co.uk; gkinabo@hotmail.com; john.crump@duke.edu FU United States National Institutes of Health (NIH) [U01 AI062563]; NIH Fogarty International Center AIDS International Training and Research Program [D43 PA-03-018]; Duke Clinical Trials Unit and Clinical Research Sites [U01 AI069484]; Duke University Center for AIDS Research [P30 AI 64518] FX This research was supported by an International Studies on AIDS Associated Co-infections (ISAAC) award, a United States National Institutes of Health (NIH) funded program (U01 AI062563). Authors received support from the NIH Fogarty International Center AIDS International Training and Research Program D43 PA-03-018 (JAC, JAB, JJO, VPM), the Duke Clinical Trials Unit and Clinical Research Sites U01 AI069484 (JAC, JAB, JJO, VPM), and the Duke University Center for AIDS Research P30 AI 64518 (JAB). NR 52 TC 34 Z9 34 U1 0 U2 13 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD AUG PY 2011 VL 85 IS 2 BP 275 EP 281 DI 10.4269/ajtmh.2011.11-0176 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 803WN UT WOS:000293613000016 PM 21813847 ER PT J AU Paul, RC Rahman, M Gurley, ES Hossain, MJ Diorditsa, S Hasan, ASMM Banu, SS Alamgir, ASM Rahman, MA Sandhu, H Fischer, M Luby, SP AF Paul, Repon C. Rahman, Mahmudur Gurley, Emily S. Hossain, M. Jahangir Diorditsa, Serguei Hasan, A. S. M. Mainul Banu, Sultana S. Alamgir, A. S. M. Rahman, Muhammad Aziz Sandhu, Hardeep Fischer, Marc Luby, Stephen P. TI A Novel Low-Cost Approach to Estimate the Incidence of Japanese Encephalitis in the Catchment Area of Three Hospitals in Bangladesh SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID CEREBROSPINAL-FLUID; CARE-SEEKING; RURAL BANGLADESH; SURVEILLANCE; IMMUNIZATION; VIRUS; EPIDEMIOLOGY; VACCINE; NEPAL; IGM AB Acute meningoencephalitis syndrome surveillance was initiated in three medical college hospitals in Bangladesh in October 2007 to identify Japanese encephalitis (JE) cases. We estimated the population-based incidence of JE in the three hospitals' catchment areas by adjusting the hospital-based crude incidence of JE by the proportion of catchment area meningoencephalitis cases who were admitted to surveillance hospitals. Instead of a traditional house-to-house survey, which is expensive for a disease with low frequency, we attempted a novel approach to identify meningoencephalitis cases in the hospital catchment area through social networks among the community residents. The estimated JE incidence was 2.7/100,000 population in Rajshahi (95% confidence interval [CI] = 1.8-4.9), 1.4 in Khulna (95% Cl = 0.9-4.1), and 0.6 in Chittagong (95% CI = 0.4-0.9). Bangladesh should consider a pilot project to introduce JE vaccine in high-incidence areas. C1 [Paul, Repon C.] ICDDR B, Program Infect Dis & Vaccine Sci, Mohakhali 1212, Draka, Bangladesh. [Paul, Repon C.; Gurley, Emily S.; Luby, Stephen P.] ICDDR B, Program Infect Dis & Vaccine Sci, Dhaka, Bangladesh. Govt Peoples Republ Bangladesh, IEDCR, Minist Hlth & Family Welf, Dhaka, Bangladesh. [Diorditsa, Serguei; Hasan, A. S. M. Mainul] World Hlth Org, Dhaka, Bangladesh. Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Hossain, M. Jahangir] ICDDR B, Div Clin Sci, Dhaka, Bangladesh. [Rahman, Muhammad Aziz] Univ Adelaide, Discipline Publ Hlth, Sch Populat Hlth & Clin Practice, Adelaide, SA, Australia. [Sandhu, Hardeep] Ctr Dis Control & Prevent, Atlanta, GA USA. [Fischer, Marc] CDC, Arboviral Dis Branch, DVBID, NCZVED, Atlanta, GA 30333 USA. RP Paul, RC (reprint author), ICDDR B, Program Infect Dis & Vaccine Sci, 68 Shahid Tajuddin Ahmed Sharani, Mohakhali 1212, Draka, Bangladesh. EM repon@icddrb.org; mrahman@citeecho.net; egurley@icddrb.org; jhossain@icddrb.org; diorditsas@searo.who.int; hasana@searo.who.int; sultana_aus@yahoo.com; aalamgir@gmail.com; drazizdmc@yahoo.com; hjs3@cdc.gov; mfischer@cdc.gov; sluby@icddrb.org RI Gurley, Emily/B-7903-2010; OI Gurley, Emily/0000-0002-8648-9403; Rahman, Muhammad Aziz/0000-0003-1665-7966 FU Centers for Disease Control and Prevention,Atlanta, GA (CDC) [I-U01-C1000298]; South-East Asia Regional Office (SEARO), World Health Organization (WHO) [SE BAN AAD 210 XC 08 8] FX This study was funded by the Centers for Disease Control and Prevention,Atlanta, GA (CDC), cooperative award number I-U01-C1000298, and South-East Asia Regional Office (SEARO), World Health Organization (WHO), allotment no. SE BAN AAD 210 XC 08 8. ICDDR,B acknowledges with gratitude the commitment of the CDC and WHO to the ICDDR,B's research efforts. NR 43 TC 15 Z9 15 U1 0 U2 5 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD AUG PY 2011 VL 85 IS 2 BP 379 EP 385 DI 10.4269/ajtmh.2011.10-0706 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 803WN UT WOS:000293613000031 PM 21813862 ER PT J AU Kucerova, Z Sriram, R Wilkins, PP Visvesvara, GS AF Kucerova, Zuzana Sriram, Rama Wilkins, Patricia P. Visvesvara, Govinda S. TI Identification of Antigenic Targets for Immunodetection of Balamuthia mandrillaris Infection SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID FREE-LIVING AMEBAS; NAEGLERIA-FOWLERI; ACANTHAMOEBA SPP.; SERUM ANTIBODIES; LEPTOMYXID-AMEBA; ENCEPHALITIS; MENINGOENCEPHALITIS; ANIMALS; HUMANS; AGENT AB The free-living amoeba Balamuthia mandrillaris causes granulomatous amoebic encephalitis (GAE) in humans. Rapid identification of balamuthiasis is critical for effective therapeutic intervention and case management. In the present study we identified target antigens for the development of a serological assay for B. mandrillaris infection. We demonstrated by silver staining that protein profiles for all eight isolates of B. mandrillaris, independent of human or animal origin or geographic origin, appeared to be similar except for some minor differences, indicating the molecular homogeneity of these strains. The profiles of all isolates, which ranged from 200 to 10 kDa, were similar, with a prominent protein visible around 30 kDa; all appeared considerably different from protein profiles of the control E6 cells and Acanthamoeba castellanii and Naegleria fowleri isolates. Western blot analysis with rabbit hyperimmune serum identified the major immunodominant antigens of 25, 50, 75, and 80 kDa; positive human sera reacted strongly with proteins around 25, 40, 50, and 75 kDa. Proteins around 40 kDa detected by human serum were not recognized by hyperimmune rabbit serum. None of the target proteins were detected by uninfected control sera. Reactivities of five patients' sera with 4 different isolates of B. mandrillaris (2 strains of human and 2 strains of animal origins) revealed that patients' sera reacted slightly differently with different B. mandrillaris isolates, although major proteins of approximately 25, 50, and 75 kDa were present in all extracts. C1 [Kucerova, Zuzana; Sriram, Rama; Wilkins, Patricia P.; Visvesvara, Govinda S.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Kucerova, Zuzana] Atlanta Res & Educ Fdn, Atlanta, GA USA. RP Visvesvara, GS (reprint author), Ctr Dis Control & Prevent, MS-D66, Atlanta, GA 30333 USA. EM gsv1@cdc.gov NR 21 TC 4 Z9 4 U1 1 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD AUG PY 2011 VL 18 IS 8 BP 1297 EP 1301 DI 10.1128/CVI.05082-11 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 800ID UT WOS:000293352100013 PM 21653740 ER PT J AU Krebs, C Breiding, MJ Browne, A Warner, T AF Krebs, Christopher Breiding, Matthew J. Browne, Angela Warner, Tara TI The Association Between Different Types of Intimate Partner Violence Experienced by Women SO JOURNAL OF FAMILY VIOLENCE LA English DT Article DE Intimate partner violence (IPV); Sexual violence; Domestic violence; Overlap ID 18 US STATES/TERRITORIES; DIGIT-DIAL SURVEYS; DOMESTIC VIOLENCE; NONRESPONSE ERROR; INJURY PREVENTION; MENTAL-HEALTH; RISK-FACTORS; PREVALENCE; ABUSE; AGGRESSION AB Those who experience intimate partner violence (IPV) are often subjected to multiple types of victimization such as physical violence, sexual violence, psychological aggression, and stalking. However, relatively few studies have used a national population-based sample and multivariate methods to analyze the associations between these different types of violence. This study uses multivariate methods to analyze a national population-based sample of women in order to document empirically the extent to which different types of IPV overlap, while controlling for personal and behavioral characteristics. Results indicated significant levels of overlap, with victims often experiencing more than one type of victimization by an intimate partner. Findings also indicated that women who had experienced violence by non-intimate partners were often more likely to experience violence by intimates. Finally, women who had experienced stalking by an intimate were more likely to experience more forms of IPV on average than those who had experienced physical violence, sexual violence, or emotional aggression. C1 [Krebs, Christopher] RTI Int Crime Violence & Justice Res Program, Res Triangle Pk, NC 27709 USA. [Breiding, Matthew J.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Browne, Angela] Vera Inst Justice, Washington, DC USA. [Warner, Tara] Bowling Green State Univ, Dept Sociol, Bowling Green, OH 43403 USA. RP Krebs, C (reprint author), RTI Int Crime Violence & Justice Res Program, 3040 Cornwallis Rd, Res Triangle Pk, NC 27709 USA. EM krebs@rti.org NR 77 TC 18 Z9 18 U1 4 U2 14 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7482 J9 J FAM VIOLENCE JI J. Fam. Violence PD AUG PY 2011 VL 26 IS 6 BP 487 EP 500 DI 10.1007/s10896-011-9383-3 PG 14 WC Psychology, Clinical; Family Studies SC Psychology; Family Studies GA 799QD UT WOS:000293300300008 ER PT J AU Schneider, JL White, PL Weiss, J Norton, D Lidgard, J Gould, LH Yee, B Vugia, DJ Mohle-Boetani, J AF Schneider, J. L. White, P. L. Weiss, J. Norton, D. Lidgard, J. Gould, L. H. Yee, B. Vugia, D. J. Mohle-Boetani, J. TI Multistate Outbreak of Multidrug-Resistant Salmonella Newport Infections Associated with Ground Beef, October to December 2007 SO JOURNAL OF FOOD PROTECTION LA English DT Article ID CALIFORNIA AB In late October 2007, an outbreak of multidrug-resistant Salmonella Newport infections affected 42 case patients in California, Arizona, Idaho, and Nevada. A case-control study implicated ground beef from one chain store. Despite detailed ground beef purchase histories-including shopper card information for several case patients-traceback efforts by both the U.S. Department of Agriculture, Food Safety and Inspection Service and the California Department of Public Health were unable to identify the source of contamination. Case patients consumed multiple types of ground beef products purchased at numerous chain store A retail locations. These stores had received beef products for grinding from multiple beef slaughter processing establishments. Detailed retail grinding logs and grinding policies that prevent cross-contamination between batches of ground beef products are crucial in the identification of contaminated beef products associated with foodborne illness. C1 [Schneider, J. L.; Lidgard, J.; Yee, B.; Vugia, D. J.; Mohle-Boetani, J.] Calif Dept Publ Hlth, Div Communicable Dis Control, Infect Dis Branch, Richmond, CA 94804 USA. [White, P. L.] US Food Safety & Inspect Serv, USDA, Omaha, NE 68102 USA. [Weiss, J.] Bur Epidemiol & Dis Control Serv, Arizona Dept Hlth Serv, Off Infect Dis Serv, Phoenix, AZ 85007 USA. [Norton, D.] Calif Emerging Infect Program, Oakland, CA 94612 USA. [Gould, L. H.] Ctr Dis Control & Prevent, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30333 USA. RP Schneider, JL (reprint author), Calif Dept Publ Hlth, Div Communicable Dis Control, Infect Dis Branch, 850 Marina Bay Pkwy, Richmond, CA 94804 USA. EM Jen.JenSchneider@gmail.com NR 10 TC 24 Z9 25 U1 0 U2 5 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X J9 J FOOD PROTECT JI J. Food Prot. PD AUG PY 2011 VL 74 IS 8 BP 1315 EP 1319 DI 10.4315/0362-028X.JFP-11-046 PG 5 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA 803UQ UT WOS:000293607700012 PM 21819658 ER PT J AU Coffey, CC LeBouf, RF Calvert, CA Slaven, JE AF Coffey, Christopher C. LeBouf, Ryan F. Calvert, Catherine A. Slaven, James E. TI Validation of an Evacuated Canister Method for Measuring Part-Per-Billion Levels of Chemical Warfare Agent Simulants SO JOURNAL OF THE AIR & WASTE MANAGEMENT ASSOCIATION LA English DT Article ID VOLATILE ORGANIC-COMPOUNDS; SUMMA POLISHED CANISTERS; AMBIENT AIR; COLLECTION AB The National Institute for Occupational Safety and Health (NIOSH) research on direct-reading instruments (DRIs) needed an instantaneous sampling method to provide independent confirmation of the concentrations of chemical warfare agent (CWA) simulants. It was determined that evacuated canisters would be the method of choice. There is no method specifically validated for volatile organic compounds (VOCs) in the NIOSH Manual of Analytical Methods. The purpose of this study was to validate an evacuated canister method for sampling seven specific VOCs that can be used as a simulant for CWA agents (cyclohexane) or influence the DRI measurement of CWA agents (acetone, chloroform, methylene chloride, methyl ethyl ketone, hexane, and carbon tetrachloride [CCl(4)]). The method used 6-L evacuated stainless-steel fused silica-lined canisters to sample the atmosphere containing VOCs. The contents of the canisters were then introduced into an autosampler/preconcentrator using a microscale purge and trap (MPT) method. The MPT method trapped and concentrated the VOCs in the air sample and removed most of the carbon dioxide and water vapor. After preconcentration, the samples were analyzed using a gas chromatograph with a mass selective detector. The method was tested, evaluated, and validated using the NIOSH recommended guidelines. The evaluation consisted of determining the optimum concentration range for the method; the sample stability over 30 days; and the accuracy, precision, and bias of the method. This method meets the NIOSH guidelines for six of the seven compounds (excluding acetone) tested in the range of 2.3-50 parts per billion (ppb), making it suitable for sampling of these VOCs at the ppb level. C1 [Coffey, Christopher C.] NIOSH, US Dept HHS, Ctr Dis Control & Prevent, Lab Res Branch,Div Resp Dis Studies, Morgantown, WV 26505 USA. [Slaven, James E.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA. RP Coffey, CC (reprint author), NIOSH, US Dept HHS, Ctr Dis Control & Prevent, Lab Res Branch,Div Resp Dis Studies, 1095 Willowdale Rd,Mailstop 2703, Morgantown, WV 26505 USA. EM ccoffey@cdc.gov RI Coffey, Christopher/I-2471-2012; LeBouf, Ryan/K-5478-2012 FU NIOSH FX This study was supported by NIOSH. The authors acknowledge Douglas Markle of Entech, Inc., for his assistance in setting up the preconcentration method. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of NIOSH. Mention of commercial product or trade name does not constitute endorsement by the Centers for-Disease Control/NIOSH. NR 17 TC 1 Z9 1 U1 0 U2 8 PU AIR & WASTE MANAGEMENT ASSOC PI PITTSBURGH PA ONE GATEWAY CENTER, THIRD FL, PITTSBURGH, PA 15222 USA SN 1047-3289 J9 J AIR WASTE MANAGE JI J. Air Waste Manage. Assoc. PD AUG PY 2011 VL 61 IS 8 BP 826 EP 833 DI 10.3155/1047-3289.61.8.826 PG 8 WC Engineering, Environmental; Environmental Sciences; Meteorology & Atmospheric Sciences SC Engineering; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences GA 803AA UT WOS:000293550900004 PM 21874953 ER PT J AU Marin, M Zhang, JX Seward, JF AF Marin, Mona Zhang, John X. Seward, Jane F. TI Near Elimination of Varicella Deaths in the US After Implementation of the Vaccination Program SO PEDIATRICS LA English DT Article DE varicella mortality; varicella deaths; varicella vaccine; NCHS; vaccine-preventable disease ID UNITED-STATES; HEALTHY-CHILDREN; IMMUNE-RESPONSES; EPIDEMIOLOGY; IMMUNIZATION; HOSPITALIZATIONS; COMPLICATIONS; MORTALITY; ERA AB OBJECTIVE: Varicella has been preventable by vaccination in the United States since 1995. Previous studies reported a 66% decline in mortality rate during the first 6 years of the program. Since then, vaccination coverage has increased substantially. We updated the analysis of US varicella mortality for 2002-2007 and assessed the impact of the first 12 years of the US varicella vaccination program on varicella deaths. METHODS: National data on deaths for which varicella was listed as an underlying or contributing cause were obtained from the Mortality Multiple Cause-of-Death records from the US National Center for Health Statistics. We calculated the age-adjusted and age-specific mortality rates for 2002-2007 and trends since the prevaccine years. RESULTS: During the 12 years of the mostly 1-dose US varicella vaccination program, the annual average mortality rate for varicella listed as the underlying cause declined 88%, from 0.41 per million population in 1990-1994 to 0.05 per million population in 2005-2007. The decline occurred in all age groups, and there was an extremely high reduction among children and adolescents younger than 20 years (97%) and among subjects younger than 50 years overall (96%). In the last 6 years analyzed (2002-2007), a total of 3 deaths per age range were reported among children aged 1 to 4 and 5 to 9 years, compared with an annual average of 13 and 16 deaths, respectively, during the prevaccine years. CONCLUSIONS: The impressive decline in varicella deaths can be directly attributed to successful implementation of the 1-dose vaccination program. With the current 2-dose program, there is potential that these most severe outcomes of a vaccine-preventable disease could be eliminated. Pediatrics 2011;128:214-220 C1 [Marin, Mona; Zhang, John X.; Seward, Jane F.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Marin, M (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS A-47, Atlanta, GA 30333 USA. EM mmarin@cdc.gov NR 27 TC 63 Z9 68 U1 2 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD AUG PY 2011 VL 128 IS 2 BP 214 EP 220 DI 10.1542/peds.2010-3385 PG 7 WC Pediatrics SC Pediatrics GA 800CK UT WOS:000293336200033 PM 21788222 ER PT J AU Staat, MA Payne, DC Donauer, S Weinberg, GA Edwards, KM Szilagyi, PG Griffin, MR Hall, CB Curns, AT Gentsch, JR Salisbury, S Fairbrother, G Parashar, UD AF Staat, Mary Allen Payne, Daniel C. Donauer, Stephanie Weinberg, Geoffrey A. Edwards, Kathryn M. Szilagyi, Peter G. Griffin, Marie R. Hall, Caroline B. Curns, Aaron T. Gentsch, Jon R. Salisbury, Shelia Fairbrother, Gerry Parashar, Umesh D. CA NVSN TI Effectiveness of Pentavalent Rotavirus Vaccine Against Severe Disease SO PEDIATRICS LA English DT Article DE rotavirus; acute gastroenteritis; vaccine effectiveness; vaccine impact; RV5; population-based surveillance ID POPULATION-BASED SURVEILLANCE; RESPIRATORY SYNCYTIAL VIRUS; POLYMERASE CHAIN-REACTION; UNITED-STATES; COST-EFFECTIVENESS; YOUNG-CHILDREN; HOSPITALIZATIONS; GASTROENTERITIS; EFFICACY; PREVENTION AB OBJECTIVE: To determine the vaccine effectiveness (VE) of complete and partial vaccination with the pentavalent rotavirus vaccine (RV5) in the prevention of rotavirus acute gastroenteritis (AGE) hospitalizations and emergency department visits during the first 3 rotavirus seasons after vaccine introduction. METHODS: Active, prospective population-based surveillance for AGE and acute respiratory infection (ARIs) in inpatient and emergency department settings provided subjects for a case-control evaluation of VE in 3 US counties from January 2006 through June 2009. Children with laboratory-confirmed rotavirus AGE (cases) were matched according to date of birth and onset of illness to 2 sets of controls: children with rotavirus-negative AGE and children with ARI. The main outcome measure was VE with complete (3 doses) or partial (1 or 2 doses) RV5 vaccination. RESULTS: Of age-eligible children enrolled, 18% of cases, 54% of AGE controls, and 54% of ARI controls received >= 1 dose of RV5. The VE of RV5 for 1, 2, and 3 doses against all rotavirus genotypes with the use of rotavirus-negative AGE controls was 74% (95% confidence interval [CI]: 37%-90%), 88% (95% CI: 66%-96%), and 87% (95% CI: 71%-94%), respectively, and with the use of ARI controls was 73% (95% CI: 43%88%), 88% (95% CI: 68%-95%), and 85% (95% CI: 72%-91%), respectively. The overall VE estimates were comparable during the first and second years of life and against AGE caused by different rotavirus strains. CONCLUSION: RV5 was highly effective in preventing severe rotavirus disease, even after a partial series, with protection persisting throughout the second year of life. Pediatrics 2011;128:e267-e275 C1 [Staat, Mary Allen] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA. [Donauer, Stephanie; Salisbury, Shelia; Fairbrother, Gerry] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Biostat, Cincinnati, OH 45229 USA. [Payne, Daniel C.; Curns, Aaron T.; Gentsch, Jon R.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Epidemiol Branch, Atlanta, GA USA. [Weinberg, Geoffrey A.; Szilagyi, Peter G.] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA. [Hall, Caroline B.] Univ Rochester, Sch Med & Dent, Dept Infect Dis, Rochester, NY 14642 USA. [Edwards, Kathryn M.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA. [Griffin, Marie R.] Vanderbilt Univ, Med Ctr, Dept Prevent Med, Nashville, TN 37232 USA. RP Staat, MA (reprint author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA. EM mary.staat@cchmc.org FU Merck Research Laboratories, Inc; GlaxoSmithKline, Inc; Novartis; Wyeth FX Dr Staat received past research funding from Merck Research Laboratories, Inc, and current funding from GlaxoSmithKline, Inc; and served on the Rotavirus Advisory Board for Merck and Company and GlaxoSmithKline, Inc; Ms Donauer received research funding from GlaxoSmithKline, Inc; Dr Weinberg served on the advisory board for MedImmune and the vaccine speaker's bureaus for Merck, GlaxoSmithKline, and Sanofi Pasteur; and Dr Edwards received research funding from Novartis and Wyeth. The other authors have indicated they have no financial relationships relevant to this article to disclose. NR 27 TC 60 Z9 62 U1 0 U2 9 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD AUG PY 2011 VL 128 IS 2 BP E267 EP E275 DI 10.1542/peds.2010-3722 PG 9 WC Pediatrics SC Pediatrics GA 800CK UT WOS:000293336200002 PM 21768317 ER PT J AU Manthripragada, AD Zhou, EH Budnitz, DS Lovegrove, MC Willy, ME AF Manthripragada, Angelika D. Zhou, Esther H. Budnitz, Daniel S. Lovegrove, Maribeth C. Willy, Mary E. TI Characterization of acetaminophen overdose-related emergency department visits and hospitalizations in the United States SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE acetaminophen overdose; liver toxicity; hospitalizations; emergency department visits ID ACUTE LIVER-FAILURE; ADULT-POPULATION; NONPRESCRIPTION; PRESCRIPTION; SURVEILLANCE; PARACETAMOL; ANALGESICS; ENGLAND AB Purpose To estimate the number of acetaminophen overdose-related emergency department (ED) visits and hospitalizations in the United States, characterize these by intentionality, age, and gender, and compare the strengths and limitations of the utilized databases. Methods We used data from the National Hospital Ambulatory Medical Care Survey (NHAMCS) and the National Electronic Injury Surveillance System (NEISS) to estimate the number of relevant ED visits in the United States between 2000 and 2007, and the National Hospital Discharge Survey (NHDS) to estimate the number of relevant hospitalizations in the United States between 1991 and 2006. National estimates and their standard errors were calculated using information provided in each database. We used the standard United States population in 2000 to calculate age-adjusted rates. Results We estimate an annual average of 44 348 (NHAMCS, 2000-2007) or 78 414 (NEISS, 2006-2007) acetaminophen overdose-related ED visits and 33 520 (NHDS, 2000-2006) hospitalizations. For 2000-2006 we calculated an age-adjusted rate of 13.9 acetaminophen overdose-related hospitalizations per 100 000 US population, with the highest rate (15.7) occurring from 2005 to 2006. Between 1991 and 2006, there was no decrease noted in hospitalizations for intentional or unintentional overdoses. The majority of overdoses reported in NEISS (69.8%) and NHDS (74.2%) were classified as intentional (suicides or suicidal gestures), whereas in NHAMCS, intentionality was evenly distributed. Conclusions Our results suggest that acetaminophen overdose, both intentional and unintentional, remains a significant public health concern. With an understanding of their methodological characteristics and limitations, these national databases can be useful tools to characterize acetaminophen overdose-related ED visits and hospitalizations. Published in 2011 by John Wiley & Sons, Ltd. C1 [Manthripragada, Angelika D.] US FDA, Div Epidemiol, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA. [Budnitz, Daniel S.; Lovegrove, Maribeth C.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Manthripragada, AD (reprint author), US FDA, Div Epidemiol, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave,Bldg 22,Room 2415, Silver Spring, MD 20993 USA. EM angelika.manthripragada@fda.hhs.gov NR 29 TC 25 Z9 26 U1 2 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD AUG PY 2011 VL 20 IS 8 BP 819 EP 826 DI 10.1002/pds.2090 PG 8 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 800PK UT WOS:000293375200006 PM 21294217 ER PT J AU Vishwanathan, SA Guenthner, PC Lin, CY Dobard, C Sharma, S Adams, DR Otten, RA Heneine, W Hendry, RM McNicholl, JM Kersh, EN AF Vishwanathan, Sundaram A. Guenthner, Patricia C. Lin, Carol Y. Dobard, Charles Sharma, Sunita Adams, Debra R. Otten, Ron A. Heneine, Walid Hendry, R. Michael McNicholl, Janet M. Kersh, Ellen N. TI High Susceptibility to Repeated, Low-Dose, Vaginal SHIV Exposure Late in the Luteal Phase of the Menstrual Cycle of Pigtail Macaques SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE SHIV; progesterone; pigtail macaque; menstrual cycle; susceptibility; HIV-1 ID RHESUS MACAQUES; IMMUNODEFICIENCY VIRUS; HORMONAL INFLUENCES; TRANSMISSION; HIV; MONKEYS; SIV; INFECTION; PREGNANCY; PRIMATES AB Fluctuations in susceptibility to HIV or SHIV during the menstrual cycle are currently not fully documented. To address this, the time point of infection was determined in 19 adult female pigtail macaques vaginally challenged during their undisturbed menstrual cycles with repeated, low-dose SHIV(SF162P3) exposures. Eighteen macaques (95%) first displayed viremia in the follicular phase, as compared with 1 macaque (5%) in the luteal phase (P < 0.0001). Due to a viral eclipse phase, we estimated a window of most frequent virus transmission between days 24 and 31 of the menstrual cycle, in the late luteal phase. Thus, susceptibility to vaginal SHIV infection is significantly elevated in the second half of the menstrual cycle when progesterone levels are high and when local immunity may be low. Such susceptibility windows have been postulated before but not definitively documented. Our data support the findings of higher susceptibility to HIV in women during progesterone-dominated periods including pregnancy and contraceptive use. C1 [Vishwanathan, Sundaram A.; Guenthner, Patricia C.; Lin, Carol Y.; Dobard, Charles; Sharma, Sunita; Adams, Debra R.; Otten, Ron A.; Heneine, Walid; Hendry, R. Michael; McNicholl, Janet M.; Kersh, Ellen N.] CDC, NCHHSTP, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. RP Kersh, EN (reprint author), CDC, NCHHSTP, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. EM egk6@cdc.gov FU CDC [Y1-A1-0681-02]; NIH [Y1-A1-0681-02] FX Supported by the CDC, and partially by Interagency Agreement Y1-A1-0681-02 between CDC and NIH. NR 22 TC 71 Z9 74 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD AUG 1 PY 2011 VL 57 IS 4 BP 261 EP 264 DI 10.1097/QAI.0b013e318220ebd3 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 782TD UT WOS:000292033500007 PM 21546848 ER PT J AU Taha, TE Li, Q Hoover, DR Mipando, L Nkanaunena, K Thigpen, MC Taylor, A Kumwenda, J Fowler, MG Mofenson, LM Kumwenda, NI AF Taha, Taha E. Li, Qing Hoover, Donald R. Mipando, Linda Nkanaunena, Kondwani Thigpen, Michael C. Taylor, Allan Kumwenda, Johnstone Fowler, Mary Glenn Mofenson, Lynne M. Kumwenda, Newton I. TI Postexposure Prophylaxis of Breastfeeding HIV-Exposed Infants With Antiretroviral Drugs to Age 14 Weeks: Updated Efficacy Results of the PEPI-Malawi Trial SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE breastfeeding; infant postexposure prophylaxis; mother-to-child transmission of HIV; PEPI-Malawi ID INFECTED WOMEN; TRANSMISSION; MORTALITY; GASTROENTERITIS; BOTSWANA; CHILDREN; UGANDA; BORN; RISK; MILK AB Background: This analysis updates and extends efficacy estimates of the PEPI-Malawi trial through age 24 months at study completion in September 2009. Methods: Infants of breastfeeding HIV-infected women were randomized at birth to the following: (1) single-dose nevirapine (NVP) + 1-week zidovudine (ZDV) (control); (2) control + extended daily NVP (ExtNVP) through 14 weeks; (3) control + extended daily NVP + ZDV (ExtNVP/ZDV) through 14 weeks. We estimated rates of HIV infection, death and HIV infection, or death using Kaplan-Meier analysis. Results: This analysis includes 3126 infants uninfected at birth as follows: 1004 control, 1071 ExtNVP, and 1051 ExtNVP/ZDV. By 9 months, HIV infection rates were 5.0% in ExtNVP, 6.0% in ExtNVP/ZDV, and 11.1% in control (P < 0.001 comparing extended regimens with control). At age 24 months, HIV infection rates had risen to; 11% in the extended arms compared with 15.6% in the controls (P, 0.05). The rates of HIV infection or death were also significantly lower in extended arms. There were no differences in severe adverse events with the exception of higher possibly related events in the ExtNVP/ZDV arm. Conclusions: Daily infant antiretroviral prophylaxis reduces postnatal HIV infection by similar to 70% during the period of prophylaxis. But continued HIV transmission after prophylaxis stops suggests more prolonged infant prophylaxis is needed. C1 [Taha, Taha E.; Kumwenda, Newton I.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA. [Li, Qing] NHGRI, Inherited Dis Branch, NIH, Baltimore, MD USA. [Hoover, Donald R.] Rutgers State Univ, Dept Stat & Biostat, Piscataway, NJ USA. [Hoover, Donald R.] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, Piscataway, NJ USA. [Mipando, Linda; Nkanaunena, Kondwani] Johns Hopkins Univ, Res Project, Coll Med, Ctr Res Mothers & Children, Blantyre, Malawi. [Thigpen, Michael C.; Taylor, Allan] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Kumwenda, Johnstone] Univ Malawi, Coll Med, Dept Internal Med, Blantyre, Malawi. [Fowler, Mary Glenn] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Mofenson, Lynne M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA. RP Taha, TE (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Rm E7138,615 N Wolfe St, Baltimore, MD 21205 USA. EM ttaha@jhsph.edu OI Mofenson, Lynne/0000-0002-2818-9808 FU Centers for Disease Control and Prevention [5 U50 PS022061-05, U50/CC0222061]; Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health; National Human Genome Research Institute, National Institutes of Health FX Supported by a Cooperative Agreement (# 5 U50 PS022061-05; Award # U50/CC0222061) from the Centers for Disease Control and Prevention and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health. Qing Li was supported in part by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health. NR 17 TC 22 Z9 22 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD AUG 1 PY 2011 VL 57 IS 4 BP 319 EP 325 DI 10.1097/QAI.0b013e318217877a PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 782TD UT WOS:000292033500016 PM 21423025 ER PT J AU Roberge, RJ Monaghan, WD Palmiero, AJ Shaffer, R Bergman, MS AF Roberge, Raymond J. Monaghan, William D. Palmiero, Andrew J. Shaffer, Ronald Bergman, Michael S. TI Infrared Imaging for Leak Detection of N95 Filtering Facepiece Respirators: A Pilot Study SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE N95 filtering facepiece respirators; fit test; leaks; thermal imaging; infrared camera ID SKIN TEMPERATURE; FACIAL SKIN; FIT; PROTECTION; SITES AB Background This study was undertaken to determine the utility of an infrared camera (IRC) for assessing leaks around filtering facepiece respirators (FFR) during quantitative respirator fit testing. Methods Eight subjects underwent quantitative fit testing on six N95 FFR models (48 total fit tests) while simultaneously being recorded with an IRC. Results The IRC detected 49 exhalation leaks during 39 tests and no leaks in nine tests. Exhalation leaks were identified in all failed fit tests (13) and a majority (26 of 35) of passed tests. Anatomically, the nasal region and malar (cheekbone) regions accounted for 71% of identified leak sites. Fit factors for fit tests without identified exhalation leaks were significantly higher than fit tests with leaks detected by IRC (P = 0.01). Conclusions Thermal imaging using IRC can detect leaks in respiratory protective equipment and has the potential as a screening tool for assessment of the adequacy of post-donning FFR fit. Am. J. Ind. Med. 54:628-636, 2011. (C) 2011 Wiley-Liss, Inc. C1 [Roberge, Raymond J.; Monaghan, William D.; Shaffer, Ronald] NIOSH, Natl Personal Protect Technol Lab, Ctr Dis Control & Prevent, Pittsburgh, PA 15236 USA. [Palmiero, Andrew J.; Bergman, Michael S.] URS Corp, Pittsburgh, PA USA. RP Roberge, RJ (reprint author), NIOSH, Natl Personal Protect Technol Lab, Ctr Dis Control & Prevent, 626 Cochrans Mill Rd, Pittsburgh, PA 15236 USA. EM dtn0@cdc.gov RI Shaffer, Ronald/I-2134-2012 NR 35 TC 12 Z9 12 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD AUG PY 2011 VL 54 IS 8 BP 628 EP 636 DI 10.1002/ajim.20970 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 796IY UT WOS:000293046200008 PM 21594885 ER PT J AU Lu, PJ Euler, GL AF Lu, Peng-jun Euler, Gary L. TI Influenza, hepatitis B, and tetanus vaccination coverage among health care personnel in the United States SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Influenza; hepatitis B; tetanus; vaccination coverage; health-care personnel ID WORKERS; QUESTIONNAIRE AB Background: Health care personnel (HCP) are at risk for exposure to and possible transmission of vaccine-preventable diseases. Maintenance of immunity is an essential prevention practice for HCP. We assessed the recent influenza, hepatitis B, and tetanus vaccination coverage among HCP in the United States. Methods: We analyzed data from the 2007 National Immunization Survey-Adult restricted to survey respondents aged 18 to 64 years. Influenza, hepatitis B, and tetanus vaccination coverage levels among HCP were assessed. Multivariable logistic regression was conducted to assess factors independently associated with receipt of vaccination among HCP. Results: Among HCP aged 18 to 64 years, 46.7% (95% confidence interval [CI]: 39.6%-53.8%) had received influenza vaccination for the 2006-2007 season, and 70.4% (95% CI: 63.9%-76.1%) received tetanus vaccination in the past 10 years; 61.7% (95% CI: 52.5%-70.2%) had received 3 or more doses of hepatitis B vaccination among HCP aged 18 to 49 years. Multiple logistic regression analysis showed that being married was associated with influenza vaccination coverage, higher education level was associated with hepatitis B vaccination coverage, and younger age was significantly associated with tetanus vaccination among HCP. Among those HCP who did not receive influenza vaccination, the most common reason reported was respondent concerns about vaccine safety and adverse effects. Conclusion: By 2007, influenza and hepatitis B vaccination coverage among HCP remained well below the Healthy People 2010 objectives. Tetanus vaccination level was 70%, and this study provided a baseline data for tetanus vaccination among HCP. Innovative strategies are needed to further increase vaccination coverage among HCP. C1 [Lu, Peng-jun; Euler, Gary L.] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Lu, PJ (reprint author), Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mail Stop E-62, Atlanta, GA 30333 USA. EM lhp8@cdc.gov NR 39 TC 14 Z9 15 U1 0 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD AUG PY 2011 VL 39 IS 6 BP 488 EP 494 DI 10.1016/j.ajic.2010.10.009 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 799IC UT WOS:000293279300008 PM 21288599 ER PT J AU Wright, MO Hebden, JN Allen-Bridson, K Morrell, GC Horan, T AF Wright, Marc-Oliver Hebden, Joan N. Allen-Bridson, Kathy Morrell, Gloria C. Horan, Teresa TI Health Care-Associated Infections Studies Project: An American Journal of Infection Control and National Healthcare Safety Network Data Quality Collaboration Case Study 6 SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Editorial Material C1 [Wright, Marc-Oliver] NorthShore Univ HealthSyst, Dept Infect Control, Evanston, IL 60201 USA. [Hebden, Joan N.] Univ Maryland, Med Ctr, Dept Infect Control, Baltimore, MD 21201 USA. [Allen-Bridson, Kathy; Morrell, Gloria C.; Horan, Teresa] Ctr Dis Control & Prevent, Natl Healthcare Safety Network, Div Healthcare Qual Promot, Atlanta, GA USA. RP Wright, MO (reprint author), NorthShore Univ HealthSyst, Dept Infect Control, 2650 Ridge Ave,Burch 124, Evanston, IL 60201 USA. EM MWright@northshore.org NR 0 TC 0 Z9 0 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD AUG PY 2011 VL 39 IS 6 BP 515 EP 516 DI 10.1016/j.ajic.2011.03.023 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 799IC UT WOS:000293279300013 PM 21704430 ER PT J AU Gase, LN Ruo, T Dunet, D Schmidt, SM Simon, PA Fielding, JE AF Gase, Lauren N. Ruo, Tony Dunet, Diane Schmidt, Steven M. Simon, Paul A. Fielding, Jonathan E. TI Estimating the Potential Health Impact and Costs of Implementing a Local Policy for Food Procurement to Reduce the Consumption of Sodium in the County of Los Angeles SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID DETERMINING BLOOD-PRESSURE; WORKSITE CAFETERIA; AMERICAN DIET; SALT; REDUCTIONS; INTERVENTION; METAANALYSIS; CHILDREN; CALORIE; SAVINGS AB Objectives. We examined approaches to reduce sodium content of food served in settings operated or funded by the government of the County of Los Angeles, California. Methods. We adapted health impact assessment methods to mathematically simulate various levels of reduction in the sodium content of food served by the County of Los Angeles and to estimate the reductions' potential impacts on mean systolic blood pressure (SBP) among food-service customers. We used data provided by county government food-service vendors to generate these simulations. Results. Our analysis predicted that if the postulated sodium-reduction strategies were implemented, adults would consume, on average, 233 fewer milligrams of sodium each day. This would correspond to an average decrease of 0.71 millimeters of mercury in SBP among adult hypertensives, 388 fewer cases of uncontrolled hypertension in the study population, and an annual decrease of $629 724 in direct health care costs. Conclusions. Our findings suggest that a food-procurement policy can contribute to positive health and economic effects at the local level. Our approach may serve as an example of sodium-reduction analysis for other jurisdictions to follow. (Am J Public Health. 2011;101:1501-1507. doi:10.2105/AJPH.2011.300138) C1 [Gase, Lauren N.; Dunet, Diane; Schmidt, Steven M.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. [Ruo, Tony; Simon, Paul A.; Fielding, Jonathan E.] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. RP Gase, LN (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Highway,Mail Stop K-47, Atlanta, GA 30341 USA. EM lgase@cdc.gov NR 39 TC 8 Z9 8 U1 1 U2 8 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD AUG PY 2011 VL 101 IS 8 BP 1501 EP 1507 DI 10.2105/AJPH.2011.300138 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 797SD UT WOS:000293149500030 PM 21680933 ER PT J AU Matthijnssens, J Ciarlet, M McDonald, SM Attoui, H Banyai, K Brister, JR Buesa, J Esona, MD Estes, MK Gentsch, JR Iturriza-Gomara, M Johne, R Kirkwood, CD Martella, V Mertens, PPC Nakagomi, O Parreno, V Rahman, M Ruggeri, FM Saif, LJ Santos, N Steyer, A Taniguchi, K Patton, JT Desselberger, U Van Ranst, M AF Matthijnssens, Jelle Ciarlet, Max McDonald, Sarah M. Attoui, Houssam Banyai, Krisztian Brister, J. Rodney Buesa, Javier Esona, Mathew D. Estes, Mary K. Gentsch, Jon R. Iturriza-Gomara, Miren Johne, Reimar Kirkwood, Carl D. Martella, Vito Mertens, Peter P. C. Nakagomi, Osamu Parreno, Viviana Rahman, Mustafizur Ruggeri, Franco M. Saif, Linda J. Santos, Norma Steyer, Andrej Taniguchi, Koki Patton, John T. Desselberger, Ulrich Van Ranst, Marc TI Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG) SO ARCHIVES OF VIROLOGY LA English DT Article ID GROUP-A ROTAVIRUS; FULL GENOMIC ANALYSIS; GROUP-B ROTAVIRUSES; GROUP-C ROTAVIRUSES; HUMAN WA-LIKE; BOVINE ROTAVIRUS; MOLECULAR CHARACTERIZATION; PORCINE ROTAVIRUS; SEQUENCE-ANALYSIS; INTERSPECIES TRANSMISSION AB In April 2008, a nucleotide-sequence-based, complete genome classification system was developed for group A rotaviruses (RVs). This system assigns a specific genotype to each of the 11 genome segments of a particular RV strain according to established nucleotide percent cutoff values. Using this approach, the genome of individual RV strains are given the complete descriptor of Gx-P[x]-Ix-Rx-Cx-Mx-Ax-Nx-Tx-Ex-Hx. The Rotavirus Classification Working Group (RCWG) was formed by scientists in the field to maintain, evaluate and develop the RV genotype classification system, in particular to aid in the designation of new genotypes. Since its conception, the group has ratified 51 new genotypes: as of April 2011, new genotypes for VP7 (G20-G27), VP4 (P[28]-P[35]), VP6 (I12-I16), VP1 (R5-R9), VP2 (C6-C9), VP3 (M7-M8), NSP1 (A15-A16), NSP2 (N6-N9), NSP3 (T8-T12), NSP4 (E12-E14) and NSP5/6 (H7-H11) have been defined for RV strains recovered from humans, cows, pigs, horses, mice, South American camelids (guanaco), chickens, turkeys, pheasants, bats and a sugar glider. With increasing numbers of complete RV genome sequences becoming available, a standardized RV strain nomenclature system is needed, and the RCWG proposes that individual RV strains are named as follows: RV group/species of origin/country of identification/common name/year of identification/G- and P-type. In collaboration with the National Center for Biotechnology Information (NCBI), the RCWG is also working on developing a RV-specific resource for the deposition of nucleotide sequences. This resource will provide useful information regarding RV strains, including, but not limited to, the individual gene genotypes and epidemiological and clinical information. Together, the proposed nomenclature system and the NCBI RV resource will offer highly useful tools for investigators to search for, retrieve, and analyze the ever-growing volume of RV genomic data. C1 [Matthijnssens, Jelle; Van Ranst, Marc] Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Lab Clin & Epidemiol Virol, B-3000 Louvain, Belgium. [Ciarlet, Max] Novartis Vaccines & Diagnost Inc, Clin Res & Dev, Cambridge, MA 02139 USA. [McDonald, Sarah M.; Patton, John T.] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA. [Attoui, Houssam; Mertens, Peter P. C.] Inst Anim Hlth, Vector Borne Dis Program, Pirbright GU24 0NF, Surrey, England. [Banyai, Krisztian] Hungarian Acad Sci, Vet Med Res Inst, H-1143 Budapest, Hungary. [Brister, J. Rodney] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20892 USA. [Buesa, Javier] Univ Valencia, Dept Microbiol & Ecol, Sch Med, Valencia 46010, Spain. [Esona, Mathew D.; Gentsch, Jon R.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Estes, Mary K.] Baylor Coll Med, Dept Mol Virol & Microbiol & Med GI, Houston, TX 77030 USA. [Iturriza-Gomara, Miren] Hlth Protect Agcy, Enter Virus Unit, Virus Reference Dept, Ctr Infect, London, England. [Johne, Reimar] Fed Inst Risk Assessment, Berlin, Germany. [Kirkwood, Carl D.] Royal Childrens Hosp, Enter Virus Res Grp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia. [Martella, Vito] Univ Bari, Dept Vet Publ Hlth, Bari, Italy. [Nakagomi, Osamu] Nagasaki Univ, Dept Mol Microbiol & Immunol, Nagasaki 8528523, Japan. [Parreno, Viviana] INTA Castelar, Inst Virol, CICVyA, Buenos Aires, DF, Argentina. [Rahman, Mustafizur] ICDDR B, Virol Lab, Dhaka 1212, Bangladesh. [Ruggeri, Franco M.] Ist Super Sanita, Dept Vet Publ Hlth & Food Safety, I-00161 Rome, Italy. [Saif, Linda J.] Ohio State Univ, Food Anim Hlth Res Program, Ohio Agr Res & Dev Ctr, Wooster, OH 44691 USA. [Santos, Norma] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Virol, BR-21941 Rio De Janeiro, Brazil. [Steyer, Andrej] Univ Ljubljana, Fac Med, Inst Microbiol & Immunol, Ljubljana 1104, Slovenia. [Taniguchi, Koki] Fujita Hlth Univ, Sch Med, Dept Virol & Parasitol, Aichi 4701192, Japan. [Desselberger, Ulrich] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England. RP Matthijnssens, J (reprint author), Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Lab Clin & Epidemiol Virol, Minderbroedersstr 10, B-3000 Louvain, Belgium. EM jelle.matthijnssens@uz.kuleuven.ac.be RI rahman, mustafizur/E-6918-2010; Iturriza Gomara, Miren/B-4351-2013; Ruggeri, Franco/B-5707-2013; Patton, John/P-1390-2014; Matthijnssens, Jelle/A-6770-2015; Buesa, Javier/D-8927-2014; Santos, Norma/H-6986-2015; Matthijnssens, Jelle/B-8634-2016; Institute, Pirbright/K-4476-2014; Martella, Vito/K-3146-2016; OI Iturriza Gomara, Miren/0000-0001-5816-6423; Buesa, Javier/0000-0002-3328-3428; Santos, Norma/0000-0002-5123-9172; Martella, Vito/0000-0002-5740-6947; Steyer, Andrej/0000-0001-6819-2406; Van Ranst, Marc/0000-0002-1674-4157; Mertens, Peter/0000-0002-3438-3738; Banyai, Krisztian/0000-0002-6270-1772 FU FWO ('Fonds voor Wetenschappelijk Onderzoek'); National Institute of Allergy and Infectious Diseases, National Institutes of Health; Hungarian Scientific Research Fund [OTKA PD76364]; Spanish Ministry of Science [FUN-C-FOOD CSD2007-063]; Deutsche Forschungsgemeinschaft [JO369/4-1]; NHMRC [607347]; Ministry of Health; Ministry of Health, CCM "Rotanet-Italy'' FX J. Matthijnssens is supported by an FWO ('Fonds voor Wetenschappelijk Onderzoek') postdoctoral fellowship. S. McDonald and J. Patton are supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. K. Banyai was supported by the Hungarian Scientific Research Fund (OTKA PD76364). J. Buesa is supported by the Consolider-Ingenio 2010 Program (FUN-C-FOOD CSD2007-063) of the Spanish Ministry of Science. R. Johne is supported by a grant from the Deutsche Forschungsgemeinschaft (JO369/4-1). CD Kirkwood is supported by an NHMRC Career Development Award (607347). V. Martella was supported by the Ministry of Health, Ricerca finalizzata 2007 "Zoonosi e infezioni virali esotiche: fronteggiare le emergenze attraverso un approccio integrato fra medicina umana e veterinaria''. F. M. Ruggeri is supported by the Ministry of Health, CCM "Rotanet-Italy'' Programme. NR 106 TC 398 Z9 421 U1 4 U2 34 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0304-8608 EI 1432-8798 J9 ARCH VIROL JI Arch. Virol. PD AUG PY 2011 VL 156 IS 8 BP 1397 EP 1413 DI 10.1007/s00705-011-1006-z PG 17 WC Virology SC Virology GA 798TW UT WOS:000293236100010 PM 21597953 ER PT J AU Mancuso, JD Tribble, D Mazurek, GH Li, YZ Olsen, C Aronson, NE Geiter, L Goodwin, D Keep, LW AF Mancuso, James D. Tribble, David Mazurek, Gerald H. Li, Yuanzhang Olsen, Cara Aronson, Naomi E. Geiter, Lawrence Goodwin, Donald Keep, Lisa W. TI Impact of Targeted Testing for Latent Tuberculosis Infection Using Commercially Available Diagnostics SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID RISK ASSESSMENT QUESTIONNAIRE; GAMMA RELEASE ASSAYS; NEW-YORK-CITY; SKIN-TEST; MYCOBACTERIUM-TUBERCULOSIS; UNITED-STATES; PREVALENCE; CONTACT; CHILDREN; MODEL AB Background. The interferon-gamma release assays (IGRAs) are increasingly being used as an alternative to the tuberculin skin test (TST). Although IGRAs may have better specificity and certain logistic advantages to the TST, their use may contribute to overtesting of low-prevalence populations if testing is not targeted. The objective of this study was to evaluate the accuracy of a risk factor questionnaire in predicting a positive test result for latent tuberculosis infection using the 3 commercially available diagnostics. Methods. A cross-sectional comparison study was performed among recruits undergoing Army basic training at Fort Jackson, South Carolina, from April through June 2009. The tests performed included: (1) a risk factor questionnaire; (2) the QuantiFERON Gold In-Tube test (Cellestis Limited, Carnegie, Victoria, Australia); (3) the T-SPOT. TB test (Oxford Immunotec Limited, Abingdon, United Kingdom); and (4) the TST (Sanofi Pasteur Ltd., Toronto, Ontario, Canada). Prediction models used logistic regression to identify factors associated with positive test results. RFQ prediction models were developed independently for each test. Results. Use of a 4-variable model resulted in 79% sensitivity, 92% specificity, and a c statistic of 0.871 in predicting a positive TST result. Targeted testing using these risk factors would reduce testing by >90%. Models predicting IGRA outcomes had similar specificities as the skin test but had lower sensitivities and c statistics. Conclusions. As with the TST, testing with IGRAs will result in false-positive results if the IGRAs are used in low-prevalence populations. Regardless of the test used, targeted testing is critical in reducing unnecessary testing and treatment. C1 [Mancuso, James D.] Walter Reed Army Inst Res, Prevent Med Residency Program, Div Prevent Med, Silver Spring, MD 20910 USA. [Mancuso, James D.; Tribble, David; Olsen, Cara; Keep, Lisa W.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA. [Aronson, Naomi E.] Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD 20814 USA. [Geiter, Lawrence] Otsuka Pharmaceut Co Ltd, TB Prod Unit, Rockville, MD USA. [Mazurek, Gerald H.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Goodwin, Donald] USAF, Sch Aerosp Med, Brooks City Base, TX USA. RP Mancuso, JD (reprint author), Walter Reed Army Inst Res, Prevent Med Residency Program, Div Prevent Med, 503 Robert Grant Rd, Silver Spring, MD 20910 USA. EM james.mancuso@us.army.mil OI Li, Yuanzhang/0000-0001-8872-4430 FU Uniformed Services University of the Health Sciences; US Army Public Health Command [IDCRP-021]; Infectious Diseases Clinical Research Program (IDCRP) [IDCRP-021]; medical and installation leadership at Fort Jackson; National Institute of Allergy and Infectious Diseases, National Institutes of Health, under Inter-Agency [Y1-AI-5072] FX This study would not have been possible without financial and other support of the Uniformed Services University of the Health Sciences, the US Army Public Health Command, the Infectious Diseases Clinical Research Program, the medical and installation leadership at Fort Jackson, and the Soldiers who participated in the study.; This study (IDCRP-021) was supported by both the US Army Public Health Command and the Infectious Disease Clinical Research Program (IDCRP). The IDCRP is a Department of Defense program executed through the Uniformed Services University of the Health Sciences. This project has been funded, in whole or in part, with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under Inter-Agency Agreement Y1-AI-5072. NR 29 TC 11 Z9 11 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 1 PY 2011 VL 53 IS 3 BP 234 EP 244 DI 10.1093/cid/cir321 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 796BK UT WOS:000293025000004 PM 21765072 ER PT J AU Payne, DC Staat, MA Edwards, KM Szilagyi, PG Weinberg, GA Hall, CB Chappell, J Curns, AT Wikswo, M Tate, JE Lopman, BA Parashar, UD AF Payne, Daniel C. Staat, Mary Allen Edwards, Kathryn M. Szilagyi, Peter G. Weinberg, Geoffrey A. Hall, Caroline B. Chappell, James Curns, Aaron T. Wikswo, Mary Tate, Jacqueline E. Lopman, Benjamin A. Parashar, Umesh D. CA NVSN TI Direct and Indirect Effects of Rotavirus Vaccination Upon Childhood Hospitalizations in 3 US Counties, 2006-2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID POPULATION-BASED SURVEILLANCE; RESPIRATORY SYNCYTIAL VIRUS; UNITED-STATES; YOUNG-CHILDREN; GASTROENTERITIS; INFECTION; DECLINE; IMPACT; RATES AB Background. Routine rotavirus vaccination of US infants began in 2006. We conducted active, population-based surveillance for rotavirus gastroenteritis hospitalizations in 3 US counties to assess vaccine impact. Methods. Children <36 months old hospitalized with diarrhea and/or vomiting were enrolled from January through June each year during the period 2006-2009 and tested for rotavirus. Age-stratified rates of hospitalization for rotavirus infection were compared with corresponding vaccination coverage among a control group of children with acute respiratory illness. To assess direct and indirect benefits, vaccination coverage rates in the control group were multiplied by vaccine effectiveness estimates to calculate expected reductions in the rate of hospitalization for rotavirus infection. Rotavirus serotypes were compared across years. Results. Compared with 2006, a significant reduction in rates of hospitalization for rotavirus infection (P < .001) was observed in 2008 among all age groups. There was an 87% reduction in the 6-11-month-old age group (coverage, 77%), a 96% reduction in the 12-23-months-old age group (coverage, 46%), and a 92% reduction in the 24-35-month-old age group (coverage, 1%), which exceeded reductions expected on the basis of coverage and vaccine effectiveness estimates. Age-specific rate reductions were nearly equivalent to those expected on the basis of age-specific vaccine coverage in 2009. Predominant strains varied annually: G1P[8] (91%) in 2006; G1P[8] (45%) and G12P[8] (36%) in 2007; G1P[8] (89%) in 2008; and G3P[8] (43%), G2P[4] (34%), and G9P[8] (27%) in 2009. Conclusions. Rotavirus vaccination has dramatically decreased rates of hospitalization for rotavirus infection among children in these US counties. In 2008, reductions were prominent among both vaccine-eligible age groups and older, largely unvaccinated children; the latter likely resulted from indirect protection. Although rates among age groups eligible for vaccination remained low in 2009, indirect benefits disappeared. C1 [Payne, Daniel C.; Curns, Aaron T.; Wikswo, Mary; Tate, Jacqueline E.; Lopman, Benjamin A.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Epidemiol Branch, Atlanta, GA 30333 USA. [Staat, Mary Allen] Univ Cincinnati, Cincinnati Childrens Hosp, Dept Pediat, Coll Med,Med Ctr, Cincinnati, OH 45221 USA. [Edwards, Kathryn M.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA. [Chappell, James] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA. [Szilagyi, Peter G.; Weinberg, Geoffrey A.; Hall, Caroline B.] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA. RP Payne, DC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Epidemiol Branch, 1600 Clifton Rd,NE,Mailstop A47, Atlanta, GA 30333 USA. EM dvp6@cdc.gov FU US Centers for Disease Control and Prevention; Merck Research Laboratories; GlaxoSmithKline; Novartis; Wyeth FX NVSN is funded by the US Centers for Disease Control and Prevention through cooperative agreements with each participating surveillance site.; M. A. S. has received research funding from Merck Research Laboratories and GlaxoSmithKline, has served on the Rotavirus Advisory Board for Merck and GlaxoSmithKline, and is a consultant for Medimmune. K. M. E. has received research funding from Novartis and Wyeth. G. A. W. has served on the Advisory Board for MedImmune and Vaccine Speaker's Bureaus for Merck, GlaxoSmithKline, and Sanofi Pasteur. All other authors: No reported conflicts. NR 23 TC 99 Z9 102 U1 0 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 1 PY 2011 VL 53 IS 3 BP 245 EP 253 DI 10.1093/cid/cir307 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 796BK UT WOS:000293025000005 PM 21705316 ER PT J AU Rouphael, N Steyn, S Bangert, M Sampson, JS Adrian, P Madhi, SA Klugman, KP Ades, EW AF Rouphael, Nadine Steyn, Sanet Bangert, Mathieu Sampson, Jackie S. Adrian, Peter Madhi, Shabir A. Klugman, Keith P. Ades, Edwin W. TI Use of 2 pneumococcal common protein real-time polymerase chain reaction assays in healthy children colonized with Streptococcus pneumoniae SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE lytA and psaA; PCR assay; Streptococcus pneumoniae ID CONJUGATE VACCINE; IDENTIFICATION; DNA; PCR AB Polymerase chain reaction (PCR) offers promise in pneumococcal diagnostics, but whether nasopharyngeal carriage causes false-positive results in people colonized with Streptococcus pneumoniae is unknown. We found in serum no positive samples for pneumococcal DNA in 100 carriers and noncarriers using 2 different real-time PCR assays targeting lytA and psaA genes. (C) 2011 Elsevier Inc. All rights reserved. C1 [Rouphael, Nadine; Bangert, Mathieu; Sampson, Jackie S.; Ades, Edwin W.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Rouphael, Nadine] Emory Univ, Sch Med, Atlanta, GA 30303 USA. [Steyn, Sanet] Emory Univ, Atlanta, GA 30322 USA. [Bangert, Mathieu] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. [Adrian, Peter; Madhi, Shabir A.; Klugman, Keith P.] Univ Witwatersrand, MRC, Resp & Meningeal Pathogens Res Unit, ZA-2131 Johannesburg, South Africa. [Adrian, Peter; Madhi, Shabir A.] Univ Witwatersrand, Natl Res Fdn, Dept Sci & Technol, ZA-2013 Johannesburg, South Africa. [Klugman, Keith P.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30329 USA. [Klugman, Keith P.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30329 USA. RP Rouphael, N (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. EM nroupha@emory.edu OI Bangert, Mathieu/0000-0003-1320-8145 NR 8 TC 9 Z9 9 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD AUG PY 2011 VL 70 IS 4 BP 452 EP 454 DI 10.1016/j.diagmicrobio.2010.09.006 PG 3 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 799WN UT WOS:000293316900005 PM 21397430 ER PT J AU Castorina, R Bradman, A Sjodin, A Fenster, L Jones, RS Harley, KG Eisen, EA Eskenazi, B AF Castorina, Rosemary Bradman, Asa Sjoedin, Andreas Fenster, Laura Jones, Richard S. Harley, Kim G. Eisen, Ellen A. Eskenazi, Brenda TI Determinants of Serum Polybrominated Diphenyl Ether (PBDE) Levels among Pregnant Women in the CHAMACOS Cohort SO ENVIRONMENTAL SCIENCE & TECHNOLOGY LA English DT Article ID FLAME RETARDANTS; POLYCHLORINATED-BIPHENYLS; THYROID-HORMONE; HOUSE-DUST; ENVIRONMENT; POPULATION; CALIFORNIA AB We measured levels of 10 polybrominated diphenyl ether (PBDE) congeners in serum collected during pregnancy and at delivery from 416 pregnant, predominantly immigrant, women living in Monterey County, CA. The most frequently detected congeners were BDE-47, -99, -100, and -153, all components of the penta mixture, detected in >97% of samples. We used multivariable regression models to examine factors associated with exposure to individual PBDE congeners as well as their total summed concentration (ng/g lipid). Prenatal and delivery total PBDE levels were correlated between sampling times (n = 21; Pearson r = 0.99, p < 0.001). In multivariable models, total PBDE levels increased significantly with time residing in the U.S. (p < 0.001) and among women with 2:3 pieces of stuffed furniture in their homes (p < 0.05). Women's total PBDE levels increased 4.0% (95% CI = 2.8, 5.3) for each additional year residing in the U.S., after adjustment for prepregnancy BMI, weight gain during pregnancy, and SES. Having >= 3 pieces of stuffed furniture in the home was associated with a 26.8% (95% CI = 2.0, 57.5) increase in women's serum PBDE levels. Findings suggest PBDE indoor contamination in California homes is contributing to human exposures in a population of recent immigrants. C1 [Castorina, Rosemary; Bradman, Asa; Fenster, Laura; Harley, Kim G.; Eisen, Ellen A.; Eskenazi, Brenda] Univ Calif Berkeley, Sch Publ Hlth, CERCH, Berkeley, CA 94720 USA. [Sjoedin, Andreas; Jones, Richard S.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Eisen, Ellen A.] Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth, Berkeley, CA 94720 USA. RP Castorina, R (reprint author), Univ Calif Berkeley, Sch Publ Hlth, CERCH, Berkeley, CA 94720 USA. EM rcastori@berkeley.edu RI Sjodin, Andreas/F-2464-2010 FU NIEHS [PO1 ES009605, RO1 ES015572]; EPA [RD 826709-01-1] FX This work was supported by PO1 ES009605 and RO1 ES015572 from NIEHS and RD 826709-01-1 from EPA. This paper has not been formally reviewed by the EPA or NIH. The views, findings and conclusions expressed in this document are solely those of the authors and do not necessarily represent the views of the EPA, NIH, or CDC. We gratefully acknowledge the CHAMACOS staff, students, community partners, and, especially, the CHAMACOS participants and their families, without whom this study would not be possible. Finally, we thank Christopher Salemme for designing our cover graphic. NR 32 TC 25 Z9 26 U1 2 U2 13 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0013-936X J9 ENVIRON SCI TECHNOL JI Environ. Sci. Technol. PD AUG 1 PY 2011 VL 45 IS 15 BP 6553 EP 6560 DI 10.1021/es104295m PG 8 WC Engineering, Environmental; Environmental Sciences SC Engineering; Environmental Sciences & Ecology GA 798IK UT WOS:000293196400052 PM 21793581 ER PT J AU D'Angelo, DV Whitehead, N Helms, K Barfield, W Ahluwalia, IB AF D'Angelo, Denise V. Whitehead, Nedra Helms, Kristen Barfield, Wanda Ahluwalia, Indu B. TI Birth outcomes of intended pregnancies among women who used assisted reproductive technology, ovulation stimulation, or no treatment SO FERTILITY AND STERILITY LA English DT Article DE PRAMS; pregnancy; infertility; ovulation stimulation; assisted reproductive technology (ART); infant birth outcomes ID IN-VITRO FERTILIZATION; INTRACYTOPLASMIC SPERM INJECTION; ASSESSMENT MONITORING-SYSTEM; CHILDREN BORN; MULTIPLE BIRTHS; UNITED-STATES; RISK; INFANTS; WEIGHT; IVF AB Objective: To study birth outcomes among live born infants conceived by women who used infertility treatment. Design: Population-based surveillance of women who recently delivered a live infant. Setting: The birth outcomes among infants whose mothers used assisted reproductive technology (ART) or ovulation stimulation medications alone were compared with the outcomes of infants conceived without treatment. Patient(s): Stratified random sample of women who were attempting conception and gave birth to a live infant in six US states (n = 16,748). Intervention(s): Assisted reproductive technology and ovulation stimulation. Main Outcome Measure(s): Adjusted odds ratios for perinatal outcomes. Result(s): The prevalence of infertility treatment use overall among women attempting conception was 10.9% (5.4% ART procedures, 5.5% ovulation stimulation medications). Singletons of mothers who received ART procedures were more likely to be born with low birthweight, preterm, and small for gestational age (SGA) than singleton infants conceived without treatment. Singleton infants of mothers who used ovulation stimulation medications alone were more likely to be SGA than singleton infants conceived without treatment. No differences were found between ART and no treatment twin infants. Conclusion(s): Among singleton infants, ART is associated with decreased fetal growth, decreased gestational length, and SGA; ovulation stimulation alone is associated with SGA. (Fertil Steril (R) 2011; 96: 314-20. (c) 2011 by American Society for Reproductive Medicine.) C1 [D'Angelo, Denise V.; Barfield, Wanda; Ahluwalia, Indu B.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Whitehead, Nedra] RTI Int, Res Triangle Pk, NC USA. [Helms, Kristen] Sci Applications Int Corp, San Diego, CA USA. RP D'Angelo, DV (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop K-22, Atlanta, GA 30341 USA. EM DDAngelo@cdc.gov NR 44 TC 34 Z9 36 U1 1 U2 29 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PD AUG PY 2011 VL 96 IS 2 BP 314 EP U367 DI 10.1016/j.fertnstert.2011.05.073 PG 9 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 795WK UT WOS:000293008700037 PM 21718990 ER PT J AU Saeed, M Shiina, M Date, T Akazawa, D Watanabe, N Murayama, A Suzuki, T Watanabe, H Hiraga, N Imamura, M Chayama, K Choi, Y Krawczynski, K Liang, TJ Wakita, T Kato, T AF Saeed, Mohsan Shiina, Masaaki Date, Tomoko Akazawa, Daisuke Watanabe, Noriyuki Murayama, Asako Suzuki, Tetsuro Watanabe, Haruo Hiraga, Nobuhiko Imamura, Michio Chayama, Kazuaki Choi, Youkyung Krawczynski, Krzysztof Liang, T. Jake Wakita, Takaji Kato, Takanobu TI In Vivo Adaptation of Hepatitis C Virus in Chimpanzees for Efficient Virus Production and Evasion of Apoptosis SO HEPATOLOGY LA English DT Article ID LIVER-INJURY; INFECTION; REPLICATION; PERFORIN; CYTOTOXICITY; DETERMINANTS; PERSISTENCE; MECHANISMS; CLEARANCE; DISEASE AB Hepatitis C virus (HCV) employs various strategies to establish persistent infection that can cause chronic liver disease. Our previous study showed that both the original patient serum from which the HCV JFH-1 strain was isolated and the cell culture-generated JFH-1 virus (JFH-1cc) established infection in chimpanzees, and that infected JFH-1 strains accumulated mutations after passage through chimpanzees. The aim of this study was to compare the in vitro characteristics of JFH-1 strains emerged in each chimpanzee at early and late stages of infection, as it could provide an insight into the phenomenon of viral persistence. We generated full-genome JFH-1 constructs with the mutations detected in patient serum-infected (JFH-1/S1 and S2) and JFH-1cc-infected (JFH-1/C) chimpanzees, and assessed their effect on replication, infectious virus production, and regulation of apoptosis in cell culture. The extracellular HCV core antigen secreted from JFH-1/S1-, S2-, and C-transfected HuH-7 cells was 2.5, 8.9, and 2.1 times higher than that from JFH-1 wild-type (JFH-1/wt) transfected cells, respectively. Single cycle virus production assay with a CD81-negative cell line revealed that the strain JFH-1/S2, isolated from the patient serum-infected chimpanzee at a later time point of infection, showed lower replication and higher capacity to assemble infectious virus particles. This strain also showed productive infection in human hepatocyte-transplanted mice. Furthermore, the cells harboring this strain displayed lower susceptibility to the apoptosis induced by tumor necrosis factor alpha or Fas ligand compared with the cells replicating JFH-1/wt. Conclusion: The ability of lower replication, higher virus production, and less susceptibility to cytokine-induced apoptosis may be important for prolonged infection in vivo. Such control of viral functions by specific mutations may be a key strategy for establishing persistent infection. (HEPATOLOGY 2011;54:425-433) C1 [Saeed, Mohsan; Date, Tomoko; Akazawa, Daisuke; Watanabe, Noriyuki; Murayama, Asako; Suzuki, Tetsuro; Wakita, Takaji; Kato, Takanobu] Natl Inst Infect Dis, Dept Virol 2, Tokyo 1628640, Japan. [Saeed, Mohsan; Watanabe, Haruo] Univ Tokyo, Dept Infect & Pathol, Grad Sch Med, Tokyo, Japan. [Shiina, Masaaki] Tohoku Univ, Grad Sch Med, Div Gastroenterol, Sendai, Miyagi 980, Japan. [Hiraga, Nobuhiko; Imamura, Michio; Chayama, Kazuaki] Hiroshima Univ, Dept Med & Mol Sci, Div Frontier Med Sci, Programs Biomed Res,Grad Sch Biomed Sci, Hiroshima, Japan. [Choi, Youkyung; Krawczynski, Krzysztof] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Liang, T. Jake] NIDDK, Liver Dis Branch, NIH, Bethesda, MD USA. RP Kato, T (reprint author), Natl Inst Infect Dis, Dept Virol 2, Tokyo 1628640, Japan. EM takato@nih.go.jp FU Japan Society for the Promotion of Science; Ministry of Health, Labor, and Welfare of Japan; Ministry of Education, Culture, Sports, Science, and Technology; Health Sciences Foundation; NIDDK, NIH FX Supported by grants-in-aid from the Japan Society for the Promotion of Science, the Ministry of Health, Labor, and Welfare of Japan, and the Ministry of Education, Culture, Sports, Science, and Technology, by the Research on Health Sciences Focusing on Drug Innovation from the Japan Health Sciences Foundation, and in part by the Intramural Research Program of the NIDDK, NIH (T. J. L.). NR 27 TC 13 Z9 13 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD AUG PY 2011 VL 54 IS 2 BP 425 EP 433 DI 10.1002/hep.24399 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 800BT UT WOS:000293333300007 PM 21538444 ER PT J AU Pelletier, AR Gilchrist, J AF Pelletier, Andrew R. Gilchrist, Julie TI Fatalities in swimming pools with lifeguards: USA, 2000-2008 SO INJURY PREVENTION LA English DT Article ID INJURY SURVEILLANCE; DEVELOPING-COUNTRY; UNITED-STATES; PREVENTION; CHILDREN; LESSONS; RISK; NEWSPAPERS; CHILDHOOD; DROWNINGS AB Background Pools with lifeguards are often perceived to represent a safe environment for swimming. Objectives To examine how often fatalities occurred in pools with lifeguards and what factors were common in these incidents. Design Case series. Setting USA. Subjects A case was defined as a death in a swimming pool with at least one lifeguard that occurred in the USA from 2000 to 2008. Potential cases were identified from media accounts using Lexis-Nexis and ProQuest databases. Supplemental information was obtained through internet based searches and review of death certificates. Results A total of 140 deaths from 37 states were identified. Of decedents, 109 (78%) were children and 93 (66%) were males. African Americans accounted for 44% of deaths among those of known race. 104 (74%) fatalities occurred during May through August; 85 (61%) deaths occurred in outdoor pools. Sites for fatal incidents included 53 (38%) municipal pools, 21 (15%) community organisations, and 20 (14%) schools. The median swimmer to lifeguard ratio was 13:1. Decedents were initially identified in the pool twice as often by non-lifeguards (eg, other swimmers or bystanders) as by lifeguards. Conclusions Deaths in pools with lifeguards are uncommon, but do occur. Groups most affected include children, males, and African Americans. While lifeguards provide an important layer of protection at swimming pools, they alone cannot prevent all drownings. Additional safety measures are needed. C1 [Pelletier, Andrew R.; Gilchrist, Julie] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Pelletier, AR (reprint author), CDC Amer Embassy, 2170 Gaborone Pl, Dulles, VA 20189 USA. EM arp1@cdc.gov NR 39 TC 9 Z9 9 U1 0 U2 8 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1353-8047 J9 INJURY PREV JI Inj. Prev. PD AUG PY 2011 VL 17 IS 4 BP 250 EP 253 DI 10.1136/ip.2010.029751 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 796UH UT WOS:000293077800009 PM 21270060 ER PT J AU Yamamoto, N Schmechel, D Chen, BT Lindsley, WG Peccia, J AF Yamamoto, Naomichi Schmechel, Detlef Chen, Bean T. Lindsley, William G. Peccia, Jordan TI Comparison of quantitative airborne fungi measurements by active and passive sampling methods SO JOURNAL OF AEROSOL SCIENCE LA English DT Article DE Fungi; Quantitative polymerase chain reaction (qPCR); Two-stage cyclone sampler; Personal Aeroallergen Sampler (PAAS); Gravitational settling; Bioaerosols ID SCANNING-ELECTRON-MICROSCOPY; PARTICLES; EXPOSURE; BIOAEROSOLS; PRECISION; SPORES; HOMES; MOLD AB The present study compared the airborne fungi collection performance of a two-stage cyclone sampler (active method) to the performance of the Personal Aeroallergen Sampler (passive method) using quantitative polymerase chain reaction (qPCR) assays. Indoor air concentrations of the common fungal species Alternaria alternata, Cladosporium cladosporioides, Epicoccum nigrum, and Penicillium chrysogenum were considered. Good correlations between the two sampling methods for the fungi A. alternata, C. cladosporioides, and E. nigrum were observed and the mean effective passive sampling rates (+/- std. dev.) for these species were 0.032 (+/- 0.006), 0.058 (+/- 0.006), and 0.066 (+/- 0.044) 1 min(-1), respectively. Gravitational settling was the dominant collection mechanism for A. alternata and E. nigrum. The root mean square precisions for the passive sampler measurements were also comparable to those of the active sampler (49-73% and 50-102%, respectively). The passive sampler did not allow for the collection of P. chrysogenum, likely due to the insufficient gravitational settling velocity of the fungal particle with its aerodynamic diameter of less than 5 pm. The passive sampler, in conjunction with growth-independent qPCR detection methodologies, can be utilized in future exposure assessment studies to deepen our understanding of how individuals are affected by inhalation of airborne fungal pathogens and allergens, especially for those with an aerodynamic diameter greater than 5 pm. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Yamamoto, Naomichi; Peccia, Jordan] Yale Univ, Dept Chem & Environm Engn, New Haven, CT 06520 USA. [Yamamoto, Naomichi] Japan Soc Promot Sci, Chiyoda Ku, Tokyo 1028472, Japan. [Schmechel, Detlef; Chen, Bean T.; Lindsley, William G.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Yamamoto, N (reprint author), Yale Univ, Dept Chem & Environm Engn, New Haven, CT 06520 USA. EM naomichi.yamamoto@yale.edu RI Yamamoto, Naomichi/D-4099-2014; OI Yamamoto, Naomichi/0000-0002-5969-5500; Lindsley, William/0000-0003-0720-5829 FU Japan Society for the Promotion of Science FX N. Yamamoto receives a grant from the Japan Society for the Promotion of Science for this research. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. NR 32 TC 7 Z9 8 U1 2 U2 29 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-8502 J9 J AEROSOL SCI JI J. Aerosol. Sci. PD AUG PY 2011 VL 42 IS 8 BP 499 EP 507 DI 10.1016/j.jaerosci.2011.05.004 PG 9 WC Engineering, Chemical; Engineering, Mechanical; Environmental Sciences; Meteorology & Atmospheric Sciences SC Engineering; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences GA 799CB UT WOS:000293260000001 ER PT J AU Bernstein, DI Kissling, GE Hershey, GK Yucesoy, B Johnson, VJ Cartier, A Gautrin, D Sastre, J Boulet, LP Malo, JL Quirce, S Tarlo, SM Langmeyer, S Luster, MI Lummus, ZL AF Bernstein, David I. Kissling, Grace E. Hershey, Gurjit Khurana Yucesoy, Berran Johnson, Victor J. Cartier, Andre Gautrin, Denyse Sastre, Joaquin Boulet, Louis-Philippe Malo, Jean-Luc Quirce, Santiago Tarlo, Susan M. Langmeyer, Stacy Luster, Michael I. Lummus, Zana L. TI Hexamethylene diisocyanate asthma is associated with genetic polymorphisms of CD14, IL-13, and IL-4 receptor alpha SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Letter ID OCCUPATIONAL ASTHMA; IL4RA C1 [Bernstein, David I.; Langmeyer, Stacy; Lummus, Zana L.] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA. [Kissling, Grace E.] NIEHS, NIH, Res Triangle Pk, NC 27709 USA. [Hershey, Gurjit Khurana] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. [Yucesoy, Berran; Johnson, Victor J.; Luster, Michael I.] NIOSH, CDC, Hlth Effects Lab Div, Morgantown, WV USA. [Cartier, Andre; Gautrin, Denyse; Malo, Jean-Luc] Univ Montreal, Hop Sacre Coeur, Quebec City, PQ, Canada. [Sastre, Joaquin; Quirce, Santiago] Univ Autonoma Madrid, Dept Allergy, E-28049 Madrid, Spain. [Boulet, Louis-Philippe] Univ Laval, Hop Laval, Ste Foy, PQ G1K 7P4, Canada. [Tarlo, Susan M.] Univ Toronto, Toronto, ON M5S 1A1, Canada. RP Bernstein, DI (reprint author), Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA. EM Bernstdd@ucmail.uc.edu FU Intramural NIH HHS [Z01 ES045005-11]; NIEHS NIH HHS [Z01 ES045005, Z01-ES045005]; NIOSH CDC HHS [1-R01 OH008795, R01 OH008795] NR 9 TC 10 Z9 10 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD AUG PY 2011 VL 128 IS 2 BP 418 EP 420 DI 10.1016/j.jaci.2011.03.007 PG 4 WC Allergy; Immunology SC Allergy; Immunology GA 799IQ UT WOS:000293280800027 PM 21489615 ER PT J AU Jorgensen, JH McElmeel, ML Fulcher, LC McGee, L Richter, SS Heilmann, KP Ferraro, MJ Spargo, J Glennen, A AF Jorgensen, James H. McElmeel, M. Leticia Fulcher, Letitia C. McGee, Lesley Richter, Sandra S. Heilmann, K. P. Ferraro, Mary Jane Spargo, Jean Glennen, Anita TI Collaborative Evaluation of an Erythromycin-Clindamycin Combination Well for Detection of Inducible Clindamycin Resistance in Beta-Hemolytic Streptococci by Use of the CLSI Broth Microdilution Method SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID MECHANISMS AB Constitutive or inducible clindamycin resistance can occur in beta-hemolytic streptococci due to the presence of an erm gene. The Clinical and Laboratory Standards Institute (CLSI) has recommended a disk approximation test (D-zone test) with erythromycin and clindamycin disks and a single-well broth test combining erythromycin and clindamycin for detection of inducible clindamycin resistance in staphylococci, but only a disk approximation test for the beta-hemolytic streptococci. This collaborative study assessed two different erythromycin and clindamycin concentration combinations in single wells (1 mu g/ml + 0.25 mu g/ml [erythromycin plus clindamycin] and 1 mu g/ml + 0.5 mu g/ml) with three different brands of Mueller-Hinton broth supplemented with 3% lysed horse blood for testing of frozen panels prepared for this study. All labs performed the D-zone test as described by the CLSI. A total of 155 nonduplicate streptococcal isolates (50 group A, 48 group B, 28 group C, and 29 group G isolates) were tested; 99 isolates showed inducible resistance by the D-zone test. There were some differences noted based upon the test medium. The sensitivity of the erythromycin plus clindamycin combination of 1 mu g/ml + 0.25 mu g/ml was 91 to 100%, while the sensitivity of the combination of 1 mu g/ml + 0.5 mu g/ml was 95 to 100%. Specificity overall was 98%. The slightly higher sensitivity of the combination of 1 mu g/ml + 0.5 mu g/ml is recommended. This study has demonstrated that a single-well microdilution test incorporating erythromycin and clindamycin in combination is a sensitive and specific indicator of inducible clindamycin resistance and could be included in routine test panels. C1 [Jorgensen, James H.; McElmeel, M. Leticia; Fulcher, Letitia C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [McGee, Lesley] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA. [Richter, Sandra S.; Heilmann, K. P.] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA. [Ferraro, Mary Jane; Spargo, Jean] Massachusetts Gen Hosp, Microbiol Lab, Boston, MA 02114 USA. [Glennen, Anita] Minnesota Dept Hlth, St Paul, MN USA. RP Jorgensen, JH (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM jorgensen@uthscsa.edu NR 12 TC 1 Z9 2 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD AUG PY 2011 VL 49 IS 8 BP 2884 EP 2886 DI 10.1128/JCM.00912-11 PG 3 WC Microbiology SC Microbiology GA 798PE UT WOS:000293221900016 PM 21697321 ER PT J AU Fosheim, GE Nicholson, AC Albrecht, VS Limbago, BM AF Fosheim, G. E. Nicholson, A. C. Albrecht, V. S. Limbago, B. M. TI Multiplex Real-Time PCR Assay for Detection of Methicillin-Resistant Staphylococcus aureus and Associated Toxin Genes SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID MECA GENE; NUCLEASE; STRAIN AB We describe a real-time PCR assay for the detection of methicillin-resistant Staphylococcus aureus and genes encoding toxic shock syndrome toxin 1 and Panton-Valentine leukocidin. Rapid screening and detection of toxins is a useful tool for surveillance studies and outbreak investigations involving large numbers of isolates. C1 [Fosheim, G. E.; Nicholson, A. C.; Albrecht, V. S.; Limbago, B. M.] CDC, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. RP Limbago, BM (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE,MS C-16, Atlanta, GA 30333 USA. EM BLimbago@cdc.gov NR 10 TC 16 Z9 18 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD AUG PY 2011 VL 49 IS 8 BP 3071 EP 3073 DI 10.1128/JCM.00795-11 PG 3 WC Microbiology SC Microbiology GA 798PE UT WOS:000293221900057 PM 21697325 ER PT J AU Henning, T Fakile, Y Phillips, C Sweeney, E Mitchell, J Patton, D Sturdevant, G Caldwell, HD Secor, WE Papp, J Hendry, RM McNicholl, J Kersh, E AF Henning, Tara Fakile, Yetunde Phillips, Christi Sweeney, Elizabeth Mitchell, James Patton, Dorothy Sturdevant, Gail Caldwell, Harlan D. Secor, W. Evan Papp, John Hendry, R. Michael McNicholl, Janet Kersh, Ellen TI Development of a pigtail macaque model of sexually transmitted infection/HIV coinfection using Chlamydia trachomatis, Trichomonas vaginalis, and SHIVSF162P3 SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Article; Proceedings Paper CT 28th Annual Symposium on Nonhuman Primate Models for AIDS CY OCT 19-22, 2010 CL Tulane Natl Primate Res Ctr, New Orleans, LA SP Agilent Technol, Capitol City Produce, Covance, Mabtech, MP Biomed, Purina Lab Diet, SPEX Sample Prep, LLC HO Tulane Natl Primate Res Ctr DE coinfection; genital; mucosal; non-human primate ID HUMAN-IMMUNODEFICIENCY-VIRUS; PELVIC-INFLAMMATORY-DISEASE; CLINICAL-MANIFESTATIONS; MACACA-NEMESTRINA; HIV-1 TRANSMISSION; NONHUMAN-PRIMATES; GENITAL-TRACT; WOMEN; SUSCEPTIBILITY; CHALLENGES AB Background Sexually transmitted infections (STIs) are associated with an increased risk of HIV infection. To model the interaction between STIs and HIV infection, we evaluated the capacity of the pigtail macaque model to sustain triple infection with Trichomonas vaginalis, Chlamydia trachomatis, and SHIVSF162P3. Methods Seven SHIVSF162P3-infected pigtail macaques were inoculated with T. vaginalis only (n = 2), C. trachomatis only (n = 1), both T. vaginalis and C. trachomatis (n = 2), or control media (no STI; n = 2). Infections were confirmed by culture and/or nucleic acid testing. Genital mucosa was visualized by colposcopy. Results Characteristic gynecologic signs were observed for both STIs, but not in control animals. Manifestations were most prominent at days 7-10 post-infection. STIs persisted between 4 and 6 weeks and were cleared with antibiotics. Conclusions These pilot studies demonstrate the first successful STI-SHIV triple infection of pigtail macaques, with clinical presentation of genital STI symptoms similar to those observed in humans. C1 [Henning, Tara; Sweeney, Elizabeth; Mitchell, James; Hendry, R. Michael; McNicholl, Janet; Kersh, Ellen] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Fakile, Yetunde; Phillips, Christi; Papp, John] CDC, Div Sexually Transmitted Dis Prevent, Atlanta, GA 30333 USA. [Patton, Dorothy] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Sturdevant, Gail; Caldwell, Harlan D.] NIAID, Intracellular Parasites Lab, Rocky Mt Labs, NIH, Hamilton, MT USA. [Secor, W. Evan] CDC, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. RP Kersh, E (reprint author), 1600 Clifton Rd NE,MS A25, Atlanta, GA 30333 USA. EM ekersh@cdc.gov FU Intramural NIH HHS [ZIA AI000672-18]; NIAID NIH HHS [Y01 AI000681, Y1-AI-0681-02] NR 46 TC 18 Z9 19 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD AUG PY 2011 VL 40 IS 4 BP 214 EP 223 DI 10.1111/j.1600-0684.2011.00488.x PG 10 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 795YL UT WOS:000293015700003 PM 21781129 ER PT J AU Pal, R Galmin, L Li, B Francis, J McNicholl, J Weiss, DE Smith, JM AF Pal, Ranajit Galmin, Lindsey Li, Bin Francis, Jesse McNicholl, Janet Weiss, Deborah E. Smith, James M. TI EXPANSION AND CHARACTERIZATION OF SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS ENCODING ENVELOPE AND REVERSE TRANSCRIPTASE GENES OF HIV-1 SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Pal, Ranajit; Galmin, Lindsey; Francis, Jesse; Weiss, Deborah E.] Adv BioSci Labs Inc, Kensington, MD USA. [Li, Bin; McNicholl, Janet; Smith, James M.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0047-2565 J9 J MED PRIMATOL JI J. Med. Primatol. PD AUG PY 2011 VL 40 IS 4 MA 8 BP 251 EP 251 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 795YL UT WOS:000293015700015 ER PT J AU Henning, T Fakile, Y Phillips, C Sweeney, E Mitchell, J Ballard, R Patton, D Caldwell, HD Secor, WE Papp, J Hendry, M McNicholl, J Kersh, E AF Henning, Tara Fakile, Yetunde Phillips, Christi Sweeney, Elizabeth Mitchell, James Ballard, Ron Patton, Dorothy Caldwell, Harlan D. Secor, William E. Papp, John Hendry, Michael McNicholl, Janet Kersh, Ellen TI DEVELOPMENT OF A PIG-TAILED MACAQUE MODEL OF SEXUALLY-TRANSMITTED INFECTION/HUMAN IMMUNODEFICIENCY VIRUS COINFECTION UTILIZING CHLAMYDIA TRACHOMATIS, TRICHOMONAS VAGINALIS, AND SHIVSF162P3 SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Henning, Tara; Sweeney, Elizabeth; Mitchell, James; Hendry, Michael; McNicholl, Janet; Kersh, Ellen] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Fakile, Yetunde; Phillips, Christi; Ballard, Ron; Papp, John] CDC, Div Sexually Transmitted Dis Prevent, Atlanta, GA 30333 USA. [Patton, Dorothy] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Caldwell, Harlan D.] NIAID, Intracellular Parasites Lab, Rocky Mt Labs, NIH, Hamilton, MT USA. [Secor, William E.] CDC, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0047-2565 J9 J MED PRIMATOL JI J. Med. Primatol. PD AUG PY 2011 VL 40 IS 4 MA 18 BP 254 EP 254 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 795YL UT WOS:000293015700025 ER PT J AU Livingston, L Sweeney, E Mitchell, J Luo, W Paul, K Powell, N Hendry, RM McNicholl, J Kersh, E AF Livingston, Lindsay Sweeney, Elizabeth Mitchell, James Luo, Wei Paul, Katherine Powell, Nathaniel Hendry, R. Michael McNicholl, Janet Kersh, Ellen TI SYNCHRONIZATION OF THE MENSTRUAL CYCLES OF PIG-TAILED MACAQUES TO FACILITATE SIMULTANEOUS SUSCEPTIBILITY WINDOWS TO REPEATED, LOW-DOSE, VAGINAL SHIV EXPOSURES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Livingston, Lindsay; Paul, Katherine; Powell, Nathaniel] CDC, Div Sci Resources, NCEZID, Atlanta, GA 30333 USA. [Sweeney, Elizabeth; Mitchell, James; Luo, Wei; Hendry, R. Michael; McNicholl, Janet; Kersh, Ellen] CDC, Div HIV AIDS Prevent, NCHHSTP, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0047-2565 J9 J MED PRIMATOL JI J. Med. Primatol. PD AUG PY 2011 VL 40 IS 4 MA 51 BP 265 EP 265 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 795YL UT WOS:000293015700058 ER PT J AU Aung, W Cong, ME Zheng, Q Youngpairoj, A Holder, A Luo, W Mitchell, J Hanson, D Kersh, E Pau, CP Ray, A Rooney, J Lee, B Heneine, W Garcia-Lerma, JG AF Aung, Wutyi Cong, Mian-er Zheng, Qi Youngpairoj, Ae Holder, Angela Luo, Wei Mitchell, James Hanson, Debra Kersh, Ellen Pau, Chou-Pong Ray, Adrian Rooney, Jim Lee, Bill Heneine, Walid Garcia-Lerma, J. Gerardo TI LACK OF PROTECTION AGAINST RECTAL SHIV TRANSMISSION BY PROPHYLACTIC TREATMENT WITH GS7340 DESPITE HIGH RECTAL AND SYSTEMIC TENOFOVIR EXPOSURE SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Aung, Wutyi; Cong, Mian-er; Zheng, Qi; Youngpairoj, Ae; Holder, Angela; Luo, Wei; Mitchell, James; Hanson, Debra; Kersh, Ellen; Pau, Chou-Pong; Heneine, Walid; Garcia-Lerma, J. Gerardo] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Ray, Adrian; Rooney, Jim; Lee, Bill] Gilead Sci Inc, Foster City, CA 94404 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0047-2565 J9 J MED PRIMATOL JI J. Med. Primatol. PD AUG PY 2011 VL 40 IS 4 MA 53 BP 266 EP 266 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 795YL UT WOS:000293015700060 ER PT J AU Dobard, C Masciotra, S Lipscomb, J Youngpairoj, A Cong, ME Sharma, S Johnson, J Garcia-Lerma, G Heneine, W AF Dobard, Charles Masciotra, Silvina Lipscomb, Jonathan Youngpairoj, Ae Cong, Mian-er Sharma, Sunita Johnson, Jeffrey Garcia-Lerma, Gerardo Heneine, Walid TI ASSESSING DRUG RESISTANCE EMERGENCE IN A MACAQUE MODEL OF ANTIRETROVIRAL PRE-EXPOSURE PROPHYLAXIS (PREP) SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Dobard, Charles; Masciotra, Silvina; Lipscomb, Jonathan; Youngpairoj, Ae; Cong, Mian-er; Sharma, Sunita; Johnson, Jeffrey; Garcia-Lerma, Gerardo; Heneine, Walid] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0047-2565 J9 J MED PRIMATOL JI J. Med. Primatol. PD AUG PY 2011 VL 40 IS 4 MA 54 BP 266 EP 266 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 795YL UT WOS:000293015700061 ER PT J AU Butler, SE Srinivasan, P Lowry, D Fetherston, S Smith, J Malcolm, K Moscoso, J AF Butler, Sara E. Srinivasan, Priya Lowry, Deborah Fetherston, Susan Smith, James Malcolm, Karl Moscoso, Jaime TI PROGESTERONE RELEASE FROM A SILICONE INTRAVAGINAL RING IN PIGTAILED MACAQUES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Butler, Sara E.; Srinivasan, Priya; Smith, James] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lowry, Deborah; Fetherston, Susan; Malcolm, Karl] Queens Univ Belfast, Sch Pharm, Belfast BT7 1NN, Antrim, North Ireland. [Moscoso, Jaime] Italfarmaco SpA, Madrid, Spain. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0047-2565 J9 J MED PRIMATOL JI J. Med. Primatol. PD AUG PY 2011 VL 40 IS 4 MA 64 BP 269 EP 269 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 795YL UT WOS:000293015700071 ER PT J AU Srinivasan, P Johnson, T Martin, A Sweeney, E McNicholl, J Hendry, M Watson, K Herold, B Buckheit, B Kiser, P Smith, JM AF Srinivasan, Priya Johnson, Todd Martin, Amy Sweeney, Elizabeth McNicholl, Janet Hendry, Michael Watson, Karen Herold, Betsy Buckheit, Bob Kiser, Patrick Smith, James M. TI VAGINAL RELEASE KINETICS OF PYRIMIDINEDIONE IQP-0528 FROM A POLYURETHANE INTRAVAGINAL RING SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Srinivasan, Priya; Martin, Amy; Sweeney, Elizabeth; McNicholl, Janet; Hendry, Michael; Smith, James M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Johnson, Todd; Kiser, Patrick] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA. [Watson, Karen; Buckheit, Bob] ImQuest BioSci, Frederick, MD USA. [Herold, Betsy] Albert Einstein Coll Med, Bronx, NY 10467 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0047-2565 J9 J MED PRIMATOL JI J. Med. Primatol. PD AUG PY 2011 VL 40 IS 4 MA 66 BP 270 EP 270 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 795YL UT WOS:000293015700073 ER PT J AU Guenthner, PC Adams, DR Sweeney, E Mitchell, J Tuscher, J Wiseman, R Li, B McNicholl, J Hendry, RM Smith, J Otten, RA AF Guenthner, Patricia C. Adams, Debra R. Sweeney, Elizabeth Mitchell, James Tuscher, Jen Wiseman, Roger Li, Bin McNicholl, Janet Hendry, R. Michael Smith, James Otten, Ron A. TI MODELING SHIV TRANSMISSION IN CYNOMOLGUS MACAQUES USING THE REPEATED-LOW DOSE MODEL SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Guenthner, Patricia C.; Adams, Debra R.; Sweeney, Elizabeth; Mitchell, James; Li, Bin; McNicholl, Janet; Hendry, R. Michael; Smith, James; Otten, Ron A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Tuscher, Jen; Wiseman, Roger] Wisconsin Natl Primate Res Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0047-2565 J9 J MED PRIMATOL JI J. Med. Primatol. PD AUG PY 2011 VL 40 IS 4 MA 77 BP 273 EP 273 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 795YL UT WOS:000293015700084 ER PT J AU Zheng, Q Switzer, WM Heneine, W Garcia-Lerma, JG AF Zheng, Qi Switzer, William M. Heneine, Walid Garcia-Lerma, J. Gerardo TI LIMITED ENV DIVERSIFICATION IN MACAQUES FAILING ANTIRETROVIRAL PRE-EXPOSURE PROPHYLAXIS SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Zheng, Qi; Switzer, William M.; Heneine, Walid; Garcia-Lerma, J. Gerardo] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0047-2565 J9 J MED PRIMATOL JI J. Med. Primatol. PD AUG PY 2011 VL 40 IS 4 MA 89 BP 277 EP 277 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 795YL UT WOS:000293015700096 ER PT J AU Barnes, SP Robin, L O'Toole, TP Dawkins, N Khan, LK Leviton, LC AF Barnes, Seraphine Pitt Robin, Leah O'Toole, Terrence P. Dawkins, Nicola Khan, Laura Kettel Leviton, Laura C. TI Results of Evaluability Assessments of Local Wellness Policies in 6 US School Districts SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE policy; nutrition and diet; physical fitness and sport; child and adolescent health ID PHYSICAL-ACTIVITY; ENVIRONMENTS AB BACKGROUND: A US federal mandate that school districts devise and implement local wellness policies (LWPs) has potential widespread impact on the nutritional content of foods and beverages available in schools and on the amount of physical activity that students engage in; however, evidence concerning the mandate's effectiveness is limited. This study describes the content of LWPs of 6 US school districts and steps taken toward their implementation and evaluation. METHODS: During visits to 6 school districts, we interviewed 88 school and community representatives about the content of their district's LWPs and how the LWPs were being implemented and evaluated. RESULTS: The 6 LWPs were consistent with the federal mandate, although they varied in content and degree of specificity, and none had been fully implemented. All 6 districts were pursuing strategies to ensure that foods and beverages available at school met nutrition standards but did not offer nutrition education to all K-12 students. All 6 districts offered students only limited opportunities for physical activity, and all 6 collected data to monitor process and outcomes of their LWPs. CONCLUSIONS: Partial implementation of LWPs in the districts we visited resulted in significant improvement in the nutritional quality of foods available at district schools, but only slight improvement in students' opportunities for school-based physical activity. We provide recommendations for school districts on implementation and evaluation. Future research is needed to determine the impact of these LWPs on students' health. C1 [Barnes, Seraphine Pitt; Robin, Leah; O'Toole, Terrence P.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA 30341 USA. [Khan, Laura Kettel] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. [Leviton, Laura C.] Robert Wood Johnson Fdn, Princeton, NJ 08543 USA. RP Barnes, SP (reprint author), Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, 4770 Buford Highway NE,Mail Stop K-33, Atlanta, GA 30341 USA. EM SPittBarnes@cdc.gov; ler7@cdc.gov; cwu9@cdc.gov; nicola.u.dawkins@macrointernational.com; LKettelKhan@cdc.gov; llevito@rwjf.org NR 25 TC 8 Z9 8 U1 2 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 J9 J SCHOOL HEALTH JI J. Sch. Health PD AUG PY 2011 VL 81 IS 8 BP 502 EP 511 DI 10.1111/j.1746-1561.2011.00620.x PG 10 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA 797PU UT WOS:000293140600010 ER PT J AU Li, HY Wu, SY Ma, Q Shi, N AF Li, H. Y. Wu, S. Y. Ma, Q. Shi, N. TI The pesticide deltamethrin increases free radical production and promotes nuclear translocation of the stress response transcription factor Nrf2 in rat brain SO TOXICOLOGY AND INDUSTRIAL HEALTH LA English DT Article DE Deltamethrin; free radical; Nrf2; oxidative stress; neurotoxicity; in vivo ID OXIDATIVE STRESS; PC12 CELLS; NF-E2-RELATED FACTOR-2; NEURODEGENERATIVE DISEASE; PYRETHROID INSECTICIDES; TERT-BUTYLHYDROQUINONE; PARKINSONS-DISEASE; THERAPEUTIC TARGET; ALTERED EXPRESSION; ACTIVATION AB The transcription factor NF-E2-related factor 2 (Nrf2) plays a critical role in the mammalian response to chemical and oxidative stress through induction of phase II detoxification enzymes and oxidative stress response proteins. We reported that Nrf2 expression was activated by deltamethrin (DM), a prototype of the widely used pyrithroid pesticides, in PC12 cells. However, no study has examined Nrf2 nuclear translocation and free radical production, two hallmarks of oxidative stress, in the mammalian brain in vivo. To this end, we examined translocation of Nrf2 and production of free radicals in rat brain exposed to DM. Indeed, DM initiated nuclear translocation of Nrf2 in a dose-dependent manner. Furthermore, Nrf2 translocation was accompanied by the expression of heme oxygenase-1 gene, an Nrf2-regulated gene linked to free radical production. Deltamethrin exposure promoted free radical formation in rat brain and reactive oxygen species generation in PC12 cells. Translocation of Nrf2 may be a response to DM-dependent induction of free radicals and DM may act as a mammalian neurotoxin by initiating oxidative stress. C1 [Li, H. Y.; Shi, N.] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, MOE Key Lab Environm & Hlth,Dept Hlth Toxicol, Wuhan 430030, Hubei, Peoples R China. [Li, H. Y.] Fujian Med Univ, Dept Occupat & Environm Hlth, Major Subject Environm & Hlth Fujian Key Univ, Inst Environm & Hlth,Sch Publ Hlth, Fuzhou, Peoples R China. [Wu, S. Y.] Fujian Med Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Fuzhou, Peoples R China. [Ma, Q.] NIOSH, Receptor Biol Lab, Toxicol & Mol Biol Branch, Hlth Effects Lab Div,Ctr Dis Control & Prevent, Morgantown, WV USA. RP Shi, N (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, MOE Key Lab Environm & Hlth,Dept Hlth Toxicol, Wuhan 430030, Hubei, Peoples R China. EM snian@mails.tjmu.edu.cn FU National Natural Science Foundation in China [30800936, 30371225] FX This work was supported by National Natural Science Foundation in China (Grant 30800936, 30371225). NR 44 TC 13 Z9 14 U1 0 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0748-2337 EI 1477-0393 J9 TOXICOL IND HEALTH JI Toxicol. Ind. Health PD AUG PY 2011 VL 27 IS 7 BP 579 EP 590 DI 10.1177/0748233710393400 PG 12 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA 797QW UT WOS:000293143600001 PM 21398409 ER PT J AU Bailey, RL Carmel, R Green, R Pfeiffer, CM Cogswell, ME Osterloh, JD Sempos, CT Yetley, EA AF Bailey, Regan L. Carmel, Ralph Green, Ralph Pfeiffer, Christine M. Cogswell, Mary E. Osterloh, John D. Sempos, Christopher T. Yetley, Elizabeth A. TI Monitoring of vitamin B-12 nutritional status in the United States by using plasma methylmalonic acid and serum vitamin B-12 SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID TOTAL HOMOCYSTEINE CONCENTRATIONS; COBALAMIN DEFICIENCY; NATIONAL-HEALTH; BIOCHEMICAL INDICATORS; COGNITIVE IMPAIRMENT; FOLATE DEFICIENCIES; ELDERLY POPULATION; PREVALENCE; FORTIFICATION; DIAGNOSIS AB Background: Various definitions, criteria, tests, and cutoffs have been used to define vitamin B-12 status; however, a need exists for the systematic study of vitamin B-12 status in the United States because of concerns about high folic acid intakes and the potential for associated adverse effects. Objective: The objective was to determine the effect of different cutoff choices on outcomes and of the different degrees of serum vitamin B-12 status, definable by the concurrent use of a functional and circulating marker as the first steps to developing a data-based consensus on the biochemical diagnosis of vitamin B-12 deficiency. Design: Data from NHANES, a nationally representative cross-sectional survey, were examined for adults aged >19 y (mean +/- SD age: 45 +/- 1 y) from 1999 to 2004 (n = 12,612). Results: Commonly used cutoffs had a greater effect on prevalence estimates of low vitamin B-12 status with the use of vitamin B-12 than with the use of methylmalonic acid (MMA; 3-26% and 2-6%, respectively). A cutoff of >148 pmol/L for vitamin B-12 and of <= 210 nmol/L for MMA resulted in significant misclassifications. Approximately 1% of adults had a clear vitamin B-12 deficiency (low vitamin B-12 and elevated MMA); 92% of adults had adequate vitamin B-12 status. A high percentage of younger women characterized the group with low vitamin B-12 and normal MMA (2% of adults) and may have falsely reflected low vitamin B-12. Adults with elevated MMA (5%) only were demographically similar (ie, by age and race) to the deficient group and may have included some individuals with early vitamin B-12 deficiency. Conclusions: These analyses indicate the challenges of assessing vitamin B-12 status when uncertainties exist about the appropriate cutoffs. Future studies should determine definable endpoints to achieve this goal. Am J Clin Nutr 2011;94:552-61. C1 [Bailey, Regan L.; Sempos, Christopher T.; Yetley, Elizabeth A.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. [Carmel, Ralph] New York Methodist Hosp, Dept Med, Brooklyn, NY USA. [Carmel, Ralph] Cornell Univ, Weill Med Coll, New York, NY 10021 USA. [Green, Ralph] Univ Calif Davis, Med Ctr, Dept Pathol & Lab Med, Sacramento, CA 95817 USA. [Pfeiffer, Christine M.; Osterloh, John D.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Cogswell, Mary E.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Bailey, RL (reprint author), NIH, Off Dietary Supplements, 6100 Execut Blvd,2B03, Bethesda, MD 20892 USA. EM baileyr@mail.nih.gov FU NIH [DK32640] FX RC was supported by NIH grant DK32640. NR 46 TC 34 Z9 35 U1 2 U2 7 PU AMER SOC CLINICAL NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD AUG PY 2011 VL 94 IS 2 BP 552 EP 561 DI 10.3945/ajcn.111.015222 PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 794TT UT WOS:000292924900025 PM 21677051 ER PT J AU Estivariz, CF Molnar, Z Venczel, L Kapusinszky, B Zingeser, JA Lipskaya, GY Kew, OM Berencsi, G Csohan, A AF Estivariz, Concepcion F. Molnar, Zsuzsanna Venczel, Linda Kapusinszky, Beatrix Zingeser, James A. Lipskaya, Galina Y. Kew, Olen M. Berencsi, Gyoergy Csohan, Agnes TI Paralytic Poliomyelitis Associated With Sabin Monovalent and Bivalent Oral Polio Vaccines in Hungary SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE adverse effects; poliomyelitis; poliovirus vaccine, oral ID UNITED-STATES; DEOXYINOSINE RESIDUES; CODON DEGENERACY; MIXED-BASE; ERADICATION; TYPE-3; POLIOVIRUSES; EPIDEMIOLOGY; STRAINS; RISK AB Historical records of patients with vaccine-associated paralytic poliomyelitis (VAPP) in Hungary during 1961-1981 were reviewed to assess the risk of VAPP after oral polio vaccine (OPV) administration. A confirmed VAPP case was defined as a diagnosis of paralytic poliomyelitis and residual paralysis at 60 days in a patient with an epidemiologic link to the vaccine. Archived poliovirus isolates were retested using polymerase chain reaction and sequencing of the viral protein 1 capsid region. This review confirmed 46 of 47 cases previously reported as VAPP. Three cases originally linked to monovalent OPV (mOPV) 3 and one case linked to mOPV1 presented after administration of bivalent OPV 1 + 3 (bOPV). The adjusted VAPP risk per million doses administered was 0.18 for mOPV1 (2 cases/11.13 million doses), 2.96 for mOPV3 (32 cases/10.81 million doses), and 12.82 for bOPV (5 cases/390,000 doses). Absence of protection from immunization with inactivated poliovirus vaccine or exposure to OPV virus from routine immunization and recent injections could explain the higher relative risk of VAPP in Hungarian children. In polio-endemic areas in which mOPV3 and bOPV are needed to achieve eradication, the higher risk of VAPP would be offset by the high risk of paralysis due to wild poliovirus and higher per-dose efficacy of mOPV3 and bOPV compared with trivalent OPV. C1 [Estivariz, Concepcion F.; Venczel, Linda; Zingeser, James A.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30084 USA. [Molnar, Zsuzsanna; Csohan, Agnes] Natl Ctr Epidemiol, Dept Communicable Dis & Epidemiol, Budapest, Hungary. [Venczel, Linda] Bill & Melinda Gates Fdn, Global Hlth Program, Seattle, WA USA. [Kapusinszky, Beatrix; Berencsi, Gyoergy] Natl Ctr Epidemiol, Dept Viral Diagnost, Budapest, Hungary. [Lipskaya, Galina Y.] World Hlth Org, Geneva, Switzerland. [Lipskaya, Galina Y.] World Hlth Org, Reg Off Europe, Copenhagen, Denmark. [Kew, Olen M.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30084 USA. [Lipskaya, Galina Y.] Moscow MV Lomonosov State Univ, AN Belozersky Inst Phys Chem Biol, Moscow, Russia. RP Estivariz, CF (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,Mailstop E05, Atlanta, GA 30084 USA. EM cge3@cdc.gov NR 53 TC 9 Z9 11 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD AUG 1 PY 2011 VL 174 IS 3 BP 316 EP 325 DI 10.1093/aje/kwr070 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 796UG UT WOS:000293077600009 PM 21685412 ER PT J AU Lee, GM Greene, SK Weintraub, ES Baggs, J Kulldorff, M Fireman, BH Baxter, R Jacobsen, SJ Irving, S Daley, MF Yin, RH Naleway, A Nordin, JD Li, LL McCarthy, N Vellozzi, C DeStefano, F Lieu, TA AF Lee, Grace M. Greene, Sharon K. Weintraub, Eric S. Baggs, James Kulldorff, Martin Fireman, Bruce H. Baxter, Roger Jacobsen, Steven J. Irving, Stephanie Daley, Matthew F. Yin, Ruihua Naleway, Allison Nordin, James D. Li, Lingling McCarthy, Natalie Vellozzi, Claudia DeStefano, Frank Lieu, Tracy A. CA Vaccine Safety Datalink Project TI H1N1 and Seasonal Influenza Vaccine Safety in the Vaccine Safety Datalink Project SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID GUILLAIN-BARRE-SYNDROME; EVENT REPORTING SYSTEM; BELLS-PALSY; UNITED-STATES; ADVERSE EVENTS; CHILDREN; SURVEILLANCE; ADULTS; ORGANIZATION; ANAPHYLAXIS AB Background: The emergence of pandemic H1N1 influenza virus in early 2009 prompted the rapid licensure and use of H1N1 monovalent inactivated (MIV) and live, attenuated (LAMV) vaccines separate from seasonal trivalent inactivated (TIV) and live, attenuated (LAIV) influenza vaccines. A robust influenza immunization program in the U. S. requires ongoing monitoring of potential adverse events associated with vaccination. Purpose: To prospectively conduct safety monitoring of H1N1 and seasonal influenza vaccines during the 2009-2010 season. Methods: The Vaccine Safety Datalink (VSD) Project monitors similar to 9.2 million members in eight U. S. medical care organizations. Electronic data on vaccines and pre-specified adverse events were updated and analyzed weekly for signal detection from November 2009 to April 2010 using either a self-controlled design or a current versus historical comparison. Statistical signals were further evaluated using alternative approaches to identify temporal clusters and to control for time-varying confounders. Results: As of May 1, 2010, a total of 1,345,663 MIV, 267,715 LAMV, 2,741,150 TIV, and 157,838 LAIV doses were administered in VSD. No significant associations were noted during sequential analyses for Guillain-Barre syndrome, most other neurologic outcomes, and allergic and cardiac events. For MIV, a statistical signal was observed for Bell's palsy for adults aged >= 25 years on March 31, 2010, using the self-controlled approach. Subsequent analyses revealed no significant temporal cluster. Case-centered logistic regression adjusting for seasonality demonstrated an OR for Bell's palsy of 1.26 (95% CI=0.97, 1.63). Conclusions: No major safety problems following H1N1 or seasonal influenza vaccines were detected in the 2009-2010 season in weekly sequential analyses. Seasonality likely contributed to the Bell's palsy signal following MIV. Prospective safety monitoring followed by rigorous signal refinement is critical to inform decision-making by regulatory and public health agencies. (Am J Prev Med 2011;41(2):121-128) (C) 2011 American Journal of Preventive Medicine C1 [Lee, Grace M.; Greene, Sharon K.; Kulldorff, Martin; Yin, Ruihua; Li, Lingling; Lieu, Tracy A.] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Ctr Child Hlth Care Studies, Boston, MA 02215 USA. Harvard Univ, Sch Med, Div Infect Dis, Boston, MA USA. [Lee, Grace M.] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA. [Lieu, Tracy A.] Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA. [Weintraub, Eric S.; Baggs, James; McCarthy, Natalie; Vellozzi, Claudia; DeStefano, Frank] CDC, Immunizat Safety Off, Div Healthcare Qual & Promot, Atlanta, GA 30333 USA. [Fireman, Bruce H.; Baxter, Roger] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA. [Jacobsen, Steven J.] Kaiser Permanente So Calif, Pasadena, CA USA. [Irving, Stephanie] Marshfield Clin Res Fdn, Marshfield, WI USA. [Daley, Matthew F.] Univ Colorado Denver, Dept Pediat, Denver, CO USA. [Naleway, Allison] Kaiser Permanente NW, Portland, OR USA. [Nordin, James D.] HealthPartners Res Fdn, Minneapolis, MN USA. RP Lee, GM (reprint author), Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Ctr Child Hlth Care Studies, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA. EM grace_lee@hphc.org RI Kulldorff, Martin/H-4282-2011; OI Jacobsen, Steven/0000-0002-8174-8533; Irving, Stephanie/0000-0001-7437-6797; Baggs, James/0000-0003-0757-4683; Naleway, Allison/0000-0001-5747-4643; Kulldorff, Martin/0000-0002-5284-2993 FU America's Health Insurance Plans (AHIP) under CDC [200-2002-00732]; Sanofi-Pasteur; Novartis; GSK; MedImmune; Merck Research Labs FX This work was supported by a subcontract with America's Health Insurance Plans (AHIP) under contract 200-2002-00732 from the CDC.; RB has research grants from Sanofi-Pasteur, Novartis, GSK and MedImmune. SJ had research grants from and served as an unpaid consultant to Merck Research Labs. NR 50 TC 56 Z9 58 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2011 VL 41 IS 2 BP 121 EP 128 DI 10.1016/j.amepre.2011.04.004 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 795FL UT WOS:000292958900002 PM 21767718 ER PT J AU Bauman, A Ainsworth, BE Sallis, JF Hagstromer, M Craig, CL Bull, FC Pratt, M Venugopal, K Chau, J Sjostrom, M AF Bauman, Adrian Ainsworth, Barbara E. Sallis, James F. Hagstromer, Maria Craig, Cora L. Bull, Fiona C. Pratt, Michael Venugopal, Kamalesh Chau, Josephine Sjostrom, Michael CA IPS Grp TI The Descriptive Epidemiology of Sitting A 20-Country Comparison Using the International Physical Activity Questionnaire (IPAQ) SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID MEASURED SEDENTARY TIME; NIH-AARP DIET; UNITED-STATES; CARDIOVASCULAR-DISEASE; ENERGY-EXPENDITURE; METABOLIC SYNDROME; AUSTRALIAN ADULTS; RISK; OBESITY; BEHAVIOR AB Background: Recent epidemiologic evidence points to the health risks of prolonged sitting, that are independent of physical activity, but few papers have reported the descriptive epidemiology of sitting in population studies with adults. Purpose: This paper reports the prevalence of "high sitting time" and its correlates in an international study in 20 countries. Methods: Representative population samples from 20 countries were collected 2002-2004, and a question was asked on usual weekday hours spent sitting. This question was part of the International Prevalence Study, using the International Physical Activity Questionnaire (IPAQ). The sitting measure has acceptable reliability and validity. Daily sitting time was compared among countries, and by age group, gender, educational attainment, and physical activity. Results: Data were available for 49,493 adults aged 18-65 years from 20 countries. The median reported sitting time was 300 minutes/day, with an interquartile range of 180-480 minutes. Countries reporting the lowest amount of sitting included Portugal, Brazil, and Colombia (medians <= 180 min/day), whereas adults in Taiwan, Norway, Hong Kong, Saudi Arabia, and Japan reported the highest sitting times (medians >= 360 min/day). In adjusted analyses, adults aged 40-65 years were significantly less likely to be in the highest quintile for sitting than adults aged 18-39 years (AOR = 0.796), and those with postschool education had higher sitting times compared with those with high school or less education (OR = 1.349). Physical activity showed an inverse relationship, with those reporting low activity on the IPAQ three times more likely to be in the highest-sitting quintile compared to those reporting high physical activity. Conclusions: Median sitting time varied widely across countries. Assessing sitting time is an important new area for preventive medicine, in addition to assessing physical activity and sedentary behaviors. Population surveys that monitor lifestyle behaviors should add measures of sitting time to physical activity surveillance. Moreover, the use of objective measures to capture the spectrum of sedentary (sitting) and physical activity behaviors is encouraged, particularly in low-and middle-income countries commencing new surveillance activities. (Am J Prev Med 2011;41(2):228-235) (C) 2011 American Journal of Preventive Medicine C1 [Bauman, Adrian] Univ Sydney, Prevent Res Collaborat, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia. [Ainsworth, Barbara E.] Arizona State Univ, Coll Nursing & Hlth Innovat, Healthy Lifestyles Res Ctr, Phoenix, AZ USA. [Sallis, James F.] San Diego State Univ, Dept Psychol & Act Living Res, San Diego, CA 92182 USA. [Hagstromer, Maria] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden. [Bauman, Adrian; Craig, Cora L.] Canadian Fitness & Lifestyle Res Inst, Ottawa, ON, Canada. [Bull, Fiona C.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia. [Pratt, Michael] CDC, Phys Act Branch, Div Nutr & Phys Act, Atlanta, GA 30333 USA. [Sjostrom, Michael] Karolinska Inst, Dept Biosci & Nutr, Unit Prevent Nutr, Stockholm, Sweden. RP Bauman, A (reprint author), Univ Sydney, Prevent Res Collaborat, Sydney Sch Publ Hlth, Level 2,Med Fdn Bldg K25, Sydney, NSW 2006, Australia. EM adrianb@health.usyd.edu.au RI Bull, Fiona/G-4148-2012; OI Hagstromer, Maria/0000-0002-4607-8677; Venugopal, Kamalesh/0000-0002-5611-6489 NR 32 TC 147 Z9 152 U1 5 U2 50 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2011 VL 41 IS 2 BP 228 EP 235 DI 10.1016/j.amepre.2011.05.003 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 795FL UT WOS:000292958900015 PM 21767731 ER PT J AU Crocker, DD Kinyota, S Dumitru, GG Ligon, CB Herman, EJ Ferdinands, JM Hopkins, DP Lawrence, BM Sipe, TA AF Crocker, Deidre D. Kinyota, Stella Dumitru, Gema G. Ligon, Colin B. Herman, Elizabeth J. Ferdinands, Jill M. Hopkins, David P. Lawrence, Briana M. Sipe, Theresa A. CA Task Force Community Preventive Se TI Effectiveness of Home-Based, Multi-Trigger, Multicomponent Interventions with an Environmental Focus for Reducing Asthma Morbidity A Community Guide Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID INNER-CITY CHILDREN; LOW-INCOME CHILDREN; HOUSE-DUST MITE; RANDOMIZED MULTIFACETED INTERVENTION; NUTRITION EXAMINATION SURVEY; INDOOR AIR-POLLUTION; 3RD NATIONAL-HEALTH; QUALITY-OF-LIFE; CHILDHOOD ASTHMA; CONTROLLED-TRIAL AB Context: Asthma exacerbations are commonly triggered by exposure to allergens and irritants within the home. The purpose of this review was to evaluate evidence that interventions that target reducing these triggers through home visits may be beneficial in improving asthma outcomes. The interventions involve home visits by trained personnel to conduct two or more components that address asthma triggers in the home. Intervention components focus on reducing exposures to a range of asthma triggers (allergens and irritants) through environmental assessment, education, and remediation. Evidence acquisition: Using methods previously developed for the Guide to Community Preventive Services, a systematic review was conducted to evaluate the evidence on effectiveness of home-based, multi-trigger, multicomponent interventions with an environmental focus to improve asthma-related morbidity outcomes. The literature search identified over 10,800 citations. Of these, 23 studies met intervention and quality criteria for inclusion in the final analysis. Evidence synthesis: In the 20 studies targeting children and adolescents, the number of days with asthma symptoms (symptom-days) was reduced by 0.8 days per 2 weeks, which is equivalent to 21.0 symptom-days per year (range of values: reduction of 0.6 to 2.3 days per year); school days missed were reduced by 12.3 days per year (range of values: reduction of 3.4 to 31.2 days per year); and the number of asthma acute care visits were reduced by 0.57 visits per year (interquartile interval: reduction of 0.33 to 1.71 visits per year). Only three studies reported outcomes among adults with asthma, finding inconsistent results. Conclusions: Home-based, multi-trigger, multicomponent interventions with an environmental focus are effective in improving overall quality of life and productivity in children and adolescents with asthma. The effectiveness of these interventions in adults is inconclusive due to the small number of studies and inconsistent results. Additional studies are needed to (1) evaluate the effectiveness of these interventions in adults and (2) determine the individual contributions of the various intervention components. (Am J Prev Med 2011;41(2S1):S5-S32) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Dumitru, Gema G.; Hopkins, David P.; Lawrence, Briana M.; Sipe, Theresa A.] CDC, Community Guide Branch, Epidemiol & Anal Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Crocker, Deidre D.; Kinyota, Stella; Dumitru, Gema G.; Ligon, Colin B.; Herman, Elizabeth J.] CDC, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Ferdinands, Jill M.] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Dumitru, GG (reprint author), CDC, Community Guide Branch, Epidemiol & Anal Program Off, Off Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd,MS E-69, Atlanta, GA 30333 USA. EM ggd7@cdc.gov RI Sipe, Theresa/C-2262-2012 FU Oak Ridge Institute for Scientific Education (ORISE); Centers for Disease Control and Prevention through Association for Prevention Teaching and Research [07-NCHM-03] FX The work of Stella Kinyota, Gema Dumitru, and Briana Lawrence was supported with funds from the Oak Ridge Institute for Scientific Education (ORISE).; Publication of this article was supported by the Centers for Disease Control and Prevention through a Cooperative Agreement with the Association for Prevention Teaching and Research award # 07-NCHM-03. NR 148 TC 67 Z9 70 U1 1 U2 27 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2011 VL 41 IS 2 SU 1 BP S5 EP S32 DI 10.1016/j.amepre.2011.05.012 PG 28 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 793ZQ UT WOS:000292863400002 PM 21767736 ER PT J AU Dumitru, GG AF Dumitru, Gema G. CA Task Force Community Preventive TI Recommendations from the Task Force on Community Preventive Services to Decrease Asthma Morbidity Through Home-Based, Multi-Trigger, Multicomponent Interventions SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material ID EXCESSIVE ALCOHOL-CONSUMPTION; ENVIRONMENTAL FOCUS; UNITED-STATES; HARMS; HEALTH; CHILDREN; CRASHES; CANCER; SALES C1 [Dumitru, Gema G.; Task Force Community Preventive] CDC, Community Guide Branch, Epidemiol & Anal Program Off, Atlanta, GA 30333 USA. RP Dumitru, GG (reprint author), CDC, Community Guide Branch, Epidemiol & Anal Program Off, 1600 Clifton Rd,MS E-69, Atlanta, GA 30333 USA. EM ggd7@cdc.gov NR 38 TC 0 Z9 0 U1 3 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2011 VL 41 IS 2 SU 1 BP S1 EP S4 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 793ZQ UT WOS:000292863400001 ER PT J AU Nurmagambetov, TA Barnett, SBL Jacob, V Chattopadhyay, SK Hopkins, DP Crocker, DD Dumitru, GG Kinyota, S AF Nurmagambetov, Tursynbek A. Barnett, Sarah Beth L. Jacob, Verughese Chattopadhyay, Sajal K. Hopkins, David P. Crocker, Deidre D. Dumitru, Gema G. Kinyota, Stella CA Task Force Community Preventive Se TI Economic Value of Home-Based, Multi-Trigger, Multicomponent Interventions with an Environmental Focus for Reducing Asthma Morbidity A Community Guide Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID INNER-CITY ASTHMA; UNITED-STATES; COST-EFFECTIVENESS; TOBACCO-SMOKE; CHILDHOOD ASTHMA; PREVENTIVE-SERVICES; DISEASE MANAGEMENT; HEALTH ECONOMICS; URBAN CHILDREN; OUTCOMES AB Context: A recent systematic review of home-based, multi-trigger, multicomponent interventions with an environmental focus showed their effectiveness in reducing asthma morbidity among children and adolescents. These interventions included home visits by trained personnel to assess the level of and reduce adverse effects of indoor environmental pollutants, and educate households with an asthma client to reduce exposure to asthma triggers. The purpose of the present review is to identify economic values of these interventions and present ranges for the main economic outcomes (e.g., program costs, benefit-cost ratios, and incremental cost-effectiveness ratios). Evidence acquisition: Using methods previously developed for Guide to Community Preventive Services economic reviews, a systematic review was conducted to evaluate the economic efficiency of home-based, multi-trigger, multicomponent interventions with an environmental focus to improve asthma-related morbidity outcomes. A total of 1551 studies were identified in the search period (1950 to June 2008), and 13 studies were included in this review. Program costs are reported for all included studies; cost-benefit results for three; and cost-effectiveness results for another three. Information on program cost was provided with varying degrees of completeness: six of the studies did not provide a list of components included in their program cost description (limited cost information), three studies provided a list of program cost components but not a cost per component (partial cost information), and four studies provided both a list of program cost components and costs per component (satisfactory cost information). Evidence synthesis: Program costs per participant per year ranged from $231-$14,858 (in 2007 U.S.$). The major factors affecting program cost, in addition to completeness, were the level of intensity of environmental remediation (minor, moderate, or major), type of educational component (environmental education or self-management), the professional status of the home visitor, and the frequency of visits by the home visitor. Benefit-cost ratios ranged from 5.3-14.0, implying that for every dollar spent on the intervention, the monetary value of the resulting benefits, such as averted medical costs or averted productivity losses, was $5.30-$14.00 (in 2007 U.S.$). The range in incremental cost-effectiveness ratios was $12-$57 (in 2007 U.S.$) per asthma symptom-free day, which means that these interventions achieved each additional symptom-free day for net costs varying from $12-$57. Conclusions: The benefits from home-based, multi-trigger, multicomponent interventions with an environmental focus can match or even exceed their program costs. Based on cost-benefit and cost-effectiveness studies, the results of this review show that these programs provide a good value for dollars spent on the interventions. (Am J Prev Med 2011;41(2S1):S33-S47) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Nurmagambetov, Tursynbek A.; Barnett, Sarah Beth L.; Crocker, Deidre D.; Dumitru, Gema G.; Kinyota, Stella] CDC, Air Pollut & Resp Hlth Branch, Div Hlth Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Jacob, Verughese; Chattopadhyay, Sajal K.; Hopkins, David P.] CDC, Community Guide Branch, Epidemiol & Anal Program Off, Atlanta, GA 30341 USA. RP Nurmagambetov, TA (reprint author), CDC, Air Pollut & Resp Hlth Branch, Div Hlth Hazards & Hlth Effects, Natl Ctr Environm Hlth, 4770 Buford Highway,MS F-58, Atlanta, GA 30341 USA. EM ten7@cdc.gov FU Air Pollution and Respiratory Health Branch, CDC; Community Guide Branch, CDC; Centers for Disease Control and Prevention through Association for Prevention Teaching and Research [07-NCHM-03] FX This project was funded by the Air Pollution and Respiratory Health Branch, CDC. This research was also supported in part by the Community Guide Branch, CDC.; Publication of this article was supported by the Centers for Disease Control and Prevention through a Cooperative Agreement with the Association for Prevention Teaching and Research award # 07-NCHM-03. NR 87 TC 28 Z9 28 U1 1 U2 19 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2011 VL 41 IS 2 SU 1 BP S33 EP S47 DI 10.1016/j.amepre.2011.05.011 PG 15 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 793ZQ UT WOS:000292863400003 PM 21767734 ER PT J AU Wilce, MA Garbe, PL AF Wilce, Maureen A. Garbe, Paul L. TI Evaluating Home-Based, Multicomponent, Multi-Trigger Interventions Your Results May Vary SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material ID PUBLIC-HEALTH POLICY; COMMUNITY C1 [Wilce, Maureen A.] CDC, Natl Ctr Environm Hlth, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Atlanta, GA 30341 USA. RP Wilce, MA (reprint author), CDC, Natl Ctr Environm Hlth, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, 4770 Buford Highway,MS F-58, Atlanta, GA 30341 USA. EM muw9@cdc.gov NR 21 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD AUG PY 2011 VL 41 IS 2 SU 1 BP S52 EP S54 DI 10.1016/j.amepre.2011.05.009 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 793ZQ UT WOS:000292863400005 PM 21767737 ER PT J AU Janssens, ACJW Ioannidis, JPA van Duijn, CM Little, J Khoury, MJ AF Janssens, A. Cecile J. W. Ioannidis, John P. A. van Duijn, Cornelia M. Little, Julian Khoury, Muin J. CA GRIPS Grp TI Strengthening the reporting of genetic risk prediction studies: the GRIPS statement SO EUROPEAN JOURNAL OF HUMAN GENETICS LA English DT Article ID EPIDEMIOLOGY; MARKER; RECOMMENDATIONS; ASSOCIATION; ELABORATION; EXPLANATION; GUIDELINES; MODELS; STROBE; IMPACT AB The rapid and continuing progress in gene discovery for complex diseases is fueling interest in the potential application of genetic risk models for clinical and public health practice. The number of studies assessing the predictive ability is steadily increasing, but the quality and completeness of reporting varies. A multidisciplinary workshop sponsored by the Human Genome Epidemiology Network developed a checklist of 25 items recommended for strengthening the reporting of Genetic RIsk Prediction Studies, building on the principles established by previous reporting guidelines. These recommendations aim to enhance the transparency of study reporting, and thereby to improve the synthesis and application of information from multiple studies that might differ in design, conduct, or analysis. A detailed Explanation and Elaboration document is published on the EJHG website. European Journal of Human Genetics (2011) 19, 833-836; doi:10.1038/ejhg.2011.25; published online 16 March 2011 C1 [Janssens, A. Cecile J. W.; van Duijn, Cornelia M.] Erasmus Univ, Dept Epidemiol, Med Ctr, NL-3000 CA Rotterdam, Netherlands. [Ioannidis, John P. A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece. [Ioannidis, John P. A.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. [Ioannidis, John P. A.] Fdn Res & Technol, Biomed Res Inst, Ioannina, Greece. [Ioannidis, John P. A.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Genet Epidemiol & Modeling, Boston, MA USA. [Ioannidis, John P. A.] Tufts Med Ctr, Tufts CTSI, Boston, MA USA. [Ioannidis, John P. A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Little, Julian] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. RP Janssens, ACJW (reprint author), Erasmus Univ, Dept Epidemiol, Med Ctr, POB 2040, NL-3000 CA Rotterdamm, Netherlands. EM a.janssens@erasmusmc.nl RI Ioannidis, John/G-9836-2011; janssens, cecile/L-1075-2015; OI Janssens, A Cecile/0000-0002-6153-4976 FU Centers for Disease Control and Prevention on behalf of the Human Genome Epidemiology Network; Erasmus University Medical Center Rotterdam; Center for Medical Systems Biology in the framework of the Netherlands Genomics Initiative; Netherlands Organisation for Scientific Research; National Institutes of Health/National Center for Research Resources [UL1 RR025752] FX The members of the GRIPS group are A Cecile JW Janssens, John PA Ioannidis, Sara Bedrosian, Paolo Boffetta, Siobhan M Dolan, Nicole Dowling, Isabel Fortier, Andrew N Freedman, Jeremy M Grimshaw, Jeffrey Gulcher, Marta Gwinn, Mark A Hlatky, Holly Janes, Peter Kraft, Stephanie Melillo, Christopher J O'Donnell, Michael J Pencina, David Ransohoff, Sheri D Schully, Daniela Seminara, Deborah M Winn, Caroline F Wright, Cornelia M van Duijn, Julian Little, and Muin J Khoury. This workshop was sponsored by the Centers for Disease Control and Prevention on behalf of the Human Genome Epidemiology Network. The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the Department of Health and Human Services. A Cecile JW Janssens is financially supported by grants from the Erasmus University Medical Center Rotterdam, the Center for Medical Systems Biology in the framework of the Netherlands Genomics Initiative and the VIDI grant of the Netherlands Organisation for Scientific Research. John PA Ioannidis: Tufts CTSI is supported by the National Institutes of Health/National Center for Research Resources (UL1 RR025752). Opinions in this paper are those of the authors and do not necessarily represent the official position or policies of the Tufts CTSI. Julian Little holds a Canada Research Chair in Human Genome Epidemiology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 26 TC 3 Z9 3 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1018-4813 J9 EUR J HUM GENET JI Eur. J. Hum. Genet. PD AUG PY 2011 VL 19 IS 8 BP 833 EP 836 DI 10.1038/ejhg.2011.25 PG 4 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 795FC UT WOS:000292957600006 PM 21407265 ER PT J AU Schully, SD Yu, W McCallum, V Benedicto, CB Dong, LM Wulf, A Clyne, M Khoury, MJ AF Schully, Sheri D. Yu, Wei McCallum, Victoria Benedicto, Camilla B. Dong, Linda M. Wulf, Anja Clyne, Melinda Khoury, Muin J. TI Cancer GAMAdb: database of cancer genetic associations from meta-analyses and genome-wide association studies SO EUROPEAN JOURNAL OF HUMAN GENETICS LA English DT Article DE cancer; meta-analyses; pooled analyses; GWAS ID EPIDEMIOLOGY; KNOWLEDGE; DISEASE AB In the field of cancer, genetic association studies are among the most active and well-funded research areas, and have produced hundreds of genetic associations, especially in the genome-wide association studies (GWAS) era. Knowledge synthesis of these discoveries is the first critical step in translating the rapidly emerging data from cancer genetic association research into potential applications for clinical practice. To facilitate the effort of translational research on cancer genetics, we have developed a continually updated database named Cancer Genome-wide Association and Meta Analyses database that contains key descriptive characteristics of each genetic association extracted from published GWAS and meta-analyses relevant to cancer risk. Here we describe the design and development of this tool with the aim of aiding the cancer research community to quickly obtain the current updated status in cancer genetic association studies. European Journal of Human Genetics (2011) 19, 928-930; doi:10.1038/ejhg.2011.53; published online 13 April 2011 C1 [Schully, Sheri D.; Benedicto, Camilla B.; Khoury, Muin J.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Yu, Wei; Wulf, Anja; Clyne, Melinda; Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. [McCallum, Victoria] NCI, Off Workforce Dev, Bethesda, MD 20892 USA. [Dong, Linda M.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. RP Schully, SD (reprint author), NCI, Div Canc Control & Populat Sci, 6130 Executive Blvd,Suite 5124,MSC 7393, Bethesda, MD 20892 USA. EM schullys@mail.nih.gov RI Liao, Linda/B-3960-2011 NR 8 TC 12 Z9 12 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1018-4813 J9 EUR J HUM GENET JI Eur. J. Hum. Genet. PD AUG PY 2011 VL 19 IS 8 BP 928 EP 930 DI 10.1038/ejhg.2011.53 PG 3 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 795FC UT WOS:000292957600022 PM 21487441 ER PT J AU Burton, DC Edwards, JR Srinivasan, A Fridkin, SK Gould, CV AF Burton, Deron C. Edwards, Jonathan R. Srinivasan, Arjun Fridkin, Scott K. Gould, Carolyn V. TI Trends in Catheter-Associated Urinary Tract Infections in Adult Intensive Care Units-United States, 1990-2007 SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID BLOOD-STREAM INFECTIONS; NOSOCOMIAL INFECTIONS; HOSPITALIZED-PATIENTS; SURVEILLANCE SYSTEM; US HOSPITALS; INTERVENTION; PREVENTION; PHYSICIANS; RATES; ICU AB BACKGROUND. Over the past 2 decades, multiple interventions have been developed to prevent catheter-associated urinary tract infections (CAUTIs). The CAUTI prevention guidelines of the Healthcare Infection Control Practices Advisory Committee were recently revised. OBJECTIVE. To examine changes in rates of CAUTI events in adult intensive care units (ICUs) in the United States from 1990 through 2007. METHODS. Data were reported to the Centers for Disease Control and Prevention (CDC) through the National Nosocomial Infections Surveillance System from 1990 through 2004 and the National Healthcare Safety Network from 2006 through 2007. Infection preventionists in participating hospitals used standard methods to identify all CAUTI events (categorized as symptomatic urinary tract infection [SUTI] or asymptomatic bacteriuria [ASB]) and urinary catheter-days (UC-days) in months selected for surveillance. Data from all facilities were aggregated to calculate pooled mean annual SUTI and ASB rates (in events per 1,000 UC-days) by ICU type. Poisson regression was used to estimate percent changes in rates over time. RESULTS. Overall, 36,282 SUTIs and 22,973 ASB episodes were reported from 367 facilities representing 1,223 adult ICUs, including combined medical/surgical (505), medical (212), surgical (224), coronary (173), and cardiothoracic (109) ICUs. All ICU types experienced significant declines of 19%-67% in SUTI rates and 29%-72% in ASB rates from 1990 through 2007. Between 2000 and 2007, significant reductions in SUTI rates occurred in all ICU types except cardiothoracic ICUs. CONCLUSIONS. Since 1990, CAUTI rates have declined significantly in all major adult ICU types in facilities reporting to the CDC. Further efforts are needed to assess prevention strategies that might have led to these decreases and to implement new CAUTI prevention guidelines. Infect Control Hosp Epidemiol 2011; 32(8): 748-756 C1 [Gould, Carolyn V.] Ctr Dis Control & Prevent, Prevent & Response Branch, Div Healthcare Qual Promot, Ntl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Gould, CV (reprint author), Ctr Dis Control & Prevent, Prevent & Response Branch, Div Healthcare Qual Promot, Ntl Ctr Emerging & Zoonot Infect Dis, Mailstop A-35,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM cgould@cdc.gov FU US Department of Health and Human Services FX Financial support. All funding and material support for this work were provided by the US Department of Health and Human Services. NR 31 TC 29 Z9 31 U1 0 U2 10 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD AUG PY 2011 VL 32 IS 8 BP 748 EP 756 DI 10.1086/660872 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 795LY UT WOS:000292976900003 PM 21768757 ER PT J AU Tohme, RA Ribner, B Huey, MJ Spradling, PR AF Tohme, Rania A. Ribner, Bruce Huey, Michael J. Spradling, Philip R. TI Hepatitis B Vaccination Coverage and Documented Seroprotection among Matriculating Healthcare Students at an Academic Institution in the United States SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID PREVENTABLE DISEASES; MEDICAL-STUDENTS; VIRUS AB We evaluated hepatitis B vaccination coverage and documentation of antibody to hepatitis B surface antigen (anti-HBs) concentration among a cohort of healthcare students. Of 4,075 students, 59.8% had documentation of vaccination and 83.8% had anti-HBs concentration greater than or equal to 10 mIU/mL. Documenting hepatitis B vaccination and anti-HBs concentration among healthcare students is needed to prevent transmission in healthcare settings. Infect Control Hosp Epidemiol 2011; 32(8): 818-821 C1 [Tohme, Rania A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Tohme, Rania A.; Spradling, Philip R.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Ribner, Bruce; Huey, Michael J.] Emory Univ, Atlanta, GA 30322 USA. RP Tohme, RA (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd NE,Mailstop G37, Atlanta, GA 30333 USA. EM rtohme@cdc.gov NR 10 TC 4 Z9 4 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD AUG PY 2011 VL 32 IS 8 BP 818 EP 821 DI 10.1086/661102 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 795LY UT WOS:000292976900014 PM 21768768 ER PT J AU Weber, DJ Sickbert-Bennett, EE Gould, CV Brown, VM Huslage, K Rutala, WA AF Weber, David J. Sickbert-Bennett, Emily E. Gould, Carolyn V. Brown, Vickie M. Huslage, Kirk Rutala, William A. TI Incidence of Catheter-Associated and Non-Catheter-Associated Urinary Tract Infections in a Healthcare System SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Editorial Material C1 [Weber, David J.; Sickbert-Bennett, Emily E.; Brown, Vickie M.; Huslage, Kirk; Rutala, William A.] Univ N Carolina Hlth Care, Chapel Hill, NC USA. [Weber, David J.; Rutala, William A.] Univ N Carolina, Chapel Hill, NC USA. [Gould, Carolyn V.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Weber, DJ (reprint author), 2163 Bioinformat,CB 7030, Chapel Hill, NC 27599 USA. EM dweber@unch.unc.edu NR 8 TC 18 Z9 21 U1 0 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD AUG PY 2011 VL 32 IS 8 BP 822 EP 823 DI 10.1086/661107 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 795LY UT WOS:000292976900015 PM 21768769 ER PT J AU Mendiola, J Jorgensen, N Andersson, AM Calafat, AM Silva, MJ Redmon, JB Sparks, A Drobnis, EZ Wang, C Liu, F Swan, SH AF Mendiola, J. Jorgensen, N. Andersson, A. -M. Calafat, A. M. Silva, M. J. Redmon, J. B. Sparks, A. Drobnis, E. Z. Wang, C. Liu, F. Swan, S. H. TI Associations between urinary metabolites of di(2-ethylhexyl) phthalate and reproductive hormones in fertile men SO INTERNATIONAL JOURNAL OF ANDROLOGY LA English DT Article DE anti-androgens; di(2-ethylhexyl) phthalate metabolites; endocrine disruptors; male hormones; phthalates ID N-BUTYL PHTHALATE; TESTICULAR DYSGENESIS SYNDROME; SEMEN QUALITY; MALE-RAT; DIETHYLHEXYL PHTHALATE; SEXUAL-DIFFERENTIATION; TEMPORAL VARIABILITY; DANISH POPULATION; FREE TESTOSTERONE; NEONATAL-RATS AB Widely used man-made chemicals, including phthalates, can induce hormonal alterations through a variety of cellular and molecular mechanisms. A number of rodent and observational studies have consistently demonstrated the antiandrogenic effect of several phthalates. However, there are only limited data on the relationship between exposure to these chemicals and reproductive hormone levels in men. All men (n = 425) were partners of pregnant women who participated in the Study for Future Families in five US cities and provided urine and serum samples on the same day. Eleven phthalate metabolites were measured in urine and serum samples were analysed for reproductive hormones, including follicle-stimulating hormone, luteinizing hormone, testosterone, inhibin B and oestradiol and sex hormone-binding globulin (SHBG). Pearson correlations and parametric tests were used for unadjusted analyses, and multiple linear regression analysis was performed controlling for appropriate covariates. We observed weak or no associations with urinary phthalates other than di(2-ethylhexyl) phthalate (DEHP). All measures of testosterone [total, calculated free testosterone and the free androgen index (FAI)] were inversely correlated with the urinary concentrations of four DEHP metabolites. After adjustment by appropriate covariates, there was no longer an association between urinary DEHP metabolite concentrations and total testosterone levels; however, FAI was significantly associated with the urinary concentrations of several DEHP metabolites. SHBG was positively related to the urinary concentrations of mono(2-ethylhexyl) phthalate, but not with other DEHP metabolites, an association that was attenuated after adjustment. Our results suggest that DEHP exposure of fertile men is associated with minor alterations of markers of free testosterone. C1 [Mendiola, J.; Liu, F.; Swan, S. H.] Univ Rochester, Sch Med & Dent, Dept Obstet & Gynecol, Rochester, NY 14642 USA. [Jorgensen, N.; Andersson, A. -M.] Univ Copenhagen, Rigshosp, Univ Dept Growth & Reprod, DK-2100 Copenhagen, Denmark. [Calafat, A. M.; Silva, M. J.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Redmon, J. B.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA. [Redmon, J. B.] Univ Minnesota, Sch Med, Dept Urol Surg, Minneapolis, MN 55455 USA. [Sparks, A.] Univ Iowa, Dept Obstet & Gynecol, Iowa City, IA 52242 USA. [Drobnis, E. Z.] Univ Missouri, Sch Med, Dept Obstet Gynecol & Womens Hlth, Columbia, MO USA. [Wang, C.] Harbor UCLA Med Ctr, Div Endocrinol, Dept Med, Torrance, CA 90509 USA. [Wang, C.] Los Angeles Biomed Res Inst, Torrance, CA USA. RP Swan, SH (reprint author), Univ Rochester, Sch Med & Dent, Dept Obstet & Gynecol, 601 Elmwood Ave,Box 668, Rochester, NY 14642 USA. EM shanna_swan@urmc.rochester.edu RI Perez , Claudio Alejandro/F-8310-2010; Jorgensen, Niels/A-8148-2012; Andersson, Anna-Maria/F-5842-2013; OI Perez , Claudio Alejandro/0000-0001-9688-184X; Jorgensen, Niels/0000-0003-4827-0838; Andersson, Anna-Maria/0000-0002-7300-1659; Redmon, J. Bruce/0000-0002-1883-9467; Drobnis, Erma Z./0000-0001-5495-3489 FU Danish Agency for Science, Technology and Innovation [271070678]; University of Iowa Center for Health Effects of Environmental Contamination; General Clinical Research Center at Harbor-UCLA Medical Center [MO1 RR00425] FX The findings and conclusions in this report are those of the author and do not necessarily represent the official position of the CDC. The authors gratefully acknowledge Ella Samandar, James Preau and Jack Reidy (CDC, Atlanta, GA) for measuring the urinary concentrations of the phthalate metabolites. This study is supported by the following grants: the Danish Agency for Science, Technology and Innovation, grant no. 271070678 to N. Jorgensen; University of Iowa Center for Health Effects of Environmental Contamination cooperative project grant to A. Sparks; and the General Clinical Research Center at Harbor-UCLA Medical Center (MO1 RR00425) to C. Wang. NR 51 TC 31 Z9 33 U1 2 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0105-6263 J9 INT J ANDROL JI Int. J. Androl. PD AUG PY 2011 VL 34 IS 4 BP 369 EP 378 DI 10.1111/j.1365-2605.2010.01095.x PN 1 PG 10 WC Andrology SC Endocrinology & Metabolism GA 794IP UT WOS:000292889200010 PM 20633195 ER PT J AU Clevenger, LM Pyrzanowski, J Curtis, CR Bull, S Crane, LA Barrow, JC Kempe, A Daley, MF AF Clevenger, Lesly-Marie Pyrzanowski, Jennifer Curtis, C. Robinette Bull, Sheana Crane, Lori A. Barrow, Jennifer C. Kempe, Allison Daley, Matthew F. TI Parents' Acceptance of Adolescent Immunizations Outside of the Traditional Medical Home SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Immunization; Adolescent; Parent; Attitudes; Survey ID UNITED-STATES; PRIMARY-CARE; HEALTH; SERVICES; CHILDREN AB Purpose: Numerous barriers to vaccination exist for adolescents. Using the medical home as the sole source of adolescent vaccination has potential limitations. The objectives of the present study were to examine parents' acceptance of adolescent vaccination outside of the medical home and parents' preferred setting for adolescent vaccination. Methods: A standardized, pilot-tested telephone survey was administered to a stratified random sample (n = 1,998) of Colorado households between August 2007 and February 2008. Households with English-speaking parents and adolescent(s) aged 11-17 years were eligible. Results: Survey response rate was 43%; there were no significant differences between respondents and nonrespondents for three known demographic variables. Although most parents (78%) preferred a doctor's office for adolescent vaccination, a majority were also definitively or probably accepting of vaccination in public health clinics (74%), school health clinics (70%), obstetrics and gynecology clinics (69%; asked for females only), and emergency departments (67%). Parents were less accepting of vaccination in family planning clinics (41%) and retail-based clinics (36%). Perceived convenience and adolescents' comfort in the setting were positively associated with vaccination acceptance in most settings; concern with keeping track of vaccines given outside of the medical home was negatively associated with acceptance. Parents in rural areas were more likely than parents in urban areas to identify a setting outside of the medical home as the preferred "best" setting for vaccination. Conclusions: Most parents assessed a doctors' office as the best setting for adolescent vaccination. However, vaccination in certain settings outside of the medical home seems to be acceptable to many parents. (C) 2011 Society for Adolescent Health and Medicine. All rights reserved. C1 [Clevenger, Lesly-Marie; Bull, Sheana; Crane, Lori A.] Colorado Sch Publ Hlth, Dept Community & Behav Hlth, Aurora, CO USA. [Pyrzanowski, Jennifer; Crane, Lori A.; Barrow, Jennifer C.; Kempe, Allison; Daley, Matthew F.] Childrens Hosp, Childrens Outcomes Res Program, Aurora, CO USA. [Curtis, C. Robinette] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Kempe, Allison; Daley, Matthew F.] Univ Colorado Denver, Dept Pediat, Aurora, CO USA. [Daley, Matthew F.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Clevenger, Lesly-Marie] Univ Colorado Denver, Dept Hlth & Behav Sci, Denver, CO USA. RP Clevenger, LM (reprint author), Univ Colorado Denver, Dept Hlth & Behav Sci, 1101 Beaumont Ctr Lane 5302, Lexington, KY 40513 USA. EM lesly.clevenger@gmail.com FU Centers for Disease Control and Prevention [1-U01-IP000110] FX This investigation was supported by Cooperative Agreement number 1-U01-IP000110 from the Centers for Disease Control and Prevention. The findings and conclusions in this report are solely the responsibility of the authors, and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services. The first author had full access to all of the data in this study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 38 TC 19 Z9 19 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD AUG PY 2011 VL 49 IS 2 BP 133 EP 140 DI 10.1016/j.jadohealth.2011.04.012 PG 8 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 795TB UT WOS:000292997600005 PM 21783044 ER PT J AU B'Hymer, C AF B'Hymer, C. TI Validation of an HPLC-MS-MS Method for the Determination of Urinary S-Benzylmercapturic Acid and S-Phenylmercapturic Acid SO JOURNAL OF CHROMATOGRAPHIC SCIENCE LA English DT Article ID CHROMATOGRAPHY-MASS SPECTROMETRY; OCCUPATIONAL-EXPOSURE; INDUSTRIAL-CHEMICALS; BENZENE METABOLITES; LC-MS; LIQUID; BIOMARKERS; TOLUENE; QUANTIFICATION; SOLVENTS C1 NIOSH, US Dept HHS, Ctr Dis Control, Div Appl Res & Technol,Taft Lab C 23, Cincinnati, OH 45226 USA. RP B'Hymer, C (reprint author), NIOSH, US Dept HHS, Ctr Dis Control, Div Appl Res & Technol,Taft Lab C 23, 4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM cbhymer@cdc.gov NR 30 TC 7 Z9 8 U1 0 U2 8 PU PRESTON PUBL INC PI NILES PA 6600 W TOUHY AVE, NILES, IL 60714-4588 USA SN 0021-9665 J9 J CHROMATOGR SCI JI J. Chromatogr. Sci. PD AUG PY 2011 VL 49 IS 7 BP 547 EP 553 PG 7 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 796KI UT WOS:000293049800009 PM 21801486 ER PT J AU Haynes, CA Allegood, JC Wang, EW Kelly, SL Sullards, MC Merrill, AH AF Haynes, Christopher A. Allegood, Jeremy C. Wang, Elaine W. Kelly, Samuel L. Sullards, M. Cameron Merrill, Alfred H., Jr. TI Factors to consider in using [U-C-13]palmitate for analysis of sphingolipid biosynthesis by tandem mass spectrometry SO JOURNAL OF LIPID RESEARCH LA English DT Article DE metabolomics; lipidomics; sphingolipidomics; stable isotope labeling; fatty acyl-CoAs; isotopomers; isotopologues ID ISOTOPOMER DISTRIBUTION ANALYSIS; MAMMALIAN-CELLS; ACYL-COENZYME; COA; METABOLISM; SPHINGOSINE; CERAMIDE; INCREASES; TOPOLOGY; SERINE AB This study describes the use of a stable-isotope labeled precursor ([U-C-13]palmitate) to analyze de novo sphingolipid biosynthesis by tandem mass spectrometry. It also describes factors to consider in interpreting the data, including the isotope's location (C-13 appears in three isotopomers and isotopologues: [M + 16] for the sphingoid base or N-acyl fatty acid, and [M + 32] for both); the isotopic enrichment of palmitoyl-CoA; and its elongation, desaturation, and incorporation into N-acyl-sphingolipids. For HEK293 cells incubated with 0.1 mM [U-C-13]palmitic acid, similar to 60% of the total palmitoyl-CoA was C-13-labeled by 3 h (which was near isotopic equilibrium); with this correction, the rates of de novo biosynthesis of C16:0-ceramide, C16:0-monohexosylceramide, and C16:0-sphingomyelin were 62 +/- 3, 13 +/- 2, and 60 +/- 11 pmol/h per mg protein, respectively, which are consistent with an estimated rate of appearance of C16: 0-ceramide using exponential growth modeling (119 +/- 11 pmol/h per mg protein). Including estimates for the very long-chain fatty acyl-CoAs, the overall rate of sphingolipid biosynthesis can be estimated to be at least similar to 1.6-fold higher. Thus, consideration of these factors gives a more accurate picture of de novo sphingolipid biosynthesis than has been possible to-date, while acknowledging that there are inherent limitations to such approximations.-Haynes, C. A., J. C. Allegood, E. W. Wang, S. L. Kelly, M. C. Sullards, and A. H. Merrill, Jr. Factors to consider in using [U-C-13] palmitate for analysis of sphingolipid biosynthesis by tandem mass spectrometry. J. Lipid Res. 2011. 52: 1583-1594. C1 [Wang, Elaine W.; Kelly, Samuel L.; Merrill, Alfred H., Jr.] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA. [Sullards, M. Cameron; Merrill, Alfred H., Jr.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. [Wang, Elaine W.; Kelly, Samuel L.; Sullards, M. Cameron] Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA. [Haynes, Christopher A.] Ctr Dis Control & Prevent, Newborn Screening & Mol Biol Branch, Atlanta, GA USA. [Allegood, Jeremy C.] Virginia Commonwealth Univ Sch Med, Dept Biochem & Mol Biol, Richmond, VA USA. RP Merrill, AH (reprint author), Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA. EM al.merrill@biology.gatech.edu FU National Institutes of Health [GM-069338 (LIPID MAPS)]; Centers for Disease Control and Prevention (CDC) FX This work was supported by National Institutes of Health Grant GM-069338 (LIPID MAPS) and by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention (CDC) administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the CDC. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or the Centers for Disease Control and Prevention. NR 50 TC 10 Z9 11 U1 3 U2 10 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD AUG PY 2011 VL 52 IS 8 BP 1583 EP 1594 DI 10.1194/jlr.D015586 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 792QJ UT WOS:000292763200017 PM 21586681 ER PT J AU Xiao, L O'Callaghan, JP O'Donnell, JM AF Xiao, Lan O'Callaghan, James P. O'Donnell, James M. TI Effects of Repeated Treatment with Phosphodiesterase-4 Inhibitors on cAMP Signaling, Hippocampal Cell Proliferation, and Behavior in the Forced-Swim Test SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID ELEMENT-BINDING PROTEIN; REPEATED ANTIDEPRESSANT TREATMENT; MICE DEFICIENT; ROLIPRAM BINDING; REDUCED SENSITIVITY; CHRONIC FLUOXETINE; CATALYTIC-ACTIVITY; PDE4 INHIBITORS; RAT-BRAIN; IN-VIVO AB The effects of repeated treatment with the phosphodiesterase-4 (PDE4) inhibitors rolipram, piclamilast, and 4-(2-(3-(cyclopentyloxy)- 4-methoxyphenyl)-2-phenylethyl) pyridine (CDP840), which differ in their interactions with high-and low-affinity binding conformers of the enzyme, were contrasted to those of acute treatment on cAMP signaling, hippocampal cell proliferation, and immobility in the forced-swim test in rats. Repeated treatment with rolipram (1 and 3 mg/kg), piclamilast (0.3 and 1 mg/kg), or CDP840 (10 and 30 mg/kg) for 16 days increased cAMP and phosphorylation of cAMP response element binding protein (pCREB) in hippocampus and prefrontal cortex. In addition, repeated treatment with the PDE4 inhibitors increased proliferation and survival of newborn cells in the hippocampus and produced antidepressant-like effects on behavior, as evidenced by decreased immobility in the forced-swim test. Acute treatment with rolipram (3 mg/kg), piclamilast (1 mg/kg), or CDP840 (30 mg/kg) induced transient increases in cAMP and pCREB in hippocampus and prefrontal cortex, but the dose and time dependence of these effects did not parallel the behavioral effects. Compared with rolipram and piclamilast, repeated treatment with CDP840 exerted lesser effects on neural and behavioral measures, probably because of its weak interaction with the high-affinity binding conformer of PDE4. This suggests the relative importance of the high-affinity binding conformer in the mediation of the long-term effects of PDE4 inhibition on cAMP/pCREB signaling, hippocampal cell proliferation, and antidepressant-like effects on behavior. C1 [Xiao, Lan] W Virginia Univ, Hlth Sci Ctr, Grad Program Pharmaceut & Pharmacol Sci, Morgantown, WV 26506 USA. [O'Donnell, James M.] W Virginia Univ, Hlth Sci Ctr, Dept Behav Med & Psychiat, Morgantown, WV 26506 USA. [O'Donnell, James M.] W Virginia Univ, Hlth Sci Ctr, Dept Neurobiol & Anat, Morgantown, WV 26506 USA. [O'Callaghan, James P.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV USA. RP Xiao, L (reprint author), Med Ctr Dr,WVU HSC N 4028, Morgantown, WV USA. EM lxiao@hsc.wvu.edu RI O'Callaghan, James/O-2958-2013; OI O'Donnell, James/0000-0002-8994-7588 FU National Institutes of Health National Institute of Mental Health [MH051175, MH040694, MH088480]; National Institutes of Health National Institute for Research Resources [RR016440, RR020866]; Lundbeck Pharmaceuticals; Memory Pharmaceuticals FX This research was supported by the National Institutes of Health National Institute of Mental Health [Grants MH051175, MH040694, MH088480]. The West Virginia University Flow Cytometry Core Facility is supported by the National Institutes of Health National Institute for Research Resources [Grants RR016440, RR020866]. J.M.O. has received research funding from Lundbeck Pharmaceuticals and Memory Pharmaceuticals. NR 46 TC 10 Z9 10 U1 0 U2 5 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD AUG PY 2011 VL 338 IS 2 BP 641 EP 647 DI 10.1124/jpet.111.179358 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 793RU UT WOS:000292841600025 PM 21566211 ER PT J AU Chen, S Erhart, LM Anderson, S Komatsu, K Park, B Chiller, T Sunenshine, R AF Chen, Sanny Erhart, Laura M. Anderson, Shoana Komatsu, Ken Park, Benjamin Chiller, Tom Sunenshine, Rebecca TI Coccidioidomycosis: knowledge, attitudes, and practices among healthcare providers - Arizona, 2007 SO MEDICAL MYCOLOGY LA English DT Article DE coccidioidomycosis; fungus; KAP survey; community-acquired pneumonia; lung disease ID COMMUNITY-ACQUIRED PNEUMONIA; ANTIBODIES; SURVEILLANCE; IMMITIS; TESTS; EIA; USA AB Coccidioidomycosis presumably causes < a parts per thousand currency sign 33% of community-acquired pneumonias cases, although < 15% of the patients are tested for coccidioidomycosis. We assessed healthcare providers'' knowledge, attitudes, and practices regarding coccidioidomycosis diagnosis and treatment in Arizona. A survey was mailed to 7,608 eligible healthcare providers licensed by the Arizona medical, osteopathic, and nursing boards in October and December 2007. We used weights to adjust for non-response and multivariate logistic regression models to identify predictors of >= a parts per thousand yen 70% correct regarding knowledge and treatment practices. Of 1,823 (24%) respondents, 53% were physicians, 52% were male, and the mean age was 51 years. Approximately 50% reported confidence in their ability to treat coccidioidomycosis, and 21% correctly answered all four treatment questions. Predictors of >= a parts per thousand yen 70% correct concerning knowledge and treatment practices included always counseling patients after diagnosis (adjusted odds ratio [AOR] == 4.4; 95% confidence interval [CI]: 2.8--7.1); specializing in infectious diseases (AOR == 2.4; 95% CI: 1.0--5.7); and having received coccidioidomycosis continuing medical education (CME) in the last year (AOR == 1.8; 95% CI: 1.2--2.6). These findings demonstrate that coccidioidomycosis CME improves knowledge of disease diagnosis and management, underscoring the need for a comprehensive coccidioidomycosis education campaign for healthcare providers in Arizona. C1 [Chen, Sanny] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Chen, Sanny; Erhart, Laura M.; Anderson, Shoana; Komatsu, Ken; Sunenshine, Rebecca] Arizona Dept Hlth Serv, Bur Epidemiol & Dis Control Serv, Phoenix, AZ 85007 USA. [Park, Benjamin; Chiller, Tom] Div Foodborne Bacterial & Mycot Dis, Atlanta, GA USA. [Sunenshine, Rebecca] CDC, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. RP Chen, S (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd,MS E-30, Atlanta, GA 30333 USA. EM sychen@cdc.gov FU Arizona Department of Health Services FX This survey was supported by the Arizona Department of Health Services. The authors wish to acknowledge Thom Wilson and Christine Wampler at the Arizona Department of Health Services, Phoenix, for their administrative support, Kris Bisgard at the Centers for Disease Control and Prevention, Atlanta, for manuscript review, and John Galgiani and Susan Hoover at the Valley Fever Center for Excellence, Tucson, for their assistance with survey development. NR 24 TC 8 Z9 8 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1369-3786 J9 MED MYCOL JI Med. Mycol. PD AUG PY 2011 VL 49 IS 6 BP 649 EP 656 DI 10.3109/13693786.2010.547995 PG 8 WC Infectious Diseases; Mycology; Veterinary Sciences SC Infectious Diseases; Mycology; Veterinary Sciences GA 792WB UT WOS:000292780000012 PM 21247229 ER PT J AU Xu, FJ Stoner, BP Taylor, SN Mena, L Tian, LH Papp, J Hutchins, K Martin, DH Markowitz, LE AF Xu, Fujie Stoner, Bradley P. Taylor, Stephanie N. Mena, Leandro Tian, Lin H. Papp, John Hutchins, Kathleen Martin, David H. Markowitz, Lauri E. TI Use of Home-Obtained Vaginal Swabs to Facilitate Rescreening for Chlamydia trachomatis Infections Two Randomized Controlled Trials SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID SEXUALLY-TRANSMITTED INFECTIONS; YOUNG-WOMEN; SCREENING APPROACH; RANDOMIZED-TRIAL; SAN-FRANCISCO; UNITED-STATES; GONORRHEA; SPECIMENS; RECURRENT; MAIL AB OBJECTIVE: To determine whether the use of home-based, self-obtained vaginal swabs among women who were treated for Chlamydia infection can increase rescreening rates in comparison with clinic-based rescreening, and to identify subgroups in which rescreening could be enhanced using self-obtained vaginal swabs. METHODS: Two randomized trials were conducted: one with enrollment in sexually transmitted disease (STD) clinics and the other in family planning clinics. Study participants were recruited from STD (n = 880) and family planning clinics (n = 412) in three cities. Females aged 16 years or older who were treated for Chlamydia infection were randomly assigned to the home group (swab collection kits mailed to home) or the clinic group (made clinic appointments) for rescreening at 3 months after treatment, with reminder calls about 2 weeks before the scheduled rescreening date. RESULTS: Groups were similar with respect to age and other demographic characteristics. Women assigned to the home group had higher rescreening rates than those in the clinic group. In STD clinics, rescreening rates were 26.7% (home) compared with 19.1% (clinic) (P<.01). In family planning clinics, rescreening rates were 40.8% (home) compared with 20.7% (clinic) (P<.001). Among women reached by reminder calls, rescreening rates were also significantly higher in the home groups: 43.5% compared with 33.0% in STD clinic participants and 59.2% compared with 37.8% in family planning clinic participants (both P<.05). The rates of reinfection ranged from 12.9% to 19.4%, and the differences by group were not statistically significant (P >=.3). CONCLUSION: In STD and family planning clinics, use of home-based, self-obtained vaginal swabs resulted in significant increases in rescreening rates compared with rescreening in the clinic. Home-based specimen collection can be an alternative to clinic-based rescreening for Chlamydia infection in women. C1 [Xu, Fujie] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. Washington Univ, Dept Anthropol, St Louis, MO 63130 USA. Washington Univ, Dept Internal Med, St Louis, MO USA. Louisiana State Univ, Hlth Sci Ctr, Sch Med, Infect Dis Sect, New Orleans, LA USA. Univ Mississippi, Med Ctr, Crossrd Clin, Mississippi State Dept Hlth, Jackson, MS 39216 USA. RP Xu, FJ (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Mailstop E-02,1600 Clifton Rd, Atlanta, GA 30333 USA. EM fax1@cdc.gov FU Centers for Disease Control and Prevention FX Funded by Centers for Disease Control and Prevention. NR 29 TC 24 Z9 24 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD AUG PY 2011 VL 118 IS 2 BP 231 EP 239 DI 10.1097/AOG.0b013e3182246a83 PN 1 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 795FB UT WOS:000292956900006 PM 21775837 ER PT J AU MacKellar, DA Hou, SI Whalen, CC Samuelsen, K Valleroy, LA Secura, GM Behel, S Bingham, T Celentano, DD Koblin, BA LaLota, M Shehan, D Thiede, H Torian, LV AF MacKellar, Duncan A. Hou, Su-I Whalen, Christopher C. Samuelsen, Karen Valleroy, Linda A. Secura, Gina M. Behel, Stephanie Bingham, Trista Celentano, David D. Koblin, Beryl A. LaLota, Marlene Shehan, Douglas Thiede, Hanne Torian, Lucia V. CA Young Mens Survey Study Grp TI HIV/AIDS Complacency and HIV Infection Among Young Men Who Have Sex With Men, and the Race-Specific Influence of Underlying HAART Beliefs SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; AFRICAN-AMERICAN MEN; LONDON GAY MEN; HIGH-RISK SEX; BISEXUAL MEN; COMBINATION THERAPIES; BEHAVIOR INCREASES; TREATMENT OPTIMISM; HOMOSEXUAL-MEN; SAN-FRANCISCO AB Background: Among men who have sex with men (MSM) in the United States, the influence of HIV/AIDS complacency and beliefs about the efficacy of highly active antiretroviral therapy (HAART) on HIV-infection risk is unknown. Methods: We analyzed data from a 1998-2000 cross-sectional 6-city survey of 1575 MSM aged 23 to 29 years who had never tested for HIV or had last tested HIV-negative to assess these plausible influences overall and by race/ethnicity. Findings: Measured as strong endorsement for reduced HIV/AIDS concern due to HAART, HIV/AIDS complacency was associated with reporting >= 10 male sex partners (odds ratio [OR], 2.94; 95% confidence interval [CI], 2.12-4.07), unprotected anal intercourse with an HIV-positive or HIV-unknown-status male partner (OR, 2.06; 95% CI, 1.51-2.81), and testing HIV-positive (adjusted OR [AOR], 2.35; 95% CI, 1.38-3.98). Strong endorsement of the belief that HAART miti-gates HIV/AIDS severity was more prevalent among black (21.8%) and Hispanic (21.3%) than white (9.6%) MSM (P < 0.001), and was more strongly associated with testing HIV-positive among black (AOR, 4.65; 95% CI, 1.97-10.99) and Hispanic (AOR, 4.12; 95% CI, 1.58-10.70) than white (AOR, 1.62; 95% CI, 0.64-4.11) MSM. Conclusions: Young MSM who are complacent about HIV/AIDS because of HAART may be more likely to engage in risk behavior and acquire HIV. Programs that target HIV/AIDS complacency as a means to reduce HIV incidence among young MSM should consider that both the prevalence of strong HAART-efficacy beliefs and the effects of these beliefs on HIV-infection risk might differ considerably by race/ethnicity. C1 [MacKellar, Duncan A.; Valleroy, Linda A.; Secura, Gina M.; Behel, Stephanie] Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA. [Hou, Su-I; Whalen, Christopher C.] Univ Georgia, Coll Publ Hlth, Athens, GA 30602 USA. [Samuelsen, Karen] Univ Georgia, Dept Educ Psychol & Instruct Technol, Athens, GA 30602 USA. [Bingham, Trista] Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA. [Celentano, David D.] Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD USA. [Koblin, Beryl A.] New York Blood Ctr, New York, NY 10021 USA. [LaLota, Marlene] Florida Dept Hlth, Tallahassee, FL USA. [Shehan, Douglas] Univ Texas SW Med Ctr Dallas, Dallas, TX USA. [Thiede, Hanne] Publ Hlth Seattle & King Cty, Seattle, WA USA. [Torian, Lucia V.] New York City Dept Hlth, New York, NY 10013 USA. RP MacKellar, DA (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Natl Ctr HIV STD & TB Prevent, 1600 Clifton Rd NE,MS E-04, Atlanta, GA 30333 USA. EM dym4@cdc.gov OI Hou, Su-I/0000-0002-4519-0974 FU NCRR NIH HHS [M01 RR000052] NR 50 TC 10 Z9 10 U1 4 U2 15 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD AUG PY 2011 VL 38 IS 8 BP 755 EP 763 DI 10.1097/OLQ.0b013e31820d5a77 PG 9 WC Infectious Diseases SC Infectious Diseases GA 792PP UT WOS:000292759900013 PM 21336231 ER PT J AU Dionne-Odom, J Tambe, P Yee, E Weinstock, H del Rio, C AF Dionne-Odom, Jodie Tambe, Pradnya Yee, Eileen Weinstock, Hillard del Rio, Carlos TI Antimicrobial Resistant Gonorrhea in Atlanta: 1988-2006 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID NEISSERIA-GONORRHOEAE; UNITED-STATES; DECREASED SUSCEPTIBILITY; FLUOROQUINOLONES; INFECTIONS; EMERGENCE AB Gonococcal isolates (n = 4336) were collected from men with urethritis at the Fulton County STD Clinic between 1988 and 2006. Antimicrobial susceptibility was performed by agar dilution. Increasing numbers of isolates from men who have sex with men and with fluoroquinolone resistance were noted. New antimicrobials effective against gonorrhea are urgently needed. C1 [Dionne-Odom, Jodie] Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Sect Infect Dis & Int Hlth, Lebanon, NH 03756 USA. [Tambe, Pradnya] Fulton Cty Dept Hlth & Wellness, STD Clin, Atlanta, GA USA. [Yee, Eileen; Weinstock, Hillard] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [del Rio, Carlos] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. RP Dionne-Odom, J (reprint author), Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Sect Infect Dis & Int Hlth, 1 Med Ctr Dr, Lebanon, NH 03756 USA. EM jodie.dionne-odom@hitchcock.org RI del Rio, Carlos/B-3763-2012 OI del Rio, Carlos/0000-0002-0153-3517 FU CDC [1H25PS001412]; NIH through the Emory Center for AIDS Research [P30 AI050409] FX Supported by the CDC through the Gonococcal Isolate Surveillance Project Contract (1H25PS001412) and by the NIH through the Emory Center for AIDS Research grant (P30 AI050409). NR 16 TC 3 Z9 3 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD AUG PY 2011 VL 38 IS 8 BP 780 EP 782 DI 10.1097/OLQ.0b013e318214e306 PG 3 WC Infectious Diseases SC Infectious Diseases GA 792PP UT WOS:000292759900017 PM 21844728 ER PT J AU Ghanem, KG Datta, SD Unger, ER Hagensee, M Shlay, JC Kerndt, P Hsu, K Koutsky, LA AF Ghanem, Khalil G. Datta, S. Deblina Unger, Elizabeth R. Hagensee, Michael Shlay, Judith C. Kerndt, Peter Hsu, Katherine Koutsky, Laura A. TI The association of current hormonal contraceptive use with type-specific HPV detection SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Article ID HUMAN-PAPILLOMAVIRUS INFECTION; CERVICAL-CANCER; ORAL-CONTRACEPTIVES; UNITED-STATES; PREVALENCE; WOMEN; RISK; FEMALES; COHORT AB Background Increased duration of hormonal contraceptive (HC) use may be positively associated with the risk of invasive cervical cancer. Methods This is a secondary analysis from the HPV Sentinel Surveillance Study. The authors examined the association between type-specific human papillomavirus (HPV) detection and current HC use among 7718 women attending 26 sexually transmitted disease, family planning and primary care clinics in the USA. Results There was an association between HC use and HPV-16 detection (adjusted prevalence rate ratio 1.34 (95% CI 1.05 to 1.71) for oral contraceptive users and 1.41 (1.01 to 2.04) for depot-medroxyprogesterone acetate users); there was no association between HC use and detection of other HPV types or any HPV overall. Conclusions Longitudinal studies are needed to better define this type-specific association and its clinical significance. C1 [Ghanem, Khalil G.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Datta, S. Deblina; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hagensee, Michael] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA. [Shlay, Judith C.] Denver Publ Hlth, Denver, CO USA. [Kerndt, Peter] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [Hsu, Katherine] Massachusetts Dept Publ Hlth, Boston, MA USA. [Koutsky, Laura A.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Ghanem, KG (reprint author), ID Div, 4940 Eastern Ave,B3N Suite 352, Baltimore, MD 21224 USA. EM kghanem@jhmi.edu OI Unger, Elizabeth/0000-0002-2925-5635 FU Centers for Disease Control and Prevention; National Institutes of Health [K23HD047395] FX All funding for the HPV Sentinel Surveillance Study was provided by the Centers for Disease Control and Prevention. Additional funding from the National Institutes of Health (K23HD047395) was provided to KGG. NR 15 TC 6 Z9 6 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD AUG PY 2011 VL 87 IS 5 BP 385 EP 388 DI 10.1136/sextrans-2011-050005 PG 4 WC Infectious Diseases SC Infectious Diseases GA 794AX UT WOS:000292867500010 PM 21772042 ER PT J AU Joseph, HA Marks, G Belcher, L Millett, GA Stueve, A Bingham, TA Lauby, J AF Joseph, Heather A. Marks, Gary Belcher, Lisa Millett, Gregorio A. Stueve, Ann Bingham, Trista A. Lauby, Jennifer TI Older partner selection, sexual risk behaviour and unrecognised HIV infection among black and Latino men who have sex with men SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Article ID UNPROTECTED ANAL INTERCOURSE; UNITED-STATES; BISEXUAL MEN; YOUNG MEN; SAN-FRANCISCO; PREVALENCE; SEROPREVALENCE; TRANSMISSION; DISPARITIES; GAY AB Objectives The authors examine whether young black and Latino men who have sex with men (MSM) who have older sex partners are more likely than those who do not have older sex partners to have unrecognised HIV infection. The authors examine whether the association stems from (1) increased sexual risk behaviour with male partners of any age, (2) heightened risk of being exposed to HIV infection by older partners or (3) a combination of these two factors. Methods The analytical sample consisted of 723 black and Latino MSM, aged 18-35 years, who were HIV negative or of unknown serostatus at study entry. Participants completed a self-administered questionnaire and were tested for HIV infection. Men who reported having a male sex partner who was at least 4 years older than themselves were compared with those who did not. Outcomes included unprotected receptive anal intercourse (URAI) with male partners of any age (past 3 months) and having unrecognised HIV infection. Results Men with older partners reported a higher prevalence of URAI (AOR=1.50, 95% CI 1.02 to 2.21). A second model found that men with older partners had increased odds of having unrecognised HIV infection (AOR=2.51, 95% CI 1.18 to 5.34) after controlling for the number of URAI partners of any age, which remained an independent predictor. Conclusions Young black and Latino MSM who had older male sex partners were at increased risk of having unrecognised HIV infection. This heightened risk was associated with sexual risk behaviour with partners of any age as well as possible increased exposure to HIV infection from older partners. C1 [Joseph, Heather A.; Marks, Gary; Belcher, Lisa; Millett, Gregorio A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Stueve, Ann] Educ Dev Ctr, New York, NY USA. Los Angeles Cty Dept Publ Hlth, HIV Epidemiol Program, Los Angeles, CA USA. [Lauby, Jennifer] Public Hlth Management Corp, Philadelphia, PA USA. RP Joseph, HA (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,MS E-37, Atlanta, GA 30333 USA. EM hjoseph1@cdc.gov FU US Centers for Disease Control and Prevention FX This study was funded through a cooperative agreement from the US Centers for Disease Control and Prevention. NR 25 TC 23 Z9 23 U1 0 U2 5 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 EI 1472-3263 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD AUG PY 2011 VL 87 IS 5 BP 442 EP 447 DI 10.1136/sextrans-2011-050010 PG 6 WC Infectious Diseases SC Infectious Diseases GA 794AX UT WOS:000292867500024 PM 21705378 ER PT J AU Grijalva, CG Zhu, YW Nuorti, JP Griffin, MR AF Grijalva, Carlos G. Zhu, Yuwei Nuorti, J. Pekka Griffin, Marie R. TI Emergence of parapneumonic empyema in the USA SO THORAX LA English DT Article ID PNEUMOCOCCAL CONJUGATE VACCINE; COMMUNITY-ACQUIRED PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE; PEDIATRIC EMPYEMA; PLEURAL INFECTION; THORACIC EMPYEMA; UNITED-STATES; CHILDREN; EPIDEMIOLOGY; DISEASE AB Background Although recent reports suggest that the incidence of parapneumonic empyema has increased in several regions of the USA, national trends in disease burden are unknown. National trends in the incidence of parapneumonic empyema hospitalisations and changes in empyema by associated pathogens were examined. Methods National hospitalisation data (1996-2008) were analysed and rates estimated using census estimates as denominators. Incidence rate ratios (IRR) compared 2008 with 1996 rates. Discharge diagnosis codes were used to characterise pathogens associated with empyema hospitalisations. Results Overall, national parapneumonic empyema-related hospitalisation rates increased from 3.04 per 100 000 in 1996 to 5.98 per 100 000 in 2008, a 2.0-fold increase (95% CI 1.8 to 2.1). The increases were observed among children (IRR 1.9 (95% CI 1.4 to 2.7)) and adults aged 18-39, 40-64 and >= 65 years (IRR 1.8 (95% CI 1.5 to 2.1), 2.0 (95% CI 1.6 to 3.1) and 1.7 (95% CI 1.5 to 2.0), respectively). Overall, pneumococcal empyema rates remained relatively stable in all age groups whereas streptococcal- (non-pneumococcal) and staphylococcal-related empyema rates increased 1.9-fold and 3.3-fold, respectively, with consistent increases across age groups. The overall in-hospital case fatality ratio for parapneumonic empyema-related hospitalisations was 8.0% (95% CI 6.4% to 9.5%) in 1996 and 7.2% (95% CI 6.3% to 8.1%) in 2008 (p = 0.395). Of the empyemas where study pathogens were listed (37.6%), staphylococcal-related empyema had the largest absolute increases across age groups and was associated with longer hospital stay and higher in-hospital mortality than other empyemas. Conclusions Although parapneumonic empyema-related hospitalisations remained relatively rare, they increased substantially during the study period. A number of pathogens, especially staphylococcus, contributed to this increase. C1 [Grijalva, Carlos G.; Griffin, Marie R.] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA. [Zhu, Yuwei] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA. [Nuorti, J. Pekka] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Griffin, Marie R.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA. RP Grijalva, CG (reprint author), Vanderbilt Univ, Sch Med, Dept Prevent Med, 1500 21st Ave Suite 2600, Nashville, TN 37232 USA. EM carlos.grijalva@vanderbilt.edu FU Centers for Disease Control and Prevention through the Association for Prevention Teaching and Research [TS-1454]; CDC [K01 CI000163]; Wyeth (now Pfizer); Med Immune FX This study was funded by the Centers for Disease Control and Prevention through a Cooperative Agreement with the Association for Prevention Teaching and Research (TS-1454). CGG is supported by a CDC career development award (K01 CI000163).; CGG received lecture fees from Wyeth (now Pfizer) and has been a consultant for GlaxoSmithKline. MRG received grant support from Med Immune. CGG and MRG received research support for an investigator-originated project from Wyeth (now Pfizer). NR 35 TC 61 Z9 61 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0040-6376 J9 THORAX JI Thorax PD AUG PY 2011 VL 66 IS 8 BP 663 EP 668 DI 10.1136/thx.2010.156406 PG 6 WC Respiratory System SC Respiratory System GA 794QQ UT WOS:000292916400007 PM 21617169 ER PT J AU Islam, S Bhuiyan, MAA Bern, C AF Islam, Shamim Bhuiyan, M. Ashraful Alam Bern, Caryn TI Images in Clinical Tropical Medicine Post-Kala-Azar Dermal Leishmaniasis in Mymensingh, Bangladesh SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Editorial Material C1 [Bern, Caryn] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30341 USA. [Islam, Shamim] Childrens Hosp & Res Ctr Oakland, Oakland, CA USA. [Bhuiyan, M. Ashraful Alam] ICDDR B, Dhaka, Bangladesh. RP Bern, C (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, MS F-22,4770 Buford Highway NE, Atlanta, GA 30341 USA. EM sizuba@yahoo.com; aabhuiyan@icddrb.org; cxb9@cdc.gov NR 2 TC 1 Z9 1 U1 2 U2 4 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD AUG PY 2011 VL 85 IS 2 BP 193 EP 194 DI 10.4269/ajtmh.2011.11-0128 PG 2 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 803WN UT WOS:000293613000001 PM 21813832 ER PT J AU Monroe, SS AF Monroe, Stephan S. TI Control and Prevention of Viral Gastroenteritis SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material ID NOROVIRUS C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Monroe, SS (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A30, Atlanta, GA 30333 USA. EM smonroe@cdc.gov OI Monroe, Stephan/0000-0002-5424-716X NR 15 TC 9 Z9 9 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD AUG PY 2011 VL 17 IS 8 BP 1347 EP 1348 DI 10.3201/eid1708.110824 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 804TF UT WOS:000293676200001 PM 21801608 ER PT J AU Date, AA Miller, B AF Date, Anand A. Miller, Bess TI Antiretroviral Therapy and Tuberculosis: What's the Connection and What's the Way Forward? SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Editorial Material ID HIV-INFECTED PATIENTS; ISONIAZID PREVENTIVE THERAPY; SOUTH-AFRICA; POSITIVE PATIENTS; HAART INITIATION; RISK; COHORT; COUNTRIES; IMPACT; TERM C1 [Date, Anand A.; Miller, Bess] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA 30333 USA. RP Miller, B (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, 1600 Clifton Rd,NE,Mailstop E-04, Atlanta, GA 30333 USA. EM bim1@cdc.gov NR 35 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD AUG 1 PY 2011 VL 57 IS 4 BP 255 EP 257 DI 10.1097/QAI.0b013e31822204fa PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 782TD UT WOS:000292033500005 PM 21602692 ER PT J AU Romitti, P Puzhankara, S Zamba, G Nabukera, S James, K Andrews, J Fox, D Cunniff, C Ciafaloni, E Druschel, C Mathews, K Matthews, D Miller, L Pandya, S Au, S Scollon, S Adams, M Street, N AF Romitti, P. Puzhankara, S. Zamba, G. Nabukera, S. James, K. Andrews, J. Fox, D. Cunniff, C. Ciafaloni, E. Druschel, C. Mathews, K. Matthews, D. Miller, L. Pandya, S. Au, S. Scollon, S. Adams, M. Street, N. CA Muscular Dystrophy Surveillance Tr TI POPULATION-BASED PREVALENCE OF DUCHENNE/BECKER MUSCULAR DYSTROPHY (DBMD) IN THE USA SO JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH LA English DT Meeting Abstract C1 [Romitti, P.; Puzhankara, S.; Zamba, G.; Nabukera, S.; Mathews, K.] Univ Iowa, Iowa City, IA USA. [Fox, D.; Druschel, C.] New York State Dept Hlth, Troy, NY USA. [Andrews, J.; Cunniff, C.] Univ Arizona, Tucson, AZ USA. [Ciafaloni, E.; Pandya, S.] Univ Rochester, Rochester, NY USA. [James, K.; Matthews, D.] Univ Colorado, Denver, CO 80202 USA. [Miller, L.] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Au, S.; Scollon, S.] Hawaii Dept Hlth, Honolulu, HI USA. [Adams, M.; Street, N.; Muscular Dystrophy Surveillance Tr] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0143-005X J9 J EPIDEMIOL COMMUN H JI J. Epidemiol. Community Health PD AUG PY 2011 VL 65 SU 1 BP A293 EP A294 DI 10.1136/jech.2011.142976j.93 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 807MG UT WOS:000293901801357 ER PT J AU Szklo, A Almeida, L Sampaio, M Malta, D Mirza, S Caixeta, R Figueiredo, V Szklo, M AF Szklo, A. Almeida, L. Sampaio, M. Malta, D. Mirza, S. Caixeta, R. Figueiredo, V. Szklo, M. TI A SNAPSHOT OF THE STRIKING DECREASE IN CIGARETTE SMOKING PREVALENCE IN BRAZIL BETWEEN 1989 AND 2008 SO JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH LA English DT Meeting Abstract C1 [Szklo, A.; Almeida, L.; Sampaio, M.; Szklo, M.] Brazilian Natl Canc Inst, Rio De Janeiro, Brazil. [Caixeta, R.] Hlth Surveillance Agcy, Brasilia, DF, Brazil. [Malta, D.] Ctr Dis Control, Atlanta, GA 30333 USA. [Mirza, S.] Panamer Hlth Org, Washington, DC USA. Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil. RI Malta, Deborah/H-7880-2012 OI Malta, Deborah/0000-0002-8214-5734 NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0143-005X J9 J EPIDEMIOL COMMUN H JI J. Epidemiol. Community Health PD AUG PY 2011 VL 65 SU 1 BP A164 EP A164 DI 10.1136/jech.2011.142976f.42 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 807MG UT WOS:000293901800488 ER PT J AU Lin, JW Lee, JK Wu, CK Caffrey, JL Chang, MH Hwang, JJ Dowling, N Lin, YS AF Lin, Jou-Wei Lee, Jen-Kuang Wu, Cho-Kai Caffrey, James L. Chang, Man-Huei Hwang, Juey-Jen Dowling, Nicole Lin, Yu-Sheng TI Metabolic Syndrome, Testosterone, and Cardiovascular Mortality in Men SO JOURNAL OF SEXUAL MEDICINE LA English DT Article DE Testosterone Deficiency and Cardiovascular Mortality; Metabolic Cardiovascular Syndrome; Mortality; Nutrition Surveys ID HORMONE-BINDING GLOBULIN; CORONARY-HEART-DISEASE; LOW SERUM TESTOSTERONE; MIDDLE-AGED MEN; NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; INSULIN-RESISTANCE; DEFICIENCY SYNDROME; ANDROGEN LEVELS; RISK-FACTORS AB Introduction. Interactions among testosterone, metabolic syndrome (MetS), and mortality risk in men remain to be elucidated. Aim. To examine relationships among testosterone, MetS, and cardiovascular mortality risk in U. S. men, middle-aged and older. Methods. The analysis included the men aged 40 years and above in Phase 1 (1988-1991) of the Third National Health and Nutrition Examination Survey (NHANES III). Serum testosterone and sex hormone binding globulin were measured, and free testosterone and bioavailable testosterone were calculated. MetS was determined according to the Adult Treatment Panel III (ATP-III) criteria. Main Outcome Measures. Cardiovascular and other causes of mortality were obtained from the NHANES III-linked follow-up file through December 31, 2006. Multivariate Cox regression models were applied to assess associations of interest. Results. Of 596 men included in the analysis, 187 men were found to have MetS. During a median follow-up of 15.6 years, 97 men died of cardiovascular causes (cardiovascular mortality rate: 9.84 and 5.77 per 1,000 person-years for those with and without MetS, respectively). Higher calculated bioavailable testosterone (CBT) was associated with a lower odds of MetS (odds ratio: 0.80 for each ng/mL, 95% confidence interval [CI]: 0.76-0.84, P < 0.001) and lower risk of cardiovascular mortality (hazard ratios [HRs]: 0.72 for each log ng/mL, 95% CI: 0.54-0.96, P = 0.03) in subjects with MetS. The influence of CBT was not observed in those without MetS (HR: 0.84 for each log ng/mL, 95% CI: 0.68-1.04, P = 0.10). Conclusions. The combination of lower bioavailable testosterone and ATP-III-defined MetS is associated with an increased cardiovascular mortality in the men aged 40 years and above. Lin J-W, Lee J-K, Wu C-K, Caffrey JL, Chang MH, Hwang J-J, Dowling N, and Lin Y-S. Metabolic syndrome, testosterone, and cardiovascular mortality in men. J Sex Med 2011;8:2350-2360. C1 [Lin, Yu-Sheng] Univ N Texas, Hlth Sci Ctr, Dept Environm & Occupat Hlth, Ft Worth, TX 76107 USA. [Lin, Jou-Wei; Wu, Cho-Kai] Natl Taiwan Univ Hosp, Yun Lin Branch, Ctr Cardiovasc, Dou Liou, Taiwan. [Lin, Jou-Wei; Wu, Cho-Kai] Natl Taiwan Univ Hosp, Yun Lin Branch, Hlth Management Ctr, Dou Liou, Taiwan. [Lin, Jou-Wei; Lee, Jen-Kuang; Wu, Cho-Kai; Hwang, Juey-Jen] Natl Taiwan Univ, Coll Med & Hosp, Dept Med, Taipei 10764, Taiwan. [Lee, Jen-Kuang] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan. [Lee, Jen-Kuang] Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, Taipei 10764, Taiwan. [Caffrey, James L.] Univ N Texas, Hlth Sci Ctr, Dept Integrat Physiol, Ft Worth, TX 76107 USA. [Caffrey, James L.] Univ N Texas, Hlth Sci Ctr, Cardiovasc Res Inst, Ft Worth, TX 76107 USA. [Chang, Man-Huei; Dowling, Nicole] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. RP Lin, YS (reprint author), Univ N Texas, Hlth Sci Ctr, Dept Environm & Occupat Hlth, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA. EM Yu-Sheng.Lin@unthsc.edu OI WU, CHO-KAI/0000-0002-3867-150X; Juey-Jen, HWANG/0000-0001-6437-0455 FU University of North Texas Health Science Center at Fort Worth [G62024]; National Taiwan University Hospital Yun-Lin Branch [97.S005, 98.X002] FX This work was in part supported by the G62024 Interdisciplinary Research Grant from the University of North Texas Health Science Center at Fort Worth and by the grants from the National Taiwan University Hospital Yun-Lin Branch (97.S005 and 98.X002). We appreciate the statistical assistance of Dr. Gordon G. Brown from RTI International. None of the authors have potential conflicts of interest to disclose. The corresponding author has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 51 TC 15 Z9 15 U1 3 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-6095 J9 J SEX MED JI J. Sex. Med. PD AUG PY 2011 VL 8 IS 8 BP 2350 EP 2360 DI 10.1111/j.1743-6109.2011.02343.x PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 798EN UT WOS:000293185500026 PM 21676188 ER PT J AU Collier, MG Taylor, MM Winscott, MM Mickey, T England, B AF Collier, Melissa G. Taylor, Melanie M. Winscott, Michelle M. Mickey, Tom England, Bob TI Assessing compliance with a county board order for third trimester syphilis screening in Maricopa County, Arizona SO SEXUAL & REPRODUCTIVE HEALTHCARE LA English DT Article DE Syphilis; Congenital; Third trimester screening; STD prevention ID WOMEN AB Objectives: Due to high rates of congenital syphilis, a Maricopa County board order was issued in 2003 to increase prenatal syphilis screening. The provisions of this order included prenatal syphilis screening during the first prenatal visit, to be repeated during the third trimester, and again at delivery. The purpose of the study was to evaluate syphilis screening practices and barriers to screening among obstetric providers. Methods: Maricopa County medical providers who delivered at least 21 infants (97.2% of all deliveries) in 2008 according to live birth records were surveyed by telephone. Results: A total of 146 surveys were completed representing 76% (319/421) of the delivering providers and 83% of delivered infants for 2008. All of the represented prenatal care providers reported testing their patients for syphilis at the first trimester, and 284(89%) reported screening again during the third trimester. Conclusions: All of the surveyed providers reported screening at least once for syphilis during pregnancy and most reported re-screening during the third trimester as recommended by the Maricopa County board order. Similar public health screening guidance should be considered in areas where congenital syphilis rates are high and/or where syphilis is prevalent among women of childbearing age. A local health order of this type is a simple intervention that can provide practice guidance on emerging health issues. (C) 2011 Elsevier B.V. All rights reserved. C1 [Collier, Melissa G.] Univ Illinois, Coll Med, Peoria, IL 61656 USA. [Taylor, Melanie M.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA. [Taylor, Melanie M.; Winscott, Michelle M.] Arizona Dept Hlth Serv, Sexually Transmitted Dis Program, Phoenix, AZ 85007 USA. [Taylor, Melanie M.; Mickey, Tom; England, Bob] Maricopa Cty Dept Publ Hlth, STD Program, Phoenix, AZ USA. RP Collier, MG (reprint author), Indiana State Dept Hlth, 2N Meridian ST, Indianapolis, IN 46202 USA. EM mcollier@isdh.in.gov NR 11 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1877-5756 J9 SEX REPROD HEALTHC JI Sex. Reprod. Healthc. PD AUG PY 2011 VL 2 IS 3 BP 125 EP 128 DI 10.1016/j.srhc.2011.05.002 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 053OH UT WOS:000312281800006 PM 21742292 ER PT J AU Miller, KS Lasswell, SM Vandenhoudt, H AF Miller, Kim S. Lasswell, Sarah M. Vandenhoudt, Hilde TI Parent-child communication for youth HIV prevention in Kenya: Letter to the Editor in response to "Voices unheard: Youth and sexuality in the wake of HIV prevention in Kenya" SO SEXUAL & REPRODUCTIVE HEALTHCARE LA English DT Letter ID RURAL WESTERN KENYA; FAMILIES MATTER; INTERVENTION C1 [Miller, Kim S.; Lasswell, Sarah M.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. [Vandenhoudt, Hilde] Inst Trop Med, B-2000 Antwerp, Belgium. RP Miller, KS (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. EM kmiller@cdc.gov; slasswell@cdc.gov; hvandenhoubt@itg.be NR 2 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1877-5756 J9 SEX REPROD HEALTHC JI Sex. Reprod. Healthc. PD AUG PY 2011 VL 2 IS 3 BP 135 EP 135 DI 10.1016/j.srhc.2011.04.001 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 053OH UT WOS:000312281800008 PM 21742294 ER PT J AU Handel, S Klingler, EJ Washburn, K Blank, S Schillinger, JA AF Handel, Shoshanna Klingler, Ellen J. Washburn, Kate Blank, Susan Schillinger, Julia A. TI Population-Based Surveillance for Neonatal Herpes in New York City, April 2006-September 2010 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SIMPLEX-VIRUS-INFECTIONS; GENITAL HERPES; UNITED-STATES; ACYCLOVIR PROPHYLAXIS; CESAREAN DELIVERY; LATE PREGNANCY; SEROPREVALENCE; TRANSMISSION; MANAGEMENT; DISEASE AB Background: Population-based data for neonatal herpes simplex virus (HSV) infection are needed to describe disease burden and to develop and evaluate prevention strategies. Methods: From April 2006 to September 2010, routine population-based surveillance was conducted using mandated provider and laboratory reports of neonatal HSV diagnoses and test results for New York City resident infants aged <= 60 days. Case investigations, including provider interviews and review of infant and maternal medical charts and vital records, were performed. Hospital discharge data were analyzed and compared with surveillance data findings. Results: Between April 2006 and September 2010, New York City neonatal HSV surveillance detected 76 cases, for an average incidence of 13.3/100,000 (1/7519) live births. Median annual incidence of neonatal HSV estimated from administrative data for 1997 to 2008 was 11.8/100,000. Among surveillance cases, 90.8% (69/76) were laboratory confirmed. Among these, 40.6% (28/69) were HSV-1; 39.1% (27/69) were HSV-2; and 20.3% (14/69) were untyped. The overall case-fatality rate was 17.1% (13/76). Five cases were detected among infants aged > 42 days. In all, 80% (20/25) of the case-infants delivered by cesarean section were known to have obstetric interventions that could have increased risk of neonatal HSV transmission to the infant before delivery. Over half (68%, or 52/76) of all cases lacked timely or ideal diagnostics or treatment. Conclusions: Administrative data may be an adequate and relatively inexpensive source for assessing neonatal HSV burden, although they lack the detail and timeliness of surveillance. Prevention strategies should address HSV-1. Incubation periods might be longer than expected for neonatal HSV. Cesarean delivery might not be protective if preceded by invasive procedures. Provider education is needed to raise awareness of neonatal HSV and to assure appropriate testing and treatment. C1 [Handel, Shoshanna] Bur STD Control, New York City Dept Hlth & Mental Hyg, BMIRH, New York, NY USA. [Handel, Shoshanna] Ctr Dis Control & Prevent, Publ Hlth Prevent Serv, Off Workforce & Career Dev, CDC, Atlanta, GA USA. [Blank, Susan; Schillinger, Julia A.] CDC, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Handel, S (reprint author), Bur STD Control, New York City Dept Hlth & Mental Hyg, BMIRH, New York, NY USA. EM shandel@health.nyc.gov NR 32 TC 13 Z9 13 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD AUG PY 2011 VL 38 IS 8 BP 705 EP 711 DI 10.1097/OLQ.0b013e31821b178f PG 7 WC Infectious Diseases SC Infectious Diseases GA 792PP UT WOS:000292759900005 PM 21844721 ER PT J AU Dee, DL Bensyl, DM Gindler, J Truman, BI Allen, BG D'Mello, T Perez, A Kamimoto, L Biggerstaff, M Blanton, L Fowlkes, A Glover, MJ Swerdlow, DL Finelli, L AF Dee, Deborah L. Bensyl, Diana M. Gindler, Jacqueline Truman, Benedict I. Allen, Barbara G. D'Mello, Tiffany Perez, Alejandro Kamimoto, Laurie Biggerstaff, Matthew Blanton, Lenee Fowlkes, Ashley Glover, Maleeka J. Swerdlow, David L. Finelli, Lyn TI Racial and Ethnic Disparities in Hospitalizations and Deaths Associated with 2009 Pandemic Influenza A (H1N1) Virus Infections in the United States SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE H1N1 Virus; Health Status Disparities; Health Care Disparities; Behavioral Risk Factor Surveillance System; Influenza ID CONJUGATE PNEUMOCOCCAL VACCINES; VACCINATION; CHILDREN; MORTALITY; SURVEILLANCE; MONOVALENT; PNEUMONIA; SYMPTOMS; DISEASE; ILLNESS AB PURPOSE: Concerns have been raised regarding possible racial-ethnic disparities in 2009 pandemic influenza A (H1N1) (pH1N1) illness severity and health consequences for U.S. minority populations. METHODS: Using data from the Centers for Disease Control and Prevention's Behavioral Risk Factor Surveillance System, Emerging Infections Program Influenza-Associated Hospitalization Surveillance, and Influenza-Associated Pediatric Mortality Surveillance, we calculated race-ethnicity-specific, age-adjusted rates of self-reported influenza-like illness (ILI) and pH1N1-associated hospitalizations. We used chi(2) tests to evaluate racial-ethnic disparities in ILI-associated health care-seeking behavior and pH1N1 hospitalization. To evaluate pediatric deaths, we compared racial-ethnic proportions of deaths against U.S. population distributions. RESULTS: Prevalence of self-reported ILI was lower among Hispanics (6.5%), higher among American Indians/Alaska Natives (16.2%), and similar among non-Hispanic blacks (7.7%) compared with non-Hispanic whites (8.5%). No racial-ethnic differences were identified in ILI-associated health care-seeking behavior. Age-adjusted pH1N1-associated Emerging Infections Program hospitalization rates were higher among all minority populations (range: 8.1-10.9/100,000 population) compared with non-Hispanic whites (3.0/100,000). The proportion of pH1N1-associated pediatric deaths was higher than expected among Hispanics (31%) and lower than expected among non-Hispanic whites (45%) given the proportions of the U.S. population they comprise (22% and 58%, respectively). CONCLUSIONS: Racial-ethnic disparities in pH1N1-associated hospitalizations and pediatric deaths were identified. Vaccination remains the primary intervention for preventing influenza. Ann Epidemiol 2011;21:623-630. Published by Elsevier Inc. C1 [Dee, Deborah L.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Bensyl, Diana M.] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA 30341 USA. [Gindler, Jacqueline] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA 30341 USA. [Truman, Benedict I.] Ctr Dis Control & Prevent, Off Minor Hlth & Hlth Dispar, Off Director, Atlanta, GA 30341 USA. [Allen, Barbara G.] Ctr Dis Control & Prevent, Div Global AIDS, Atlanta, GA 30341 USA. [D'Mello, Tiffany; Perez, Alejandro; Kamimoto, Laurie; Biggerstaff, Matthew; Blanton, Lenee; Fowlkes, Ashley; Swerdlow, David L.; Finelli, Lyn] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30341 USA. [Glover, Maleeka J.] Ctr Dis Control & Prevent, Off Crit Informat Integrat & Exchange, Atlanta, GA 30341 USA. RP Dee, DL (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Hwy NE,MS K-22, Atlanta, GA 30341 USA. EM ddee@cdc.gov NR 39 TC 26 Z9 26 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD AUG PY 2011 VL 21 IS 8 BP 623 EP 630 DI 10.1016/j.annepidem.2011.03.002 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 793GQ UT WOS:000292808800009 PM 21737049 ER PT J AU Lockhart, SR Zimbeck, AJ Baddley, JW Marr, KA Andes, DR Walsh, TJ Kauffman, CA Kontoyiannis, DP Ito, JI Pappas, PG Chiller, T AF Lockhart, Shawn R. Zimbeck, Alicia J. Baddley, John W. Marr, Kieren A. Andes, David R. Walsh, Thomas J. Kauffman, Carol A. Kontoyiannis, Dimitrios P. Ito, James I. Pappas, Peter G. Chiller, Tom TI In Vitro Echinocandin Susceptibility of Aspergillus Isolates from Patients Enrolled in the Transplant-Associated Infection Surveillance Network SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID INVASIVE FUNGAL-INFECTIONS; ANTIFUNGAL AGENTS; RECIPIENTS; ANIDULAFUNGIN; CASPOFUNGIN; TRANSNET AB We determined the echinocandin minimum effective concentration (MEC) values for caspofungin, micafungin, and anidulafungin against 288 Aspergillus isolates prospectively collected from transplant patients with proven or probable invasive aspergillosis between 2001 and 2006 as part of the Transplant-Associated Infection Surveillance Network (TRANSNET). We demonstrated that the vast majority of Aspergillus isolates had MEC values at or below the epidemiological cutoff values for caspofungin, micafungin, and anidulafungin, including those from patients who had received caspofungin. C1 [Lockhart, Shawn R.; Zimbeck, Alicia J.; Chiller, Tom] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA. [Baddley, John W.] Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Baddley, John W.] Birmingham Vet Affairs Med Ctr, Dept Med, Infect Dis Sect, Birmingham, AL USA. [Marr, Kieren A.] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA. [Andes, David R.] Univ Wisconsin, Dept Med, Div Infect Dis, Madison, WI USA. [Walsh, Thomas J.] Cornell Univ, Weill Cornell Med Coll, New York, NY 10021 USA. [Walsh, Thomas J.] New York Presbyterian Hosp, New York, NY USA. [Walsh, Thomas J.] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA. [Kauffman, Carol A.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. [Kauffman, Carol A.] Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Dept Med, Houston, TX 77030 USA. [Ito, James I.] City Hope Natl Med Ctr, Dept Med, Div Infect Dis, Duarte, CA 91010 USA. [Pappas, Peter G.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. RP Lockhart, SR (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, 1600 Clifton Rd,Mailstop G-11, Atlanta, GA 30333 USA. EM gyi2@cdc.gov FU Association of Public Health Laboratories (APHL); Astellas; Pfizer; Merck; Schering-Plough; Enzon FX A.J.Z. was supported by the Association of Public Health Laboratories (APHL). TRANSNET was sponsored by Astellas, Pfizer, Merck, and Schering-Plough. This work was funded by a grant from Merck. Potential conflicts of interest are as follows: P.G.P. receives research support and is an ad hoc advisor for Merck, Pfizer, and Astellas; J.W.B. received research grants from Merck, Astellas, and Pfizer and is a consultant/advisor for Merck and Pfizer; J.I.I. received honoraria for speakers' activities from Astellas, Cubist, Merck, and Pfizer and is a consultant for Sigma Tau; D.R.A. has received grants from and is a consultant for Merck, Astellas, and Pfizer; C.A.K. receives research support from Merck and chairs a data adjudication committee for Pfizer; K.A.M. received research grants from Merck, Astellas, and Pfizer and is on the advisory board or is consulting for Astellas, Basilea, Merck, and Pfizer; D.P.K. received research support and honoraria from Schering-Plough, Pfizer, Astellas, Enzon, and Merck; T.J.W. is in consultation with iCo, Vestagen, Trius, and Sigma Tau. All other authors have no potential conflicts. NR 17 TC 13 Z9 13 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD AUG PY 2011 VL 55 IS 8 BP 3944 EP 3946 DI 10.1128/AAC.00428-11 PG 3 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 792HV UT WOS:000292733800040 PM 21670187 ER PT J AU Polson, KA Rawlins, SC Brogdon, WG Chadee, DD AF Polson, K. A. Rawlins, S. C. Brogdon, W. G. Chadee, D. D. TI Characterisation of DDT and Pyrethroid Resistance in Trinidad and Tobago populations of Aedes aegypti SO BULLETIN OF ENTOMOLOGICAL RESEARCH LA English DT Article DE Aedes aegypti; insecticide resistance; DDT; pyrethroids; Trinidad; Tobago ID MOSQUITO PROTEIN MICROASSAY; INSECTICIDE RESISTANCE; ANOPHELES-GAMBIAE; ELEVATED OXIDASE; MECHANISMS; CULICIDAE; DIPTERA AB Insecticide resistance is an important factor in the effectiveness of Aedes aegypti control and the related spread of dengue. The objectives of this study were to investigate the status of the organochlorine dichlorodiphenyltrichloroethane (DDT) and pyrethroid (permethrin and deltamethrin) resistance in Trinidad and Tobago populations of Ae. aegypti and the underlying biochemical mechanisms. Nine populations of Ae. aegypti larvae from Trinidad and Tobago were assayed to DDT and PYs using the Centers for Disease Control and Prevention (CDC) time-mortality-based bioassay method. A diagnostic dosage (DD) was established for each insecticide using the CAREC reference susceptible Ae. aegypti strain and a resistance threshold (RT), time in which 98-100% mortality was observed in the CAREC strain, was calculated for each insecticide. Mosquitoes which survived the DD and RT were considered as resistant, and the resistance status of each population was categorised based on the WHO criteria with mortality <80% indicative of resistance. Biochemical assays were conducted to determine the activities of alpha and beta esterases, mixed function oxidases (MFO) and glutathione-S-transferases (GST) enzymes which are involved in resistance of mosquitoes to DDT and PYs. Enzymatic activity levels in each population were compared with those obtained for the CAREC susceptible strain, and significant differences were determined by Kruskal-Wallis and Tukey's non-parametric tests (P < 0.05). The established DDs were 0.01mgl(-1), 0.2mgl(-1) and 1.0mgl(-1) for deltamethrin, permethrin and DDT, respectively; and the RTs for deltamethrin, permethrin and DDT were 30, 75 and 120 min, respectively. All Ae. aegypti populations were resistant to DDT (<80% mortality); two strains were incipiently resistant to deltamethrin and three to permethrin (80-98% mortality). Biochemical assays revealed elevated levels of alpha-esterase and MFO enzymes in all Ae. aegypti populations. All, except three populations, showed increased levels of beta-esterases; and all populations, except Curepe, demonstrated elevated GST levels. Metabolic detoxification of enzymes is correlated with the manifestation of DDT and PY resistance in Trinidad and Tobago populations of Ae. aegypti. The presence of this resistance also suggests that knock down (kdr)-type resistance may be involved, hence the need for further investigations. This information can contribute to the development of an insecticide resistance surveillance programme and improvement of resistance management strategies aimed at combatting the spread of dengue in Trinidad and Tobago. C1 [Polson, K. A.; Chadee, D. D.] Univ W Indies, St Augustine, Trinid & Tobago. [Rawlins, S. C.] Caribbean Epidemiol Ctr CAREC, Port Of Spain, Trinid & Tobago. [Brogdon, W. G.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Chadee, DD (reprint author), Univ W Indies, St Augustine, Trinid & Tobago. EM chadee@tstt.net.tt NR 30 TC 7 Z9 7 U1 0 U2 14 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 0007-4853 J9 B ENTOMOL RES JI Bull. Entomol. Res. PD AUG PY 2011 VL 101 IS 4 BP 435 EP 441 DI 10.1017/S0007485310000702 PG 7 WC Entomology SC Entomology GA 790TR UT WOS:000292612600008 PM 21272394 ER PT J AU DeStefano, F Haber, M Currivan, D Farris, T Burrus, B Stone-Wiggins, B McCalla, A Guled, H Shih, H Edelson, P Wetterhall, S AF DeStefano, F. Haber, M. Currivan, D. Farris, T. Burrus, B. Stone-Wiggins, B. McCalla, A. Guled, H. Shih, H. Edelson, P. Wetterhall, S. TI Factors associated with social contacts in four communities during the 2007-2008 influenza season SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Infectious disease control; influenza; mathematical modelling; transmission; prevention ID 8 EUROPEAN COUNTRIES; PANDEMIC INFLUENZA; SCHOOL CLOSURE; TRANSMISSION; SPREAD; INFECTIONS; INTERVENTIONS; PATTERNS; CHILDREN; IMPACT AB Mathematical models of influenza pandemics are sensitive to changes in contact rates between individuals. We conducted population-based telephone surveys in four North Carolina counties to determine the number of social interactions between individuals during the 2007-2008 influenza season. Influenza activity was monitored through sentinel medical practices. Among 3845 adults, the number of social contacts varied with age, was lower on weekends than on weekdays, and further decreased during school holiday periods. Adults with influenza-like illnesses had fewer social contacts. Adults' contacts in the community setting increased during periods of peak influenza activity. Among 290 children, potential contacts (i.e. other people in the same location) were lowest among preschool-age children and decreased on weekends and during school holidays. In adjusted analyses, children's potential social contacts did not change during periods of peak influenza activity. These results should be useful for modelling influenza epidemics and pandemics and in planning mitigation and response strategies. C1 [DeStefano, F.; Edelson, P.] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA 30333 USA. [DeStefano, F.; Guled, H.; Wetterhall, S.] RTI Int, Atlanta, GA USA. [Haber, M.; Shih, H.] Emory Univ, Atlanta, GA 30322 USA. [Currivan, D.; Farris, T.; Burrus, B.; Stone-Wiggins, B.; McCalla, A.] RTI Int, Res Triangle Pk, NC USA. RP DeStefano, F (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, MS D-26, Atlanta, GA 30333 USA. EM fdestefano@cdc.gov FU Centers for Disease Control and Prevention FX We gratefully acknowledge the contributions of Jeffrey Engel for support in implementing the survey in North Carolina and Rodney Baxter for technical support with data analysis. Financial support for the study was provided by a cooperative agreement from the Centers for Disease Control and Prevention. NR 19 TC 12 Z9 12 U1 1 U2 5 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD AUG PY 2011 VL 139 IS 8 BP 1181 EP 1190 DI 10.1017/S095026881000230X PG 10 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 790TS UT WOS:000292612700007 PM 20943002 ER PT J AU Ran, L Wu, SY Gao, YJ Zhang, X Feng, ZJ Wang, ZJ Kan, BA Klena, JD Wong, DMALF Angulo, FJ Varma, JK AF Ran, Lu Wu, Shuyu Gao, Yongjun Zhang, Xin Feng, Zijian Wang, Zijun Kan, Biao Klena, John D. Wong, Danilo M. A. Lo Fo Angulo, Frederick J. Varma, Jay K. TI Laboratory-Based Surveillance of Nontyphoidal Salmonella Infections in China SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID ENTERICA SEROTYPE TYPHIMURIUM; ANTIMICROBIAL RESISTANCE; UNITED-STATES; BURDEN; HUMANS; GASTROENTERITIS; CIPROFLOXACIN; ILLNESS; SUSCEPTIBILITY; EPIDEMIOLOGY AB Foodborne infections are an important public health problem in China. In 2008, we conducted surveillance for laboratory-confirmed nontyphoidal Salmonella to monitor trends for this infection in China and to build capacity for rapid detection and response to foodborne outbreaks. Salmonella isolates from patients with diarrhea were sent from hospitals to local public health laboratories for confirmation, serotyping, and antimicrobial susceptibility testing. A total of 126 hospitals in 44 cities and counties from 8 provinces provided isolates and epidemiologic data for analysis. Of 23,140 stool specimens submitted to clinical laboratories, 662 (3%) grew Salmonella enterica. Salmonella were most commonly detected between April and October. The median age of infected patients was 27 years; 34% of infections occurred in patients < 5 years old. Of the 662 isolates, we found 73 serotypes, of which serotype Enteritidis (31%) and serotype Typhimurium (26%) were the most common. The prevalence of resistance was high for clinically important antimicrobial agents, including ampicillin (41%) and ciprofloxacin (6%). More than 60% of isolates, including 35% of all Typhimurium, were resistant to three or more antimicrobial agents. In this first multiprovince surveillance report of laboratory-confirmed Salmonella infections in China, we found that Enteritidis and Typhimurium are the most common serotypes and that efforts to reduce antimicrobial resistance among Salmonella in China are needed. Although no outbreaks were detected using this system, efforts to improve this system's capacity to do so are underway. C1 [Ran, Lu; Gao, Yongjun; Zhang, Xin; Feng, Zijian; Wang, Zijun; Kan, Biao] Chinese Ctr Dis Control & Prevent, Beijing 102206, Peoples R China. [Wu, Shuyu; Klena, John D.; Varma, Jay K.] US Ctr Dis Control & Prevent, China Off, Beijing, Peoples R China. [Wong, Danilo M. A. Lo Fo] WHO, CH-1211 Geneva, Switzerland. [Angulo, Frederick J.] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Feng, ZJ (reprint author), Chinese Ctr Dis Control & Prevent, 155 Changbai Rd, Beijing 102206, Peoples R China. EM fengzj@chinacdc.cn FU WHO Global Foodborne Infections Network (GFN); U.S. CDC [5U2GGH000018-02] FX This study was supported by WHO Global Foodborne Infections Network (GFN) and the China-U.S. Collaborative Program on Emerging and Re-Emerging Infectious Diseases, U.S. CDC (5U2GGH000018-02). We are grateful for the participation and excellent work of local CDCs and sentinel hospitals in Beijing, Chongqing, Fujian, Guangdong, Guangxi, Henan, Shanghai, and Sichuan. In addition, we thank the technical experts from WHO GFN, including Jaap Wagenaar (Utrecht University, The Netherlands), Rene Hendriksen (National Food Institute, Denmark), Shaohua Zhao (Food and Drug Administration, USA), Lai-king Ng (Public Health Agency of Canada, Canada), and Matthew Mikoleit and Xin Liu (CDC, USA). NR 47 TC 32 Z9 36 U1 2 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD AUG PY 2011 VL 8 IS 8 BP 921 EP 927 DI 10.1089/fpd.2010.0827 PG 7 WC Food Science & Technology SC Food Science & Technology GA 794AZ UT WOS:000292867700010 PM 21492026 ER PT J AU Li, CY Dick, AW Fiscella, K Conwell, Y Friedman, B AF Li, Chunyu Dick, Andrew W. Fiscella, Kevin Conwell, Yeates Friedman, Bruce TI Effect of Usual Source of Care on Depression among Medicare Beneficiaries: An Application of a Simultaneous-Equations Model SO HEALTH SERVICES RESEARCH LA English DT Article DE Access to care; health care use; usual source of care; depression; Medicare ID PREVENTIVE SERVICES; HEALTH-CARE; MAJOR DEPRESSION; RANDOMIZED-TRIAL; SOCIAL SUPPORT; OLDER-ADULTS; LATER LIFE; SYMPTOMS; ACCESS; INSURANCE AB Objective. To investigate whether having a usual source of care (USOC) resulted in lower depression prevalence among the elderly. Data Sources. The 2001-2003 Medicare Current Beneficiaries Survey and 2002 Area Resource File. Study Design. Twenty thousand four hundred and fifty-five community-dwelling person-years were identified for respondents aged 651, covered by both Medicare Parts A and B in Medicare fee-for-service for a full year. USOC was defined by the question "Is there a particular medical person or a clinic you usually go to when you are sick or for advice about your health?'' Ambulatory care use (ACU) was defined by having at least one physician office visit and/or hospital outpatient visit using Medicare claims. Depression was identified by a two-item screen (sadness and/or anhedonia). All measures were for the past 12 months. A simultaneous-equations (trivariate probit) model was estimated, adjusted for sampling weights and study design effects. Principal Findings. Based on the simultaneous-equations model, USOC is associated with 3.8 percent lower probability of having depression symptoms (p=.03). Also, it had a positive effect on having any ACU (p<.001). Having any ACU had no statistically significant effect on depression (p=.96). Conclusions. USOC was associated with lower depression prevalence and higher realized access (ACU) among community-dwelling Medicare beneficiaries. C1 [Li, Chunyu] Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Friedman, Bruce] Univ Rochester, Sch Med & Dent, Dept Community & Prevent Med, Rochester, NY USA. [Dick, Andrew W.] RAND Corp, Boston, MA USA. [Fiscella, Kevin] Univ Rochester, Sch Med & Dent, Dept Family Med, Rochester, NY USA. [Conwell, Yeates] Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY USA. RP Li, CY (reprint author), Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, 4770 Buford Hwy NE,Mailstop K-55, Atlanta, GA 30341 USA. EM chunyu.li@cdc.hhs.gov FU NIMH NIH HHS [R24 MH071604] NR 45 TC 1 Z9 1 U1 1 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD AUG PY 2011 VL 46 IS 4 BP 1059 EP 1081 DI 10.1111/j.1475-6773.2011.01240.x PG 23 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 788NA UT WOS:000292450500004 PM 21306366 ER PT J AU Gross, JM Rogers, MF Teplinskiy, I Oywer, E Wambua, D Kamenju, A Arudo, J Riley, PL Higgins, M Rakuom, C Kiriinya, R Waudo, A AF Gross, Jessica M. Rogers, Martha F. Teplinskiy, Ilya Oywer, Elizabeth Wambua, David Kamenju, Andrew Arudo, John Riley, Patricia L. Higgins, Melinda Rakuom, Chris Kiriinya, Rose Waudo, Agnes TI The Impact of Out-Migration on the Nursing Workforce in Kenya SO HEALTH SERVICES RESEARCH LA English DT Article DE Human resource information systems; Kenya; nursing workforce; emigration; database; professional regulatory bodies ID SUB-SAHARAN AFRICA; HEALTH-CARE WORKERS; BRAIN-DRAIN; NURSES; PROFESSIONALS; RECRUITMENT; CHALLENGES AB Objective. To examine the impact of out-migration on Kenya's nursing workforce. Study Setting. This study analyzed deidentified nursing data from the Kenya Health Workforce Informatics System, collected by the Nursing Council of Kenya and the Department of Nursing in the Ministry of Medical Services. Study Design. We analyzed trends in Kenya's nursing workforce from 1999 to 2007, including supply, deployment, and intent to out-migrate, measured by requests for verification of credentials from destination countries. Principle Findings. From 1999 to 2007, 6 percent of Kenya's nursing workforce of 41,367 nurses applied to out-migrate. Eighty-five percent of applicants were registered or B.Sc.N. prepared nurses, 49 percent applied within 10 years of their initial registration as a nurse, and 82 percent of first-time applications were for the United States or United Kingdom. For every 4.5 nurses that Kenya adds to its nursing workforce through training, 1 nurse from the workforce applies to out-migrate, potentially reducing by 22 percent Kenya's ability to increase its nursing workforce through training. Conclusions. Nurse out-migration depletes Kenya's nursing workforce of its most highly educated nurses, reduces the percentage of younger nurses in an aging nursing stock, decreases Kenya's ability to increase its nursing workforce through training, and represents a substantial economic loss to the country. C1 [Gross, Jessica M.; Rogers, Martha F.; Teplinskiy, Ilya; Higgins, Melinda] Emory Univ, Dept Family & Community Nursing, Atlanta, GA 30322 USA. [Oywer, Elizabeth; Wambua, David] Nurses Council Kenya, Nairobi, Kenya. [Kamenju, Andrew; Kiriinya, Rose; Waudo, Agnes] Kenya Hlth Workforce Project, Nairobi, Kenya. [Arudo, John] Aga Khan Univ, Nairobi, Kenya. [Riley, Patricia L.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA USA. [Rakuom, Chris] Kenyan Minist Med Serv, Nairobi, Kenya. RP Gross, JM (reprint author), Emory Univ, Dept Family & Community Nursing, 1520 Clifton Rd,NE, Atlanta, GA 30322 USA. EM jessicamadigangross@gmail.com RI Higgins, Melinda/B-6459-2013 OI Higgins, Melinda/0000-0001-6579-5885 FU CDC; PEPFAR FX Joint Acknowledgment/Disclosure Statement: This project is supported by the CDC and funded with resources provided by the PEPFAR. CDC's Global AIDS Program awarded the project and oversees project activity. The findings and conclusions in this report are those of the author(s) and do not necessarily reflect the views of the Centers for Disease Control and Prevention. The Global Field Experience program at the Rollins School of Public Health, Emory University, with a gift from the O.C. Hubert Charitable Trust, provided additional support for field activities for which the authors are extremely grateful. NR 36 TC 8 Z9 8 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD AUG PY 2011 VL 46 IS 4 BP 1300 EP 1318 DI 10.1111/j.1475-6773.2011.01251.x PG 19 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 788NA UT WOS:000292450500015 PM 21413982 ER PT J AU De Cock, KM El-Sadr, WM Ghebreyesus, TA AF De Cock, Kevin M. El-Sadr, Wafaa M. Ghebreyesus, Tedros A. TI Game Changers: Why Did the Scale-Up of HIV Treatment Work Despite Weak Health Systems? SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE AIDS; health systems; HIV; innovations; scale-up ID EARLY-DIAGNOSIS; PROGRAM; AFRICA; CARE; PREVENTION; MORTALITY; INFANTS AB Game changers are radical innovations that result in fundamental and durable changes. The global HIV program scale-up witnessed over the past decade has included some innovations that are not well appreciated. The willingness to rapidly adopt and implement innovations, the flexibility and speed of program implementation, and the readiness to re-examine professional roles are just a few of such game changers. However, moving ahead, further work is needed to enhance the quality of programs, to energetically tackle HIV prevention, to build on this success, and to address other health threats that these same communities face. C1 [De Cock, Kevin M.] US Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [El-Sadr, Wafaa M.] Columbia Univ, Dept Epidemiol, ICAP, Mailman Sch Publ Hlth, New York, NY USA. [El-Sadr, Wafaa M.] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA. [Ghebreyesus, Tedros A.] Minist Hlth, Addis Ababa, Ethiopia. RP De Cock, KM (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, 1600 Clifton Rd,MS D69, Atlanta, GA 30333 USA. EM kmd2@cdc.gov NR 22 TC 21 Z9 21 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD AUG 1 PY 2011 VL 57 SU 2 BP S61 EP S63 DI 10.1097/QAI.0b013e3182217f00 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 792PW UT WOS:000292761100002 PM 21857297 ER PT J AU El-Sadr, WM Rabkin, M Atun, R De Cock, KM AF El-Sadr, Wafaa M. Rabkin, Miriam Atun, Rifat De Cock, Kevin M. TI Bridging the Divide INTRODUCTION SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Editorial Material C1 [El-Sadr, Wafaa M.; Rabkin, Miriam] Columbia Univ, ICAP, New York, NY 10032 USA. [El-Sadr, Wafaa M.; Rabkin, Miriam] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA. [El-Sadr, Wafaa M.; Rabkin, Miriam] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA. [Atun, Rifat] Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland. [Atun, Rifat] Imperial Coll London, London, England. [De Cock, Kevin M.] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP El-Sadr, WM (reprint author), Columbia Univ, ICAP, 722 W 168th St,13th Floor, New York, NY 10032 USA. EM wme1@columbia.edu NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD AUG 1 PY 2011 VL 57 SU 2 BP S59 EP S60 DI 10.1097/QAI.0b013e31821dba91 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 792PW UT WOS:000292761100001 PM 21857296 ER PT J AU Holmes, CB Atun, R Avila, C Blandford, JM AF Holmes, Charles B. Atun, Rifat Avila, Carlos Blandford, John M. TI Expanding the Generation and Use of Economic and Financial Data to Improve HIV Program Planning and Efficiency: A Global Perspective SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE cost; finance; global fund; HIV; PEPFAR ID SOUTH-AFRICA; ANTIRETROVIRAL THERAPY; COST; CARE AB Cost information is needed at multiple levels of health care systems to inform the public health response to HIV. To date, most attention has been paid to identifying the cost drivers of providing antiretroviral treatment, and these data have driven interventions that have been successful in reducing drug and human resource costs. The need for further cost information, especially for less well-studied areas such as HIV prevention, is particularly acute given global budget constraints and ongoing efforts to extract the greatest possible value from money spent on the response. Cost information can be collected from multiple perspectives and levels of the health care system (site, program, and national levels), and it is critical to choose the appropriate methodology in order to generate the appropriate information for decision-making. Organizations such as United States President's Emergency Plan for AIDS Relief, the Global Fund to Fight AIDS, Tuberculosis, and Malaria, and other organizations are working together to bridge the divide between the fields of economics and HIV program implementation by accelerating the collection of cost data and building further local demand and capacity for their use. C1 [Holmes, Charles B.] Off US Global AIDS Coordinator, US Presidents Emergency Plan AIDS Relief, Washington, DC 20522 USA. [Atun, Rifat] Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland. [Atun, Rifat] Imperial Coll London, London, England. [Avila, Carlos] UNAIDS, Geneva, Switzerland. [Blandford, John M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Holmes, CB (reprint author), Off US Global AIDS Coordinator, US Presidents Emergency Plan AIDS Relief, SA-29,2nd Floor, Washington, DC 20522 USA. EM holmescb@state.gov NR 20 TC 6 Z9 6 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD AUG 1 PY 2011 VL 57 SU 2 BP S104 EP S108 DI 10.1097/QAI.0b013e31821fa12d PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 792PW UT WOS:000292761100013 PM 21857291 ER PT J AU Kimberly, N Zahran, H Iqbal, S Peng, J Boulay, E AF Kimberly Nguyen Zahran, Hatice Iqbal, Shahed Peng, Justin Boulay, Eileen TI Factors Associated with Asthma Control among Adults in Five New England States, 2006--2007 SO JOURNAL OF ASTHMA LA English DT Article DE access to health care; asthma; cross-sectional study; education; socio-demographic factors ID FACTOR SURVEILLANCE SYSTEM; UNITED-STATES; POOR ASTHMA; COSTS; PREDICTORS; MEDICATION AB Background. Despite the National Asthma Education and Prevention Program (NAEPP) guidelines that specify the goals of asthma control and management strategies, the number of patients with uncontrolled asthma remains high, and factors associated with uncontrolled asthma are unknown. Objective. The aim was to examine the relationship between asthma control and socio-demographic characteristics, health-care access and use, asthma education, and medication use among adults with active asthma residing in New England. Methods. Data from the 2006--2007 Behavior Risk Factor Surveillance System Adult Asthma Call-Back Survey were analyzed using multinomial logistic regression. Asthma control was categorized as ""well controlled,"" ""not well controlled,"" or ""very poorly controlled"" according to the NAEPP guidelines. Results. Of the respondents (n == 3079), 30%% met the criteria for well-controlled asthma, 46%% for not well-controlled asthma, and 24%% for very poorly controlled asthma. Being of Hispanic ethnicity (odds ratio [OR] == 4.0; 95%% confidence interval [CI] == 1.2--13.7), unemployed or unable to work (OR == 17.9; 95%% CI == 6.0--53.4), high school educated or less (OR == 2.8; 95%% CI == 1.6--4.7), current smokers (OR == 2.5; 95%% CI == 1.3--5.1), or being unable to see a doctor or specialist for asthma care or unable to buy medication for asthma because of cost (OR == 7.6; 95%% CI == 3.4--17.1) were associated with very poorly controlled asthma. In addition, having Coronary Obstructive Pulmonary Disease (COPD) (OR == 2.6; 95%% CI == 1.5--4.5), two or more routine checkups for asthma (OR == 4.5; 95%% CI == 2.3--8.9), or an emergency department visit, urgent care facility visit, and hospitalization in the past year (OR == 3.9; 95%% CI == 2.1--7.3) were also associated with having very poorly controlled asthma. Using controller medication in the past year (OR == 2.6; 95%% CI == 1.6--4.2) and taking a course on how to manage asthma (OR == 3.0; 95%% CI == 1.2--7.8) were significantly associated with poor asthma control. Conclusion. The high prevalence (70%%) of not well-controlled asthma and poorly controlled asthma in this study emphasizes the need to identify factors associated with poor asthma control for development of targeted intervention. A health policy of increasing asthma education, health-care access, and smoking cessation may be effective and result in better asthma control and management.100-fold) level of FTC resistance conferred by M184V, all five treated animals were protected from infection, while the five untreated macaques were infected (P = 0.0008). Our results show that Truvada maintains high prophylactic efficacy against an FTC-resistant isolate. Increased susceptibility to tenofovir due to M184V and other factors, including residual antiviral activity by FTC and/or reduced virus fitness due to M184V, may all have contributed to the observed protection. C1 [Cong, Mian-er; Youngpairoj, Ae S.; Zheng, Qi; Aung, Wutyi; Mitchell, James; Sweeney, Elizabeth; Hanson, Debra L.; Hendry, R. Michael; Dobard, Charles; Heneine, Walid; Garcia-Lerma, J. Gerardo] CDC, Branch Lab, Div HIV AIDS Prevent,Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30329 USA. RP Garcia-Lerma, JG (reprint author), CDC, Branch Lab, Div HIV AIDS Prevent,Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, MS G45,1600 Clifton Rd, Atlanta, GA 30329 USA. EM ggarcia-lerma@cdc.gov FU CDC [Y1-AI-0681-02]; NIH [Y1-AI-0681-02] FX his work was partially supported by Interagency Agreement Y1-AI-0681-02 between the CDC and NIH. NR 29 TC 17 Z9 18 U1 1 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD AUG PY 2011 VL 85 IS 15 BP 7933 EP 7936 DI 10.1128/JVI.00843-11 PG 4 WC Virology SC Virology GA 788LV UT WOS:000292447300046 PM 21632769 ER PT J AU Xu, XH Nembhard, WN Kan, HD Kearney, G Zhang, ZJ Talbott, EO AF Xu, Xiaohui Nembhard, Wendy N. Kan, Haidong Kearney, Greg Zhang, Zhi-Jiang Talbott, Evelyn O. TI Urinary trichlorophenol levels and increased risk of attention deficit hyperactivity disorder among US school-aged children SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID PRENATAL EXPOSURE; HEXACHLOROCYCLOHEXANE; HEXACHLOROBENZENE; CHLOROPHENOLS; METABOLISM; HEALTH; EPIDEMIOLOGY; MUTAGENICITY; PESTICIDE; TOXICITY AB Background Trichlorophenols (TCPs) are organochlorine compounds which are ubiquitous in the environment and well known for their carcinogenic effects. However, little is known about their neurotoxicity in humans. Objectives Our goal was to examine the association between body burden of TCPs (ie, 2,4,5-TCP and 2,4,6-TCP) and attention deficit hyperactivity disorder (ADHD). Methods We calculated ORs and 95% CIs from logistic regression analyses using data from the 1999-2004 National Health and Nutrition Examination Survey (NHANES) to evaluate the association between urinary TCPs and parent-reported ADHD among 2546 children aged 6-15 years. Results Children with low levels (<3.58 mu g/g) and high levels (>= 3.58 mu g/g) of urinary 2,4,6-TCP had a higher risk of parent-reported ADHD compared to children with levels below the limit of detection (OR 1.54, 95% CI 0.97 to 2.43 and OR 1.77, 95% CI 1.18 to 2.66, respectively; p for trend=0.006) after adjusting for covariates. No association was found between urinary 2,4,5-TCP and parent-reported ADHD. Conclusion Exposure to TCP may increase the risk of behavioural impairment in children. The potential neurotoxicity of these chemicals should be considered in public health efforts to reduce environmental exposures/contamination, especially in countries where organochlorine pesticides are still commonly used. C1 [Xu, Xiaohui] Univ Florida, Dept Epidemiol & Biostat, Coll Publ Hlth & Hlth Profess, Gainesville, FL USA. [Nembhard, Wendy N.] Univ S Florida, Coll Publ Hlth, Dept Epidemiol & Biostat, Tampa, FL USA. [Kan, Haidong] Fudan Univ, Sch Publ Hlth, Dept Environm Hlth, Shanghai 200433, Peoples R China. [Kearney, Greg] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Zhang, Zhi-Jiang] Shanghai Jiao Tong Univ, Dept Epidemiol, Sch Publ Hlth, Shanghai 200030, Peoples R China. [Talbott, Evelyn O.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. RP Xu, XH (reprint author), 101 S Newell Dr,Room 3119, Gainesville, FL 32610 USA. EM xhxu@phhp.ufl.edu OI Talbott, Evelyn/0000-0002-5198-7939 NR 40 TC 9 Z9 9 U1 3 U2 12 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD AUG PY 2011 VL 68 IS 8 BP 557 EP 561 DI 10.1136/oem.2010.063859 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 788MT UT WOS:000292449800002 PM 21540483 ER PT J AU Parks, CG DeRoo, LA Miller, DB McCanlies, EC Cawthon, RM Sandler, DP AF Parks, C. G. DeRoo, L. A. Miller, D. B. McCanlies, E. C. Cawthon, R. M. Sandler, D. P. TI Employment and work schedule are related to telomere length in women SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID CORONARY-HEART-DISEASE; LIFE-STYLE; CIGARETTE-SMOKING; PERCEIVED STRESS; HEALTH BEHAVIORS; LONG WORKHOURS; OVERTIME WORK; MORTALITY; ASSOCIATION; RECOVERY AB Objectives To examine the association of employment and work schedule with shorter DNA telomeres, a marker of cellular ageing and disease risk factor, and consider whether differences were related to health, behaviours and sociodemographic factors, or varied by stress levels or menopausal status. Methods This cross-sectional analysis of 608 women aged 35-74 in the Sister Study examined determinants of relative telomere length (rTL) measured by quantitative PCR in leucocyte DNA. Age-adjusted regression models estimated base pair (bp) rTL differences for current and lifetime schedule characteristics (ie, part-time, full-time or overtime hours; multiple jobs; irregular hours; shiftwork; work at night). Covariates included race, smoking, perceived stress, sleep, physical activity, health and menopausal status, education, marital status, live births, children under 18, measured body mass index and urinary stress hormones. oResults Compared with non-employed women with moderate or substantial past work histories (n=190), those currently working full-time (n=247; median 40 h/week) had a shorter rTL, an age-adjusted difference of -329 bp (95% CI -110 to -548). Longer-duration full-time work was also associated with shorter rTL (age-adjusted difference of -472 bp, 95% CI -786 to -158 for 20+ vs 1-5 years). Findings were not explained by health and demographic covariates. However, rTL differences for working at least full-time were greater in women with higher stress and epinephrine levels. Conclusions Current and long-term full-time work were associated with shorter rTL, with differences of similar magnitude to smoking and history of heart disease or diabetes. Longitudinal data with specific stress measures are needed to further evaluate the impact of work schedule on rTL. C1 [Parks, C. G.; DeRoo, L. A.; Sandler, D. P.] NIEHS, Epidemiol Branch, NIH, Res Triangle Pk, NC 27599 USA. [Miller, D. B.] NIOSH, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. [McCanlies, E. C.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. [Cawthon, R. M.] Univ Utah, Dept Human Genet, Salt Lake City, UT USA. RP Parks, CG (reprint author), NIEHS, Epidemiol Branch, NIH, A3-05,POB 12233, Res Triangle Pk, NC 27599 USA. EM parks1@mail.nih.gov RI Miller, Diane/O-2927-2013; OI Parks, Christine/0000-0002-5734-3456; Sandler, Dale/0000-0002-6776-0018 FU NIH, National Institute of Environmental Health Sciences [Z01 ES044005]; Department of Defense [BC045286] FX This research was supported in part by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01 ES044005), and by Department of Defense Breast Cancer Research Concept Award (BC045286). NR 39 TC 19 Z9 19 U1 1 U2 13 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 EI 1470-7926 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD AUG PY 2011 VL 68 IS 8 BP 582 EP 589 DI 10.1136/oem.2010.063214 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 788MT UT WOS:000292449800006 PM 21540175 ER PT J AU Dement, JM Loomis, D Richardson, D Wolf, SH Kuempel, ED AF Dement, John M. Loomis, Dana Richardson, David Wolf, Susanne H. Kuempel, Eileen D. TI Estimates of historical exposures by phase contrast and transmission electron microscopy for pooled exposure-response analyses of North Carolina and South Carolina, USA asbestos textile cohorts SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID FIBER DIMENSIONS; CHRYSOTILE; WORKERS; MORTALITY AB Objectives To develop pooled size-specific asbestos fiber exposure estimates for North Carolina and South Carolina asbestos textile plants. Methods Airborne sample data and prior exposure estimates by phase-contrast microscopy (PCM) for the two cohorts were reviewed and compared. Estimates by transmission electron microscopy (TEM) for 160 membrane filter samples from all plant were pooled. Poisson regression models were developed to predict bivariate diameter/length airborne fiber size distributions based on independent categorical variables for fiber diameter, fiber length, plant, and exposure zone. The model predicted bivariate diameter/length distributions were expressed as the proportion of fibers in 28 size-specific cells and these data were used to calculate PCM to TEM adjustment factors in order to estimate fiber size-specific exposures for the pooled cohort. Results Exposure levels in the North Carolina plants were in excess of 50 f/cc for many operations through about 1955 owing to lack of dust control measures in early years whereas levels in the South Carolina plant were generally less than 10 f/cc by about 1950. The Poisson regression models found covariates for plant department to be a stronger predictor of bivariate size proportions than plant; however, a plant effect was observed. The final Poisson models demonstrated good fit to the observed data. Conclusions Consistent with early studies, fiber exposures in the North Carolina plants were much higher than in South Carolina plant. Use of the predicted size-specific TEM exposures by plant and department based on the Poisson model predictions should reduce exposure. C1 [Dement, John M.] Duke Univ, Med Ctr, Dept Community & Family Med, Div Occupat & Environm Med, Durham, NC 27705 USA. [Loomis, Dana] Univ Nebraska, Med Ctr, Dept Epidemiol, Coll Publ Hlth, Omaha, NE USA. [Loomis, Dana] Univ Nebraska, Med Ctr, Eppley Canc Ctr, Omaha, NE USA. [Richardson, David; Wolf, Susanne H.] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA. [Kuempel, Eileen D.] NIOSH, Educ & Informat Div, Cincinnati, OH 45226 USA. RP Dement, JM (reprint author), Duke Univ, Med Ctr, Dept Community & Family Med, Div Occupat & Environm Med, 2200 W Main St,Suite 400, Durham, NC 27705 USA. EM john.dement@duke.edu FU National Institute for Occupational Safety and Health (NIOSH) [R01 OH007803] FX The National Institute for Occupational Safety and Health (NIOSH) supported this research (grant number R01 OH007803). NR 12 TC 11 Z9 11 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD AUG PY 2011 VL 68 IS 8 BP 593 EP 598 DI 10.1136/oem.2010.059972 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 788MT UT WOS:000292449800008 PM 21217162 ER PT J AU Alvy, LM McKirnan, DJ Mansergh, G Koblin, B Colfax, GN Flores, SA Hudson, S AF Alvy, Lisa M. McKirnan, David J. Mansergh, Gordon Koblin, Beryl Colfax, Grant N. Flores, Stephen A. Hudson, Sharon CA Project MIX Study Grp TI Depression is Associated with Sexual Risk Among Men Who Have Sex with Men, but is Mediated by Cognitive Escape and Self-Efficacy SO AIDS AND BEHAVIOR LA English DT Article DE Depression; Sexual risk; MSM; Cognitive escape; Self-efficacy ID GAY MEN; PSYCHOSOCIAL PREDICTORS; CONFIDENCE-LIMITS; COPING STRATEGIES; BISEXUAL MEN; YOUNG MEN; HEALTH; BEHAVIORS; SYMPTOMS; MODEL AB Men who have sex with men (MSM) show high rates of HIV infection, and higher rates of depression than non-MSM. We examined the association between depression and sexual risk among "high risk" MSM. Evidence has been mixed regarding the link between depression and risky sex, although researchers have rarely considered the role of psychosocial vulnerabilities such as self-efficacy for sexual safety or "escape" coping styles. In a national sample (N = 1,540) of HIV-positive and HIV-negative MSM who reported unprotected sex and drug use with sex partners, we found evidence that depression is related to HIV transmission risk. Self-efficacy for sexual safety and cognitive escape mediated the link between depression and risk behavior, suggesting that psychosocial vulnerability plays an important role in the association of depression with sexual risk. These findings may help us construct more accurate theories regarding depression and sexual behavior, and may inform the design of sexual safety interventions. C1 [Alvy, Lisa M.; McKirnan, David J.] Univ Illinois, Dept Psychol, Chicago, IL 60607 USA. [Alvy, Lisa M.; McKirnan, David J.] Howard Brown Hlth Ctr, Chicago, IL USA. [Mansergh, Gordon; Flores, Stephen A.] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Koblin, Beryl] New York Blood Ctr, New York, NY 10021 USA. [Colfax, Grant N.] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Hudson, Sharon] Hlth Res Assoc, Los Angeles, CA USA. RP Alvy, LM (reprint author), Univ Illinois, Dept Psychol, 1007 W Harrison St,M-C 285, Chicago, IL 60607 USA. EM Ealvy2@uic.edu NR 42 TC 50 Z9 51 U1 3 U2 11 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS behav. PD AUG PY 2011 VL 15 IS 6 BP 1171 EP 1179 DI 10.1007/s10461-010-9678-z PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 785YF UT WOS:000292268400010 PM 20217471 ER PT J AU Li, CS Inn, KGW Jones, R Jourdain, JR Priest, N Wilkinson, D Sadi, B Ko, R Capello, K Kramer, GH AF Li, Chunsheng Inn, Kenneth G. W. Jones, Robert Jourdain, Jean-Rene Priest, Nicholas Wilkinson, Diana Sadi, Baki Ko, Raymond Capello, Kevin Kramer, Gary H. TI INTERNATIONAL WORKSHOP ON EMERGENCY RADIOBIOASSAY: CONSIDERATIONS, GAPS AND RECOMMENDATIONS SO HEALTH PHYSICS LA English DT Article DE bioassay; dosimetry; internal; emergencies; radiological; radiological terrorism AB An international workshop on emergency radiobioassay was held in Ottawa, Canada, 1-3 September 2010. Sixty-five scientists and public health officials from five countries attended the workshop and gave 36 presentations. During the workshop, many considerations were raised, gaps identified, and recommendations given for emergency radiobioassay for both preparedness and response in case of a radiological or nuclear incident. In short, some bioassay methods and protocols need to be developed, validated, and exercised; national and international radiobioassay laboratory networks should be established; and communications and collaborations among public health officials, monitoring experts, and medical staff are encouraged. All these activities are required to make us better prepared for an RN emergency. Health Phys. 101(2): 107-111; 2011 C1 [Li, Chunsheng; Sadi, Baki; Ko, Raymond; Capello, Kevin; Kramer, Gary H.] Hlth Canada, Radiat Protect Bur, Ottawa, ON K1A 1C1, Canada. [Inn, Kenneth G. W.] Natl Inst Stand & Technol, Gaithersburg, MD 20899 USA. [Jones, Robert] Ctr Dis Control & Prevent, Atlanta, GA USA. [Jourdain, Jean-Rene] Inst Radiol Protect & Nucl Safety IRSN, F-92262 Fontenay Aux Roses 17, France. [Priest, Nicholas] Atom Energy Canada Ltd, Chalk River, ON K0J 1J0, Canada. [Wilkinson, Diana] Def R&D Canada, Ottawa, ON K1A 0Z4, Canada. RP Li, CS (reprint author), Hlth Canada, Radiat Protect Bur, Ottawa, ON K1A 1C1, Canada. EM li.chunsheng@hc-sc.gc.ca RI Jones, Robert/E-1170-2011; Sanders, Susan/G-1957-2011 FU Ortec, Canberra and Eichrom Technologies; CRTI [CRTI 06-230RD, CRTI 08-241TD] FX The authors thank all of the participants of the International Workshop on Emergency Radiobioassay for their presentations and discussion. Special thanks are given to Ortec, Canberra and Eichrom Technologies for their generous sponsorship, and to the staff at the Lord Elgin hotel for their assistance. We also thank CRTI for funding this workshop (CRTI 06-230RD and CRTI 08-241TD). NR 4 TC 4 Z9 4 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0017-9078 EI 1538-5159 J9 HEALTH PHYS JI Health Phys. PD AUG PY 2011 VL 101 IS 2 BP 107 EP 111 DI 10.1097/HP.0b013e318213a5da PG 5 WC Environmental Sciences; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging GA 784CB UT WOS:000292130100001 PM 21709495 ER PT J AU Miller, CW Ansari, A Martin, C Chang, A Buzzell, J Whitcomb, RC AF Miller, Charles W. Ansari, Armin Martin, Colleen Chang, Art Buzzell, Jennifer Whitcomb, Robert C., Jr. TI USE OF EPIDEMIOLOGICAL DATA AND DIRECT BIOASSAY FOR PRIORITIZATION OF AFFECTED POPULATIONS IN A LARGE-SCALE RADIATION EMERGENCY SO HEALTH PHYSICS LA English DT Article DE bioassay; emergencies; radiological; emergency planning; contamination; internal AB Following a radiation emergency, evacuated, sheltered or other members of the public would require monitoring for external and/or internal contamination and, if indicated, decontamination. In addition, the potentially-impacted population would be identified for biodosimetry/bioassay or needed medical treatment (chelation therapy, cytokine treatment, etc.) and prioritized for follow-up. Expeditious implementation of these activities presents many challenges, especially when a large population is affected. Furthermore, experience from previous radiation incidents has demonstrated that the number of people seeking monitoring for radioactive contamination (both external and internal) could be much higher than the actual number of contaminated individuals. In the United States, the Department of Health and Human Services is the lead agency to coordinate federal support for population monitoring activities. Population monitoring includes (1) monitoring people for external contamination; (2) monitoring people for internal contamination; (3) population decontamination; (4) collecting epidemiologic data regarding potentially exposed and/or contaminated individuals to prioritize the affected population for limited medical resources; (5) administering available pharmaceuticals for internal decontamination as deemed necessary by appropriate health officials; (6) performing dose reconstruction; and (7) establishing a registry to conduct long-term monitoring of this population for potential long-term health effects. This paper will focus on screening for internal contamination and will describe the use of early epidemiologic data as well as direct bioassay techniques to rapidly identify and prioritize the affected population for further analysis and medical attention. Health Phys. 101(2):209-215; 2011 C1 [Miller, Charles W.; Ansari, Armin; Buzzell, Jennifer; Whitcomb, Robert C., Jr.] Ctr Dis Control & Prevent, Radiat Studies Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Martin, Colleen; Chang, Art] Ctr Dis Control & Prevent, Hlth Studies Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Miller, CW (reprint author), Ctr Dis Control & Prevent, Radiat Studies Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, MS F-58,4770 Buford Highway, Atlanta, GA 30341 USA. EM CMiller1@cdc.gov NR 23 TC 1 Z9 1 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0017-9078 EI 1538-5159 J9 HEALTH PHYS JI Health Phys. PD AUG PY 2011 VL 101 IS 2 BP 209 EP 215 DI 10.1097/HP.0b013e31821dd9a2 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging GA 784CB UT WOS:000292130100016 PM 21709510 ER PT J AU Brookmeyer, KA Henrich, CC Cohen, G Shahar, G AF Brookmeyer, Kathryn A. Henrich, Christopher C. Cohen, Guina Shahar, Golan TI Israeli Adolescents Exposed to Community and Terror Violence: The Protective Role of Social Support SO JOURNAL OF EARLY ADOLESCENCE LA English DT Article DE early adolescence; community violence; terrorism; social support; social ecology ID PSYCHOLOGICAL IMPACT; URBAN ADOLESCENTS; STRESS; SCHOOL; YOUTH; CHILDREN; BEHAVIOR; HEALTH; ADJUSTMENT; CONSEQUENCES AB This study investigates how social support may protect Israeli early adolescents who have witnessed community violence from engaging in violent behavior when they have also witnessed terror violence. The study examines how support from parents, school, and friends could serve as protective, despite the interactive risk effects of witnessing community and terror violence. In general, results indicate that support from parents operated as a protective factor, whereas support from friends acted as a risk by increasing the likelihood of violent behavior. Support from school has both a protective and risk effect, depending on the type of violence exposure witnessed. The extent to which these facets of social support operated as risk or protective factors is conditional on whether youth had also witnessed terror violence, and terror violence appear to moderate each of the three facets of support differently. The implications of these findings and intervention initiatives for Israeli youth are discussed. C1 [Brookmeyer, Kathryn A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, Atlanta, GA 30333 USA. [Henrich, Christopher C.] Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA. [Cohen, Guina; Shahar, Golan] Ben Gurion Univ Negev, IL-84105 Beer Sheva, Israel. RP Brookmeyer, KA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, Atlanta, GA 30333 USA. EM KBrookmeyer@cdc.gov RI Shahar, Golan/F-1502-2012 NR 52 TC 9 Z9 9 U1 0 U2 10 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-4316 J9 J EARLY ADOLESCENCE JI J. Early Adolesc. PD AUG PY 2011 VL 31 IS 4 BP 577 EP 603 DI 10.1177/0272431610366247 PG 27 WC Family Studies; Psychology, Developmental SC Family Studies; Psychology GA 778DL UT WOS:000291680100004 ER PT J AU Mitchell, CE Hudgens, MG King, CC Cu-Uvin, S Lo, Y Rompalo, A Sobel, J Smith, JS AF Mitchell, C. E. Hudgens, M. G. King, C. C. Cu-Uvin, S. Lo, Y. Rompalo, A. Sobel, J. Smith, J. S. TI Discrete-time semi-Markov modeling of human papillomavirus persistence SO STATISTICS IN MEDICINE LA English DT Article DE panel data; stochastic process ID NATURAL-HISTORY; PANEL-DATA; INFECTION; WOMEN; METAANALYSIS; RELIABILITY; CLEARANCE; NEOPLASIA; HPV AB Multi-state modeling is often employed to describe the progression of a disease process. In epidemiological studies of certain diseases, the disease state is typically only observed at periodic clinical visits, producing incomplete longitudinal data. In this paper we consider fitting semi-Markov models to estimate the persistence of human papillomavirus (HPV) type-specific infection in studies where the status of HPV type(s) is assessed periodically. Simulation study results are presented indicating that the semi-Markov estimator is more accurate than an estimator currently used in the HPV literature. The methods are illustrated using data from the HIV Epidemiology Research Study. Copyright (C) 2011 John Wiley & Sons, Ltd. C1 [Mitchell, C. E.; Hudgens, M. G.] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27515 USA. [King, C. C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Cu-Uvin, S.] Brown Med Sch, Providence, RI USA. [Lo, Y.] Montefiore Med Ctr, Bronx, NY 10467 USA. [Lo, Y.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Rompalo, A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Sobel, J.] Wayne State Univ, Sch Med, Detroit, MI USA. [Smith, J. S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. RP Hudgens, MG (reprint author), Univ N Carolina, Dept Biostat, 135 Dauer Dr,CB 7420, Chapel Hill, NC 27515 USA. EM mhudgens@bios.unc.edu FU NCI [R01 CA114773-05] FX This work was supported by a grant from NCI (R01 CA114773-05). NR 24 TC 6 Z9 6 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0277-6715 J9 STAT MED JI Stat. Med. PD JUL 30 PY 2011 VL 30 IS 17 BP 2160 EP 2170 DI 10.1002/sim.4257 PG 11 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 792JK UT WOS:000292739500011 PM 21538985 ER PT J AU Prosser, LA Lavelle, TA Fiore, AE Bridges, CB Reed, C Jain, S Dunham, KM Meltzer, MI AF Prosser, Lisa A. Lavelle, Tara A. Fiore, Anthony E. Bridges, Carolyn B. Reed, Carrie Jain, Seema Dunham, Kelly M. Meltzer, Martin I. TI Cost-Effectiveness of 2009 Pandemic Influenza A(H1N1) Vaccination in the United States SO PLOS ONE LA English DT Article ID GUILLAIN-BARRE-SYNDROME; HUMAN-PAPILLOMAVIRUS; A H1N1; IMMUNIZATION-PROGRAM; ECONOMIC-IMPACT; VACCINES; CHILDREN; BENEFITS; EFFICACY; HEALTH AB Background: Pandemic influenza A(H1N1) (pH1N1) was first identified in North America in April 2009. Vaccination against pH1N1 commenced in the U. S. in October 2009 and continued through January 2010. The objective of this study was to evaluate the cost-effectiveness of pH1N1 vaccination. Methodology: A computer simulation model was developed to predict costs and health outcomes for a pH1N1 vaccination program using inactivated vaccine compared to no vaccination. Probabilities, costs and quality-of-life weights were derived from emerging primary data on pH1N1 infections in the US, published and unpublished data for seasonal and pH1N1 illnesses, supplemented by expert opinion. The modeled target population included hypothetical cohorts of persons aged 6 months and older stratified by age and risk. The analysis used a one-year time horizon for most endpoints but also includes longer-term costs and consequences of long-term sequelae deaths. A societal perspective was used. Indirect effects (i.e., herd effects) were not included in the primary analysis. The main endpoint was the incremental cost-effectiveness ratio in dollars per quality-adjusted life year (QALY) gained. Sensitivity analyses were conducted. Results: For vaccination initiated prior to the outbreak, pH1N1 vaccination was cost-saving for persons 6 months to 64 years under many assumptions. For those without high risk conditions, incremental cost-effectiveness ratios ranged from $8,000-$52,000/QALY depending on age and risk status. Results were sensitive to the number of vaccine doses needed, costs of vaccination, illness rates, and timing of vaccine delivery. Conclusions: Vaccination for pH1N1 for children and working-age adults is cost-effective compared to other preventive health interventions under a wide range of scenarios. The economic evidence was consistent with target recommendations that were in place for pH1N1 vaccination. We also found that the delays in vaccine availability had a substantial impact on the cost-effectiveness of vaccination. C1 [Prosser, Lisa A.; Dunham, Kelly M.] Univ Michigan Hlth Syst, Div Gen Pediat, Child Hlth Evaluat & Res Unit, Ann Arbor, MI USA. [Lavelle, Tara A.] Harvard Univ, PhD Program Hlth Policy, Cambridge, MA 02138 USA. [Fiore, Anthony E.; Bridges, Carolyn B.; Reed, Carrie; Jain, Seema; Meltzer, Martin I.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Prosser, LA (reprint author), Univ Michigan Hlth Syst, Div Gen Pediat, Child Hlth Evaluat & Res Unit, Ann Arbor, MI USA. EM lisapros@med.umich.edu FU Harvard-CDC Joint Initiative in Vaccine Economics FX Funding for this project was provided from the Harvard-CDC Joint Initiative in Vaccine Economics. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 59 TC 15 Z9 15 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 29 PY 2011 VL 6 IS 7 AR e22308 DI 10.1371/journal.pone.0022308 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 799KV UT WOS:000293286500012 PM 21829456 ER PT J AU Pathak, EB Reader, S Tanner, JP Casper, ML AF Pathak, Elizabeth Barnett Reader, Steven Tanner, Jean Paul Casper, Michele L. TI Spatial clustering of non-transported cardiac decedents: the results of a point pattern analysis and an inquiry into social environmental correlates SO INTERNATIONAL JOURNAL OF HEALTH GEOGRAPHICS LA English DT Article ID HEART-DISEASE MORTALITY; MYOCARDIAL-INFARCTION; INFORMATION; PREVALENCE; AREA AB Background: People who die from heart disease at home before any attempt at transport has been made may represent missed opportunities for life-saving medical intervention. In this study, we undertook a point-pattern spatial analysis of heart disease deaths occurring before transport in a large metropolitan area to determine whether there was spatial clustering of non-transported decedents and whether there were significant differences between the clusters of non-transported cardiac decedents and the clusters of transported cardiac decedents in terms of average travel distances to nearest hospital and area socioeconomic characteristics. These analyses were adjusted for individual predictors of transport status. Methods: We obtained transport status from the place of death variable on the death certificate. We geocoded heart disease decedents to residential street addresses using a rigorous, multistep process with 97% success. Our final study population consisted of 11,485 adults aged 25-74 years who resided in a large metropolitan area in west-central Florida and died from heart disease during 1998-2002. We conducted a kernel density analysis to identify clusters of the residential locations of cardiac decedents where there was a statistically significant excess probability of being either transported or not transported prior to death; we controlled for individual-level covariates using logistic regression-derived probability estimates. Results: The majority of heart disease decedents were married (53.4%), male (66.4%), white (85.6%), and aged 65-74 years at the time of death (54.7%), and a slight majority were transported prior to death (57.7%). After adjustment for individual predictors, 21 geographic clusters of non-transported heart disease decedents were observed. Contrary to our hypothesis, clusters of non-transported decedents were slightly closer to hospitals than clusters of transported decedents. The social environmental characteristics of clusters varied in the expected direction, with lower socioeconomic and household resources in the clusters of non-transported heart disease deaths. Conclusions: These results suggest that in this large metropolitan area unfavorable household and neighborhood resources played a larger role than distance to hospital with regard to transport status of cardiac patients; more research is needed in different geographic areas of the United States and in other industrialized nations. C1 [Pathak, Elizabeth Barnett; Tanner, Jean Paul] Univ S Florida, Dept Epidemiol & Biostat, Coll Publ Hlth, Tampa, FL 33612 USA. [Reader, Steven] Univ S Florida, Dept Geog Environm & Planning, Tampa, FL 33629 USA. [Casper, Michele L.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Pathak, EB (reprint author), Univ S Florida, Dept Epidemiol & Biostat, Coll Publ Hlth, 13201 Bruce B Downs Blvd,MDC 56, Tampa, FL 33612 USA. EM epathak@health.usf.edu RI Pathak, Elizabeth/H-2683-2013 OI Pathak, Elizabeth/0000-0002-9702-0782 NR 21 TC 1 Z9 1 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-072X J9 INT J HEALTH GEOGR JI Int. J. Health Geogr. PD JUL 28 PY 2011 VL 10 AR 46 DI 10.1186/1476-072X-10-46 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 816KG UT WOS:000294596800001 PM 21798051 ER PT J AU Hwang, J Alemayehu, BH Hoos, D Melaku, Z Tekleyohannes, SG Teshi, T Birhanu, SG Demeke, L Gobena, K Kassa, M Jima, D Reithinger, R Nettey, H Green, M Malone, JL Kachur, SP Filler, S AF Hwang, Jimee Alemayehu, Bereket H. Hoos, David Melaku, Zenebe Tekleyohannes, Samuel G. Teshi, Takele Birhanu, Sintayehu G. Demeke, Leykun Gobena, Kedir Kassa, Moges Jima, Daddi Reithinger, Richard Nettey, Henry Green, Michael Malone, Joseph L. Kachur, S. Patrick Filler, Scott TI In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Central Ethiopia SO MALARIA JOURNAL LA English DT Article ID SOUTH-WEST ETHIOPIA; RESISTANT FALCIPARUM; ARTEMETHER/LUMEFANTRINE COARTEM(R); POPULATION PHARMACOKINETICS; THERAPEUTIC-EFFICACY; COMBINATION THERAPY; ANTIMALARIAL-DRUG; RANDOMIZED-TRIAL; 6-DOSE REGIMEN; SAFETY AB Background: In vivo efficacy assessments of the first-line treatments for Plasmodium falciparum malaria are essential for ensuring effective case management. In Ethiopia, artemether-lumefantrine (AL) has been the first-line treatment for uncomplicated P. falciparum malaria since 2004. Methods: Between October and November 2009, we conducted a 42-day, single arm, open label study of AL for P. falciparum in individuals >6 months of age at two sites in Oromia State, Ethiopia. Eligible patients who had documented P. falciparum mono-infection were enrolled and followed according to the standard 2009 World Health Organization in vivo drug efficacy monitoring protocol. The primary and secondary endpoints were PCR uncorrected and corrected cure rates, as measured by adequate clinical and parasitological response on days 28 and 42, respectively. Results: Of 4426 patients tested, 120 with confirmed falciparum malaria were enrolled and treated with AL. Followup was completed for 112 patients at day 28 and 104 patients at day 42. There was one late parasitological failure, which was classified as undetermined after genotyping. Uncorrected cure rates at both day 28 and 42 for the per protocol analysis were 99.1% (95% CI 95.1-100.0); corrected cure rates at both day 28 and 42 were 100.0%. Uncorrected cure rates at day 28 and 42 for the intention to treat analysis were 93.3% (95% CI 87.2-97.1) and 86.6% (95% CI 79.1-92.1), respectively, while the corrected cure rates at day 28 and 42 were 94.1% (95% CI 88.2-97.6) and 87.3% (95% CI 79.9-92.7), respectively. Using survival analysis, the unadjusted cure rate was 99.1% and 100.0% adjusted by genotyping for day 28 and 42, respectively. Eight P. falciparum patients (6.7%) presented with Plasmodium vivax infection during follow-up and were excluded from the per protocol analysis. Only one patient had persistent parasitaemia at day 3. No serious adverse events were reported, with cough and nausea/vomiting being the most common adverse events. Conclusions: AL remains a highly effective and well-tolerated treatment for uncomplicated falciparum malaria in the study setting after several years of universal access to AL. A high rate of parasitaemia with P. vivax possibly from relapse or new infection was observed. C1 [Hwang, Jimee; Nettey, Henry; Green, Michael; Kachur, S. Patrick] US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Hwang, Jimee] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94143 USA. [Alemayehu, Bereket H.; Melaku, Zenebe; Tekleyohannes, Samuel G.; Teshi, Takele; Birhanu, Sintayehu G.; Demeke, Leykun] Int Ctr AIDS Care & Treatment Programs, Addis Ababa, Ethiopia. [Hoos, David] Int Ctr AIDS Care & Treatment Programs, New York, NY USA. [Gobena, Kedir] Oromia Reg Hlth Bur, Addis Ababa, Ethiopia. [Kassa, Moges] Ethiopian Hlth & Nutr Res Inst, Addis Ababa, Ethiopia. [Jima, Daddi] Fed Minist Hlth, Addis Ababa, Ethiopia. [Reithinger, Richard] US Agcy Int Dev, Addis Ababa, Ethiopia. [Malone, Joseph L.] US Ctr Dis Control & Prevent, Addis Ababa, Ethiopia. [Filler, Scott] Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland. RP Hwang, J (reprint author), US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM jhwang@cdc.gov OI Malone, Joseph/0000-0002-5515-6171 FU President's Malaria Initiative via the Office of Health, Infectious Diseases, and Nutrition, Bureau for Global Health; U.S. Agency for International Development; U.S. Centers for Disease Control and Prevention FX This research was made possible through support provided by the President's Malaria Initiative via the Office of Health, Infectious Diseases, and Nutrition, Bureau for Global Health, U.S. Agency for International Development, under the terms of an Interagency Agreement with the U.S. Centers for Disease Control and Prevention. The opinions expressed herein are those of the author(s) and do not necessarily reflect the views of the U.S. Centers for Disease Control and Prevention or the U.S. Agency for International Development. NR 52 TC 13 Z9 13 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD JUL 28 PY 2011 VL 10 AR 209 DI 10.1186/1475-2875-10-209 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 813AU UT WOS:000294338900001 PM 21798054 ER PT J AU Brener, ND Merlo, C Eaton, D Kann, L Park, S Blanck, HM AF Brener, Nancy D. Merlo, Caitlin Eaton, Danice Kann, Laura Park, Sohyun Blanck, Heidi M. TI Beverage Consumption Among High School Students-United States, 2010 (Reprinted from MMWR, vol 60, pg 778-780, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID SUGAR-SWEETENED BEVERAGES; ADOLESCENTS; CHILDREN; DRINKS; ENERGY C1 [Brener, Nancy D.; Merlo, Caitlin; Eaton, Danice; Kann, Laura] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adolescent & Sch Hlth, Atlanta, GA 30333 USA. [Park, Sohyun; Blanck, Heidi M.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. RP Brener, ND (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adolescent & Sch Hlth, Atlanta, GA 30333 USA. EM nbrener@cdc.gov NR 11 TC 1 Z9 1 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 27 PY 2011 VL 306 IS 4 BP 369 EP 371 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 797KL UT WOS:000293125800009 ER PT J AU Lowell, J Higgins, DP Drebot, M Makowski, K Staples, JE AF Lowell, Jennifer Higgins, Denise P. Drebot, Michael Makowski, Kai Staples, J. Erin TI Human Jamestown Canyon Virus Infection-Montana, 2009 (Reprinted from MMWR, vol 60, pg 652-655, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID MOSQUITOS DIPTERA; CONNECTICUT; CULICIDAE C1 [Staples, J. Erin] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Vector Borne Dis, Atlanta, GA 30333 USA. EM jlowell@mt.gov NR 11 TC 0 Z9 0 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 27 PY 2011 VL 306 IS 4 BP 371 EP 376 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 797KL UT WOS:000293125800010 ER PT J AU Yaeger, J Hudecek, P Fritz, CL Gilliss, D Vugia, DJ Inami, G Brenden, RA Adams, JK Bopp, CA Trees, E Hill, V Kahler, A Pringle, J Williams, I Behravesh, CB Bennett, SD Mettee, SL AF Yaeger, Jill Hudecek, Phil Fritz, Curtis L. Gilliss, Debra Vugia, Duc J. Inami, Gregory Brenden, Rita A. Adams, Jennifer K. Bopp, Cheryl A. Trees, Eija Hill, Vincent Kahler, Amy Pringle, Jeshua Williams, Ian Behravesh, Casey Barton Bennett, Sarah D. Mettee, Shauna L. TI Notes From the Field: Update on Human Salmonella Typhimurium Infections Associated With Aquatic Frogs-United States, 2009-2011 (Reprinted) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Bennett, Sarah D.; Mettee, Shauna L.] CDC, Atlanta, GA 30333 USA. RP Bennett, SD (reprint author), CDC, Atlanta, GA 30333 USA. EM sbennett@cdc.gov NR 2 TC 0 Z9 0 U1 3 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 27 PY 2011 VL 306 IS 4 BP 376 EP 376 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 797KL UT WOS:000293125800011 ER PT J AU Fulton, JE Carroll, DD Galuska, DA Lee, SM Eaton, DK Brener, ND Song, M AF Fulton, Janet E. Carroll, Dianna D. Galuska, Deborah A. Lee, Sarah M. Eaton, Danice K. Brener, Nancy D. Song, MinKyoung TI Physical Activity Levels of High School Students-United States, 2010 (Reprinted from MMWR, vol 60, pg 773-777, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Song, MinKyoung] CDC, Atlanta, GA 30333 USA. RP Song, M (reprint author), CDC, Atlanta, GA 30333 USA. EM msong@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 27 PY 2011 VL 306 IS 4 BP 367 EP 369 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 797KL UT WOS:000293125800008 ER PT J AU Said, MA O'Brien, KL Nuorti, JP Singleton, R Whitney, CG Hennessy, TW AF Said, Maria A. O'Brien, Katherine L. Nuorti, J. Pekka Singleton, Rosalyn Whitney, Cynthia G. Hennessy, Thomas W. TI The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations SO VACCINE LA English DT Article DE Streptococcus pneumoniae; 23-Valent pneumococcal polysaccharide vaccine; Native American; Pneumococcus; Alaska Native; American Indian ID INFECTIOUS-DISEASE HOSPITALIZATIONS; INVASIVE STREPTOCOCCUS-PNEUMONIAE; SMOKELESS TOBACCO USE; CONJUGATE VACCINE; RISK-FACTORS; UNITED-STATES; NAVAJO ADULTS; GENERAL-POPULATION; CIGARETTE-SMOKING; CHILDREN YOUNGER AB Alaska Native and some American Indian (AI/AN) populations suffer disproportionately high rates of invasive pneumococcal disease (IPD) in both the pediatric and adult populations compared to the general U.S. population. Two pneumococcal vaccines are currently available in the U.S.: a 23-valent pneumococcal polysaccharide vaccine (PPSV23), available since 1983 and recommended for the elderly and those over 2 years of age with underlying medical conditions, and a 13-valent pneumococcal conjugate vaccine (PCV13), used in the routine infant immunization schedule since 2010. The U.S. Advisory Committee on Immunization Practice (ACIP) previously recommended use of PPSV23 for persons living in special environments or social settings, including AN and certain AI persons 2-64 years of age, on the basis of higher disease rates. The recommendation for routine PPSV23 use among AI/AN persons <65 years of age, regardless of underlying conditions, was removed in 2008, although the option for use among those 50-64 years of age living in areas with high pneumococcal disease rates was maintained. The rationale for the revised recommendations lay in the recognition that much of the excess disease burden occurs among those with an existing medical indication for PPSV23. Other considerations for the change were the potential risks of giving multiple PPSV23 doses and the considerable heterogeneity in pneumococcal disease risk among American Indian populations requiring a more tailored approach to local recommendations based on local epidemiology. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Said, Maria A.; O'Brien, Katherine L.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Amer Indian Hlth, Baltimore, MD 21205 USA. [Nuorti, J. Pekka; Whitney, Cynthia G.] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Singleton, Rosalyn] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. [Hennessy, Thomas W.] Ctr Dis Control & Prevent, Arct Invest Program, Natl Ctr Emerging & Zoonot Dis, Anchorage, AK USA. RP Said, MA (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Amer Indian Hlth, 621N Washington St, Baltimore, MD 21205 USA. EM said.maria@gmail.com FU Pfizer FX Katherine O'Brien, Rosalyn Singleton and the CDC Arctic Investigations Program have received research grant funding from Pfizer. NR 89 TC 8 Z9 8 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JUL 26 PY 2011 VL 29 IS 33 BP 5355 EP 5362 DI 10.1016/j.vaccine.2011.05.086 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 805XV UT WOS:000293765300004 PM 21664217 ER PT J AU Johansson, MA Arana-Vizcarrondo, N Biggerstaff, BJ Staples, JE Gallagher, N Marano, N AF Johansson, Michael A. Arana-Vizcarrondo, Neysari Biggerstaff, Brad J. Staples, J. Erin Gallagher, Nancy Marano, Nina TI On the Treatment of Airline Travelers in Mathematical Models SO PLOS ONE LA English DT Article ID AEDES-AEGYPTI DIPTERA; INFECTIOUS-DISEASES; PANDEMIC INFLUENZA; UNITED-STATES; AIR-TRAVEL; HONG-KONG; SPREAD; SURVEILLANCE; DENGUE; IMPACT AB The global spread of infectious diseases is facilitated by the ability of infected humans to travel thousands of miles in short time spans, rapidly transporting pathogens to distant locations. Mathematical models of the actual and potential spread of specific pathogens can assist public health planning in the case of such an event. Models should generally be parsimonious, but must consider all potentially important components of the system to the greatest extent possible. We demonstrate and discuss important assumptions relative to the parameterization and structural treatment of airline travel in mathematical models. Among other findings, we show that the most common structural treatment of travelers leads to underestimation of the speed of spread and that connecting travel is critical to a realistic spread pattern. Models involving travelers can be improved significantly by relatively simple structural changes but also may require further attention to details of parameterization. C1 [Johansson, Michael A.; Arana-Vizcarrondo, Neysari] Ctr Dis Control & Prevent, Div Vector Borne Dis, San Juan, PR USA. [Biggerstaff, Brad J.; Staples, J. Erin] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. [Gallagher, Nancy; Marano, Nina] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. RP Johansson, MA (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, San Juan, PR USA. EM mjohansson@cdc.gov NR 33 TC 9 Z9 9 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 25 PY 2011 VL 6 IS 7 AR e22151 DI 10.1371/journal.pone.0022151 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 798AP UT WOS:000293172900013 PM 21799782 ER PT J AU Sable, SB Cheruvu, M Nandakumar, S Sharma, S Bandyopadhyay, K Kellar, KL Posey, JE Plikaytis, BB Amara, RR Shinnick, TM AF Sable, Suraj B. Cheruvu, Mani Nandakumar, Subhadra Sharma, Sunita Bandyopadhyay, Kakali Kellar, Kathryn L. Posey, James E. Plikaytis, Bonnie B. Amara, Rama Rao Shinnick, Thomas M. TI Cellular Immune Responses to Nine Mycobacterium tuberculosis Vaccine Candidates following Intranasal Vaccination SO PLOS ONE LA English DT Article ID BACILLUS-CALMETTE-GUERIN; CD8(+) T-CELLS; 45/47-KILODALTON ANTIGEN COMPLEX; FIBRONECTIN ATTACHMENT PROTEIN; BOVIS BCG; PROTECTIVE EFFICACY; PULMONARY TUBERCULOSIS; MUCOSAL IMMUNIZATION; DENDRITIC CELLS; VIRUS ANKARA AB Background: The identification of Mycobacterium tuberculosis vaccines that elicit a protective immune response in the lungs is important for the development of an effective vaccine against tuberculosis. Methods and Principal Findings: In this study, a comparison of intranasal (i.n.) and subcutaneous (s.c.) vaccination with the BCG vaccine demonstrated that a single moderate dose delivered intranasally induced a stronger and sustained M. tuberculosis-specific T-cell response in lung parenchyma and cervical lymph nodes of BALB/c mice than vaccine delivered subcutaneously. Both BCG and a multicomponent subunit vaccine composed of nine M. tuberculosis recombinant proteins induced strong antigen-specific T-cell responses in various local and peripheral immune compartments. Among the nine recombinant proteins evaluated, the alanine proline rich antigen (Apa, Rv1860) was highly antigenic following i.n. BCG and immunogenic after vaccination with a combination of the nine recombinant antigens. The Apa-induced responses included induction of both type 1 and type 2 cytokines in the lungs as evaluated by ELISPOT and a multiplexed microsphere-based cytokine immunoassay. Of importance, i.n. subunit vaccination with Apa imparted significant protection in the lungs and spleen of mice against M. tuberculosis challenge. Despite observed differences in the frequencies and location of specific cytokine secreting T cells both BCG vaccination routes afforded comparable levels of protection in our study. Conclusion and Significance: Overall, our findings support consideration and further evaluation of an intranasally targeted Apa-based vaccine to prevent tuberculosis. C1 [Sable, Suraj B.; Cheruvu, Mani; Nandakumar, Subhadra; Posey, James E.; Plikaytis, Bonnie B.; Shinnick, Thomas M.] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Sharma, Sunita; Amara, Rama Rao] Emory Univ, Dept Microbiol & Immunol, Emory Vaccine Ctr, Atlanta, GA 30322 USA. [Sharma, Sunita; Amara, Rama Rao] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA. [Bandyopadhyay, Kakali; Kellar, Kathryn L.] Ctr Dis Control & Prevent, Biotechnol Core Facil Branch, Div Sci Resources, Atlanta, GA USA. RP Sable, SB (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM ssable@cdc.gov RI Nandakumar, Subhadra/F-5892-2011; OI Sable, Suraj/0000-0001-8440-1693 FU National Centers for Infectious Diseases, CDC, USA; ASM-NCID; ORISE FX This work was carried out at the Laboratory Branch, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, and is supported by intramural funds. Part of this work was performed during an American Society for Microbiology and National Centers for Infectious Diseases, CDC, USA, fellowship to SBS, for which TMS served as the preceptor. MC and SN acknowledge the postdoctoral financial assistance from ASM-NCID and ORISE fellowships, respectively. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 66 TC 13 Z9 13 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 25 PY 2011 VL 6 IS 7 AR e22718 DI 10.1371/journal.pone.0022718 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 798AP UT WOS:000293172900071 PM 21799939 ER PT J AU Helfrich, CD Blevins, D Smith, JL Kelly, PA Hogan, TP Hagedorn, H Dubbert, PM Sales, AE AF Helfrich, Christian D. Blevins, Dean Smith, Jeffrey L. Kelly, P. Adam Hogan, Timothy P. Hagedorn, Hildi Dubbert, Patricia M. Sales, Anne E. TI Predicting implementation from organizational readiness for change: a study protocol SO IMPLEMENTATION SCIENCE LA English DT Article ID HEPATITIS PREVENTION SERVICES; CHRONIC LIVER-DISEASE; PRIMARY-CARE; ATYPICAL ANTIPSYCHOTICS; SCHIZOPHRENIA; MODEL; DEPRESSION; CLINICS; RISK; INSTRUMENTS AB Background: There is widespread interest in measuring organizational readiness to implement evidence-based practices in clinical care. However, there are a number of challenges to validating organizational measures, including inferential bias arising from the halo effect and method bias - two threats to validity that, while well-documented by organizational scholars, are often ignored in health services research. We describe a protocol to comprehensively assess the psychometric properties of a previously developed survey, the Organizational Readiness to Change Assessment. Objectives: Our objective is to conduct a comprehensive assessment of the psychometric properties of the Organizational Readiness to Change Assessment incorporating methods specifically to address threats from halo effect and method bias. Methods and Design: We will conduct three sets of analyses using longitudinal, secondary data from four partner projects, each testing interventions to improve the implementation of an evidence-based clinical practice. Partner projects field the Organizational Readiness to Change Assessment at baseline (n = 208 respondents; 53 facilities), and prospectively assesses the degree to which the evidence-based practice is implemented. We will conduct predictive and concurrent validities using hierarchical linear modeling and multivariate regression, respectively. For predictive validity, the outcome is the change from baseline to follow-up in the use of the evidence-based practice. We will use intra-class correlations derived from hierarchical linear models to assess inter-rater reliability. Two partner projects will also field measures of job satisfaction for convergent and discriminant validity analyses, and will field Organizational Readiness to Change Assessment measures at follow-up for concurrent validity (n = 158 respondents; 33 facilities). Convergent and discriminant validities will test associations between organizational readiness and different aspects of job satisfaction: satisfaction with leadership, which should be highly correlated with readiness, versus satisfaction with salary, which should be less correlated with readiness. Content validity will be assessed using an expert panel and modified Delphi technique. Discussion: We propose a comprehensive protocol for validating a survey instrument for assessing organizational readiness to change that specifically addresses key threats of bias related to halo effect, method bias and questions of construct validity that often go unexplored in research using measures of organizational constructs. C1 [Helfrich, Christian D.] VA Puget Sound Healthcare Syst, NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. [Helfrich, Christian D.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Blevins, Dean] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Atlanta, GA USA. [Kelly, P. Adam] SE Louisiana Vet Hlth Care Network, Res Serv, New Orleans, LA USA. [Smith, Jeffrey L.] VA Mental Hlth Qual Enhancement Res Initiat, N Little Rock, AR USA. [Hogan, Timothy P.] Edward Hines Jr Vet Affairs Hosp, Ctr Management Complex Chron Care, eHlth Qual Enhancement Res Initiat, Hines, IL USA. [Hogan, Timothy P.] Edward Hines Jr Vet Affairs Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL USA. [Hogan, Timothy P.] Loyola Univ, Stritch Sch Med, Program Hlth Serv Res, Chicago, IL 60611 USA. [Hagedorn, Hildi] Minneapolis VA Healthcare Syst, VA Subst Use Disorders Qual Enhancement Res Initi, Minneapolis, MN USA. [Dubbert, Patricia M.] S Cent VA Mental Illness Res Educ & Clin Ctr MIRE, N Little Rock, AR USA. [Dubbert, Patricia M.] S Cent VA Geriatr Res Educ & Clin Ctr GRECC, N Little Rock, AR USA. [Sales, Anne E.] VA Inpatient Evaluat Ctr, Cincinnati, OH USA. [Sales, Anne E.] VA Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI USA. RP Helfrich, CD (reprint author), VA Puget Sound Healthcare Syst, NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. EM christian.helfrich@va.gov RI Sales, Anne/D-9678-2012; Helfrich, Christian/D-2382-2016; OI Helfrich, Christian/0000-0002-9827-4768; Sales, Anne/0000-0001-9360-3334 FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [IIR 09-067] FX This study has been funded by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service, project grant number IIR 09-067. We wish to thank Rachel Orlando and Penny White for project support for this research study. The views expressed in this article are the authors' and do not necessarily reflect the position or policy of the US Department of Veterans Affairs. NR 80 TC 10 Z9 10 U1 5 U2 27 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD JUL 22 PY 2011 VL 6 AR 76 DI 10.1186/1748-5908-6-76 PG 12 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 808MU UT WOS:000293982600001 PM 21777479 ER PT J AU Skarbinski, J Mwandama, D Luka, M Jafali, J Wolkon, A Townes, D Campbell, C Zoya, J Ali, D Mathanga, DP AF Skarbinski, Jacek Mwandama, Dyson Luka, Madalitso Jafali, James Wolkon, Adam Townes, David Campbell, Carl Zoya, John Ali, Doreen Mathanga, Don P. TI Impact of Health Facility-Based Insecticide Treated Bednet Distribution in Malawi: Progress and Challenges towards Achieving Universal Coverage SO PLOS ONE LA English DT Article ID INTEGRATED CAMPAIGN; MALARIA MORBIDITY; CHILD-MORTALITY; MOSQUITO NETS; TARGET GROUPS; OWNERSHIP; TANZANIA; KENYA; TOGO; DELIVERY AB Background: High levels of insecticide treated bednet (ITN) use reduce malaria burden in countries with intense transmission such as Malawi. Since 2007 Malawi has implemented free health facility-based ITN distribution for pregnant women and children <5 years old (under-5s). We evaluated the progress of this targeted approach toward achieving universal ITN coverage. Methods: We conducted a cross-sectional household survey in eight districts in April 2009. We assessed household ITN possession, ITN use by all household members, and P. falciparum asexual parasitemia and anemia (hemoglobin <11 grams/deciliter) in under-5s. Results: We surveyed 7,407 households containing 29,806 persons. Fifty-nine percent of all households (95% confidence interval [ 95% CI]: 56-62), 67% (95% CI: 64-70) of eligible households (i.e., households with pregnant women or under-5s), and 40% (95% CI: 36-45) of ineligible households owned an ITN. In households with at least one ITN, 76% (95% CI: 74-78) of all household members, 88% (95% CI: 87-90) of under-5s and 90% (95% CI: 85-94) of pregnant women used an ITN the previous night. Of 6,677 ITNs, 92% (95% CI: 90-94) were used the previous night with a mean of 2.4 persons sleeping under each ITN. In multivariable models adjusting for district, socioeconomic status and indoor residual spraying use, ITN use by under-5s was associated with a significant reduction in asexual parasitemia (adjusted odds ratio (aOR) 0.79; 95% CI: 0.640.98; p-value 0.03) and anemia (aOR 0.79; 95% CI 0.62-0.99; p-value 0.04). Of potential targeted and non-targeted mass distribution strategies, a campaign distributing 1 ITN per household might increase coverage to 2.1 household members per ITN, and thus achieve near universal coverage often defined as 2 household members per ITN. Conclusions: Malawi has substantially increased ITN coverage using health facility-based distribution targeting pregnant women and under-5s, but needs to supplement these activities with non-targeted mass distribution campaigns to achieve universal coverage and maximum public health impact. C1 [Mwandama, Dyson; Luka, Madalitso; Jafali, James; Mathanga, Don P.] Univ Malawi Coll Med, Malaria Alert Ctr, Blantyre, Malawi. [Townes, David] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Townes, David] Univ Washington, Div Emergency Med, Seattle, WA 98195 USA. [Campbell, Carl] Univ Georgia, Ctr Trop & Global Emerging Dis, Athens, GA 30602 USA. [Zoya, John; Ali, Doreen] Minist Hlth, Natl Malaria Control Programme, Lilongwe, Malawi. [Mathanga, Don P.] Univ Malawi Coll Med, Dept Community Hlth, Blantyre, Malawi. RP Skarbinski, J (reprint author), Ctr Dis Control & Prevent, Malaria Branch, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA 30329 USA. EM jskarbinski@cdc.gov FU U.S. Agency for International Development, under the terms of an Interagency Agreement with the Centers for Disease Control and Prevention (CDC) [5 U01 CI000189] FX This publication was made possible through support provided by the United States President's Malaria Initiative, U.S. Agency for International Development, under the terms of an Interagency Agreement with the Centers for Disease Control and Prevention (CDC) and through a Cooperative Agreement (Number 5 U01 CI000189) between the CDC and the Malaria Alert Centre, College of Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests: The authors have declared that no competing NR 32 TC 13 Z9 13 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 21 PY 2011 VL 6 IS 7 AR e21995 DI 10.1371/journal.pone.0021995 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 795FA UT WOS:000292956800018 PM 21811553 ER PT J AU Hoffmann, D Garcia, AD Harrigan, PR Johnston, ICD Nakasone, T Garcia-Lerma, JG Heneine, W AF Hoffmann, Dieter Garcia, Albert D. Harrigan, P. Richard Johnston, Ian C. D. Nakasone, Tadashi Garcia-Lerma, J. Gerardo Heneine, Walid TI Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing SO PLOS ONE LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; PHENOTYPIC RESISTANCE; MUTATIONS; EMTRICITABINE; EFAVIRENZ; TENOFOVIR; PLASMA; ASSAY AB Simple and cost-effective approaches for HIV drug-resistance testing are highly desirable for managing increasingly expanding HIV-1 infected populations who initiate antiretroviral therapy (ART), particularly in resource-limited settings. Non-nucleoside reverse trancriptase inhibitor (NNRTI)-based regimens with an NRTI backbone containing lamivudine (3TC) or emtricitabine (FTC) are preferred first ART regimens. Failure with these drug combinations typically involves the selection of NNRTI- and/or 3TC/FTC- resistant viruses. Therefore, the availability of simple assays to measure both types of drug resistance is critical. We have developed a high throughput screening test for assessing enzymatic resistance of the HIV-1 RT in plasma to 3TC/FTC and NNRTIs. The test uses the sensitive "Amp-RT" assay with a newly-developed real-time PCR format to screen biochemically for drug resistance in single reactions containing either 3TC-triphosphate (3TC-TP) or nevirapine (NVP). Assay cut-offs were defined based on testing a large panel of subtype B and non-subtype B clinical samples with known genotypic profiles. Enzymatic 3TC resistance correlated well with the presence of M184I/V, and reduced NVP susceptibility was strongly associated with the presence of K103N, Y181C/I, Y188L, and G190A/Q. The sensitivity and specificity for detecting resistance were 97.0% and 96.0% in samples with M184V, and 97.4% and 96.2% for samples with NNRTI mutations, respectively. We further demonstrate the utility of an HIV capture method in plasma by using magnetic beads coated with CD44 antibody that eliminates the need for ultracentifugation. Thus our results support the use of this simple approach for distinguishing WT from NNRTI- or 3TC/FTC-resistant viruses in clinical samples. This enzymatic testing is subtype-independent and can assist in the clinical management of diverse populations particularly in resource-limited settings. C1 [Hoffmann, Dieter; Garcia, Albert D.; Garcia-Lerma, J. Gerardo; Heneine, Walid] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA. [Harrigan, P. Richard] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada. [Johnston, Ian C. D.] Miltenyi Biotec, Bergisch Gladbach, Germany. [Nakasone, Tadashi] Natl Inst Infect Dis, AIDS Res Ctr, Tokyo, Japan. RP Hoffmann, D (reprint author), Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA. EM hoffmann@virologie.med.tum.de FU CDC FX This study was supported by intramural CDC funds. Dieter Hoffmann was partially supported by an International Emerging Infectious Diseases Fellowship from CDC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study. NR 26 TC 1 Z9 1 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 20 PY 2011 VL 6 IS 7 AR e22019 DI 10.1371/journal.pone.0022019 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 794WE UT WOS:000292931200021 PM 21799767 ER PT J AU Stevens, JA Haas, EN Haileyesus, T AF Stevens, Judy A. Haas, Elizabeth N. Haileyesus, Tadesse TI Nonfatal Bathroom Injuries Among Persons Aged >= 15 Years-United States, 2008 (Reprinted from MMWR vol 60, pg 729-733, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID GENDER-DIFFERENCES; SYNCOPE; ADULTS; FALLS C1 [Stevens, Judy A.; Haas, Elizabeth N.] CDC, Div Unintent Injury Prevent, Atlanta, GA 30333 USA. [Haileyesus, Tadesse] CDC, Off Program & Stat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Stevens, JA (reprint author), CDC, Div Unintent Injury Prevent, Atlanta, GA 30333 USA. EM jas2@cdc.gov NR 11 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 20 PY 2011 VL 306 IS 3 BP 258 EP 260 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 794BS UT WOS:000292870500009 ER PT J AU Lum, FC Hoskins, HD Moorthy, RS Read, RW Starr, MC Montgomery, SP Jones, JL Woodhall, DM AF Lum, Flora C. Hoskins, H. Dunbar, Jr. Moorthy, Ramana S. Read, Russell W. Starr, Michelle C. Montgomery, Susan P. Jones, Jeffrey L. Woodhall, Dana M. TI Ocular Toxocariasis-United States, 2009-2010 (Reprinted from MMWR vol 60, pg 734-736, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID RISK-FACTORS; EPIDEMIOLOGY; PREVALENCE; INFECTION C1 [Woodhall, Dana M.] CDC, Atlanta, GA 30333 USA. [Lum, Flora C.; Hoskins, H. Dunbar, Jr.] Fdn Amer Acad Ophthalmol, Ctr Qual Eye Care, San Francisco, CA USA. [Moorthy, Ramana S.] Indiana Univ Sch Med, South Bend, IN USA. [Read, Russell W.] Univ Alabama, Birmingham, AL USA. RP Woodhall, DM (reprint author), CDC, Atlanta, GA 30333 USA. EM dwoodhall@cdc.gov NR 10 TC 0 Z9 0 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 20 PY 2011 VL 306 IS 3 BP 261 EP 262 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 794BS UT WOS:000292870500010 ER PT J AU Hootman, JM Murphy, LB Helmick, CG Barbour, KE AF Hootman, Jennifer M. Murphy, Louise B. Helmick, Charles G. Barbour, Kamil E. TI Arthritis as a Potential Barrier to Physical Activity Among Adults With Obesity-United States, 2007 and 2009 (Reprinted) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Barbour, Kamil E.] CDC, Atlanta, GA 30333 USA. [Hootman, Jennifer M.; Murphy, Louise B.; Helmick, Charles G.] Natl Ctr Chron Dis Prevent & Hlth Promot, Arthrit Program, Div Adult & Community Hlth, Atlanta, GA USA. RP Barbour, KE (reprint author), CDC, Atlanta, GA 30333 USA. EM kbarbour@cdc.gov NR 0 TC 0 Z9 0 U1 1 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 20 PY 2011 VL 306 IS 3 BP 262 EP 264 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 794BS UT WOS:000292870500011 ER PT J AU Baur, C Ostrove, N AF Baur, Cynthia Ostrove, Nancy TI Testing Rules of Thumb and the Science of Health Literacy SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material C1 [Baur, Cynthia] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Ostrove, Nancy] US FDA, Silver Spring, MD 20993 USA. RP Baur, C (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E21, Atlanta, GA 30333 USA. EM cynthia.baur@cdc.hhs.gov NR 0 TC 2 Z9 2 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUL 19 PY 2011 VL 155 IS 2 BP 129 EP + DI 10.7326/0003-4819-155-2-201107190-00010 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 793KW UT WOS:000292822000021 PM 21768587 ER PT J AU Taha, TE James, MM Hoover, DR Sun, J Laeyendecker, O Mullis, CE Kumwenda, JJ Lingappa, JR Auvert, B Morrison, CS Mofensen, LM Taylor, A Fowler, MG Kumenda, NI Eshleman, SH AF Taha, E. Taha James, Maria M. Hoover, Donald R. Sun, Jin Laeyendecker, Oliver Mullis, Caroline E. Kumwenda, Johnstone J. Lingappa, Jairam R. Auvert, Bertran Morrison, Charles S. Mofensen, Lynne M. Taylor, Allan Fowler, Mary G. Kumenda, Newton I. Eshleman, Susan H. TI Association of recent HIV infection and in-utero HIV-1 transmission SO AIDS LA English DT Article DE HIV; incidence; Malawi; mother-to-child transmission; multiassay algorithm ID CAPTURE ENZYME-IMMUNOASSAY; TO-CHILD TRANSMISSION; PERINATAL TRANSMISSION; PREGNANT-WOMEN; PREVENTION; RISK; AFRICA; TRIAL; RNA; PROPHYLAXIS AB Objective: We previously developed a multiassay algorithm (MAA) to identify recent HIV infection that includes the BED-capture enzyme immunoassay, an avidity assay based on the Genetic Systems HIV-1/HIV-2+O enzyme immunoassay, CD4 cell count, and HIV viral load. We used this MAA to evaluate the association between recent maternal HIV infection and in-utero transmission of HIV. Methods: Plasma samples were collected at delivery from 2561 HIV-infected women in the postexposure prophylaxis of infants-Malawi trial. The MAA described above was used to identify women with recent HIV infection. Logistic regression models assessed association between recent HIV infection and in-utero HIV transmission (defined as a positive infant HIV DNA test at birth). Results: Seventy-three women were identified as recently infected using the MAA. Those women were younger and had lower parity than women who were identified as not recently infected using the MAA (P<0.0001 for age and parity). The frequency of in-utero HIV transmission was 17.8% among women identified as recently infected, compared with 6.7% among women identified as not recently infected (13/73 vs. 166/2488, P = 0.001). In a multivariate model, three factors were independently associated with in-utero HIV transmission: recent infection [adjusted odds ratio (AOR): 2.49, 95% confidence interval (CI): 1.30-4.78, P = 0.006], log(10) HIV viral load at delivery (AOR: 2.01, 95% CI: 1.60-2.51, P<0.0001), and younger age (per 10 year increase, AOR: 0.66, 95% CI: 0.43-0.93, P = 0.02). Conclusion: Results obtained using a MAA suggest that recent maternal HIV acquisition is strongly associated with in-utero HIV transmission, independent of HIV viral load at delivery. (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [James, Maria M.; Fowler, Mary G.; Eshleman, Susan H.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA. [Taha, E. Taha; Sun, Jin; Kumenda, Newton I.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA. [Hoover, Donald R.] Rutgers State Univ, Dept Stat & Biostat, Piscataway, NJ USA. [Hoover, Donald R.] Rutgers State Univ, Inst Hlth Healthcare Policy & Aging Res, Piscataway, NJ USA. [Laeyendecker, Oliver] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA. [Laeyendecker, Oliver; Mullis, Caroline E.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Kumwenda, Johnstone J.] Univ Malawi, Dept Med, Coll Med, Blantyre, Malawi. [Lingappa, Jairam R.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Lingappa, Jairam R.] Univ Washington, Dept Med, Seattle, WA USA. [Lingappa, Jairam R.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Auvert, Bertran] INSERM, U1018, CESP, Villejuif, France. [Auvert, Bertran] Hop Ambroise Pare, AP HP, Boulogne, France. [Auvert, Bertran] Univ Versailles, Guyancourt, France. [Morrison, Charles S.] Family Hlth Int, Clin Sci, Durham, NC USA. [Mofensen, Lynne M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Adolescent & Maternal AIDS Branch, NIH, Rockville, MD USA. [Taylor, Allan] Ctr Dis Control & Prevent, Epidemiol Branch, Div HIV AIDS Prevent, Atlanta, GA USA. RP Eshleman, SH (reprint author), Johns Hopkins Univ, Sch Med, Dept Pathol, Ross Bldg,Room 646,720 Rutland Ave, Baltimore, MD 21205 USA. EM seshlem@jhmi.edu RI Laeyendecker, Oliver/B-9331-2009; OI Laeyendecker, Oliver/0000-0002-6429-4760 FU International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group [U01-AI068633]; American Recovery and Reinvestment Act award [3U01AI068632-05S3]; National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH); National Institute on Drug Abuse, National Institutes of Health (NIH); National Institute of Mental Health, National Institutes of Health (NIH); Office of AIDS Research, National Institutes of Health (NIH); Department of Health and Human Services (DHHS) [U01AI068613]; Centers for Disease Control and Prevention [U50/CCU022061]; Partners in Prevention HSV/HIV Transmission Study [26469]; Hormonal Contraception and HIV Acquisition (HC-HIV) Study [N01-HD-0-3310]; Division of Intramural Research, NIAID, NIH FX The sources of support are as follows: First, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group, American Recovery and Reinvestment Act award (cooperative agreement 3U01AI068632-05S3). Second, The HPTN sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute on Drug Abuse, the National Institute of Mental Health, and the Office of AIDS Research, of the National Institutes of Health (NIH), Department of Health and Human Services (DHHS) (U01AI068613). Third, The Centers for Disease Control and Prevention (cooperative agreement U50/CCU022061). Fourth, IMPAACT Group (U01-AI068633). Fifth, The Partners in Prevention HSV/HIV Transmission Study (grant #26469, Bill and Melinda Gates Foundation). Sixth, the Hormonal Contraception and HIV Acquisition (HC-HIV) Study (contract N01-HD-0-3310 through Family Health International, The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH, DHHS). Seventh, The Division of Intramural Research, NIAID, NIH. NR 43 TC 10 Z9 10 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD JUL 17 PY 2011 VL 25 IS 11 BP 1357 EP 1364 DI 10.1097/QAD.0b013e3283489d45 PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 784UO UT WOS:000292183900002 PM 21572305 ER PT J AU Jaffe, HW De Stavola, BL Carpenter, LM Porter, K Cox, DR AF Jaffe, Harold W. De Stavola, Bianca L. Carpenter, Lucy M. Porter, Kholoud Cox, David R. CA CASCADE Collaboration TI Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults SO AIDS LA English DT Article DE HAART; immune reconstitution inflammatory syndrome; Kaposi sarcoma; non-Hodgkin lymphoma ID POTENT ANTIRETROVIRAL THERAPY; INFLAMMATORY SYNDROME; INITIATION AB Objective: Given the well documented occurrence of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients who recently started combination antiretroviral therapy (cART), we examined whether cART initiation increased the risk of Kaposi sarcoma and non-Hodgkin lymphoma (NHL) using data from the Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE) collaboration. Design: A nested matched case-control study design was used to assess the effects of individual CD4 cell trajectories and exposure to cART close to the time of cancer diagnosis. Methods: Cases were patients diagnosed with either cancer during follow-up with a minimum of two consecutive CD4 cell readings within the year preceding diagnosis. For each case, up to 10 controls, matched by sex and cohort, were selected by random sampling. Changes in CD4 cell count, calculated by simple and piecewise linear regression, and recent exposure to cART were compared within matched case-control sets using conditional logistic regression. Results: Using data on 689 cases and 4588 controls, we found that an initially low and decreasing CD4 cell count during the year prior to cancer diagnosis is predictive of both Kaposi sarcoma and NHL. Most of this cancer risk is explained by the immunodeficiency characteristic of the period before cART initiation; however, an increased cancer risk was seen in patients who initiated cART in the previous 3 months (odds ratio 2.31; 95% confidence interval 1.33, 4.00). Conclusion: Although IRIS may transiently increase the risk of Kaposi sarcoma or NHL in HIV-infected patients, the timely initiation of cART remains the best strategy to avoid the development of these malignancies. (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Jaffe, Harold W.] Univ Oxford, Dept Publ Hlth, Oxford, England. [De Stavola, Bianca L.] London Sch Hyg & Trop Med, Dept Med Stat, London WC1, England. [Carpenter, Lucy M.; Cox, David R.] Univ Oxford Nuffield Coll, Oxford OX1 1NF, England. [Porter, Kholoud] MRC, Clin Trials Unit, London, England. RP Jaffe, HW (reprint author), Ctr Dis Control & Prevent, MS D-14,1600 Clifton Rd, Atlanta, GA 30333 USA. EM hwj1@cdc.gov RI SHCS, int. coll. B/G-4090-2011; SHCS, all/G-4072-2011; lutsar, irja/H-3177-2015; REZZA, GIOVANNI/D-4393-2016; DEL AMO VALERO, JULIA/M-7020-2015; OI REZZA, GIOVANNI/0000-0003-0268-6790; DEL AMO VALERO, JULIA/0000-0002-3104-540X; Muga, Roberto/0000-0001-6301-431X FU European Union [FP7/2007-2013, 260694] FX The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under EuroCoord grant agreement number 260694. NR 23 TC 18 Z9 19 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD JUL 17 PY 2011 VL 25 IS 11 BP 1395 EP 1403 DI 10.1097/QAD.0b013e3283489c8b PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 784UO UT WOS:000292183900007 PM 21572307 ER PT J AU Abernathy, ES Hubschen, JM Muller, CP Jin, L Brown, D Komase, K Mori, Y Xu, WB Zhu, Z Siqueira, MM Shulga, S Tikhonova, N Pattamadilok, S Incomserb, P Smit, SB Akoua-Koffi, C Bwogi, J Lim, WWL Woo, GKS Triki, H Jee, Y Mulders, MN de Filippis, AMB Ahmed, H Ramamurty, N Featherstone, D Icenogle, JP AF Abernathy, Emily S. Huebschen, Judith M. Muller, Claude P. Jin, Li Brown, David Komase, Katsuhiro Mori, Yoshio Xu, Wenbo Zhu, Zhen Siqueira, Marilda M. Shulga, Sergey Tikhonova, Nina Pattamadilok, Sirima Incomserb, Patcha Smit, Sheilagh B. Akoua-Koffi, Chantal Bwogi, Josephine Lim, Wilina W. L. Woo, Gibson K. S. Triki, Hinda Jee, Youngmee Mulders, Mick N. de Filippis, Ana Maria Bispo Ahmed, Hinda Ramamurty, Nalini Featherstone, David Icenogle, Joseph P. TI Status of Global Virologic Surveillance for Rubella Viruses SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID PHYLOGENETIC ANALYSIS; MEASLES; EPIDEMIOLOGY; TRANSMISSION; CIRCULATION; ELIMINATION; POLIOVIRUS; OUTBREAK AB The suspected measles case definition captures rubella cases. Therefore, measles surveillance will be improved in the course of the control and eventual elimination of rubella transmission. One aspect of rubella control, virologic surveillance, is reviewed here. A systematic nomenclature for rubella viruses (RVs) based on 13 genotypes has been established and is updated when warranted by increases in information about RVs. From 2005 through 2010, the genotypes of RVs most frequently reported were 1E, 1G, and 2B, and genotypes 1a, 1B, 1C, 1h, 1j, and 2C were less frequently reported. Virologic surveillance can support rubella control and elimination. Synopses of rubella virologic surveillance in various countries, regions, and globally are given, including characterization of viruses from imported cases in a country that has eliminated rubella and studies of endemic viruses circulating in countries without rubella control objectives. Current challenges are discussed. C1 [Abernathy, Emily S.; Icenogle, Joseph P.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Huebschen, Judith M.; Muller, Claude P.] Ctr Rech Publ Sante, Lab Natl Sante, Inst Immunol, Luxembourg, Luxembourg. [Jin, Li; Brown, David] Hlth Protect Agcy, Ctr Infect, Virus Reference Dept, London, England. [Komase, Katsuhiro; Mori, Yoshio] Natl Inst Infect Dis, Dept Virol 3, Tokyo, Japan. [Xu, Wenbo; Zhu, Zhen] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China. [Siqueira, Marilda M.] Minist Hlth, Oswaldo Cruz Fdn, Inst Oswaldo Cruz, Measles Natl Reference Lab, Rio De Janeiro, Brazil. [Shulga, Sergey; Tikhonova, Nina] Gabricheysky GN Res Inst Epidemiol & Microbiol, Moscow, Russia. [Pattamadilok, Sirima; Incomserb, Patcha] Natl Inst Hlth, Dept Med Sci, Nonthaburi, Thailand. [Smit, Sheilagh B.] Natl Inst Communicable Dis, Johannesburg, South Africa. [Akoua-Koffi, Chantal] Inst Pasteur Cote dIvoire, Reg Reference Lab Measles Rubella, Abidjan, Cote Ivoire. [Bwogi, Josephine] Minist Hlth, Expanded Program Immunizat Lab, Uganda Virus Res Inst, Entebbe, Uganda. [Lim, Wilina W. L.; Woo, Gibson K. S.] Ctr Hlth Protect, Publ Hlth Lab Serv, Dept Hlth, Kowloon, Hong Kong, Peoples R China. [Triki, Hinda] Inst Pateur Tunis, Lab Clin Virol, Tunis, Tunisia. [Jee, Youngmee] World Hlth Org WHO Reg Off Western Pacific, Manila, Philippines. [Mulders, Mick N.] WHO Reg Off Europe, Copenhagen, Denmark. [de Filippis, Ana Maria Bispo] WHO, Pan Amer Hlth Org, Washington, DC USA. [Ahmed, Hinda] WHO Reg Off Eastern Mediterranean, Cairo, Egypt. [Ramamurty, Nalini] WHO Reg Off SE Asia, New Delhi, India. [Featherstone, David] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. RP Icenogle, JP (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,Mail Stop C-22, Atlanta, GA 30333 USA. EM jci1@cdc.gov FU Centers for Disease Control and Prevention FX This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention. NR 48 TC 28 Z9 31 U1 0 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S524 EP S532 DI 10.1093/infdis/jir099 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600067 PM 21666209 ER PT J AU Bankamp, B Takeda, M Zhang, Y Xu, WB Rota, PA AF Bankamp, Bettina Takeda, Makoto Zhang, Yan Xu, Wenbo Rota, Paul A. TI Genetic Characterization of Measles Vaccine Strains SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID VIRUS-V-PROTEIN; SUBACUTE SCLEROSING-PANENCEPHALITIS; DEFECTIVE INTERFERING PARTICLES; AMINO-ACID CHANGE; ACTIVATION MOLECULE SLAM; CD46 DOWN-REGULATION; VIRAL-RNA SYNTHESIS; C-TERMINAL DOMAIN; WILD-TYPE STRAINS; USE RECEPTOR CD46 AB The complete genomic sequences of 9 measles vaccine strains were compared with the sequence of the Edmonston wild-type virus. AIK-C, Moraten, Rubeovax, Schwarz, and Zagreb are vaccine strains of the Edmonston lineage, whereas CAM-70, Changchun-47, Leningrad-4 and Shanghai-191 were derived from 4 different wild-type isolates. Nucleotide substitutions were found in the noncoding regions of the genomes as well as in all coding regions, leading to deduced amino acid substitutions in all 8 viral proteins. Although the precise mechanisms involved in the attenuation of individual measles vaccines remain to be elucidated, in vitro assays of viral protein functions and recombinant viruses with defined genetic modifications have been used to characterize the differences between vaccine and wild-type strains. Although almost every protein contributes to an attenuated phenotype, substitutions affecting host cell tropism, virus assembly, and the ability to inhibit cellular antiviral defense mechanisms play an especially important role in attenuation. C1 [Bankamp, Bettina; Rota, Paul A.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Takeda, Makoto] Natl Inst Infect Dis, Dept Virol 3, Tokyo, Japan. [Xu, Wenbo] China Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China. RP Bankamp, B (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd,MS C-22, Atlanta, GA 30333 USA. EM bbankamp@cdc.gov FU Centers for Disease Control and Prevention FX This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention. NR 206 TC 25 Z9 26 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S533 EP S548 DI 10.1093/infdis/jir097 PG 16 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600068 PM 21666210 ER PT J AU Cairns, KL Perry, RT Ryman, TK Nandy, RK Grais, RF AF Cairns, K. Lisa Perry, Robert T. Ryman, Tove K. Nandy, Robin K. Grais, Rebecca F. TI Should Outbreak Response Immunization Be Recommended for Measles Outbreaks in Middle- and Low-Income Countries? An Update SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID MARSHALL-ISLANDS; VACCINATION; TRANSMISSION; NIGER; EPIDEMIC; EXPOSURE; NIAMEY; INTERRUPTION; POPULATION; EXPERIENCE AB Background. Measles caused mortality in >164,000 children in 2008, with most deaths occurring during outbreaks. Nonetheless, the impact and desirability of conducting measles outbreak response immunization (ORI) in middle- and low-income countries has been controversial. World Health Organization guidelines published in 1999 recommended against ORI in such settings, although recently these guidelines have been reversed for countries with measles mortality reduction goals. Methods. We searched literature published during 1995-2009 for papers reporting on measles outbreaks. Papers identified were reviewed by 2 reviewers to select those that mentioned ORI. World Bank classification of country income was used to identify reports of outbreaks in middle- and low-income countries. Results. We identified a total of 485 articles, of which 461 (95%) were available. Thirty-eight of these papers reported on a total of 38 outbreaks in which OR1 was used. ORI had a clear impact in 16 (42%) of these outbreaks. In the remaining outbreaks, we were unable to independently assess the impact of ORI. Conclusions. These findings generally support ORI in middle- and low-income countries. However, the decision to conduct ORI and the nature and extent of the vaccination response need to be made on a case-by-case basis. C1 [Cairns, K. Lisa; Perry, Robert T.; Ryman, Tove K.] US Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. [Nandy, Robin K.] UNICEF, New York, NY USA. [Grais, Rebecca F.] Epicentre, Paris, France. RP Cairns, KL (reprint author), MS E-05,1600 Clifton Rd, Atlanta, GA 30306 USA. EM kfc4@cdc.gov FU Centers for Disease Control and Prevention FX This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention. NR 57 TC 7 Z9 9 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S35 EP S46 DI 10.1093/infdis/jir072 PG 12 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600007 PM 21666184 ER PT J AU Cochi, SL AF Cochi, Stephen L. CA World Hlth Org TI Proceedings of the Global Technical Consultation to Assess the Feasibility of Measles Eradication, 28-30 July 2010 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material C1 [Cochi, Stephen L.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. RP Cochi, SL (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, Mailstop E-05,1600 Clifton Rd, Atlanta, GA 30333 USA. EM slc1@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S4 EP S13 DI 10.1093/infdis/jir100 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600002 ER PT J AU El Sayed, N Kandeel, N Barakat, I Moussa, I Alexander, JP Naouri, B Reef, SE AF El Sayed, N. Kandeel, N. Barakat, I. Moussa, I. Alexander, J. P., Jr. Naouri, B. Reef, S. E. TI Progress Toward Measles and Rubella Elimination in Egypt SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC AB Measles and rubella were common infectious diseases in Egypt during the prevaccine era. Monovalent measles vaccine was introduced in 1977, and measles vaccination coverage increased from <50% to >90% from 1980 to 1999; however, measles outbreaks continued to occur at 2- to 4-year intervals during this period. After the introduction of a second routine dose of measles vaccine as a combined measles-mumps-rubella (MMR) vaccine in 1999 and the implementation of measles immunization campaigns targeting 6- to 16-year-old children during 2000-2003, reported measles cases dramatically decreased by 2003. In 2002, Egypt established a goal to eliminate measles and rubella and to prevent congenital rubella syndrome (CRS) by 2010. Large-scale rubella and measles outbreaks in 2005-2007, however, led to a revision of the plan of action to achieve the 2010 goals. A nation-wide measles-rubella immunization campaign, targeting children, adolescents, and young adults 2-20 years old, was conducted in 2 phases during 2008-2009 and achieved coverage >95%. With the decrease to record low levels of cases of measles and rubella in 2009 and 2010, Egypt should achieve measles and rubella elimination in the near future, but high coverage(>95%) with 2 doses of measles rubella vaccine needs to be maintained, measles-rubella surveillance strengthened, and CRS surveillance developed. C1 [Alexander, J. P., Jr.; Reef, S. E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Kandeel, N.] Endem Dis & Cent Labs, Baghdad, Iraq. [Naouri, B.] World Hlth Org, Reg Off Eastern Mediterranean, Cairo, Egypt. RP Reef, SE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,NE,Mailstop E-05, Atlanta, GA 30333 USA. EM ser2@cdc.gov FU Egyptian Ministry of Health, Measles Initiative; World Health Organization; UNICEF; CDC; Centers for Disease Control and Prevention FX Financial support for the work presented in this article was provided by Egyptian Ministry of Health, Measles Initiative, World Health Organization, UNICEF, and CDC.; This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention. NR 14 TC 4 Z9 4 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S318 EP S324 DI 10.1093/infdis/jir123 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600041 PM 21666180 ER PT J AU Featherstone, DA Rota, PA Icenogle, J Mulders, MN Jee, Y Ahmed, H de Filippis, AMB Ramamurty, N Gavrilin, E Byabamazima, C Dosseh, A Xu, WB Komase, K Tashiro, M Brown, D Bellini, WJ Strebel, P AF Featherstone, David A. Rota, Paul A. Icenogle, Joseph Mulders, Mick N. Jee, Youngmee Ahmed, Hinda de Filippis, Ana Maria Bispo Ramamurty, Nalini Gavrilin, Eugene Byabamazima, Charles Dosseh, Annick Xu, Wenbo Komase, Katsuhiro Tashiro, Masato Brown, David Bellini, William J. Strebel, Peter TI Expansion of the Global Measles and Rubella Laboratory Network 2005-09 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID IMMUNOGLOBULIN-M; ENZYME IMMUNOASSAYS; ORAL FLUID; DIAGNOSIS; SURVEILLANCE; ROTAVIRUS; VACCINES; VIRUSES; SAMPLES AB Enhancing measles surveillance with integration of epidemiologic and laboratory information is one of the key strategies for accelerated measles control and elimination. The World Health Organization (WHO) Global Measles and Rubella Laboratory Network (LabNet) has been developed since 2000 to currently include 690 laboratories serving 183 countries. The LabNet testing strategy follows well-validated, standardized procedures for confirming suspected cases and for monitoring measles and rubella virus transmission patterns. The strength of the LabNet is a strong quality assurance program that monitors the performance of all laboratories through annual proficiency testing and continuous assessment. In the 5-year period 2005-2009, the results of >1 million measles immunoglobulin M (IgM) tests have been reported by the LabNet and, in addition, sequence information on >7000 measles and 600 rubella viruses has been shared. Progress with the development of the LabNet during 2005-2009 is discussed. C1 [Featherstone, David A.] WHO, Expanded Programme Immunizat, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. [Rota, Paul A.; Icenogle, Joseph; Bellini, William J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mulders, Mick N.; Gavrilin, Eugene] WHO Reg Off Europe, Copenhagen, Denmark. [Jee, Youngmee] WHO Reg Off Western Pacific, Manila, Philippines. [Ahmed, Hinda] WHO Reg Off Eastern Mediterranean, Cairo, Egypt. [de Filippis, Ana Maria Bispo] PAHO, Washington, DC USA. [Ramamurty, Nalini] WHO SEARO, Delhi, India. [Byabamazima, Charles] WHO AFRO, Harare, Zimbabwe. [Dosseh, Annick] WHO Reg Off Africa, Ouagadougou, Burkina Faso. [Xu, Wenbo] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China. [Komase, Katsuhiro; Tashiro, Masato] Natl Inst Infect Dis, Dept Virol, Tokyo, Japan. [Brown, David] Hlth Protect Agcy, London, England. RP Featherstone, DA (reprint author), WHO, Expanded Programme Immunizat, Dept Immunizat Vaccines & Biol, Ave Appia 20, CH-1211 Geneva, Switzerland. EM featherstoned@who.int FU Centers for Disease Control and Prevention [CDC PMS U66/IP000161-03] FX This article is part of a supplement entitled ''Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention.; The development of the LabNet is supported in part by a grant (CDC PMS U66/IP000161-03) from the Centers for Disease Control and Prevention. NR 35 TC 26 Z9 28 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S491 EP S498 DI 10.1093/infdis/jir107 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600063 PM 21666205 ER PT J AU Fowlkes, A Witte, D Beeler, J Audet, S Garcia, P Curns, A Yang, CF Fudzulani, R Broadhead, R Bellini, WJ Cutts, F Helfand, RF AF Fowlkes, Ashley Witte, Desiree Beeler, Judy Audet, Susette Garcia, Philip Curns, Aaron Yang, Chunfu Fudzulani, Richard Broadhead, Robin Bellini, William J. Cutts, Felicity Helfand, Rita F. TI Persistence of Vaccine-Induced Measles Antibody Beyond Age 12 Months: A Comparison of Response to One and Two Doses of Edmonston-Zagreb Measles Vaccine Among HIV-Infected and Uninfected Children in Malawi SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID ZAMBIAN CHILDREN; 6-MONTH-OLD INFANTS; NEUTRALIZATION TEST; PLACENTAL-TRANSFER; IMMUNOGENICITY; IMMUNIZATION; IMMUNITY; MOTHERS; STRAIN; TITERS AB Background. Previously, we demonstrated that measles antibody prevalence was lower at age 12 months among children infected with human immunodeficiency virus (HIV) than uninfected children following measles vaccination (MV) at ages 6 and 9 months. Among HIV-uninfected children, measles antibody prevalence was lower among 1- than 2-dose MV recipients. Here, we report results through age 24 months. Methods. Children born to HIV-infected mothers received MV at 6 and 9 months, and children of HIV-uninfected mothers were randomized to MV at 6 and 9 months or MV at 9 months. We followed children through age 24 months. The child's HIV status was determined and measles immunoglobulin G (IgG) level was measured by enzyme immunoassay (PIA) and by plaque reduction neutralization (PRN) on a subset. Results. Among HIV-uninfected children, the difference in measles antibody prevalence at age 12 months between one- and two-dose recipients reported previously by EIA was shown to be smaller by PRN. By age 24 months, 84% and 87% of HIV-uninfected children receiving 1 or 2 doses, respectively, were seroprotected. Only 41% of 22 HIV-infected children were measles seroprotected at age 20 months. Discussion. Measles seroprotection persisted through age 24 months among HIV-uninfected children who received 1 or 2 doses of MV. HIV-infected children demonstrated seroprotection through age 12 months, but this was not sustained. C1 [Fowlkes, Ashley; Garcia, Philip; Curns, Aaron; Yang, Chunfu; Bellini, William J.; Helfand, Rita F.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Witte, Desiree; Fudzulani, Richard; Broadhead, Robin] Univ Malawi, Coll Med, Blantyre, Malawi. [Beeler, Judy; Audet, Susette] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD USA. [Cutts, Felicity] London Sch Hyg & Trop Med, London, England. RP Fowlkes, A (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A34, Atlanta, GA 30333 USA. EM afowlkes@cdc.gov RI Yang, Chunfu/G-6890-2013 FU Centers for Disease Control and Prevention; World Health Organization; CDC; Measles Steering Committee of the World Health Organization FX This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention.; This study was funded by the World Health Organization and CDC.; We would like to thank Drs Peter Strebel, Laura Walls, Sun Bae, and the Ndirande Health Centre staff for their many contributions to the research presented. We would also like to thank the following people and organizations for their technical guidance and support: Drs Robin Biellik, Pegi Henderson, Samuel Katz, Renu Lal, and Cathy Wilfert; the Measles Steering Committee of the World Health Organization; the members of the Data Safety Monitoring Board, and the Malawi Ministry of Health and Expanded Programme of Immunization. We would also like to acknowledge Carl Campbell for his logistic support. NR 31 TC 10 Z9 10 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S149 EP S157 DI 10.1093/infdis/jir135 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600020 PM 21666156 ER PT J AU Goodson, JL Sosler, S Pasi, O Johnson, T Kobella, M Monono, ME Uzicanin, A AF Goodson, James L. Sosler, Steve Pasi, Omer Johnson, Ticha Kobella, Marie Monono, Martin E. Uzicanin, Amra TI Impact of a Measles Outbreak Response Immunization Campaign: Maroua, Cameroon, 2009 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID MASS VACCINATION; EPIDEMIC; YAOUNDE; AFRICA AB A large measles outbreak occurred in Maroua, Cameroon during October 2008 April 2009; a nine-day outbreak response immunization (ORI) campaign was initiated 15 weeks after the start of the outbreak during high transmission season. To assess the impact of ORI, we described changes to case counts and characteristics before and after ORI, and the reporting efficiency of measles cases to the surveillance system. A sharp decrease in cases occurred from 555 cases during the period before ORI to 162 cases during the period after ORI; reporting efficiency was 79.5% before ORI and 93.0% after ORI. These findings highlight the potential benefits of rapid implementation of recommended ORI strategies during measles outbreaks in Africa. C1 [Goodson, James L.; Pasi, Omer; Uzicanin, Amra] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. [Sosler, Steve] WHO, Cent Africa Intercountry Support Team, Libreville, Gabon. [Johnson, Ticha] WHO, Yaounde, Cameroon. [Kobella, Marie] Minist Hlth, Expanded Programme Immunizat, Yaounde, Cameroon. [Monono, Martin E.] Minist Hlth, Family Hlth Dept, Yaounde, Cameroon. RP Pasi, O (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,Mailstop E05, Atlanta, GA 30333 USA. EM opasi@cdc.gov FU Ministry of Health of Cameroon; World Health Organization; Centers for Disease Control and Prevention FX Ministry of Health of Cameroon (M. K. and M. E. M.), World Health Organization (S. S. and T. J.), and Centers for Disease Control and Prevention (J. L. G., O. P., A. U.). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 27 TC 3 Z9 3 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S252 EP S259 DI 10.1093/infdis/jir151 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600032 PM 21666170 ER PT J AU Goodson, JL Masresha, B Dosseh, A Byabamazima, C Nshimirimana, D Cochi, S Reef, S AF Goodson, James L. Masresha, Balcha Dosseh, Annick Byabamazima, Charles Nshimirimana, Deogratias Cochi, Stephen Reef, Susan TI Rubella Epidemiology in Africa in the Prevaccine Era, 2002-2009 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID CONGENITAL-RUBELLA; DEVELOPING-COUNTRIES; SYNDROME CRS; IMMUNIZATION C1 [Goodson, James L.; Cochi, Stephen; Reef, Susan] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. [Masresha, Balcha; Nshimirimana, Deogratias] WHO, Immunisat & Vaccines Dev Programme, Reg Off Africa, Brazzaville, Zaire. [Dosseh, Annick] W Africa Intercountry Support Team, Ouagadougou, Burkina Faso. [Byabamazima, Charles] E&S Africa Intercountry Support Team, Harare, Zimbabwe. RP Goodson, JL (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,MS-E05, Atlanta, GA 30333 USA. EM jgoodson@cdo.gov FU World Health Organization; Centers for Disease Control and Prevention FX This work was supported by the World Health Organization (B. M., A. D., C. B., D. N.); and the Centers for Disease Control and Prevention (J. L. G., S. R., S. C.). NR 29 TC 18 Z9 19 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S215 EP S225 DI 10.1093/infdis/jir108 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600027 PM 21666164 ER PT J AU Goodson, JL Masresha, BG Wannemuehler, K Uzicanin, A Cochi, S AF Goodson, James L. Masresha, Balcha G. Wannemuehler, Kathleen Uzicanin, Amra Cochi, Stephen TI Changing Epidemiology of Measles in Africa SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID TROPICAL AFRICA; UNITED-STATES; VACCINATION; ELIMINATION; AMERICA; RUBELLA; AGE; ERADICATION; ANTIBODY; YAOUNDE AB Background. In Africa before the introduction of measles vaccination, measles primarily affected young children. To describe measles epidemiology in Africa since the start of accelerated measles control activities in 2001, we analyzed regional mesasles case-based surveillance data for 2002-2009. Methods. Country-years were grouped by 10-year moving average of routine measles vaccination coverage (aMCV1). Age was log transformed, and pair-wise comparisons of means were made. A chi(2) test was used to assess association between coverage and age groups. Cumulative percent curves and percentiles of age, dot plots with Loess curve, and Spearman rank correlation coefficient were calculated. Results. Of 180,284 suspected cases, 73,009 (41%) were confirmed as measles. Of these, the mean age was 79 months (median, 36 months; interquartile range, 16-96 months) and significantly younger in country-years with <50% aMCV1 than those with 50%-74% aMCV1 (P = .03) and >= 75% (P = .02). With increasing coverage, there was a slight decrease in age in the 10th and 25th and moderate increase in age in the 50th, 75th, and 90th percentiles. Conclusions. During 2002-2009, the median age of confirmed measles was 36 months. In countries with >= 50% aMCV1 coverage compared with low-coverage countries, age shifted to older children and young adults; for infants, age decreased slightly with higher coverage. C1 [Goodson, James L.; Wannemuehler, Kathleen; Uzicanin, Amra; Cochi, Stephen] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. [Masresha, Balcha G.] WHO, Immunisat & Vaccines Dev Programme, Africa Reg Off, Brazzaville, Congo. RP Goodson, JL (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd,NE,MS-E05, Atlanta, GA 30333 USA. EM jgoodson@cdc.gov FU Centers for Disease Control and Prevention; Measles Initiative; World Health Organization Regional Office for Africa, Brazzaville, Congo; Centers for Disease Control and Prevention, Atlanta, Georgia FX This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention.; We acknowledge the great efforts of the immunization officers, surveillance medical officers, and measles laboratory staff throughout the African Region. We also thank the Measles Initiative for providing financial and operational support to member states, leading to measles mortality reduction and progress toward the measles pre-elimination goal in Africa.; World Health Organization Regional Office for Africa, Brazzaville, Congo; and the Centers for Disease Control and Prevention, Atlanta, Georgia. NR 49 TC 23 Z9 27 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S205 EP S214 DI 10.1093/infdis/jir129 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600026 PM 21666163 ER PT J AU Hickman, CJ Hyde, TB Sowers, SB Mercader, S McGrew, M Williams, NJ Beeler, JA Audet, S Kiehl, B Nandy, R Tamin, A Bellini, WJ AF Hickman, Carole J. Hyde, Terri B. Sowers, Sun Bae Mercader, Sara McGrew, Marcia Williams, Nobia J. Beeler, Judy A. Audet, Susette Kiehl, Bryan Nandy, Robin Tamin, Azaibi Bellini, William J. TI Laboratory Characterization of Measles Virus Infection in Previously Vaccinated and Unvaccinated Individuals SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID UNITED-STATES; MARSHALL-ISLANDS; INDUCED IMMUNITY; HIGH-RISK; OUTBREAK; ELIMINATION; TRANSMISSION; POPULATION; ANTIBODIES; SPOTLIGHT AB Waning immunity or secondary vaccine failure (SVF) has been anticipated by some as a challenge to global measles elimination efforts. Although such cases are infrequent, measles virus (MeV) infection can occur in vaccinated individuals following intense and/or prolonged exposure to an infected individual and may present as a modified illness that is unrecognizable as measles outside of the context of a measles outbreak. The immunoglobulin M response in previously vaccinated individuals may be nominal or fleeting, and viral replication may be limited. As global elimination proceeds, additional methods for confirming modified measles cases may be needed to understand whether SVF cases contribute to continued measles virus (MeV) transmission. In this report, we describe clinical symptoms and laboratory results for unvaccinated individuals with acute measles and individuals with SVF identified during MeV outbreaks. SVF cases were characterized by the serological parameters of high-avidity antibodies and distinctively high levels of neutralizing antibody. These parameters may represent useful biomarkers for classification of SVF cases that previously could not be confirmed as such using routine laboratory diagnostic techniques. C1 [Hickman, Carole J.] Ctr Dis Control & Prevent, Div Viral Dis, MMRHLB, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Hyde, Terri B.; Nandy, Robin] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. [Beeler, Judy A.; Audet, Susette] Off Vaccines Res & Review, Lab Pediat & Resp Virus Dis, Div Viral Prod, Bethesda, MD USA. [Kiehl, Bryan] GenBio, San Diego, CA USA. RP Hickman, CJ (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, MMRHLB, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,M-S-C22, Atlanta, GA 30333 USA. EM cjh3@cdc.gov FU Centers for Disease Control and Prevention; US Food and Drug Administration FX This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention.; This study was supported by the Centers for Disease Control and Prevention and US Food and Drug Administration. NR 48 TC 29 Z9 29 U1 0 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S549 EP S558 DI 10.1093/infdis/jir106 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600069 PM 21666212 ER PT J AU Jawed, JS Al-Sayyad, AS Sataih, F Naouri, B Alexander, JP AF Jawed, Jaleela S. Al-Sayyad, Adel S. Sataih, Fathiya Naouri, Boubker Alexander, James P., Jr. TI Toward Measles Elimination in Bahrain-A Middle East Country Experience SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC AB Measles was a leading cause of infant and child morbidity and mortality in Bahrain before the introduction of measles vaccine in 1974. With the establishment of the Expanded Program on Immunization (EPI) in 1981 and the introduction of a second dose of measles vaccine in 1985, coverage for first and second doses of measles vaccine increased to 94% by 1997 and has been sustained >97% since 2001. Measles, mumps, and rubella (MMR) immunization campaigns targeting 12-year-old students were conducted annually during 1998-2006 and achieved coverage of >95%. As a result, the incidence of measles in Bahrain has declined markedly over the past 4 decades, to 2.7 cases per million persons in 2009. Recent confirmed measles cases have occurred sporadically, in undervaccinated children or in infants too young or adults too old to receive measles vaccine. Bahrain has made significant progress toward measles elimination by sustaining high immunization coverage and strengthening case-based measles surveillance activities. Further success will depend on improved identification and immunization of undervaccinated expatriate workers and their families. C1 [Jawed, Jaleela S.; Sataih, Fathiya] Minist Hlth, Publ Hlth Directorate, Immunizat Unit, Manama, Bahrain. [Alexander, James P., Jr.] Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Al-Sayyad, Adel S.] Minist Hlth, Publ Hlth Directorate, Communicable Dis Control Unit, Manama, Bahrain. [Naouri, Boubker] WHO, Reg Off Eastern Mediterranean, Cairo, Egypt. RP Alexander, JP (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,NE Mailstop E-05, Atlanta, GA 30333 USA. EM axj1@cdc.gov FU Ministry of Health; World Health Organization; Centers for Disease Control and Prevention FX This work was supported by the Ministry of Health (JSJ, ASal-S, FS); World Health Organization (BN); and Centers for Disease Control and Prevention (JPA). NR 9 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S299 EP S304 DI 10.1093/infdis/jir105 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600038 ER PT J AU Keegan, R Dabbagh, A Strebel, PM Cochi, SL AF Keegan, Robert Dabbagh, Alya Strebel, Peter M. Cochi, Stephen L. TI Comparing Measles With Previous Eradication Programs: Enabling and Constraining Factors SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID GLOBAL ERADICATION; LESSONS AB Background. Five major disease eradication initiatives were initiated during the second half of the 20th century. The enabling and constraining factors-political, social, economic, and other-for these previous and current eradication programs can inform decision making regarding a proposed measles eradication initiative. Methods. We reviewed the literature on the yaws, malaria, smallpox, guinea worm, and polio eradication programs and compared enabling and constraining factors for each of these programs with the same factors as they relate to a possible measles eradication initiative. Results. A potential measles eradication program would enjoy distinct advantages in comparison with earlier eradication programs, including strong political and societal support, economic analyses demonstrating a high level of cost-effectiveness, and a rigorous upfront process, compared with previous eradication initiatives, that has validated the feasibility of achieving measles eradication. However, increasing population density, urbanization, and wars/civil conflicts will pose serious challenges. Conclusions. Measles eradication will be very challenging but probably not as difficult to achieve as polio eradication. Measles eradication should be undertaken only if the commitments and resources will be adequate to meet the political, social, economic, and technical challenges. C1 [Strebel, Peter M.] World Hlth Org, IVB EPI, Dept Immunizat Vaccines & Biol, CH-1211 Geneva 27, Switzerland. [Cochi, Stephen L.] Ctr Dis Control & Prevent, Global Immunizat Div, Dept Hlth & Human Serv, Atlanta, GA USA. RP Strebel, PM (reprint author), World Hlth Org, IVB EPI, Dept Immunizat Vaccines & Biol, 20 Ave Appia, CH-1211 Geneva 27, Switzerland. EM strebelp@who.int FU Centers for Disease Control and Prevention FX This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention. NR 28 TC 9 Z9 10 U1 0 U2 14 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S54 EP S61 DI 10.1093/infdis/jir119 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600009 PM 21666211 ER PT J AU Khetsuriani, N Deshevoi, S Goel, A Spika, J Martin, R Emiroglu, N AF Khetsuriani, Nino Deshevoi, Sergei Goel, Ajay Spika, John Martin, Rebecca Emiroglu, Nedret TI Supplementary Immunization Activities to Achieve Measles Elimination: Experience of the European Region SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID RUBELLA; PROGRESS; TRANSMISSION; CAMPAIGN; GEORGIA AB Background. Supplementary immunization activities (SIAs) using measles-containing vaccine (MCV) have had a substantial impact on reducing mortality associated with measles worldwide. Methods. To assess impact of SIAs on measles incidence in the World Health Organization European Region and their role at the final stages of measles elimination efforts in Europe, we reviewed information on SIAs, measles surveillance, and routine vaccination coverage during 2000-2009. Results. During 2000-2009, >57 million persons received MCV through SIAs in 16 countries. The Region primarily focused on catch-up campaigns with wider target age groups than in other regions and subsequently relied on routine vaccination rather than periodic follow-up SIAs for the second MCV dose. In addition, the concept of SIAs has been expanded from short-term (<30 days) mass campaigns implemented in other regions to incorporate vaccination efforts over longer periods and outbreak response vaccination. In 2009, 14 of 16 countries that conducted SIAs reported no measles cases or <1 case per 1,000,000 population, reflecting the post-SIA decrease in incidence. Conclusions. SIAs have made a substantial contribution to the success of measles elimination efforts and will likely remain an important strategy for interrupting measles virus transmission in the European Region, although specific approaches will vary by country. C1 [Khetsuriani, Nino] Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Infect Dis, Atlanta, GA 30033 USA. [Deshevoi, Sergei; Goel, Ajay; Spika, John; Martin, Rebecca; Emiroglu, Nedret] WHO, Reg Off Europe, DK-2100 Copenhagen, Denmark. RP Khetsuriani, N (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Infect Dis, 1600 Clifton Rd,MS-05, Atlanta, GA 30033 USA. EM nck7@cdc.gov FU Centers for Disease Control and Prevention FX This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention. NR 23 TC 13 Z9 15 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S343 EP S352 DI 10.1093/infdis/jir074 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600044 PM 21666183 ER PT J AU Mankertz, A Mulders, MN Shulga, S Kremer, JR Brown, KE Santibanez, S Muller, CP Tikhonova, N Lipskaya, G Jankovic, D Khetsuriani, N Martin, R Gavrilin, E AF Mankertz, Annette Mulders, Mick N. Shulga, Sergey Kremer, Jacques R. Brown, Kevin E. Santibanez, Sabine Muller, Claude P. Tikhonova, Nina Lipskaya, Galina Jankovic, Dragan Khetsuriani, Nino Martin, Rebecca Gavrilin, Eugene TI Molecular Genotyping and Epidemiology of Measles Virus Transmission in the World Health Organization European Region, 2007-2009 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID MMR VACCINATION; ELIMINATION AB Background. In 2002, the World Health Organization (WHO) adopted a goal to eliminate measles in the European Region by 2010. Measles elimination is defined as the interruption of indigenous measles virus (MV) transmission. The molecular epidemiology of MV transmission in the WHO European Region was studied through the investigation of reported cases and outbreaks to monitor the region's progress toward its measles elimination goal. Methods. National and regional laboratories performed molecular characterization of MV detected between 2007 and 2009 in the WHO European Region. To document indigenous transmission and importations into the region, we analyzed genotyping results and epidemiological data on measles outbreaks reported by the member states. Results. Since 2007, MV genotype D6 has not been reported in the WHO European Region, suggesting that its chains of transmission have been interrupted, whereas several other MV genotypes are still circulating. Although several European countries have already interrupted indigenous MV transmission, genotyping showed that 3 endemic MV transmission chains have been reestablished in other countries. Conclusions. The WHO European Region 2010 goal will not be met, as indigenous transmission of MV has not been interrupted. As the region begins to document its process of elimination verification to monitor progress toward the goal, countries will need to ensure that genotyping is performed in all measles outbreaks. C1 [Mankertz, Annette; Santibanez, Sabine] WHO, Robert Koch Inst, Div Viral Infect, European Reg Reference Lab, D-13353 Berlin, Germany. [Mulders, Mick N.; Jankovic, Dragan; Martin, Rebecca; Gavrilin, Eugene] WHO, Reg Off Europe, DK-2100 Copenhagen, Denmark. [Shulga, Sergey; Tikhonova, Nina] WHO, European Reg Reference Lab, GN Gabrichevsky Res Inst, Moscow, Russia. [Kremer, Jacques R.; Muller, Claude P.] WHO, European Reg Reference Lab, Inst Immunol, Ctr Rech Publ Sante,Lab Natl Sante, Luxembourg, Luxembourg. [Brown, Kevin E.] WHO, Global Specialised Lab, Ctr Infect, Hlth Protect Agcy, London, England. [Lipskaya, Galina] Moscow MV Lomonosov State Univ, Moscow, Russia. [Khetsuriani, Nino] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Mankertz, A (reprint author), WHO, Natl Reference Ctr Measles Mumps & Rubella, Viral Infect Robert Koch Inst FG12, European Reg Reference Lab, Nordufer 20, D-13353 Berlin, Germany. EM mankertza@rki.de OI Mankertz, Annette/0000-0002-0131-5739 FU Centers for Disease Control and Prevention FX This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention. NR 36 TC 15 Z9 16 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S335 EP S342 DI 10.1093/infdis/jir101 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600043 PM 21666182 ER PT J AU Martin, R Wassilak, S Emiroglu, N Uzicanin, A Deshesvoi, S Jankovic, D Goel, A Khetsuriani, N AF Martin, Rebecca Wassilak, Steven Emiroglu, Nedret Uzicanin, Amra Deshesvoi, Sergei Jankovic, Dragan Goel, Ajay Khetsuriani, Nino TI What Will It Take to Achieve Measles Elimination in the World Health Organization European Region: Progress From 2003-2009 and Essential Accelerated Actions SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID RUBELLA AB Background. The Member States of the European Region (EUR) of the World Health Organization (WHO) have made great progress towards achieving the goal of measles elimination by 2010. Methods. Measles surveillance and vaccine coverage data from 2003-2009 reported to WHO were analyzed. A review of feasibility of reaching the elimination goal by the 2010 target date was conducted in 2009. Results. From 2003-2009, the measles incidence decreased dramatically and coverage with 2 doses of measles vaccine increased among wide age groups of susceptible persons. With the decrease of disease incidence and the reduction of outbreaks in the eastern part of EUR, the proportion of reported cases in the western part increased. In 2009, outbreaks in 5 countries accounted for 89.6% of reported cases. Challenges to reach the 2010 goal include ongoing outbreaks with reestablished endemicity in some countries, decreased demand for vaccines with an increased focus on the measles vaccine safety, and population groups with limited access to immunization services. Conclusions. Measles elimination in EUR is attainable, albeit not by 2010. EUR countries should ensure political commitment and resources to protect the gains made to date and address these challenges to sustain the progress and achieve the elimination goal. C1 [Martin, Rebecca; Emiroglu, Nedret; Deshesvoi, Sergei; Jankovic, Dragan; Goel, Ajay] WHO, Reg Off Europe, DK-2100 Copenhagen, Denmark. [Wassilak, Steven; Uzicanin, Amra; Khetsuriani, Nino] US Ctr Dis Control & Prevent, Vaccine Preventable Dis & Immunizat Programme, Atlanta, GA USA. RP Martin, R (reprint author), WHO European Reg, Div Communicable Dis Hlth Secur & Environm, Scherfigsvej 8, DK-2100 Copenhagen 0, Denmark. EM rma@euro.who.int FU US Centers for Disease Control through the World Health Organization, Geneva; Measles Initiative; United Nations Foundation; American Red Cross; Centers for Disease Control and Prevention; WHO; UNICEF FX Direct financial support was not received for the work presented. Measles and rubella surveillance laboratory testing and capacity building in the World Health Organization European Region is partially supported by the US Centers for Disease Control through the World Health Organization, Geneva; We acknowledge the 53 Member States of the WHO European Region of the World Health Organization. Data for EU Member States are collected by EUVAC.NET. Measles SIAs in the European Region have been funded by the Measles Initiative, a partnership of the United Nations Foundation, American Red Cross, the Centers for Disease Control and Prevention, WHO and UNICEF. NR 20 TC 9 Z9 10 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S325 EP S334 DI 10.1093/infdis/jir137 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600042 PM 21666181 ER PT J AU Masresha, BG Fall, A Eshetu, M Sosler, S Alleman, M Goodson, JL Katsande, R Nshimirimana, D AF Masresha, Balcha G. Fall, Amadou Eshetu, Messeret Sosler, Steve Alleman, Mary Goodson, James L. Katsande, Reggis Nshimirimana, Deogratias TI Measles Mortality Reduction and Pre-Elimination in the African Region, 2001-2009 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC AB Introduction. In 2001, countries in the African region adopted the measles-associated mortality reduction strategy recommended by the World Health Organization and the United Nations Children's Fund. With support from partners, these strategies were implemented during 2001-2009. Methods. To assess implementation, estimates of the first dose of measles vaccination through routine services (MCVI) and reported coverage for measles supplemental immunization activities (SI As) were reviewed. Measles surveillance data were analyzed. Results. During 2001-2009, regional MCV1 coverage increased from 56% to 69%, and >425 million children received measles vaccination through 125 SIAs. Measles case-based surveillance was established in 40 of 46 countries; the remaining 6 have aggregated case reporting. From 2001 through 2008, reported measles cases decreased by 92%, from 492,116 to 37,010; however, in 2009, cases increased to 83,625. Conclusions. The implementation of the recommended strategies led to a marked decrease in measles cases in the region; however, the outbreaks occurring since 2008 indicate suboptimal vaccination coverage. To achieve high MCV1 coverage, provide a second dose through either periodic SI As or routine services, and to ensure further progress toward attaining the regional measles pre-elimination goal by 2012, a renewed commitment from implementing partners and donors is needed. C1 [Masresha, Balcha G.; Katsande, Reggis; Nshimirimana, Deogratias] World Hlth Org, Reg Off Africa, Immunisat & Vaccines Dev Programme, Brazzaville, Congo. [Fall, Amadou; Alleman, Mary] World Hlth Org, Immunisat & Vaccines Dev Programme, W Africa Intercountry Support Team, Ouagadougou, Burkina Faso. [Eshetu, Messeret] World Hlth Org, Immunisat & Vaccines Dev Programme, E&S Africa Intercountry Support Team, Harare, Zimbabwe. [Sosler, Steve] World Hlth Org, Immunisat & Vaccines Dev Programme, Cent Africa Intercountry Support Team, Libreville, Gabon. [Goodson, James L.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. RP Masresha, BG (reprint author), World Hlth Org, Reg Off Africa, Immunisat & Vaccines Dev Programme, Boite Postale 6, Brazzaville, Congo. EM masreshab@zw.afro.who.int FU World Health Organization; Centers for Disease Control and Prevention; Measles Initiative FX This work was supported by the World Health Organization (to B. M, A. F., M. E., R. K., and D. N.) and the Centers for Disease Control and Prevention (to S. S., M. A., and J. G.); We thank all immunization officers, surveillance medical officers, and measles laboratory personnel across the African region who were involved in the implementation of the strategies for measles control and the Measles Initiative for providing financial and logistical support to member states towards measles mortality reduction and pre-elimination in the African region. NR 27 TC 16 Z9 17 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S198 EP S204 DI 10.1093/infdis/jir116 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600025 PM 21666162 ER PT J AU Naouri, B Ahmed, H Bekhit, R Teleb, N Mohsni, E Alexander, JP AF Naouri, Boubker Ahmed, Hinda Bekhit, Raef Teleb, Nadia Mohsni, Ezzeddine Alexander, James P., Jr. TI Progress Toward Measles Elimination in the Eastern Mediterranean Region SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID VIRUS GENOTYPES; MOROCCO AB Since 1997, when the goal of interrupting measles transmission by 2010 was adopted, substantial progress has been made toward the elimination of measles in the Eastern Mediterranean Region (EMR). For the 22 EMR member countries, routine coverage with the first dose of a measles-containing vaccine (MCV) increased from 70% in 1997 to 82% in 2009. All 22 countries conducted measles catch-up vaccination campaigns during 1994-2009, and most conducted follow-up campaigns as needed. Of the 22 EMR countries, 19 have established case-based surveillance for measles with laboratory confirmation. Reported measles cases decreased by 86% during 1998-2008, and estimated measles mortality decreased by 93% during 2000-2008, accounting for 17% of global measles mortality reduction during that period. Despite these successes, several significant challenges remain, and the EMR will not be able to achieve measles elimination by the end of 2010. Achieving and maintaining high population immunity with 2 doses of MCV, improving sensitive case-based surveillance, identifying and vaccinating high-risk subpopulation groups, and appropriately responding to outbreaks are key steps needed to achieve the goal. C1 [Alexander, James P., Jr.] Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Naouri, Boubker; Ahmed, Hinda; Bekhit, Raef; Teleb, Nadia; Mohsni, Ezzeddine] WHO, Reg Off Eastern Mediterranean, Cairo, Egypt. RP Alexander, JP (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,NE,Mailstop E-05, Atlanta, GA 30333 USA. EM axj1@cdc.gov FU World Health Organization; Centers for Disease Control and Prevention FX This work was supported by the World Health Organization (to B. N., H. A., N. T., E. M., and R. B.) and Centers for Disease Control and Prevention (Dr Alexander). NR 16 TC 4 Z9 4 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S289 EP S298 DI 10.1093/infdis/jir140 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600037 PM 21666176 ER PT J AU O'Connor, PM Liyanage, JBL Mach, O Anand, A Ramamurty, N Balakrishnan, MR Singh, S AF O'Connor, Patrick M. Liyanage, Jayantha B. L. Mach, Ondrej Anand, Abhijeet Ramamurty, Nalini Balakrishnan, Madhava Ram Singh, Simarjit TI South-East Asia Regional Update on Measles Mortality Reduction and Elimination, 2003-2008 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC AB In 2005, the World Health Assembly endorsed a global goal of 90% reduction in measles mortality from 2000 to 2010. Substantial progress has been made toward achieving this goal in countries of the South-East Asia Region (SEAR). More than 120 million children received a second dose of measles-containing vaccine during supplemental immunization activities conducted from 2000 to 2008; routine first-dose measles-containing vaccine coverage increased from 63% in 2000 to 75% by 2008; and measles surveillance is supported in all countries by the Measles-Rubella Laboratory Network. Overall, the estimated number of measles deaths decreased by 46% from 2000 to 2008, and all countries with the exception of India have already achieved the 90% mortality reduction target. Sustained political and financial commitment from SEAR countries is needed to achieve regional measles mortality reduction and elimination. C1 [O'Connor, Patrick M.; Liyanage, Jayantha B. L.; Ramamurty, Nalini; Balakrishnan, Madhava Ram; Singh, Simarjit] WHO, Reg Off SE Asia, New Delhi 110002, India. [Mach, Ondrej; Anand, Abhijeet] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. RP O'Connor, PM (reprint author), WHO, Reg Off SE Asia, World Hlth House,Mahatma Gandhi Marg, New Delhi 110002, India. EM oconnorp@searo.who.int FU Centers for Disease Control and Prevention FX This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome", which was sponsored by the Centers for Disease Control and Prevention. NR 19 TC 3 Z9 3 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S396 EP S402 DI 10.1093/infdis/jir085 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600050 PM 21666190 ER PT J AU Reef, SE Strebel, P Dabbagh, A Gacic-Dobo, M Cochi, S AF Reef, S. E. Strebel, P. Dabbagh, A. Gacic-Dobo, M. Cochi, S. TI Progress Toward Control of Rubella and Prevention of Congenital Rubella Syndrome-Worldwide, 2009 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID DEVELOPING-COUNTRIES AB Rubella, usually a mild rash illness in children and adults, can cause serious consequences when a pregnant woman is infected, particularly in early pregnancy. These serious consequences include miscarriage, fetal death or an infant born with birth defects (i.e., congenital rubella syndrome (CRS)). The primary purpose for rubella vaccination is the prevention of congenital rubella infection including CRS. Since 1969, several rubella virus vaccines have been licensed for use; however, until the 1990s, use of rubella-containing vaccine (RCV) was limited primarily to developed countries. In 1996, it was estimated that 110,000 infants with CRS were born annually in developing countries. In 2000, the first World Health Organization rubella vaccine position paper was published to guide introduction of RCV in national childhood immunization schedules. From 1996 to 2009, the number of countries that introduced RCV into their national routine childhood immunization programs increased by 57% from 83 countries in 1996 to 130 countries in 2009. In addition, three of the six WHO regions established rubella control and CRS prevention goals: Region of the Americas and Europe rubella elimination by 2010 and 2015, respectively, and Western Pacific Region-accelerated rubella control and CRS prevention by 2015. Also, during this time period, the number of rubella cases reported decreased from 670,894 in 2000 to 121,344 in 2009. Rubella control and prevention of CRS can be accelerated by integrating with current global measles mortality reduction and regional elimination activities. C1 [Reef, S. E.; Cochi, S.] Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Strebel, P.; Dabbagh, A.; Gacic-Dobo, M.] World Hlth Org, Dept Immunizat Vaccines & Biol, Geneva, Switzerland. RP Reef, SE (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, MS E-05,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM ser2@cdc.gov FU Centers for Disease Control and Prevention FX This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention. NR 10 TC 27 Z9 28 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S24 EP S27 DI 10.1093/infdis/jir155 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600005 PM 21666168 ER PT J AU Rota, JS Hickman, CJ Sowers, SB Rota, PA Mercader, S Bellini, WJ AF Rota, Jennifer S. Hickman, Carole J. Sowers, Sun Bae Rota, Paul A. Mercader, Sara Bellini, William J. TI Two Case Studies of Modified Measles in Vaccinated Physicians Exposed to Primary Measles Cases: High Risk of Infection But Low Risk of Transmission SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID PROTECTIVE TITERS; VIRUS-INFECTION; ANTIBODY; POPULATION; OUTBREAK AB In 2009, measles outbreaks in Pennsylvania and Virginia resulted in the exposure and apparent infection of 2 physicians, both of whom had a documented history of vaccination with >2 doses of measles-mumps-rubella vaccine. These physicians were suspected of having been infected with measles after treating patients who subsequently received a diagnosis of measles. The clinical presentation was nonclassical in regard to progression, duration, and severity. It is hypothesized that the 2 physicians mounted vigorous secondary immune responses typified by high avidity measles immunoglobulin G antibody and remarkably high neutralizing titers in response to intense and prolonged exposure to a primary measles case patient. Both of the physicians continued to see patients, because neither considered that they could have measles. Despite surveillance for cases among contacts, including unvaccinated persons, no additional cases were identified. C1 [Rota, Jennifer S.; Hickman, Carole J.; Sowers, Sun Bae; Rota, Paul A.; Mercader, Sara; Bellini, William J.] Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpesvirus Lab Branch, Div Viral Dis, Atlanta, GA 30333 USA. RP Rota, JS (reprint author), Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpesvirus Lab Branch, Div Viral Dis, 1600 Clifton Rd NE,MS C-22, Atlanta, GA 30333 USA. EM jjs4@cdc.gov FU Centers for Disease Control and Prevention; US Food and Drug Administration FX This study was supported by the Centers for Disease Control and Prevention and the US Food and Drug Administration. NR 14 TC 30 Z9 30 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S559 EP S563 DI 10.1093/infdis/jir098 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600070 PM 21666213 ER PT J AU Rota, PA Brown, K Mankertz, A Santibanez, S Shulga, S Muller, CP Hubschen, JM Siqueira, M Beirnes, J Ahmed, H Triki, H Al-Busaidy, S Dosseh, A Byabamazima, C Smit, S Akoua-Koffi, C Bwogi, J Bukenya, H Wairagkar, N Ramamurty, N Incomserb, P Pattamadilok, S Jee, Y Lim, W Xu, WB Komase, K Takeda, M Tran, T Castillo-Solorzano, C Chenoweth, P Brown, D Mulders, MN Bellini, WJ Featherstone, D AF Rota, Paul A. Brown, Kevin Mankertz, Annette Santibanez, Sabine Shulga, Sergey Muller, Claude P. Huebschen, Judith M. Siqueira, Marilda Beirnes, Jennifer Ahmed, Hinda Triki, Henda Al-Busaidy, Suleiman Dosseh, Annick Byabamazima, Charles Smit, Sheilagh Akoua-Koffi, Chantal Bwogi, Josephine Bukenya, Henry Wairagkar, Niteen Ramamurty, Nalini Incomserb, Patcha Pattamadilok, Sirima Jee, Youngmee Lim, Wilina Xu, Wenbo Komase, Katsuhiro Takeda, Makoto Tran, Thomas Castillo-Solorzano, Carlos Chenoweth, Paul Brown, David Mulders, Mick N. Bellini, William J. Featherstone, David TI Global Distribution of Measles Genotypes and Measles Molecular Epidemiology SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID VIRUS GENOTYPES; GEOGRAPHICAL-DISTRIBUTION; GENETIC-CHARACTERIZATION; UNITED-STATES; TAMIL-NADU; TRANSMISSION; STRAINS; AFRICA; INDIA; IDENTIFICATION AB A critical component of laboratory surveillance for measles is the genetic characterization of circulating wildtype viruses. The World Health Organization (WHO) Measles and Rubella Laboratory Network (LabNet), provides for standardized testing in 183 countries and supports genetic characterization of currently circulating strains of measles viruses. The goal of this report is to describe the lessons learned from nearly 20 years of virologic surveillance for measles, to describe the global databases for measles sequences, and to provide regional updates about measles genotypes detected by recent surveillance activities. Virologic surveillance for measles is now well established in all of the WHO regions, and most countries have conducted at least some baseline surveillance. The WHO Global Genotype Database contains >7000 genotype reports, and the Measles Nucleotide Surveillance (MeaNS) contains >4000 entries. This sequence information has proven to be extremely useful for tracking global transmission patterns and for documenting the interruption of transmission in some countries. The future challenges will be to develop quality control programs for molecular methods and to continue to expand virologic surveillance activities in all regions. C1 [Rota, Paul A.; Chenoweth, Paul; Bellini, William J.] World Hlth Org WHO Global Specialized Lab, Atlanta, GA USA. [Brown, Kevin; Brown, David] WHO Reg Reference Lab, WHO Global Specialized Lab, London, England. [Mankertz, Annette] WHO Reg Reference Lab, Berlin, Germany. [Shulga, Sergey] WHO Reg Reference Lab, Moscow, Russia. [Muller, Claude P.] WHO Reg Reference Lab, Luxembourg, Luxembourg. [Siqueira, Marilda] WHO Reg Reference Lab, Rio De Janeiro, Brazil. [Beirnes, Jennifer] WHO Reg Reference Lab, Winnipeg, MB, Canada. [Ahmed, Hinda] WHO Reg Off, Cairo, Egypt. [Triki, Henda] WHO Reg Reference Lab, Tunis, Tunisia. [Al-Busaidy, Suleiman] WHO Reg Reference Lab, Muscat, Oman. [Dosseh, Annick] WHO Reg Off, Ouagadougou, Burkina Faso. [Byabamazima, Charles] WHO Reg Off, Harare, Zimbabwe. [Smit, Sheilagh] WHO Reg Reference Lab, Johannesburg, South Africa. [Akoua-Koffi, Chantal] WHO Reg Reference Lab, Abidjan, Cote Ivoire. [Bwogi, Josephine; Bukenya, Henry] WHO Reg Reference Lab, Entebbe, Uganda. [Wairagkar, Niteen; Ramamurty, Nalini] WHO Reg Off SE Asian Reg, Delhi, India. [Incomserb, Patcha; Pattamadilok, Sirima] WHO Reg Reference Lab, Bangkok, Thailand. [Jee, Youngmee] WHO Reg Off, Manila, Philippines. [Lim, Wilina] WHO Reg Reference Lab, Hong Kong, Hong Kong, Peoples R China. [Xu, Wenbo] WHO Reg Reference Lab, Beijing, Peoples R China. [Komase, Katsuhiro; Takeda, Makoto] WHO Global Specialized Lab, Tokyo, Japan. [Tran, Thomas] WHO Reg Reference Lab, Western Pacific Region, Vic, Australia. [Castillo-Solorzano, Carlos] WHO Reg Off, Washington, DC USA. [Mulders, Mick N.] WHO Reg Off, Copenhagen, Denmark. [Featherstone, David] WHO Headquarters, Geneva, Switzerland. RP Rota, PA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS C-22, Atlanta, GA 30333 USA. EM prota@cdc.gov OI Mankertz, Annette/0000-0002-0131-5739 FU World Health Organization FX This study was supported in part by the World Health Organization NR 68 TC 85 Z9 91 U1 0 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S514 EP S523 DI 10.1093/infdis/jir118 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600066 PM 21666208 ER PT J AU Rota, PA Brown, KE Hubschen, JM Muller, CP Icenogle, J Chen, MH Bankamp, B Kessler, JR Brown, DW Bellini, WJ Featherstone, D AF Rota, Paul A. Brown, Kevin E. Huebschen, Judith M. Muller, Claude P. Icenogle, Joseph Chen, Min-Hsin Bankamp, Bettina Kessler, Julia R. Brown, David W. Bellini, William J. Featherstone, David TI Improving Global Virologic Surveillance for Measles and Rubella SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID TIME RT-PCR; MOLECULAR EPIDEMIOLOGY; VIRUS GENOTYPES; GENETIC-CHARACTERIZATION; MULTIPLEX PCR; FILTER-PAPER; THROAT SWABS; TAQMAN PCR; IDENTIFICATION; ASSAY AB An important aspect of laboratory surveillance for measles and rubella is the genetic characterization of circulating wild-type viruses to support molecular epidemiologic studies and to track transmission pathways. Virologic surveillance that is sufficient to document the interruption of transmission of measles and rubella viruses will be an essential criterion for verification of elimination. Laboratories in the World Health Organization (WHO) Measles and Rubella Laboratory Network have worked to improve and expand virologic surveillance as many regions move toward elimination of measles and rubella/congenital rubella syndrome. As countries approach elimination, it will be necessary to obtain genetic information from as many chains of transmission as possible. In addition, baseline virologic surveillance, especially for rubella, needs to be improved in many countries. This report contains a summary of recent improvements to the methods used for virologic surveillance. C1 [Rota, Paul A.; Icenogle, Joseph; Chen, Min-Hsin; Bankamp, Bettina; Bellini, William J.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Brown, Kevin E.; Brown, David W.] Hlth Protect Agcy, London, England. [Huebschen, Judith M.; Muller, Claude P.; Kessler, Julia R.] Lab Natl Sante, Luxembourg, Luxembourg. [Huebschen, Judith M.; Muller, Claude P.; Kessler, Julia R.] CRP Sante, Luxembourg, Luxembourg. [Featherstone, David] WHO, CH-1211 Geneva, Switzerland. RP Rota, PA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS C-22, Atlanta, GA 30333 USA. EM prota@cdc.gov FU Centers for Disease Control and Prevention; Health Protection Agency, London, UK; Laboratoire National de Sante and CRP-Sante, Luxembourg, Luxembourg; WHO FX This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention.; This work was supported by in-house funds from the Centers for Disease Control and Prevention; the Health Protection Agency, London, UK; Laboratoire National de Sante and CRP-Sante, Luxembourg, Luxembourg; and the WHO. Additional financial support was provided to some WHO network laboratories by the WHO. NR 42 TC 26 Z9 27 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S506 EP S513 DI 10.1093/infdis/jir117 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600065 PM 21666207 ER PT J AU Strebel, PM Cochi, SL Hoekstra, E Rota, PA Featherstone, D Bellini, WJ Katz, SL AF Strebel, Peter M. Cochi, Stephen L. Hoekstra, Edward Rota, Paul A. Featherstone, David Bellini, William J. Katz, Samuel L. TI A World Without Measles SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material C1 [Strebel, Peter M.] WHO, Expanded Programme Immunizat, Dept Immunizat Vaccines & Biol, CH-1211 Geneva 27, Switzerland. [Cochi, Stephen L.; Rota, Paul A.; Bellini, William J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hoekstra, Edward] UNICEF, New York, NY USA. [Katz, Samuel L.] Duke Univ, Med Ctr, Durham, NC USA. RP Strebel, PM (reprint author), WHO, Expanded Programme Immunizat, Dept Immunizat Vaccines & Biol, Ave Appia, CH-1211 Geneva 27, Switzerland. EM strebelp@who.int NR 9 TC 44 Z9 44 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S1 EP S3 DI 10.1093/infdis/jir111 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600001 PM 21666150 ER PT J AU Sugerman, DE Fall, A Guigui, MT N'dolie, M Balogun, T Wurie, A Goodson, JL AF Sugerman, David E. Fall, Amadou Guigui, Marie-Therese N'dolie, Michael Balogun, Terry Wurie, Alie Goodson, James L. TI Preplanned National Measles Vaccination Campaign at the Beginning of a Measles Outbreak-Sierra Leone, 2009-2010 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID VIRUS; EPIDEMIOLOGY; AFRICA AB Background. Large-scale measles outbreaks occurred throughout Africa from 2008-2010. In Sierra Leone, in November 2009, preceding a measles supplemental immunization activity (SIA), the largest measles outbreak in a decade started. Methods. We analyzed data from the national measles case-based surveillance system, developed a susceptibility profile of the population, and calculated vaccine effectiveness (VE) among children 12-59 months of age. Results. From November 1, 2009 to July 13, 2010, 1,094 confirmed cases, including 9 deaths, were reported; 716 (66%) were <5 years of age. B3 genotype was identified. Measles attack rates per 100,000 population were highest among infants aged 6-8 months (56.4) and in Bo district (49.4). Districts with higher estimated SIA coverage tended to have lower attack rates (Spearman Correlation Coefficient = -0.63), p = 0.07. Among 473 cases with information on vaccination status, 222 (47%) were unvaccinated; estimated VE was 74%. The 2009 measles SIA led to 165,000 fewer estimated susceptible individuals. Conclusions. The 2009 measles SIA reduced the overall magnitude of the outbreak, though routine and SIA coverage was insufficient to prevent it entirely. Maintaining high coverage through routine services and SIAs in all districts and conducting follow-up SIAs prior to the end of the low transmission season may prevent future outbreaks. C1 [Sugerman, David E.; Goodson, James L.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. [Fall, Amadou] WHO, Intercountry Support Team W Africa, Ouagadougou, Burkina Faso. [Guigui, Marie-Therese] UNICEF, Reg Off W & Cent Africa, Dakar, Senegal. [N'dolie, Michael; Balogun, Terry] WHO, Expanded Programme Immunizat, Freetown, Sierra Leone. [Wurie, Alie] Minist Hlth & Sanitat, Expanded Programme Immunizat, Freetown, Sierra Leone. RP Sugerman, DE (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd,NE MS-E05, Atlanta, GA 30333 USA. EM ggi4@cdc.gov FU World Health Organization; United Nations Children's Fund; Ministry of Health and Sanitation of Sierra Leone; Centers for Disease Control and Prevention FX World Health Organization (to A. F., M. N., and T. B.), United Nations Children's Fund (to M. -T. G.), the Ministry of Health and Sanitation of Sierra Leone (to A. W.), and the Centers for Disease Control and Prevention (to D. E. S. and J. L. G.). NR 29 TC 3 Z9 3 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S260 EP S269 DI 10.1093/infdis/jir110 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600033 PM 21666171 ER PT J AU Upreti, SR Thapa, K Pradhan, YV Shakya, G Sapkota, YD Anand, A Taylor, T Mach, O Reef, S Pattamadilok, S Liyanage, J O'Connor, P Sedai, T Bhandary, SR Partridge, J Schluter, W AF Upreti, Shyam Raj Thapa, Kusum Pradhan, Yasho Vardan Shakya, Geeta Sapkota, Yuddha Dhoj Anand, Abhijeet Taylor, Thomas Mach, Ondrej Reef, Susan Pattamadilok, Sirima Liyanage, Jayantha O'Connor, Patrick Sedai, Tika Bhandary, Sagar Ram Partridge, Jeffrey Schluter, William TI Developing Rubella Vaccination Policy in Nepal-Results From Rubella Surveillance and Seroprevalence and Congenital Rubella Syndrome Studies SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID DEVELOPING-COUNTRIES; SYNDROME CRS AB Background. The Government of Nepal is interested in preventing congenital rubella syndrome (CRS). Surveillance data were analyzed and studies conducted to assess the burden of rubella and CRS and aid in developing a rubella vaccination strategy. Methods. (1) Analysis of rubella cases reported through measles surveillance, 2004 - 2009; (2) in 2008, rubella seroprevalence among women 15 to 39 years of age was evaluated; and (3) in 2009, children attending a school for the deaf were examined for ocular defects associated with CRS. Results. From 2004-2009, there were 3,710 confirmed rubella cases and more than 95% of these cases were less than 15 years of age. Of 2,224 women of childbearing age (WCBA) tested for anti-rubella IgG, 2,020 (90.8%) were seropositive. Using a catalytic infection model, approximately 1,426 infants were born with CRS (192/100,000 live births) in 2008. Among 243 students attending a school for the deaf, 18 (7.4%) met the clinical criteria for CRS. Conclusions. Rubella and CRS were documented as significant public health problems in Nepal. A comprehensive approach is necessary, including introducing rubella vaccine in the routine program, assuring immunity among WCBA, strengthening routine immunization, integrating rubella surveillance with measles case-based surveillance, and establishing CRS surveillance. C1 [Upreti, Shyam Raj; Pradhan, Yasho Vardan; Shakya, Geeta] Minist Hlth & Populat, Dept Hlth Serv, Kathmandu, Nepal. [Thapa, Kusum] Paropakar Mother & Womens Hosp, Minist Hlth & Populat, Kathmandu, Nepal. [Sapkota, Yuddha Dhoj] Nepal Netra Jyoti Sangh, Kathmandu, Nepal. [Anand, Abhijeet; Taylor, Thomas; Mach, Ondrej; Reef, Susan] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. [Pattamadilok, Sirima] Natl Inst Hlth, Rubella Virus Lab, Nonthaburi, Thailand. [Liyanage, Jayantha; O'Connor, Patrick] World Hlth Org, Reg Off SE Asia, New Delhi, India. [Sedai, Tika; Bhandary, Sagar Ram; Partridge, Jeffrey; Schluter, William] World Hlth Org, Country Off Nepal, Programme Immunizat Preventable Dis, Kathmandu, Nepal. RP Schluter, W (reprint author), UN House,POB 108, Kathmandu, Nepal. EM schluterw@searo.who.int FU Centers for Disease Control and Prevention; United States Agency for International Development; World Health Organization, Nepal Country Office, Kathmandu, Nepal FX This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention.; We thank the World Health Organization Surveillance Medical Officers. This study was conducted as part of vaccine preventable disease surveillance, which is supported by the United States Agency for International Development.; This work was supported by the World Health Organization, Nepal Country Office, Kathmandu, Nepal. NR 14 TC 3 Z9 3 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S433 EP S438 DI 10.1093/infdis/jir078 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600055 PM 21666196 ER PT J AU Uzicanin, A Lubega, I Nanuynja, M Mercader, S Rota, P Bellini, W Helfand, R AF Uzicanin, Amra Lubega, Irene Nanuynja, Miriam Mercader, Sara Rota, Paul Bellini, William Helfand, Rita TI Dried Blood Spots on Filter Paper as an Alternative Specimen for Measles Diagnostics: Detection of Measles Immunoglobulin M Antibody by a Commercial Enzyme Immunoassay SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID SAMPLES; VIRUS; IGM; SERUM AB Background. We compared the results of a serum-based measles immunoglobulin M (IgM) test with results of tests using paired reconstituted dried filter paper blood spot (DBS) samples to assess the feasibility of using DBS samples for measles diagnostic procedures. Methods. We collected 588 paired serum and DBS samples from 349 children aged 8 months through 12 years at Mulago Hospital in Kampala, Uganda; of these samples, 513 (87%) were collected from children with a clinical diagnosis of measles 0-33 days after rash, and 75(13%) were collected from children hospitalized for other reasons. Eluted DBS and serum samples were tested using a commercial measles IgM enzyme immunoassay. Detection of viral RNA was attempted on a subset of 20 DBS by reverse-transcriptase polymerase chain reaction. Results. Among the 513 sample pairs collected from children with measles, the concordances for samples collected during days 0-6 and >1 week after rash were 95.7% and 100%, respectively (P < .01). The relative sensitivity and specificity of the DBS-based assay during the first week were 98.7% and 88.9%, respectively, and the sensitivity and specificity >1 week after rash were 100% and 100%, respectively. Viral RNA was detected in 5 (26%) of 19 DBS samples tested. Among 75 sample pairs collected from children hospitalized for other reasons, concordance was 94.7%. Conclusions. DBS samples are a feasible alternative sample for measles diagnostic procedures in high-incidence settings. C1 [Uzicanin, Amra; Mercader, Sara; Rota, Paul; Bellini, William; Helfand, Rita] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Lubega, Irene] Makerere Univ, Kampala, Uganda. [Nanuynja, Miriam] Uganda Virus Res Inst, Entebbe, Uganda. RP Uzicanin, A (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mail Stop E-03, Atlanta, GA 30333 USA. EM aau5@cdc.gov FU Centers for Disease Control and Prevention FX This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention. NR 16 TC 8 Z9 8 U1 1 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S564 EP S569 DI 10.1093/infdis/jir088 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600071 PM 21666214 ER PT J AU Uzicanin, A Zimmerman, L AF Uzicanin, Amra Zimmerman, Laura TI Field Effectiveness of Live Attenuated Measles-Containing Vaccines: A Review of Published Literature SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID SCHOOL POPULATION; UNITED-STATES; RISK-FACTORS; IMMUNIZATION STRATEGIES; VACCINATION COVERAGE; OUTBREAK; EFFICACY; EPIDEMIC; CHILDREN; TRANSMISSION AB Background. Information on measles vaccine effectiveness (VE) is critical to help inform policies for future global measles control goals. Methods. We reviewed results of VE studies published during 1960-2010. Results. Seventy papers with 135 VE point estimates were identified. For a single dose of vaccine administered at 9-11 months of age and >= 12 months, the median VE was 77.0% (interquartile range [IQR], 62%-91%) and 92.0% (IQR, 86%-96%), respectively. When analysis was restricted to include only point estimates for which vaccination history was verified and cases were laboratory confirmed, the median VE was 84.0% (IQR, 72.0%-95.0%) and 92.5% (IQR, 84.8%-97.0%) when vaccine was received at 9-11 and >= 12 months, respectively. Published VE vary by World Health Organization region, with generally lower estimates in countries belonging to the African and South East Asian Regions. For 2 doses of measles-containing vaccine, compared with no vaccination, the median VE was 94.1% (IQR, 88.3%-98.3%). Conclusions. The VE of the first dose of measles-containing vaccine administered at 9-11 months was lower than what would be expected from serologic evaluations but was higher than expected when administered at >= 12 months. The median VE increased in a subset of articles in which classification bias was reduced through verified vaccination history and laboratory confirmation. In general, 2 doses of measles-containing vaccine provided excellent protection against measles. C1 [Uzicanin, Amra; Zimmerman, Laura] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Uzicanin, A (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mail Stop E-03, Atlanta, GA 30333 USA. EM aau5@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported by the Centers for Disease Control and Prevention. NR 85 TC 45 Z9 47 U1 0 U2 12 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S133 EP S148 DI 10.1093/infdis/jir102 PG 16 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600019 PM 21666154 ER PT J AU van den Ent, MMVX Brown, DW Hoekstra, EJ Christie, A Cochi, SL AF van den Ent, Maya M. V. X. Brown, David W. Hoekstra, Edward J. Christie, Athalia Cochi, Stephen L. TI Measles Mortality Reduction Contributes Substantially to Reduction of All Cause Mortality Among Children Less Than Five Years of Age, 1990-2008 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID DEATH AB Background. The Millennium Development Goal 4 (MDG4) to reduce mortality in children aged <5 years by two-thirds from 1990 to 2015 has made substantial progress. We describe the contribution of measles mortality reduction efforts, including those spearheaded by the Measles Initiative (launched in 2001, the Measles Initiative is an international partnership committed to reducing measles deaths worldwide and is led by the American Red Cross, the Centers for Disease Control and Prevention, UNICEF, the United Nations Foundation, and the World Health Organization). Methods. We used published data to assess the effect of measles mortality reduction on overall and disease-specific global mortality rates among children aged <5 years by reviewing the results from studies with the best estimates on causes of deaths in children aged 0-59 months. Results. The estimated measles-related mortality among children aged <5 years worldwide decreased from 872,000 deaths in 1990 to 556,000 in 2001 (36% reduction) and to 118,000 in 2008 (86% reduction). All-cause mortality in this age group decreased from >12 million in 1990 to 10.6 million in 2001 (13% reduction) and to 8.8 million in 2008 (28% reduction). Measles accounted for about 7% of deaths in this age group in 1990 and 1% in 2008, equal to 23% of the global reduction in all-cause mortality in this age group from 1990 to 2008. Conclusions. Aggressive efforts to prevent measles have led to this remarkable reduction in measles deaths. The current funding gap and insufficient political commitment for measles control jeopardizes these achievements and presents a substantial risk to achieving MDG4. C1 [van den Ent, Maya M. V. X.; Brown, David W.; Hoekstra, Edward J.] United Nations Childrens Fund UNICEF, New York, NY USA. [Christie, Athalia] Amer Red Cross, Int Serv, Washington, DC 20006 USA. [Cochi, Stephen L.] Ctr Dis Control & Prevent, Global Immunizat Div, Dept Hlth & Human Serv, Atlanta, GA USA. RP van den Ent, MMVX (reprint author), UNICEF Headquarters, 3 UN Plaza, New York, NY 10017 USA. EM mvandenent@unicef.org FU Centers for Disease Control and Prevention FX This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention. NR 16 TC 25 Z9 26 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S18 EP S23 DI 10.1093/infdis/jir081 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600004 PM 21666160 ER PT J AU Weldegebriel, GG Gasasira, A Harvey, P Masresha, B Goodson, JL Pate, MA Abanida, E Chevez, A AF Weldegebriel, Goitom G. Gasasira, Alex Harvey, Pauline Masresha, Balcha Goodson, James L. Pate, Muhammad A. Abanida, Emmanuel Chevez, Ana TI Measles Resurgence Following a Nationwide Measles Vaccination Campaign in Nigeria, 2005-2008 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC AB Introduction. From 1990 through 2008, routine immunization coverage of measles vaccine in Nigeria ranged from 35% to 70%. Nigeria conducted a nationwide measles vaccination campaign in 2 phases during 2005-2006 that targeted children aged 9 months to 14 years; in 2008, a nationwide follow-up campaign that targeted children aged 9 months to 4 years was conducted in 2 phases. Despite these efforts, measles cases continued to occur. Methods. This is a descriptive study that reviewed the measles immunization coverage data from administrative, World Health Organization, United Nations Children's Fund, survey, and supplemental immunization activities data. Measles surveillance data were analyzed from case-based surveillance reports. Results. Confirmed measles cases increased from 383 in 2006 to 2542 in 2007 and to 9510 in 2008. Of the confirmed cases in 2008, 717 (30%) occurred in children <2 years of age, 1145 (48%) in children 2-4 years of age, and 354 (14%) were in children 5-14 years of age. In 2008, the measles case fatality rate was 1.2%. Conclusions. Suboptimal routine coverage and the wide interval between the catch-up and follow-up campaigns likely led to an accumulation of children susceptible to measles. C1 [Weldegebriel, Goitom G.; Gasasira, Alex; Harvey, Pauline; Chevez, Ana] WHO, Country Off, Abuja, Nigeria. [Masresha, Balcha] WHO, African Reg Off, Brazzaville, Congo. [Goodson, James L.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. [Pate, Muhammad A.; Abanida, Emmanuel] Natl Primary Hlth Care Dev Agcy, Benin, Nigeria. RP Weldegebriel, GG (reprint author), WHO, Country Off, Abuja, Nigeria. EM weldegebrielg@ng.afro.who.int FU Centers for Disease Control and Prevention FX This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention. NR 19 TC 11 Z9 11 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S226 EP S231 DI 10.1093/infdis/jir136 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600028 PM 21666165 ER PT J AU Wiesen, E Wannemuehler, K Goodson, JL Anand, A Mach, O Thapa, A O'Connor, P Linayage, J Diorditsa, S Hasan, ASMM Uzzaman, S Mondal, MAJ AF Wiesen, Eric Wannemuehler, Kathleen Goodson, James L. Anand, Abhijeet Mach, Ondrej Thapa, Arun O'Connor, Patrick Linayage, Jayantha Diorditsa, Serguei Hasan, A. S. M. Mainul Uzzaman, Sharif Mondal, Md Abdul Jalil TI Stability of the Age Distribution of Measles Cases Over Time During Outbreaks in Bangladesh, 2004-2006 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID VACCINATION; CAMPAIGN AB Despite recommendations from WHO to conduct measles outbreak response vaccination campaigns based on the age distribution of cases at the beginning of an outbreak, few data exist to specifically examine whether the age distribution of cases remains constant over time in a measles outbreak. This analysis explores this question with use of measles outbreak surveillance data from Bangladesh from the period 2004-2006. Pearson chi(2) tests were conducted of age distributions over 2 periods during 41 large laboratory-confirmed measles outbreaks. Statistically significant changes in age distribution over time were observed in 24% of the outbreaks. No single pattern was detected in the shifts in age distribution; however, an increase in the proportion of cases occurring among infants <9 months of age was evident in 6 outbreaks. These findings suggest a need to consider the possibility of a shift in the age distribution over time when planning an outbreak response vaccination campaign. C1 [Wiesen, Eric; Wannemuehler, Kathleen; Goodson, James L.; Anand, Abhijeet; Mach, Ondrej] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. [Thapa, Arun; O'Connor, Patrick; Linayage, Jayantha] WHO Reg Off SE Asia, New Delhi, India. [Diorditsa, Serguei; Hasan, A. S. M. Mainul; Uzzaman, Sharif] WHO Bangladesh, Expanded Programme Immunizat, Dhaka, Bangladesh. [Mondal, Md Abdul Jalil] Expanded Programme Immunizat Child Hlth & Ltd Cur, Rajshahi, Bangladesh. RP Wiesen, E (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd,MS E05, Atlanta, GA 30333 USA. EM ewiesen@cdc.gov FU Centers for Disease Control and Prevention FX This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention. NR 21 TC 1 Z9 1 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S414 EP S420 DI 10.1093/infdis/jir146 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600052 PM 21666193 ER PT J AU Zahraei, SM Gouya, MM Azad, TM Soltanshahi, R Sabouri, A Naouri, B Alexander, JP AF Zahraei, Seyed Mohsen Gouya, Mohamad M. Azad, Talat Mokhtari Soltanshahi, Rambod Sabouri, Azam Naouri, Boubker Alexander, James P., Jr. TI Successful Control and Impending Elimination of Measles in the Islamic Republic of Iran SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC AB Measles is still one of the most common infectious killers of children in the world, especially in developing countries. In Iran, during the prevaccine era, 150,000-500,000 cases of measles were reported annually, with a death rate of 10%-15%. After the establishment of Expanded Program on Immunization program in 1984, vaccination rates for the first and second doses of measles vaccine increased to >90% by the mid-1990s, and the number of measles cases decreased to 2652 in 1996. In response to increased numbers of cases in older age groups during 1996-2002, a nationwide measles-rubella vaccination campaign was conducted in 2003, and 33,100,000 persons (99%) aged 5-25 years were vaccinated. During 2004-2009, 221 laboratory-confirmed measles cases (<1 case per million population) were detected, primarily in rural areas and among migrant groups who traveled to or came from high-incidence countries. High routine immunization coverage, low disease incidence, and surveillance system data suggest that interruption of endemic virus transmission might have already been achieved in Iran, but challenges remain and continued efforts are needed to sustain this accomplishment. C1 [Alexander, James P., Jr.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. [Zahraei, Seyed Mohsen; Gouya, Mohamad M.; Soltanshahi, Rambod; Sabouri, Azam] Ctr Communicable Dis Control, Vaccine Preventable Dis Dept, Minist Hlth & Med Educ, Raleigh, NC USA. [Azad, Talat Mokhtari] Univ Tehran Med Sci, Natl Reference Lab Measles & Rubella, Tehran, Iran. [Naouri, Boubker] WHO, Reg Off Eastern Mediterranean, Cairo, Egypt. RP Alexander, JP (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd,NE,Mailstop E-05, Atlanta, GA 30333 USA. EM axj1@cdc.gov NR 16 TC 12 Z9 13 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S305 EP S311 DI 10.1093/infdis/jir076 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600039 PM 21666178 ER PT J AU Zimmerman, L Rogalska, J Wannemuehler, KA Haponiuk, M Kosek, A Pauch, E Plonska, E Veltze, D Czarkowski, MP Buddh, N Reef, S Stefanoff, P AF Zimmerman, Laura Rogalska, Justyna Wannemuehler, Kathleen A. Haponiuk, Marzena Kosek, Adam Pauch, Ewa Plonska, Elzbieta Veltze, Daniel Czarkowski, Miroslaw P. Buddh, Nilesh Reef, Susan Stefanoff, Pawel TI Toward Rubella Elimination in Poland: Need for Supplemental Immunization Activities, Enhanced Surveillance, and Further Integration with Measles Elimination Efforts SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC ID OUTBREAK AB Background. All Member States of the World Health Organization (WHO) European Region have endorsed rubella elimination and congenital rubella syndrome (CRS) prevention. However, Poland has continued high levels of reported rubella. Methods. We reviewed rubella incidence in Poland since 1966 and analyzed national aggregated surveillance data from the period 2003-2008 and case-based data from 4 provinces from the period 2006-2008. We described CRS cases since 1997 and assessed maternal receipt of vaccine. We reviewed national vaccination coverage from 1992 through 2008. Results. Since 1966, rubella outbreaks have occurred every 4-6 years in Poland. Aggregate and case-based data from the period 2003-2008 indicate that rubella virus transmission has occurred across wide age ranges (from <1 year to 60 years), with disproportionately higher percentage of cases among adolescent boys. Of 18 children with reported CRS cases from 1997 through 2008, 15 (83%) of their mothers had not been vaccinated. Measles-mumps-rubella dose 1 vaccination coverage ranged from 97% to 99%. Conclusions. Poland had the highest incidence of rubella in the WHO European Region in 2007 and 2008. Rubella occurs predominantly in age and sex cohorts historically not included in vaccination recommendations. The risk for CRS continues. To achieve rubella elimination, supplemental immunization activities among adolescent boys are needed, as is integration with measles elimination efforts. C1 [Zimmerman, Laura; Wannemuehler, Kathleen A.; Reef, Susan] Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Rogalska, Justyna; Czarkowski, Miroslaw P.; Stefanoff, Pawel] Natl Publ Hlth Inst, Natl Inst Hyg, Dept Epidemiol, Warsaw, Poland. [Haponiuk, Marzena] Voyvodship Sanit Epidemiol Stn, Sect Epidemiol & Surveillance, Kielce, Poland. [Kosek, Adam] Voyvodship Sanit Epidemiol Stn, Sect Epidemiol & Surveillance, Krakow, Poland. [Pauch, Ewa] Voyvodship Sanit Epidemiol Stn, Sect Epidemiol & Surveillance, Poznan, Poland. [Plonska, Elzbieta] Voyvodship Sanit Epidemiol Stn, Sect Epidemiol & Surveillance, Warsaw, Poland. [Veltze, Daniel] Voyvodship Sanit Epidemiol Stn, Sect Epidemiol & Surveillance, Gdansk, Poland. [Buddh, Nilesh] WHO, Reg Off Europe Consultant, Copenhagen, Denmark. RP Zimmerman, L (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,MS E-61, Atlanta, GA 30333 USA. EM laz5@cdc.gov RI Stefanoff, Pawel/E-5506-2013 OI Stefanoff, Pawel/0000-0003-0087-0906 FU GSK Biologicals; Centers for Disease Control and Prevention FX P. S. has accepted funding for research purposes from GSK Biologicals for a study of pertussis epidemiology in Poland.; This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome'', which was sponsored by the Centers for Disease Control and Prevention. NR 17 TC 8 Z9 9 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S389 EP S395 DI 10.1093/infdis/jir082 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600049 PM 21666189 ER PT J AU Zimmerman, LA Muscat, M Jankovic, D Goel, A Bang, H Khetsuriani, N Martin, R AF Zimmerman, Laura A. Muscat, Mark Jankovic, Dragan Goel, Ajay Bang, Henrik Khetsuriani, Nino Martin, Rebecca TI Status of Rubella and Congenital Rubella Syndrome Surveillance, 2005-2009, the World Health Organization European Region SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Global Technical Consultation to Assess the Feasibility of Measles Eradication CY JUL 28-30, 2010 CL Washington, DC AB Background. The World Health Organization European Region has a goal for rubella elimination and congenital rubella syndrome (CRS) prevention. Although all Member States recommend a rubella-containing vaccine in their national immunization programs, rubella and CRS continue to occur, and surveillance quality varies throughout the region. Methods. To describe the status of regional rubella and CRS surveillance and assess progress toward elimination, we reviewed surveillance practices by surveying all 53 Member States and analyzed rubella and CRS surveillance data during 2005-2009. Results. Overall, 41(91%) of 45 responding Member States have nationwide rubella surveillance, and 39 (87%) have nationwide CRS surveillance. During 2005-2009, rubella cases reported in the region decreased by 94% from 206,359 cases to 11,623 cases. The greatest decrease (99%) was observed in newly independent states of the former Soviet Union. In the rest of the region, high rubella incidence was observed in Poland, Romania, Italy, and San Marino during 2005-2008 and in Poland, Bosnia and Herzegovina, and Austria in 2009. A total of 68 CRS cases were reported during 2005-2009. Conclusions. As the foundation to achieving and verifying rubella elimination, high-quality rubella and CRS surveillance needs to be implemented and sustained in all Member States. C1 [Zimmerman, Laura A.; Khetsuriani, Nino] Ctr Dis Control & Prevent, Atlanta, GA USA. [Muscat, Mark; Bang, Henrik] Statens Serum Inst, EUVAC NET, DK-2300 Copenhagen, Denmark. [Jankovic, Dragan; Goel, Ajay; Martin, Rebecca] WHO, Reg Off Europe, DK-2100 Copenhagen, Denmark. RP Zimmerman, LA (reprint author), NCIRD, 1600 Clifton Rd,MS E-61, Atlanta, GA 30333 USA. EM laz5@cdc.gov FU Centers for Disease Control and Prevention FX This article is part of a supplement entitled "Global Progress Toward Measles Eradication and Prevention of Rubella and Congenital Rubella Syndrome," which was sponsored by the Centers for Disease Control and Prevention. NR 7 TC 12 Z9 12 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 SU 1 BP S381 EP S388 DI 10.1093/infdis/jir104 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 802YT UT WOS:000293547600048 PM 21666188 ER PT J AU Deutscher, M Lewis, M Zell, ER Taylor, TH Van Beneden, C Schrag, S AF Deutscher, Meredith Lewis, Melissa Zell, Elizabeth R. Taylor, Thomas H., Jr. Van Beneden, Chris Schrag, Stephanie CA Active Bacterial Core Surveillance TI Incidence and Severity of Invasive Streptococcus pneumoniae, Group A Streptococcus, and Group B Streptococcus Infections Among Pregnant and Postpartum Women SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; NONPREGNANT ADULTS; DISEASE; EPIDEMIOLOGY; INFLUENZA; SURVEILLANCE; PREVENTION; VACCINES; SEPSIS; IMPACT AB Background. The epidemiology of streptococcal infection in pregnant and postpartum women is poorly described in recent literature. We used data from multistate surveillance for invasive Streptococcus pneumoniae, group A Streptococcus (GAS), and group B Streptococcus (GBS) infections to estimate disease incidence and severity in these populations. Methods. Cases were reported through the Centers for Disease Control and Prevention Active Bacterial Core surveillance, an active population- and laboratory-based system. A case was defined as illness in a woman aged 15-44 years with streptococcus isolated from a normally sterile body site during 2007-2009. Pregnant or postpartum status was recorded at the time of culture. Incidence was calculated as cases per 1000 woman-years with use of national Census data; 95% confidence intervals were calculated on the basis of lambda distribution. We used multivariable logistic regression to explore associations between pregnant or postpartum status and hospital length of stay, a marker of disease severity. Results. We identified 1848 cases in women; 6.0% of women were pregnant, and 7.5% were postpartum. Pregnant women had a higher mean incidence of GBS disease, compared with nonpregnant women (0.04 cases per 1000 woman-years [range, 0.03-0.05 cases per 1000 woman-years] vs 0.02 cases per 1000 woman-years [range, 0.02-0.02 cases per 1000 woman-years]). Postpartum women had elevated mean incidence of all 3 pathogens, compared with nonpregnant women (S. pneumoniae: 0.15 cases per 1000 woman-years [range, 0.09-0.25 cases per 1000 woman-years] vs 0.052 cases per 1000 woman-years [range, 0.049-0.056 cases per 1000 woman-years]; GAS: 0.56 cases per 1000 woman-years [range, 0.42-0.70 cases per 1000 woman-years] vs 0.019 cases per 1000 woman-years [range, 0.017-0.021 cases per 1000 woman-years]; GBS: 0.49 cases per 1000 woman-years [range, 0.36-0.64 cases per 1000 woman-years] vs 0.018 [range, 0.016-0.020 cases per 1000 woman-years]). Neither pregnancy nor postpartum status was associated with longer length of stay among women infected with any of the 3 pathogens. Conclusions. Although invasive streptococcal infections do not appear to be more severe in pregnant or postpartum women, postpartum women have a 20-fold increased incidence of GAS and GBS, compared with nonpregnant women. C1 [Deutscher, Meredith; Lewis, Melissa; Zell, Elizabeth R.; Taylor, Thomas H., Jr.; Van Beneden, Chris; Schrag, Stephanie] Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Deutscher, Meredith] Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Off Workforce & Career Dev, Atlanta, GA 30333 USA. RP Schrag, S (reprint author), Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,Mailstop C-23, Atlanta, GA 30333 USA. EM zha6@cdc.gov FU Emerging Infections Program Network, Centers for Disease Control and Prevention; CSIRO, Australia FX This work was supported by the Emerging Infections Program Network, Centers for Disease Control and Prevention.; E. R. Z. has received payment for lectures from CSIRO, Australia. All other authors: No reported conflicts. NR 45 TC 35 Z9 38 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUL 15 PY 2011 VL 53 IS 2 BP 114 EP 123 DI 10.1093/cid/cir325 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 796BA UT WOS:000293024000002 PM 21690617 ER PT J AU Rosen, JB Thomas, AR Lexau, CA Reingold, A Hadler, JL Harrison, LH Bennett, NM Schaffner, W Farley, MM Beall, BW Moore, MR AF Rosen, Jennifer B. Thomas, Ann R. Lexau, Catherine A. Reingold, Art Hadler, Jim L. Harrison, Lee H. Bennett, Nancy M. Schaffner, William Farley, Monica M. Beall, Bernard W. Moore, Matt R. CA CDC Emerging Infect Program Networ TI Geographic Variation in Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccine Introduction in the United States SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID RESISTANT STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE; CHANGING EPIDEMIOLOGY; CHILDREN; SEROTYPE; ERA; IMMUNIZATION; SURVEILLANCE; INFECTION; EMERGENCE AB Background. Rates of invasive pneumococcal disease (IPD) varied among the United States before pneumococcal conjugate vaccine (PCV7) introduction. We compared trends in IPD rates among diverse US sites over 10 years since PCV7 introduction. Methods. Patients with IPD of all ages were identified through active population and laboratory-based surveillance in 8 geographic areas under continuous surveillance during 1998-2009. Isolates were serotyped. IPD incidence rates and percent changes were calculated by site, serotype group, age, and year. Results. Reductions in rates of IPD ranged, by site, from 19 to 29.9 cases per 100,000 population during 1998-1999 to 11.2-18.0 cases per 100,000 population during 2009 (rate reduction, 5.1-15.3 cases per 100,000 population). Reductions in IPD rates among children aged < 5 years ranged from 35.7 to 117.2 cases per 100,000 population across the sites. Reductions in rates of IPD due to PCV7 serotypes were seen in all age groups at all sites, ranging from 12 to 21.4 cases per 100,000 population during 1998-1999 to < 2 cases per 100,000 population during 2009 (92%-98% reductions). Serotype 19A rates ranged from 0.4 to 1.5 cases per 100,000 population during 1998-1999 to 1.3 to 3.4 cases per 100,000 population during 2009 (rate difference, 0.9-2.8 cases per 100,000 population); modest increases were observed for most age groups across the sites. Rates of IPD due to all other serotypes ranged from 6.3 to 10.3 cases per 100,000 population during 1998-1999 to 8.3-13.6 cases per 100,000 population during 2009 (rate difference, -0.4 to 5.7 cases per 100,000 population). Across the sites, the greatest rate increases were seen in the 50-64 and > 65 year age groups. Conclusions. Reductions in IPD due to vaccine serotypes were consistent across sites. Changes in serotype 19A and all other serotypes were variable. Although relative increases in non-vaccine type serotypes were large in some sites, absolute rate increases were small. C1 [Rosen, Jennifer B.; Beall, Bernard W.; Moore, Matt R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rosen, Jennifer B.] Off Workforce & Career Dev, Epidem Intelligence Serv, Atlanta, GA USA. [Thomas, Ann R.] Oregon Publ Hlth Div, Portland, OR USA. [Lexau, Catherine A.] Minnesota Dept Hlth, St Paul, MN USA. [Reingold, Art] Calif Emerging Infect Program, Oakland, CA USA. [Hadler, Jim L.] Yale Univ, Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT USA. [Harrison, Lee H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Bennett, Nancy M.] Univ Rochester, Sch Med & Dent, Ctr Community Hlth, Rochester, NY USA. [Schaffner, William] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA. [Farley, Monica M.] Emory Univ, Dept Med, Sch Med, Georgia Emerging Infect Program, Atlanta, GA 30322 USA. [Farley, Monica M.] VA Med Ctr, Atlanta, GA USA. RP Rosen, JB (reprint author), NYC Dept Hlth & Mental Hyg, 2 Lafayette St, New York, NY 10007 USA. EM jrosen4@health.nyc.gov FU Centers for Disease Control and Prevention Emerging Infections; National Center for Immunization and Respiratory Diseases; CDC; CT Department of Public Health; CDC-Office of Infectious Diseases Board of Scientific Counselors; Sanofi Pasteur; Novartis; Pfizer; Dynavax; GlaxoSmithKline; Wyeth FX This work was supported by the Centers for Disease Control and Prevention Emerging Infections Program and the National Center for Immunization and Respiratory Diseases.; C. A. L. has received institutional grant funding from the CDC. J. L. H. has received CDC and CT Department of Public Health grant funding and has received payment for a board membership with CDC-Office of Infectious Diseases Board of Scientific Counselors, for a consultancy with Council of State and Territorial Epidemiologists, and for a lecture with American Academy of Family Practitioners. L. H. H. has received payment for serving on the scientific advisory board for Sanofi Pasteur, Novartis Vaccines, GlaxoSmithKline, and Pfizer; has received an institutional grant from Sanofi Pasteur; and has received payment for lectures from Sanofi Pasteur and Novartis and for development of educational presentations by Discovery Institute of Medical Education. W. S. has received institutional grant funding from CDC; has received payment as an occasional consultant for Pfizer, Dynavax, Novartis, and GlaxoSmithKline; and has been a member of the data safety monitoring board at Merck. M. M. F. has received institutional grant funding from the CDC. N. M. B. has received payment for meeting consultancy with Wyeth. NR 23 TC 42 Z9 43 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUL 15 PY 2011 VL 53 IS 2 BP 137 EP 143 DI 10.1093/cid/cir326 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 796BA UT WOS:000293024000005 PM 21690620 ER PT J AU Talan, DA Krishnadasan, A Gorwitz, RJ Fosheim, GE Limbago, B Albrecht, V Moran, GJ AF Talan, David A. Krishnadasan, Anusha Gorwitz, Rachel J. Fosheim, Gregory E. Limbago, Brandi Albrecht, Valerie Moran, Gregory J. CA EMERGEncy ID Net Study Grp TI Comparison of Staphylococcus aureus From Skin and Soft-Tissue Infections in US Emergency Department Patients, 2004 and 2008 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID UNCOMPLICATED SKIN; INVASIVE DISEASE; UNITED-STATES; RESISTANT; USA300; POPULATION; CEPHALEXIN; ABSCESSES; ADULTS; RISK AB Background. In the past decade, new methicillin-resistant Staphylococcus aureus (MRSA) strains have emerged as a predominant cause of community-associated skin and soft-tissue infections (SSTIs). Little information exists regarding trends in MRSA prevalence and molecular characteristics or regarding antimicrobial susceptibility profiles of S. aureus isolates. Methods. We enrolled adults with acute, purulent SSTIs presenting to a US network of 12 emergency departments during August 2008. Cultures and clinical information were collected. S. aureus isolates were characterized by antimicrobial susceptibility testing, pulsed-field gel electrophoresis, and toxin genes detection. The prevalence of S. aureus and MRSA and isolate genetic characteristics and susceptibilities were compared with those from a similar study conducted in August 2004. Results. The prevalence of MRSA was 59% among all SSTIs during both study periods; however, the prevalence by site varied less in 2008 (38%-84%), compared with 2004 (15%-74%). Pulsed-field type USA300 continued to account for almost all MRSA isolates (98%). Susceptibility to trimethoprim-sulfamethoxazole, clindamycin, and tetracycline among MRSA isolates remained greater than 90% in 2008. A higher proportion of MRSA infections were treated with an agent to which the infecting isolate was susceptible in vitro in 2008 (97%), compared with 2004 (57%). Conclusions. Similar to 2004, MRSA remained the most common identifiable cause of purulent SSTIs among patients presenting to a network of US emergency departments in 2008. The infecting MRSA isolates continued to be predominantly pulsed-field type USA300 and susceptible to recommended non-beta-lactam oral agents. Clinician prescribing practices have shifted from MRSA-inactive to MRSA-active empirical antimicrobial regimens. C1 [Talan, David A.; Krishnadasan, Anusha; Moran, Gregory J.] Univ Calif Los Angeles, Dept Emergency Med, Olive View UCLA Med Ctr, David Geffen Sch Med, Sylmar, CA 94132 USA. [Talan, David A.; Moran, Gregory J.] Univ Calif Los Angeles, Div Infect Dis, Olive View UCLA Med Ctr, David Geffen Sch Med, Sylmar, CA 94132 USA. [Gorwitz, Rachel J.; Fosheim, Gregory E.; Limbago, Brandi; Albrecht, Valerie] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Talan, DA (reprint author), Univ Calif Los Angeles, Dept Emergency Med, Olive View UCLA Med Ctr, David Geffen Sch Med, 14445 Olive View Dr, Sylmar, CA 94132 USA. EM dtalan@ucla.edu FU Forest Pharmaceuticals FX D. A. T. has received payment as a consultant from Forest, Cepheid, Astellas, Cubist, and Pfizer. G. M. has received payment from Forest Pharmaceuticals for consultancy and lectures and has also received payment from Cubist Pharmaceuticals for lectures. All other authors: No reported conflicts. NR 25 TC 133 Z9 136 U1 1 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUL 15 PY 2011 VL 53 IS 2 BP 144 EP 149 DI 10.1093/cid/cir308 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 796BA UT WOS:000293024000006 PM 21690621 ER PT J AU Xia, Y Xu, M Alexander, RR Bernert, JT AF Xia, Yang Xu, Meng Alexander, Ricky R. Bernert, John T. TI Measurement of nicotine, cotinine and trans-3 '-hydroxycotinine in meconium by liquid chromatography-tandem mass spectrometry SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES LA English DT Article DE Meconium; Nicotine; Cotinine; Trans-3 '-hydroxycotinine; Tobacco; Biomarker ID TOBACCO-SMOKE EXPOSURE; CIGARETTE-SMOKING; METABOLITES; DRUGS; ABUSE; QUANTIFICATION; DISPOSITION AB Nicotine (NIC), cotinine (COT) and trans-3'-hydroxycotinine (OHCOT) are the most prevalent and abundant tobacco biomarkers in meconium. We have developed and validated an accurate and precise method for the measurement of these analytes in meconium in which potassium hydroxide is used to digest the meconium sample, followed by solid phase extraction from the liquified sample. The precision of OHCOT, COT and NIC measurements (intra-day and inter-day) were 4.8-10.6%, 3.4-11.6% and 9.3-15.8%. respectively. Evaluation of accuracy indicated bias of -4.0, 2.0 and 0.8% for OHCOT at concentrations of 0.5, 2.5 and 7.5 ng/g. The accuracy estimates for COT at concentrations of 0.5, 2.5 and 7.5 ng/g are 4.0, 4.0 and 5.7%, respectively. For NIC at 2, 10 and 30 ng/g the accuracy was calculated to be 3.0, 5.0 and 5.1%, respectively. The linear range of standard solutions was 0.125-37.5 ng/mL for OHCOT and COT, and 0.75-150 ng/mL for NIC. This method was applied to the analysis of 374 meconium samples from infants of both smoking and nonsmoking mothers. Positive correlations with r(2) >= 0.63 were observed between NIC and COT, COT and OHCOT, NIC and OHCOT, and NIC and (OHCOT + COT) in these samples. Published by Elsevier B.V. C1 [Xia, Yang; Xu, Meng; Alexander, Ricky R.; Bernert, John T.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Xia, Y (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway,MS F47, Atlanta, GA 30341 USA. EM yax1@cdc.gov NR 32 TC 6 Z9 7 U1 2 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1570-0232 J9 J CHROMATOGR B JI J. Chromatogr. B PD JUL 15 PY 2011 VL 879 IS 22 BP 2142 EP 2148 DI 10.1016/j.jchromb.2011.05.054 PG 7 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 799DA UT WOS:000293262500018 PM 21689995 ER PT J AU Costa, MA Huang, SS Moore, M Kulldorff, M Finkelstein, JA AF Costa, Marcelo A. Huang, Susan S. Moore, Matthew Kulldorff, Martin Finkelstein, Jonathan A. TI New Approaches to Estimating National Rates of Invasive Pneumococcal Disease SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE estimation; pneumococcal infections; sentinel surveillance; statistics as topic; Streptococcus pneumoniae ID STREPTOCOCCUS-PNEUMONIAE INFECTIONS; CONJUGATE VACCINE; YOUNG-CHILDREN; COMMUNITY-LEVEL; UNITED-STATES; SURVEILLANCE; CARRIAGE; EPIDEMIOLOGY; DECLINE; BURDEN AB National infectious disease incidence rates are often estimated by standardizing locally derived rates using national-level age and race distributions. Data on other factors potentially associated with incidence are often not available in the form of patient-level covariates. Including characteristics of patients' area of residence may improve the accuracy of national estimates. The authors used data from the Centers for Disease Control and Prevention's Active Bacterial Core Surveillance program (2004-2005), adjusted for census-based variables, to estimate the national incidence of invasive pneumococcal disease (IPD). The authors tested Poisson and negative binomial models in a cross-validation procedure to select variables best predicting the incidence of IPD in each county. Including census-level information on race and educational attainment improved the fit of both Poisson and negative binomial models beyond that achieved by adjusting for other census variables or by adjusting for an individual's race and age alone. The Poisson model with census-based predictors led to a national estimate of IPD of 16.0 cases per 100,000 persons as compared with 13.5 per 100,000 persons using an individual's age and race alone. Accuracy of, and confidence intervals for, these estimates can only be determined by obtaining data from other randomly selected US counties. However, incorporating census-derived characteristics should be considered when estimating national incidence of IPD and other diseases. C1 [Kulldorff, Martin; Finkelstein, Jonathan A.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02215 USA. [Kulldorff, Martin; Finkelstein, Jonathan A.] Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA. [Costa, Marcelo A.] Univ Fed Minas Gerais, Dept Stat, Belo Horizonte, MG, Brazil. [Huang, Susan S.] Univ Calif Irvine, Sch Med, Div Infect Dis, Irvine, CA 92717 USA. [Huang, Susan S.] Univ Calif Irvine, Sch Med, Hlth Policy Res Inst, Irvine, CA 92717 USA. [Moore, Matthew] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA. RP Finkelstein, JA (reprint author), Harvard Univ, Sch Med, Dept Populat Med, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA. EM jonathan_finkelstein@harvardpilgrim.org RI Kulldorff, Martin/H-4282-2011; OI Kulldorff, Martin/0000-0002-5284-2993 FU US Centers for Disease Control and Prevention through the Association of Prevention Teaching and Research [TS1363] FX This work was supported by a cooperative agreement (TS1363) with the US Centers for Disease Control and Prevention through the Association of Prevention Teaching and Research. NR 20 TC 2 Z9 3 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUL 15 PY 2011 VL 174 IS 2 BP 234 EP 242 DI 10.1093/aje/kwr058 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 792VN UT WOS:000292778600014 PM 21617259 ER PT J AU Demchuk, E Ruiz, P Chou, S Fowler, BA AF Demchuk, Eugene Ruiz, Patricia Chou, Selene Fowler, Bruce A. TI SAR/QSAR methods in public health practice SO TOXICOLOGY AND APPLIED PHARMACOLOGY LA English DT Article DE Structure-activity relationships; SAR/QSAR; Modeling; Computational toxicology; Public health practice ID COMPUTATIONAL TOXICOLOGY METHODS; BIOLOGICAL-ACTIVITY; PREDICTION; SUBSTANCES; MOLECULES; CHEMICALS AB Methods of (Quantitative) Structure-Activity Relationship ((Q)SAR) modeling play an important and active role in ATSDR programs in support of the Agency mission to protect human populations from exposure to environmental contaminants. They are used for cross-chemical extrapolation to complement the traditional toxicological approach when chemical-specific information is unavailable. SAR and QSAR methods are used to investigate adverse health effects and exposure levels, bioavailability, and pharmacokinetic properties of hazardous chemical compounds. They are applied as a part of an integrated systematic approach in the development of Health Guidance Values (HGVs), such as ATSDR Minimal Risk Levels, which are used to protect populations exposed to toxic chemicals at hazardous waste sites. (Q)SAR analyses are incorporated into ATSDR documents (such as the toxicological profiles and chemical-specific health consultations) to support environmental health assessments, prioritization of environmental chemical hazards, and to improve study design, when filling the priority data needs (PDNs) as mandated by Congress, in instances when experimental information is insufficient. These cases are illustrated by several examples, which explain how ATSDR applies (Q)SAR methods in public health practice. Published by Elsevier Inc. C1 [Demchuk, Eugene; Ruiz, Patricia; Chou, Selene; Fowler, Bruce A.] ATSDR, Div Toxicol & Environm Med, Atlanta, GA 30333 USA. RP Demchuk, E (reprint author), Agcy Toxic Subst & Dis Registry F62, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM edemchuk@cdc.gov NR 37 TC 10 Z9 10 U1 1 U2 11 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0041-008X J9 TOXICOL APPL PHARM JI Toxicol. Appl. Pharmacol. PD JUL 15 PY 2011 VL 254 IS 2 SI SI BP 192 EP 197 DI 10.1016/j.taap.2010.10.017 PG 6 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 793HJ UT WOS:000292810700015 PM 21034766 ER PT J AU Ruiz, P Mumtaz, M Gombar, V AF Ruiz, Patricia Mumtaz, Moiz Gombar, Vijay TI Assessing the toxic effects of ethylene glycol ethers using Quantitative Structure Toxicity Relationship models SO TOXICOLOGY AND APPLIED PHARMACOLOGY LA English DT Article DE Quantitative structure toxicity relationship; Ethylene glycol mono-n-alkyl ethers; Developmental toxicity; QSAR; QSTR ID SALMONELLA MUTAGENICITY; DEVELOPMENTAL TOXICITY; MOLECULAR GRAPHS; ALKYL ETHERS; PREDICTION; HEALTH; CHEMICALS; CARCINOGENICITY; SUBSTANCES; 2-METHOXYETHANOL AB Experimental determination of toxicity profiles consumes a great deal of time, money, and other resources. Consequently, businesses, societies, and regulators strive for reliable alternatives such as Quantitative Structure Toxicity Relationship (QSTR) models to fill gaps in toxicity profiles of compounds of concern to human health. The use of glycol ethers and their health effects have recently attracted the attention of international organizations such as the World Health Organization (WHO). The board members of Concise International Chemical Assessment Documents (CICAD) recently identified inadequate testing as well as gaps in toxicity profiles of ethylene glycol mono-n-alkyl ethers (EGEs). The CICAD board requested the ATSDR Computational Toxicology and Methods Development Laboratory to conduct QSTR assessments of certain specific toxicity endpoints for these chemicals. In order to evaluate the potential health effects of EGEs, CICAD proposed a critical QSTR analysis of the mutagenicity, carcinogenicity, and developmental effects of EGEs and other selected chemicals. We report here results of the application of QSTRs to assess rodent carcinogenicity, mutagenicity, and developmental toxicity of four EGEs: 2-methoxyethanol, 2-ethoxyethanol, 2-propoxyethanol, and 2-butoxyethanol and their metabolites. Neither mutagenicity nor carcinogenicity is indicated for the parent compounds, but these compounds are predicted to be developmental toxicants. The predicted toxicity effects were subjected to reverse QSTR (rQSTR) analysis to identify structural attributes that may be the main drivers of the developmental toxicity potential of these compounds. Published by Elsevier Inc. C1 [Gombar, Vijay] Lilly Corp Ctr, Lilly Res Labs, Drug Disposit & Toxicol, Indianapolis, IN 46285 USA. [Ruiz, Patricia] Agcy Tox Subst & Dis Registry, Div Toxicol & Environm Med, Computat Toxicol & Methods Dev Unit, Computat Toxicol Methods Dev Lab, Atlanta, GA 30333 USA. RP Ruiz, P (reprint author), Agcy Tox Subst & Dis Registry, Div Toxicol & Environm Med, Computat Toxicol & Methods Dev Unit, Computat Toxicol Methods Dev Lab, 1600 Clifton Rd,MS-F62, Atlanta, GA 30333 USA. EM pruiz@cdc.gov NR 43 TC 10 Z9 10 U1 2 U2 20 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0041-008X J9 TOXICOL APPL PHARM JI Toxicol. Appl. Pharmacol. PD JUL 15 PY 2011 VL 254 IS 2 SI SI BP 198 EP 205 DI 10.1016/j.taap.2010.10.024 PG 8 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 793HJ UT WOS:000292810700016 PM 21034757 ER PT J AU Reynolds, BJ AF Reynolds, Barbara J. TI When the facts are just not enough: Credibly communicating about risk is riskier when emotions run high and time is short SO TOXICOLOGY AND APPLIED PHARMACOLOGY LA English DT Article DE Risk communication; Cognitive psychology; Risk perceptions; Uncertainty; Public trust; Empathy; Public meetings ID TRUST; CRISIS; CHALLENGES; UNCERTAINTY; TERRORISM; ATTACK; EVENT AB When discussing risk with people, commonly subject matter experts believe that conveying the facts will be enough to allow people to assess a risk and respond rationally to that risk. Because of this expectation, experts often become exasperated by the seemingly illogical way people assess personal risk and choose to manage that risk. In crisis situations when the risk information is less defined and choices must be made within impossible time constraints, the thought processes may be even more susceptible to faulty heuristics. Understanding the perception of risk is essential to understanding why the public becomes more or less upset by events. This article explores the psychological underpinnings of risk assessment within emotionally laden events and the risk communication practices that may facilitate subject matter experts to provide the facts in a manner so they can be more certain those facts are being heard. Source credibility is foundational to risk communication practices. The public meeting is one example in which these best practices can be exercised. Risks are risky because risk perceptions differ and the psychosocial environment in which risk is discussed complicates making risk decisions. Experts who want to influence the actions of the public related to a threat or risk should understand that decisions often involve emotional as well as logical components. The media and other social entities will also influence the risk context. The Center for Disease Control and Prevention's crisis and emergency-risk communication (CERC) principles are intended to increase credibility and recognize emotional components of an event. During a risk event, CERC works to calm emotions and increase trust which can help people apply the expertise being offered by response officials. (C) 2011 Published by Elsevier Inc. C1 US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Reynolds, BJ (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM Bsr0@cdc.gov NR 63 TC 11 Z9 11 U1 3 U2 28 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0041-008X EI 1096-0333 J9 TOXICOL APPL PHARM JI Toxicol. Appl. Pharmacol. PD JUL 15 PY 2011 VL 254 IS 2 SI SI BP 206 EP 214 DI 10.1016/j.taap.2010.10.023 PG 9 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 793HJ UT WOS:000292810700017 PM 21034761 ER PT J AU Huang, FF Barnes, PF Feng, Y Donis, R Chroneos, ZC Idell, S Allen, T Perez, DR Whitsett, JA Dunussi-Joannopoulos, K Shams, H AF Huang, Fang-Fang Barnes, Peter F. Feng, Yan Donis, Ruben Chroneos, Zissis C. Idell, Steven Allen, Timothy Perez, Daniel R. Whitsett, Jeffrey A. Dunussi-Joannopoulos, Kyri Shams, Homayoun TI GM-CSF in the Lung Protects against Lethal Influenza Infection SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE GM-CSF; influenza; alveolar macrophages ID COLONY-STIMULATING FACTOR; T-CELL RESPONSES; ALVEOLAR MACROPHAGES; VIRUS INFECTION; A VIRUS; PROINFLAMMATORY CYTOKINES; GENETIC IMMUNIZATION; IMMUNE-RESPONSE; MICE; PNEUMONIA AB Rationale: Alveolar macrophages contribute to host defenses against influenza in animal models. Enhancing alveolar macrophage function may contribute to protection against influenza. Objectives: To determine if increased expression of granulocyte/macrophagecolony-stimulating factor (GM-CSF) in the lung increases resistance to influenza. Methods: Wild-type mice and transgenic mice that expressed GM-CSF in the lung were infected with influenza virus, and lung pathology, weight loss, and mortality were measured. We also administered GM-CSF to the lungs of wild-type mice that were infected with influenza virus. Measurements and Main Results: Wild-type mice all died after infection with different strains of influenza virus, but all transgenic mice expressing GM-CSF in the lungs survived. The latter also had greatly reduced weight loss and lung injury, and showed histologic evidence of a rapid host inflammatory response that controlled infection. The resistance of transgenic mice to influenza was abrogated by elimination of alveolar phagocytes, but not by depletion of T cells, B cells, or neutrophils. Transgenic mice had far more alveolar macrophages than did wild-type mice, and they were more resistant to influenza induced apoptosis. Delivery of intranasal GM-CSF to wild-type mice also conferred resistance to influenza. Conclusions: GM-CSF confers resistance to influenza by enhancing innate immune mechanisms that depend on alveolar macrophages. Pulmonary delivery of this cytokine has the potential to reduce the morbidity and mortality due to influenza virus. C1 [Huang, Fang-Fang; Barnes, Peter F.; Feng, Yan; Shams, Homayoun] UTHSCT, Ctr Pulm & Infect Dis Control, Tyler, TX 75708 USA. [Chroneos, Zissis C.; Idell, Steven] UTHSCT, Ctr Biomed Res, Tyler, TX 75708 USA. [Allen, Timothy] UTHSCT, Dept Pathol, Tyler, TX 75708 USA. [Donis, Ruben] Ctr Dis Control & Prevent, Atlanta, GA USA. [Perez, Daniel R.] Univ Maryland, VA MD Reg Coll Vet Med, College Pk, MD 20742 USA. [Whitsett, Jeffrey A.] Cincinnatti Childrens Hosp, Cincinnati, OH USA. [Dunussi-Joannopoulos, Kyri] Pfizer Res, Cambridge, MA USA. RP Shams, H (reprint author), UTHSCT, Ctr Pulm & Infect Dis Control, US Hwy 271, Tyler, TX 75708 USA. EM homayoun.shams@uthct.edu OI Perez, Daniel/0000-0002-6569-5689 FU American Heart Association [09GRNT2390010]; Flight Attendant Medical Research Institute [092015]; Cain Foundation for Infectious Disease Research FX This work was in part supported by grants from the American Heart Association (09GRNT2390010) and the Flight Attendant Medical Research Institute (092015-Clinical Innovator Award), both to H. Shams, and the Cain Foundation for Infectious Disease Research. NR 50 TC 50 Z9 51 U1 2 U2 5 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD JUL 15 PY 2011 VL 184 IS 2 BP 259 EP 268 DI 10.1164/rccm.201012-2036OC PG 10 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 792RT UT WOS:000292767500019 PM 21474645 ER PT J AU Behravesh, CB Jones, TF Vugia, DJ Long, C Marcus, R Smith, K Thomas, S Zansky, S Fullerton, KE Henao, OL Scallan, E AF Behravesh, Casey Barton Jones, Timothy F. Vugia, Duc J. Long, Cherie Marcus, Ruthanne Smith, Kirk Thomas, Stephanie Zansky, Shelley Fullerton, Kathleen E. Henao, Olga L. Scallan, Elaine CA FoodNet Working Grp TI Deaths Associated With Bacterial Pathogens Transmitted Commonly Through Food: Foodborne Diseases Active Surveillance Network (FoodNet), 1996-2005 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; INFECTIOUS-DISEASE; ILLNESS; CAMPYLOBACTER; GASTROENTERITIS; EPIDEMIOLOGY; SALMONELLA; TRENDS AB Background. Foodborne diseases are typically mild and self-limiting but can cause severe illness and death. We describe the epidemiology of deaths associated with bacterial pathogens using data from the Foodborne Diseases Active Surveillance Network (FoodNet) in the United States. Methods. We analyzed FoodNet data from 1996-2005 to determine the numbers and rates of deaths occurring within 7-days of laboratory-confirmation. Results. During 1996-2005, FoodNet ascertained 121,536 cases of laboratory-confirmed bacterial infections, including 552 (. 5%) deaths, of which 215 (39%) and 168 (30%) were among persons infected with Salmonella and Listeria, respectively. The highest age-specific average annual population mortality rates were in older adults (>= 65 years) for all pathogens except Shigella, for which the highest age-specific average annual population mortality rate was in children <5 years (.2/1 million population). Overall, most deaths (58%; 318) occurred in persons >= 65 years old. Listeria had the highest case fatality rate overall (16.9%), followed by Vibrio (5.8%), Shiga toxin-producing Escherichia coli O157 (0.8%), Salmonella (0.5%), Campylobacter (0.1%), and Shigella (0.1%). Conclusions. Salmonella and Listeria remain the leading causes of death in the United States due to bacterial pathogens transmitted commonly through food. Most such deaths occurred in persons >= 65 years old, indicating that this age group could benefit from effective food safety interventions. C1 [Behravesh, Casey Barton; Long, Cherie; Fullerton, Kathleen E.; Henao, Olga L.; Scallan, Elaine] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA 30340 USA. [Behravesh, Casey Barton] Ctr Dis Control & Prevent, Epidem Intelligence Serv Program Off Sci Educ & P, Div Appl Sci, Atlanta, GA 30340 USA. [Thomas, Stephanie] Georgia Emerging Infect Program, Div Publ Hlth, Atlanta, GA USA. [Jones, Timothy F.] Tennessee Dept Hlth, Nashville, TN USA. [Vugia, Duc J.] Calif Dept Publ Hlth Infect Dis Branch, Richmond, CA USA. [Marcus, Ruthanne] Connecticut Emerging Infect Program, New Haven, CT USA. [Marcus, Ruthanne] Connecticut Emerging Infect Program, Hartford, CT USA. [Smith, Kirk] Minnesota Dept Hlth, Minneapolis, MN USA. [Zansky, Shelley] New York State Dept Hlth, New York Emerging Infect Program, Albany, NY USA. RP Behravesh, CB (reprint author), Ctr Dis Control & Prevent, Outbreak Response Team, Outbreak Response & Prevent Branch, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd,MS A-38, Atlanta, GA 30340 USA. EM dlx9@cdc.gov FU CDC; US Department of Agriculture's Food Safety and Inspection Service; US Food and Drug Administration FX This work was supported by the CDC, the US Department of Agriculture's Food Safety and Inspection Service, and the US Food and Drug Administration. NR 21 TC 50 Z9 51 U1 2 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 15 PY 2011 VL 204 IS 2 BP 263 EP 267 DI 10.1093/infdis/jir263 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 790AZ UT WOS:000292562200015 ER PT J AU Earley, MC Laxova, A Farrell, PM Driscoll-Dunn, R Cordovado, S Mogayzel, PJ Konstan, MW Hannon, WH AF Earley, Marie C. Laxova, Anita Farrell, Philip M. Driscoll-Dunn, Rena Cordovado, Suzanne Mogayzel, Peter J., Jr. Konstan, Michael W. Hannon, W. Harry TI Implementation of the first worldwide quality assurance program for cystic fibrosis multiple mutation detection in population-based screening SO CLINICA CHIMICA ACTA LA English DT Article DE Newborn screening; Proficiency testing; CFTR mutations ID NEWBORN; DIAGNOSIS; GENE AB Background: CDC's Newborn Screening Quality Assurance Program collaborated with several U.S. Cystic Fibrosis Care Centers to collect specimens for development of a molecular CFTR proficiency testing program using dried-blood spots for newborn screening laboratories. Methods: Adult and adolescent patients or carriers donated whole blood that was aliquoted onto filter paper cards. Five blind-coded specimens were sent to participating newborn screening laboratories quarterly. Proficiency testing results were evaluated based on presumptive clinical assessment. Individual evaluations and summary reports were sent to each participating laboratory and technical consultations were offered if incorrect assessments were reported. Results: The current CDC repository contains specimens with 39 different CFTR mutations. Up to 45 laboratories have participated in the program. Three years of data showed that correct assessments were reported 97.7% of the time overall when both mutations could be determined. Incorrect assessments that could have lead to a missed case occurred 0.9% of the time, and no information was reported 1.1% of the time due to sample failure. Conclusions: Results show that laboratories using molecular assays to detect CFTR mutations are performing satisfactorily. The programmatic results presented demonstrate the importance and complexity of providing proficiency testing for DNA-based assays. Published by Elsevier B.V. C1 [Earley, Marie C.; Driscoll-Dunn, Rena; Cordovado, Suzanne; Hannon, W. Harry] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Laxova, Anita; Farrell, Philip M.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53726 USA. [Mogayzel, Peter J., Jr.] Johns Hopkins Med Inst, Cyst Fibrosis Ctr, Baltimore, MD 21287 USA. [Konstan, Michael W.] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA. [Konstan, Michael W.] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA. RP Earley, MC (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,MS F-19, Atlanta, GA 30341 USA. EM MEarley@cdc.gov FU National Institutes of Health [DK34108]; University of Wisconsin; Centers for Disease Control and Prevention; U.S. Department of Energy FX Dr. Farrell was supported by National Institutes of Health grant DK34108 and the Robert Turrell Professorship of the University of Wisconsin. Rena Driscoll-Dunn was funded by the Research Participation Program at the Centers for Disease Control and Prevention, an interagency agreement with the U.S. Department of Energy administered by the Oak Ridge Institute for Science and Education. NR 17 TC 6 Z9 6 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD JUL 15 PY 2011 VL 412 IS 15-16 BP 1376 EP 1381 DI 10.1016/j.cca.2011.04.011 PG 6 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 781GB UT WOS:000291917500014 PM 21514289 ER PT J AU Chace, DH De Jesus, VR Lim, TH Hannon, WH Clark, RH Spitzer, AR AF Chace, Donald H. De Jesus, Victor R. Lim, Timothy H. Hannon, W. Harry Clark, Reese H. Spitzer, Alan R. TI Detection of TPN contamination of dried blood spots used in newborn and metabolic screening and its impact on quantitative measurement of amino acids SO CLINICA CHIMICA ACTA LA English DT Article DE Tandem mass spectrometry; Dextrose total parenteral nutrition; Newborn screening; Premature infants ID TANDEM MASS-SPECTROMETRY; RAPID DIAGNOSIS; SPECIMENS; PHENYLKETONURIA; PHENYLALANINE; TYROSINE AB Background: Markers derived from dextrose (D-glucose) are observed in the MS/MS-based acylcarnitine profiles from dried-blood spots of some premature infants receiving intravenous nutrition. The presence of these markers at m/z 325, 399 and 473 are thought to arise from contamination of blood by total parenteral nutrition (TPN) solutions during specimen collection from premature infants. These solutions contain high concentrations of amino acids and as a result, false-positive screening results for amino acid disorders may occur. This study investigates quantitative parameters of dextrose and amino acids in blood samples enriched with different TPN solutions. Methods: Whole blood collected in heparin was enriched with three different TPN solutions containing 5, 10 or 12.5% dextrose and amino acids that were originally prepared for delivery of 2.5, 3 or 4 g/kg/day of Premasol (R) then spotted onto filter paper cards. Acylcarnitine and amino acid profiles using MS/MS were obtained. Ion ratios of dextrose relative to specific acylcarnitine stable isotope internal standards and amino acid concentrations were obtained. Results: The ion ratios for each of the dextrose markers at m/z 325, 399 and 473 exhibit linearity with the concentration of the dextrose component of TPN added to blood. The lowest detectable dextrose concentration added to blood was 7.6 mmol/l at 1:80 v/v TPN in blood. Furthermore, the concentrations of amino acids were linear with the concentration of the amino acid component of TPN added to blood. At the lowest detectable concentrations of dextrose marker, the amino acid concentrations were at or above the values considered abnormal in newborn screening laboratories. The molar ratios of amino acids approached the relative quantity of amino acid in the TPN solution with increasing enrichments in blood. Conclusions: Detection of the combinations of dextrose markers, very high elevations of amino acids and unusual molar ratios can be used to reject a specimen as improperly collected rather than declaring it a false positive and hence reduce false positive rates. This process enhances efficiency, reduces parental anxiety, and improves positive predictive values. (C) 2011 Elsevier B.V. All rights reserved. C1 [Chace, Donald H.; Clark, Reese H.; Spitzer, Alan R.] Pediat Med Grp Inc, Pediat Ctr Res Educ & Qual, Sunrise, FL 33323 USA. [De Jesus, Victor R.; Lim, Timothy H.; Hannon, W. Harry] Ctr Dis Control & Prevent, Newborn Screening Qual Assurance Program, Atlanta, GA 30341 USA. RP Chace, DH (reprint author), Pediat Med Grp Inc, Pediat Ctr Res Educ & Qual, 1301 Concord Terrace, Sunrise, FL 33323 USA. EM donald_chace@pediatrix.com NR 15 TC 8 Z9 8 U1 1 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD JUL 15 PY 2011 VL 412 IS 15-16 BP 1385 EP 1390 DI 10.1016/j.cca.2011.04.009 PG 6 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 781GB UT WOS:000291917500016 PM 21514290 ER PT J AU Hettick, JM Siegel, PD AF Hettick, Justin M. Siegel, Paul D. TI Determination of the toluene diisocyanate binding sites on human serum albumin by tandem mass spectrometry SO ANALYTICAL BIOCHEMISTRY LA English DT Article DE Diisocyanate; Serum albumin; Tandem mass spectrometry ID 4,4'-METHYLENEDIPHENYL DIISOCYANATE; HEXAHYDROPHTHALIC ANHYDRIDE; PROTEIN ADDUCTS; IN-VIVO; ISOCYANATE; EXPOSURE; WORKERS; ASTHMA; IDENTIFICATION; ANTIGENICITY AB Diisocyanates are highly reactive chemical compounds widely used in the manufacture of polyurethanes. Although diisocyanates have been identified as causative agents of allergic respiratory diseases, the specific mechanism by which these diseases occur is largely unknown. To better understand the chemical species produced when diisocyanates react with protein, tandem mass spectrometry was employed to unambiguously identify the binding sites of the industrially important isomers, 2,4- and 2,6-toluene diisocyanate, on human serum albumin at varying diisocyanate/protein ratios. The 2,4-isomer results in approximately 2-fold higher conjugation product ion abundances than does the 2,6-isomer, suggesting that the 2,4-isomer has a higher reactivity toward albumin. Both isomers preferentially react with the N-terminal amine of the protein and the epsilon-NH(2) of lysine. At a low (1:2) diisocyanate/protein ratio, five binding sites are identified, whereas at a high (40:1) ratio, near-stoichiometric conjugation is observed with a maximum of 37 binding sites identified. Binding sites observed at the lowest conjugation ratios are conserved at higher binding ratios, suggesting a subset of 5-10 preferential binding sites on albumin. Diisocyanate-protein conjugation results in a variety of reaction products, including intra- and intermolecular crosslinking, diisocyanate self-polymerization, and diisocyanate hydrolysis. Published by Elsevier Inc. C1 [Hettick, Justin M.; Siegel, Paul D.] NIOSH, Ctr Dis Control & Prevent, Hlth Effects Lab Div, Morgantown, WV 26505 USA. RP Hettick, JM (reprint author), NIOSH, Ctr Dis Control & Prevent, Hlth Effects Lab Div, Morgantown, WV 26505 USA. EM jhettick@cdc.gov RI Hettick, Justin/E-9955-2010 NR 27 TC 14 Z9 14 U1 0 U2 11 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0003-2697 J9 ANAL BIOCHEM JI Anal. Biochem. PD JUL 15 PY 2011 VL 414 IS 2 BP 232 EP 238 DI 10.1016/j.ab.2011.03.035 PG 7 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 771SW UT WOS:000291182000009 PM 21458408 ER PT J AU Torian, L Chen, M Rhodes, P Hall, I AF Torian, Lucia Chen, Mi Rhodes, Philip Hall, Irene TI HIV Surveillance-United States, 1981-2008 (Reprinted from MMWR vol 60, pg 689-693, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID PREVENTION C1 [Chen, Mi; Rhodes, Philip; Hall, Irene] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Torian, Lucia] New York City Dept Hlth & Mental Hyg, New York, NY USA. RP Chen, M (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM mchen2@cdc.gov NR 11 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 13 PY 2011 VL 306 IS 2 BP 146 EP 149 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 791CO UT WOS:000292639400009 ER PT J AU Caixeta, RB Blanco, A Fouad, H Khoury, RN Sinha, DN Rarick, J d'Espaignet, ET Bettcher, D Mirza, SA Kaufmann, RB Andes, LJ Blutcher-Nelson, G Hsia, J Asma, S Pechacek, T AF Caixeta, Roberta B. Blanco, Adriana Fouad, Heba Khoury, Rula N. Sinha, Dhirendra N. Rarick, James d'Espaignet, Edouard Tursan Bettcher, Douglas Mirza, Sara A. Kaufmann, Rachel B. Andes, Linda J. Blutcher-Nelson, Glenda Hsia, Jason Asma, Samira Pechacek, Terry TI Cigarette Package Health Warnings and Interest in Quitting Smoking-14 Countries, 2008-2010 (Reprinted from MMWR vol 60, pg 645-651, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID LABELS C1 [Mirza, Sara A.; Kaufmann, Rachel B.; Andes, Linda J.; Blutcher-Nelson, Glenda; Hsia, Jason; Asma, Samira; Pechacek, Terry] CDC, Off Smoking & Hlth, Atlanta, GA 30333 USA. [Caixeta, Roberta B.; Blanco, Adriana] Pan Amer Hlth Org, Washington, DC USA. [Fouad, Heba] Eastern Mediterranean Reg Off, Nasr City, Egypt. [Khoury, Rula N.] European Reg Off, Geneva, Switzerland. [Sinha, Dhirendra N.] SE Asian Reg Off, New Delhi, India. [Rarick, James] Western Pacific Reg Off, Manila, Philippines. [d'Espaignet, Edouard Tursan; Bettcher, Douglas] World Hlth Org, Tobacco Free Initiat, GATS Collaborat Grp, Geneva, Switzerland. RP Mirza, SA (reprint author), CDC, Off Smoking & Hlth, Atlanta, GA 30333 USA. EM smirza@cdc.gov NR 11 TC 0 Z9 0 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 13 PY 2011 VL 306 IS 2 BP 149 EP 151 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 791CO UT WOS:000292639400010 ER PT J AU Ogbuanu, IU AF Ogbuanu, Ikechukwu U. TI Progress Toward Interruption of Wild Poliovirus Transmission-Worldwide, January 2010-March 2011 (Reprinted from MMWR vol 60, pg 582-586, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID ERADICATION C1 [Ogbuanu, Ikechukwu U.] CDC, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. [Ogbuanu, Ikechukwu U.] World Hlth Org, Polio Eradicat Dept, Geneva, Switzerland. RP Ogbuanu, IU (reprint author), CDC, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. EM ige2@cdc.gov NR 11 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 13 PY 2011 VL 306 IS 2 BP 151 EP 154 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 791CO UT WOS:000292639400011 ER PT J AU Fry, AM Perez, A Finelli, L AF Fry, Alicia M. Perez, Alejandro Finelli, Lyn TI Use of Intravenous Neuraminidase Inhibitors During the 2009 Pandemic: Results From Population-Based Surveillance SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID INFLUENZA C1 [Fry, Alicia M.; Perez, Alejandro; Finelli, Lyn] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. RP Fry, AM (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. EM afry@cdc.gov NR 5 TC 7 Z9 7 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 13 PY 2011 VL 306 IS 2 BP 160 EP 162 DI 10.1001/jama.2011.950 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 791CO UT WOS:000292639400019 PM 21750292 ER PT J AU Decker, SL AF Decker, Sandra L. TI Medicaid Payment Levels to Dentists and Access to Dental Care Among Children and Adolescents SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID ODDS RATIO AB Context Although Medicaid removes most financial barriers to receipt of dental care among children and adolescents, Medicaid recipients may not be able to access dental care if dentists decline to participate in Medicaid because of low payment levels or other reasons. Objective To describe the association between state Medicaid dental fees in 2 years (2000 and 2008) and children's receipt of dental care. Design, Setting, and Participants Data on Medicaid dental fees in 2000 and 2008 for 42 states plus the District of Columbia were merged with data from 33 657 children and adolescents (aged 2-17 years) in the National Health Interview Survey (NHIS) for the years 2000-2001 and 2008-2009. Logit models were used to estimate the probability that children and adolescents had seen a dentist in the past 6 months as a function of the Medicaid prophylaxis fee and control variables including age group, race, poverty status, and state and year effects. The effect of fees on children with Medicaid relative to a control group, privately insured counterparts, served to separate Medicaid's effect on access to care from any correlation between the Medicaid fee or changes in fees by state and other attributes of states. Main Outcome Measure Whether a child or adolescent had seen a dentist in the past 6 months. Results On average, Medicaid dental payment levels did not change significantly in inflation-adjusted terms between 2000 and 2008, although a difference existed for some states, including in 5 states plus the District of Columbia, where payments increased at least 50%. In 2008-2009, more children and adolescents covered by Medicaid (55%, 95% confidence interval [CI], 53%-57%) had seen a dentist in the past 6 months than did uninsured children (27%, 95% CI, 24%-30%), but fewer than children covered by private insurance (68%, 95% CI, 67%-70%). Changes in state Medicaid dental payment fees between 2000 and 2008 were positively associated with use of dental care among children and adolescents covered by Medicaid. For example, a $10 increase in the Medicaid prophylaxis payment level (from $ 20 to $30) was associated with a 3.92 percentage point (95% CI, 0.54-7.50) increase in the chance that a child or adolescent covered by Medicaid had seen a dentist. Conclusion Higher Medicaid payment levels to dentists were associated with higher rates of receipt of dental care among children and adolescents. JAMA. 2011;306(2):187-193 www.jama.com C1 Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Hlth Care Stat, Hyattsville, MD 20782 USA. RP Decker, SL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Hlth Care Stat, 3311 Toledo Rd,Room 3316, Hyattsville, MD 20782 USA. EM sdecker@cdc.gov NR 27 TC 41 Z9 41 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 13 PY 2011 VL 306 IS 2 BP 187 EP 193 DI 10.1001/jama.2011.956 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 791CO UT WOS:000292639400026 PM 21750296 ER PT J AU McCarthy, NL Gee, J Weintraub, E Donahue, JG Nordin, JD Daley, MF Naleway, A Henninger, M Baxter, R Crane, B Aukes, L Wagner, N Fisher, S Jacobsen, SJ Sy, L Baggs, J AF McCarthy, Natalie L. Gee, Julianne Weintraub, Eric Donahue, James G. Nordin, James D. Daley, Matthew F. Naleway, Allison Henninger, Michelle Baxter, Roger Crane, Bradley Aukes, Laurie Wagner, Nicole Fisher, Sarah Jacobsen, Steven J. Sy, Lina Baggs, James TI Monitoring vaccine safety using the Vaccine Safety Datalink: Utilizing immunization registries for pandemic influenza SO VACCINE LA English DT Article DE Vaccine; Safety; Pandemic; Influenza; Registry; Immunization ID SURVEILLANCE; SYSTEM; ACCURACY AB Mass vaccination campaigns during which new vaccines may be administered to many millions of people in a short period of time call for timely and accurate post-licensure surveillance to monitor vaccine safety. To address the need for timely H1N1 influenza vaccine safety information during the 2009-2010 H1N1 influenza pandemic, the Vaccine Safety Datalink (VSD) project assessed the feasibility and potential mechanisms for utilizing data from state and local immunization registries to capture vaccinations that would not otherwise be captured by the data systems of the participating VSD managed care organizations (MCOs). Three of the eight VSD sites were able to capture H1N1 immunization data electronically from the state and local registries, and one site was able to capture the immunizations through a paper-based system; however, the remaining four sites encountered various obstacles that prevented capture of such data. Additional work will be required at these sites to overcome the barriers, which included privacy and confidentiality laws, time constraints brought on by the pandemic, as well as data quality concerns. Published by Elsevier Ltd. C1 [McCarthy, Natalie L.; Gee, Julianne; Weintraub, Eric; Baggs, James] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Donahue, James G.] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA. [Nordin, James D.] HealthPartners Res Fdn, Minneapolis, MN USA. [Daley, Matthew F.; Wagner, Nicole] Kaiser Permanente Colorado, Denver, CO USA. [Naleway, Allison; Henninger, Michelle; Crane, Bradley] Kaiser Perrnanente NW, Portland, OR USA. [Baxter, Roger; Aukes, Laurie] No Calif Kaiser Permanente, Oakland, CA USA. [Fisher, Sarah; Jacobsen, Steven J.; Sy, Lina] So Calif Kaiser Permanente, Pasadena, CA USA. RP McCarthy, NL (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS-D26, Atlanta, GA 30333 USA. EM gvz7@cdc.gov OI Naleway, Allison/0000-0001-5747-4643; Baggs, James/0000-0003-0757-4683; Jacobsen, Steven/0000-0002-8174-8533 FU Centers for Disease Control and Prevention FX This study was supported by the Vaccine Safety Data link contract with America's Health Insurance Plans, funded by the Centers for Disease Control and Prevention. Thanks to Jerry Tokars, MD, MPH and Frank Destefano, MD, MPH for editorial assistance. NR 14 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD JUL 12 PY 2011 VL 29 IS 31 BP 4891 EP 4896 DI 10.1016/j.vaccine.2011.05.003 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 796HX UT WOS:000293043500004 PM 21596088 ER PT J AU Yao, X Hamilton, RG Weng, NP Xue, QL Bream, JH Li, HF Tian, J Yeh, SH Resnick, B Xu, XY Walston, J Fried, LP Leng, SX AF Yao, Xu Hamilton, Robert G. Weng, Nan-ping Xue, Qian-Li Bream, Jay H. Li, Huifen Tian, Jing Yeh, Shu-Hui Resnick, Barbara Xu, Xiyan Walston, Jeremy Fried, Linda P. Leng, Sean X. TI Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults SO VACCINE LA English DT Article DE Frailty; Influenza immunization; Antibody response; Influenza infection; Influenza-like illness; Older adults ID CELLULAR IMMUNE-RESPONSES; MORTALITY BENEFITS; CONTROLLED TRIAL; SERUM INTERLEUKIN-6; GERIATRIC SYNDROME; ELDERLY-PEOPLE; UNITED-STATES; INFLAMMATION; PROTECTION; WOMEN AB Annual immunization with a trivalent inactivated vaccine (TIV) is considered efficacious for prevention of seasonal influenza in older adults. However, significant controversy exists in the current literature regarding the clinical effectiveness of TIV immunization in this highly heterogeneous population. Frailty is an important geriatric syndrome characterized by decreased physiologic reserve and increased vulnerability to stressors. Using a validated set of frailty criteria, we conducted a prospective observational study to evaluate TIV-induced strain-specific hemagglutination inhibition (HI) antibody titers and post-vaccination rates of influenza-like illness (ILI) and infection in frail and nonfrail older adults. The results indicate that frailty was associated with significant impairment in TIV-induced strain-specific HI titers and increased rates of ILI and laboratory-confirmed influenza infection. These findings suggest that assessing frailty status in the elderly may identify those who are less likely to respond to TIV immunization and be at higher risk for seasonal influenza and its complications. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Yao, Xu; Xue, Qian-Li; Li, Huifen; Tian, Jing; Walston, Jeremy; Leng, Sean X.] Johns Hopkins Univ, Sch Med, Dept Med, Div Geriatr Med, Baltimore, MD 21224 USA. [Yao, Xu; Xue, Qian-Li; Li, Huifen; Tian, Jing; Walston, Jeremy; Leng, Sean X.] Johns Hopkins Univ, Sch Med, Dept Med, Div Gerontol, Baltimore, MD 21224 USA. [Bream, Jay H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA. [Weng, Nan-ping] NIA, Lab Mol Biol & Immunol, Baltimore, MD 21224 USA. [Resnick, Barbara] Univ Maryland, Sch Nursing, Baltimore, MD 21201 USA. [Xu, Xiyan] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Fried, Linda P.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. RP Leng, SX (reprint author), Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Div Geriatr Med & Gerontol,Dept Med, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA. EM sleng1@jhmi.edu FU National Institute on Aging; American Federation for Aging Research; John A. Hartford Foundation; Atlantic Philanthropies; Starr Foundation FX Sean Leng is a current recipient of the Paul Beeson Career Development Award in Aging Research, K23 AG028963, (supported by the National Institute on Aging, the American Federation for Aging Research, The John A. Hartford Foundation, The Atlantic Philanthropies, The Starr Foundation and an anonymous donor). NR 45 TC 39 Z9 40 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD JUL 12 PY 2011 VL 29 IS 31 BP 5015 EP 5021 DI 10.1016/j.vaccine.2011.04.077 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 796HX UT WOS:000293043500019 PM 21565245 ER PT J AU DeStefano, F Vellozzi, C Schonberger, LB Chen, RT AF DeStefano, Frank Vellozzi, Claudia Schonberger, Lawrence B. Chen, Robert T. TI Safety of adjuvanted pandemic influenza A (H1N1) 2009 vaccines SO BRITISH MEDICAL JOURNAL LA English DT Editorial Material ID GUILLAIN-BARRE-SYNDROME; UNITED-STATES C1 [DeStefano, Frank; Vellozzi, Claudia] Ctr Dis Control & Prevent CDC, Immunizat Safety Off MS D26, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Schonberger, Lawrence B.] CDC, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Chen, Robert T.] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP DeStefano, F (reprint author), Ctr Dis Control & Prevent CDC, Immunizat Safety Off MS D26, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM bchen@cdc.gov NR 9 TC 3 Z9 3 U1 0 U2 2 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BRIT MED J JI Br. Med. J. PD JUL 12 PY 2011 VL 343 AR d4159 DI 10.1136/bmj.d4159 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 794NX UT WOS:000292908200003 PM 21750073 ER PT J AU Pevzner, ES Vandebriel, G Lowrance, DW Gasana, M Finlay, A AF Pevzner, Eric S. Vandebriel, Greet Lowrance, David W. Gasana, Michel Finlay, Alyssa TI Evaluation of the Rapid Scale-up of Collaborative TB/HIV Activities in TB Facilities in Rwanda, 2005-2009 SO BMC PUBLIC HEALTH LA English DT Article ID SUB-SAHARAN AFRICA; HIV CARE; ANTIRETROVIRAL THERAPY; TUBERCULOSIS PATIENTS; MORTALITY; SURVIVAL; THAILAND; OUTCOMES; PROGRAM; CITY AB Background: In 2005, Rwanda drafted a national TB/HIV policy and began scaling-up collaborative TB/HIV activities. Prior to the scale-up, we evaluated existing TB/HIV practices, possible barriers to policy and programmatic implementation, and patient treatment outcomes. We then used our evaluation data as a baseline for evaluating the national scale-up of collaborative TB/HIV activities from 2005 through 2009. Methods: Our baseline evaluation included a cross-sectional evaluation of 23/161 TB clinics. We conducted structured interviews with patients and clinic staff and reviewed TB registers and patient records to assess HIV testing practices, provision of HIV care and treatment for people with TB that tested positive for HIV, and patients' TB treatment outcomes. Following our baseline evaluation, we used nationally representative TB/HIV surveillance data to monitor the scale-up of collaborative TB/HIV activities Results: Of 207 patients interviewed, 76% were offered HIV testing, 99% accepted, and 49% reported positive test results. Of 40 staff interviewed, 68% reported offering HIV testing to >50% of patients. From 2005-2009, scaled-up TB/HIV activities resulted in increased HIV testing of patients with TB (69% to 97%) and provision of cotrimoxazole (15% to 92%) and antiretroviral therapy (13% to 49%) for patients with TB disease and HIV infection (TB/HIV). The risk of death among patients with TB/HIV relative to patients with TB not infected with HIV declined from 2005 (RR = 6.1, 95%CI 2.6, 14.0) to 2007 (RR = 1.8, 95%CI 1.68, 1.94). Conclusions: Our baseline evaluation highlighted that staff and patients were receptive to HIV testing. However, expanded access to testing, care, and treatment was needed based on the proportion of patients with TB having unknown HIV status and the high rate of HIV infection and poorer TB treatment outcomes for patients with TB/HIV. Following our evaluation, scale-up of TB/HIV services resulted in almost all patients with TB knowing their HIV status. Scale-up also resulted in dramatic increases in the uptake of lifesaving HIV care and treatment coinciding with a decline in the risk of death among patients with TB/HIV. C1 [Pevzner, Eric S.; Finlay, Alyssa] US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [Vandebriel, Greet] Columbia Univ, Int Ctr AIDS Care & Treatment Programs, Kigali, Rwanda. [Lowrance, David W.] US Ctr Dis Control & Prevent, Global AIDS Program, Kigali, Rwanda. [Gasana, Michel] Rwanda Biomed Ctr, Natl TB Programme, Kigali, Rwanda. RP Pevzner, ES (reprint author), US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. EM ecp9@cdc.gov FU President's Emergency Plan for AIDS Relief, Global AIDS Program of Rwanda FX Funding for this study was provided by the President's Emergency Plan for AIDS Relief, Global AIDS Program of Rwanda. NR 29 TC 11 Z9 11 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD JUL 11 PY 2011 VL 11 AR 550 DI 10.1186/1471-2458-11-550 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 800AO UT WOS:000293329200001 PM 21745385 ER PT J AU Yang, QH Liu, TB Kuklina, EV Flanders, WD Hong, YL Gillespie, C Chang, MH Gwinn, M Dowling, N Khoury, MJ Hu, FB AF Yang, Quanhe Liu, Tiebin Kuklina, Elena V. Flanders, W. Dana Hong, Yuling Gillespie, Cathleen Chang, Man-Huei Gwinn, Marta Dowling, Nicole Khoury, Muin J. Hu, Frank B. TI Sodium and Potassium Intake and Mortality Among US Adults Prospective Data From the Third National Health and Nutrition Examination Survey SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID NUTRITION-EXAMINATION-SURVEY; EPISODICALLY CONSUMED FOODS; REDUCED DIETARY-SODIUM; CORONARY-HEART-DISEASE; 3RD NATIONAL-HEALTH; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; URINARY SODIUM; FOLLOW-UP; HYPERTENSION PREVENTION AB Background: Several epidemiologic studies suggested that higher sodium and lower potassium intakes were associated with increased risk of cardiovascular diseases (CVD). Few studies have examined joint effects of dietary sodium and potassium intake on risk of mortality. Methods: To investigate estimated usual intakes of sodium and potassium as well as their ratio in relation to risk of all-cause and CVD mortality, the Third National Health and Nutrition Examination Survey Linked Mortality File (19882006), a prospective cohort study of a nationally representative sample of 12 267 US adults, studied all-cause, cardiovascular, and ischemic heart (IHD) diseases mortality. Results: During a mean follow-up period of 14.8 years, we documented a total of 2270 deaths, including 825 CVD deaths and 443 IHD deaths. After multivariable adjustment, higher sodium intake was associated with increased all-cause mortality (hazard ratio [HR], 1.20; 95% confidence interval ECU, 1.03-1.41 per 1000 mg/d), whereas higher potassium intake was associated with lower mortality risk (HR, 0.80; 95% CI, 0.67-0.94 per 1000 mg/d). For sodium-potassium ratio, the adjusted HRs comparing the highest quartile with the lowest quartile were HR, 1.46 (95% CI, 1.27-1.67) for all-cause mortality; HR, 1.46(95% CI, 1.11-1.92) for CVD mortality; and FIR, 2.15 (95% CI, 1.48-3.12) for IHD mortality. These findings did not differ significantly by sex, race/ethnicity, body mass index, hypertension status, education levels, or physical activity. Conclusion: Our findings suggest that a higher sodium-potassium ratio is associated with significantly increased risk of CVD and all-cause mortality, and higher sodium intake is associated with increased total mortality in the general US population. C1 [Kuklina, Elena V.; Hong, Yuling; Gillespie, Cathleen] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. [Yang, Quanhe; Liu, Tiebin; Gwinn, Marta; Dowling, Nicole; Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30341 USA. [Flanders, W. Dana] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Hu, Frank B.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Hu, Frank B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Yang, QH (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Hwy NE,Mail Stop K-47, Atlanta, GA 30341 USA. EM qay0@cdc.gov NR 59 TC 137 Z9 142 U1 3 U2 23 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0003-9926 EI 1538-3679 J9 ARCH INTERN MED JI Arch. Intern. Med. PD JUL 11 PY 2011 VL 171 IS 13 BP 1183 EP 1191 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 791IJ UT WOS:000292658100008 PM 21747015 ER PT J AU Sikulu, M Dowell, KM Hugo, LE Wirtz, RA Michel, K Peiris, KHS Moore, S Killeen, GF Dowell, FE AF Sikulu, Maggy Dowell, Kayla M. Hugo, Leon E. Wirtz, Robert A. Michel, Kristin Peiris, Kamaranga H. S. Moore, Sarah Killeen, Gerry F. Dowell, Floyd E. TI Evaluating RNAlater (R) as a preservative for using near-infrared spectroscopy to predict Anopheles gambiae age and species SO MALARIA JOURNAL LA English DT Article ID BED NETS; MALARIA TRANSMISSION; IDENTIFICATION; MOSQUITOS; POPULATION; EXPRESSION; MORTALITY; SPECIMENS; TANZANIA; COMPLEX AB Background: Mosquito age and species identification is a crucial determinant of the efficacy of vector control programmes. Near-infrared spectroscopy (NIRS) has previously been applied successfully to rapidly, non-destructively, and simultaneously determine the age and species of freshly anesthetized African malaria vectors from the Anopheles gambiae s.l. species complex: An. gambiae s. s. and Anopheles arabiensis. However, this has only been achieved on freshly-collected specimens and future applications will require samples to be preserved between field collections and scanning by NIRS. In this study, a sample preservation method (RNAlater (R)) was evaluated for mosquito age and species identification by NIRS against scans of fresh samples. Methods: Two strains of An. gambiae s. s. (CDC and G3) and two strains of An. arabiensis (Dongola, KGB) were reared in the laboratory while the third strain of An. arabiensis (Ifakara) was reared in a semi-field system. All mosquitoes were scanned when fresh and rescanned after preservation in RNAlater (R) for several weeks. Age and species identification was determined using a cross-validation. Results: The mean accuracy obtained for predicting the age of young (<7 days) or old (>= 7 days) of all fresh (n = 633) and all preserved (n = 691) mosquito samples using the cross-validation technique was 83% and 90%, respectively. For species identification, accuracies were 82% for fresh against 80% for RNAlater (R) preserved. For both analyses, preserving mosquitoes in RNAlater (R) was associated with a highly significant reduction in the likelihood of a misclassification of mosquitoes as young or old using NIRS. Important to note is that the costs for preserving mosquito specimens with RNAlater (R) ranges from 3-13 cents per insect depending on the size of the tube used and the number of specimens pooled in one tube. Conclusion: RNAlater (R) can be used to preserve mosquitoes for subsequent scanning and analysis by NIRS to determine their age and species with minimal costs and with accuracy similar to that achieved from fresh insects. Cold storage availability allows samples to be stored longer than a week after field collection. Further study to develop robust calibrations applicable to other strains from diverse ecological settings is recommended. C1 [Dowell, Kayla M.; Dowell, Floyd E.] USDA ARS, Engn & Wind Eros Res Unit, Ctr Grain & Anim Hlth Res, Manhattan, KS USA. [Sikulu, Maggy] Griffith Univ, Nathan, Qld 4111, Australia. [Sikulu, Maggy; Hugo, Leon E.] Queensland Inst Med Res, Herston, Qld 4006, Australia. [Sikulu, Maggy; Moore, Sarah; Killeen, Gerry F.] Ifakara Hlth Inst, Biomed & Environm Sci Themat Grp, Morogoro, Tanzania. [Wirtz, Robert A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Michel, Kristin] Kansas State Univ, Div Biol, Manhattan, KS 66506 USA. [Peiris, Kamaranga H. S.] Kansas State Univ, Dept Biol & Agr Engn, Manhattan, KS 66506 USA. [Moore, Sarah] London Sch Hyg & Trop Med, Dis Control & Vector Biol Unit, London WC1, England. [Killeen, Gerry F.] Univ Liverpool, Liverpool Sch Trop Med, Vector Grp, Liverpool L3 5QA, Merseyside, England. RP Dowell, FE (reprint author), USDA ARS, Engn & Wind Eros Res Unit, Ctr Grain & Anim Hlth Res, Manhattan, KS USA. EM floyd.dowell@ars.usda.gov RI Michel, Kristin/F-3400-2011 FU Bill & Melinda Gates Foundation [51431, 45114]; National Health and Medical Research Council, Australia [496601]; NIH [P20RR017686]; Wellcome Trust [076806]; IAEA FX We thank Paul Howell (Malaria Research and Reference Reagent Resource Center, CDC) for providing mosquitoes; Tinea Graves and KaraJo Sprigg for rearing mosquitoes at KSU; Ally Daraja for rearing mosquitoes at IHI; and Peter O'Rourke (QIMR) for advice with statistical analysis. Thanks also to Hassan Mtambala, Peter Pazia, Daniel Lugiko, Nuru Nchimbi and Japheth Kihonda of IHI for their technical assistance. This study was supported by the Bill & Melinda Gates Foundation (awards 51431 and 45114), a National Health and Medical Research Council, Australia, programme grant (496601), NIH grant P20RR017686 subaward to KM, as well as a Research Career Development Fellowship (076806) provided to GFK by the Wellcome Trust, and IAEA fellowship funding provided to FED. NR 36 TC 9 Z9 10 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD JUL 8 PY 2011 VL 10 AR 186 DI 10.1186/1475-2875-10-186 PG 7 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 808SV UT WOS:000293999600001 PM 21740582 ER PT J AU Piercefield, EW Collier, SA Hlavsa, MC Beach, MJ AF Piercefield, Emily W. Collier, Sarah A. Hlavsa, Michele C. Beach, Michael J. TI Estimated Burden of Acute Otitis Externa-United States, 2003-2007 (Reprinted) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Collier, Sarah A.; Hlavsa, Michele C.; Beach, Michael J.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM healthywater@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 6 PY 2011 VL 306 IS 1 BP 31 EP 33 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 787LV UT WOS:000292378700008 ER PT J AU Katz, KA Pierce, EF Aiem, H Henderson, P Pandori, M Wu, A Buono, S Barry, PM Samuel, M Kong, C Dixon, P Bolan, G Weinstock, HS Yee, EL Kirkcaldy, RD Khaokham, CB AF Katz, Kenneth A. Pierce, Elaine F. Aiem, Heidi Henderson, Philip Pandori, Mark Wu, Abel Buono, Sean Barry, Pennan M. Samuel, Michael Kong, Carol Dixon, Paula Bolan, Gail Weinstock, Hillard S. Yee, Eileen L. Kirkcaldy, Robert D. Khaokham, Christina B. TI Neisseria gonorrhoeae With Reduced Susceptibility to Azithromycin-San Diego County, California, 2009 (Reprinted from MMWR, vol 60, pg 579-581, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID RESISTANCE; EMERGENCE C1 [Pandori, Mark; Wu, Abel; Buono, Sean] San Francisco Dept Publ Hlth Lab, San Francisco, CA USA. [Barry, Pennan M.] San Francisco Dept Publ Hlth, STD Prevent & Control Svcs, San Francisco, CA USA. [Dixon, Paula] Univ Alabama, Reg Gonoccoccal Isolate Surveillance Project Lab, Tuscaloosa, AL 35487 USA. [Khaokham, Christina B.] CDC, Atlanta, GA 30333 USA. RP Khaokham, CB (reprint author), CDC, Atlanta, GA 30333 USA. EM ckhaokham@cdc.gov NR 11 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 6 PY 2011 VL 306 IS 1 BP 33 EP 35 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 787LV UT WOS:000292378700009 ER PT J AU Koppaka, R AF Koppaka, Ram CA Domestic Public Hlth Achievements TI Ten Great Public Health Achievements-United States, 2001-2010 (Reprinted) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Koppaka, Ram] CDC, Epidemiol & Anal Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Koppaka, R (reprint author), CDC, Epidemiol & Anal Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. EM rkoppaka@cdc.gov NR 0 TC 7 Z9 7 U1 1 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 6 PY 2011 VL 306 IS 1 BP 36 EP 38 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 787LV UT WOS:000292378700010 ER PT J AU Al Mheid, I Patel, R Murrow, J Morris, A Rahman, A Fike, L Kavtaradze, N Uphoff, I Hooper, C Tangpricha, V Alexander, RW Brigham, K Quyyumi, AA AF Al Mheid, Ibhar Patel, Riyaz Murrow, Jonathan Morris, Alanna Rahman, Ayaz Fike, Lucy Kavtaradze, Nino Uphoff, Irina Hooper, Craig Tangpricha, Vin Alexander, R. Wayne Brigham, Kenneth Quyyumi, Arshed A. TI Vitamin D Status Is Associated With Arterial Stiffness and Vascular Dysfunction in Healthy Humans SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE arterial stiffness; endothelial function; vitamin D ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; CARDIOVASCULAR RISK-FACTORS; TYPE-2 DIABETES-MELLITUS; BLOOD-PRESSURE; 1,25-DIHYDROXYVITAMIN D-3; ENDOTHELIAL FUNCTION; 25-HYDROXYVITAMIN-D LEVELS; D DEFICIENCY; HYPERTENSION AB Objectives The primary objective of this study was to elucidate mechanisms underlying the link between vitamin D status and cardiovascular disease by exploring the relationship between 25-hydroxyvitamin D (25-OH D), an established marker of vitamin D status, and vascular function in healthy adults. Background Mechanisms underlying vitamin D deficiency-mediated increased risk of cardiovascular disease remain unknown. Vitamin D influences endothelial and smooth muscle cell function, mediates inflammation, and modulates the renin-angiotensin-aldosterone axis. We investigated the relationship between vitamin D status and vascular function in humans, with the hypothesis that vitamin D insufficiency will be associated with increased arterial stiffness and abnormal vascular function. Methods We measured serum 25-OH D in 554 subjects. Endothelial function was assessed as brachial artery flow-mediated dilation, and microvascular function was assessed as digital reactive hyperemia index. Carotid-femoral pulse wave velocity and radial tonometry-derived central augmentation index and subendocardial viability ratio were measured to assess arterial stiffness. Results Mean 25-OH D was 31.8 +/- 14 ng/ml. After adjustment for age, sex, race, body mass index, total cholesterol, low-density lipoprotein, triglycerides, C-reactive protein, and medication use, 25-OH D remained independently associated with flow-mediated vasodilation (beta = 0.1, p = 0.03), reactive hyperemia index (beta = 0.23, p < 0.001), pulse wave velocity (beta = -0.09, p = 0.04), augmentation index (beta = -0.11, p = 0.03), and subendocardial viability ratio (beta = 0.18, p = 0.001). In 42 subjects with vitamin D insufficiency, normalization of 25-OH D at 6 months was associated with increases in reactive hyperemia index (0.38 +/- 0.14, p = 0.009) and subendocardial viability ratio (7.7 +/- 3.1, p = 0.04), and a decrease in mean arterial pressure (4.6 +/- 2.3 mm Hg, p = 0.02). Conclusions Vitamin D insufficiency is associated with increased arterial stiffness and endothelial dysfunction in the conductance and resistance blood vessels in humans, irrespective of traditional risk burden. Our findings provide impetus for larger trials to assess the effects of vitamin D therapy in cardiovascular disease. (J Am Coll Cardiol 2011;58:186-92) (C) 2011 by the American College of Cardiology Foundation C1 [Al Mheid, Ibhar; Patel, Riyaz; Morris, Alanna; Rahman, Ayaz; Fike, Lucy; Kavtaradze, Nino; Uphoff, Irina; Alexander, R. Wayne; Brigham, Kenneth; Quyyumi, Arshed A.] Emory Univ, Sch Med, Atlanta, GA USA. [Patel, Riyaz] Cardiff Univ, Cardiff, S Glam, Wales. [Murrow, Jonathan] Med Coll Georgia Univ Georgia Med Partnership, Athens, GA USA. [Hooper, Craig] Ctr Dis Control & Prevent, Atlanta, GA USA. [Brigham, Kenneth] Emory Georgia Inst Technol Predict Hlth Inst, Atlanta, GA USA. [Tangpricha, Vin] Atlanta VA Med Ctr, Atlanta, GA USA. RP Quyyumi, AA (reprint author), Emory Univ Hosp, 1364 Clifton Rd,Suite D403C, Atlanta, GA 30322 USA. EM aquyyum@emory.edu RI Tangpricha, Vin/A-8645-2009; Library, Woodruff Health/A-6096-2012; OI Tangpricha, Vin/0000-0002-4021-5853 FU American Heart Association; Emory Predictive Health Institute; Woodruff Fund; National Institutes of Health [UL1RR025008, M01RR0039] FX This study was supported by the American Heart Association, The Emory Predictive Health Institute, Woodruff Fund, and in part by National Institutes of Health Grants UL1RR025008 from the Clinical and Translational Science Award program and M01RR0039. The authors have reported that they have no relationships to disclose. NR 41 TC 117 Z9 120 U1 1 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD JUL 5 PY 2011 VL 58 IS 2 BP 186 EP 192 DI 10.1016/j.jacc.2011.02.051 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 784WN UT WOS:000292189300015 PM 21718915 ER PT J AU Schrag, SJ AF Schrag, Stephanie J. CA Global Grp B Streptococcal Vaccine TI Group B streptococcal vaccine for resource-poor countries SO LANCET LA English DT Editorial Material ID CONJUGATE VACCINE; DISEASE; MORTALITY; INFANTS C1 [Schrag, Stephanie J.; Global Grp B Streptococcal Vaccine] Ctr Dis Control & Prevent CDC, Div Bacterial Dis, Atlanta, GA 30333 USA. RP Schrag, SJ (reprint author), Ctr Dis Control & Prevent CDC, Div Bacterial Dis, Atlanta, GA 30333 USA. EM sschrag@cdc.gov NR 14 TC 7 Z9 7 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD JUL 2 PY 2011 VL 378 IS 9785 BP 11 EP 12 DI 10.1016/S0140-6736(10)61932-0 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 791IU UT WOS:000292659700008 PM 21377722 ER PT J AU Bailey, A Snead, M Costenbader, E Townsend, M Anderson, C Warner, L Hylton-Kong, T Steiner, M AF Bailey, A. Snead, M. Costenbader, E. Townsend, M. Anderson, C. Warner, L. Hylton-Kong, T. Steiner, M. TI HELP ME UNDERSTAND YOUR LAB RESULTS: "AN EXPLORATORY, QUALITATIVE STUDY OF DISCORDANCE BETWEEN BIOLOGIC AND SELF-REPORTED MEASURES OF SEMEN EXPOSURE IN JAMAICA" SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Bailey, A.; Townsend, M.] Univ W Indies Mona, Kingston, Jamaica. [Snead, M.; Warner, L.] Ctr Dis Control, Atlanta, GA 30333 USA. [Hylton-Kong, T.] Comprehens Hlth Ctr, Kingston, Jamaica. NR 0 TC 0 Z9 0 U1 1 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A264 EP A264 DI 10.1136/sextrans-2011-050108.395 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201287 ER PT J AU Bradley, H Satterwhite, C AF Bradley, H. Satterwhite, C. TI PREVALENCE OF NEISSERIA GONORRHOEAE INFECTIONS AMONG MEN AND WOMEN ENTERING THE NATIONAL JOB TRAINING PROGRAM-USA, 2004-2009 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Bradley, H.; Satterwhite, C.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A114 EP A114 DI 10.1136/sextrans-2011-050108.36 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200275 ER PT J AU Bradley, H Asbel, L Bernstein, K Mattson, M Pathela, P Pino, R Samuel, M Schwebke, J Stenger, M Tabidze, I Zenilman, J Dowell, D Weinstock, H AF Bradley, H. Asbel, L. Bernstein, K. Mattson, M. Pathela, P. Pino, R. Samuel, M. Schwebke, J. Stenger, M. Tabidze, I. Zenilman, J. Dowell, D. Weinstock, H. TI HIV TESTING AMONG PATIENTS INFECTED WITH NEISSERIA GONORRHOEAE-STD SURVEILLANCE NETWORK, USA, 2009-2010 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Bradley, H.; Dowell, D.; Weinstock, H.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Asbel, L.] Philadelphia Dept Publ Hlth, Philadelphia, PA USA. [Bernstein, K.] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Pathela, P.] Dept Hlth & Mental Hyg, New York, NY USA. [Schwebke, J.] Univ Alabama, Birmingham, AL USA. [Stenger, M.] Dept Hlth, Washington, DC USA. [Tabidze, I.] Dept Publ Hlth, Chicago, IL USA. [Zenilman, J.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A97 EP A98 DI 10.1136/sextrans-2011-050109.171 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200236 ER PT J AU Brewer, TH Peterman, TA Newman, DR Shiver, S AF Brewer, T. H. Peterman, T. A. Newman, D. R. Shiver, S. TI IDENTIFYING WOMEN AT RISK: CAN AN STD DIAGNOSIS HELP TARGET WOMEN FOR RISK REDUCTION COUNSELLING? MIAMI-FORT-LAUDERDALE, 2000-2009 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Brewer, T. H.] CDC Florida DOH, Miami, FL USA. [Peterman, T. A.; Newman, D. R.] CDC, Atlanta, GA 30333 USA. [Shiver, S.] Florida Dept Hlth, Tallahassee, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A216 EP A216 DI 10.1136/sextrans-2011-050108.272 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201168 ER PT J AU Chen, CY Chi, KH Pillay, A Nachamkin, E Ballard, R AF Chen, C. Y. Chi, K. H. Pillay, A. Nachamkin, E. Ballard, R. TI DETECTION OF THE 23S RRNA POINT MUTATIONS (A2058G AND A2059G) ASSOCIATED WITH AZITHROMYCIN RESISTANCE IN TREPONEMA PALLIDUM USING A TAQMAN-BASED REAL-TIME TRIPLEX-PCR ASSAY SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Chen, C. Y.; Chi, K. H.; Pillay, A.; Nachamkin, E.; Ballard, R.] CDC, Atlanta, GA 30333 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A298 EP A298 DI 10.1136/sextrans-2011-050108.482 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874202032 ER PT J AU Chesson, H Markowitz, L AF Chesson, H. Markowitz, L. TI THE COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINATION OF FEMALES OVER AGE 12 YEARS IN THE USA SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Chesson, H.; Markowitz, L.] US Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A62 EP A62 DI 10.1136/sextrans-2011-050109.87 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200153 ER PT J AU Chi, KH Chen, CY Ye, T Nachamkin, E Ballard, R AF Chi, K. H. Chen, C. Y. Ye, T. Nachamkin, E. Ballard, R. TI THE MOLECULAR DIAGNOSIS OF RECTAL GC AND CT INFECTIONS USING THE FTA ELUTE CARD FOR SPECIMEN COLLECTION AND THE REAL-TIME MULTIPLEX PCR FOR DETECTION SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Chi, K. H.; Chen, C. Y.; Ye, T.; Nachamkin, E.; Ballard, R.] CDC, Atlanta, GA 30333 USA. NR 0 TC 1 Z9 1 U1 1 U2 2 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A272 EP A272 DI 10.1136/sextrans-2011-050108.415 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201306 ER PT J AU Conrad, M Gorman, A Schilinger, J Sullivan, S Upcroft, J Gonzalez, J Fiori, PL Arroyo, R Ravel, J Secor, E Carlton, J AF Conrad, M. Gorman, A. Schilinger, J. Sullivan, S. Upcroft, J. Gonzalez, J. Fiori, P. L. Arroyo, R. Ravel, J. Secor, E. Carlton, J. TI POPULATION GENOMICS OF TRICHOMONAS VAGINALIS REVEALS A GLOBALLY DISTRIBUTED TWO-PHYLOTYPE POPULATION STRUCTURE SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Conrad, M.; Gorman, A.; Sullivan, S.; Carlton, J.] NYU, Sch Med, New York, NY 4006 USA. [Schilinger, J.] New York City Dept Hlth & Mental Hygeine, New York, NY USA. [Upcroft, J.] Queensland Inst Med Res, I-07100 Brisbane, Qld, Australia. [Gonzalez, J.] Univ Antofogasta, Antofagasta, Chile. [Fiori, P. L.] Univ Sassari, Sassari, 20742, Italy. [Arroyo, R.] IPN, Ctr Invest & Estudios Avanzados, Mexico City, DF, Mexico. [Ravel, J.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Secor, E.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 EI 1472-3263 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A314 EP A315 DI 10.1136/sextrans-2011-050108.522 PG 3 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874202072 ER PT J AU Cox, DL AF Cox, D. L. TI PROGRESS IN DEVELOPMENT OF DUAL RAPID SYPHILIS TEST TECHNOLOGY SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Cox, D. L.] CDC, Atlanta, GA 30333 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A5 EP A6 DI 10.1136/sextrans-2011-050102.17 PG 3 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200018 ER PT J AU D'Anna, L Margolis, A Warner, L Korosteleva, O O'Donnell, L Rietmeijer, C Klausner, J Malotte, CK AF D'Anna, L. Margolis, A. Warner, L. Korosteleva, O. O'Donnell, L. Rietmeijer, C. Klausner, J. Malotte, C. K. TI CHARACTERISTICS ASSOCIATED WITH CONDOM BREAKAGE/SLIPPAGE OR PARTIAL USE DURING VAGINAL SEX WITH MAIN AND NON-MAIN PARTNERS: FINDINGS FROM THE SAFE CITY PROJECT STUDY SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [D'Anna, L.; Korosteleva, O.; Malotte, C. K.] Calif State Univ Long Beach, Long Beach, CA 90840 USA. [Margolis, A.; Warner, L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [O'Donnell, L.] Educ Dev Ctr, Boston, MA USA. [Rietmeijer, C.] Denver Publ Hlth, Denver, CO USA. [Klausner, J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A244 EP A245 DI 10.1136/sextrans-2011-050108.342 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201236 ER PT J AU de Ravello, L Rushing, SC Doshi, S Smith, MU Tulloch, S AF de Ravello, L. Rushing, S. C. Doshi, S. Smith, M. U. Tulloch, S. TI EVALUATING NATIVE STAND: A PEER EDUCATION CURRICULUM FOR HEALTHY DECISION-MAKING FOR NATIVE YOUTH SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Rushing, S. C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Smith, M. U.] Mercer Univ, Macon, GA 31207 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A226 EP A226 DI 10.1136/sextrans-2011-050108.295 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201191 ER PT J AU Dittus, P De Rosa, C Jeffries, R Afifi, A Cumberland, W Loosier, P Ethier, K Chung, E Martinez, E Kerndt, P AF Dittus, P. De Rosa, C. Jeffries, R. Afifi, A. Cumberland, W. Loosier, P. Ethier, K. Chung, E. Martinez, E. Kerndt, P. TI THE PROJECT CONNECT HEALTH SYSTEMS INTERVENTION: STD SCREENING AND HIV TESTING OUTCOMES FOR FEMALE ADOLESCENTS SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Dittus, P.; Loosier, P.; Ethier, K.] Ctr Dis Control & Prevent, Atlanta, GA USA. [De Rosa, C.] Los Angeles Cty Dept Hlth, Los Angeles, CA USA. [Jeffries, R.; Afifi, A.; Cumberland, W.] Univ Calif Los Angeles, Los Angeles, CA USA. [Chung, E.; Kerndt, P.] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A56 EP A56 DI 10.1136/sextrans-2011-050109.73 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200139 ER PT J AU Domeika, M Savicheva, A Shipitsyna, E Chen, CY Skov-Jenssen, J Hjelmevoll, O Ballard, R Unemo, M AF Domeika, M. Savicheva, A. Shipitsyna, E. Chen, C. Y. Skov-Jenssen, J. Hjelmevoll, O. Ballard, R. Unemo, M. TI INTERNATIONAL VALIDATION OF AMPLISENS NAAT SYSTEMS MANUFACTURED IN RUSSIA FOR DIAGNOSIS OF NEISSERIA GONORRHOEAE, CHLAMYDIA TRACHOMATIS, MYCOPLASMA GENITALIUM AND TRICHOMONAS VAGINALIS SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Domeika, M.] Uppsala Univ, Uppsala, Sweden. [Savicheva, A.; Shipitsyna, E.] Inst Obstet & Gynecol DI Ott, St Petersburg, Russia. [Chen, C. Y.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Skov-Jenssen, J.; Ballard, R.] State Serum Inst, Copenhagen, Denmark. [Hjelmevoll, O.] Univ Hosp N Norway, Tromso, Norway. [Unemo, M.] Orebro Univ Hosp, Orebro, Sweden. NR 0 TC 1 Z9 1 U1 1 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A353 EP A354 DI 10.1136/sextrans-2011-050119.10 PG 4 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874202166 ER PT J AU Doshi, S Owusu-Edusei, K AF Doshi, S. Owusu-Edusei, K. TI STD SURVEILLANCE AND CONTROL: DO STD AND FAMILY PLANNING CLINICS MATTER? SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Doshi, S.; Owusu-Edusei, K.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A330 EP A330 DI 10.1136/sextrans-2011-050108.565 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874202109 ER PT J AU Douglas, J Fenton, K AF Douglas, J. Fenton, K. TI DEVELOPING AND IMPLEMENTING A PUBLIC HEALTH APPROACH TO IMPROVE SEXUAL HEALTH IN THE USA SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Douglas, J.; Fenton, K.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A11 EP A12 DI 10.1136/sextrans-2011-050102.41 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200042 ER PT J AU Fakile, Y Kikkert, S Ballard, R Cox, D AF Fakile, Y. Kikkert, S. Ballard, R. Cox, D. TI PERFORMANCE CHARACTERISTICS OF BIOPLEX 2200 SYPHILIS IGG AND LIAISON TREPONEMA AUTOMATED ASSAYS FOR DETECTION OF ANTIBODIES TO TREPONEMA PALLIDUM SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Fakile, Y.; Kikkert, S.; Ballard, R.; Cox, D.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A70 EP A70 DI 10.1136/sextrans-2011-050109.106 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200172 ER PT J AU Flagg, E Weinstock, H Workowski, K Peterman, T AF Flagg, E. Weinstock, H. Workowski, K. Peterman, T. TI ORAL SEX AND RISK OF SEXUALLY TRANSMITTED INFECTIONS SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Flagg, E.; Weinstock, H.; Workowski, K.; Peterman, T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Workowski, K.] Emory Univ, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A176 EP A177 DI 10.1136/sextrans-2011-050108.184 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201083 ER PT J AU Flagg, EW Datta, SD Lyu, C Nagaraja, J Copeland, G Silva, W Peters, E Cole, L Tucker, T Byrne, MJ Unger, ER Saraiya, M Weinstock, H AF Flagg, E. W. Datta, S. Deblina Lyu, C. Nagaraja, J. Copeland, G. Silva, W. Peters, E. Cole, L. Tucker, T. Byrne, M. J. Unger, E. R. Saraiya, M. Weinstock, H. TI POPULATION BASED SURVEILLANCE FOR CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE 3 AND ADENOCARCINOMA IN SITU IN THREE CENTRAL CANCER REGISTRIES, USA 2009 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Flagg, E. W.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Datta, S. Deblina; Unger, E. R.; Saraiya, M.; Weinstock, H.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lyu, C.; Nagaraja, J.] Battelle Mem Inst, Columbus, OH 43201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A25 EP A25 DI 10.1136/sextrans-2011-050109.11 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200077 ER PT J AU Friedman, A Habel, M Kachur, R McFarlane, M Williamson, L Mishel, M Levine, S Binns, A Kapsimalis, C Patel, A AF Friedman, A. Habel, M. Kachur, R. McFarlane, M. Williamson, L. Mishel, M. Levine, S. Binns, A. Kapsimalis, C. Patel, A. TI GYT (GET YOURSELF TESTED) CAMPAIGN: GETTING YOUNG PEOPLE TALKING AND TESTED AND SPARKING A SOCIAL MOVEMENT SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Friedman, A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Habel, M.; Kachur, R.; McFarlane, M.; Kapsimalis, C.] CDC, Atlanta, GA 30333 USA. [Williamson, L.] MTV Networks, New York, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A257 EP A257 DI 10.1136/sextrans-2011-050108.378 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201270 ER PT J AU Friedman, A Forsythe, A Poehlman, J Harris, S Smith, J Uhrig, J AF Friedman, A. Forsythe, A. Poehlman, J. Harris, S. Smith, J. Uhrig, J. TI EXPLORING PERCEPTIONS OF THE SOCIAL DETERMINANTS OF STIS IN AFRICAN AMERICAN COMMUNITIES OF THE USA SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Friedman, A.; Forsythe, A.] CDC, Atlanta, GA 30333 USA. [Poehlman, J.; Harris, S.; Uhrig, J.] RTI Int, Res Triangle Pk, NC USA. [Smith, J.] Univ N Carolina, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A237 EP A237 DI 10.1136/sextrans-2011-050108.322 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201217 ER PT J AU Gallo, M Macaluso, M Warner, L Fleenor, M Hook, E Brill, I Weaver, M AF Gallo, M. Macaluso, M. Warner, L. Fleenor, M. Hook, E., III Brill, I. Weaver, M. TI RELATIONSHIP BETWEEN INCIDENT BACTERIAL VAGINOSIS, GONORRHOEA AND CHLAMYDIAL INFECTION AMONG WOMEN ATTENDING A SEXUALLY TRANSMITTED DISEASE CLINIC SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Gallo, M.; Macaluso, M.; Warner, L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Fleenor, M.; Hook, E., III] Jefferson Cty Dept Hlth, Birmingham, AL USA. [Hook, E., III; Brill, I.] Univ Alabama, Birmingham, AL USA. RI Macaluso, Maurizio/J-2076-2015 OI Macaluso, Maurizio/0000-0002-2977-9690 NR 0 TC 1 Z9 1 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A187 EP A188 DI 10.1136/sextrans-2011-050108.207 PG 3 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201104 ER PT J AU Gallo, M Warner, L King, C Sobel, J Rompalo, A Cu-Uvin, S Klein, R Schoenbaum, E Jamieson, D AF Gallo, M. Warner, L. King, C. Sobel, J. Rompalo, A. Cu-Uvin, S. Klein, R. Schoenbaum, E. Jamieson, D. TI BIOLOGICAL EVIDENCE OF SEMEN EXPOSURE IS ASSOCIATED WITH INCIDENT BACTERIAL VAGINOSIS SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Gallo, M.; Warner, L.; King, C.; Jamieson, D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sobel, J.] Wayne State Univ, Sch Med, Detroit, MI USA. [Rompalo, A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Cu-Uvin, S.] Brown Univ, Sch Med, Providence, RI 02912 USA. [Klein, R.] Mt Sinai Sch Med, New York, NY USA. [Schoenbaum, E.] Albert Einstein Coll Med, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A32 EP A32 DI 10.1136/sextrans-2011-050109.26 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200092 ER PT J AU Gallo, MF AF Gallo, M. F. TI APPLYING SEMEN BIOMARKERS TO HIV/STI RESEARCH SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Gallo, M. F.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A1 EP A1 DI 10.1136/sextrans-2011-050102.2 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200003 ER PT J AU Gift, T Bernstein, K Chesson, H Marcus, J Pipkin, S Kent, C AF Gift, T. Bernstein, K. Chesson, H. Marcus, J. Pipkin, S. Kent, C. TI THE COST-EFFECTIVENESS OF SCREENING MEN WHO HAVE SEX WITH MEN FOR RECTAL CHLAMYDIAL AND GONOCOCCAL INFECTION TO PREVENT HIV INFECTION SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Gift, T.; Chesson, H.; Kent, C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bernstein, K.; Marcus, J.; Pipkin, S.] San Francisco Dept Publ Hlth, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A252 EP A252 DI 10.1136/sextrans-2011-050108.363 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201256 ER PT J AU Gottlieb, S McRee, AL Reiter, P Dittus, P Halpern, C Brewer, N AF Gottlieb, S. McRee, A. L. Reiter, P. Dittus, P. Halpern, C. Brewer, N. TI THE INTERFACE BETWEEN HPV VACCINE IMPLEMENTATION AND STI PREVENTION: HPV VACCINE DISCUSSIONS AS AN OPPORTUNITY TO PROVIDE MESSAGES ABOUT SEXUAL HEALTH SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Gottlieb, S.; Dittus, P.] CDC, Atlanta, GA 30333 USA. [McRee, A. L.; Reiter, P.; Halpern, C.; Brewer, N.] UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A323 EP A323 DI 10.1136/sextrans-2011-050108.545 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874202095 ER PT J AU Habel, M Leichliter, JS AF Habel, M. Leichliter, J. S. TI THE SEX LIVES OF EMERGENCY CONTRACEPTION USERS IN THE USA, 2006-2008 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Habel, M.; Leichliter, J. S.] CDC, Atlanta, GA 30333 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A261 EP A262 DI 10.1136/sextrans-2011-050108.389 PG 3 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201281 ER PT J AU Habel, MA Richman, L Haecker, S Verma, R Meneghetti, A Kachur, R Collins, B Barnes, R Thompson, N Workowski, K AF Habel, M. A. Richman, L. Haecker, S. Verma, R. Meneghetti, A. Kachur, R. Collins, B. Barnes, R. Thompson, N. Workowski, K. TI DID YOU HEAR ABOUT THE 2010 STD TREATMENT GUIDELINES? RE-STRATEGIZING HOW WE E-COMMUNICATE ABOUT STD GUIDANCE SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Habel, M. A.; Richman, L.; Haecker, S.; Verma, R.; Kachur, R.; Collins, B.; Barnes, R.; Thompson, N.; Workowski, K.] CDC, Atlanta, GA 30333 USA. [Meneghetti, A.] Epocrates, San Mateo, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A257 EP A257 DI 10.1136/sextrans-2011-050108.377 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201269 ER PT J AU Hadgu, A Dendukuri, N Wang, L AF Hadgu, A. Dendukuri, N. Wang, L. TI EVALUATION OF SCREENING TESTS FOR CHLAMYDIA TRACHOMATIS: BIAS ASSOCIATED WITH THE PATIENT INFECTED STATUS ALGORITHM SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Hadgu, A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dendukuri, N.] McGill Univ, Montreal, PQ, Canada. [Wang, L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A267 EP A267 DI 10.1136/sextrans-2011-050108.402 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201294 ER PT J AU Heijne, J Althaus, C Herzog, S Tao, G Kent, C Low, N AF Heijne, J. Althaus, C. Herzog, S. Tao, G. Kent, C. Low, N. TI ESTIMATING THE RATE OF ANNUAL CHLAMYDIA SCREENING UPTAKE IN US WOMEN SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Heijne, J.; Althaus, C.; Herzog, S.; Low, N.] Univ Bern, Bern, Switzerland. [Tao, G.; Kent, C.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A22 EP A22 DI 10.1136/sextrans-2011-050109.5 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200071 ER PT J AU Hobbs, M Anderson, C Hylton-Kong, T Eastman, S Rich, K Gallo, M Legardy-Williams, J Costenbader, E Steiner, M Warner, L AF Hobbs, M. Anderson, C. Hylton-Kong, T. Eastman, S. Rich, K. Gallo, M. Legardy-Williams, J. Costenbader, E. Steiner, M. Warner, L. TI SYNDROMIC MANAGEMENT OF CERVICITIS AND VAGINAL DISCHARGE AT A STI CLINIC IN JAMAICA: LOW CURE RATES FOR CHLAMYDIAL INFECTION AND TRICHOMONIASIS SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Hobbs, M.] Univ N Carolina, Chapel Hill, NC USA. [Anderson, C.; Hylton-Kong, T.; Eastman, S.] Ctr Excellence, Comprehens Hlth Ctr, Kingston, Jamaica. [Gallo, M.; Legardy-Williams, J.; Warner, L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Costenbader, E.; Steiner, M.] Family Hlth Int, Res Triangle Pk, NC 27709 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A272 EP A273 DI 10.1136/sextrans-2011-050108.417 PG 3 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201308 ER PT J AU Hood, J Hogben, M Chartier, M Bolan, G Bauer, H AF Hood, J. Hogben, M. Chartier, M. Bolan, G. Bauer, H. TI DUAL CONTRACEPTIVE USE AMONG ADOLESCENTS AND YOUNG ADULTS: CORRELATES AND IMPLICATIONS FOR CONDOM USE AND STI OUTCOMES SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Hood, J.; Hogben, M.; Bolan, G.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A222 EP A223 DI 10.1136/sextrans-2011-050108.286 PG 3 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201182 ER PT J AU Hoover, K Tao, G Nye, M Body, B Kent, C AF Hoover, K. Tao, G. Nye, M. Body, B. Kent, C. TI MONITORING CHLAMYDIA TESTING AND POSITIVITY IN THE USA USING DATA FROM A LARGE COMMERCIAL LABORATORY CORPORATION, 2008-2010 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Hoover, K.; Tao, G.; Body, B.; Kent, C.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A209 EP A210 DI 10.1136/sextrans-2011-050108.257 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201153 ER PT J AU Hoover, K Tao, G Body, B Nye, M Kent, C AF Hoover, K. Tao, G. Body, B. Nye, M. Kent, C. TI SUBOPTIMAL REPEAT TESTING OF WOMEN WITH POSITIVE CHLAMYDIA TESTS IN THE USA, 2008-2010 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Hoover, K.; Tao, G.; Kent, C.] CDC, Atlanta, GA 30333 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A22 EP A22 DI 10.1136/sextrans-2011-050109.4 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200070 ER PT J AU Hoover, KW AF Hoover, K. W. TI PROBLEMS ENCOUNTERED WITH REVERSE SEQUENCE SYPHILIS SCREENING SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Hoover, K. W.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A12 EP A13 DI 10.1136/sextrans-2011-050102.44 PG 3 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200045 ER PT J AU Janes, G Beard, A Tao, G Hoover, K Kent, C AF Janes, G. Beard, A. Tao, G. Hoover, K. Kent, C. TI PERINATAL SCREENING FOR STIS IN THE USA: ADHERENCE TO PREVENTIVE SCREENING RECOMMENDATIONS FOR HIV AND SYPHILIS AMONG THE COMMERCIALLY INSURED (2008) SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Janes, G.; Beard, A.; Tao, G.; Hoover, K.; Kent, C.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A203 EP A204 DI 10.1136/sextrans-2011-050108.244 PG 3 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201140 ER PT J AU Javanbakht, M Stahlman, S Walker, S Gottlieb, S Markowitz, L Liddon, N Plant, A Guerry, S AF Javanbakht, M. Stahlman, S. Walker, S. Gottlieb, S. Markowitz, L. Liddon, N. Plant, A. Guerry, S. TI QUALITATIVE ASSESSMENT OF FACILITATORS AND BARRIERS TO HPV VACCINATION AMONG PROVIDERS SERVING A HIGH-RISK COMMUNITY SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Javanbakht, M.; Stahlman, S.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA. [Walker, S.; Plant, A.; Guerry, S.] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [Gottlieb, S.; Markowitz, L.; Liddon, N.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A331 EP A332 DI 10.1136/sextrans-2011-050108.570 PG 3 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874202114 ER PT J AU Johnson, R Ware, D Mena, L Xu, F AF Johnson, R. Ware, D. Mena, L. Xu, F. TI PER CENT ADDITIONAL TEST POSITIVE OLLOWING POSITIVE COMBO 2 CHLAMYDIA (CT) AND GONORRHOEA (GC) SPECIMENS: ASSESSING THE IMPACT OF PREVALENCE SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Johnson, R.; Xu, F.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mena, L.] Univ Mississippi, Med Ctr, University, MS 38677 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A270 EP A270 DI 10.1136/sextrans-2011-050108.411 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201302 ER PT J AU Jost, H Kikkert, S Fakile, Y Castro, A Ye, T Zaidi, A Ballard, R Cox, D AF Jost, H. Kikkert, S. Fakile, Y. Castro, A. Ye, T. Zaidi, A. Ballard, R. Cox, D. TI COMPARING THE ANALYTICAL SENSITIVITIES OF SIX TREPONEMAL TESTS SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Jost, H.; Kikkert, S.; Fakile, Y.; Castro, A.; Ye, T.; Zaidi, A.; Ballard, R.; Cox, D.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A297 EP A298 DI 10.1136/sextrans-2011-050108.479 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874202030 ER PT J AU Kachur, R Thompson, N Haecker, S Jones, R AF Kachur, R. Thompson, N. Haecker, S. Jones, R. TI WHAT ARE THEY ASKING? AN ANALYSIS OF STD RELATED CALLS TO CDC-INFO SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Kachur, R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Thompson, N.; Haecker, S.; Jones, R.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A259 EP A259 DI 10.1136/sextrans-2011-050108.383 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201275 ER PT J AU Kamb, M AF Kamb, M. TI MATERNAL SYPHILIS TESTING AND TREATMENT TO IMPROVE MATERNAL AND CHILD HEALTH SERVICES: PROGRESS AND CHALLENGES SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Kamb, M.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A6 EP A6 DI 10.1136/sextrans-2011-050102.18 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200019 ER PT J AU Kent, C Tao, G Hoover, K Body, B Nye, M AF Kent, C. Tao, G. Hoover, K. Body, B. Nye, M. TI CHARACTERISTICS OF CHLAMYDIA TESTING BY A LARGE COMMERCIAL LABORATORY CORPORATION, USA, 2008-2010 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Kent, C.; Tao, G.; Hoover, K.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A204 EP A205 DI 10.1136/sextrans-2011-050108.246 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201142 ER PT J AU Kirkcaldy, R Dowell, D AF Kirkcaldy, R. Dowell, D. TI EFFECTIVENESS OF GENTAMICIN FOR GONORRHOEA TREATMENT: A SYSTEMATIC REVIEW SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Kirkcaldy, R.; Dowell, D.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A277 EP A277 DI 10.1136/sextrans-2011-050108.429 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201320 ER PT J AU Kirkcaldy, R Murray, E Del Rio, C Hall, G Hook, E Whittington, W Papp, J Weinstock, H AF Kirkcaldy, R. Murray, E. Del Rio, C. Hall, G. Hook, E. Whittington, W. Papp, J. Weinstock, H. TI CEPHALOSPORIN SUSCEPTIBILITY OF NEISSERIA GONORRHOEAE ISOLATES IN THE USA, 2000-2010 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Kirkcaldy, R.; Murray, E.; Papp, J.; Weinstock, H.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hall, G.] Cleveland Clin, Cleveland, OH USA. [Del Rio, C.] Emory Univ, Atlanta, GA 30322 USA. [Hook, E.] Univ Alabama, Birmingham, AL USA. [Whittington, W.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A26 EP A26 DI 10.1136/sextrans-2011-050109.14 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200080 ER PT J AU Kroeger, K Sangaramoorthy, T Vallila-Buchman, P Robitz, R Moore, P Clymore, J AF Kroeger, K. Sangaramoorthy, T. Vallila-Buchman, P. Robitz, R. Moore, P. Clymore, J. TI SEX WORKERS, MOBILITY AND MIGRANT LATINO MEN IN THE US SOUTH: FINDINGS FROM AN EXPLORATORY RAPID ETHNOGRAPHIC ASSESSMENT IN NORTH CAROLINA SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Kroeger, K.; Sangaramoorthy, T.; Vallila-Buchman, P.; Robitz, R.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A228 EP A229 DI 10.1136/sextrans-2011-050108.300 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201196 ER PT J AU Lansky, A DiNenno, EA Wejnert, C AF Lansky, A. DiNenno, E. A. Wejnert, C. TI USE OF RESPONDENT-DRIVEN SAMPLING FOR MONITORING HIV BEHAVIOURS AMONG INJECTING DRUG USERS IN THE UNITED STATES SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Lansky, A.; DiNenno, E. A.; Wejnert, C.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A16 EP A16 DI 10.1136/sextrans-2011-050102.55 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200056 ER PT J AU Leichliter, J Lewis, D Paz-Bailey, G AF Leichliter, J. Lewis, D. Paz-Bailey, G. TI ACUTE GENITAL ULCERATION IN SOUTH AFRICAN MEN: IMPORTANCE OF AGE AND SEXUAL RISK BEHAVIOURS SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Leichliter, J.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A178 EP A178 DI 10.1136/sextrans-2011-050108.188 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201086 ER PT J AU Leichliter, J Aral, S AF Leichliter, Jami Aral, Sevgi TI DURATION OF RECENT SEXUAL PARTNERSHIPS IN SEXUALLY ACTIVE MEN AND WOMEN SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Leichliter, Jami; Aral, Sevgi] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A59 EP A59 DI 10.1136/sextrans-2011-050109.81 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200147 ER PT J AU Lewis, D Chirwa, T Msimang, V Radebe, F Kamb, M Sanne, I Firnhaber, C AF Lewis, D. Chirwa, T. Msimang, V. Radebe, F. Kamb, M. Sanne, I. Firnhaber, C. TI BURDEN OF GENITAL DISCHARGE PATHOGENS AND ASSOCIATED CHARACTERISTICS OF ASYMPTOMATIC HIV-INFECTED PATIENTS IN JOHANNESBURG, SOUTH AFRICA SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Lewis, D.; Msimang, V.; Radebe, F.] Natl Inst Communicable Dis, Natl Hlth Lab Serv, Johannesburg, South Africa. [Chirwa, T.] Univ Witwatersrand Johannesburg, Johannesburg, South Africa. [Kamb, M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sanne, I.; Firnhaber, C.] Right Care, Johannesburg, South Africa. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A53 EP A53 DI 10.1136/sextrans-2011-050109.66 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200132 ER PT J AU Lewis, F Mettey, A Anschuetz, G Asbel, L Reyes, ADL Salmon, M AF Lewis, F. Mettey, A. Anschuetz, G. Asbel, L. Reyes, A. De Los Salmon, M. TI RISK ASSESSMENT IN A LARGE COHORT OF URBAN PUBLIC HIGH SCHOOL STUDENTS INFECTED WITH CT OR GC: PHILADELPHIA, 2009-2010 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Lewis, F.; Mettey, A.; Anschuetz, G.; Asbel, L.; Reyes, A. De Los; Salmon, M.] CDC, Dept Publ Hlth, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A151 EP A151 DI 10.1136/sextrans-2011-050108.123 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201022 ER PT J AU Liddon, N Leichliter, JS Hood, J Markowitz, LE AF Liddon, N. Leichliter, J. S. Hood, J. Markowitz, L. E. TI HPV VACCINE AND SEXUAL BEHAVIOUR AMONG US ADOLESCENT AND YOUNG ADULT WOMEN SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Liddon, N.; Leichliter, J. S.; Hood, J.; Markowitz, L. E.] US Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A213 EP A213 DI 10.1136/sextrans-2011-050108.266 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201162 ER PT J AU Llata, E Pugsley, R Tabidze, I Asbel, L Bernstein, K Kerani, R Schwebke, J Longfellow, L Mettenbrink, C Guerry, S Zenilman, J Klingler, E Weinstock, H AF Llata, E. Pugsley, R. Tabidze, I. Asbel, L. Bernstein, K. Kerani, R. Schwebke, J. Longfellow, L. Mettenbrink, C. Guerry, S. Zenilman, J. Klingler, E. Weinstock, H. TI PREVALENCE OF ANOGENITAL WARTS AMONG STD CLINIC PATIENTS-STD SURVEILLANCE NETWORK, USA, JANUARY 2010-SEPTEMBER 2010 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Llata, E.; Weinstock, H.] CDC, Atlanta, GA 30333 USA. [Pugsley, R.] Virginia Dept Hlth, Richmond, VA USA. [Tabidze, I.] Chicago Dept Publ Hlth, Chicago, IL USA. [Bernstein, K.] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Kerani, R.] Publ Hlth Seattle & King Co, Seattle, WA USA. [Schwebke, J.] Univ Alabama, Birmingham, AL USA. [Longfellow, L.] Louisiana Off Publ Hlth, Metairie, LA USA. [Guerry, S.] LA Cty Dept Publ Hlth, Los Angeles, CA USA. [Zenilman, J.] Johns Hopkins Sch Med, Baltimore, MD USA. [Klingler, E.] NYC Dept Hlth & Mental Hyg, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A120 EP A120 DI 10.1136/sextrans-2011-050108.51 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200290 ER PT J AU Mark, J Hariri, S Ilunga, R Forhan, S Likibi, M Kamb, ML Lewis, D AF Mark, J. Hariri, S. Ilunga, R. Forhan, S. Likibi, M. Kamb, M. L. Lewis, D. TI EVALUATION OF SEXUALLY TRANSMITTED INFECTION CLINICAL SERVICES IN GAUTENG PROVINCE, SOUTH AFRICA: KNOWLEDGE, ATTITUDES, AND BELIEFS AMONG HEALTH CARE PROVIDERS SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Mark, J.; Hariri, S.; Forhan, S.; Kamb, M. L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ilunga, R.; Lewis, D.] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Johannesburg, South Africa. [Likibi, M.] Gauteng Dept Hlth, Gauteng, South Africa. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A92 EP A93 DI 10.1136/sextrans-2011-050109.160 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200226 ER PT J AU Meites, E Xu, F Hutchins, K Ackerson, B Gee, J Eriksen, E Naleway, A Markowitz, L Zangwill, K AF Meites, E. Xu, F. Hutchins, K. Ackerson, B. Gee, J. Eriksen, E. Naleway, A. Markowitz, L. Zangwill, K. TI VARIATIONS IN TESTING AND TREATMENT RECEIVED BY INFANTS WITH POSSIBLE NEONATAL HERPES SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Meites, E.; Xu, F.; Hutchins, K.; Gee, J.; Markowitz, L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ackerson, B.] So Calif Kaiser Permanente Med Grp, Los Angeles, CA USA. [Eriksen, E.; Zangwill, K.] UCLA Ctr Vaccine Res, Torrance, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A283 EP A284 DI 10.1136/sextrans-2011-050108.446 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201337 ER PT J AU Mulder, T Johnson, K Lifflander, A Schillinger, J Rogers, M Blank, S AF Mulder, T. Johnson, K. Lifflander, A. Schillinger, J. Rogers, M. Blank, S. TI USING ELECTRONIC MEDICAL RECORD DATA TO GUIDE EXPEDITED PARTNER THERAPY IMPLEMENTATION IN AN URBAN STD CLINIC SYSTEM, 2009 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Mulder, T.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Johnson, K.; Lifflander, A.; Schillinger, J.; Rogers, M.; Blank, S.] US Ctr Dis Control & Prevent, NYC Dept Hlth, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A269 EP A270 DI 10.1136/sextrans-2011-050108.410 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201301 ER PT J AU Newman, DR Peterman, TA Collins, DE AF Newman, D. R. Peterman, T. A. Collins, D. E. TI TRENDS IN SCREENING FEMALES FOR CHLAMYDIA IN JUVENILE DETENTION CENTERS US 2005-2009 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Newman, D. R.; Peterman, T. A.; Collins, D. E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Newman, D. R.; Peterman, T. A.; Collins, D. E.] Div STD Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A342 EP A343 DI 10.1136/sextrans-2011-050108.597 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874202141 ER PT J AU Newman, L Hawkes, S Kamb, M Toskin, I Say, L Broutet, N AF Newman, L. Hawkes, S. Kamb, M. Toskin, I. Say, L. Broutet, N. TI CHALLENGES IN GLOBAL ESTIMATES OF SYPHILIS IN PREGNANCY SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Newman, L.; Toskin, I.; Say, L.; Broutet, N.] WHO, CH-1211 Geneva, Switzerland. [Hawkes, S.] UCL, London, England. [Kamb, M.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A4 EP A4 DI 10.1136/sextrans-2011-050102.14 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200015 ER PT J AU Niccola, L Mehta, N Julian, P Bilinski, A Sosa, L Meek, J Hariri, S Markowitz, L Hadler, J AF Niccola, L. Mehta, N. Julian, P. Bilinski, A. Sosa, L. Meek, J. Hariri, S. Markowitz, L. Hadler, J. TI HPV VACCINE COVERAGE AMONG HIGH-RISK WOMEN: RACIAL AND SOCIOECONOMIC DISPARITIES AND BARRIERS SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Niccola, L.; Mehta, N.; Julian, P.; Meek, J.; Hadler, J.] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Bilinski, A.] Yale Coll, New Haven, CT USA. [Sosa, L.] Connecticut Dept Publ Hlth, Hartford, CT USA. [Hariri, S.; Markowitz, L.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A213 EP A214 DI 10.1136/sextrans-2011-050108.267 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201163 ER PT J AU Owusu-Edusei, K Chesson, H Leichliter, J Kent, C Aral, S AF Owusu-Edusei, K. Chesson, H. Leichliter, J. Kent, C. Aral, S. TI DISPARITIES IN SEXUALLY TRANSMITTED DISEASES ACROSS RACE-INCOME "COUNTIES IN THE USA: A RACE-SPECIFIC MORBIDITY ANALYSIS" SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Owusu-Edusei, K.; Chesson, H.; Leichliter, J.; Kent, C.; Aral, S.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A194 EP A195 DI 10.1136/sextrans-2011-050108.221 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201118 ER PT J AU Pathela, P Braunstein, S Schillinger, J Shepard, C Sweeney, M Blank, S AF Pathela, P. Braunstein, S. Schillinger, J. Shepard, C. Sweeney, M. Blank, S. TI MEN WHO HAVE SEX WITH MEN (MSM) HAVE A 140-FOLD RISK FOR HIV AND SYPHILIS COMPARED WITH OTHER MEN IN NEW YORK CITY SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Pathela, P.; Braunstein, S.; Shepard, C.; Sweeney, M.] NYC Dept Hlth & Mental Hyg, Queens, NY USA. [Schillinger, J.; Blank, S.] Ctr Dis Control & Prevent, Queens, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A351 EP A352 DI 10.1136/sextrans-2011-050119.5 PG 3 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874202161 ER PT J AU Pathela, P Braunstein, S Blank, S Schillinger, J AF Pathela, P. Braunstein, S. Blank, S. Schillinger, J. TI HIV INCIDENCE AND TIME TO DIAGNOSIS AMONG MEN WITH BACTERIAL RECTAL INFECTIONS, NEW YORK CITY, 2008-2010 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Pathela, P.; Braunstein, S.; Blank, S.; Schillinger, J.] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Blank, S.; Schillinger, J.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A184 EP A184 DI 10.1136/sextrans-2011-050108.201 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201098 ER PT J AU Paz-Bailey, G Alvarez, B Miller, W Sabrina, B Barrington, C Kim, A Morales, S Chen, S AF Paz-Bailey, G. Alvarez, B. Miller, W. Sabrina, B. Barrington, C. Kim, A. Morales, S. Chen, S. TI POPULATION SIZE ESTIMATES FOR MEN WHO HAVE SEX WITH MEN IN GUATEMALA CITY USING TIME LOCATION SAMPLING AND RESPONDENT DRIVEN SAMPLING SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Paz-Bailey, G.; Sabrina, B.] Tephinet Inc, Guatemala City, Guatemala. [Alvarez, B.; Miller, W.; Morales, S.] Del Valle Univ Guatemala, Guatemala City, Guatemala. [Barrington, C.] Univ N Carolina, Chapel Hill, NC 27515 USA. [Kim, A.; Chen, S.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A163 EP A163 DI 10.1136/sextrans-2011-050108.152 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201051 ER PT J AU Peterman, TA Brewer, TH Newman, DR Shiver, S AF Peterman, T. A. Brewer, T. H. Newman, D. R. Shiver, S. TI ONGOING RISK BEHAVIOURS: NEW STD DIAGNOSES IN PERSONS KNOWN TO BE HIV-INFECTED IN MIAMI-FORT LAUDERDALE (SOUTH FLORIDA), 2000-2009 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Peterman, T. A.; Newman, D. R.] CDC, Atlanta, GA 30333 USA. [Brewer, T. H.] CDC, Florida DOH, Miami, FL USA. [Shiver, S.] Florida Dept Hlth, Tallahassee, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A177 EP A177 DI 10.1136/sextrans-2011-050108.185 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201084 ER PT J AU Pillay, A Chen, CY Morshed, MG Philip, S Ballard, RC AF Pillay, A. Chen, C. Y. Morshed, M. G. Philip, S. Ballard, R. C. TI SUBTYPING OF TREPONEMA PALLIDUM STRAINS BY SEQUENCE ANALYSIS OF TP0279 AND TP0548 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Pillay, A.; Chen, C. Y.; Ballard, R. C.] CDC, Atlanta, GA 30333 USA. [Morshed, M. G.] British Columbia Ctr Dis Control, Publ Hlth Microbiol & Reference Labs, Atlanta, GA USA. [Philip, S.] San Francisco Dept Publ Hlth, San Francisco, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A312 EP A312 DI 10.1136/sextrans-2011-050108.517 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874202067 ER PT J AU Powell, SE Hariri, S Steinau, M Bauer, H Bennett, N Bloch, K Schafer, S Niccolai, L Unger, ER Markowitz, L AF Powell, S. E. Hariri, S. Steinau, M. Bauer, H. Bennett, N. Bloch, K. Schafer, S. Niccolai, L. Unger, E. R. Markowitz, L. TI DETECTION OF CERVICAL CANCER PRECURSORS AND ASSOCIATED HPV TYPES IN THE USA: HPV-IMPACT PRELIMINARY RESULTS SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Powell, S. E.; Hariri, S.; Steinau, M.; Unger, E. R.; Markowitz, L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bauer, H.] Dept Publ Hlth, Richmond, CA USA. [Bennett, N.] Univ Rochester, Med Ctr, Rochester, NY 14627 USA. [Bloch, K.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Schafer, S.] Oregon Hlth Author, Portland, OR USA. [Niccolai, L.] Yale Univ, New Haven, CT 06520 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A25 EP A26 DI 10.1136/sextrans-2011-050109.12 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200078 ER PT J AU Radebe, F Jemmott, J Klopper, A Jemmott, L O'Leary, A Ngwane, Z Carty, C Tyler, J Maseko, V Lewis, D AF Radebe, F. Jemmott, J., III Klopper, A. Jemmott, L. O'Leary, A. Ngwane, Z. Carty, C. Tyler, J. Maseko, V. Lewis, D. TI INCIDENCE AND PREVALENCE OF SEXUALLY TRANSMITTED INFECTIONS AMONG SCHOOL STUDENTS IN THE EASTERN CAPE, SOUTH AFRICA SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Radebe, F.; Maseko, V.; Lewis, D.] Natl Inst Communicable Dis, Natl Hlth Lab Serv, Johannesburg, South Africa. [Jemmott, J., III; Jemmott, L.; Carty, C.] Univ Penn, Philadelphia, PA 19104 USA. [O'Leary, A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ngwane, Z.] Haverford Coll, Haverford, PA 19041 USA. [Tyler, J.] Univ Ft Hare, Alice, South Africa. NR 0 TC 0 Z9 0 U1 1 U2 2 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A30 EP A31 DI 10.1136/sextrans-2011-050109.23 PG 3 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200089 ER PT J AU Safran, M Guoyu, T Butler, M Hoover, K AF Safran, M. Guoyu, T. Butler, M. Hoover, K. TI SEXUAL RISK BEHAVIOURS AND MENTAL HEALTH CONCERNS AMONG HIV-INFECTED MSM SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Safran, M.; Guoyu, T.; Butler, M.; Hoover, K.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A317 EP A318 DI 10.1136/sextrans-2011-050108.531 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874202081 ER PT J AU Safran, M Tian, LH Hogben, M Braxton, J Robitz, R Koumans, E AF Safran, M. Tian, L. Hui Hogben, M. Braxton, J. Robitz, R. Koumans, E. TI SADNESS, POOR SCHOOL WORK, RUNNING AWAY, AND SEXUAL RISK BEHAVIOUR AMONG URBAN FEMALE AFRICAN AMERICAN ADOLESCENTS SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Safran, M.; Tian, L. Hui; Hogben, M.; Braxton, J.; Robitz, R.; Koumans, E.] Ctr Dis Control & Prevent, CDC, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A221 EP A222 DI 10.1136/sextrans-2011-050108.285 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201181 ER PT J AU Satterwhite, C Weinstock, H Datta, D AF Satterwhite, C. Weinstock, H. Datta, D. TI CHLAMYDIA TRENDS IN THE USA: RESULTS FROM MULTIPLE DATA SOURCES SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Satterwhite, C.; Weinstock, H.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A21 EP A21 DI 10.1136/sextrans-2011-050109.1 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200067 ER PT J AU Scott, J Sampson, LA Clymore, JM Moore, PR Leone, PA AF Scott, J. Sampson, L. A. Clymore, J. M. Moore, P. R. Leone, P. A. TI INTEGRATED HIV, SYPHILIS, AND OTHER STI TESTING IN NORTH CAROLINA COUNTY JAILS SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Scott, J.; Moore, P. R.] Ctr Dis Control & Prevent, Raleigh, NC USA. [Sampson, L. A.; Clymore, J. M.; Leone, P. A.] NC Div Publ Hlth, Raleigh, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A207 EP A207 DI 10.1136/sextrans-2011-050108.252 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201148 ER PT J AU Su, J AF Su, J. TI HIV AND SYPHILIS COINFECTION AMONG MEN WHO HAVE SEX WITH MEN, 34 STATES, USA-2009 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Su, J.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A139 EP A140 DI 10.1136/sextrans-2011-050108.97 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200336 ER PT J AU Surie, D Koumans, E Furness, B Perkins, R Brewer, T Turner, D Hernandez-Kline, P Gamerdinger, K Workowski, K Markowitz, L AF Surie, D. Koumans, E. Furness, B. Perkins, R. Brewer, T. Turner, D. Hernandez-Kline, P. Gamerdinger, K. Workowski, K. Markowitz, L. TI ARE MSM LOOKING FOR LESIONS? EXAMINING SELF AND PARTNERS FOR SYPHILIS SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Surie, D.; Koumans, E.; Markowitz, L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Furness, B.] Ctr Dis Control & Prevent, Dept Hlth, Washington, DC USA. [Perkins, R.] Whitman Walker GMHW Clin, Washington, DC USA. [Brewer, T.] Dept Hlth, Miami, FL USA. [Brewer, T.] Ctr Dis Control & Prevent, Miami, FL USA. [Hernandez-Kline, P.; Gamerdinger, K.] FIT Hlth Care Clin, Phoenix, AZ USA. [Workowski, K.] Emory Univ, Ctr Dis Control & Prevent, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A65 EP A66 DI 10.1136/sextrans-2011-050109.95 PG 3 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200161 ER PT J AU Tao, G Hoover, K Romaguera, R Kent, C AF Tao, G. Hoover, K. Romaguera, R. Kent, C. TI ASSESSMENT OF CHLAMYDIA TESTING COVERAGE USING HEDIS DATA: USA, 2009 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Tao, G.; Hoover, K.; Romaguera, R.; Kent, C.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A345 EP A345 DI 10.1136/sextrans-2011-050108.603 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874202147 ER PT J AU Tao, G Hoover, K Body, B Nye, M Kent, C AF Tao, G. Hoover, K. Body, B. Nye, M. Kent, C. TI RARE EVENT: RECTAL SPECIMEN COLLECTION FROM MALES FOR CHLAMYDIAL INFECTION IN THE USA SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Tao, G.; Hoover, K.; Kent, C.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A40 EP A40 DI 10.1136/sextrans-2011-050109.41 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200107 ER PT J AU Taylor, M Winscott, M Skinner, J Ereth, R Kenney, K Bailey, R AF Taylor, M. Winscott, M. Skinner, J. Ereth, R. Kenney, K. Bailey, R. TI HIV/STD COINFECTION IN ARIZONA, 2000-2008: IDENTIFYING OPPORTUNITIES FOR INTEGRATED SURVEILLANCE AND PARTNER SERVICES SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Taylor, M.; Kenney, K.] CDC, Phoenix, AZ USA. [Winscott, M.; Skinner, J.; Ereth, R.; Bailey, R.] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A160 EP A160 DI 10.1136/sextrans-2011-050108.145 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201044 ER PT J AU Torrone, E Bertolli, J Li, J Sweeney, P Jeffries, W Peterman, IVT AF Torrone, E. Bertolli, J. Li, J. Sweeney, P. Jeffries, W. Peterman, I. V. T. TI INCREASED HIV AND PRIMARY AND SECONDARY SYPHILIS DIAGNOSES AMONG YOUNG MEN WHO HAVE SEX WITH MEN, 2004-2008 SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A137 EP A138 DI 10.1136/sextrans-2011-050108.92 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200331 ER PT J AU Trees, D Burroughs, M Harris, S Johnson, S AF Trees, D. Burroughs, M. Harris, S. Johnson, S. TI POLYMERASE CHAIN REACTION-BASED TYPING OF PENA GENES EXHIBITING ELEVATED MIC VALUES TO CEPHALOSPORINS IN ISOLATES OF NEISSERIA GONORRHOEAE SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Trees, D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Burroughs, M.; Harris, S.; Johnson, S.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A308 EP A308 DI 10.1136/sextrans-2011-050108.507 PG 1 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874202057 ER PT J AU Tulloch, S Taylor, M AF Tulloch, S. Taylor, M. TI CHLAMYDIA SCREENING COVERAGE AMONG AMERICAN INDIAN AND ALASKA NATIVE WOMEN IN THE USA SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Tulloch, S.; Taylor, M.] Ctr Dis Control & Prevent, Albuquerque, NM USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A345 EP A346 DI 10.1136/sextrans-2011-050108.605 PG 3 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874202149 ER PT J AU Warner, L Anderson, J Macaluso, M AF Warner, L. Anderson, J. Macaluso, M. TI CONDOM USE AMONG US ADULTS AT LAST SEXUAL INTERCOURSE, 1996-2008: AN ANALYSIS OF GENERAL SOCIAL SURVEY (GSS) DATA SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Warner, L.; Anderson, J.] CDC Atlanta, Atlanta, GA USA. [Macaluso, M.] Cincinatti Childrens Ctr, Cincinnati, OH USA. RI Macaluso, Maurizio/J-2076-2015 OI Macaluso, Maurizio/0000-0002-2977-9690 NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A237 EP A238 DI 10.1136/sextrans-2011-050108.323 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201218 ER PT J AU Warner, L M, K Gavin, L Macaluso, M AF Warner, L. M, K. Gavin, L. Macaluso, M. TI FACTORS SURROUNDING LACK OF CONDOM USE AT FIRST INTERCOURSE AND LATER ONSET OF CONDOM USE: A STUDY OF COLLEGE-AGE MEN SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Warner, L.; M, K.; Gavin, L.] CDC, Atlanta, GA 30333 USA. [Macaluso, M.] Cincinatti Childrens Ctr, Cincinnati, OH USA. RI Macaluso, Maurizio/J-2076-2015 OI Macaluso, Maurizio/0000-0002-2977-9690 NR 0 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A223 EP A224 DI 10.1136/sextrans-2011-050108.289 PG 2 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874201185 ER PT J AU Xu, F Stoner, B Taylor, S Mena, L Tian, L Papp, J Hutchins, K Martin, D Markowitz, L AF Xu, F. Stoner, B. Taylor, S. Mena, L. Tian, L. Papp, J. Hutchins, K. Martin, D. Markowitz, L. TI RESCREENING FOR CHLAMYDIAL INFECTION USING HOME-BASED, SELF-OBTAINED VAGINAL SWABS: A RANDOMISED CONTROLLED TRIAL IN FAMILY PLANNING CLINIC CLIENTS SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Meeting Abstract C1 [Xu, F.; Tian, L.; Papp, J.; Hutchins, K.; Markowitz, L.] CDC, Atlanta, GA 30333 USA. [Stoner, B.] Washington Univ, St Louis, MO USA. [Taylor, S.; Martin, D.] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA. [Mena, L.] Univ Mississippi, Med Ctr, University, MS 38677 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD JUL PY 2011 VL 87 SU 1 BP A75 EP A76 DI 10.1136/sextrans-2011-050109.120 PG 3 WC Infectious Diseases SC Infectious Diseases GA 926ZQ UT WOS:000302874200186 ER PT J AU Castro-Sesquen, YE Gilman, RH Yauri, V Angulo, N Verastegui, M Velasquez, DE Sterling, CR Martin, D Bern, C AF Castro-Sesquen, Yagahira E. Gilman, Robert H. Yauri, Veronica Angulo, Noelia Verastegui, Manuela Velasquez, Daniel E. Sterling, Charles R. Martin, Diana Bern, Caryn TI Cavia porcellus as a Model for Experimental Infection by Trypanosoma cruzi SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID EXPERIMENTAL CHAGAS-DISEASE; POLYMERASE-CHAIN-REACTION; EXCRETED-SECRETED ANTIGENS; HEART-DISEASE; ENDEMIC AREA; GUINEA-PIGS; GASTROINTESTINAL MANIFESTATIONS; INDETERMINATE PHASE; TRIATOMA-INFESTANS; NATURAL INFECTION AB The guinea pig (Cavia porcellus) is a natural reservoir for Trypanosoma cruzi but has seldom been used as an experimental infection model. We developed a guinea pig infection model for acute and chronic Chagas disease. Seventy-two guinea pigs were inoculated intradermally with 10(4) trypomastigotes of T cruzi strain Y (experimental group); 18 guinea pigs were used as control group. Eight animals from the experimental group and two from the control group were sacrificed 5, 15, 20, 25, 40, 55, 115, 165, and 365 days after inoculation. During the acute phase (15 to 55 days), we observed parasitemia (with a peak on day 20) and positive IgM and IgG Western blots with antished acute-phase antigen bands. The cardiac tissue showed vasculitis, necrosis (on days 40 to 55), moderate to severe inflammation, and abundant amastigote nests. Smaller numbers of amastigote nests were also present in kidney, brain, and other organs. In the early chronic phase (115 to 165 days), parasitemia disappeared and anti-T. cruzi IgG antibodies were still detectable. In cardiac tissue, the number of amastigote nests and the grade of inflammation decreased. In the chronic phase (365 days), the cardiac tissue showed vasculitis and fibrosis; detectable parasite DNA was associated with higher grades of inflammation. The experimental T. cruzi infection model in guinea pigs shows kinetics and pathologic changes similar to those of the human disease. (A, J Pathol 2011, 179:281-284; DOI: 10.1016/j.ajpath.2011.03.043) C1 [Gilman, Robert H.] Johns Hopkins Univ, Dept Int Hlth, Bloombetg Sch Hyg & Publ Hlth, Baltimore, MD 21205 USA. [Verastegui, Manuela] Univ Peruana Cayetano Heredia, Dept Microbiol, Lima, Peru. [Castro-Sesquen, Yagahira E.; Yauri, Veronica; Angulo, Noelia] PRISMA, San Miguel, Lima, Peru. [Velasquez, Daniel E.; Martin, Diana; Bern, Caryn] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA USA. [Sterling, Charles R.] Univ Arizona, Dept Vet Sci & Microbiol, Tucson, AZ USA. RP Gilman, RH (reprint author), Johns Hopkins Univ, Dept Int Hlth, Bloombetg Sch Hyg & Publ Hlth, 615 N Wolfe St,Room W 5515, Baltimore, MD 21205 USA. EM rgilman@jhsph.edu FU NIH [5 T35 AI0653855, 1R01AI087776-01] FX Supported by NIH training grant in infectious and tropical diseases 5 T35 AI065385 and NIH grant 1R01AI087776-01. NR 65 TC 9 Z9 9 U1 3 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 EI 1525-2191 J9 AM J PATHOL JI Am. J. Pathol. PD JUL PY 2011 VL 179 IS 1 BP 281 EP 288 DI 10.1016/j.ajpath.2011.03.043 PG 8 WC Pathology SC Pathology GA 865JL UT WOS:000298307100029 PM 21703410 ER PT J AU Steinau, M Patel, SS Unger, ER AF Steinau, Martin Patel, Sonya S. Unger, Elizabeth R. TI Efficient DNA Extraction for HPV Genotyping in Formalin-Fixed, Paraffin-Embedded Tissues SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Article ID HUMAN PAPILLOMAVIRUSES; AMPLIFICATION; ASSAY; LIPA; RNA AB DNA from archived FFPE can be used for papillomavirus genotyping, but potential problems include paraffin as a physical barrier, DNA cross-linking, and PCR inhibitors. To address these complications, we combined a commercially available DNA isolation kit (Qiagen DNeasy) with a heat treatment and evaluated the resulting DNA with regards to HPV typing. DNA was extracted from 10-mu m sections from 150 FFPE cancer samples. One protocol followed the manufacturer's recommendation, including paraffin removal by xylene and tissue lysis at 56 degrees C. A second section was directly incubated at 120 degrees C and subsequently lysed at 65 degrees C. After spin-column purification, both extracts were tested with a linear array HPV genotyping assay. Additionally, cellular DNA yield, HPV16 DNA copies, and PCR inhibitors were assessed by real-time qPCR assays. Inadequate linear array HPV genotyping assay results were significantly more frequent (P = 0.0003) in xylene-treated (29/150, 19.3%) than in heat-treated extracts (8/150, 5.3%). HPV detection also differed, with 94/150 (62.7%) and 110/150 (73.3%) positive results, respectively (P = 0.0026). The heat method also yielded more PCR-amplifiable cellular DNA (8.2-fold; P < 0.001) and HPV16 copies (6.5-fold; P = 0.009), although PCR inhibitors also had a greater effect (P = 0.035). Aggressive heat treatment demonstrated an advantage over traditional xylene purification protocols, resulting in higher DNA yields and increased sensitivity for HPV testing. (J Mol Diagn 2011, 13:377-381; DOI: 10.1016/j.jmoldx.2011.03.007) C1 [Steinau, Martin; Patel, Sonya S.; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Chron Viral Dis Branch, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. RP Steinau, M (reprint author), Ctr Dis Control & Prevent, Chron Viral Dis Branch, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, 1600 Clifton Rd NE,Mailstop G-41, Atlanta, GA 30333 USA. EM MSteinau@cdc.gov OI Unger, Elizabeth/0000-0002-2925-5635 NR 13 TC 48 Z9 50 U1 0 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 J9 J MOL DIAGN JI J. Mol. Diagn. PD JUL PY 2011 VL 13 IS 4 BP 377 EP 381 DI 10.1016/j.jmoldx.2011.03.007 PG 5 WC Pathology SC Pathology GA 865JF UT WOS:000298306500003 PM 21704270 ER PT J AU Hayes, DK Greenlund, KJ Denny, CH Neyer, JR Croft, JB Keenan, NL AF Hayes, Donald K. Greenlund, Kurt J. Denny, Clark H. Neyer, Jonathan R. Croft, Janet B. Keenan, Nora L. TI Racial/Ethnic and Socioeconomic Disparities in Health-Related Quality of Life Among People With Coronary Heart Disease, 2007 SO PREVENTING CHRONIC DISEASE LA English DT Article ID FACTOR SURVEILLANCE SYSTEM; UNITED-STATES; CARDIOVASCULAR-DISEASE; RISK-FACTORS; VALIDITY; RELIABILITY; PREVALENCE; ADULTS; WOMEN AB Introduction Health-related quality of life (HRQOL) refers to a person's or group's perceived physical and mental health over time. Coronary heart disease (CHD) affects HRQOL and likely varies among groups. This study examined disparities in HRQOL among adults with self-reported CHD. Methods We examined disparities in HRQOL by using the unhealthy days measurements among adults who self-reported CHD in the 2007 Behavioral Risk Factor Surveillance System state-based telephone survey. CHD was based on self-reported medical history of heart attack, angina, or coronary heart disease. We assessed differences in fair/poor health status, 14 or more physically unhealthy days, 14 or more mentally unhealthy days, 14 or more total unhealthy days (total of physically and mentally unhealthy days), and 14 or more activity-limited days. Multivariate logistic regression models included age, race/ethnicity, sex, education, annual household income, household size, and health insurance coverage. Results Of the population surveyed, 35,378 (6.1%) self-reported CHD. Compared with non-Hispanic whites, Native Americans were more likely to report fair/poor health status (adjusted odds ratio [AOR], 1.7), 14 or more total unhealthy days (AOR, 1.6), 14 or more physically unhealthy days (AOR, 1.7), and 14 or more activity-limited days (AOR, 1.9). Hispanics were more likely than non-Hispanic whites to report fair/poor health status (AOR, 1.5) and less likely to report 14 or more activity-limited days (AOR, 0.5), and Asians were less likely to report 14 or more activity-limited days (AOR, 0.2). Non-Hispanic blacks did not differ in unhealthy days measurements from non-Hispanic whites. The proportion reporting 14 or more total unhealthy days increased with increasing age, was higher among women than men, and was lower with increasing levels of education and income. Conclusion There are sex, racial/ethnic, and socioeconomic disparities in HRQOL among people with CHD. Tailoring interventions to people who have both with CHD and poor HRQOL may assist in the overall management of CHD. C1 [Hayes, Donald K.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Neyer, Jonathan R.] Univ Calif Los Angeles, Los Angeles, CA USA. RP Hayes, DK (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,MS K22, Atlanta, GA 30341 USA. EM dhayes@cdc.gov NR 30 TC 17 Z9 19 U1 1 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JUL PY 2011 VL 8 IS 4 AR A78 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 874OY UT WOS:000298969100008 PM 21672402 ER PT J AU Hosey, G Ichiho, H Satterfield, D Dankwa-Mullan, I Kuartei, S Rhee, K Belyeu-Camacho, T Debrum, I Demei, Y Lippwe, K Luces, PS Roby, F AF Hosey, Gwen Ichiho, Henry Satterfield, Dawn Dankwa-Mullan, Irene Kuartei, Stevenson Rhee, Kyu Belyeu-Camacho, Tayna deBrum, Ione Demei, Yorah Lippwe, Kipier Luces, Patrick Solidum Roby, Faiese TI Chronic Disease Surveillance Systems Within the US Associated Pacific Island Jurisdictions SO PREVENTING CHRONIC DISEASE LA English DT Article AB In recent years, illness and death due to chronic disease in the US Associated Pacific Islands (USAPI) jurisdictions have dramatically increased. Effective chronic disease surveillance can help monitor disease trends, evaluate public policy, prioritize resource allocation, and guide program planning, evaluation, and research. Although chronic disease surveillance is being conducted in the USAPI, no recently published capacity assessments for chronic disease surveillance are available. The objective of this study was to assess the quality of existing USAPI chronic disease data sources and identify jurisdictional capacity for chronic disease surveillance. The assessment included a chronic disease data source inventory, literature review, and review of surveillance documentation available from the web or through individual jurisdictions. We used the World Health Organization's Health Metric Network Framework to assess data source quality and to identify jurisdictional capacity. Results showed that USAPI data sources are generally aligned with widely accepted chronic disease surveillance indicators and use standardized data collection methodology to measure chronic disease behavioral risks, preventive practices, illness, and death. However, all jurisdictions need to strengthen chronic disease surveillance through continued assessment and expanded support for valid and reliable data collection, analysis and reporting, dissemination, and integration among population-based and institution-based data sources. For sustained improvement, we recommend investment and technical assistance in support of a chronic disease surveillance system that integrates population-based and institution-based data sources. An integrated strategy that bridges and links USAPI data sources can support evidence-based policy and population health interventions. C1 [Ichiho, Henry] Pacific Diabet Educ Program, Honolulu, HI USA. [Satterfield, Dawn] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dankwa-Mullan, Irene] Natl Inst Minor Hlth & Hlth Dispar, Bethesda, MD USA. [Kuartei, Stevenson] Minist Hlth, Koror, Palau. [Rhee, Kyu] Hlth Resources & Serv Adm, Rockville, MD USA. RP Hosey, G (reprint author), Ctr Dis Control & Prevent, 4150 Technol Way,Ste 210, Carson City, NV 89706 USA. EM ghh0@cdc.gov FU Nia Aitaoto and Dorraine Watts FX We thank the following Pacific Island representatives who contributed to this project: Tuiasina Salamo Laumoli, Dottie Siavii, and Pasa Turituri, American Samoa; Joseph K. Villagomez, Rebecca Ann Covarrubias, Isidro Ogarto, John Tagabuel, Commonwealth of the Northern Mariana Islands; Vita A. Skilling, Marcus Samo, Shra Alik, and Brenda Hadley Eperiam, Federated States of Micronesia; J. Peter Roberto, Roselie Zabala, and Gil S. Suguitan, Guam; Amenta Matthew, Justina Langidrik, Donny Andrike, and Godfrey Waidubu, Republic of the Marshall Islands; Augusta Rengiil, Republic of Palau. We also recognize the contributions of Lawrence Barker, Kaetz Beartusk, Michelle Carlberg, Gloria Colclough, Jack Colbert, Ed Gregg, Ann Goding, Laura Kann, Juliette Lee, Veronica Lea, Kristen McCall, Barbara Park, Karen Siener, Castine Verrill, Charles Warren, and MaryBeth Welton, Centers for Disease Control and Prevention; and Susan Tanner, End-Stage Renal Disease Network 17. Finally, we thank Nia Aitaoto and Dorraine Watts for their support and encouragement during this project. NR 20 TC 3 Z9 3 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JUL PY 2011 VL 8 IS 4 AR A86 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 874OY UT WOS:000298969100016 PM 21672410 ER PT J AU Jones, SE Anderson, K Lowry, R Conner, H AF Jones, Sherry Everett Anderson, Khadija Lowry, Richard Conner, Holly TI Risks to Health Among American Indian/Alaska Native High School Students in the United States SO PREVENTING CHRONIC DISEASE LA English DT Article ID DISPARITIES; BEHAVIOR; SURVEILLANCE; ADOLESCENTS; CHILDREN; INDIANS; ALCOHOL; TOBACCO; ACCESS AB Introduction According to the World Health Organization, the 10 leading risk factor causes of death in high-income countries are tobacco use, high blood pressure, overweight and obesity, physical inactivity, high blood glucose, high cholesterol, low fruit and vegetable intake, urban air pollution, alcohol use, and occupational risks. We examined the prevalence of some of the leading risks to health among nationally representative samples of American Indian/Alaska Native (AI/AN) high school students and compared rates across racial/ethnic groups. Methods We combined data from the 2001, 2003, 2005, 2007, and 2009 national Youth Risk Behavior Survey. The survey is a biennial, self-administered, school-based survey of 9th-through 12th-grade students in the United States. Overall response rates for the surveys ranged from 63% to 72%. Of 73,183 participants, 952 were AI/AN students. Results For 7 of the 16 variables examined in this study, the prevalence among AI/AN high school students was higher than the prevalence among white high school students. For 1 variable (ate fruit and vegetables <5 times per day), the prevalence among AI/AN students was significantly lower than that among white students. The prevalence for the remaining 8 variables was similar among AI/AN students and white students. These findings also show differences in the prevalence of some behaviors among AI/AN, black, and Hispanic students. Conclusion These findings show the prevalence of some health risk behaviors was significantly higher among AI/AN high school students than among high school students in other racial/ethnic groups. C1 [Jones, Sherry Everett] Ctr Dis Control & Prevent, Div Adolescent, Atlanta, GA 30041 USA. [Anderson, Khadija] Care Resource Inc, Miami, FL USA. RP Jones, SE (reprint author), Ctr Dis Control & Prevent, Div Adolescent, 4770 Buford Hwy NE,MS K33, Atlanta, GA 30041 USA. EM sce2@cdc.gov NR 29 TC 2 Z9 2 U1 2 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JUL PY 2011 VL 8 IS 4 AR A76 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 874OY UT WOS:000298969100006 PM 21672400 ER PT J AU Khan, JA Casper, M Asimos, AW Clarkson, L Enright, D Fehrs, LJ George, M Heidari, K Huston, SL Mettam, LH Williams, GI Schieb, L Greer, S AF Khan, Jenna A. Casper, Michele Asimos, Andrew W. Clarkson, Lydia Enright, Dianne Fehrs, Laura J. George, Mary Heidari, Khosrow Huston, Sara L. Mettam, Laurie H. Williams, G. Ishmael, Jr. Schieb, Linda Greer, Sophia TI Geographic and Sociodemographic Disparities in Drive Times to Joint Commission-Certified Primary Stroke Centers in North Carolina, South Carolina, and Georgia SO PREVENTING CHRONIC DISEASE LA English DT Article ID ACUTE ISCHEMIC-STROKE; RT-PA STROKE; TELESTROKE NETWORK; CARE; ESTABLISHMENT; STATES; RECOMMENDATIONS; THROMBOLYSIS; ASSOCIATION; POPULATION AB Introduction Timely access to facilities that provide acute stroke care is necessary to reduce disabilities and death from stroke. We examined geographic and sociodemographic disparities in drive times to Joint Commission-certified primary stroke centers (JCPSCs) and other hospitals with stroke care quality improvement initiatives in North Carolina, South Carolina, and Georgia. Methods We defined boundaries for 30- and 60-minute drive-time areas to JCPSCs and other hospitals by using geographic information systems (GIS) mapping technology and calculated the proportions of the population living in these drive-time areas by sociodemographic characteristics. Age-adjusted county-level stroke death rates were overlaid onto the drive-time areas. Results Approximately 55% of the population lived within a 30-minute drive time to a JCPSC; 77% lived within a 60-minute drive time. Disparities in percentage of the population within 30-minute drive times were found by race/ethnicity, education, income, and urban/rural status; the disparity was largest between urban areas (70% lived within 30-minute drive time) and rural areas (26%). The rural coastal plains had the largest concentration of counties with high stroke death rates and the fewest JCPSCs. Conclusion Many areas in this tri-state region lack timely access to JCPSCs. Alternative strategies are needed to expand provision of quality acute stroke care in this region. GIS modeling is valuable for examining and strategically planning the distribution of hospitals providing acute stroke care. C1 [Khan, Jenna A.; Casper, Michele; George, Mary; Williams, G. Ishmael, Jr.; Schieb, Linda; Greer, Sophia] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Khan, Jenna A.] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Asimos, Andrew W.] Carolinas Med Ctr, Charlotte, NC 28203 USA. [Clarkson, Lydia; Fehrs, Laura J.] Georgia Dept Community Hlth, Atlanta, GA USA. [Enright, Dianne] N Carolina State Ctr Hlth Stat, Raleigh, NC USA. [Heidari, Khosrow] S Carolina Dept Hlth & Environm Control, Columbia, SC 29201 USA. [Huston, Sara L.] Maine Ctr Dis Control & Prevent, Augusta, ME USA. [Huston, Sara L.] Univ So Maine, Portland, ME USA. [Huston, Sara L.; Mettam, Laurie H.] Tri State Stroke Network, Raleigh, NC USA. [Huston, Sara L.] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. RP Casper, M (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE,Mailstop K-47, Atlanta, GA 30341 USA. EM mcasper@cdc.gov NR 31 TC 5 Z9 5 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JUL PY 2011 VL 8 IS 4 AR A79 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 874OY UT WOS:000298969100009 PM 21672403 ER PT J AU Zhang, XZ Kahende, J Fan, AZ Barker, L Thompson, TJ Mokdad, AH Li, Y Saaddine, JB AF Zhang, Xinzhi Kahende, Jennifer Fan, Amy Z. Barker, Lawrence Thompson, Theodore J. Mokdad, Ali H. Li, Yan Saaddine, Jinan B. TI Smoking and Visual Impairment Among Older Adults With Age-Related Eye Diseases SO PREVENTING CHRONIC DISEASE LA English DT Article ID OPEN-ANGLE GLAUCOMA; LONG-TERM INCIDENCE; BLUE MOUNTAINS EYE; CIGARETTE-SMOKING; UNITED-STATES; MACULAR DEGENERATION; RISK-FACTORS; CHOROIDAL NEOVASCULARIZATION; DIABETIC-RETINOPATHY; ASSOCIATION AB Introduction Tobacco use is the leading preventable cause of death in the United States. Visual impairment, a common cause of disability in the United States, is associated with shorter life expectancy and lower quality of life. The relationship between smoking and visual impairment is not clearly understood. We assessed the association between smoking and visual impairment among older adults with age-related eye diseases. Methods We analyzed Behavioral Risk Factor Surveillance System data from 2005 through 2008 on older adults with age-related eye diseases (cataract, glaucoma, age-related macular degeneration, and diabetic retinopathy; age >= 50 y, N = 36,522). Visual impairment was defined by self-reported difficulty in recognizing a friend across the street or difficulty in reading print or numbers. Current smokers were respondents who reported having smoked at least 100 cigarettes ever and still smoked at the time of interview. Former smokers were respondents who reported having ever smoked at least 100 cigarettes but currently did not smoke. We used multivariate logistic regressions to examine the association and to adjust for potential confounders. Results Among respondents with age-related eye diseases, the estimated prevalence of visual impairment was higher among current smokers (48%) than among former smokers (41%, P < .05) and respondents who had never smoked (42%, P < .05). After adjustment for age, sex, race/ethnicity, education, and general health status, current smokers with age-related eye diseases were more likely to have visual impairment than respondents with age-related eye diseases who had never smoked (odds ratio, 1.16, P < .05). Furthermore, respondents with cataract who were current smokers were more likely to have visual impairment than respondents with cataract who had never smoked (predictive margin, 44% vs 40%, P =.03), and the same was true for respondents with age-related macular degeneration (65% of current smokers vs 57% of never smokers, P = .02). This association did not hold true among respondents with glaucoma or diabetic retinopathy. Conclusion Smoking is linked to self-reported visual impairment among older adults with age-related eye diseases, particularly cataract and age-related macular degeneration. Longitudinal evaluation is needed to assess smoking cessation's effect on vision preservation. C1 [Zhang, Xinzhi; Kahende, Jennifer] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30341 USA. [Mokdad, Ali H.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA. [Fan, Amy Z.; Li, Yan] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adult & Community Hlth, Atlanta, GA 30341 USA. [Barker, Lawrence; Thompson, Theodore J.; Saaddine, Jinan B.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA 30341 USA. RP Zhang, XZ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, 4770 Buford Hwy NE,MS K-10, Atlanta, GA 30341 USA. EM XZhang4@cdc.gov NR 34 TC 9 Z9 9 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JUL PY 2011 VL 8 IS 4 AR A84 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 874OY UT WOS:000298969100014 PM 21672408 ER PT J AU Peterman, TA Newman, DR Collins, DE Doshi, SR Berman, SM AF Peterman, Thomas A. Newman, Daniel R. Collins, Dayne E. Doshi, Sonal R. Berman, Stuart M. TI Sexually Transmitted Diseases Program Performance Measures: How Are They Performing? SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID PELVIC-INFLAMMATORY-DISEASE; HEALTH-CARE; QUALITY; PREVENTION; INFECTION; PNEUMONIA; ACT AB Background: Performance measures were developed in order to improve the performance of sexually transmitted disease (STD) prevention programs. Methods: A consultant worked with persons from STD programs and Centers for Disease Control and Prevention to identify possible measures. Measures were pilot tested for feasibility and relevance in several programs, then implemented nationwide in 2004. Data were collated and shared with programs and presented at national meetings. Site visits, webinars, and technical assistance focused on program improvement related to the measures. Reported data were analyzed to see if national performance improved on the activities measured. Results: Some measures were dropped or revised, and quality of reported data improved over time. There was little evidence that overall program performance improved. Conclusions: Performance measures are one way to monitor performance, and might contribute to program improvement, but additional efforts are needed to improve performance. C1 [Peterman, Thomas A.; Newman, Daniel R.; Collins, Dayne E.; Doshi, Sonal R.; Berman, Stuart M.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. RP Peterman, TA (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Mailstop E-02,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM tap1@cdc.gov NR 30 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD JUL PY 2011 VL 38 IS 7 BP 610 EP 616 DI 10.1097/OLQ.0b013e31820a8d9b PG 7 WC Infectious Diseases SC Infectious Diseases GA 777BD UT WOS:000291586900006 PM 21278623 ER PT J AU Jones, AK Bejugam, NK Nettey, H Addo, R D'Souza, MJ AF Jones, Alphia K. Bejugam, Naveen K. Nettey, Henry Addo, Richard D'Souza, Martin J. TI Spray-dried doxorubicin-albumin microparticulate systems for treatment of multidrug resistant melanomas SO JOURNAL OF DRUG TARGETING LA English DT Article DE Microspheres; doxorubicin; multidrug resistance; spray-drying; melanoma tumor cells ID DRUG-DELIVERY; MICROSPHERES; FORMULATION; RELEASE AB As multidrug resistance continues to be a problem in cancer treatment, controlled release delivery systems, such as microspheres, may aid to give a slower release of anticancer drugs into drug resistant tumor cells. In this study doxorubicin microspheres microencapsulated in an albumin matrix were prepared via the spray-drying method and characterized for particle size, content analysis, and release studies. They were then evaluated in vitro using drug resistant murine melanoma tumor cells for uptake and efflux studies. Spray-drying produced a dispersed powder with a mean particle size of 4.91 +/- 1.2 mu m, 60% product yield, and encapsulation efficiency of 85% and a zeta potential range of 37 to -40 mV. Intracellular doxorubicin concentrations were higher in drug resistant tumor cells treated with microspheres as opposed to solution, and efflux of doxorubicin from the tumor cell was inhibited. Greater cytotoxic effects were seen in tumor cells treated with doxorubicin microspheres versus solution up to and after 3 days. In vivo pharmacokinetic studies conducted in male Sprague-Dawley rats, revealed a plasma-level time curve indicative of a two-compartment model, and showed prolonged half-life of doxorubicin, greater area under the plasma concentration time curve, and increased plasma concentrations of doxorubicin in rats at 8 and 24 h after administration of doxorubicin microspheres. C1 [Jones, Alphia K.; Bejugam, Naveen K.; Nettey, Henry; Addo, Richard; D'Souza, Martin J.] Mercer Univ, Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Atlanta, GA USA. [Bejugam, Naveen K.] SRI Int, Menlo Pk, CA 94025 USA. [Nettey, Henry] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Addo, Richard] Shenandoah Univ, Bernard J Dunn Sch Pharm, Winchester, VA USA. RP Jones, AK (reprint author), 4351 Thorngate Lane, Acworth, GA 30101 USA. EM kjon74@aol.com NR 18 TC 7 Z9 7 U1 0 U2 5 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1061-186X J9 J DRUG TARGET JI J. Drug Target. PD JUL PY 2011 VL 19 IS 6 BP 427 EP 433 DI 10.3109/1061186X.2010.504270 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 776RS UT WOS:000291555800004 PM 20678033 ER PT J AU Alverson, CJ Strickland, MJ Gilboa, SM Correa, A AF Alverson, Clinton J. Strickland, Matthew J. Gilboa, Suzanne M. Correa, Adolfo TI Maternal Smoking and Congenital Heart Defects in the Baltimore-Washington Infant Study EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material C1 [Alverson, Clinton J.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. Emory Univ, Dept Environm Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Alverson, CJ (reprint author), Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. NR 2 TC 0 Z9 0 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD JUL PY 2011 VL 66 IS 7 BP 408 EP 409 DI 10.1097/OGX.0b013e31823385ff PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 825ZC UT WOS:000295319900010 ER PT J AU Mortensen, ME Wong, LY Osterloh, JD AF Mortensen, Mary Ellen Wong, Lee-Yang Osterloh, John D. TI Smoking status and urine cadmium above levels associated with subclinical renal effects in US adults without chronic kidney disease SO INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH LA English DT Article DE Urine cadmium; Smoking; Tobacco; Renal effects; NHANES ID CIGARETTE-SMOKING; TOBACCO-SMOKE; TUBULAR DYSFUNCTION; GENERAL-POPULATION; MASS-SPECTROMETRY; UNITED-STATES; EXPOSURE; WOMEN; PREVALENCE; BLOOD AB Tobacco smoke is a major source of adult exposure to cadmium (Cd). Urine Cd levels (CdU) above 1.0, 0.7, and 0.5 mu g Cd/g creatinine have been associated with increased rates of microproteinuria and reduction in glomerular filtration rate. The two study objectives were to determine the prevalence and relative risk (RR) by smoking status for CdU above 1.0, 0.7, and 0.5 mu g Cd/g creatinine in U.S. adults; and to describe geometric mean CdU by smoking status, age, and sex. NHANES 1999-2006 data for adults without chronic kidney disease were used to compute prevalence rates above the three CdU in current and former cigarette smokers, and non-smokers. RRs for smokers adjusted for age and sex were computed by logistic regression. Analysis of covariance was used to calculate geometric means of CdU adjusted for age, sex, smoking status, log urine creatinine, and interaction terms: age-smoking status and sex-smoking status. At selected ages, adjusted RR for exceeding each risk-associated CdU was highest for current smokers (3-13 times), followed by former smokers (2-3 times), compared to non-smokers. Adjusted RR for smokers increased with age and was higher in females than males. Adjusted geometric means of CdUs increased with age, were higher in females than in males regardless of smoking status, and were higher in current smokers than former smokers, who had higher levels than non-smokers at any age. Cigarette smoking greatly increases RR of exceeding renal risk-associated CdU. Former smokers retain significant risk of exceeding these levels compared to non-smokers. CdU increased with age, particularly in current smokers. Published by Elsevier GmbH. C1 [Mortensen, Mary Ellen; Wong, Lee-Yang; Osterloh, John D.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Mortensen, ME (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway,MS F-20, Atlanta, GA 30341 USA. EM zeo4@cdc.gov NR 55 TC 22 Z9 22 U1 0 U2 4 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 1438-4639 EI 1618-131X J9 INT J HYG ENVIR HEAL JI Int. J. Hyg. Environ. Health. PD JUL PY 2011 VL 214 IS 4 BP 305 EP 310 DI 10.1016/j.ijheh.2011.03.004 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 815IN UT WOS:000294519400003 PM 21555245 ER PT J AU Hubbard, B Sarisky, J Gelting, R Baffigo, V Seminario, R Centurion, C AF Hubbard, Brian Sarisky, John Gelting, Richard Baffigo, Virginia Seminario, Raul Centurion, Carlos TI A community demand-driven approach toward sustainable water and sanitation infrastructure development SO INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH LA English DT Article DE Water; Sanitation; Community participation; Demand-driven; Health; Sustainability ID EARLY-CHILDHOOD DIARRHEA; HEALTH; IMPACT; CHILDREN; INTERVENTIONS; FACILITIES; HYGIENE; DISEASE; BURDEN AB In September 2001, Cooperative Assistance and Relief Everywhere, Peru Country Office (CARE Peru), obtained funding from the United States Agency for International Development (USAID) to implement community-supported, condominial water and sanitation interventions in Manuel Cardozo Davila, a settlement in Iquitos, Peru. With technical support from the Centers for Disease Control and Prevention (CDC), CARE Peru's Urban Environmental Health Models (Modelos Urbanos de Salud Ambiental [MUSA]) project built on previous work from implementing the Protocol for Assessing Community Excellence in Environmental Health in this same community. The project led to the municipal water supply distribution system being extended 1.3 kilometers into the Southern zone of Iquitos, where it connected to the condominial water system. Altogether, 1030 households were connected to the water supply system after the installation of a condominial water and sewerage system in Cardozo. Diarrheal disease decreased by 37% for children less than 5 years of age from 2003 to 2004. This paper illustrates the strategy used by CARE Peru in conjunction with the Cardozo community to assure that the local demand for improved water and sanitation was met. Published by Elsevier GmbH. C1 [Hubbard, Brian; Sarisky, John; Gelting, Richard] US Ctr Dis Control & Prevent, Environm Hlth Serv Branch, Natl Ctr Environm Hlth, Dept Hlth & Human Serv, Atlanta, GA 30341 USA. [Baffigo, Virginia; Centurion, Carlos] CARE Peru, Lima 11, Peru. [Seminario, Raul] Cardozo Hlth Ctr, Loreto Reg Hlth Directorate, Reg Govt Loreto, Minist Hlth, Punchana, Peru. RP Hubbard, B (reprint author), US Ctr Dis Control & Prevent, Environm Hlth Serv Branch, Natl Ctr Environm Hlth, Dept Hlth & Human Serv, 4770 Buford Highway NE,MS F-60, Atlanta, GA 30341 USA. EM bhubbard@cdc.gov; vbaffigo@care.org.pe; juanrau142@hotmail.com NR 39 TC 5 Z9 6 U1 2 U2 19 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 1438-4639 J9 INT J HYG ENVIR HEAL JI Int. J. Hyg. Environ. Health. PD JUL PY 2011 VL 214 IS 4 BP 326 EP 334 DI 10.1016/j.ijheh.2011.05.005 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 815IN UT WOS:000294519400006 PM 21680241 ER PT J AU Reese, SM Petersen, JM Sheldon, SW Dolan, MC Dietrich, G Piesman, J Eisen, RJ AF Reese, Sara M. Petersen, Jeannine M. Sheldon, Sarah W. Dolan, Marc C. Dietrich, Gabrielle Piesman, Joseph Eisen, Rebecca J. TI Transmission Efficiency of Francisella tularensis by Adult American Dog Ticks (Acari: Ixodidae) SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE tularemia; Dermacentor variabilis; vector efficiency; vector competency; tick-borne diseases ID BORRELIA-BURGDORFERI TRANSMISSION; MOUNTAIN SPOTTED-FEVER; DERMACENTOR-VARIABILIS; UNITED-STATES; HUMAN TULAREMIA; LYME-DISEASE; DYNAMICS; DIVERSITY; INFECTION; OUTBREAK AB The American dog tick, Dermacentor variabilis (Say) (Acari: Ixodidae), has been implicated as a potential bridging vector to humans of Francisella tularensis, the etiological agent of tularemia. Since the initial studies evaluating vector competency of D. variabilis were conducted, F. tularensis has been subdivided into subspecies and clades that differ in their geographical distribution in the United States and in the severity of infections caused in humans. Here, we demonstrate that D. variabilis nymphs efficiently acquire, transtadially maintain, and transmit each of the strains tested (clades A1b and A2, and type B). Transmission efficiency by adult females was similarly high among infection groups and ranged from 58% for type B to 89% for A2 infections. In addition, we demonstrated that transmission can occur shortly after tick attachment. These findings support the concept that D. variabilis adults may play a significant role in epizootic transmission of F. tularensis, and as a bridging vector to humans. C1 [Reese, Sara M.; Petersen, Jeannine M.; Sheldon, Sarah W.; Dolan, Marc C.; Dietrich, Gabrielle; Piesman, Joseph; Eisen, Rebecca J.] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO USA. RP Eisen, RJ (reprint author), Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, 3150 Rampart Rd, Ft Collins, CO USA. EM dyn2@cdc.gov NR 38 TC 10 Z9 10 U1 1 U2 7 PU ENTOMOLOGICAL SOC AMER PI LANHAM PA 10001 DEREKWOOD LANE, STE 100, LANHAM, MD 20706-4876 USA SN 0022-2585 J9 J MED ENTOMOL JI J. Med. Entomol. PD JUL PY 2011 VL 48 IS 4 BP 884 EP 890 DI 10.1603/ME11005 PG 7 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA 810KJ UT WOS:000294123900020 PM 21845949 ER PT J AU Durham, MD Buchacz, K Armon, C Patel, P Wood, K Brooks, JT AF Durham, Marcus D. Buchacz, Kate Armon, Carl Patel, Pragna Wood, Kathy Brooks, John T. CA HOPS Invest TI Rates and correlates of influenza vaccination among HIV-infected adults in the HIV Outpatient Study (HOPS), USA, 1999-2008 SO PREVENTIVE MEDICINE LA English DT Article DE HIV; Influenza; Vaccination; Adults ID HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNIZATION PRACTICES ACIP; UNITED-STATES; VACCINES RECOMMENDATIONS; ADVISORY-COMMITTEE; SEASONAL INFLUENZA; MORTALITY; PREVENTION; COVERAGE AB Background: We sought to describe rates of vaccination among HIV-infected adults in care and identify factors associated with vaccination. Methods: Using data abstracted from medical records of participants in the HIV Outpatient Study (HOPS) during 8 influenza seasons (1999-2008) and negative binomial models with generalized estimating equation methods, we examined factors associated with increased prevalence of annual influenza vaccination. Results: Among active patients. 25.8% to 43.3% were vaccinated for influenza each year (annual mean = 35%. test for trend p = 0.71). Vaccination rates peaked in October and November of each season and decreased sharply thereafter. In multivariable analysis, patients who were male (67.2%), non-Hispanic white (70%) or Hispanic (66%), had lower HIV viral loads (73.5%), were prescribed antiretroviral treatment (72.7%), or had a greater number of clinical encounters per year (86.7%) were more likely to receive influenza vaccination. Discussion: The decreased likelihood of vaccination among women and non-Hispanic black patients suggests the need for focused efforts to reduce disparities. Increasing patient and clinician education on the importance of universal vaccination, and ensuring that vaccination activities continue in HIV clinics during the later months of the influenza season may improve influenza vaccine coverage. Published by Elsevier Inc. C1 [Durham, Marcus D.; Buchacz, Kate; Patel, Pragna; Brooks, John T.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Armon, Carl; Wood, Kathy] Cerner Corp, Vienna, VA USA. RP Durham, MD (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E45, Atlanta, GA 30333 USA. EM mvd8@cdc.gov FU Centers for Disease Control and Prevention [200-2001-00133, 200-2006-18797] FX Centers for Disease Control and Prevention (contract nos. 200-2001-00133 and 200-2006-18797). NR 29 TC 6 Z9 6 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD JUL-AUG PY 2011 VL 53 IS 1-2 BP 89 EP 94 DI 10.1016/j.ypmed.2011.04.015 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 807ZC UT WOS:000293940600019 PM 21569791 ER PT J AU Conklin, L Sejvar, JJ Sabogal, R Sanchez, CA Kieszak, S Ackermann, B Jovane, R Victoria, G Tulloch, F Schier, JG AF Conklin, Laura Sejvar, James J. Sabogal, Raquel Sanchez, Carlos A. Kieszak, Stephanie Ackermann, Bertram Jovane, Rosemarie Victoria, Gerardo Tulloch, Felicia Schier, Joshua G. TI PROSPECTIVE ASSESSMENT OF THE HEALTH EFFECTS OF DIETHYLENE GLYCOL EXPOSURE AMONG PERSONS IN PANAMA (2007-2008) SO CLINICAL TOXICOLOGY LA English DT Meeting Abstract C1 [Conklin, Laura; Sejvar, James J.; Sabogal, Raquel; Sanchez, Carlos A.; Kieszak, Stephanie; Ackermann, Bertram; Schier, Joshua G.] CDC, Atlanta, GA 30333 USA. [Jovane, Rosemarie; Victoria, Gerardo; Tulloch, Felicia] Santo Tomas Hosp, Panama City, Panama. RI Schier, Joshua/F-9861-2013 NR 0 TC 0 Z9 0 U1 0 U2 4 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1556-3650 J9 CLIN TOXICOL JI Clin. Toxicol. PD JUL PY 2011 VL 49 IS 6 MA 165 BP 520 EP 520 PG 1 WC Toxicology SC Toxicology GA 804YS UT WOS:000293692600034 ER PT J AU Schier, JG Hunt, DR Filary, MJ Perala, AW McMartin, KE Bartels, MJ Flanders, D AF Schier, Joshua G. Hunt, Danielle R. Filary, Mark J. Perala, Adam W. McMartin, Kenneth E. Bartels, Michael J. Flanders, Dana TI ANALYSIS OF DIETHYLENE GLYCOL (DEG) AND SUSPECTED METABOLITES IN PATIENTS FROM THE 2006 PANAMA DEG MASS POISONING SO CLINICAL TOXICOLOGY LA English DT Meeting Abstract C1 [Schier, Joshua G.; Hunt, Danielle R.; Flanders, Dana] CDC, Atlanta, GA 30333 USA. [Filary, Mark J.; Perala, Adam W.; Bartels, Michael J.] Dow Chem Co USA, Midland, MI 48674 USA. [McMartin, Kenneth E.] Louisiana State Univ, Hlth Sci Ctr, Shreveport, LA 71105 USA. RI Schier, Joshua/F-9861-2013 NR 0 TC 0 Z9 0 U1 0 U2 2 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1556-3650 J9 CLIN TOXICOL JI Clin. Toxicol. PD JUL PY 2011 VL 49 IS 6 MA 166 BP 520 EP 521 PG 2 WC Toxicology SC Toxicology GA 804YS UT WOS:000293692600035 ER PT J AU Smith, J Ruha, AM Curry, SC Biswas, K Nasr, S Ye, W Caldwell, K LoVecchio, F Burkhart, K Westenberger, B AF Smith, Jennifer Ruha, Anne-Michelle Curry, Steven C. Biswas, Kallol Nasr, Samia Ye, Wei Caldwell, Kathleen LoVecchio, Frank Burkhart, Keith Westenberger, Benjamin TI DETERMINATION OF PLASMA DMPS CONCENTRATION AND URINE MERCURY EXCRETION AFTER DERMAL APPLICATION OF "TD-DMPS" SO CLINICAL TOXICOLOGY LA English DT Meeting Abstract C1 [Smith, Jennifer; Ruha, Anne-Michelle; Curry, Steven C.] Banner Good Samaritan Med Ctr, Phoenix, AZ USA. [Biswas, Kallol; Nasr, Samia; Ye, Wei; Burkhart, Keith; Westenberger, Benjamin] US FDA, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA. [Caldwell, Kathleen] CDC, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [LoVecchio, Frank] Maricopa Cty Gen Hosp, Phoenix, AZ USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1556-3650 J9 CLIN TOXICOL JI Clin. Toxicol. PD JUL PY 2011 VL 49 IS 6 MA 72 BP 543 EP 543 PG 1 WC Toxicology SC Toxicology GA 804YS UT WOS:000293692600101 ER PT J AU Wang, J Geiss, LS Cheng, YLJ Imperatore, G Saydah, SH James, C Gregg, EW AF Wang, Jing Geiss, Linda S. Cheng, Yiling J. Imperatore, Giuseppina Saydah, Sharon H. James, Cherie Gregg, Edward W. TI Long-Term and Recent Progress in Blood Pressure Levels Among US Adults With Diagnosed Diabetes, 1988-2008 SO DIABETES CARE LA English DT Article ID UNITED-STATES; VASCULAR-DISEASE; RISK-FACTORS; HYPERTENSION; PREVALENCE; TRENDS; TRIAL AB OBJECTIVE-To examine whether there were long-term (between 1988-1994 and 2001-2008) and recent (between 2001-2004 and 2005-2008) changes in blood pressure (BP) levels among U.S. adults with diagnosed diabetes. RESEARCH DESIGN AND METHODS-Using data from National Health and Nutrition Examination Surveys (NHANES), we examined changes in BP distributions, mean BPs, and proportion with BP <140/90 mmHg. RESULTS-Between 1988-1994 and 2001-2008, for adults with diabetes, mean BPs decreased from 135/72 mmHg to 131/69 mmHg (P < 0.01) and the proportion with BP <140/90 mmHg increased from 64 to 69% (P = 0.01). Although hypertension prevalence increased, hypertension awareness, treatment, and control improved. However, there was no evidence of improvement for adults 20-44 years old. Between 2001-2004 and 2005-2008, there were no significant changes in BP levels. CONCLUSIONS-BP levels among adults with diabetes improved between 1988-1994 and 2001-2008, but the progress stalled between 2001-2004 and 2005-2008. The lack of improvement among young adults is concerning. C1 [Wang, Jing; Geiss, Linda S.; Cheng, Yiling J.; Imperatore, Giuseppina; Saydah, Sharon H.; James, Cherie; Gregg, Edward W.] US Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Wang, J (reprint author), US Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM zrr4@cdc.gov NR 15 TC 24 Z9 24 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JUL PY 2011 VL 34 IS 7 BP 1579 EP 1581 DI 10.2337/dc11-0178 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 799CN UT WOS:000293261200026 PM 21602427 ER PT J AU Dabelea, D Pihoker, C Talton, JW D'Agostino, RB Fujimoto, W Klingensmith, GJ Lawrence, JM Linder, B Marcovina, SM Mayer-Davis, EJ Imperatore, G Dolan, LM AF Dabelea, Dana Pihoker, Catherine Talton, Jennifer W. D'Agostino, Ralph B., Jr. Fujimoto, Wilfred Klingensmith, Georgeanna J. Lawrence, Jean M. Linder, Barbara Marcovina, Santica M. Mayer-Davis, Elizabeth J. Imperatore, Giuseppina Dolan, Lawrence M. CA SEARCH Diabet Youth Study TI Etiological Approach to Characterization of Diabetes Type The SEARCH for Diabetes in Youth Study SO DIABETES CARE LA English DT Article ID BETA-CELL FUNCTION; CHILDREN; MELLITUS; DIAGNOSIS; GENOTYPES; CLASSIFICATION; INSULIN; AUTOIMMUNITY; ADOLESCENTS; ADULTS AB OBJECTIVE-To describe an etiologic approach to classification of diabetes types in youth based on the 1997 American Diabetes Association (ADA) framework, using data from the SEARCH for Diabetes in Youth Study. RESEARCH DESIGN AND METHODS-SEARCH conducted a comprehensive assessment of 2,291 subjects aged <20 years with recently diagnosed diabetes. Using autoimmunity (at least one of two diabetes autoantibodies) and insulin sensitivity (equation validated against hyperinsulinemic-euglycemic clamps) as the main etiologic markers, we described four categories along a bidimensional spectrum: autoimmune plus insulin-sensitive (IS), autoimmune plus insulin-resistant (IR), nonautoimmune plus IS, and nonautoimmune plus IR. We then explored how characteristics, including genetic susceptibility to autoimmunity (HLA genotypes), insulin deficiency, and clinical factors varied across these four categories. RESULTS-Most subjects fell into either the autoimmune plus IS (54.5%) or nonautoimmune plus IR categories (15.9%) and had characteristics that align with traditional descriptions of type 1 or type 2 diabetes. The group classified as autoimmune plus IR (19.5%) had similar prevalence and titers of diabetes autoantibodies and similar distribution of HLA risk genotypes to those in the autoimmune plus IS group, suggesting that it includes individuals with type 1 diabetes who are obese. The group classified as nonautoimmune plus IS (10.1%) likely includes individuals with undetected autoimmunity but may also include those with monogenic diabetes and thus requires further testing. CONCLUSIONS-The SEARCH study offers researchers and clinicians a practical application for the etiologic classification of diabetes type and at the same time identifies a group of youths who would benefit from further testing. C1 [Dabelea, Dana] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO 80045 USA. [Pihoker, Catherine] Univ Washington, Dept Washington, Seattle, WA 98195 USA. [Talton, Jennifer W.; D'Agostino, Ralph B., Jr.] Wake Forest Univ, Bowman Gray Sch Med, Dept Biostat Sci, Winston Salem, NC 27109 USA. [Fujimoto, Wilfred] Kuakini Med Ctr, Honolulu, HI USA. [Klingensmith, Georgeanna J.] Univ Colorado Denver, Barbara Davis Ctr, Sch Med, Aurora, CO USA. [Klingensmith, Georgeanna J.] Univ Colorado Denver, Dept Pediat, Sch Med, Aurora, CO USA. [Lawrence, Jean M.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA USA. [Linder, Barbara] NIDDK, NIH, Bethesda, MD USA. [Marcovina, Santica M.] Univ Washington, Dept Med, Seattle, WA USA. [Mayer-Davis, Elizabeth J.] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA. [Mayer-Davis, Elizabeth J.] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Imperatore, Giuseppina] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Dolan, Lawrence M.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp, Cincinnati, OH USA. RP Dabelea, D (reprint author), Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO 80045 USA. EM dana.dabelea@ucdenver.edu RI Dagostino Jr, Ralph/C-4060-2017 OI Dagostino Jr, Ralph/0000-0002-3550-8395 FU NCRR NIH HHS [UL1 RR025014] NR 25 TC 67 Z9 69 U1 0 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JUL PY 2011 VL 34 IS 7 BP 1628 EP 1633 DI 10.2337/dc10-2324 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 799CN UT WOS:000293261200036 PM 21636800 ER PT J AU O'Connor, PJ Bodkin, NL Fradkin, J Glasgow, RE Greenfield, S Gregg, E Kerr, EA Pawlson, LG Selby, JV Sutherland, JE Taylor, ML Wysham, CH AF O'Connor, Patrick J. Bodkin, Noni L. Fradkin, Judith Glasgow, Russell E. Greenfield, Sheldon Gregg, Edward Kerr, Eve A. Pawlson, L. Gregory Selby, Joseph V. Sutherland, John E. Taylor, Michael L. Wysham, Carol H. TI Diabetes Performance Measures: Current Status and Future Directions SO DIABETES CARE LA English DT Article ID QUALITY-OF-CARE; GLYCEMIC CONTROL; CLINICAL-QUALITY; CARDIOTHORACIC SURGEONS; MEDICATION NONADHERENCE; UNINTENDED CONSEQUENCES; INTERMEDIATE OUTCOMES; TRANSLATING RESEARCH; SURGICAL MORTALITY; COST-EFFECTIVENESS C1 [O'Connor, Patrick J.] Hlth Partners Res Fdn, Minneapolis, MN 55440 USA. [Bodkin, Noni L.] Ctr Medicare & Medicaid Serv, Baltimore, MD USA. [Fradkin, Judith] NIDDK, Bethesda, MD USA. [Glasgow, Russell E.] NCI, Rockville, MD USA. [Greenfield, Sheldon] Univ Calif Irvine, Irvine, CA USA. [Gregg, Edward] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kerr, Eve A.] Univ Michigan, Ann Arbor, MI 48109 USA. [Pawlson, L. Gregory] Natl Comm Qual Assurance, Washington, DC USA. [Selby, Joseph V.] Kaiser Permanente No Calif, Oakland, CA USA. [Sutherland, John E.] NE Iowa Med Educ Fdn, Waterloo, IA USA. [Taylor, Michael L.] Caterpillar Inc, Peoria, IL 61629 USA. [Wysham, Carol H.] Univ Washington, Sch Med, Spokane, WA USA. RP O'Connor, PJ (reprint author), Hlth Partners Res Fdn, Minneapolis, MN 55440 USA. EM patrick.j.oconnor@healthpartners.com RI Kerr, Eve/I-3330-2013 FU sanofi-aventis FX The consensus development conference was supported by an unrestricted grant from sanofi-aventis. The company had no input into the content of the report. No other potential conflicts of interest relevant to this article were reported. NR 93 TC 51 Z9 51 U1 3 U2 12 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JUL PY 2011 VL 34 IS 7 BP 1651 EP 1659 DI 10.2337/dc11-0735 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 799CN UT WOS:000293261200041 PM 21709298 ER PT J AU Ozpinar, A Golub, MS Poppenga, RH Blount, BC Gillespie, JR AF Ozpinar, Aysel Golub, Mari S. Poppenga, Robert H. Blount, Benjamin C. Gillespie, Jerry R. TI Thyroid status of female rhesus monkeys and preliminary information on impact of perchlorate administration SO LABORATORY ANIMALS LA English DT Article DE Iodide uptake; non-human primate; thyroid hormones; ammonium perchlorate; thyroid ID LOW-DOSE PERCHLORATE; TANDEM MASS-SPECTROMETRY; MACACA-MULATTA; ENVIRONMENTAL CHEMICALS; SYMPORTER INHIBITORS; CYNOMOLGUS MACAQUES; HORMONE; HEALTH; THYROTROPIN; DISEASE AB Thyroid status was assessed in adult female rhesus monkey breeders at the California National Primate Research Center at the beginning of the breeding season. The 95% confidence intervals for thyrotropin (TSH), thyroxine (T(4)) and triiodothyronine (T(3)) (n = 66-80) were similar to those previously reported in smaller samples of macaque monkeys. Based on human criteria, 10 of 80 monkeys (12%) were hypothyroid (TSH > 2.01 mu lU/mL). Because hypothyroxinaemia can be a risk factor in pregnancy, T(4) status was compared with past breeding history, breeding outcome for that season and general health records in a subset of 42 breeders. Age, weight and parity did not differ between monkeys in the lowest T(4) quartile as compared with those in the upper three quartiles. However, T(4) concentrations were significantly associated with the number of missed menstrual cycles during the previous breeding season. In additional work, three healthy lactating rhesus monkeys were given three different doses of environmental contaminant and thyroid iodine uptake inhibitor, ammonium perchlorate (0.006, 0.34, 12.8 mg/kg/day, respectively) in food for two weeks. Thyroid status variables (TSH, T(4), T(3), thyroid radioactive iodine uptake) were then measured. In the monkey receiving the highest perchlorate dose, iodine uptake was suppressed relative to baseline. The study shows the availability of tools to study thyroid status in rhesus monkeys, the variability of thyroid status in the breeder colony and the potential ability of environmental factors to influence thyroid status. C1 [Ozpinar, Aysel] Acibadem Univ, Sch Med, Dept Biochem, Istanbul, Turkey. [Golub, Mari S.] Univ Calif Davis, BMB, CNPRC, Davis, CA 95616 USA. [Poppenga, Robert H.] Univ Calif Davis, Sch Vet Med, Calif Anim Hlth & Food Safety Lab CAHFS, Davis, CA 95616 USA. [Blount, Benjamin C.] Ctr Dis Control & Prevent, Div Sci Lab, Atlanta, GA 30341 USA. [Gillespie, Jerry R.] Univ Calif Davis, Western Inst Food Safety & Secur, Davis, CA 95616 USA. RP Ozpinar, A (reprint author), Acibadem Univ, Sch Med, Dept Med Biochem, Dogan Sok 1, Istanbul, Turkey. EM aozpinar@acibadem.edu.tr RI Ozpinar, Aysel/D-5150-2016 OI Ozpinar, Aysel/0000-0002-7399-4929 FU Western Institute for Food Safety and Security (WIFSS); California National Primate Research Center [RR00169] FX We would like to thank Sarah Davis and Toni Trail! for their help handling the primates, Lisa Laughlin for performing the thyroid status analyses, Casey Hogrefe for assembling colony record data and Mike Filigenzi for perchlorate analysis. This study was funded by Western Institute for Food Safety and Security (WIFSS) and RR00169 (California National Primate Research Center). NR 46 TC 2 Z9 2 U1 1 U2 6 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 0023-6772 J9 LAB ANIM-UK JI Lab. Anim. PD JUL PY 2011 VL 45 IS 3 BP 209 EP 214 DI 10.1258/la.2011.010047 PG 6 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 808OA UT WOS:000293987100013 PM 21669905 ER PT J AU Gelting, RJ Baloch, MA Zarate-Bermudez, MA Selman, C AF Gelting, Richard J. Baloch, Mansoor A. Zarate-Bermudez, Max A. Selman, Carol TI Irrigation water issues potentially related to the 2006 multistate E. coli O157:H7 outbreak associated with spinach SO AGRICULTURAL WATER MANAGEMENT LA English DT Article DE California; Agriculture; Food safety; Outbreak investigation; Fresh produce; Groundwater-surface water interactions ID ESCHERICHIA-COLI; GROUNDWATER; O157-H7; WISCONSIN; TRANSPORT; SURVIVAL; O157H7; CATTLE; CONTAMINATION; PREVALENCE AB A multistate Escherichia coli O157:H7 outbreak in August and September 2006 was found to be associated with consumption of fresh bagged spinach traced to California. The California Food Emergency Response Team (CALFERT), consisting of personnel from the California Department of Public Health Food and Drug Branch (FDB) and the U.S. Food and Drug Administration (FDA) undertook an environmental investigation to determine how and why the spinach became contaminated. At the invitation of FDA and FDB, the Centers for Disease Control and Prevention (CDC) also participated in the environmental investigation. This paper presents findings from the portion of the environmental investigation focusing on environmental factors related to irrigation water that may have contributed to contamination of the spinach and hence to the outbreak. Analysis of the available data suggests that depths to groundwater and groundwater-surface water interactions may pose risks to ready-to-eat crops. These risks should be further evaluated and quantified to understand and identify the factors that contributed to this and similar outbreaks. One implication of this analysis is the need to continue to conceptually broaden the scope of produce-related outbreak investigations. Where feasible, investigation strategies should integrate possible contamination sources beyond those actually found on the farms that are identified as sources of produce involved in outbreaks. (C) 2011 Elsevier B.V. All rights reserved. C1 [Gelting, Richard J.; Baloch, Mansoor A.; Zarate-Bermudez, Max A.; Selman, Carol] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Emergency & Environm Hlth Serv, Environm Hlth Serv Branch, Atlanta, GA 30341 USA. RP Baloch, MA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Emergency & Environm Hlth Serv, Environm Hlth Serv Branch, 4770 Buford Highway,MS F-60, Atlanta, GA 30341 USA. EM RGelting@cdc.gov; MBaloch@cdc.gov; MZarateBermudez@cdc.gov; CSelman@cdc.gov OI Baloch, Mansoor/0000-0002-1502-086X NR 45 TC 29 Z9 29 U1 1 U2 34 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-3774 J9 AGR WATER MANAGE JI Agric. Water Manage. PD JUL PY 2011 VL 98 IS 9 BP 1395 EP 1402 DI 10.1016/j.agwat.2011.04.004 PG 8 WC Agronomy; Water Resources SC Agriculture; Water Resources GA 804RU UT WOS:000293672500007 ER PT J AU Molina, M Romaguera, RA Valentine, J Tao, G AF Molina, M. Romaguera, R. A. Valentine, J. Tao, G. TI Seroprevalence of herpes simplex virus 2 among Hispanics in the USA: National Health and Nutrition Examination Survey, 2007-2008 SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE herpes simplex virus type 2; HSV-2; Hispanic Americans; HIV; STI; genital herpes; antibodies; NHANES ID SEXUALLY-TRANSMITTED INFECTIONS; TYPE-2 INFECTION; GENITAL HERPES; GLYCOPROTEIN-G; UNITED-STATES; WOMEN; ACQUISITION; HIV-1; HSV-2; RISK AB To examine the seroprevalence of herpes simplex virus type 2 (HSV-2) among Hispanics in the USA, we used the cross-sectional, nationally representative National Health and Nutrition Examination Survey to compare the seroprevalence of HSV-2 between Hispanic persons of Mexican heritage and non-Mexican heritage aged 14-44 years, from survey years 2007-2008. The overall HSV-2 seroprevalence among Hispanics aged 14-44 years was 17.5% (95% confidence interval [CI], 15.2, 20.1) in the USA. HSV-2 seroprevalence was significantly lower among Mexican Americans than among other Hispanics (11.7% vs. 27.8%, P < 0.01). Prevalence of HSV-2 was also significantly associated with gender and age. The significant difference in HSV-2 seroprevalence between Hispanic persons of Mexican heritage and non-Mexican heritage suggested that targeting specific subgroups of Hispanics for preventive interventions may be a strategy to reduce the transmission of HSV-2 and HIV among Hispanics in the USA. C1 [Molina, M.; Romaguera, R. A.; Valentine, J.; Tao, G.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Tao, G (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS-E80, Atlanta, GA 30333 USA. EM gat3@cdc.gov NR 30 TC 3 Z9 3 U1 0 U2 0 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 0956-4624 J9 INT J STD AIDS JI Int. J. STD AIDS PD JUL PY 2011 VL 22 IS 7 BP 387 EP 390 DI 10.1258/ijsa.2011.010474 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 797AX UT WOS:000293095700007 PM 21729957 ER PT J AU Grefsheim, SF LaBeause, JH Satterthwaite, RK AF Grefsheim, Suzanne F. LaBeause, Jan H. Satterthwaite, Rebecca K. TI Jocelyn Anne Rankin, PhD, FMLA, 1946-2010 OBITUARY SO JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION LA English DT Biographical-Item C1 [Grefsheim, Suzanne F.] NIH, Div Lib Serv, Off Res Serv, Bethesda, MD 20892 USA. [LaBeause, Jan H.] Mercer Univ, Sch Med, Med Lib, Macon, GA 31207 USA. [LaBeause, Jan H.] Mercer Univ, Sch Med, Peyton T Anderson Learning Resources Ctr, Macon, GA 31207 USA. [Satterthwaite, Rebecca K.] Ctr Dis Control & Prevent, TechSoft Grp, Atlanta, GA 30333 USA. RP Grefsheim, SF (reprint author), NIH, Div Lib Serv, Off Res Serv, 10 Ctr Dr, Bethesda, MD 20892 USA. EM grefshes@mail.nih.gov; labeause_j@mercer.edu; bus8@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 1 PU MEDICAL LIBRARY ASSOC PI CHICAGO PA 65 EAST WACKER PLACE, STE 1900, CHICAGO, IL 60601-7298 USA SN 1536-5050 J9 J MED LIBR ASSOC JI J. Med. Libr. Assoc. PD JUL PY 2011 VL 99 IS 3 BP 183 EP 184 DI 10.3163/1536-5050.99.3.002 PG 2 WC Information Science & Library Science SC Information Science & Library Science GA 801ND UT WOS:000293445700002 PM 21874675 ER PT J AU Pastor, PN Reuben, CA AF Pastor, Patricia N. Reuben, Cynthia A. TI Maternal Reports of Child Health Status and Health Conditions: The Influence of Self-Reported Maternal Health Status SO ACADEMIC PEDIATRICS LA English DT Article DE child health conditions; child health status; maternal health status ID RATED HEALTH; PHYSICIAN SERVICES; BEHAVIOR PROBLEMS; CARE UTILIZATION; MENTAL-ILLNESS; PARENT REPORTS; MORTALITY; POPULATION; IMPACT; PREVALENCE AB OBJECTIVE: The aim of this study was to examine the influence of maternal health status (MHS) on the relationship between child health conditions and child health status (CHS). METHODS: The study sample included 38 207 children aged 5 to 17 years in the 2001 to 2008 National Health Interview Surveys whose mothers were the survey respondent for the child and herself. Information was collected about CHS, MHS, diagnosed child health conditions, and sociodemographic characteristics. Responses to a question on general health status were used to rate CHS and MHS as "better" (excellent/very good health) or "worse" (good/fair/poor health). The percentage of children with worse CHS, adjusted for sociodemographic characteristics, was estimated using logistic regression. RESULTS: Adjusting for child and family sociodemographic characteristics had a negligible effect on the association between CHS and a 4-level variable that classified children by both MHS and child health conditions. The adjusted percentage of children with worse CHS was higher among children whose mothers had worse MHS compared with children whose mothers had better MHS. Moreover, among children whose mothers had worse MHS, there was a weak relationship between child health conditions and worse CHS. Among children whose mothers had better MHS, there was a strong relationship between child health conditions and worse CHS. CONCLUSION: Because mother-reported CHS is used widely in epidemiological studies as a measure of a child's actual state of health, it is important to consider how maternal characteristics may influence a mother's report of a child's status. In particular, CHS reported by mothers with worse health status merits further investigation. C1 [Pastor, Patricia N.; Reuben, Cynthia A.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Pastor, PN (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 6437, Hyattsville, MD 20782 USA. EM php3@cdc.gov NR 39 TC 3 Z9 3 U1 4 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 J9 ACAD PEDIATR JI Acad. Pediatr. PD JUL-AUG PY 2011 VL 11 IS 4 BP 311 EP 317 PG 7 WC Pediatrics SC Pediatrics GA 797EJ UT WOS:000293107000009 PM 21764015 ER PT J AU Shires, DA Divine, G Schum, M Gunter, MJ Baumer, DL Kasprzyk, D Montano, DE Smith, JL Elston-Lafata, J AF Shires, Deirdre A. Divine, George Schum, Michael Gunter, Margaret J. Baumer, Dorothy L. Kasprzyk, Danuta Montano, Daniel E. Smith, Judith Lee Elston-Lafata, Jennifer TI Colorectal Cancer Screening Use Among Insured Primary Care Patients SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID AMERICAN-COLLEGE; UNITED-STATES; PREFERENCES; POPULATION; GUIDELINES; RECOMMENDATION; SURVEILLANCE; DISPARITIES; RATIONALE; SOCIETY AB Objective: To compare colorectal cancer (CRC) screening use, including changes over time and demographic characteristics associated with screening receipt, between 2 insured primary care populations. Study Design: Clinical and administrative records from 2 large health systems, one in New Mexico and the other in Michigan, were used to determine use of CRC screening tests between 2004 and 2008 among patients aged 51 to 74 years. Methods: Generalized estimating equations were used to evaluate trends in CRC screening use over time and the association of demographic and other factors with screening receipt. Results: Rates of CRC screening use ranged from 48.1% at the New Mexico site to 68.7% at the Michigan site, with colonoscopy being the most frequently used modality. Fecal occult blood test was used inconsistently by substantial proportions of patients who did not meet the definition of screening users. Screening use was positively and significantly associated with older age, male sex, and more periodic health examinations and other types of primary care visits; at the Michigan site, it was also associated with African American race, married status, and higher annual estimated household income. Conclusions: Among insured primary care patients, CRC screening use falls short. Further research is needed to determine what factors are barriers to routine fecal occult blood test or colonoscopy use among insured patients who have access to and regularly use primary care and how those barriers can be eliminated. (Am J Manag Care. 2011; 17(7):480-488) C1 [Shires, Deirdre A.; Elston-Lafata, Jennifer] Henry Ford Hlth Syst, Ctr Hlth Serv Res, Detroit, MI 48202 USA. [Divine, George] Henry Ford Hlth Syst, Biostat & Res Epidemiol, Detroit, MI 48202 USA. [Schum, Michael; Gunter, Margaret J.; Baumer, Dorothy L.] LCF Res, Albuquerque, NM USA. [Kasprzyk, Danuta; Montano, Daniel E.] Battelle Mem Inst, Ctr Publ Hlth Res & Evaluat, Seattle, WA USA. [Smith, Judith Lee] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Elston-Lafata, Jennifer] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA. RP Shires, DA (reprint author), Henry Ford Hlth Syst, Ctr Hlth Serv Res, 1 Ford Pl,Ste 3A, Detroit, MI 48202 USA. EM dshires1@hfhs.org FU Division of Cancer Prevention and Control, Centers for Disease Control and Prevention [200-2002-F-00838] FX This study was supported by contract 200-2002-F-00838 from the Division of Cancer Prevention and Control, Centers for Disease Control and Prevention. The findings and conclusions in this study are those of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. NR 33 TC 10 Z9 10 U1 2 U2 10 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD JUL PY 2011 VL 17 IS 7 BP 480 EP 488 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 801QJ UT WOS:000293455000008 PM 21819168 ER PT J AU O'Neill, OA Feldman, DC Vandenberg, RJ Dejoy, DM Wilson, MG AF O'Neill, Olivia A. Feldman, Daniel C. Vandenberg, Robert J. DeJoy, David M. Wilson, Mark G. TI ORGANIZATIONAL ACHIEVEMENT VALUES, HIGH-INVOLVEMENT WORK PRACTICES, AND BUSINESS UNIT PERFORMANCE SO HUMAN RESOURCE MANAGEMENT LA English DT Article DE achievement values; high-involvement work practices (HIWP); performance ID HUMAN-RESOURCE MANAGEMENT; FIRM PERFORMANCE; INTERRATER RELIABILITY; EMPLOYEE INVOLVEMENT; GOAL ORIENTATION; CULTURAL-VALUES; CLIMATE; SYSTEMS; PRODUCTIVITY; MOTIVATION AB This study examines the relationships among organizational achievement values, high-involvement work practices (HIWP), and business unit performance. Specifically, we examine whether HIWP mediate or moderate the effect of achievement values on retail store performance. Using data collected at three points in time from more than 1,000 employees, we found support for the mediation model. The article concludes with directions for future research and implications for management practice. (C) 2011 Wiley Periodicals, Inc. C1 [O'Neill, Olivia A.] George Mason Univ, Sch Management, Dept Management, Fairfax, VA 22030 USA. [Feldman, Daniel C.; Vandenberg, Robert J.] Univ Georgia, Terry Coll Business, Athens, GA 30602 USA. [DeJoy, David M.; Wilson, Mark G.] Univ Georgia, Coll Publ Hlth, Dept Hlth Promot & Behav, Athens, GA 30602 USA. [Wilson, Mark G.] Univ Georgia, Coll Publ Hlth, Workpl Hlth Grp, Athens, GA 30602 USA. [Wilson, Mark G.] Dow Chem Co USA, Midland, MI 48674 USA. [Wilson, Mark G.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP O'Neill, OA (reprint author), George Mason Univ, Sch Management, Dept Management, 4400 Univ Dr,MS 5F5, Fairfax, VA 22030 USA. EM ooneill@gmu.edu RI Vandenberg, Robert/Q-2180-2015 NR 88 TC 7 Z9 7 U1 2 U2 22 PU WILEY PERIODICALS, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN, MA 02148-529 USA SN 0090-4848 J9 HUM RESOUR MANAGE-US JI Hum. Resour. Manage. PD JUL-AUG PY 2011 VL 50 IS 4 BP 541 EP 558 DI 10.1002/hrm.20437 PG 18 WC Psychology, Applied; Management SC Psychology; Business & Economics GA 799AZ UT WOS:000293257200007 ER PT J AU Cui, FQ Luo, HM Zhou, L Yin, DP Zheng, CJ Wang, DM Gong, J Fang, G He, JF McFarland, J Yu, HJ AF Cui, Fuqiang Luo, Huiming Zhou, Lei Yin, Dapeng Zheng, Canjun Wang, Dingming Gong, Jian Fang, Gang He, Jianfeng McFarland, Jeffrey Yu, Hongjie TI Transmission of Pandemic Influenza A (H1N1) Virus in a Train in China SO JOURNAL OF EPIDEMIOLOGY LA English DT Article DE pandemic influenza A (H1N1); outbreak; train ID ACUTE-RESPIRATORY-SYNDROME; OUTBREAK; DISEASE; INFECTION; FLIGHT AB Background: Pandemic influenza A (H1N1) virus emerged in North America in April 2009 and spread globally. We describe the epidemiology and public health response to the first known outbreak of 2009 H1N1 in a train, which occurred in June :2009 in China. Methods: After 2 provinces provided initial reports of 2009 H1N1 infection in 2 persons who had travelled on the same train, we conducted a retrospective epidemiologic investigation to collect information from the passengers, crew members, contacts, and health care providers. We explored the source of infection and possible routes of transmission ill the train. All cases were confirmed by real-time reverse transcription polymerase chain reaction testing. Results: Train #1223 traveled 40 hours, made 28 stops in 4 Chinese provinces, and boarded 2555 passengers, who logged a total of 59 144 person-hours of travel time. Nineteen confirmed 2009 H1N1 cases were identified. Of these, 13 were infected and developed symptoms on the train and 6 occurred among contacts who developed illness during medical monitoring. In addition, 3 asymptomatic cases were identified based on RT-PCR testing of respiratory swabs from contacts. The attack rate among contacts of confirmed cases in the same car was higher than that among contacts in other cars (3.15% vs. 0%, P < 0.001). Attack rates increased with exposure time. Conclusions: Close contact and long exposure may have contributed to the transmission of 2009 H1N1 virus in the train. Trains may have played an important role in the 2009 influenza pandemic. C1 [Yu, Hongjie] Chinese Ctr Dis Control & Prevent, Off Dis Control & Emergency Response, Beijing 102206, Peoples R China. [Wang, Dingming] Guizhou Ctr Dis Control & Prevent, Guiyang, Peoples R China. [Gong, Jian] Guangxi Ctr Dis Control & Prevent, Nanning, Peoples R China. [Fang, Gang] Sichuan Ctr Dis Control & Prevent, Chengdu, Peoples R China. [He, Jianfeng] Guangdong Ctr Dis Control & Prevent, Guangzhou, Guangdong, Peoples R China. [McFarland, Jeffrey] China US Collaborat Program Emerging & Re Emergin, Beijing, Peoples R China. [McFarland, Jeffrey] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Yu, HJ (reprint author), Chinese Ctr Dis Control & Prevent, Off Dis Control & Emergency Response, 155 Changbai Rd, Beijing 102206, Peoples R China. EM yuhj@chiancdc.cn OI Zhou, Lei/0000-0002-6640-0774 FU China-US Collaborative Program on Emerging and Re-Emerging Infectious Diseases FX We thank all local staff who contributed to the investigation, the laboratory professionals who tested specimens, and all participants who completed questionnaires and reported their disease history. We also thank the Ministry of Railways, which provided detailed information on passengers and train 1223. Special thanks to Dr. Yvan J. Hutin for kindly guiding this paper. We also thank Carolyn B. Bridges, MD from the Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, USA for critical comments on the manuscript. This work was supported by the China-US Collaborative Program on Emerging and Re-Emerging Infectious Diseases. NR 26 TC 9 Z9 9 U1 0 U2 5 PU JAPAN EPIDEMIOLOGICAL ASSOC PI TOCHIGI PA JICHI MEDICAL SCHOOL, DEPT PUBLIC HEALTH, 3311-1 YAKUSHIJI, MINAMIKAWACH, TOCHIGI, 329-0498, JAPAN SN 0917-5040 J9 J EPIDEMIOL JI J. Epidemiol. PD JUL PY 2011 VL 21 IS 4 BP 271 EP 277 DI 10.2188/jea.JE20100119 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 800NZ UT WOS:000293369400006 PM 21646746 ER PT J AU Bhattacharya, A Leigh, JP AF Bhattacharya, Anasua Leigh, J. Paul TI Musculoskeletal Disorder Costs and Medical Claim Filing in the US Retail Trade Sector SO INDUSTRIAL HEALTH LA English DT Article DE Low back syndrome; Lumbar region; Market Scan ID WORK; CARE; DISABILITY; TRENDS AB The average costs of Musculoskeletal Disorder (MSD) and odds ratios for tiling medical claims related to MSD were examined. The medical claims were identified by ICD 9 codes for four US Census regions within retail trade. Large private firms' medical claims data from Thomson Reuters Inc. Market Scan databases for the years 2003 through 2006 were used. Average costs were highest for claims related to lumbar region (ICD 9 Code: 724.02) and number of claims were largest for low back syndrome (ICD 9 Code: 724.2). Whereas the odds of filing an MSD claim did not vary greatly over time, average costs declined over time. The odds of filing claims rose with age and were higher for females and southerners than men and non-southerners. Total estimated national medical costs for MSDs within retail trade were $389 million (2007 USD). C1 [Bhattacharya, Anasua] NIOSH, Risk Evaluat Branch, Educ & Informat Div, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Leigh, J. Paul] Univ Calif Davis, Ctr Healthcare Policy & Res, Davis, CA 95616 USA. [Leigh, J. Paul] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA. RP Bhattacharya, A (reprint author), NIOSH, Risk Evaluat Branch, Educ & Informat Div, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,MS C-15, Cincinnati, OH 45226 USA. EM ABhattacharya1@cdc.gov RI Leigh, J. Paul/I-5772-2013 FU National Institute for Occupational Safety and Health [OH008248-01] FX JP Leigh acknowledges partial support from the National Institute for Occupational Safety and Health (OH008248-01). NR 13 TC 5 Z9 5 U1 0 U2 3 PU NATL INST OCCUPATIONAL SAFETY & HEALTH, JAPAN PI KAWASAKI KANAGAWA PA 21-1 NAGAO 6-CHOME TAMA-KU, KAWASAKI KANAGAWA, 214, JAPAN SN 0019-8366 J9 IND HEALTH JI Ind. Health PD JUL PY 2011 VL 49 IS 4 BP 517 EP 522 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 799VA UT WOS:000293313000015 PM 21697616 ER PT J AU Yin, DX Morris, CR Bates, JH German, RR AF Yin, Daixin Morris, Cyllene R. Bates, Janet H. German, Robert R. TI Effect of Misclassified Underlying Cause of Death on Survival Estimates of Colon and Rectal Cancer SO JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID COLORECTAL-CANCER; CERTIFICATE COMPLETION; UNITED-STATES; TUMOR CHARACTERISTICS; MORTALITY STATISTICS; SOCIOECONOMIC-STATUS; RACIAL DISPARITIES; ACCURACY; NEED AB Inaccurate coding of patients' Underlying Cause of Death (UCOD) has constrained cause-specific survival estimates for colon and rectal cancers. Using California data from the Accuracy of Cancer Mortality study, we compared the cancer site data from the California Cancer Registry (CCR) with UCODs reported on death certificates and reclassified the UCODs based on cancer registry data when they disagreed. We then calculated 1-, 3-, 5-, and 10-year cause-specific survival for colon and rectal cancers separately, before and after the reclassification. Records from 26 312 colon and 10 687 rectal cancer patients were examined. UCOD records disagreed with CCR records for 700 (6%) of 11 404 colon cancer deaths and with 1958 (39%) of 5011 rectal cancer deaths, and 82% of the misclassified rectal cancer deaths were coded as colon cancer deaths in the UCOD. Reclassification decreased cause-specific survival for both colon and rectal cancers, but the impact was more pronounced for rectal cancer (eg, 5-year cause-specific survival of colon cancer decreased by 2.8% and of rectal cancer decreased by 20.0% relative to previous estimates; absolute rates changed from 65.4% to 63.6%, and 81.2% to 64.9%, respectively, after reclassification). Interchangeable use of the terms colon cancer and colorectal cancer is likely to be one of the reasons for UCOD misclassification. Educational measures could improve the accuracy of UCOD for colon and rectal cancer deaths. C1 [Yin, Daixin; Morris, Cyllene R.] Calif Canc Registry, Inst Publ Hlth, Sacramento, CA 95825 USA. [Bates, Janet H.] Calif Dept Publ Hlth, Canc Surveillance Sect, Sacramento, CA USA. [German, Robert R.] Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Morris, CR (reprint author), Calif Canc Registry, Inst Publ Hlth, 1825 Bell St,Ste 102, Sacramento, CA 95825 USA. EM cmorris@ccr.ca.gov FU Center for Disease Control and Prevention [CDC NPCR / 200-2002-0574] FX Supported in part by a contract (CDC NPCR / 200-2002-0574, Order # 16) with the National Program of Cancer Registries, Center for Disease Control and Prevention. NR 28 TC 19 Z9 19 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 J NATL CANCER I JI J. Natl. Cancer Inst. PD JUL PY 2011 VL 103 IS 14 BP 1130 EP 1133 DI 10.1093/jnci/djr207 PG 4 WC Oncology SC Oncology GA 796BB UT WOS:000293024100012 PM 21697545 ER PT J AU Machado-Ferreira, E Dietrich, G Hojgaard, A Levin, M Piesman, J Zeidner, NS Soares, CAG AF Machado-Ferreira, Erik Dietrich, Gabrielle Hojgaard, Andrias Levin, Michael Piesman, Joseph Zeidner, Nordin S. Soares, Carlos A. G. TI Coxiella Symbionts in the Cayenne Tick Amblyomma cajennense SO MICROBIAL ECOLOGY LA English DT Article ID RICKETTSIA-RICKETTSII; BORNE RICKETTSIAE; ACARI; AMERICANUM; BURNETII; IXODIDAE; VECTOR; ARGASIDAE; PATHOGENS; BORRELIA AB Members of the Coxiella genus are intracellular bacteria that can infect a variety of animals including humans. A symbiotic Coxiella was recently described in Amblyomma americanum ticks in the Northern Hemisphere with no further investigations of other Amblyomma species in other geographic regions. These ixodid ticks represent a group of important vectors for human infectious agents. In the present work, we have demonstrated that symbiotic Coxiella (SCox) are widespread, occurring in South America and infecting 100% of all life stages and eggs of the Cayenne ticks Amblyomma cajennense from Brazil and the USA. Using light microscopy, in situ hybridization, and PCR, we demonstrated SCox in salivary glands, ovaries, and the intestines of A. cajennense. These symbionts are vertically and transtadially transmitted in laboratory reared A. cajennense, and quantitative PCR analyses indicate that SCox are more abundant in adult female ticks, reaching values corresponding to an 11x, 38x, and 200x increase in SCox 16S rRNA gene copy number in unfed females, compared to unfed nymphs, larvae, and eggs, respectively. Phylogenetic analyses showed distinct SCox subpopulations in the USA and Brazil and demonstrated that SCox bacteria do not group with pathogenic Coxiella burnetii. C1 [Machado-Ferreira, Erik; Soares, Carlos A. G.] Univ Fed Rio de Janeiro, Inst Biol, Dept Genet, Lab Genet Mol Eucariontes & Simbiontes, BR-21944970 Rio De Janeiro, Brazil. [Machado-Ferreira, Erik; Soares, Carlos A. G.] CCS, Ilha Fundao, Rio De Janeiro, Brazil. [Dietrich, Gabrielle; Hojgaard, Andrias; Levin, Michael; Piesman, Joseph; Zeidner, Nordin S.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. RP Soares, CAG (reprint author), Univ Fed Rio de Janeiro, Inst Biol, Dept Genet, Lab Genet Mol Eucariontes & Simbiontes, BR-21944970 Rio De Janeiro, Brazil. EM soares@biologia.ufrj.br RI Machado Ferreira, Erik/K-1472-2013; Soares, Carlos/H-9464-2016 OI Soares, Carlos/0000-0001-9058-9266 FU CAPES; CDC FX Erik Machado-Ferreira's graduate fellowship was supported by the Brazilian federal agency CAPES and by the CDC. This is part of Erik Machado-Ferreira's PhD thesis work. The authors would like to thank to Mr. Manoel Itamar do Nascimento for tick sampling and Ms. Maria de Fatima S. Cardoso, Mr. Luiz F. P. Frade, and Mr. Silvio P. Nascimento for their excellent technical assistance. The authors would also like to thank Dr. Robert Massung for his constructive comments. NR 29 TC 19 Z9 19 U1 1 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0095-3628 J9 MICROB ECOL JI Microb. Ecol. PD JUL PY 2011 VL 62 IS 1 BP 134 EP 142 DI 10.1007/s00248-011-9868-x PG 9 WC Ecology; Marine & Freshwater Biology; Microbiology SC Environmental Sciences & Ecology; Marine & Freshwater Biology; Microbiology GA 796DM UT WOS:000293030400012 PM 21611689 ER PT J AU Van Kerkhove, MD Vandemaele, KAH Shinde, V Jaramillo-Gutierrez, G Koukounari, A Donnelly, CA Carlino, LO Owen, R Paterson, B Pelletier, L Vachon, J Gonzalez, C Yu, HJ Feng, ZJ Chuang, SK Au, A Buda, S Krause, G Haas, W Bonmarin, I Taniguichi, K Nakajima, K Shobayashi, T Takayama, Y Sunagawa, T Heraud, JM Orelle, A Palacios, E van der Sande, MAB Wielders, CCHL Hunt, D Cutter, J Lee, VJ Thomas, J Santa-Olalla, P Sierra-Moros, MJ Hanshaoworakul, W Ungchusak, K Pebody, R Jain, S Mounts, AW AF Van Kerkhove, Maria D. Vandemaele, Katelijn A. H. Shinde, Vivek Jaramillo-Gutierrez, Giovanna Koukounari, Artemis Donnelly, Christl A. Carlino, Luis O. Owen, Rhonda Paterson, Beverly Pelletier, Louise Vachon, Julie Gonzalez, Claudia Yu Hongjie Feng Zijian Chuang, Shuk Kwan Au, Albert Buda, Silke Krause, Gerard Haas, Walter Bonmarin, Isabelle Taniguichi, Kiyosu Nakajima, Kensuke Shobayashi, Tokuaki Takayama, Yoshihiro Sunagawa, Tomi Heraud, Jean Michel Orelle, Arnaud Palacios, Ethel van der Sande, Marianne A. B. Wielders, C. C. H. Lieke Hunt, Darren Cutter, Jeffrey Lee, Vernon J. Thomas, Juno Santa-Olalla, Patricia Sierra-Moros, Maria J. Hanshaoworakul, Wanna Ungchusak, Kumnuan Pebody, Richard Jain, Seema Mounts, Anthony W. CA WHO Working Grp Risk Factors Sever TI Risk Factors for Severe Outcomes following 2009 Influenza A (H1N1) Infection: A Global Pooled Analysis SO PLOS MEDICINE LA English DT Article ID CRITICALLY-ILL PATIENTS; PANDEMIC INFLUENZA; PREGNANT-WOMEN; VIRUS-INFECTION; UNITED-STATES; HOSPITALIZED-PATIENTS; A(H1N1) INFECTION; ADULT PATIENTS; NEW-ZEALAND; SURVEILLANCE AB Background: Since the start of the 2009 influenza A pandemic (H1N1pdm), the World Health Organization and its member states have gathered information to characterize the clinical severity of H1N1pdm infection and to assist policy makers to determine risk groups for targeted control measures. Methods and Findings: Data were collected on approximately 70,000 laboratory-confirmed hospitalized H1N1pdm patients, 9,700 patients admitted to intensive care units (ICUs), and 2,500 deaths reported between 1 April 2009 and 1 January 2010 from 19 countries or administrative regions-Argentina, Australia, Canada, Chile, China, France, Germany, Hong Kong SAR, Japan, Madagascar, Mexico, the Netherlands, New Zealand, Singapore, South Africa, Spain, Thailand, the United States, and the United Kingdom-to characterize and compare the distribution of risk factors among H1N1pdm patients at three levels of severity: hospitalizations, ICU admissions, and deaths. The median age of patients increased with severity of disease. The highest per capita risk of hospitalization was among patients <5 y and 5-14 y (relative risk [RR] = 3.3 and 3.2, respectively, compared to the general population), whereas the highest risk of death per capita was in the age groups 50-64 y and >65 y (RR = 1.5 and 1.6, respectively, compared to the general population). Similarly, the ratio of H1N1pdm deaths to hospitalizations increased with age and was the highest in the >= 65-y-old age group, indicating that while infection rates have been observed to be very low in the oldest age group, risk of death in those over the age of 64 y who became infected was higher than in younger groups. The proportion of H1N1pdm patients with one or more reported chronic conditions increased with severity (median = 31.1%, 52.3%, and 61.8% of hospitalized, ICU-admitted, and fatal H1N1pdm cases, respectively). With the exception of the risk factors asthma, pregnancy, and obesity, the proportion of patients with each risk factor increased with severity level. For all levels of severity, pregnant women in their third trimester consistently accounted for the majority of the total of pregnant women. Our findings suggest that morbid obesity might be a risk factor for ICU admission and fatal outcome (RR = 36.3). Conclusions: Our results demonstrate that risk factors for severe H1N1pdm infection are similar to those for seasonal influenza, with some notable differences, such as younger age groups and obesity, and reinforce the need to identify and protect groups at highest risk of severe outcomes. C1 [Van Kerkhove, Maria D.; Vandemaele, Katelijn A. H.; Shinde, Vivek; Jaramillo-Gutierrez, Giovanna; Mounts, Anthony W.] WHO, Global Influenza Programme, London, England. [Van Kerkhove, Maria D.; Koukounari, Artemis; Donnelly, Christl A.] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, Med Res Council Ctr Outbreak Anal & Modelling, London, England. [Carlino, Luis O.] Minist Salud Nac, Buenos Aires, DF, Argentina. [Owen, Rhonda; Paterson, Beverly] Dept Hlth & Ageing, Off Hlth Protect, Surveillance Branch, Influenza Surveillance Sect, Woden, ACT, Australia. [Pelletier, Louise; Vachon, Julie] Publ Hlth Agcy Canada, Influenza Surveillance Sect, Toronto, ON, Canada. [Gonzalez, Claudia] Minist Salud Chile, Div Planificac Sanitaria, Dept Epidemiol, Santiago, Chile. [Yu Hongjie; Feng Zijian] Chinese Ctr Dis Control & Prevent Beijing, Off Dis Control & Emergency Response, Beijing, Peoples R China. [Chuang, Shuk Kwan; Au, Albert] Ctr Hlth Protect, Surveillance & Epidemiol Branch, Dept Hlth, Hong Kong, Hong Kong, Peoples R China. [Buda, Silke; Krause, Gerard; Haas, Walter] Robert Koch Inst, Dept Infect Dis Epidemiol, D-1000 Berlin, Germany. [Bonmarin, Isabelle] Inst Veille, Dept Malad Infect, Sanitaire, Saint Maurice, France. [Taniguichi, Kiyosu; Sunagawa, Tomi] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo, Japan. [Nakajima, Kensuke; Shobayashi, Tokuaki; Takayama, Yoshihiro] Minist Hlth Labour & Welf, Tokyo, Japan. [Heraud, Jean Michel; Orelle, Arnaud] Inst Pasteur Madagascar, Virol Unit, Antananarivo, Madagascar. [Palacios, Ethel] Directorate Gen Epidemiol, Mexico City, DF, Mexico. [van der Sande, Marianne A. B.; Wielders, C. C. H. Lieke] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, Epidemiol & Surveillance Unit, NL-3720 BA Bilthoven, Netherlands. [Hunt, Darren] New Zealand Minist Hlth, Wellington, New Zealand. [Cutter, Jeffrey] Minist Hlth, Communicable Dis Div, Singapore, Singapore. [Lee, Vernon J.] Minist Def, Biodef Ctr, Singapore, Singapore. [Lee, Vernon J.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Epidemiol & Publ Hlth, Singapore 117595, Singapore. [Thomas, Juno] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Resp Virus Unit, Epidemiol & Surveillance Unit, Johannesburg, South Africa. [Santa-Olalla, Patricia; Sierra-Moros, Maria J.] Minist Sanidad & Polit Social, Direcc Gen Salud Publ & Sanidad Exterior, Coordinating Ctr Hlth Alerts & Emergencies, Madrid, Spain. [Hanshaoworakul, Wanna; Ungchusak, Kumnuan] Minist Publ Hlth, Dept Dis Control, Nonthaburi, Thailand. [Pebody, Richard] Hlth Protect Agcy, London, England. [Jain, Seema] Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Influenza Div, Atlanta, GA USA. RP Van Kerkhove, MD (reprint author), WHO, Global Influenza Programme, London, England. EM mountsa@who.int RI Paterson, Beverley/C-6189-2012; HERAUD, Jean-Michel/O-1464-2013; OI Paterson, Beverley/0000-0001-5108-103X; HERAUD, Jean-Michel/0000-0003-1107-0859; Krause, Gerard/0000-0003-3328-8808; Donnelly, Christl/0000-0002-0195-2463; Pebody, Richard/0000-0002-9069-2885 FU Medical Research Council UK; Bill and Melinda Gates Foundation; Pan American Health Organization (PAHO); GlaxoSmithKline; Centers for Disease Control and Prevention FX MDVK, CAD, and AK acknowledge funding from the Medical Research Council UK and the Bill and Melinda Gates Foundation (MDVK) for funding. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; CG worked for the Ministry of Health of Chile from 1997 to August 2010, in the Department of Epidemiology. CG has been involved in the process of preparing and developing the National Pandemic Plan since 2002. During the pandemic CG was in charge of the coordination of the Executive Committee for outbreaks and health emergencies in Chile. This committee was responsible for making decisions and implementing measures for prevention and control. Also, until August 2010, CG participated in the implementation of IHR 2005 in Chile. During the pandemic, the Pan American Health Organization (PAHO) provided funds to the Ministry of Health and the Institute of Public Health for studies and improvement of epidemiological surveillance. CG was not responsible for managing these resources. PAHO also delivered primers and other supplies for the laboratory diagnosis of influenza (RT-PCR). They provided computers for influenza sentinel centers for improving the opportunity of reporting, which also included the development of a web application for online notification. CG was a member of the Review Committee on the Functioning of the International Health Regulations (2005) and on Pandemic Influenza A (H1N1), 2009, between April 2010 and April 2011. The result of the work of this committee was submitted to the World Health Assembly in May 2011. In December 2010 (29 November to 15 December) CG was part of a mission to assess the health sector response to pandemic influenza A (H1N1) in Mexico. This mission was requested by the Ministry of Health of Mexico to PAHO. Other mission members were Dr. Jarbas Barbosa (Brazil), Dr. Hande Harmanci (WHO), Dr. Juan Pablo Sarmiento (Colombia), Dr. Ronald St. John (Canada). For this work CG received airfare and per diem supplemented by the standards of PAHO. CG has been invited to present the Chilean experience during the influenza pandemic 2009 in various national and international conferences. CG currently works at the Universidad del Desarrollo (Santiago, Chile) as a teacher and researcher; also at EPI-Sur Consultants, an institution dedicated to providing advisory services and consulting in the field of international health for agencies, governments, and NGOs. EPI-Sur Consultants have worked for PAHO in the field of infectious diseases (not on influenza). VJL has received unrelated research funding from GlaxoSmithKline. JT received a travel grant from the Centers for Disease Control and Prevention (via an Influenza Cooperative Agreement Grant) to attend the "Options for the Control of Influenza VII" conference in Hong Kong, 3-7 September 2010, to present a poster entitled "Fatal pandemic influenza A(H1N1) 2009 infections in HIV-infected persons, South Africa." All other authors have declared that no competing interests exist. NR 83 TC 173 Z9 175 U1 3 U2 34 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1549-1277 J9 PLOS MED JI PLos Med. PD JUL PY 2011 VL 8 IS 7 AR e1001053 DI 10.1371/journal.pmed.1001053 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 797ZQ UT WOS:000293169700003 PM 21750667 ER PT J AU Plante, K Wang, EY Partidos, CD Weger, J Gorchakov, R Tsetsarkin, K Borland, EM Powers, AM Seymour, R Stinchcomb, DT Osorio, JE Frolov, I Weaver, SC AF Plante, Kenneth Wang, Eryu Partidos, Charalambos D. Weger, James Gorchakov, Rodion Tsetsarkin, Konstantin Borland, Erin M. Powers, Ann M. Seymour, Robert Stinchcomb, Dan T. Osorio, Jorge E. Frolov, Ilya Weaver, Scott C. TI Novel Chikungunya Vaccine Candidate with an IRES-Based Attenuation and Host Range Alteration Mechanism SO PLOS PATHOGENS LA English DT Article ID EQUINE ENCEPHALITIS-VIRUS; REUNION ISLAND; MOUSE MODEL; INFECTION; EPIDEMIC; OUTBREAK; DISEASE; STRAIN; DENGUE; FEVER AB Chikungunya virus (CHIKV) is a reemerging mosquito-borne pathogen that has recently caused devastating urban epidemics of severe and sometimes chronic arthralgia. As with most other mosquito-borne viral diseases, control relies on reducing mosquito populations and their contact with people, which has been ineffective in most locations. Therefore, vaccines remain the best strategy to prevent most vector-borne diseases. Ideally, vaccines for diseases of resource-limited countries should combine low cost and single dose efficacy, yet induce rapid and long-lived immunity with negligible risk of serious adverse reactions. To develop such a vaccine to protect against chikungunya fever, we employed a rational attenuation mechanism that also prevents the infection of mosquito vectors. The internal ribosome entry site (IRES) from encephalomyocarditis virus replaced the subgenomic promoter in a cDNA CHIKV clone, thus altering the levels and host-specific mechanism of structural protein gene expression. Testing in both normal outbred and interferon response-defective mice indicated that the new vaccine candidate is highly attenuated, immunogenic and efficacious after a single dose. Furthermore, it is incapable of replicating in mosquito cells or infecting mosquitoes in vivo. This IRES-based attenuation platform technology may be useful for the predictable attenuation of any alphavirus. C1 [Plante, Kenneth; Wang, Eryu; Gorchakov, Rodion; Tsetsarkin, Konstantin; Seymour, Robert; Weaver, Scott C.] Univ Texas Med Branch, Inst Human Infect & Immun, Sealy Ctr Vaccine Dev, Galveston, TX 77555 USA. [Plante, Kenneth; Wang, Eryu; Gorchakov, Rodion; Tsetsarkin, Konstantin; Seymour, Robert; Weaver, Scott C.] Univ Texas Med Branch, Dept Pathol, Galveston, TX USA. [Partidos, Charalambos D.; Weger, James; Stinchcomb, Dan T.] Inviragen Inc, Madison, WI USA. [Partidos, Charalambos D.; Weger, James; Stinchcomb, Dan T.] Inviragen Inc, Ft Collins, CO USA. [Weger, James; Osorio, Jorge E.] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA. [Borland, Erin M.; Powers, Ann M.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO USA. [Frolov, Ilya] Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA. RP Plante, K (reprint author), Univ Texas Med Branch, Inst Human Infect & Immun, Sealy Ctr Vaccine Dev, Galveston, TX 77555 USA. EM sweaver@utmb.edu RI Weaver, Scott/D-6490-2011; OI Stinchcomb, Dan/0000-0002-3634-7503; Weger-Lucarelli, James/0000-0002-9483-1694 FU National Institute of Allergy and Infectious Disease (NIAID) through the Western Regional Center of Excellence for Biodefense and Emerging Infectious Disease Research, National Institutes of Health (NIH) [U54 AIO57156]; NIH [AI082202]; CDC Division of Vector-Borne Diseases; John S. Dunn Foundation; Sealy Center for Vaccine Development FX This work was supported by a grant from the National Institute of Allergy and Infectious Disease (NIAID) through the Western Regional Center of Excellence for Biodefense and Emerging Infectious Disease Research, National Institutes of Health (NIH) grant U54 AIO57156, by NIH grant AI082202, by the CDC Division of Vector-Borne Diseases, and by the John S. Dunn Foundation. KP was supported by a fellowship from the Sealy Center for Vaccine Development. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 63 Z9 63 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7366 J9 PLOS PATHOG JI PLoS Pathog. PD JUL PY 2011 VL 7 IS 7 AR e1002142 DI 10.1371/journal.ppat.1002142 PG 11 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 800DG UT WOS:000293339300030 PM 21829348 ER PT J AU Morris, AA Zhao, LP Ahmed, Y Stoyanova, N De Staercke, C Hooper, WC Gibbons, G Din-Dzietham, R Quyyumi, A Vaccarino, V AF Morris, Alanna Amyre Zhao, Liping Ahmed, Yusuf Stoyanova, Neli De Staercke, Christine Hooper, William Craig Gibbons, Gary Din-Dzietham, Rebecca Quyyumi, Arshed Vaccarino, Viola TI Association Between Depression and Inflammation-Differences by Race and Sex: The META-Health Study SO PSYCHOSOMATIC MEDICINE LA English DT Article DE depression; inflammation; race/ethnicity; sex ID C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; INVENTORY-II; SYMPTOMS; MARKERS; WOMEN; ADULTS; RISK AB Objective: To test whether the association between depression and inflammation differs by race and sex. Depressive symptoms have been associated with higher levels of C-reactive protein (CRP). However, few studies have examined this association in samples including a significant number of African Americans, or examined whether the association differs by race and sex. Methods: Depressive symptoms and CRP were assessed in 512 African American and white participants, age 30 to 65 years, as part of the community-based Morehouse and Emory Team up to Eliminate Health Disparities (META-Health) Study. Depression was determined by responses to the Beck Depression Inventory II (BDI-II). Multivariable linear regression models were used to adjust for demographic and metabolic risk factors. Results: African American men had higher total BDI-II scores than white men (p = .03), whereas there was no difference in women. There was a significant race-sex-depression interaction in predicting CRP levels (p = .02). White women with mild to severe depressive symptoms had higher levels of CRP compared with those with minimal to no depressive symptoms (p < .05). There were no differences in levels of CRP by severity of depressive symptoms in white men or African Americans of either sex. Higher BDI-II scores were related to higher CRP levels in white women after adjusting for age and level of education (beta = 0.227, p = .006). However, the association was eliminated after further adjustment for metabolic risk factors (beta = 0.077, p = .35). Conclusions: Although depressive symptoms are associated with inflammation, the association varies by race and sex. C1 [Morris, Alanna Amyre; Zhao, Liping; Ahmed, Yusuf; Quyyumi, Arshed; Vaccarino, Viola] Emory Univ, Sch Med, Atlanta, GA USA. [Stoyanova, Neli; Gibbons, Gary; Din-Dzietham, Rebecca] Morehouse Sch Med, Atlanta, GA 30310 USA. [De Staercke, Christine; Hooper, William Craig] Ctr Dis Control & Prevent, Atlanta, GA USA. [Zhao, Liping; Vaccarino, Viola] Emory Rollins Sch Publ Hlth, Atlanta, GA USA. RP Morris, AA (reprint author), 1364 Clifton Rd,Suite D403B, Atlanta, GA 30322 USA. EM aamorr3@emory.edu RI Library, Woodruff Health/A-6096-2012 FU National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute [1 U01 HL079156-01, 1 U01 HL79214-01]; NIH, National Center for Research Resources (NCRR) [M01-RR00039, 5P20RR11104, 5U54RR022814]; NIH [K24HL077506-06] FX This work was supported by the funding from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute 1 U01 HL079156-01 (A. Q.) and 1 U01 HL79214-01 (G. G.); NIH, National Center for Research Resources (NCRR) Grant M01-RR00039 for the Emory General Clinical Research Center and NIH/NCRR 5P20RR11104 for the Morehouse Clinical Research Center; NIH K24HL077506-06 (V. V.); and NIH/NCRR 5U54RR022814 (R.D.-D.). NR 39 TC 23 Z9 23 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0033-3174 J9 PSYCHOSOM MED JI Psychosom. Med. PD JUL PY 2011 VL 73 IS 6 BP 462 EP 468 DI 10.1097/PSY.0b013e318222379c PG 7 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA 796RM UT WOS:000293069500005 PM 21715300 ER PT J AU Akgul, Y Derk, RC Meighan, T Rao, KMK Murono, EP AF Akgul, Yucel Derk, Raymond C. Meighan, Terence Rao, K. Murali Krishna Murono, Eisuke P. TI The methoxychlor metabolite, HPTE, inhibits rat luteal cell progesterone production SO REPRODUCTIVE TOXICOLOGY LA English DT Article DE Methoxychlor; HPTE; Ovarian steroidogenesis; Cholesterol side-chain cleavage; P450scc; Luteal cells ID REPORTED ACTIVE METABOLITE; ESTROGEN-RECEPTORS ALPHA; OVARIAN GRANULOSA-CELLS; CULTURED LEYDIG-CELLS; ADULT FEMALE MOUSE; TESTOSTERONE FORMATION; REPRODUCTIVE-SYSTEM; IN-VITRO; PESTICIDE METHOXYCHLOR; BETA AB The methoxychlor metabolite, HPTE, was shown to inhibit P450-cholesterol side-chain cleavage (P450scc) activity resulting in decreased progesterone production by cultured ovarian follicular cells in previous studies. It is not known whether HPTE has any effect on progesterone formation by the corpus luteum. Results: Exposure to 100 nM HPTE reduced progesterone production by luteal cells with progressive declines to <22% of control at 500 nM HFTE. Similarly, HPTE progressively inhibited progesterone formation and P450scc catalytic activity of hCG- or 8 Br-cAMP-stimulated luteal cells. However, HPTE did not alter mRNA and protein levels of P450scc. Compounds acting as estrogen (17 beta-estradiol, bisphenol-A or octylphenol), antiestrogen (ICI) or antiandrogen (monobutyl phthalate, flutamide or M-2) added alone to luteal cells did not mimic the action of HPTE on progesterone and P450scc activity. These results suggest that HPTE directly inhibits P450scc catalytic activity resulting in reduced progesterone formation, and this action was not mediated through estrogen or androgen receptors. Published by Elsevier Inc. C1 [Akgul, Yucel; Murono, Eisuke P.] W Virginia Univ Sch Med, Dept Physiol & Pharmacol, Morgantown, WV 26506 USA. [Derk, Raymond C.; Meighan, Terence; Rao, K. Murali Krishna; Murono, Eisuke P.] NIOSH, Ctr Dis Control & Prevent, Hlth Effects Lab Div, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA. RP Akgul, Y (reprint author), W Virginia Univ Sch Med, Dept Physiol & Pharmacol, POB 9229, Morgantown, WV 26506 USA. EM akgulyucel@gmail.com RI akgul, yucel/E-5599-2012; Akgul, Yucel/M-1745-2013 NR 37 TC 7 Z9 7 U1 1 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0890-6238 J9 REPROD TOXICOL JI Reprod. Toxicol. PD JUL PY 2011 VL 32 IS 1 BP 77 EP 84 DI 10.1016/j.reprotox.2011.05.013 PG 8 WC Reproductive Biology; Toxicology SC Reproductive Biology; Toxicology GA 799YO UT WOS:000293323200009 PM 21664964 ER PT J AU Krahn, GL AF Krahn, Gloria L. TI WHO World Report on Disability: A review SO DISABILITY AND HEALTH JOURNAL LA English DT Review DE Disability; WHO; World; ICF AB The World Health Organization in collaboration with the World Bank developed the World Report on Disability to inform governments of countries about the importance of disability, analyze scientific information, and provide recommendations for action at the national and international levels. The report is remarkably readable, comprehensive, and concise. There are recurrent themes of the connection between disability and poverty, and within disability groups, the relatively greater vulnerability of women, children, and persons with mental health disabilities. Chapter content includes an overview of disability, global view addressing measurement and prevalence, general health care; rehabilitation, assistance and supports, enabling environments, education, work and employment, and recommendations for moving forward. The report successfully illustrates a great need for improved data, policies, and programs, while describing promising practices that can inform policy makers in addressing these needs. This report is highly recommended reading for anyone interested in a global view on disability and should be required reading for any students in disability and public health. Published by Elsevier Inc. C1 [Krahn, Gloria L.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Krahn, GL (reprint author), 1600 Clifton Rd NE,MS E88, Atlanta, GA 30320 USA. EM Gfk2@cdc.gov NR 1 TC 7 Z9 7 U1 0 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 J9 DISABIL HEALTH J JI Brain Stimul. PD JUL PY 2011 VL 4 IS 3 BP 141 EP 142 DI 10.1016/j.dhjo.2011.05.001 PG 2 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA 792XU UT WOS:000292784500001 PM 21723520 ER PT J AU Schieve, LA Boulet, SL Kogan, MD Yeargin-Allsopp, M Boyle, CA Visser, SN Blumberg, SJ Rice, C AF Schieve, Laura A. Boulet, Sheree L. Kogan, Michael D. Yeargin-Allsopp, Marshalyn Boyle, Coleen A. Visser, Susanna N. Blumberg, Stephen J. Rice, Catherine TI Parenting aggravation and autism spectrum disorders: 2007 National Survey of Children's Health SO DISABILITY AND HEALTH JOURNAL LA English DT Article DE Autistic disorder; Developmental disabilities; Parent-child relations; Stress; Psychological ID SOCIAL SUPPORT; PRESCHOOL-CHILDREN; UNITED-STATES; MEDICAL HOME; CARE NEEDS; STRESS; MOTHERS; SERVICES; PREDICTORS; FATHERS AB Background: Studies suggest autism spectrum disorders (ASDs) are associated with high parenting stress and aggravation. Research on specific risk factors is needed. Objective/Hypotheses: To assess aggravation level among parents of children with and without ASDs. Methods: The sample of 73,030 children aged 4 to 17 years in the 2007 National Survey of Children's Health and their parent respondents were divided into mutually exclusive groups based on child ASD status and other special health care needs. Adjusted prevalence ratios (aPR) for associations between a high Aggravation in Parenting scale score and various risk factors were computed from multivariable models. Results: High-aggravation percentages were comparable for parents of children with a current ASD (36.6%), ASD reported previously but not currently (35.2%), and another (non-ASD) developmental problem (31.2%) but were significantly lower for parents of children with other special health care needs (6.5%) and no special health care needs (5.1%). Within the current-ASD group, high aggravation was associated with young child age (aPR = 1.8 [1.2-2.6]), lack of health insurance (aPR = 1.5 [1.0-2.4]), lack of a medical home (aPR = 2.2 [1.4-3.5]), recent child mental health treatment (aPR = 2.1 [1.5-3.0]), lack of parenting emotional support (aPR = 1.5 [1.1-2.1]), and ASD severity (aPR = 1.4 [1.0-1.6]). Some of these same factors were associated with aggravation in the non-ASD groups. However, the medical home finding was specific to the ASD groups. Conclusions: Parenting a child with ASD is associated with high aggravation; however, there is variability within health care and social support subgroups. Strategies to strengthen medical home components for children with ASDs should be considered. Published by Elsevier Inc. C1 [Schieve, Laura A.; Boulet, Sheree L.; Yeargin-Allsopp, Marshalyn; Boyle, Coleen A.; Visser, Susanna N.; Rice, Catherine] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Kogan, Michael D.] Hlth Res & Serv Adm, Maternal & Child Hlth Bur, Rockville, MD 20857 USA. [Blumberg, Stephen J.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Schieve, LA (reprint author), MS E-86,1600 Clifton Rd, Atlanta, GA 30320 USA. EM LSchieve@cdc.gov RI Rice, Catherine/D-6305-2016 NR 30 TC 18 Z9 18 U1 4 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 J9 DISABIL HEALTH J JI Disabil. Health J. PD JUL PY 2011 VL 4 IS 3 BP 143 EP 152 DI 10.1016/j.dhjo.2010.09.002 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA 792XU UT WOS:000292784500002 PM 21723521 ER PT J AU Zilberberg, MD Tabak, YP Sievert, DM Derby, KG Johannes, RS Sun, XW McDonald, LC AF Zilberberg, Marya D. Tabak, Ying P. Sievert, Dawn M. Derby, Karen G. Johannes, Richard S. Sun, Xiaowu McDonald, L. Clifford TI Using Electronic Health Information to Risk-Stratify Rates of Clostridium difficile Infection in US Hospitals SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID SURVEILLANCE; EPIDEMIOLOGY; MULTICENTER; DIAGNOSIS; AMERICA; DISEASE AB BACKGROUND. Expanding hospitalized patients' risk stratification for Clostridium difficile infection (CDI) is important for improving patient safety. We applied definitions for hospital-onset (HO) and community-onset (CO) CDI to electronic data from 85 hospitals between January 2007 and June 2008 to identify factors associated with higher HO CDI rates. METHODS. Nonrecurrent CDI cases were identified among adult (>= 18-year-old) inpatients by a positive C. difficile toxin assay result more than 8 weeks after any previous positive result. Case categories included HO, CO-hospital associated (CO-HA), CO-indeterminate hospital association (CO-IN), and CO-non-hospital associated (CO-NHA). C. difficile testing intensity (CDTI) was defined as the total number of C. difficile tests performed, normalized to the number of patients with at least 1 C. difficile toxin test recorded. We calculated both the incidence density and the prevalence of CDI where appropriate. We fitted a multivariable Poisson model to identify factors associated with higher HO CDI rates. RESULTS. Among 1,351,156 unique patients with 2,022,213 admissions, 9,803 cases of CDI were identified; of these, 50.6% were HO, 17.4% were CO-HA, 9.0% were CO-IN, and 23.0% were CO-NHA. The incidence density of HO was 6.3 per 10,000 patient-days. The prevalence of CO CDI on admission was, per 10,000 admissions, 8.4 for CO-HA, 4.4 for CO-IN, and 11.1 for CO-NHA. Factors associated (P < .0001) with higher HO CDI rates included older age, higher CO-NHA prevalence on admission, and increased CDTI. CONCLUSION. Electronic health information can be leveraged to risk-stratify HO CDI rates by patient age and CO-NHA prevalence on admission. Hospitals should optimize diagnostic testing to improve patient care and measured CDI rates. Infect Control Hosp Epidemiol 2011;32(7):649-655 C1 [McDonald, L. Clifford] Ctr Dis Control & Prevent, Prevent & Response Branch, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Zilberberg, Marya D.] Univ Massachusetts, Amherst, MA 01003 USA. [Zilberberg, Marya D.] EviMed Res Grp, Amherst, MA 01003 USA. [Tabak, Ying P.; Derby, Karen G.; Johannes, Richard S.; Sun, Xiaowu] CareFusion, MedMined Serv, Clin Res, Marlborough, MA USA. [Johannes, Richard S.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Johannes, Richard S.] Harvard Univ, Sch Med, Boston, MA USA. RP McDonald, LC (reprint author), Ctr Dis Control & Prevent, Prevent & Response Branch, Div Healthcare Qual Promot, 1600 Clifton Rd NE,MS A-35, Atlanta, GA 30333 USA. EM cmcdonald1@cdc.gov NR 23 TC 19 Z9 20 U1 0 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JUL PY 2011 VL 32 IS 7 BP 649 EP 655 DI 10.1086/660360 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 795LR UT WOS:000292976200003 PM 21666394 ER PT J AU Abbo, L Sinkowitz-Cochran, R Smith, L Ariza-Heredia, E Gomez-Marin, O Srinivasan, A Hooton, TM AF Abbo, Lilian Sinkowitz-Cochran, Ronda Smith, Laura Ariza-Heredia, Ella Gomez-Marin, Orlando Srinivasan, Arjun Hooton, Thomas M. TI Faculty and Resident Physicians' Attitudes, Perceptions, and Knowledge about Antimicrobial Use and Resistance SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID GUIDELINES; BELIEFS AB We surveyed faculty and residents to assess attitudes, perceptions, and knowledge about antimicrobial use and resistance. Most respondents were concerned about resistance when prescribing antibiotics and agreed that antibiotics are overused, that inappropriate use is professionally unethical, and that others, but not themselves, overprescribe antibiotics. Antimicrobial stewardship programs should capitalize on these perceptions. Infect Control Hosp Epidemiol 2011;32(7):714-718 C1 [Abbo, Lilian; Ariza-Heredia, Ella; Gomez-Marin, Orlando; Hooton, Thomas M.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA. [Abbo, Lilian; Smith, Laura] Jackson Mem Hosp, Antimicrobial Stewardship Program, Miami, FL 33136 USA. [Sinkowitz-Cochran, Ronda; Srinivasan, Arjun] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Gomez-Marin, Orlando] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA. RP Abbo, L (reprint author), Univ Miami, Miller Sch Med, Dept Med, 1400 NW 10th St,Suite 813A,D 90A, Miami, FL 33136 USA. EM labbo@med.miami.edu NR 13 TC 26 Z9 26 U1 2 U2 7 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JUL PY 2011 VL 32 IS 7 BP 714 EP 718 DI 10.1086/660761 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 795LR UT WOS:000292976200014 PM 21666405 ER PT J AU Moore, ZS Schaefer, MK Hoffmann, KK Thompson, SC Xia, GL Lin, YL Khudyakov, Y Maillard, JM Engel, JP Perz, JF Patel, PR Thompson, ND AF Moore, Zack S. Schaefer, Melissa K. Hoffmann, Karen K. Thompson, Susan C. Xia, Guo-Liang Lin, Yulin Khudyakov, Yury Maillard, Jean-Marie Engel, Jeffrey P. Perz, Joseph F. Patel, Priti R. Thompson, Nicola D. TI Transmission of Hepatitis C Virus During Myocardial Perfusion Imaging in an Outpatient Clinic SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID HEALTH-CARE SETTINGS; UNITED-STATES; INFECTION; PREVALENCE AB Reports of health care associated viral hepatitis transmission have been increasing in the United States. Transmission due to poor infection control practices during myocardial perfusion imaging (MPI) has not previously been reported. The aim of this study was to identify the source of incident hepatitis C virus (HCV) infection in a patient without identified risk factors who had undergone MPI 6 weeks before diagnosis. Practices at the cardiology clinic and nuclear pharmacy were evaluated, and HCV testing was performed in patients with shared potential exposures. Clinical and epidemiologic information was obtained for patients with HCV infection, and molecular testing was performed to assess viral relatedness. Evidence of HCV transmission among patients who had undergone MPI at the cardiology clinic on 2 separate dates was found, involving 2 potential source patients and a total of 5 newly infected patients. Molecular testing identified a high degree of genetic homology among viruses from patients with common procedure dates. The nuclear medicine technologist routinely drew up flush from multidose vials of saline solution using the same needle and syringe that had been used to administer radiopharmaceutical doses. Multipatient use of vials was not observed, but a review of purchasing invoices and interviews with staff members suggested that this had occurred. No evidence of transmission via contamination of radiopharmaceuticals at the nuclear pharmacy was found. In conclusion, transmission of HCV occurred because of unsafe injection practices during MPI. Cardiologists should carefully review their infection control practices and the practices of other staff members involved with these procedures. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;108:126-132) C1 [Moore, Zack S.; Thompson, Susan C.; Maillard, Jean-Marie; Engel, Jeffrey P.] N Carolina Dept Hlth & Human Serv, Raleigh, NC USA. [Schaefer, Melissa K.; Xia, Guo-Liang; Lin, Yulin; Khudyakov, Yury; Perz, Joseph F.; Patel, Priti R.; Thompson, Nicola D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hoffmann, Karen K.] N Carolina Statewide Program Infect Control & Epi, Chapel Hill, NC USA. RP Moore, ZS (reprint author), N Carolina Dept Hlth & Human Serv, Raleigh, NC USA. EM zack.moore@dhhs.nc.gov NR 18 TC 15 Z9 15 U1 0 U2 3 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD JUL 1 PY 2011 VL 108 IS 1 BP 126 EP 132 DI 10.1016/j.amjcard.2011.03.010 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 792YF UT WOS:000292785600021 PM 21529725 ER PT J AU Wilson, NO Ceesay, FK Obed, SA Adjei, AA Gyasi, RK Rodney, P Ndjakani, Y Anderson, WA Lucchi, NW Stiles, JK AF Wilson, Nana O. Ceesay, Fatou K. Obed, Samuel A. Adjei, Andrew A. Gyasi, Richard K. Rodney, Patricia Ndjakani, Yassa Anderson, Winston A. Lucchi, Naomi W. Stiles, Jonathan K. TI Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine against Malaria and Anemia in Pregnant Women SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID SUB-SAHARAN AFRICA; TREATED BED NETS; UNCOMPLICATED FALCIPARUM-MALARIA; PLACEBO-CONTROLLED TRIAL; DAR-ES-SALAAM; PLASMODIUM-FALCIPARUM; CONGENITAL MALARIA; PLACENTAL MALARIA; WESTERN KENYA; BIRTH-WEIGHT AB The effectiveness of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) against malaria and anemia is unclear because of the spread of SP-resistant Plasmodium falciparum. This study evaluates the effectiveness of IPTp-SP among pregnant women attending the antenatal clinic at Korle-Bu Teaching Hospital in Accra, Ghana. A cross-sectional study comparing malaria and anemia prevalence among pregnant women using IPTp-SP with non-IPTp-SP users was conducted during June August 2009. A total of 363 pregnant women (202 of IPTp users and 161 non-IPTp users) were recruited. A total of 15.3% of IPTp users had malaria compared with 44.7% of non-IPTp users (P < 0.001). A total of 58.4% of non-IPTp users were anemic compared with 22.8% of IPTp users (P < 0.001). When we controlled for other variables, the difference in the prevalence of malaria (odds ratio = 0.18, 95% confidence interval = 0.08-0.37) and anemia (odds ratio = 0.20,95% confidence interval = 0.12-0.34) remained significant. The recommended IPTp-SP regimen is useful in preventing malaria and anemia among pregnant women in Ghana. C1 [Wilson, Nana O.] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA. Morehouse Sch Med, Dept Community Hlth & Prevent Med, Atlanta, GA 30310 USA. Univ Ghana, Sch Med, Dept Obstet & Gynecol, Korle Bu, Accra, Ghana. Univ Ghana, Sch Med, Dept Pathol, Korle Bu, Accra, Ghana. Howard Univ, Dept Biol, Washington, DC 20059 USA. Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. RP Wilson, NO (reprint author), Morehouse Sch Med, Dept Microbiol Biochem & Immunol, HG Room 350,720 Westview Dr SW, Atlanta, GA 30310 USA. EM nwilson@msm.edu FU Center for Disease Diagnosis and Research in Ghana; Centers for Disease Control and Prevention; Howard University; National Institutes of Health [NIH-RCMI (RR03034)]; NIHNIGM- MBRS [SO6GM08248]; NIH-FIC [R21TW006804-01] FX We thank the pregnant women attending antenatal care at Korle-Bu Teaching Hospital for participating in this study, the nurses of Obstetrics and Gynecology Department of Korle-Bu Teaching Hospital, the laboratory staff of Korle-Bu Teaching Hospital's Child Health Department, the staff of Ghana Ministry of Health, Reproductive and Child Health Department, and the staff of Ghana National Malaria Control Program for their assistance. The support of Center for Disease Diagnosis and Research in Ghana is acknowledged.; This study was supported by the Centers for Disease Control and Prevention "Reproductive Epidemiological" grant to the Master of Public Health Program, Morehouse School of Medicine; the Minority International Health Disparities Research Training Program at Howard University; National Institutes of Health grants NIH-RCMI (RR03034), NIHNIGM- MBRS (SO6GM08248), and NIH-FIC (R21TW006804-01). NR 86 TC 16 Z9 16 U1 0 U2 5 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUL PY 2011 VL 85 IS 1 BP 12 EP 21 DI 10.4269/ajtmh.2011.10-0512 PG 10 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 788GK UT WOS:000292433200004 PM 21734118 ER PT J AU Dahlgren, FS Mandel, EJ Krebs, JW Massung, RF McQuiston, JH AF Dahlgren, F. Scott Mandel, Eric J. Krebs, John W. Massung, Robert F. McQuiston, Jennifer H. TI Increasing Incidence of Ehrlichia chaffeensis and Anaplasma phagocytophilum in the United States, 2000-2007 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID HUMAN GRANULOCYTIC EHRLICHIOSIS; HUMAN MONOCYTIC EHRLICHIOSIS; WHITE-TAILED DEER; AMBLYOMMA-AMERICANUM; TRANSPLANT RECIPIENT; DIAGNOSTIC-TESTS; ETIOLOGIC AGENT; INFECTION; EWINGII; SEROPREVALENCE AB Ehrlichia chaffeensis causes human monocytic ehrlichiosis, and Anaplasma phagocytophilum causes human granulocytic anaplasmosis. These related tick-borne rickettsial organisms can cause severe and fatal illness. During 2000-2007, the reported incidence rate of E. chaffeensis increased from 0.80 to 3.0 cases/million persons/year. The case-fatality rate was 1.9%, and the hospitalization rate was 49%. During 2000-2007, the reported incidence of A. phagocytophilum increased from 1.4 to 3.0 cases/million persons/year. The case-fatality rate was 0.6%, and the hospitalization rate was 36%. Rates among female patients were lower than among male patients for ehrlichiosis (rate ratio = 0.68) and anaplasmosis (rate ratio = 0.70). Most (80%) ehrlichiosis and anaplasmosis cases met only a probable case definition, although, use of a polymerase chain reaction to confirm infections increased during 2000-2007. Heightened reporting of these diseases will likely continue with improving recognition, changing surveillance practices, and appropriate application of diagnostic assays. C1 [Dahlgren, F. Scott; Mandel, Eric J.; Krebs, John W.; Massung, Robert F.; McQuiston, Jennifer H.] Ctr Dis Control & Prevent, Div Vectorborne Infect Dis, Natl Ctr Enter Zoonot & Infect Dis, Atlanta, GA 30333 USA. RP McQuiston, JH (reprint author), Ctr Dis Control & Prevent, Div Vectorborne Infect Dis, Natl Ctr Enter Zoonot & Infect Dis, 1600 Clifton Rd,Mailstop G44, Atlanta, GA 30333 USA. EM fzh7@cdc.gov FU Oak Ridge Institute for Science and Education; United States Department of Energy; Centers for Disease Control and Prevention FX This study was supported by the Oak Ridge Institute for Science and Education, the United States Department of Energy, and the Centers for Disease Control and Prevention. NR 47 TC 57 Z9 60 U1 2 U2 10 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUL PY 2011 VL 85 IS 1 BP 124 EP 131 DI 10.4269/ajtmh.2011.10-0613 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 788GK UT WOS:000292433200023 PM 21734137 ER PT J AU Bolling, BG Eisen, L Moore, CG Blair, CD AF Bolling, Bethany G. Eisen, Lars Moore, Chester G. Blair, Carol D. TI Insect-Specific Flaviviruses from Culex Mosquitoes in Colorado, with Evidence of Vertical Transmission SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID WEST-NILE-VIRUS; FUSING AGENT VIRUS; YELLOW-FEVER VIRUS; AEDES-AEGYPTI; ENCEPHALITIS-VIRUS; PCR ASSAY; VECTOR; POPULATION; ALBOPICTUS; SEQUENCES AB Mosquitoes were collected in Colorado during 2006 and 2007 to examine spatial and seasonal patterns of risk for exposure to Culex vectors and West Nile virus. We used universal flavivirus primers to test pools of Culex mosquitoes for viral RNA. This led to the detection and subsequent isolation of two insect-specific flaviviruses: Culex flavivirus (CxFV), which was first described from Japan, and a novel insect flavivirus, designated Calbertado virus (CLBOV), which has also been detected in California and Canada. We recorded both viruses in Cx. tarsalis and Cx. pipiens from Colorado. Furthermore, quantitative reverse transcription polymerase chain reaction (RT-PCR) revealed the presence of CxFV RNA in Cx. pipiens eggs and larvae from a laboratory colony established in 2005 and naturally infected with CxFV, suggesting vertical transmission as a means of viral maintenance in natural Culex populations. Finally, we present phylogenetic analyses of the relationships between insect-specific flaviviruses and other selected flaviviruses. C1 [Bolling, Bethany G.; Eisen, Lars; Moore, Chester G.; Blair, Carol D.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Arthropod Borne & Infect Dis Lab, Ft Collins, CO 80523 USA. RP Bolling, BG (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM bbolling@cdc.gov; lars.eisen@colostate.edu; chester.moore@colostate.edu; carol.blair@colostate.edu FU National Institutes of Allergy and Infectious Diseases [N01-AI-25489] FX This research project was supported in part by contract N01-AI-25489 from the National Institutes of Allergy and Infectious Diseases. NR 47 TC 45 Z9 45 U1 1 U2 12 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUL PY 2011 VL 85 IS 1 BP 169 EP 177 DI 10.4269/ajtmh.2011.10-0474 PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 788GK UT WOS:000292433200030 PM 21734144 ER PT J AU Feng, YY Li, N Dearen, T Lobo, ML Matos, O Cama, V Xiao, LH AF Feng, Yaoyu Li, Na Dearen, Theresa Lobo, Maria L. Matos, Olga Cama, Vitaliano Xiao, Lihua TI Development of a Multilocus Sequence Typing Tool for High-Resolution Genotyping of Enterocytozoon bieneusi SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID MOLECULAR CHARACTERIZATION; MICROSPORIDIOSIS; MAMMALS; GENES; LIMA; PERU AB Thus far, genotyping of Enterocytozoon bieneusi has been based solely on DNA sequence analysis of the internal transcribed spacer (ITS) of the rRNA gene. Both host-adapted and zoonotic (human-pathogenic) genotypes of E. bieneusi have been identified. In this study, we searched for microsatellite and minisatellite sequences in the whole-genome sequence database of E. bieneusi isolate H348. Seven potential targets (MS1 to MS7) were identified. Testing of the seven targets by PCR using two human-pathogenic E. bieneusi genotypes (A and Peru10) led to the selection of four targets (MS1, MS3, MS4, and MS7). Further analysis of the four loci with an additional 24 specimens of both host-adapted and zoonotic E. bieneusi genotypes indicated that most host-adapted genotypes were not amplified by PCR targeting these loci. In contrast, 10 or 11 of the 13 specimens of the zoonotic genotypes were amplified by PCR at each locus. Altogether, 12, 8, 7, and 11 genotypes of were identified at MS1, MS3, MS4, and MS7, respectively. Phylogenetic analysis of the nucleotide sequences obtained produced a genetic relationship that was similar to the one at the ITS locus, with the formation of a large group of zoonotic genotypes that included most E. bieneusi genotypes in humans. Thus, a multilocus sequence typing tool was developed for high-resolution genotyping of E. bieneusi. Data obtained in the study should also have implications for understanding the taxonomy of Enterocytozoon spp., the public health significance of E. bieneusi in animals, and the sources of human E. bieneusi infections. C1 [Feng, Yaoyu] E China Univ Sci & Technol, Sch Resource & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. [Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Li, Na] Tongji Univ, Sch Life Sci & Technol, Shanghai 200295, Peoples R China. [Lobo, Maria L.; Matos, Olga] Univ Nova Lisboa, Inst Higiene & Med Trop, P-1349008 Lisbon, Portugal. [Cama, Vitaliano] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. RP Feng, YY (reprint author), E China Univ Sci & Technol, Sch Resource & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. EM yyfeng@ecust.edu.cn; lxiao@cdc.gov RI Lobo, Maria/I-3527-2012; Xiao, Lihua/B-1704-2013; MATOS, OLGA/J-8859-2012; Feng, Yaoyu/B-3076-2014; santos, sofia/I-1637-2012; OI Lobo, Maria/0000-0001-5811-7568; Xiao, Lihua/0000-0001-8532-2727; MATOS, OLGA/0000-0001-5793-7716 FU National Natural Science Foundation of China [30771881, 30928019, 81041078]; Fundamental Research Funds for the Central Universities, China [WB0914044]; Shanghai Science and Technology Committee [09540704400]; State Key Laboratory of Veterinary Etiological Biology at the Lanzhou Veterinary Research Institute FX This work was supported in part by the National Natural Science Foundation of China (grants 30771881, 30928019, and 81041078), Fundamental Research Funds for the Central Universities, China (grant WB0914044), the Shanghai Science and Technology Committee (grant 09540704400), and the State Key Laboratory of Veterinary Etiological Biology at the Lanzhou Veterinary Research Institute. NR 15 TC 32 Z9 34 U1 1 U2 12 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD JUL PY 2011 VL 77 IS 14 BP 4822 EP 4828 DI 10.1128/AEM.02803-10 PG 7 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA 789IZ UT WOS:000292510400014 PM 21622791 ER PT J AU Caraballo, RS Holiday, DB Stellman, SD Mowery, PD Giovino, GA Muscat, JE Eriksen, MP Bernert, JT Richter, PA Kozlowski, LT AF Caraballo, Ralph S. Holiday, David B. Stellman, Steven D. Mowery, Paul D. Giovino, Gary A. Muscat, Joshua E. Eriksen, Michael P. Bernert, John T. Richter, Patricia A. Kozlowski, Lynn T. TI Comparison of Serum Cotinine Concentration within and across Smokers of Menthol and Nonmenthol Cigarette Brands among Non-Hispanic Black and Non-Hispanic White US Adult Smokers, 2001-2006 SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID RACIAL-DIFFERENCES; CARCINOGEN 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; NICOTINE DEPENDENCE; EXPOSURE; SMOKING; WOMEN; GLUCURONIDATION; METABOLISM; TIME AB Background: The Food and Drug Administration (FDA) is examining options for regulating menthol content in cigarettes. There are many pharmacologic properties of menthol that may facilitate exposure to tobacco smoke, and it has been suggested that the preference for menthol cigarettes in black smokers accounts for their higher cotinine levels. Objective: To assess cigarettes smoked per day-adjusted cotinine levels in relation to smoking a menthol or nonmenthol cigarette brand among non-Hispanic black and white U. S. adult smokers under natural smoking conditions. Method: Serum cotinine concentrations were measured in 1,943 smokers participating in the 2001 to 2006 National Health and Nutrition Examination Surveys (NHANES). The effect of smoking a menthol brand on cigarettes smoked per day-adjusted serum cotinine levels in these two populations was modeled by adjusting for sex, age, number of smokers living in the home, body weight, time since last smoked, and FTC (Federal Trade Commission)-measured nicotine levels. The 8- or 12-digit Universal Product Code (UPC) on the cigarette label was used to determine the cigarette brand and whether it was menthol. Results: Smoking a menthol cigarette brand versus smoking a nonmenthol cigarette brand was not associated (P >= 0.05) with mean serum cotinine concentration in either black or white smokers. Conclusions: The higher levels of cotinine observed in black smokers compared with white smokers are not explained by their higher preference for menthol cigarette brands. Impact: Further studies like ours are needed to improve our ability to understand health consequences of future changes in tobacco product design. Cancer Epidemiol Biomarkers Prev; 20(7); 1329-40. (C)2011 AACR. C1 [Caraballo, Ralph S.; Richter, Patricia A.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Bernert, John T.] Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Holiday, David B.] Atlanta Reg Off, RTI Int, Atlanta, GA USA. [Mowery, Paul D.] Biostat Inc, Atlanta, GA USA. [Eriksen, Michael P.] Georgia State Univ, Inst Publ Hlth, Atlanta, GA 30303 USA. [Stellman, Steven D.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10027 USA. [Giovino, Gary A.; Kozlowski, Lynn T.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA. [Muscat, Joshua E.] Penn State Coll Med, Penn State Canc Inst, Div Populat Sci, Hershey, PA USA. RP Caraballo, RS (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 3005 Chamblee Tucker Rd, Atlanta, GA 30341 USA. EM rfc8@cdc.gov NR 36 TC 14 Z9 16 U1 4 U2 11 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JUL PY 2011 VL 20 IS 7 BP 1329 EP 1340 DI 10.1158/1055-9965.EPI-10-1330 PG 12 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 789FK UT WOS:000292499700009 PM 21430301 ER PT J AU Lu, YN Ma, HY Malone, KE Norman, SA Sullivan-Halley, J Strom, BL Simon, MS Marchbanks, PA McDonald, JA West, DW Henderson, KD Deapen, D Ursin, G Bernstein, L AF Lu, Yani Ma, Huiyan Malone, Kathleen E. Norman, Sandra A. Sullivan-Halley, Jane Strom, Brian L. Simon, Michael S. Marchbanks, Polly A. McDonald, Jill A. West, Dee W. Henderson, Katherine D. Deapen, Dennis Ursin, Giske Bernstein, Leslie TI Oral Contraceptive Use and Survival in Women with Invasive Breast Cancer SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID RISK-FACTORS; CALIFORNIA TEACHERS; YOUNG-WOMEN; PROGNOSIS; MORTALITY; AGE AB Background: Oral contraceptives (OC) are widely used in the United States. Although the relation between OC use and breast cancer incidence has been widely studied, the few studies examining associations between OC use prior to breast cancer diagnosis and survival are inconsistent. Methods: Women with invasive breast cancer participating in the Women's Contraceptive and Reproductive Experiences (CARE) Study, a population-based case-control study (4565 women ages 35-64 years), and the California Teachers Study (CTS) cohort (3929 women ages 28-91 years) were followed for vital status. A total of 1,064 women died in the CARE Study (median follow-up, 8.6 years) and 523 died in the CTS (median follow-up, 6.1 years). Cox proportional hazards regression provided hazard rate ratio estimates [(relative risk, RR)] with 95% confidence intervals (CIs) for risk of death from any cause and from breast cancer. Results: No association was observed for any OC use prior to diagnosis and all-cause mortality [CARE Study: RR = 1.01 (95% CI = 0.86-1.19); CTS: RR = 0.84 (95% CI = 0.67-1.05)]. A decreased risk of all-cause mortality was observed in the CTS among women with more than 10 years of OC use (RR = 0.67, 95% CI = 0.47-0.96); however, no trend of decreasing risk with increasing OC duration was observed (P(trend) = 0.22), and no association was observed in the CARE study. No associations were observed for breast cancer-specific mortality. Conclusions: OC use is not associated with all-cause or breast cancer-specific mortality among women with invasive breast cancer. Impact: These 2 independent studies demonstrated no overall association between OC use and survival among women with breast cancer. Cancer Epidemiol Biomarkers Prev; 20(7); 1391-7. (C)2011 AACR. C1 [Lu, Yani] City Hope Natl Med Ctr, Beckman Res Inst, Div Canc Etiol, Dept Populat Sci, Duarte, CA 91010 USA. [West, Dee W.] Canc Prevent Inst Calif, Fremont, CA USA. [Deapen, Dennis; Ursin, Giske] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Malone, Kathleen E.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. [Norman, Sandra A.; Strom, Brian L.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Norman, Sandra A.; Strom, Brian L.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Simon, Michael S.] Wayne State Univ, Div Hematol & Oncol, Detroit, MI USA. [Simon, Michael S.] Wayne State Univ, Populat Studies & Prevent Program, Karmanos Canc Inst, Dept Oncol, Detroit, MI USA. [Marchbanks, Polly A.; McDonald, Jill A.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Lu, YN (reprint author), City Hope Natl Med Ctr, Beckman Res Inst, Div Canc Etiol, Dept Populat Sci, 1500 E Duarte Rd, Duarte, CA 91010 USA. EM yalu@coh.org FU California Breast Cancer Research Program [15FB-0004]; National Institute of Child Health and Human Development (NICHD); National Cancer Institute; National Cancer Institute through Emory University [N01-HD-2-3168]; National Cancer Institute through Fred Hutchinson Cancer Research Center [N01-HD-2-3166]; National Cancer Institute through Karmanos Cancer Institute at Wayne State University [N01-HD-3-3174]; National Cancer Institute through University of Pennsylvania [N01-HD-3-3176]; National Cancer Institute through University of Southern California [N01-HD-3-3175]; Centers for Disease Control and Prevention [Y01-HD-7022, U55/CCR921930-02]; California Breast Cancer; National Institutes of Health [R01 CA77398, K05 CA136967]; California Breast Cancer Research Fund [97-10500]; California Department of Public Health; National Cancer Institute [N01-PC-35136, N01-PC-35139, N02-PC-15105]; [N01-PC-67006 (Atlanta)]; [N01-CN-65064 (Detroit)]; [N01-PC-67010 (Los Angeles)]; [N01-CN-05230 (Seattle)] FX These analyses were funded by the California Breast Cancer Research Program (15FB-0004). The Women's Contraceptive and Reproductive Experiences (CARE) Study was funded by the National Institute of Child Health and Human Development (NICHD), with additional support from the National Cancer Institute, through contracts with Emory University (N01-HD-2-3168), Fred Hutchinson Cancer Research Center (N01-HD-2-3166), Karmanos Cancer Institute at Wayne State University (N01-HD-3-3174), the University of Pennsylvania (N01-HD-3-3176), and the University of Southern California (N01-HD-3-3175); and through an intraagency agreement with the Centers for Disease Control and Prevention (Y01-HD-7022). Support for use of Surveillance, Epidemiology, and End Results cancer registries for case identification was through contracts N01-PC-67006 (Atlanta), N01-CN-65064 (Detroit), N01-PC-67010 (Los Angeles), and N01-CN-05230 (Seattle). The California Teachers Study was supported by the California Breast Cancer Act of 1993; National Institutes of Health (grants R01 CA77398 and K05 CA136967 to L. Bernstein); and the California Breast Cancer Research Fund (contract 97-10500). Collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's Surveillance, Epidemiology, and End Results Program under contract N01-PC-35136 awarded to the Cancer Prevention Institute of California (formerly the Northern California Cancer Center), contract N01-PC-35139 awarded to the University of Southern California, and contract N02-PC-15105 awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement #U55/CCR921930-02 awarded to the Public Health Institute. NR 24 TC 4 Z9 4 U1 0 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JUL PY 2011 VL 20 IS 7 BP 1391 EP 1397 DI 10.1158/1055-9965.EPI-11-0022 PG 7 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 789FK UT WOS:000292499700015 PM 21551244 ER PT J AU Robitz, R Gottlieb, SL De Rosa, CJ Guerry, SL Liddon, N Zaidi, A Walker, S Smith, JS Brewer, NT Markowitz, LE AF Robitz, Rachel Gottlieb, Sami L. De Rosa, Christine J. Guerry, Sarah L. Liddon, Nicole Zaidi, Akbar Walker, Susan Smith, Jennifer S. Brewer, Noel T. Markowitz, Lauri E. TI Parent Attitudes about School Requirements for Human Papillomavirus Vaccine in High-Risk Communities of Los Angeles, California SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID AGED 13-17 YEARS; HPV VACCINATION; UNITED-STATES; IMMUNIZATION REQUIREMENTS; ADVISORY-COMMITTEE; CLINICAL-TRIALS; COVERAGE; MANDATES; ADOLESCENTS; DISPARITIES AB Background: Human papillomavirus (HPV) immunization requirements for school entry could increase HPV vaccine uptake but are controversial. This study assessed parents' attitudes about HPV immunization requirements. Methods: During October 2007 to June 2008, we conducted telephone surveys with 484 parents of girls attending middle/high schools serving communities in Los Angeles County with elevated cervical cancer rates. Results: Parents were mostly Hispanic (81%) or African American (15%); 71% responded in Spanish. Many parents did not know if HPV vaccine works well (42%) or is unsafe (41%). Overall, 59% of parents agreed that laws requiring HPV vaccination for school attendance "are a good idea." In multivariable analysis, African Americans and Hispanics responding in English were less likely than Hispanics responding in Spanish to agree (aOR 0.1, 95% CI: 0.1-0.3; aOR 0.4, 95% CI: 0.2-0.8, respectively). Parents were less likely to agree with these laws if they did not believe the vaccine works well (aOR 0.2, 95% CI: 0.1-0.5) but more likely to agree if they believed the vaccine is not "too new for laws like these" (aOR 4.5, 95% CI: 2.6-8.0). Agreement with laws increased to 92% when including agreement that "these laws are okay only if parents can opt out." Conclusions: In this at-risk community, more than half of the parents agreed with HPV immunization requirements generally, and the vast majority agreed when including opt-out provisions. Impact: Support for HPV vaccine requirements may depend on race/ethnicity and inclusion of opt-out provisions. Information about vaccine efficacy and safety may increase support and reduce uncertainty about HPV vaccine in high-risk populations. Cancer Epidemiol Biomarkers Prev; 20(7); 1421-9. (C)2011 AACR. C1 [Robitz, Rachel; Gottlieb, Sami L.; Liddon, Nicole; Zaidi, Akbar; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [De Rosa, Christine J.; Guerry, Sarah L.; Walker, Susan] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [Smith, Jennifer S.; Brewer, Noel T.] Univ N Carolina, UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Smith, Jennifer S.; Brewer, Noel T.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. RP Markowitz, LE (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd NE,MS E-02, Atlanta, GA 30333 USA. EM lem2@cdc.gov FU CDC [MM-1006-07/07]; External Medical Affairs, Pfizer Inc.; Merck and Co, Inc.; GlaxoSmithKline FX R. Robitz' work was made possible through The CDC Experience Applied Epidemiology Fellowship, a public/private partnership supported by a grant to the CDC Foundation from External Medical Affairs, Pfizer Inc. N. Brewer has received research grants from Merck and Co, Inc. and GlaxoSmithKline. J. Smith has received research grants, contracts, honoraria and consulting fees during the last 4 years from Merck and Co, Inc. and GlaxoSmithKline. S. Guerry has received honoraria from Merck and Co, Inc. The other authors of this paper have no financial disclosures or potential conflicts of interest to report.; This research was supported by the Centers for Disease Control and Prevention (CDC Grant #MM-1006-07/07). NR 44 TC 10 Z9 10 U1 2 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JUL PY 2011 VL 20 IS 7 BP 1421 EP 1429 DI 10.1158/1055-9965.EPI-10-1236 PG 9 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 789FK UT WOS:000292499700018 PM 21551243 ER PT J AU O'Sullivan, BP Torres, B Conidi, G Smole, S Gauthier, C Stauffer, KE Glass, MB Gee, JE Blaney, D Smith, TL AF O'Sullivan, Brian P. Torres, Brenda Conidi, Giuseppe Smole, Sandra Gauthier, Cheryl Stauffer, Kendra E. Glass, Mindy B. Gee, Jay E. Blaney, David Smith, Theresa L. TI Burkholderia pseudomallei Infection in a Child With Cystic Fibrosis Acquisition in the Western Hemisphere SO CHEST LA English DT Article ID MELIOIDOSIS; PATIENT AB Melioidosis, an infection caused by the bacterium Burkholderia pseudomallei, is endemic to Southeast Asia and northern Australia but is only very rarely seen in patients in the United States. We report pulmonary B pseudomallei infection in a young girl with cystic fibrosis (CF) who had never traveled to Asia or Australia. Biochemical and epidemiologic investigation determined Aruba as the likely site of disease acquisition. This report highlights the ability of patients with CF to acquire this organism outside of Southeast Asia and describes an aggressive treatment regimen that has kept this patient culture-negative for the organism over a long period of time. CHEST 2011; 140(1):239-242 C1 [O'Sullivan, Brian P.] UMass Mem Hlth Care, Dept Pediat, Worcester, MA 01655 USA. [O'Sullivan, Brian P.] Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA USA. [Torres, Brenda] UMass Mem Hlth Care, Dept Lab Sci, Worcester, MA 01655 USA. [Conidi, Giuseppe] Massachusetts Dept Publ Hlth, Div Epidemiol & Immunizat, Bur Infect Dis, Jamaica Plain, MA USA. [Smole, Sandra; Gauthier, Cheryl] Massachusetts Dept Publ Hlth, Bur Lab Sci, William A Hinton State Lab Inst, Jamaica Plain, MA USA. [Stauffer, Kendra E.] US Anim & Plant Hlth Inspect Serv, USDA, Gainesville, FL USA. [Glass, Mindy B.; Gee, Jay E.; Blaney, David; Smith, Theresa L.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. RP O'Sullivan, BP (reprint author), UMass Mem Hlth Care, Dept Pediat, 55 Lake Ave, Worcester, MA 01655 USA. EM osullivb@ummhc.org NR 18 TC 9 Z9 9 U1 0 U2 1 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD JUL PY 2011 VL 140 IS 1 BP 239 EP 242 DI 10.1378/chest.10-3336 PG 4 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 793BZ UT WOS:000292796700038 PM 21729895 ER PT J AU Green, BJ Cummings, KJ Rittenour, WR Hettick, JM Bledsoe, TA Blachere, FM Siegel, PD Gaughan, DM Kullman, GJ Kreiss, K Cox-Ganser, J Beezhold, DH AF Green, B. J. Cummings, K. J. Rittenour, W. R. Hettick, J. M. Bledsoe, T. A. Blachere, F. M. Siegel, P. D. Gaughan, D. M. Kullman, G. J. Kreiss, K. Cox-Ganser, J. Beezhold, D. H. TI Occupational sensitization to soy allergens in workers at a processing facility SO CLINICAL AND EXPERIMENTAL ALLERGY LA English DT Article DE allergy; asthma; dust; exposure; IgE; IgG; occupational; respiratory; soy; workplace ID EPIDEMIC ASTHMA; SOYBEAN HULL; BETA-CONGLYCININ; BEAN WORKERS; PROTEIN; BAKERS; DUST; OUTBREAKS; SYMPTOMS; FLOUR AB Background Exposure to soy antigens has been associated with asthma in community outbreaks and in some workplaces. Recently, 135 soy flake processing workers (SPWs) in a Tennessee facility were evaluated for immune reactivity to soy. Allergic sensitization to soy was common and was five times more prevalent than in health care worker controls (HCWs) with no known soy exposure. Objective To characterize sensitization to soy allergens in SPWs. Methods Sera that were positive to soy ImmunoCAP (n = 27) were tested in IgE immunoblots. Wild-type (WT) and transgenic (TG) antigens were sequenced using nanoscale Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry (nanoUPLC MS/MS). IgE reactivity towards 5-enolpyruvylshikimate-3-phosphate synthase (CP4-EPSP), a protein found in TG soy, was additionally investigated. De-identified sera from 50 HCWs were used as a control. Results Immunoblotting of WT and TG soy flake extracts revealed IgE against multiple soy antigens with reactivity towards 48, 54, and 62 kDa bands being the most common. The prominent proteins that bound SPW IgE were identified by nanoUPLC MS/MS analysis to be the high molecular weight soybean storage proteins, beta-conglycinin (Gly m 5), and Glycinin (Gly m 6). No specific IgE reactivity could be detected to lower molecular weight soy allergens, Gly m 1 and Gly m 2, in soybean hull (SH) extracts. IgE reactivity was comparable between WT and TG extracts; however, IgE antibodies to CP4-EPSP could not be detected. Conclusions and Clinical Relevance SPWs with specific IgE to soy reacted most commonly with higher molecular weight soybean storage proteins compared with the lower molecular weight SH allergens identified in community asthma studies. IgE reactivity was comparable between WT and TG soy extracts, while no IgE reactivity to CP4-EPSP was observed. High molecular weight soybean storage allergens, Gly m 5 and Gly m 6, may be respiratory sensitizers in occupational exposed SPWs. C1 [Green, B. J.; Rittenour, W. R.; Hettick, J. M.; Bledsoe, T. A.; Blachere, F. M.; Siegel, P. D.; Beezhold, D. H.] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Cummings, K. J.; Gaughan, D. M.; Kullman, G. J.; Kreiss, K.; Cox-Ganser, J.] NIOSH, Field Studies Branch, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Green, BJ (reprint author), NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd,MS 4020, Morgantown, WV 26505 USA. EM dox6@cdc.gov RI Hettick, Justin/E-9955-2010 FU NIEHS [Y1-ES-0001] FX We wish to thank the members of the NIOSH medical and environmental field teams for their contributions to data collection. We also wish to thank Larry W. Bledsoe, MS (Purdue University) for providing samples of crushed soybean hull. This work was supported in part by an interagency agreement with NIEHS (Y1-ES-0001). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. NR 48 TC 14 Z9 16 U1 0 U2 8 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0954-7894 J9 CLIN EXP ALLERGY JI Clin. Exp. Allergy PD JUL PY 2011 VL 41 IS 7 BP 1022 EP 1030 DI 10.1111/j.1365-2222.2011.03756.x PG 9 WC Allergy; Immunology SC Allergy; Immunology GA 791WQ UT WOS:000292699700015 PM 21545549 ER PT J AU Epping, JN AF Epping, Jacqueline N. TI Dog Ownership and Dog Walking to Promote Physical Activity and Health in Patients SO CURRENT SPORTS MEDICINE REPORTS LA English DT Review ID PET OWNERSHIP; DETERMINANTS; POPULATION; BEHAVIOR; TRENDS; TRIAL AB Lack of physical activity is a significant risk factor for many chronic diseases and conditions and is associated with significant medical costs. Approximately half of adults and more than a third of adolescents and youth in the United States do not achieve recommended levels of physical activity. Effective population-level strategies are needed to promote activities that are practical, accessible, and sustainable and that can reach a large proportion of the population. Dog walking may be such a strategy. Walking is popular, easy, and sustainable and has a low risk of injury. Owning dogs confers many health benefits, and dog walking, in particular, can help promote physical activity and improve health. Physicians and other health care providers can play a unique and integral role in promoting physical activity among patients by recommending dog walking both to dog owners and to non-dog owners as a purposeful, enjoyable, and sustainable form of regular physical activity. C1 Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Epping, JN (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, MSK-46, Atlanta, GA 30333 USA. EM jepping@cdc.gov NR 38 TC 7 Z9 7 U1 3 U2 19 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1537-890X J9 CURR SPORT MED REP JI Curr. Sport. Med. Rep. PD JUL PY 2011 VL 10 IS 4 BP 224 EP 227 DI 10.1249/JSR.0b013e318223ee41 PG 4 WC Sport Sciences SC Sport Sciences GA 789UN UT WOS:000292542000010 PM 23531898 ER PT J AU Romer, Y Seijo, AC Crudo, F Nicholson, WL Varela-Stokes, A Lash, RR Paddock, CD AF Romer, Yamila Seijo, Alfredo C. Crudo, Favio Nicholson, William L. Varela-Stokes, Andrea Lash, R. Ryan Paddock, Christopher D. TI Rickettsia parkeri Rickettsiosis, Argentina SO EMERGING INFECTIOUS DISEASES LA English DT Article ID MOUNTAIN-SPOTTED-FEVER; UNITED-STATES; URUGUAY; BRAZIL; TICKS AB Rickettsia parkeri, a recently identified cause of spotted fever rickettsiosis in the United States, has been found in Amblyomma triste ticks in several countries of South America, including Argentina, where it is believed to cause disease in humans. We describe the clinical and epidemiologic characteristics of 2 patients in Argentina with confirmed R. parkeri infection and 7 additional patients with suspected R. parkeri rickettsiosis identified at 1 hospital during 2004-2009. The frequency and character of clinical signs and symptoms among these 9 patients closely resembled those described for patients in the United States (presence of an inoculation eschar, maculopapular rash often associated with pustules or vesicles, infrequent gastrointestinal manifestations, and relatively benign clinical course). Many R. parkeri infections in South America are likely to be misdiagnosed as other infectious diseases, including Rocky Mountain spotted fever, dengue, or leptospirosis. C1 [Romer, Yamila; Seijo, Alfredo C.; Crudo, Favio] Hosp FJ Muniz, RA-1282 Buenos Aires, DF, Argentina. [Nicholson, William L.; Paddock, Christopher D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Varela-Stokes, Andrea] Mississippi State Univ, Mississippi State, MS 39762 USA. [Lash, R. Ryan] Univ Georgia, Athens, GA 30602 USA. RP Romer, Y (reprint author), Hosp FJ Muniz, Uspallata 2272, RA-1282 Buenos Aires, DF, Argentina. EM yromer@hotmail.com RI Lash, R. Ryan/E-4115-2013 NR 23 TC 45 Z9 47 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUL PY 2011 VL 17 IS 7 BP 1169 EP 1173 DI 10.3201/eid1707.101857 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 790IL UT WOS:000292581600002 PM 21762568 ER PT J AU MacNeil, A Ksiazek, TG Rollin, PE AF MacNeil, Adam Ksiazek, Thomas G. Rollin, Pierre E. TI Hantavirus Pulmonary Syndrome, United States, 1993-2009 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID TO-PERSON TRANSMISSION; EXTRACORPOREAL MEMBRANE-OXYGENATION; WHITE-FOOTED MOUSE; CREEK-CANAL VIRUS; RETROSPECTIVE DIAGNOSIS; CARDIOPULMONARY SYNDROME; PEROMYSCUS-MANICULATUS; GENETIC IDENTIFICATION; NORTH-AMERICA; INFECTION AB Hantavirus pulmonary syndrome (HPS) is a severe respiratory illness identified in 1993. Since its identification, the Centers for Disease Control and Prevention has obtained standardized information about and maintained a registry of all laboratory-confirmed HPS cases in the United States. During 1993-2009, a total of 510 HPS cases were identified. Case counts have varied from 11 to 48 per year (case-fatality rate 35%). However, there were no trends suggesting increasing or decreasing case counts or fatality rates. Although cases were reported in 30 states, most cases occurred in the western half of the country; annual case counts varied most in the southwestern United States. Increased hematocrits, leukocyte counts, and creatinine levels were more common in HPS case-patients who died. HPS is a severe disease with a high case-fatality rate, and cases continue to occur. The greatest potential for high annual HPS incidence exists in the southwestern United States. C1 [MacNeil, Adam; Ksiazek, Thomas G.; Rollin, Pierre E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Ksiazek, Thomas G.] Univ Texas Med Branch, Galveston, TX USA. RP MacNeil, A (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G14, Atlanta, GA 30333 USA. EM aho3@cdc.gov FU Centers for Disease Control and Prevention FX This study was supported by the Centers for Disease Control and Prevention. NR 40 TC 44 Z9 45 U1 2 U2 9 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUL PY 2011 VL 17 IS 7 BP 1195 EP 1201 DI 10.3201/eid1707.101306 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 790IL UT WOS:000292581600006 PM 21762572 ER PT J AU Kandeel, A Deming, M Kereem, EA El-Refay, S Afifi, S Abukela, M Earhart, K El-Sayed, N El-Gabaly, H AF Kandeel, Amr Deming, Michael Kereem, Eman Abdel El-Refay, Samir Afifi, Salma Abukela, Mohammed Earhart, Kenneth El-Sayed, Nasr El-Gabaly, Hatem TI Pandemic (H1N1) 2009 and Haji Pilgrims Who Received Predeparture Vaccination, Egypt SO EMERGING INFECTIOUS DISEASES LA English DT Article ID INFLUENZA; INFECTIONS AB In Egypt, vaccination against pandemic (H1N1) 2009 virus was required of pilgrims departing for the 2009 Hajj. A survey of 551 pilgrims as they returned to Egypt found 542 (98.1% [weighted]) reported receiving the vaccine; 6(1.0% [weighted]) were infected with influenza virus A (H3N2) but none with pandemic (H1N1) 2009 virus. C1 [Deming, Michael] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Kandeel, Amr; Kereem, Eman Abdel; El-Refay, Samir; Abukela, Mohammed; El-Sayed, Nasr; El-Gabaly, Hatem] Minist Hlth Cairo, Cairo, Egypt. [Afifi, Salma; Earhart, Kenneth] US Naval Med Res Unit 3, Cairo, Egypt. RP Deming, M (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop F22, Atlanta, GA 30333 USA. EM msd1@cdc.gov FU Global Emerging Infections Surveillance and Response System of the US Department of Defense FX The Global Emerging Infections Surveillance and Response System of the US Department of Defense provided funding for laboratory testing. NR 14 TC 15 Z9 16 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUL PY 2011 VL 17 IS 7 BP 1266 EP 1268 DI 10.3201/eid1707.101484 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 790IL UT WOS:000292581600017 PM 21762583 ER PT J AU Bai, Y Kosoy, M Recuenco, S Alvarez, D Moran, D Turmelle, A Ellison, J Garcia, DL Estevez, A Lindblade, K Rupprecht, C AF Bai, Ying Kosoy, Michael Recuenco, Sergio Alvarez, Danilo Moran, David Turmelle, Amy Ellison, James Garcia, Daniel L. Estevez, Alejandra Lindblade, Kim Rupprecht, Charles TI Bartonella spp. in Bats, Guatemala SO EMERGING INFECTIOUS DISEASES LA English DT Article ID KELLEYI ACARI; ARGASIDAE AB To better understand the role of bats as reservoirs of Bartonella spp., we estimated Bartonella spp. prevalence and genetic diversity in bats in Guatemala during 2009. We found prevalence of 33% and identified 21 genetic variants of 13 phylogroups. Vampire bat associated Bartonella spp. may cause undiagnosed illnesses in humans. C1 [Bai, Ying] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Recuenco, Sergio; Turmelle, Amy; Ellison, James; Rupprecht, Charles] Ctr Dis Control & Prevent, Atlanta, GA USA. [Alvarez, Danilo; Moran, David; Estevez, Alejandra] Univ Valle Guatemala, Guatemala City, Guatemala. [Garcia, Daniel L.; Lindblade, Kim] Ctr Dis Control & Prevent, Reg Off Cent Amer & Panama, Guatemala City, Guatemala. RP Bai, Y (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM ybai1@cdc.gov RI Ellison, James/C-1402-2013; OI Ellison, James/0000-0003-4492-4857; Recuenco-Cabrera, Sergio/0000-0002-8446-7411 NR 15 TC 32 Z9 33 U1 0 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUL PY 2011 VL 17 IS 7 BP 1269 EP 1272 DI 10.3201/eid1707.101867 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 790IL UT WOS:000292581600018 PM 21762584 ER PT J AU Stewart, T Engelthaler, DM Blaney, DD Tuanyok, A Wangsness, E Smith, TL Pearson, T Komatsu, KK Keim, P Currie, BJ Levy, C Sunenshine, R AF Stewart, Tasha Engelthaler, David M. Blaney, David D. Tuanyok, Apichai Wangsness, Eric Smith, Theresa L. Pearson, Talima Komatsu, Kenneth K. Keim, Paul Currie, Bart J. Levy, Craig Sunenshine, Rebecca TI Epidemiology and Investigation of Melioidosis, Southern Arizona SO EMERGING INFECTIOUS DISEASES LA English DT Article ID BURKHOLDERIA-PSEUDOMALLEI AB Burkholderia pseudomallei is a bacterium endemic to Southeast Asia and northern Australia, but it has not been found to occur endemically in the United States. We report an ostensibly autochthonous case of melioidosis in the United States. Despite an extensive investigation, the source of exposure was not identified. C1 [Stewart, Tasha; Wangsness, Eric; Komatsu, Kenneth K.; Levy, Craig; Sunenshine, Rebecca] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. [Engelthaler, David M.; Keim, Paul] Translat Genom Res Inst, Flagstaff, AZ USA. [Blaney, David D.; Smith, Theresa L.; Sunenshine, Rebecca] Ctr Dis Control & Prevent, Atlanta, GA USA. [Tuanyok, Apichai; Pearson, Talima; Keim, Paul] No Arizona Univ, Flagstaff, AZ 86011 USA. [Currie, Bart J.] Menzies Sch Hlth Res, Darwin, NT, Australia. [Currie, Bart J.] Royal Darwin Hosp, Darwin, NT, Australia. RP Stewart, T (reprint author), Arizona Dept Hlth Serv, 150 N 18th Ave, Phoenix, AZ 85007 USA. EM stewarttasha@gmail.com RI Keim, Paul/A-2269-2010 FU NIAID NIH HHS [U54 AI065359] NR 7 TC 14 Z9 15 U1 1 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUL PY 2011 VL 17 IS 7 BP 1286 EP 1288 DI 10.3201/eid1707.100661 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 790IL UT WOS:000292581600023 PM 21762589 ER PT J AU Shafir, SC Sorvillo, FJ Sorvillo, T Eberhard, ML AF Shafir, Shira C. Sorvillo, Frank J. Sorvillo, Teresa Eberhard, Mark L. TI Viability of Baylisascaris procyonis Eggs SO EMERGING INFECTIOUS DISEASES LA English DT Article ID ASCARIS-SUUM; PREVALENCE; RACCOONS; ROUNDWORM; ANTIGENS; LOTOR; USA AB Infection with Baylisascaris procyonis roundworms is rare but often fatal and typically affects children. We attempted to determine parameters of viability and methods of inactivating the eggs of these roundworms. Loss of viability resulted when eggs were heated to 62 degrees C or desiccated for 7 months but not when frozen at -15 degrees C for 6 months. C1 [Shafir, Shira C.] Univ Calif Los Angeles, Sch Publ Hlth, Ctr Hlth Sci, Dept Epidemiol, Los Angeles, CA 90024 USA. [Sorvillo, Frank J.] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [Eberhard, Mark L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sorvillo, Frank J.] Trident Univ Int, Cypress, CA USA. RP Shafir, SC (reprint author), Univ Calif Los Angeles, Sch Publ Hlth, Ctr Hlth Sci, Dept Epidemiol, Rm 21-245,650 Charles E Young Dr, Los Angeles, CA 90024 USA. EM sshafir@ucla.edu FU Associated Schools of Public Health [S3049]; Centers for Disease Control and Prevention; UCLA FX This study was supported by grant S3049 from the Associated Schools of Public Health and the Centers for Disease Control and Prevention and by the UCLA Weisman Fund. NR 15 TC 11 Z9 12 U1 2 U2 18 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUL PY 2011 VL 17 IS 7 BP 1293 EP 1295 DI 10.3201/eid1707.101774 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 790IL UT WOS:000292581600025 PM 21762591 ER PT J AU Zalonis, CA Pillay, A Secor, W Humburg, B Aber, R AF Zalonis, Crystal A. Pillay, Allan Secor, William Humburg, Burt Aber, Robert TI Rare Case of Trichomonal Peritonitis SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID TRITRICHOMONAS-FETUS; METRONIDAZOLE; VAGINALIS; CATTLE C1 [Zalonis, Crystal A.] Penn State Milton S Hershey Med Ctr, Div Infect Dis & Epidemiol, Dept Med, Hershey, PA 17033 USA. [Pillay, Allan; Secor, William] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Zalonis, CA (reprint author), Penn State Milton S Hershey Med Ctr, Div Infect Dis & Epidemiol, Dept Med, 500 Univ Dr,POB 850,Mail Code H036, Hershey, PA 17033 USA. EM czalonis@hmc.psu.edu NR 10 TC 7 Z9 8 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUL PY 2011 VL 17 IS 7 BP 1312 EP 1313 DI 10.3201/eid1707.100892 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 790IL UT WOS:000292581600034 PM 21762600 ER PT J AU Mattar, S Guzman, C Arrazola, J Soto, E Barrios, J Pini, N Levis, S Salazar-Bravo, J Mills, JN AF Mattar, Salim Guzman, Camilo Arrazola, Justiniano Soto, Ella Barrios, Jose Pini, Noemi Levis, Silvana Salazar-Bravo, Jorge Mills, James N. TI Antibody to Arenaviruses in Rodents, Caribbean Colombia SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID VENEZUELA C1 [Salazar-Bravo, Jorge] Texas Tech Univ, Dept Biol Sci, Lubbock, TX 79409 USA. [Mattar, Salim; Guzman, Camilo; Arrazola, Justiniano; Soto, Ella; Barrios, Jose] Univ Cordoba, Monteria, Colombia. [Pini, Noemi; Levis, Silvana] Inst Nacl Enfermedades Virales Humanas Dr Julio I, Pergamino, Argentina. [Mills, James N.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Salazar-Bravo, J (reprint author), Texas Tech Univ, Dept Biol Sci, Lubbock, TX 79409 USA. EM j.salazar-bravo@ttu.edu NR 7 TC 1 Z9 1 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUL PY 2011 VL 17 IS 7 BP 1315 EP 1317 DI 10.3201/eid1707.101961 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 790IL UT WOS:000292581600036 PM 21762602 ER PT J AU Knust, B MacNeil, A Wong, SJ Backenson, PB Gibbons, A Rollin, PE Nichol, ST AF Knust, Barbara MacNeil, Adam Wong, Susan J. Backenson, P. Bryon Gibbons, Aridth Rollin, Pierre E. Nichol, Stuart T. TI Exposure to Lymphocytic Choriomeningitis Virus, New York, USA SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID INFECTION C1 [Knust, Barbara; MacNeil, Adam; Gibbons, Aridth; Rollin, Pierre E.; Nichol, Stuart T.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Wong, Susan J.; Backenson, P. Bryon] New York State Dept Hlth, Albany, NY USA. RP Knust, B (reprint author), Ctr Dis Control & Prevent, Mailstop G14,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM bknust@cdc.gov NR 10 TC 4 Z9 4 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUL PY 2011 VL 17 IS 7 BP 1324 EP 1325 DI 10.3201/eid1707.101349 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 790IL UT WOS:000292581600041 PM 21762607 ER PT J AU Scallan, E Hoekstra, RM Widdowson, MA Hall, AJ Griffin, PM AF Scallan, Elaine Hoekstra, Robert M. Widdowson, Marc-Alain Hall, Aron J. Griffin, Patricia M. TI Foodborne Illness Acquired in the United States Response SO EMERGING INFECTIOUS DISEASES LA English DT Letter C1 [Scallan, Elaine] Univ Colorado Denver, Aurora, CO USA. [Hoekstra, Robert M.; Widdowson, Marc-Alain; Hall, Aron J.; Griffin, Patricia M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Scallan, E (reprint author), Colorado Sch Publ Hlth, Dept Epidemiol, UCD AMC Bldg 500,Rm W3146,Mailstop B119,13001 E 1, Aurora, CO 80045 USA. EM elaine.scallan@ucdenver.edu NR 6 TC 12 Z9 13 U1 2 U2 39 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUL PY 2011 VL 17 IS 7 BP 1339 EP 1340 DI 10.3201/eid1707.110572 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 790IL UT WOS:000292581600052 ER PT J AU Montgomery, SP Xiao, LH Cama, V AF Montgomery, Susan P. Xiao, Lihua Cama, Vitaliano TI Comment on Zoonoses in the Bedroom SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID EPIDEMIOLOGY; GIARDIASIS; DOGS C1 [Montgomery, Susan P.; Xiao, Lihua; Cama, Vitaliano] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Montgomery, SP (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,Mailstop F22, Atlanta, GA 30341 USA. EM zqu6@cdc.gov RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 NR 5 TC 2 Z9 2 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUL PY 2011 VL 17 IS 7 BP 1340 EP 1340 DI 10.3201/eid1707.110317 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 790IL UT WOS:000292581600053 PM 21762619 ER PT J AU Potter, P AF Potter, Polyxeni TI The Tortoise and the Hut SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM PMP1@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUL PY 2011 VL 17 IS 7 BP 1342 EP 1343 DI 10.3201/eid1707.AC1707 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 790IL UT WOS:000292581600055 PM 21762623 ER PT J AU Simmerman, JM Suntarattiwong, P Levy, J Jarman, RG Kaewchana, S Gibbons, RV Cowling, BJ Sanasuttipun, W Maloney, SA Uyeki, TM Kamimoto, L Chotipitayasunondh, T AF Simmerman, James M. Suntarattiwong, Piyarat Levy, Jens Jarman, Richard G. Kaewchana, Suchada Gibbons, Robert V. Cowling, Ben J. Sanasuttipun, Wiwan Maloney, Susan A. Uyeki, Timothy M. Kamimoto, Laurie Chotipitayasunondh, Tawee TI Findings from a household randomized controlled trial of hand washing and face masks to reduce influenza transmission in Bangkok, Thailand SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE face mask; hand washing; influenza; non-pharmaceutical intervention; Thailand ID PANDEMIC INFLUENZA; VIRUSES; RESISTANCE; OSELTAMIVIR; HYGIENE; DISEASE; RISK; RUB AB Background Evidence is needed on the effectiveness of non-pharmaceutical interventions (NPIs) to reduce influenza transmission. Methodology We studied NPIs in households with a febrile, influenza-positive child. Households were randomized to control, hand washing (HW), or hand washing plus paper surgical face masks (HW + FM) arms. Study nurses conducted home visits within 24 hours of enrollment and on days 3, 7, and 21. Respiratory swabs and serum were collected from all household members and tested for influenza by RT-PCR or serology. Principal Findings Between April 2008 and August 2009, 991 (16.5%) of 5995 pediatric influenza-like illness patients tested influenza positive. Four hundred and forty-two index children with 1147 household members were enrolled, and 221 (50.0%) were aged <6 years. Three hundred and ninety-seven (89.8%) households reported that the index patient slept in the parents' bedroom. The secondary attack rate was 21.5%, and 56/345 (16.3%; 95% CI 12.4-20.2%) secondary cases were asymptomatic. Hand-washing subjects reported 4 7 washing episodes/day, compared to 4.9 times/day in the HW + FM arm and 3 9 times/day in controls (P = 0.001). The odds ratios (ORs) for secondary influenza infection were not significantly different in the HW arm (OR = 1.20; 95% CI 0.76-1.88; P-0.442), or the HW + FM arm (OR = 1.16; 95% CI 0.74-1.82; P = 0.525). Conclusions Influenza transmission was not reduced by interventions to promote hand washing and face mask use. This may be attributable to transmission that occurred before the intervention, poor facemask compliance, little difference in hand-washing frequency between study groups, and shared sleeping arrangements. A prospective study design and a careful analysis of sociocultural factors could improve future NPI studies. C1 [Simmerman, James M.; Levy, Jens; Kaewchana, Suchada; Sanasuttipun, Wiwan; Maloney, Susan A.] Thailand MOPH US CDC Collaborat, Int Emerging Infect Program, Nonthaburi 96546, Thailand. [Suntarattiwong, Piyarat; Chotipitayasunondh, Tawee] Queen Sirikit Natl Inst Child Hlth, Bangkok, Thailand. [Jarman, Richard G.; Gibbons, Robert V.] USAF, Res Inst Med Sci, Bangkok, Thailand. [Cowling, Ben J.] Univ Hong Kong, Sch Publ Hlth, Pokfulam, Hong Kong, Peoples R China. [Uyeki, Timothy M.; Kamimoto, Laurie] US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Simmerman, JM (reprint author), Thailand MOPH US CDC Collaborat, Int Emerging Infect Program, Box 68 CDC,APO AP, Nonthaburi 96546, Thailand. EM marksimmerman@hotmail.com RI Cowling, Benjamin/C-4263-2009; Valle, Ruben/A-7512-2013 OI Cowling, Benjamin/0000-0002-6297-7154; FU MedImmune Inc. FX BJC has received research funding from MedImmune Inc. The opinions, assertions, findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the Department of the Army or the Department of Defense. NR 29 TC 41 Z9 42 U1 2 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD JUL PY 2011 VL 5 IS 4 BP 256 EP 267 DI 10.1111/j.1750-2659.2011.00205.x PG 12 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 789EU UT WOS:000292497700007 PM 21651736 ER PT J AU Wall, PA AF Wall, Patrick A. TI And That Is How the Story Goes: CDC's National Environmental Health Tracking Network SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material C1 Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Atlanta, GA 30341 USA. RP Wall, PA (reprint author), Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, 4770 Buford Hwy,MS F-57, Atlanta, GA 30341 USA. EM Pwall@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD JUL-AUG PY 2011 VL 74 IS 1 BP 36 EP 37 PG 2 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 793DY UT WOS:000292801800005 PM 21830688 ER PT J AU Mainous, AG Knoll, ME Everett, CJ Matheson, EM Hulihan, MM Grant, AM AF Mainous, Arch G., III Knoll, Michele E. Everett, Charles J. Matheson, Eric M. Hulihan, Mary M. Grant, Althea M. TI Uric Acid as a Potential Cue to Screen for Iron Overload SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE LA English DT Article DE Iron Overload; NHANES; Uric Acid ID HEREDITARY HEMOCHROMATOSIS; SERUM FERRITIN; RENAL-DISEASE; ASSOCIATION; HUMANS; LEVEL; GOUT AB Background: It is suggested that targeted screening for hemochromatosis and iron overload may be worthwhile. The aim of this study was to examine uric acid as a potential indicator of the presence of iron overload. Methods: We analyzed adults aged 20 and older in the National Health and Nutrition Examination Survey 1999 to 2002. We computed logistic regressions controlling for age, sex, race/ethnicity, liver or kidney condition, and alcohol use to see the relationship between combinations of uric acid and ferritin with the outcomes of elevated liver enzymes and proteinuria. Results: In unadjusted analyses, 20.7% of individuals with high uric acid had high ferritin levels versus 8.8% of individuals with low uric acid levels (P < .001). Individuals with both elevated uric acid and elevated ferritin levels had significantly higher liver enzymes than individuals with either elevated uric acid or ferritin. With low uric acid and low ferritin as the reference category, individuals with high uric acid and high ferritin were significantly more likely to also have proteinuria (odds ratio, 2.66; 95% CI, 1.82-3.91). Conclusions: Elevated levels of uric acid is associated with elevated ferritin levels and may serve as a risk stratification variable for presence of iron overload and hemochromatosis. (J Am Board Fam Med 2011;24:415-421.) C1 [Mainous, Arch G., III; Knoll, Michele E.; Everett, Charles J.; Matheson, Eric M.] Med Univ S Carolina, Dept Family Med, Charleston, SC 29425 USA. [Hulihan, Mary M.; Grant, Althea M.] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA. RP Mainous, AG (reprint author), Med Univ S Carolina, Dept Family Med, 295 Calhoun St, Charleston, SC 29425 USA. EM mainouag@musc.edu OI Mainous, Arch/0000-0002-2535-7685 FU Centers for Disease Control and Prevention [MM1144] FX Funded in part by cooperative agreement (MM1144) from the Centers for Disease Control and Prevention. As a cooperative agreement authors Mary M. Hulihan and Althea M. Grant from the Centers of Disease Control helped in all aspects of this study. NR 30 TC 8 Z9 8 U1 0 U2 1 PU AMER BOARD FAMILY MEDICINE PI LEXINGTON PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA SN 1557-2625 J9 J AM BOARD FAM MED JI J. Am. Board Fam. Med. PD JUL-AUG PY 2011 VL 24 IS 4 BP 415 EP 421 DI 10.3122/jabfm.2011.04.110015 PG 7 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 789FL UT WOS:000292499800012 PM 21737766 ER PT J AU Hartholt, KA Stevens, JA Polinder, S van der Cammen, TJM Patka, P AF Hartholt, Klaas A. Stevens, Judy A. Polinder, Suzanne van der Cammen, Tischa J. M. Patka, Peter TI Increase in Fall-Related Hospitalizations in the United States, 2001-2008 SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article DE Falls; Hospitalization; Injury; Older adults ID OLDER-ADULTS; INJURIES; ADMISSIONS; DEATHS; TRENDS; RISK AB Background: The objective was to determine secular trends in unintentional fall-related hospitalizations in people aged 65 years and older in the United States. Materials: Data were obtained from a nationally representative sample of emergency department visits from January 1, 2001, to December 31, 2008, available through the National Electronic Injury Surveillance System-All Injury Program. These data were weighted to estimate the number, incidence rates, and the annual percent change of fall-related hospitalizations. Results: From 2001 to 2008, the estimated number of fall-related hospitalizations in older adults increased 50%, from 373,128 to 559,355 cases. During the same time period, the age-adjusted incidence rate, expressed per 100,000 population, increased from 1,046 to 1,368. Rates were higher in women compared with men throughout the study period. The age-adjusted incidence rate showed an average annual increase of 3.3% (95% CI, 1.66-4.95). Discussion: Both the number and rate of fall-related hospitalizations in the United States increased significantly over the 8-year study period. Unless preventive action is taken, rising hospitalization rates in combination with the aging US population over the next decades will exacerbate the already stressed healthcare system and may result in poorer health outcomes for older adults in the future. Further research is needed to determine the underlying causes for this rising trend. C1 [Hartholt, Klaas A.; van der Cammen, Tischa J. M.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Internal Med, Geriatr Med Sect, NL-3000 CA Rotterdam, Netherlands. [Hartholt, Klaas A.; Patka, Peter] Univ Med Ctr Rotterdam, Erasmus MC, Dept Surg Traumatol, NL-3000 CA Rotterdam, Netherlands. [Stevens, Judy A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Polinder, Suzanne] Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands. RP Hartholt, KA (reprint author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Internal Med, Geriatr Med Sect, POB 2040, NL-3000 CA Rotterdam, Netherlands. EM k.hartholt@erasmusmc.nl RI Hartholt, Klaas/Q-1782-2016 OI Hartholt, Klaas/0000-0001-5019-9239 FU "the Netherlands Organization for Health Research and Development" (ZonMw) [170.885.607] FX Klaas Hartholt is a research fellow at the Erasmus MC, appointed on a research grant from "the Netherlands Organization for Health Research and Development" (ZonMw), project number 170.885.607. We thank Caspar W.N. Looman, MSc, of the Department of Public Health, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, for his statistical expertise. NR 18 TC 31 Z9 32 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5282 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD JUL PY 2011 VL 71 IS 1 BP 255 EP 258 DI 10.1097/TA.0b013e31821c36e7 PG 4 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 790RR UT WOS:000292607400054 PM 21818033 ER PT J AU Zhang, YL Riehle-Colarusso, T Correa, A Li, S Feng, XH Gindler, J Lin, H Webb, C Li, W Trines, J Berry, RJ Yeung, L Luo, Y Jiang, MF Chen, H Sun, XM Li, Z AF Zhang, Yali Riehle-Colarusso, Tiffany Correa, Adolfo Li, Song Feng, Xinheng Gindler, Jacqueline Lin, Hui Webb, Catherine Li, Wei Trines, Jean Berry, Robert J. Yeung, Lorraine Luo, Ying Jiang, Meifang Chen, Hua Sun, Xiamei Li, Zhu TI Observed Prevalence of Congenital Heart Defects From a Surveillance Study in China SO JOURNAL OF ULTRASOUND IN MEDICINE LA English DT Article DE congenital heart defects; fetal echocardiography; neonatal echocardiography; prevalence ID PRENATAL-DIAGNOSIS; BIRTH PREVALENCE; DISEASE; POPULATION; EXPERIENCE; CHILDREN; ENGLAND AB Objectives-The purpose of this study was to estimate the prevalence of major and minor congenital heart defects among fetuses and neonates using sonography in a general population of 4 areas surrounding Shanghai, China. Methods-Pregnant women were recruited between April 2004 and December 2005 in Jiaxing City, Suzhou City, Changshu County, and Haining County. All participants could have 3 sonographic examinations performed by specially trained physicians regardless of medical indication: a fetal sonographic screen and fetal echocardiography between 20 and 28 weeks' gestation and neonatal echocardiography. Diagnoses of congenital heart defects were made on the basis of review of all available scans by an international group of experts in pediatric cardiology. Prevalence rates were calculated per 1000 births. Results-Among 4006 scanned fetuses and neonates, there were 75 congenital heart defects, including 12 major defects. The observed prevalence for all congenital heart defects was 18.7 (95% confidence interval, 14.8-23.5) per 1000 births, and the prevalence for major defects was 3.0 (95% confidence interval, 1.6-5.2) per 1000 births. The most common defects were ventricular septal defects (n = 47 [62.7%]);atrial septal defects (n = 14 [18.7%]), tetralogy of Fallot (n = 4 [5.3%]), and hypoplastic left heart syndrome (n = 3 [4.0%]). Conclusions-The prevalence of all congenital heart defects in the 4 areas of China studied was higher than that reported in other countries, with ventricular septal defects being the most frequent defects. Our data likely reflect a better estimate of the total prevalence of congenital heart defects in China than reported previously. C1 [Zhang, Yali; Li, Zhu] Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Beijing 100191, Peoples R China. [Li, Song; Lin, Hui; Li, Wei] Peking Univ, Natl Ctr Maternal & Infant Hlth, Sch Publ Hlth, Beijing 100191, Peoples R China. [Riehle-Colarusso, Tiffany; Correa, Adolfo; Gindler, Jacqueline; Berry, Robert J.; Yeung, Lorraine] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Li, Song; Feng, Xinheng] Peking Univ, Hosp 3, Beijing 100191, Peoples R China. [Webb, Catherine] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Trines, Jean] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Luo, Ying] Changshu Maternal & Child Hlth Care Hosp, Changshu, Peoples R China. [Jiang, Meifang] Suzhou Mother & Child Hlth Care Ctr, Suzhou, Peoples R China. Jiaxing Maternal & Child Hlth Care Hosp, Jiaxing, Peoples R China. [Sun, Xiamei] Haining Maternal & Child Hlth Care Hosp, Haining, Peoples R China. RP Li, Z (reprint author), Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, 38 Xueyuan Rd, Beijing 100191, Peoples R China. EM lizhu3699@gmail.com OI Berry, Robert/0000-0002-7162-5046 FU Centers for Disease Control and Prevention [U11/CCU015586] FX We thank Shixin Hong, MD (Peking University Health Science Center), Ann Chao, PhD (Centers for Disease Control and Prevention), Taimei Wang, MD, Xiujing Kou, MD, Zhaoping Li, MD, and Weihong Li,MD (Peking University Third Hospital), Chunyan Shi, MD (Peking University First Hospital), Yongqing Li; MD (Chinese Academy of Medical Science Fuwai Hospital), Guizhen Zhang, MD, and Bin Geng, MD (Beijing Anzhen Hospital, Capital University of Medical Science), and government, public health, and maternal and child health workers from the Zhejiang and Jiangsu provincial, city, county, and township levels in China. This work was supported in part by cooperative agreement U11/CCU015586 from the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 33 TC 16 Z9 18 U1 0 U2 7 PU AMER INST ULTRASOUND MEDICINE PI LAUREL PA SUBSCRIPTION DEPT, 14750 SWEITZER LANE, STE 100, LAUREL, MD 20707-5906 USA SN 0278-4297 J9 J ULTRAS MED JI J. Ultrasound Med. PD JUL PY 2011 VL 30 IS 7 BP 989 EP 995 PG 7 WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging GA 788HF UT WOS:000292435300015 PM 21705732 ER PT J AU Sow, FB Nandakumar, S Velu, V Kellar, KL Schlesinger, LS Amara, RR Lafuse, WP Shinnick, TM Sable, SB AF Sow, Fatoumata B. Nandakumar, Subhadra Velu, Vijayakumar Kellar, Kathryn L. Schlesinger, Larry S. Amara, Rama R. Lafuse, William P. Shinnick, Thomas M. Sable, Suraj B. TI Mycobacterium tuberculosis components stimulate production of the antimicrobial peptide hepcidin SO TUBERCULOSIS LA English DT Article DE Mycobacteria; Tuberculosis; Dendritic cells; Epithelial cells; Innate immunity ID ALVEOLAR EPITHELIAL-CELLS; HUMAN PERIPHERAL-BLOOD; DENDRITIC CELLS; HUMAN MACROPHAGES; IRON-ABSORPTION; EXPRESSION; WALL; LIPOARABINOMANNAN; BIOGENESIS; RESPONSES AB We investigated the in vitro production of the antimicrobial peptide hepcidin by cells of the innate immune system that harbor Mycobacterium tuberculosis. Stimulation of mouse lung macrophages with M. tuberculosis or IFN-gamma + M. tuberculosis induced hepcidin mRNA. In human alveolar A549 epithelial cells, lipoglycans of M. tuberculosis, in particular mannose-capped lipoarabinomannan and phosphatidyl-myo-inositol mannosides, were strong inducers of hepcidin mRNA. In mouse dendritic cells, hepcidin mRNA was increased by subcellular fractions and culture filtrate proteins of M. tuberculosis and by TLR2 and TLR4 agonists, but not by TLR9 agonists, IL-1 alpha, IL-6 or TNF-alpha. Flow cytometry evaluation of human peripheral blood mononuclear cells demonstrated that CD11c(1) myeloid dendritic cells stimulated with killed M. tuberculosis or live M. bovis BCG produced hepcidin. The production of the antimicrobial peptide hepcidin by cells that interact with M. tuberculosis suggests a host defense mechanism against mycobacteria. Published by Elsevier Ltd. C1 [Sow, Fatoumata B.; Nandakumar, Subhadra; Shinnick, Thomas M.; Sable, Suraj B.] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Velu, Vijayakumar; Amara, Rama R.] Emory Univ, Emory Vaccine Res Ctr, Atlanta, GA 30333 USA. [Kellar, Kathryn L.] Ctr Dis Control & Prevent, Biotechnol Core Facil Branch, Atlanta, GA 30333 USA. [Schlesinger, Larry S.; Lafuse, William P.] Ohio State Univ, Ctr Microbial Interface Biol, Dept Internal Med, Columbus, OH 43210 USA. [Schlesinger, Larry S.; Lafuse, William P.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA. RP Shinnick, TM (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM sow.4@osu.edu; ifd0@cdc.gov; vvelu@emory.edu; klk1@cdc.gov; larry.schlesinger@osumc.edu; ramara@emory.edu; lafuse.1@osu.edu; tms1@cdc.gov; dpt7@cdc.gov RI Nandakumar, Subhadra/F-5892-2011; OI Sable, Suraj/0000-0001-8440-1693; Velu, Vijayakumar/0000-0003-4238-1924 NR 54 TC 25 Z9 26 U1 0 U2 6 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1472-9792 J9 TUBERCULOSIS JI Tuberculosis PD JUL PY 2011 VL 91 IS 4 BP 314 EP 321 DI 10.1016/j.tube.2011.03.003 PG 8 WC Immunology; Microbiology; Respiratory System SC Immunology; Microbiology; Respiratory System GA 791AJ UT WOS:000292631900006 PM 21482189 ER PT J AU Dharmadhikari, AS Basaraba, RJ Van Der Walt, ML Weyer, K Mphahlele, M Venter, K Jensen, PA First, MW Parsons, S McMurray, DN Orme, IM Nardell, EA AF Dharmadhikari, Ashwin S. Basaraba, Randall J. Van Der Walt, Martie L. Weyer, Karin Mphahlele, Matsie Venter, Kobus Jensen, Paul A. First, Melvin W. Parsons, Sydney McMurray, David N. Orme, Ian M. Nardell, Edward A. TI Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis SO TUBERCULOSIS LA English DT Article DE MDR/XDR tuberculosis; Guinea pig model; Natural infection; Skin test reactivity ID MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; ANIMAL-MODELS; TRANSMISSION; FITNESS; AIR; EPIDEMIOLOGY; STRATEGIES; DISEASE AB A natural TB infection model using guinea pigs may provide useful information for investigating differences in transmission efficiency and establishment of active disease by clinical TB strains in a highly susceptible host under controlled environmental conditions. We sought to examine the capacity of naturally transmitted multidrug-resistant Mycobacterium tuberculosis to establish infection and produce active disease in guinea pigs. Guinea pigs were continuously exposed for 4 months to the exhaust air of a 6-bed multidrug-resistant tuberculosis inpatient hospital ward in South Africa. Serial tuberculin skin test reactions were measured to determine infection. All animals were subsequently evaluated for histologic disease progression at necropsy. Although 75% of the 362 exposed guinea pigs had positive skin test reactions [>= 6 mm], only 12% had histopathologic evidence of active disease. Reversions (>= 6 mm change) in skin test reactivity were seen in 22% of animals, exclusively among those with reactions of 6 -13 mm. Only two of 86 guinea pigs with reversion had histological evidence of disease compared to 47% (31/66) of guinea pigs with large, non-reverting reactions. Immunosuppression of half the guinea pigs across all skin test categories did not significantly accelerate disease progression. In guinea pigs that reverted a skin test, a second positive reaction in 27 (33%) of them strongly suggested re-infection due to ongoing exposure. These results show that a large majority of guinea pigs naturally exposed to human-source strains of multidrug-resistant tuberculosis became infected, but that many resolved their infection and a large majority failed to progress to detectable disease. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Dharmadhikari, Ashwin S.; Nardell, Edward A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA. [Dharmadhikari, Ashwin S.; Nardell, Edward A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA. [Basaraba, Randall J.; Orme, Ian M.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Coll Vet Med & Biomed Sci, Ft Collins, CO 80523 USA. [Van Der Walt, Martie L.; Mphahlele, Matsie; Venter, Kobus] S African MRC, TB Epidemiol & Intervent Res Unit, ZA-0001 Pretoria, South Africa. [Weyer, Karin] WHO, CH-1211 Geneva, Switzerland. [Jensen, Paul A.] CDC, Atlanta, GA 30333 USA. [First, Melvin W.; Nardell, Edward A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [McMurray, David N.] Texas A&M Hlth Sci Ctr, Dept Microbial & Mol Pathogenesis, College Stn, TX 77843 USA. RP Dharmadhikari, AS (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pulm & Crit Care Med, 7th Floor,FXB Bldg,651 Huntington Ave, Boston, MA 02115 USA. EM adharmadhikari@partners.org; randall.basaraba@colostate.edu; mvdwalt@mrc.ac.za; weyerk@who.int; pej4@cdc.gov; mfirst@hsph.harvard.edu; saparsons@csir.co.za; mcmurray@medicine.tamhsc.edu; ian.orme@colostate.edu; enardell@pih.org FU USAID; US Centers for Disease Control and Prevention; National Institute of Occupational Safety and Health [R01 OH009050, EN]; South African Medical Research Council; Center for Scientific and Industrial Research (South Africa); Harvard University, with cooperation from the Mpumalanga Provincial Department of Health in South Africa; NIAID, NIH [AI070456]; [T32 HL007633]; [K23 AI084548] FX This AIR Facility was established through grants from USAID, US Centers for Disease Control and Prevention, National Institute of Occupational Safety and Health (R01 OH009050, EN), South African Medical Research Council, Center for Scientific and Industrial Research (South Africa), and Harvard University, with cooperation from the Mpumalanga Provincial Department of Health in South Africa and staff from the eMahlahleni (formerly known as Witbank) Hospital. Additional contributions were made by Brigham and Women's Hospital. Research was also supported by grant AI070456 from the NIAID, NIH. Dr. Dharmadhikari was supported by grants T32 HL007633 and K23 AI084548. The funders had no role in the study design, the collection, analysis, or interpretation of data, or in the writing of the manuscript. The establishment of the AIR Facility was largely due to early efforts of Dr. Bernard Fourie and Dr. Charles Wells. Dr. Lourens Roberts contributed importantly to the success of this experiment. NR 39 TC 35 Z9 36 U1 0 U2 1 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1472-9792 J9 TUBERCULOSIS JI Tuberculosis PD JUL PY 2011 VL 91 IS 4 BP 329 EP 338 DI 10.1016/j.tube.2011.03.002 PG 10 WC Immunology; Microbiology; Respiratory System SC Immunology; Microbiology; Respiratory System GA 791AJ UT WOS:000292631900009 PM 21478054 ER PT J AU Hammond, D Garcia, A Feng, HA AF Hammond, Duane Garcia, Alberto Feng, H. Amy TI Occupational Exposures to Styrene Vapor in a Manufacturing Plant for Fiber-Reinforced Composite Wind Turbine Blades SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Article DE alternative energy; styrene; task-based sampling; wind blade; wind turbine AB Methods: All samples were collected during the course of normal employee work activities and analyzed for styrene using NIOSH Method 1501. All sampling was task based since full-shift sampling from a prior Occupational Safety and Health Administration (OSHA) compliance inspection did not show any exposures to styrene above the OSHA permissible exposure limit. During the initial NIOSH site visit, 67 personal breathing zone and 18 area air samples were collected while workers performed tasks of VARTM, gelcoating, glue wipe, and installation of a safety platform. After the initial site visit, the company made changes to the glue wipe task that eliminated the need for workers to enter the confined space inside of the wind turbine blade. During the follow-up site visit, 12 personal breathing zone and 8 area air samples were collected from workers performing the modified glue wipe task. Results: During the initial site visit, the geometric means of the personal breathing zone styrene air samples were 1.8 p.p.m. (n = 21) for workers performing the VARTM task, 68 p.p.m. (n = 5) for workers installing a safety platform, and 340 p.p.m. (n = 14) for workers performing the glue wipe task, where n is the number of workers sampled for a given mean result. Gelcoating workers included job categories of millers, gelcoat machine operators, and gelcoaters. Geometric mean personal breathing zone styrene air samples were 150 p.p.m. (n = 6) for millers, 87 p.p.m. (n = 2) for the gelcoat machine operators, and 66 p.p.m. (n = 19) for gelcoaters. The geometric mean of the personal breathing zone styrene air samples from the glue wipe task measured during the follow-up site visit was 31 p.p.m. (n = 12). Conclusions: The closed molding VARTM process was very effective at controlling worker exposures to styrene. Personal breathing zone styrene air samples were reduced by an order of magnitude after changes were made to the glue wipe task. The company used chemical substitution to eliminate styrene exposure during the installation of the safety platform. Recommendations were provided to reduce styrene concentrations during gelcoating. C1 [Hammond, Duane; Garcia, Alberto; Feng, H. Amy] NIOSH, Div Appl Res & Technol, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Hammond, D (reprint author), NIOSH, Div Appl Res & Technol, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,Mail Stop R5, Cincinnati, OH 45226 USA. EM ahz0@cdc.gov FU National Institute for Occupational Safety and Health [CAN 9270099] FX National Institute for Occupational Safety and Health internal operating funds (CAN 9270099). NR 11 TC 5 Z9 5 U1 1 U2 8 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD JUL PY 2011 VL 55 IS 6 BP 591 EP 600 DI 10.1093/annhyg/mer021 PG 10 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA 789XX UT WOS:000292553900006 PM 21597049 ER PT J AU Hines, CJ Deddens, JA Coble, J Kamel, F Alavanja, MCR AF Hines, Cynthia J. Deddens, James A. Coble, Joseph Kamel, Freya Alavanja, Michael C. R. TI Determinants of Captan Air and Dermal Exposures among Orchard Pesticide Applicators in the Agricultural Health Study SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Article DE agriculture; captan; dermal exposure-pesticides; determinants of exposure; exposure assessment-mixed models; orchards; pesticide exposure; variance components ID FARM APPLICATORS; ALGORITHM; FAMILIES; WORKERS; FRANCE AB Methods: External exposure metrics included personal air, hand rinse, and dermal patch samples collected from each applicator on 2 days in 2002-2003. A 24-h urine sample was also collected. Exposure determinants were identified for each external metric using multiple linear regression models via the NLMIXED procedure in SAS. The AHS algorithm was adjusted, consistent with the identified determinants. Mixed-effect models were used to evaluate the correlation between the adjusted and unadjusted algorithm and urinary captan metabolite levels. Results: Consistent determinants of captan exposure were a measure of application size (kilogram of captan sprayed or application method), wearing chemical-resistant (CR) gloves and/or a coverall/suit, repairing spray equipment, and product formulation. Application by airblast was associated with a 4- to 5-fold increase in exposure as compared to hand spray. Exposure reduction to the hands, right thigh, and left forearm from wearing CR gloves averaged similar to 80%, to the right and left thighs and right forearm from wearing a coverall/suit by similar to 70%. Applicators using wettable powder formulations had significantly higher air, thigh, and forearm exposures than those using liquid formulations. Application method weights in the AHS algorithm were adjusted to nine for airblast and two for hand spray; protective equipment reduction factors were adjusted to 0.2 (CR gloves), 0.3 (coverall/suit), and 0.1 (both). Conclusions: Adjustment of application method, CR glove, and coverall weights in the AHS algorithm based on our exposure determinant findings substantially improved the correlation between the AHS algorithm and urinary metabolite levels. C1 [Hines, Cynthia J.; Deddens, James A.] NIOSH, Cincinnati, OH 45226 USA. [Deddens, James A.] Univ Cincinnati, Dept Math Sci, Cincinnati, OH 45221 USA. [Coble, Joseph; Alavanja, Michael C. R.] NCI, Rockville, MD 20892 USA. [Kamel, Freya] NIEHS, Res Triangle Pk, NC 27709 USA. RP Hines, CJ (reprint author), NIOSH, 4676 Columbia Pkwy,R-14, Cincinnati, OH 45226 USA. EM chines@cdc.gov OI Kamel, Freya/0000-0001-5052-6615 FU National Institute for Occupational Safety and Health; National Institutes of Health, National Cancer Institute [Z01-CP010119]; National Institute of Environmental Health Sciences [Z01-ES049030] FX This work has been supported in part by the Intramural research program of the National Institute for Occupational Safety and Health; National Institutes of Health, National Cancer Institute (Z01-CP010119); National Institute of Environmental Health Sciences (Z01-ES049030). NR 27 TC 9 Z9 10 U1 1 U2 15 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD JUL PY 2011 VL 55 IS 6 BP 620 EP 633 DI 10.1093/annhyg/mer008 PG 14 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA 789XX UT WOS:000292553900009 PM 21427168 ER PT J AU Hanson, MP Kwan-Gett, TS Baer, A Rietberg, K Ohrt, M Duchin, JS AF Hanson, Matthew P. Kwan-Gett, Tao S. Baer, Atar Rietberg, Krista Ohrt, Mara Duchin, Jeffrey S. TI Infant Pertussis Epidemiology and Implications for Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccination King County, Washington, 2002 Through 2007 SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID IMMUNIZATION PRACTICES ACIP; AGED 13-17 YEARS; UNITED-STATES; ADVISORY-COMMITTEE; YOUNG INFANTS; NONMEDICAL EXEMPTIONS; BORDETELLA-PERTUSSIS; PREVENTING TETANUS; ADOLESCENTS; RECOMMENDATIONS AB Objectives: To describe the epidemiology of infant pertussis in King County, Washington, and to better understand the implications for tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination among older children, adolescents, and adults. Design: Retrospective analysis of reported pertussis cases among infants younger than 1 year, January 1, 2002, through December 31, 2007. Setting: King County, Washington. Participants: Reported pertussis cases among infants younger than 1 year between 2002 and 2007. Main Outcome Measures: Bordetella pertussis from a household member or close contact was the primary exposure. The main outcome measures were age and vaccination status, incidence by race/ethnicity, suspected exposure, and Tdap eligibility of household members and close contacts. Results: Among 176 confirmed cases of infants with pertussis, the median age was 3 months(age range, 0-11 months); 80.1% were younger than 6 months. Seventy-seven percent were age-appropriately vaccinated. Between 2002 and 2007, the overall mean annual incidence was 136 cases per 100 000 infant population. Compared with a mean annual incidence of 73 cases per 100 000 infant population among whites, the incidence was 246 cases per 100 000 infant population among blacks (rate ratio [RR], 3.37; 95% confidence interval [CI], 2.59-4.44) and 194 cases per 100 000 infant population among Hispanics (RR, 2.66; 95% CI, 2.02-3.53). Households were the suspected exposure location for 70.0% of cases. Case households had a median of 3 (range, 1-15) Tdap-eligible persons. Conclusions: The burden of infant pertussis in King County, Washington, was high between 2002 and 2007, especially among racial/ethnic minorities. Tdap vaccination of eligible household members and close contacts should be promoted as an additional means of protecting infants from pertussis. C1 [Hanson, Matthew P.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Hanson, Matthew P.; Kwan-Gett, Tao S.; Baer, Atar; Rietberg, Krista; Duchin, Jeffrey S.] Univ Washington, Communicable Dis Epidemiol & Immunizat Sect, Seattle, WA 98195 USA. [Duchin, Jeffrey S.] Univ Washington, Dept Med, Div Infect Dis, Seattle, WA USA. [Ohrt, Mara] Dept Hlth & Social Serv, Div Publ Hlth, Epidemiol Sect, Immunizat Program, Anchorage, AK USA. RP Hanson, MP (reprint author), Bill & Melinda Gates Fdn, Global Hlth Program, 500 5th Ave N, Seattle, WA 98109 USA. NR 28 TC 5 Z9 5 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD JUL PY 2011 VL 165 IS 7 BP 647 EP 652 PG 6 WC Pediatrics SC Pediatrics GA 787JT UT WOS:000292373100011 PM 21727277 ER PT J AU Richardson, S Browne, ML Rasmussen, SA Druschel, CM Sun, LX Jabs, EW Romitti, PA AF Richardson, Sandra Browne, Marilyn L. Rasmussen, Sonja A. Druschel, Charlotte M. Sun, Lixian Jabs, Ethylin Wang Romitti, Paul A. CA Natl Birth Defects Prevention Stud TI Associations Between Periconceptional Alcohol Consumption and Craniosynostosis, Omphalocele, and Gastroschisis SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE alcohol drinking; case-control studies; congenital abnormalities; craniosynostosis; gastroschisis; omphalocele ID BIRTH-DEFECTS PREVENTION; RETINOIC ACID; RISK-FACTORS; PREGNANCY; EXPOSURE; SMOKING; BIOLOGY; GROWTH; WOMEN; MICE AB BACKGROUND: Alcohol consumption during pregnancy is known to be associated with certain birth defects, but the risk of other birth defects is less certain. The authors examined associations between maternal alcohol consumption during pregnancy and craniosynostosis, omphalocele, and gastroschisis among participants in the National Birth Defects Prevention Study, a large, multicenter case-control study. METHODS: A total of 6622 control infants and 1768 infants with birth defects delivered from 1997-2005 were included in the present analysis. Maternal alcohol consumption was assessed as any periconceptional consumption (1 month prepregnancy through the third pregnancy month), and by quantity-frequency, duration, and beverage type. Alcohol consumption throughout pregnancy was explored for craniosynostosis since the period of development may extend beyond the first trimester. Adjusted odds ratios (OR) and 95% confidence intervals (CI) were estimated using unconditional logistic regression analysis. OR were adjusted for age, race/ethnicity, and state of residence at time of infant's birth. Gastroschisis OR were also adjusted for periconceptional smoking. RESULTS: Periconceptional alcohol consumption and craniosynostosis showed little evidence of an association (OR = 0.92; CI: 0.78-1.08), but alcohol consumption in the second (OR = 0.65; CI: 0.47-0.92) and third trimesters (OR = 0.68; CI: 0.49-0.95) was inversely associated with craniosynostosis. Periconceptional alcohol consumption was associated with omphalocele (OR = 1.50; CI: 1.15-1.96) and gastroschisis (OR = 1.40; CI: 1.17-1.67). CONCLUSIONS: Results suggest that maternal periconceptional alcohol consumption is associated with omphalocele and gastroschisis, and second and third trimester alcohol consumption are inversely associated with craniosynostosis. Birth Defects Research (Part A) 91:623-630, 2011. (C) 2011 Wiley-Liss, Inc. C1 [Richardson, Sandra; Browne, Marilyn L.; Druschel, Charlotte M.] Bur Environm & Occupat Epidemiol, Congenital Malformat Registry, New York State Dept Hlth, Troy, NY 12180 USA. [Browne, Marilyn L.; Druschel, Charlotte M.] SUNY Albany, Sch Publ Hlth, Dept Epidemiol & Biostat, Rensselaer, NY USA. [Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Sun, Lixian; Romitti, Paul A.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA. [Sun, Lixian] Dana Farber Canc Inst, Boston, MA 02115 USA. [Jabs, Ethylin Wang] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA. [Jabs, Ethylin Wang] Mt Sinai Sch Med, Dept Pediat, New York, NY USA. [Jabs, Ethylin Wang] Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY USA. RP Richardson, S (reprint author), Bur Environm & Occupat Epidemiol, Congenital Malformat Registry, New York State Dept Hlth, 547 River St,Room 200, Troy, NY 12180 USA. EM sdr06@health.state.ny.us RI Publications, NBDPS/B-7692-2013; OI Jabs, Ethylin/0000-0001-8983-5466 FU Centers for Disease Control and Prevention [5U01DD000487-02, 5R01DD000350] FX This work was supported by the Centers for Disease Control and Prevention, grant number 5U01DD000487-02; and in part by Centers for Disease Control and Prevention, grant number 5R01DD000350. NR 31 TC 17 Z9 18 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD JUL PY 2011 VL 91 IS 7 BP 623 EP 630 DI 10.1002/bdra.20823 PG 8 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 790PY UT WOS:000292602900005 PM 21630421 ER PT J AU Gallagher, ML Sturchio, C Smith, A Koontz, D Jenkins, MM Honein, MA Rasmussen, SA AF Gallagher, Margaret L. Sturchio, Cynthia Smith, Ashley Koontz, Deborah Jenkins, Mary M. Honein, Margaret A. Rasmussen, Sonja A. TI Evaluation of Mailed Pediatric Buccal Cytobrushes for Use in a Case-Control Study of Birth Defects SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE DNA; buccal cells; cytobrush; genotyping; whole genome amplification ID WHOLE-GENOME AMPLIFICATION; DNA COLLECTION; CELL-DNA; SAMPLES; MOUTHWASH; POPULATIONS; YIELD; SWABS; POLYMERASE; QUALITY AB BACKGROUND: Buccal cell collection is a convenient DNA collection method; however, little attention has been given to the quality of DNA obtained from pediatric populations. The purpose of this study was to determine the effect of a modified cytobrush collection method on the yield and quality of infant buccal DNA collected as part of a population-based case-control study of birth defects. METHODS: Cytobrushes were collected from infants, mothers, and fathers using a standard collection method in 1997 to 2003 and a modified protocol that allows air-drying of the cytobrushes after collection from 2003 to the present. Yield and quality of DNA from 1057 cytobrushes was assessed by quantitative PCR and short tandem repeat (STR) genotyping, respectively. RESULTS: Air-dried cytobrushes from infants had higher median DNA yields (1300 ng) and STR completion rates (99.5%) than standard collection method cytobrushes (60 ng and 59.5%, respectively). A subset of DNA aliquots was genotyped for six single nucleotide polymorphisms (SNPs). Aliquots from both collection methods that passed the quality protocol (DNA concentration >1 ng/mu l, and successful amplification of >= 1 STR) had high genotype completion rates (99-100%). The median DNA yield following whole genome amplification was more than twofold higher for air-dried than standard collection specimens (p < 0.001). CONCLUSION: Yield and quality of buccal DNA collected from infants are improved by using a method that incorporates air-drying; however, DNA collected by both methods is suitable for genotyping if stringent quality control procedures are instituted. These findings may be helpful for future epidemiologic studies of birth defects and other adverse pediatric outcomes. Birth Defects Research (Part A) 91:642-648, 2011. (C) 2011 Wiley-Liss, Inc. C1 [Gallagher, Margaret L.; Koontz, Deborah] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Sturchio, Cynthia; Smith, Ashley] Battelle Mem Inst, Columbus, OH 43201 USA. [Jenkins, Mary M.; Honein, Margaret A.; Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Gallagher, ML (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway,M-S F-24, Chamblee, GA 30341 USA. EM MGallagher1@cdc.gov NR 37 TC 8 Z9 8 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD JUL PY 2011 VL 91 IS 7 BP 642 EP 648 DI 10.1002/bdra.20829 PG 7 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 790PY UT WOS:000292602900007 PM 21630425 ER PT J AU Dauphin, LA Walker, RE Petersen, JM Bowen, MD AF Dauphin, Leslie A. Walker, Roblena E. Petersen, Jeannine M. Bowen, Michael D. TI Comparative evaluation of automated and manual commercial DNA extraction methods for detection of Francisella tularensis DNA from suspensions and spiked swabs by real-time polymerase chain reaction SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE Francisella tularensis; DNA extraction; Tularemia; Real-time PCR; Bioterrorism ID BACILLUS-ANTHRACIS SPORES; UNITED-STATES; PCR; RECOVERY; SAMPLES; TULAREMIA; KITS; IDENTIFICATION; SPECIMENS; RNA AB This study evaluated commercial automated and manual DNA extraction methods for the isolation of Francisella tularensis DNA suitable for real-time polymerase chain reaction (PCR) analysis from cell suspensions and spiked cotton, foam, and polyester swabs. Two automated methods, the MagNA Pure Compact and the QIAcube, were compared to 4 manual methods, the IT 1-2-3 DNA sample purification kit, the MasterPure Complete DNA and RNA purification kit, the QIAamp DNA blood mini kit, and the UltraClean Microbial DNA isolation kit. The methods were compared using 6 F. tularensis strains representing the 2 subspecies which cause the majority of reported cases of tularemia in humans. Cell viability testing of the DNA extracts showed that all 6 extraction methods efficiently inactivated F. tularensis at concentrations of <= 10(6) CFU/mL. Real-time PCR analysis using a multitarget 5' nuclease assay for F. tularensis revealed that the PCR sensitivity was equivalent using DNA extracted by the 2 automated methods and the manual MasterPure and QIAamp methods. These 4 methods resulted in significantly better levels of detection from bacterial suspensions and performed equivalently for spiked swab samples than the remaining 2. This study identifies optimal DNA extraction methods for processing swab specimens for the subsequent detection of F. tularensis DNA using real-time PCR assays. Furthermore, the results provide diagnostic laboratories with the option to select from 2 automated DNA extraction methods as suitable alternatives to manual methods for the isolation of DNA from F. tularensis. Published by Elsevier Inc. C1 [Dauphin, Leslie A.; Walker, Roblena E.; Bowen, Michael D.] Ctr Dis Control & Prevent, BRRAT Lab, LPRB, DPEI,CDC, Atlanta, GA 30333 USA. [Petersen, Jeannine M.] CDC, Diagnost & Reference Lab, Bacterial Dis Branch, Div Vector Borne Dis, Ft Collins, CO 80521 USA. RP Dauphin, LA (reprint author), Ctr Dis Control & Prevent, BRRAT Lab, LPRB, DPEI,CDC, Atlanta, GA 30333 USA. EM ldauphin@cdc.gov NR 30 TC 12 Z9 14 U1 1 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD JUL PY 2011 VL 70 IS 3 BP 299 EP 306 DI 10.1016/j.diagmicrobio.2011.02.010 PG 8 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 788JL UT WOS:000292441100003 PM 21546201 ER PT J AU Kim, JH Coca, A Williams, WJ Roberge, RJ AF Kim, Jung-Hyun Coca, Aitor Williams, W. Jon Roberge, Raymond J. TI Effects of Liquid Cooling Garments on Recovery and Performance Time in Individuals Performing Strenuous Work Wearing a Firefighter Ensemble SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE core temperature; firefighter ensembles; heat stress; liquid cooling garments ID UNCOMPENSABLE HEAT-STRESS; WARM ENVIRONMENTS; AEROBIC FITNESS; EXERCISE; TOLERANCE; BODY; STRAIN; TEMPERATURE; HYDRATION; AIR AB This study investigated the effects of body cooling using liquid cooling garments (LCG) on performance time (PT) and recovery in individuals wearing a fully equipped prototype firefighter ensemble (PFE) incorporating a self-contained breathing apparatus (SCBA). Six healthy male participants (three firefighters and three non-firefighters) completed six experimental sessions in an environmental chamber (35 degrees C, 50% relative humidity), consisting of three stages of 15 min exercise at 75% VO(2max), and 10 min rest following each exercise stage. During each session, one of the following six conditions was administered in a randomized order: control (no cooling, CON); air ventilation of exhaust SCBA gases rerouted into the PFE (AV): top cooling garment (TCG); TCG combined with AV (TCG+AV); a shortened whole body cooling garment (SCG), and SCG combined with AV (SCG+AV). Results showed that total PT completed was longer tinder SCG and SCG+AV compared with CON, AV, TCG, and TCG+AV (p < 0.01). Magnitude of core temperature (T(c)) elevation was significantly decreased when SCG was utilized (p < 0.01), and heart rate recovery rate (10 min) was enhanced under SCG, SCG+AV, TCG, and TCG+AV compared with CON (p < 0.05). Estimated E(sw) rate (kg.h(-1)) was the greatest in CON, 1.62 (0.37), and the least in SCG+AV 0.98 (0.44): (descending order: CON > AV > TCG = TCG+AV > SCG > SCG+AV) without a statistical difference between the conditions (p < 0.05). Results of the present study suggest that the application of LCG underneath the PFE significantly improves the recovery during a short period of rest and prolongs performance time in subsequent bouts of exercise. LCG also appears to be an effective method for body cooling that promotes heat dissipation during uncompensable heat stress. C1 [Coca, Aitor] NIOSH, Natl Personal Protect Technol Lab, CDC, Pittsburgh, PA 15236 USA. RP Coca, A (reprint author), NIOSH, Natl Personal Protect Technol Lab, CDC, 626 Cochrans Mill Rd,B29-107, Pittsburgh, PA 15236 USA. EM esq6@cdc.gov NR 26 TC 11 Z9 11 U1 1 U2 8 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD JUL PY 2011 VL 8 IS 7 BP 409 EP 416 DI 10.1080/15459624.2011.584840 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 789OV UT WOS:000292526100006 PM 21660834 ER PT J AU Viscusi, DJ Bergman, MS Novak, DA Faulkner, KA Palmiero, A Powell, J Shaffer, RE AF Viscusi, Dennis J. Bergman, Michael S. Novak, Debra A. Faulkner, Kimberly A. Palmiero, Andrew Powell, Jeffrey Shaffer, Ronald E. TI Impact of Three Biological Decontamination Methods on Filtering Facepiece Respirator Fit, Odor, Comfort, and Donning Ease SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE comfort; health care workers; N95 decontamination; N95 respirator fit; pandemic influenza; respirator reuse ID HEALTH-CARE WORKERS AB The objective of this study was to determine if ultraviolet germicidal irradiation (UVGI), moist heat incubation (MHI), or microwave-generated steam (MGS) decontamination affects the fitting characteristics, odor, comfort, or donning ease of six N95 filtering facepiece respirator (FFR) models. For each model, 10 experienced test subjects qualified for the study by passing a standard OSHA quantitative fit test. Once qualified, each subject performed a series of fit tests to assess respirator fit and completed surveys to evaluate odor, comfort, and donning ease with FFRs that were not decontaminated (controls) and with FFRs of the same model that had been decontaminated. Respirator fit was quantitatively measured using a multidonning protocol with the TSI PORTACOUNT Plus and the N95 Companion accessory (designed to count only particles resulting from face to face-seal leakage). Participants' subjective appraisals of the respirator's odor, comfort, and donning ease were captured using a visual analog scale survey. Wilcoxon signed rank tests compared median values for fit, odor; comfort, and donning ease for each FFR and decontamination method against their respective controls for a given model. Two of the six FFRs demonstrated a statistically significant reduction (p < 0.05) in fit after MHI decontamination. However, for these two FFR models, post-decontamination mean fit factors were still >= 100. One of the other FFRs demonstrated a relatively small though statistically significant increase (p < 0.05) in median odor response after MHI decontamination. These data suggest that FFR users with characteristics similar to those in this study population would be unlikely to experience a clinically meaningful reduction in fit, increase in odor, increase in discomfort, or increased difficulty in donning with the six FFRs included in this study after UVGI, MHI, or MGS decontamination. Further research is needed before decontamination of N95 FFRs for purposes of reuse can be recommended. C1 [Viscusi, Dennis J.; Novak, Debra A.; Faulkner, Kimberly A.; Powell, Jeffrey; Shaffer, Ronald E.] NIOSH, Technol Res Branch, Natl Personal Protect Technol Lab, Ctr Dis Control & Prevent, Pittsburgh, PA 15236 USA. [Bergman, Michael S.; Palmiero, Andrew] URS Corp, Pittsburgh, PA USA. RP Shaffer, RE (reprint author), NIOSH, Technol Res Branch, Natl Personal Protect Technol Lab, Ctr Dis Control & Prevent, 626 Cochrans Mill Rd,Bldg 29,POB 18070, Pittsburgh, PA 15236 USA. EM RShaffer@cdc.gov RI Shaffer, Ronald/I-2134-2012 FU Technical Support Working Group (TSWG) FX The authors would like to express their sincere gratitude to Ed Fisher, Evanly Vo, Samy Rengasamy, Ziqing Zhuang, Ray Roberge (NIOSH/NPPTL), Brian Heimbuch (Applied Research Associates), and Joe Wander (Air Force Research Laboratory), for their consultation, insightful comments, and critical reviews of the manuscript. The Technical Support Working Group (TSWG) is acknowledged for providing funding for this work. NR 23 TC 16 Z9 16 U1 0 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD JUL PY 2011 VL 8 IS 7 BP 426 EP 436 DI 10.1080/15459624.2011.585927 PG 11 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 789OV UT WOS:000292526100008 PM 21732856 ER PT J AU Schlecht, P O'Connor, PF Key-Schwartz, R Lunsford, A Gagnon, Y AF Schlecht, Paul O'Connor, Paula Fey Key-Schwartz, Rosa Lunsford, Alan Gagnon, Yvonne TI NIOSH Manual of Analytical Methods 5th Edition-New Resources and Direction SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Editorial Material C1 [O'Connor, Paula Fey; Key-Schwartz, Rosa; Gagnon, Yvonne] Ctr Dis Control & Prevent, US Dept Hlth & Human Serv, Natl Inst Occupat Safety & Hlth, Cincinnati, OH USA. EM pfo1@cdc.gov; rjk9@cdc.gov NR 3 TC 0 Z9 0 U1 0 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD JUL PY 2011 VL 8 IS 7 BP D59 EP D62 DI 10.1080/15459624.2011.584767 PG 4 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 789OV UT WOS:000292526100001 PM 21660831 ER PT J AU Kitt, MM Decker, JA Delaney, L Funk, R Halpin, J Tepper, A Spahr, J Howard, J AF Kitt, Margaret M. Decker, John A. Delaney, Lisa Funk, Renee Halpin, John Tepper, Allison Spahr, James Howard, John TI Protecting Workers in Large-Scale Emergency Responses NIOSH Experience in the Deepwater Horizon Response SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article C1 [Kitt, Margaret M.] NIOSH, Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Howard, John] NIOSH, Washington, DC USA. [Tepper, Allison] NIOSH, Cincinnati, OH 45226 USA. RP Kitt, MM (reprint author), NIOSH, Ctr Dis Control & Prevent, 1600 Clifton Rd,Mail Stop E-20, Atlanta, GA 30333 USA. EM mkitt@cdc.gov NR 9 TC 4 Z9 4 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD JUL PY 2011 VL 53 IS 7 BP 711 EP 715 DI 10.1097/JOM.0b013e31822543b6 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 789TQ UT WOS:000292539600004 PM 21697736 ER PT J AU Ajmera, V Xia, G Vaughan, G Forbi, JC Ganova-Raeva, LM Khudyakov, Y Opio, CK Taylor, R Restrepo, R Munoz, S Fontana, RJ Lee, WM AF Ajmera, V. Xia, G. Vaughan, G. Forbi, J. C. Ganova-Raeva, L. M. Khudyakov, Y. Opio, C. K. Taylor, R. Restrepo, R. Munoz, S. Fontana, R. J. Lee, W. M. CA Acute Liver Failure Study Grp TI What factors determine the severity of hepatitis A-related acute liver failure? SO JOURNAL OF VIRAL HEPATITIS LA English DT Article DE acute liver failure; epidemiology; genome sequencing; hepatitis A ID FULMINANT-HEPATITIS; UNITED-STATES; VIRUS; INFECTION; STRAINS AB The reason(s) that hepatitis A virus (HAV) infection may progress infrequently to acute liver failure are poorly understood. We examined host and viral factors in 29 consecutive adult patients with HAV-associated acute liver failure enrolled at 10 sites participating in the US ALF Study Group. Eighteen of twenty-four acute liver failure sera were PCR positive while six had no detectable virus. HAV genotype was determined using phylogenetic analysis and the full-length genome sequences of the HAV from a cute liver failure sera were compared to those from self-limited acute HAV cases selected from the CDC database. We found that rates of nucleotide substitution did not vary significantly between the liver failure and non-liver failure cases and there was no significant variation in amino acid sequences between the two groups. Four of 18 HAV isolates were sub-genotype IB, acquired from the same study site over a 3.5-year period. Sub-genotype IB was found more frequently among acute liver failure cases compared to the non-liver failure cases (chi-square test, P < 0.01). At another centre, a mother and her son presented with HAV and liver failure within 1 month of each other. Predictors of spontaneous survival included detectable serum HAV RNA, while age, gender, HAV genotype and nucleotide substitutions were not associated with outcome. The more frequent appearance of rapid viral clearance and its association with poor outcomes in acute liver failure as well as the finding of familial cases imply a possible host genetic predisposition that contributes to a fulminant course. Recurrent cases of the rare sub-genotype IB over several years at a single centre imply a community reservoir of infection and possible increased pathogenicity of certain infrequent viral genotypes. C1 [Ajmera, V.; Opio, C. K.; Lee, W. M.] Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX 75390 USA. [Xia, G.; Vaughan, G.; Forbi, J. C.; Ganova-Raeva, L. M.; Khudyakov, Y.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Taylor, R.; Fontana, R. J.] Univ Michigan, Med Ctr, Div Gastroenterol, Ann Arbor, MI USA. [Restrepo, R.; Munoz, S.] Albert Einstein Med Ctr, Liver Transplant Ctr, Philadelphia, PA 19141 USA. RP Lee, WM (reprint author), Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, 5959 Harry Hines Blvd,HP 4-420, Dallas, TX 75390 USA. EM william.lee@utsouthwestern.edu FU NIH [DK U-01 58369]; Northwestern Medical Foundation; Southwestern Medical Foundation; UT Southwestern Medical School FX This work was funded by NIH grant DK U-01 58369 for the Acute Liver Failure Study Group. Additional funding provided by the Tips Fund of Northwestern Medical Foundation and the Jeanne Roberts and Rollin and Mary Ella King Funds of the Southwestern Medical Foundation. VA received a summer research fellowship as a first year medical student at UT Southwestern Medical School. NR 24 TC 13 Z9 14 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1352-0504 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD JUL PY 2011 VL 18 IS 7 BP E167 EP E174 DI 10.1111/j.1365-2893.2010.01410.x PG 8 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA 785XE UT WOS:000292265400001 PM 21143345 ER PT J AU Vaid, I Wigington, C Borbely, D Ferry, P Manheim, D AF Vaid, Isam Wigington, Charles Borbely, Deborah Ferry, Patricia Manheim, Diane TI WISEWOMAN: Addressing the Needs of Women at High Risk for Cardiovascular Disease SO JOURNAL OF WOMENS HEALTH LA English DT Article ID ADULTS; HEALTH AB In the United States, the cardiovascular health of women is affected by the disparate impact of cardiovascular diseases (CVDs) on many minority ethnic and racial groups. Women with low income also endure a disproportionate impact of the burden of CVD. The Centers for Disease Control and Prevention's (CDC's) Well-Integrated Screening and Evaluation for Women Across the Nation (WISEWOMAN) Program was authorized by Congress in 1993 to extend the preventive health services offered to participants of the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). These are low-income, uninsured, and underinsured women. The intent was to expand services of an existing federal program to address cardiovascular health concerns in this vulnerable, high-risk population. CDC funds 19 state health departments and 2 tribal organizations (both in Alaska) to implement WISEWOMAN. In the first 2 years of the current 5-year funding cycle, which began in June 2008, the WISEWOMAN grantees succeeded in providing almost 78,000 screenings, of which 46% were to women of minority racial and ethnic groups. The individual successes are important, and the WISEWOMAN Program also has achieved success in the broader arenas of healthcare and the communities in which WISEWOMAN is implemented. WISEWOMAN impacts clinical systems of care, provider education, physician extenders, and the broader community and will continue to play an important role in connecting low-income, uninsured, and underinsured women with clinical systems of care and other community resources that will result in the prevention, treatment, and management of their CVD risk. C1 [Vaid, Isam; Wigington, Charles; Borbely, Deborah; Ferry, Patricia; Manheim, Diane] Ctr Dis Control & Prevent, WISEWOMAN Program, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Vaid, I (reprint author), 2877 Brandywine Rd,Mailstop K47,Williams Bldg, Chamblee, GA 30341 USA. EM Isam.Vaid@CDC.HHS.gov NR 26 TC 7 Z9 7 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD JUL PY 2011 VL 20 IS 7 BP 977 EP 982 DI 10.1089/jwh.2011.2850 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 789UF UT WOS:000292541100001 PM 21668383 ER PT J AU Frade, JP Arthington-Skaggs, BA AF Frade, Joao Pedro Arthington-Skaggs, Beth A. TI Effect of serum and surface characteristics on Candida albicans biofilm formation SO MYCOSES LA English DT Article DE Biofilms; Candida albicans bloodstream isolates; biosurfaces; serum ID BLOOD-STREAM INFECTIONS; IN-VITRO; DRUG-RESISTANCE; SURVEILLANCE; ADHESION; BIOMATERIALS; POPULATION; ADHERENCE; MATRIX; MODEL AB Candida spp. biofilms can be established on a wide range of materials, including implanted medical devices, and can display a resistant phenotype to antifungal drugs. Several factors, including host and surface properties, may influence the establishment and the development of Candida albicans biofilms on biotic and abiotic surfaces. We therefore selected a collection of C. albicans clinical isolates to evaluate the effect of surface and serum on biofilm attachment and development. Disc coupons from the CDC biofilm reactor were used in a well plate assay to study biofilm production on six different surfaces with or without the addition of serum: polycarbonate, polystyrene, stainless steel, Teflon, polyvinyl chloride or hydroxyapatite. Our results showed that serum increases in vitro C. albicans biofilm formation on a wide range of distinct surfaces including metallic and non-metallic materials, and that roughness and hydrophobicity can modulate C. albicans biofilm formation. These findings were also confirmed by scanning electron microscopy and it revealed the deposition of extracellular material on hyphae attached to a solid surface. Interestingly, adhesion can be significantly increased in the early stages of colonisation when serum is provided as a conditioning film in a surface-dependent manner. C1 [Frade, Joao Pedro; Arthington-Skaggs, Beth A.] Ctr Dis Control & Prevent, Mycot Dis Branch, Div Food Borne Bacterial & Mycot Dis, Atlanta, GA 30333 USA. RP Frade, JP (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, Div Food Borne Bacterial & Mycot Dis, 1600 Clifton Rd NE,Mailstop G-11, Atlanta, GA 30333 USA. EM fvm0@cdc.gov FU American Society FX The authors would like to thank Janice Carr (Centers for Disease Control and Prevention) for the SEM. JPF thanks American Society for Microbiology for the fellowship in the ASM/CCID PostDoctoral Research Associates Program in Infectious Diseases and Public Health Microbiology. The authors also wish to thank Rodney Donlan (Biofilm Laboratory, Centers for Disease Control and Prevention) and Shawn Lockhart (Mycotic Diseases Branch, Centers for Disease Control and Prevention) for critical reading of the manuscript. NR 32 TC 15 Z9 16 U1 1 U2 16 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0933-7407 J9 MYCOSES JI Mycoses PD JUL PY 2011 VL 54 IS 4 BP E154 EP E162 DI 10.1111/j.1439-0507.2010.01862.x PG 9 WC Dermatology; Mycology SC Dermatology; Mycology GA 789FY UT WOS:000292501600022 PM 20337936 ER PT J AU Cannon, MJ Hyde, TB Schmid, DS AF Cannon, Michael J. Hyde, Terri B. Schmid, D. Scott TI Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection SO REVIEWS IN MEDICAL VIROLOGY LA English DT Review ID DAY-CARE-CENTERS; SENSORINEURAL HEARING-LOSS; EPSTEIN-BARR-VIRUS; PREGNANT-WOMEN; YOUNG-CHILDREN; UNITED-STATES; MOLECULAR EPIDEMIOLOGY; NONPREGNANT WOMEN; SEXUAL-ACTIVITY; CMV INFECTION AB Congenital cytomegalovirus (CMV) infections are a leading cause of sensorineural hearing loss (SNHL) and neurological impairment. Congenital transmission of CMV can occur with maternal primary infection, reactivation, or reinfection during pregnancy. We reviewed studies of CMV shedding in bodily fluids (defined as CMV detected by culture or CMV DNA detected by polymerase chain reaction). Following diagnosis at birth, children with congenital CMV infection exhibited the highest prevalences of CMV shedding (median = 80%, number of sample population prevalences [N] = 6) and duration of shedding, with a steep decline by age five. Healthy children attending day care shed more frequently (median=23%, N=24) than healthy children not attending day care (median = 12%, N = 11). Peak shedding prevalences in children occurred at 1-2 years of age, confirming that young children are the key transmission risk for pregnant women. CMV shedding among children was more prevalent in urine specimens than in oral secretions (median prevalence difference = 11.5%, N = 12). Adults with risk factors such as STD clinic attendance had higher shedding prevalences (median = 22%, N = 20) than adults without risk factors (median = 7%, N = 44). In adults with risk factors, CMV was shed more frequently in urine; in adults without risk factors genital shedding was most common. The prevalence of CMV shedding in nine sample populations of pregnant women increased with advancing gestation. In seven sample populations of children with congenital CMV infection, higher viral load at birth was consistently associated with an elevated risk of SNHL. Higher CMV viral load at birth also consistently correlated with the presence of symptoms of congenital CMV at birth. Published 2011. This article is a US Government work and is in the public domain in the USA. C1 [Cannon, Michael J.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30345 USA. [Hyde, Terri B.; Schmid, D. Scott] Ctr Dis Control & Prevent CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Cannon, MJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1825 Century Blvd,Mailstop E 86, Atlanta, GA 30345 USA. EM mcannon@cdc.gov RI Cannon, Michael/E-5894-2011 OI Cannon, Michael/0000-0001-5776-5010 FU Intramural CDC HHS [CC999999] NR 126 TC 74 Z9 75 U1 0 U2 14 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1052-9276 J9 REV MED VIROL JI Rev. Med. Virol. PD JUL PY 2011 VL 21 IS 4 BP 240 EP 255 DI 10.1002/rmv.695 PG 16 WC Virology SC Virology GA 789YK UT WOS:000292555300005 PM 21674676 ER PT J AU Abramowicz, KF Rood, MP Krueger, L Eremeeva, ME AF Abramowicz, Kyle F. Rood, Michael P. Krueger, Laura Eremeeva, Marina E. TI Urban Focus of Rickettsia typhi and Rickettsia felis in Los Angeles, California SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Rattus norvegicus; Rickettsia felis; Rickettsia typhi; Xenopsylla cheopis ID FLEAS CTENOCEPHALIDES-FELIS; MURINE TYPHUS; XENOPSYLLA-CHEOPIS; ENDEMIC TYPHUS; CAT FLEAS; MOLECULAR-IDENTIFICATION; INFECTION; TEXAS; OPOSSUMS; COUNTY AB Classic murine typhus, caused by Rickettsia typhi, is endemic in the continental United States in areas of Texas and southern California. We conducted an environmental investigation in an urban area of Los Angeles identified as the probable exposure site for a case of murine typhus. Four Rattus norvegicus heavily infested with Xenopsylla cheopis (average 32.5 fleas per animal, range 20-42) were trapped, and fleas, blood, and tissues were collected. DNAs from all specimens were tested for R. typhi and Rickettsia felis using a TaqMan assay targeting the rickettsial citrate synthase gene. Although rickettsiemia was not detected, DNA of R. felis was detected in at least one tissue from each rat. Tissues from 3 rats were also positive for R. typhi DNA. R. typhi and R. felis DNAs were detected in fleas collected from each animal with average minimal infection rates of 10% and 32.3%, respectively. Although R. typhi still circulates in urban Los Angeles in the classic Oriental flea-rat cycle, R. felis is more prevalent, even in this association. C1 [Abramowicz, Kyle F.; Eremeeva, Marina E.] Ctr Dis Control & Prevent, Natl Ctr Zoonot & Emerging Infect Dis, Atlanta, GA 30333 USA. [Rood, Michael P.] Los Angeles Cty Dept Publ Hlth, Vector Management Program, Baldwin Pk, CA USA. [Krueger, Laura] Calif Dept Publ Hlth, Ctr Infect Dis, Vector Borne Dis Sect, Ontario, CA USA. RP Eremeeva, ME (reprint author), Ctr Dis Control & Prevent, Natl Ctr Zoonot & Emerging Infect Dis, Mail Stop G13,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM meremeeva@cdc.gov FU Oak Ridge Institute for Science and Education through Oak Ridge Associated Universities; U.S. Department of Energy FX Kyle F. Abramowicz was supported by a fellowship with the Oak Ridge Institute for Science and Education through Oak Ridge Associated Universities and the U.S. Department of Energy. The authors thank Kathryn Dirks and Sandor Karpathy for laboratory and protocol assistance, and Gregory A. Dasch for reviewing the article and helpful suggestions. NR 46 TC 12 Z9 13 U1 2 U2 12 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 EI 1557-7759 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD JUL PY 2011 VL 11 IS 7 BP 979 EP 984 DI 10.1089/vbz.2010.0117 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 789TV UT WOS:000292540100029 PM 21142968 ER PT J AU Yetley, EA Coates, PM Johnson, CL AF Yetley, Elizabeth A. Coates, Paul M. Johnson, Clifford L. TI Overview of a roundtable on NHANES monitoring of biomarkers of folate and vitamin B-12 status: measurement procedure issues SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article AB A roundtable dialogue to discuss "NHANES Monitoring of Biomarkers of Folate and Vitamin B-12 Status" took place in July 2010. This article provides an overview of the meeting and this supplement issue. Although the focus of the roundtable dialogue was on the measurement of folate and vitamin B-12 status biomarkers in NHANES, this article also describes the relevance and importance of these issues for clinical and research laboratories. The roundtable identified the microbiological assay (MA) as the gold standard for measurement of serum and red blood cell folate concentrations. The roundtable noted that differences in results between the Bio-Rad Quantaphase II procedure (Bio-Rad Laboratories, Hercules, CA) that NHANES1991-1994 and 1999-2006 used and the MA that NHANES 2007-2010 used will require adjustment equations to evaluate time trends. The roundtable found that the close agreement between the serum results for the MA and liquid chromatography-tandem mass spectrometry (LC-MS/MS) procedures supported the conversion to LC-MS/MS for serum folate in future NHANES. The roundtable recognized the uncertainty about whether subclinical vitamin B-12 deficiency is a public health concern but encouraged reinstatement of at least one circulating vitamin B-12 measure and one functional vitamin B-12 status measure in future NHANES. The use of serum vitamin B-12 and plasma methylmalonic acid would provide continuity with past NHANES. The roundtable supported the continued use of the National Institute of Standards and Technology (NIST) reference materials in NHANES biomarker analyses and the further development of additional reference materials by the NIST. Am J Clin Nutr 2011;94(suppl):297S-302S. C1 [Yetley, Elizabeth A.; Coates, Paul M.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. [Johnson, Clifford L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Coates, PM (reprint author), NIH, Off Dietary Supplements, 6100 Execut Blvd,Room 3B01,MSC 7517, Bethesda, MD 20892 USA. EM beth@yetley.com; coatesp@od.nih.gov FU Office of Dietary Supplements, NIH; National Center for Health Statistics, CDC FX Supported by the National Center for Health Statistics, CDC, and the Office of Dietary Supplements, NIH. NR 11 TC 14 Z9 14 U1 0 U2 6 PU AMER SOC CLINICAL NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD JUL PY 2011 VL 94 IS 1 BP 297S EP 302S DI 10.3945/ajcn.111.017392 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 779QK UT WOS:000291794800044 PM 21593504 ER PT J AU Yetley, EA Pfeiffer, CM Phinney, KW Fazili, Z Lacher, DA Bailey, RL Blackmore, S Bock, JL Brody, LC Carmel, R Curtin, LR Durazo-Arvizu, RA Eckfeldt, JH Green, R Gregory, JF Hoofnagle, AN Jacobsen, DW Jacques, PF Molloy, AM Massaro, J Mills, JL Nexo, E Rader, JI Selhub, J Sempos, C Shane, B Stabler, S Stover, P Tamura, T Tedstone, A Thorpe, SJ Coates, PM Johnson, CL Picciano, MF AF Yetley, Elizabeth A. Pfeiffer, Christine M. Phinney, Karen W. Fazili, Zia Lacher, David A. Bailey, Regan L. Blackmore, Sheena Bock, Jay L. Brody, Lawrence C. Carmel, Ralph Curtin, L. Randy Durazo-Arvizu, Ramon A. Eckfeldt, John H. Green, Ralph Gregory, Jesse F., III Hoofnagle, Andrew N. Jacobsen, Donald W. Jacques, Paul F. Molloy, Anne M. Massaro, Joseph Mills, James L. Nexo, Ebba Rader, Jeanne I. Selhub, Jacob Sempos, Christopher Shane, Barry Stabler, Sally Stover, Patrick Tamura, Tsunenobu Tedstone, Alison Thorpe, Susan J. Coates, Paul M. Johnson, Clifford L. Picciano, Mary Frances TI Biomarkers of folate status in NHANES: a roundtable summary SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID TANDEM MASS-SPECTROMETRY; FOLIC-ACID FORTIFICATION; WHOLE-BLOOD FOLATE; BIO-RAD RADIOASSAY; B-VITAMIN STATUS; HUMAN SERUM; MICROBIOLOGIC ASSAY; INTERNATIONAL STANDARD; UNITED-STATES; HUMAN PLASMA AB A roundtable to discuss the measurement of folate status biomarkers in NHANES took place in July 2010. NHANES has measured serum folate since 1974 and red blood cell (RBC) folate since 1978 with the use of several different measurement procedures. Data on serum 5-methyltetrahydrofolate (5MTHF) and folic acid (FA) concentrations in persons aged >= 60 y are available in NHANES 1999-2002. The roundtable reviewed data that showed that folate concentrations from the Bio-Rad Quantaphase II procedure (Bio-Rad Laboratories, Hercules, CA; used in NHANES 1991-1994 and NHANES 1999-2006) were, on average, 29% lower for serum and 45% lower for RBC than were those from the microbiological assay (MA), which was used in NHANES 2007-2010. Round-table experts agreed that these differences required a data adjustment for time-trend analyses. The roundtable reviewed the possible use of an isotope-dilution liquid chromatography-tandem mass spectrometry (LC-MS/MS) measurement procedure for future NHANES and agreed that the close agreement between the MA and LC-MS/MS results for serum folate supported conversion to the LC-MS/MS procedure. However, for RBC folate, the MA gave 25% higher concentrations than did the LC-MS/MS procedure. The roundtable agreed that the use of the LC-MS/MS procedure to measure RBC folate is premature at this time. The roundtable reviewed the reference materials available or under development at the National Institute of Standards and Technology and recognized the challenges related to, and the scientific need for, these materials. They noted the need for a commutability study for the available reference materials for serum 5MTHF and FA. Am J Clin Nutr 2011;94(suppl):303S-12S. C1 [Yetley, Elizabeth A.; Bailey, Regan L.; Sempos, Christopher; Coates, Paul M.; Picciano, Mary Frances] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. [Brody, Lawrence C.] NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA. [Mills, James L.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA. [Pfeiffer, Christine M.; Fazili, Zia] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Phinney, Karen W.] NIST, Div Analyt Chem, Gaithersburg, MD 20899 USA. [Lacher, David A.; Curtin, L. Randy; Johnson, Clifford L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Blackmore, Sheena] United Kingdom Natl External Qual Assessment Serv, Dept Haematol, Sutton, Coldfield, England. [Bock, Jay L.] SUNY Stony Brook, Dept Pathol, Med Ctr, Stony Brook, NY 11794 USA. [Carmel, Ralph] New York Methodist Hosp, Dept Med, Brooklyn, NY USA. [Carmel, Ralph] Cornell Univ, Weill Med Coll, New York, NY 10021 USA. [Durazo-Arvizu, Ramon A.] Loyola Univ Chicago, Stritch Sch Med, Dept Epidemiol & Prevent Med, Maywood, IL USA. [Eckfeldt, John H.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA. [Green, Ralph] Univ Calif Davis, Dept Med Pathol & Lab Med & Med, Sacramento, CA 95817 USA. [Gregory, Jesse F., III] Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL 32611 USA. [Hoofnagle, Andrew N.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Hoofnagle, Andrew N.] Univ Washington, Dept Med, Seattle, WA USA. [Jacobsen, Donald W.] Case Western Reserve Univ, Lerner Coll Med, Dept Mol Med, Cleveland Clin, Cleveland, OH 44106 USA. [Jacobsen, Donald W.] Cleveland Clin, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44106 USA. [Jacques, Paul F.; Selhub, Jacob] Tufts Univ, Jean Mayer US Dept Agr, Human Nutr Res Ctr Aging, Boston, MA 02111 USA. [Molloy, Anne M.] Trinity Coll Dublin, Sch Med, Dept Clin Med, Dublin, Ireland. [Massaro, Joseph] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Nexo, Ebba] Aarhus Univ Hosp, Dept Clin Biochem, DK-8000 Aarhus, Denmark. [Rader, Jeanne I.] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA. [Shane, Barry] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA. [Stabler, Sally] Univ Colorado, Hlth Sci Ctr, Div Hematol, Dept Med, Aurora, CO USA. [Stover, Patrick] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA. [Tamura, Tsunenobu] Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. [Tedstone, Alison] Dept Hlth, London SE1 6TE, England. RP Coates, PM (reprint author), NIH, Off Dietary Supplements, 6100 Execut Blvd,Room 3B01,MSC 7517, Bethesda, MD 20892 USA. EM beth@yetley.com; coatesp@od.nih.gov RI Thorpe, Susan/E-1808-2013; OI Molloy, Anne/0000-0002-1688-9049 FU National Center for Health Statistics, Centers for Disease Control and Prevention; Office of Dietary Supplements, NIH FX Supported by the National Center for Health Statistics, Centers for Disease Control and Prevention, and the Office of Dietary Supplements, NIH. NR 52 TC 39 Z9 40 U1 0 U2 11 PU AMER SOC CLINICAL NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD JUL PY 2011 VL 94 IS 1 BP 303S EP 312S DI 10.3945/ajcn.111.013011 PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 779QK UT WOS:000291794800045 PM 21593502 ER PT J AU Yetley, EA Pfeiffer, CM Phinney, KW Bailey, RL Blackmore, S Bock, JL Brody, LC Carmel, R Curtin, LR Durazo-Arvizu, R Eckfeldt, JH Green, R Gregory, JF Hoofnagle, AN Jacobsen, DW Jacques, PF Lacher, DA Molloy, AM Massaro, J Mills, JL Nexo, E Rader, JI Selhub, J Sempos, C Shane, B Stabler, S Stover, P Tamura, T Tedstone, A Thorpe, SJ Coates, PM Johnson, CL Picciano, MF AF Yetley, Elizabeth A. Pfeiffer, Christine M. Phinney, Karen W. Bailey, Regan L. Blackmore, Sheena Bock, Jay L. Brody, Lawrence C. Carmel, Ralph Curtin, L. Randy Durazo-Arvizu, Ramon Eckfeldt, John H. Green, Ralph Gregory, Jesse F., III Hoofnagle, Andrew N. Jacobsen, Donald W. Jacques, Paul F. Lacher, David A. Molloy, Anne M. Massaro, Joseph Mills, James L. Nexo, Ebba Rader, Jeanne I. Selhub, Jacob Sempos, Christopher Shane, Barry Stabler, Sally Stover, Patrick Tamura, Tsunenobu Tedstone, Alison Thorpe, Susan J. Coates, Paul M. Johnson, Clifford L. Picciano, Mary Frances TI Biomarkers of vitamin B-12 status in NHANES: a roundtable summary SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID PLASMA METHYLMALONIC ACID; TANDEM MASS-SPECTROMETRY; 3RD NATIONAL-HEALTH; TOTAL HOMOCYSTEINE; LIQUID-CHROMATOGRAPHY; COGNITIVE IMPAIRMENT; BIOCHEMICAL INDICATORS; SRM-1955 HOMOCYSTEINE; AUTOMATED-ASSAY; OLDER-ADULTS AB A roundtable to discuss the measurement of vitamin B-12 (cobalamin) status biomarkers in NHANES took place in July 2010. NHANES stopped measuring vitamin B-12-related biomarkers after 2006. The roundtable reviewed 3 biomarkers of vitamin B-12 status used in past NHANES-serum vitamin B-12, methylmalonic acid (MMA), and total homocysteine (tHcy)-and discussed the potential utility of measuring holotranscobalamin (holoTC) for future NHANES. The roundtable focused on public health considerations and the quality of the measurement procedures and reference methods and materials that past NHANES used or that are available for future NHANES. Roundtable members supported reinstating vitamin B-12 status measures in NHANES. They noted evolving concerns and uncertainties regarding whether subclinical (mild, asymptomatic) vitamin B-12 deficiency is a public health concern. They identified the need for evidence from clinical trials to address causal relations between subclinical vitamin B-12 deficiency and adverse health outcomes as well as appropriate cutoffs for interpreting vitamin B-12-related biomarkers. They agreed that problems with sensitivity and specificity of individual biomarkers underscore the need for including at least one biomarker of circulating vitamin B-12 (serum vitamin B-12 or holoTC) and one functional biomarker (MMA or tHcy) in NHANES. The inclusion of both serum vitamin B-12 and plasma MMA, which have been associated with cognitive dysfunction and anemia in NHANES and in other population-based studies, was preferable to provide continuity with past NHANES. Reliable measurement procedures are available, and National Institute of Standards and Technology reference materials are available or in development for serum vitamin B-12 and MMA. Am J Clin Nutr 2011;94(suppl):313S-21S. C1 [Yetley, Elizabeth A.; Bailey, Regan L.; Sempos, Christopher; Coates, Paul M.; Picciano, Mary Frances] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. [Pfeiffer, Christine M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Phinney, Karen W.] NIST, Div Analyt Chem, Gaithersburg, MD 20899 USA. [Blackmore, Sheena] United Kingdom Natl External Qual Assessment Serv, Dept Haematol, Sutton, Coldfield, England. [Bock, Jay L.] SUNY Stony Brook, Dept Pathol, Med Ctr, Stony Brook, NY 11794 USA. [Brody, Lawrence C.] NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA. [Carmel, Ralph] New York Methodist Hosp, Dept Med, Brooklyn, NY USA. [Carmel, Ralph] Cornell Univ, Weill Med Coll, New York, NY 10021 USA. [Curtin, L. Randy; Lacher, David A.; Johnson, Clifford L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Durazo-Arvizu, Ramon] Loyola Univ Chicago, Stritch Sch Med, Dept Epidemiol & Prevent Med, Maywood, IL USA. [Eckfeldt, John H.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA. [Green, Ralph] Univ Calif Davis, Dept Med Pathol & Lab Med & Med, Sacramento, CA 95817 USA. [Gregory, Jesse F., III] Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL 32611 USA. [Hoofnagle, Andrew N.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Jacobsen, Donald W.] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Dept Mol Med, Cleveland, OH 44106 USA. [Jacobsen, Donald W.] Cleveland Clin, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44106 USA. [Jacques, Paul F.; Selhub, Jacob] Tufts Univ, Jean Mayer US Dept Agr, Human Nutr Res Ctr Aging, Boston, MA 02111 USA. [Molloy, Anne M.] Trinity Coll Dublin, Dept Clin Med, Sch Med, Dublin, Ireland. [Massaro, Joseph] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Mills, James L.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA. [Nexo, Ebba] Aarhus Univ Hosp, Dept Clin Biochem, DK-8000 Aarhus, Denmark. [Rader, Jeanne I.] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA. [Shane, Barry] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA. [Stabler, Sally] Univ Colorado, Hlth Sci Ctr, Div Hematol, Dept Med, Aurora, CO USA. [Stover, Patrick] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA. [Tamura, Tsunenobu] Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. [Tedstone, Alison] Dept Hlth, London SE1 6TE, England. [Thorpe, Susan J.] Natl Inst Biol Stand & Controls, Potters Bar, Herts, England. RP Coates, PM (reprint author), NIH, Off Dietary Supplements, 6100 Execut Blvd,Room 3B01,MSC 7517, Bethesda, MD 20892 USA. EM beth@yetley.com; coatesp@od.nih.gov RI Thorpe, Susan/E-1808-2013; OI Molloy, Anne/0000-0002-1688-9049; Gregory, Jesse/0000-0002-9976-2085 FU National Center for Health Statistics, Centers for Disease Control and Prevention; Office of Dietary Supplements, National Institutes of Health; Axis Shield Diagnostics FX Supported by the National Center for Health Statistics, Centers for Disease Control and Prevention, and MFP, CLJ, EAY, and PMC: conceived and sponsored the roundtable project; MFP, CLJ, EAY, PMC, RLB, DAL, AMM, JLM, CMP, KWP, CS, BS, and TT: served on the planning committee; EAY, CLJ, JHE, JM, RAD- A, CS, BS, CMP, KWP, JS, RC, EN, RLB, and DAL: presented data and backgroundinformation; EAY: drafted the manuscript with considerable input from CMP and KWP; EAY, CLJ, and PMC: had primary responsibility for the final manuscript content; and all authors: fully participated in the roundtable discussions and read and approved the final manuscript. RG and DWJ serve on the Scientific Advisory Boards of Emisphere Technologies Inc of Cedar Knolls, NJ, and PARPharmaceuticals of Woodcliff Lake, NJ. DWJ also serves on the Scientific Advisory Board of Diazyme-GA, La Jolla, CA. For the past 3 y, AMM carried out a research project that was funded by Axis Shield Diagnostics and also carried a consulting agreement with this firm. RC's hospital filed a patent application for his work on the genetics of transcobalamin I deficiency. None of the other authors had any personal or financial conflicts of interest.Office of Dietary Supplements, National Institutes of Health. NR 58 TC 60 Z9 60 U1 0 U2 14 PU AMER SOC CLINICAL NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD JUL PY 2011 VL 94 IS 1 BP 313S EP 321S DI 10.3945/ajcn.111.013243 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 779QK UT WOS:000291794800046 PM 21593512 ER PT J AU Yetley, EA Johnson, CL AF Yetley, Elizabeth A. Johnson, Clifford L. TI Folate and vitamin B-12 biomarkers in NHANES: history of their measurement and use SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; FOLIC-ACID FORTIFICATION; TOTAL HOMOCYSTEINE CONCENTRATIONS; SERUM 25-HYDROXYVITAMIN D; UNITED-STATES; BIOCHEMICAL INDICATORS; CARDIOVASCULAR-DISEASE; COGNITIVE IMPAIRMENT; TOTAL HOMOCYST(E)INE AB NHANES measured folate and vitamin B-12 status biomarkers, starting with serum folate from NHANES I (1974-1975) through 2010. Subsequent NHANES measured additional biomarkers [eg, red blood cell folate, serum vitamin B-12, total homocysteine (tHcy), methylmalonic acid, serum folic acid, and 5-methyltetrahydrofolic acid]. Examples of the uses of these data are wide ranging and include public policy applications, the derivation of reference intervals, and research. Periodically, the National Center for Health Statistics and its federal partners convene expert panels to review the use of the folate-and vitamin B-12-related biomarkers in NHANES. These panels have evaluated the need for results to be comparable across time and with published data and the use of crossover studies and adjustment equations to ensure comparability. With the recent availability of reference methods and materials for serum folate and tHcy, NHANES has started to use traceability approaches to enhance the accuracy and comparability of its results. A major user concern over the years has been the use of cutoffs to estimate the prevalence of inadequate folate and vitamin B-12 status. Because these cutoffs depend on the measurement procedure, several expert panels suggested approaches for dealing with cutoff challenges. This review summarizes the history and use of folate and vitamin B-12-related biomarkers beginning with NHANES I (1974-1975) through 2010. Am J Clin Nutr 2011;94(suppl):1S-10S. C1 [Yetley, Elizabeth A.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. [Johnson, Clifford L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. EM beth@yetley.com FU Office of Dietary Supplements, National Institutes of Health; National Center for Health Statistics, Centers for Disease Control and Prevention FX Supported by the Office of Dietary Supplements, National Institutes of Health, and the National Center for Health Statistics, Centers for Disease Control and Prevention. NR 68 TC 15 Z9 15 U1 0 U2 7 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD JUL PY 2011 VL 94 IS 1 DI 10.3945/ajcn.111.013300 PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 779QK UT WOS:000291794800047 PM 21593508 ER PT J AU Whitmore, SK Zhang, XJ Taylor, AW Blair, JM AF Whitmore, Suzanne K. Zhang, Xinjian Taylor, Allan W. Blair, Janet M. TI Estimated Number of Infants Born to HIV-Infected Women in the United States and Five Dependent Areas, 2006 SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV-exposed births in the United States; perinatal HIV; prevalence HIV-infected women ID HUMAN-IMMUNODEFICIENCY-VIRUS; PERINATAL HIV; ANTIRETROVIRAL THERAPY; HIV-1-INFECTED WOMEN; CHILDREN BORN; PREGNANCY; TRENDS; TRANSMISSION; PREVALENCE; SURVEILLANCE AB Objective: Although perinatal HIV infections are declining in the United States, there is no single source of nationally representative data available to estimate the number of infants born to HIV-infected women in the United States and its dependencies. This study determines the total number of births to HIV-positive women in the United States and 5 dependent areas in 2006. Study Design: Diagnosed stage 1 or 2 HIV disease in the United States were based on reported data from 39 areas that conducted confidential name-based HIV case reporting and stage 3 HIV from all areas in the United States. A zero-inflated Poisson model was used to estimate the number of women aged 13-44 years living with diagnosed stage 1 or 2 HIV disease in the United States. The number of undiagnosed HIV-infected women (stage 1 or 2) of childbearing age was estimated from the number of reported Stage 3 HIV (ie, AIDS) cases using a back-calculation method. Results: An estimated 115,200 women aged 13-44 years were living with stage 1 or 2 HIV disease in 2006. A total of 56,200 women were living with diagnosed stage 3 disease. The estimated number of births to all women living with HIV disease (diagnosed or undiagnosed) was 8700 [95% Confidence Interval (CI): 8400 to 8800] in 2006. Conclusions: The number of infants born to HIV-infected women in 2006 was approximately 30% greater than the number of such births (6075-6422) in 2000. This increase highlights the need to continue and strengthen efforts to prevent perinatal HIV transmission in the United States. C1 [Whitmore, Suzanne K.; Zhang, Xinjian; Taylor, Allan W.; Blair, Janet M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Whitmore, SK (reprint author), 1600 Clifton Rd NE,MS E-47, Atlanta, GA 30333 USA. EM swhitmore@cdc.gov NR 44 TC 33 Z9 33 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JUL 1 PY 2011 VL 57 IS 3 BP 218 EP 222 DI 10.1097/QAI.0b013e3182167dec PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 778CM UT WOS:000291676800016 PM 21372725 ER PT J AU Huber, DR Blount, BC Mage, DT Letkiewicz, FJ Kumar, A Allen, RH AF Huber, David R. Blount, Benjamin C. Mage, David T. Letkiewicz, Frank J. Kumar, Amit Allen, Ruth H. TI Estimating perchlorate exposure from food and tap water based on US biomonitoring and occurrence data SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY LA English DT Article DE perchlorate; drinking water; food; occurrence; NHANES; biomonitoring; UCMR ID NUTRITION EXAMINATION SURVEY; LOW-DOSE PERCHLORATE; UNITED-STATES; THYROID-FUNCTION; NATIONAL-HEALTH; AMMONIUM-PERCHLORATE; URINARY PESTICIDE; IODIDE UPTAKE; BREAST-MILK; CREATININE AB Human biomonitoring data show that exposure to perchlorate is widespread in the United States. The predominant source of intake is food, whereas drinking water is a less frequent and far smaller contributor. We used spot urine samples for over 2700 subjects and estimated 24 h intake using new creatinine adjustment equations. Merging data from surveys of national health (NHANES) with drinking water monitoring (UCMR), we categorized survey participants according to their potential exposure through drinking water or food. By subtracting daily food doses of perchlorate from the oral reference dose (RfD), we derive an allowances for perchlorate in tap water for several populations. The calculated mean food perchlorate dose in the United States was 0.081 mu g/kg/day compared to 0.101 mu g/kg/day for those who also had a potential drinking water component. The calculated 95th percentile doses, typically falling between 0.2 and 0.4 mu g/kg/day, were well below the RfD (0.7 mu g/kg/day) in all populations analyzed. Children aged 6-11 years had the highest mean perchlorate doses in food (0.147 mu g/kg/day), with an additional water contribution of only 0.003 mu g/kg/day representing just 2% of exposure. Pregnant women had a mean food dose of 0.093 vs 0.071 mu g/kg/day for all women of reproductive age. At the 95th percentile intake for both the total population and women of child-bearing age (15-44), the perchlorate contribution from food was 86% and from drinking water 14% (respectively, 30% and 5% of the RfD). At the mean for the same groups, the food to water contribution ratio is approximately 80: 20. We calculate that an average 66 kg pregnant woman consuming a 90th percentile food dose (0.198 mu g/kg/day) could also drink the 90th percentile of community water for pregnant women (0.033 l/kg/day) containing 15 mu g/l perchlorate without exceeding the 0.7 mu g/kg/day reference dose. Journal of Exposure Science and Environmental Epidemiology (2011) 21, 395-407; doi: 10.1038/jes.2010.31; published online 23 June 2010 C1 [Huber, David R.] US EPA, Off Ground Water & Drinking Water, Stand & Risk Management Div, Washington, DC 20460 USA. [Blount, Benjamin C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mage, David T.] Danya Int, Silver Spring, MD USA. [Letkiewicz, Frank J.; Kumar, Amit] Cadmus Grp, Arlington, VA USA. [Allen, Ruth H.] US EPA, Off Chem Safety & Pollut Prevent, Washington, DC 20460 USA. RP Huber, DR (reprint author), US EPA, Off Ground Water & Drinking Water, Stand & Risk Management Div, 4607M,1200 Penn Ave, Washington, DC 20460 USA. EM huber.david@epa.gov OI Mage, David/0000-0002-3880-566X NR 46 TC 24 Z9 26 U1 2 U2 28 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD JUL-AUG PY 2011 VL 21 IS 4 BP 395 EP 407 DI 10.1038/jes.2010.31 PG 13 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 780LT UT WOS:000291858700007 PM 20571527 ER PT J AU Zhou, H Fernhoff, P Vogt, RF AF Zhou, Hui Fernhoff, Paul Vogt, Robert F. TI Newborn Bloodspot Screening for Lysosomal Storage Disorders SO JOURNAL OF PEDIATRICS LA English DT Article ID TANDEM MASS-SPECTROMETRY; X-LINKED ADRENOLEUKODYSTROPHY; CELL GENE-THERAPY; YORK-STATE MODEL; KRABBE-DISEASE; FILTER-PAPER; ENZYMATIC DIAGNOSIS; POMPE-DISEASE; MUCOPOLYSACCHARIDOSIS-I; FABRY-DISEASE C1 [Zhou, Hui] Natl Fdn Ctr Dis Control & Prevent Inc, Newborn Screening Translat Res Initiat, Atlanta, GA USA. [Fernhoff, Paul] Emory Univ, Div Med Genet, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA. [Vogt, Robert F.] Ctr Dis Control & Prevent, Div Sci Lab, Newborn Screening & Mol Biol Branch, Atlanta, GA 30341 USA. RP Vogt, RF (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Newborn Screening & Mol Biol Branch, Mailstop F19,4770 Buford Hwy, Atlanta, GA 30341 USA. EM rvogt@cdc.gov FU Centers for Disease Control Foundation FX Supported by the Centers for Disease Control Foundation through an agreement with Genzyme Corporation (H.Z.) and educational and research activities from Genzyme Corporation (P. F.). R. V. serves as Principal Investigator of the Newborn Screening Translation Research Initiative (NSTRI), a collaboration between the CDC Foundation and the Newborn Screening and Molecular Biology Branch, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention. NR 68 TC 11 Z9 11 U1 0 U2 7 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 J9 J PEDIATR-US JI J. Pediatr. PD JUL PY 2011 VL 159 IS 1 BP 7 EP U205 DI 10.1016/j.jpeds.2011.02.026 PG 8 WC Pediatrics SC Pediatrics GA 776LL UT WOS:000291536200004 PM 21492868 ER PT J AU Miller, A Riehle-Colarusso, T Alverson, CJ Frias, JL Correa, A AF Miller, Assia Riehle-Colarusso, Tiffany Alverson, C. J. Frias, Jaime L. Correa, Adolfo TI Congenital Heart Defects and Major Structural Noncardiac Anomalies, Atlanta, Georgia, 1968 to 2005 SO JOURNAL OF PEDIATRICS LA English DT Article ID CARDIOVASCULAR MALFORMATIONS; EXTRACARDIAC MALFORMATIONS; METROPOLITAN ATLANTA; DISEASE; POPULATION; PREVALENCE; ABNORMALITIES; SURVEILLANCE; ASSOCIATION; SPECTRUM AB Objective To identify the proportion of major structural noncardiac anomalies identified with congenital heart defects (CHDs). Study design Records of infants with CHDs in the Metropolitan Atlanta Congenital Defects Program who were born during the period 1968 through 2005 were classified as having isolated, syndromic, multiple CHD (ie, having an unrecognized pattern of multiple congenital anomalies or a recognized pattern of multiple congenital anomalies of unknown etiology), or laterality defects. Frequencies of associated noncardiac anomalies were obtained. Results We identified 7984 live-born and stillborn infants and fetuses with CHDs. Among them, 5695 (71.3%) had isolated, 1080 (13.5%) had multiple, 1048 (13.1%) had syndromic, and 161 (2.0%) had laterality defects. The percentage of multiple congenital anomalies was highest for case with atrial septal defects (18.5%), cardiac looping defects (17.2%), and conotruncal defects (16.0%), and cases with atrioventricular septal defects represented the highest percentages of those with syndromic CHDs (66.7%). Conclusions Including those with syndromes and laterality defects, 28.7% of case infants with CHDs had associated major noncardiac malformations. Thus, infants with CHDs warrant careful examination for the presence of noncardiac anomalies. (J Pediatr 2011;159:70-8). C1 [Miller, Assia; Riehle-Colarusso, Tiffany; Alverson, C. J.; Frias, Jaime L.; Correa, Adolfo] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Frias, Jaime L.] McKing Consulting Corp, Fairfax, VA USA. [Miller, Assia] Res Triangle Inst Int, Atlanta, GA USA. RP Correa, A (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, Mailstop E-86,1600 Clifton Rd, Atlanta, GA 30333 USA. EM acorrea@cdc.gov NR 34 TC 23 Z9 26 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 J9 J PEDIATR-US JI J. Pediatr. PD JUL PY 2011 VL 159 IS 1 BP 70 EP U98 DI 10.1016/j.jpeds.2010.12.051 PG 11 WC Pediatrics SC Pediatrics GA 776LL UT WOS:000291536200017 PM 21329942 ER PT J AU Arias, R Andrews, J Pandya, S Pettit, K Trout, C Apkon, S Karwoski, J Cunniff, C Matthews, D Miller, T Davis, MF Meaney, FJ AF Arias, Rebeca Andrews, Jennifer Pandya, Shree Pettit, Kathleen Trout, Christina Apkon, Susan Karwoski, Jane Cunniff, Christopher Matthews, Dennis Miller, Timothy Davis, Melinda F. Meaney, F. John TI PALLIATIVE CARE SERVICES IN FAMILIES OF MALES WITH DUCHENNE MUSCULAR DYSTROPHY SO MUSCLE & NERVE LA English DT Article DE advance directives; Duchenne muscular dystrophy; health services model; healthcare barriers; palliative care ID ACCULTURATION; PERCEPTIONS; SURVIVAL; DISEASE AB Introduction: Palliative care services that address physical pain and emotional, psychosocial, and spiritual needs may benefit individuals with Duchenne muscular dystrophy (DMD). Methods: The objective of this study was to describe the palliative care services that families of males with DMD report they receive. A questionnaire was administered to families of males with DMD born prior to January 1, 1982. Thirty-four families responded. Results: Most families (85%) had never heard the term palliative care. Only attendant care and skilled nursing services showed much usage, with 44% and 50% indicating receipt of these services, respectively. Receipt of other services was reported less frequently: pastoral care (27%); respite care (18%); pain management (12%); and hospice care (6%). Only 8 respondents (25%) reported having any type of directive document in place. Conclusion: The data suggest a need for improved awareness of palliative care and related services among families of young men with DMD. Muscle Nerve 44: 93-101, 2011 C1 [Arias, Rebeca; Andrews, Jennifer; Pettit, Kathleen; Cunniff, Christopher; Miller, Timothy; Meaney, F. John] Univ Arizona, Dept Pediat, Tucson, AZ 85724 USA. [Arias, Rebeca; Andrews, Jennifer; Pettit, Kathleen; Cunniff, Christopher; Miller, Timothy; Meaney, F. John] Univ Arizona, Steele Res Ctr, Tucson, AZ 85724 USA. [Pandya, Shree] Univ Rochester, Dept Neurol, Rochester, NY USA. [Trout, Christina] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA. [Apkon, Susan] Seattle Childrens Hosp, Seattle, WA USA. [Karwoski, Jane] Oak Ridge Inst Sci & Educ, Atlanta, GA USA. [Karwoski, Jane] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Matthews, Dennis] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO USA. [Matthews, Dennis] Childrens Hosp, Denver, CO 80218 USA. [Davis, Melinda F.] Univ Arizona, Dept Psychol, Tucson, AZ 85721 USA. RP Meaney, FJ (reprint author), Univ Arizona, Dept Pediat, 1501 N Campbell Ave,POB 245073, Tucson, AZ 85724 USA. EM fmeaney@email.arizona.edu FU Association of University Centers on Disabilities [AUCD RTOI 2004-03-03]; Centers for Disease Control and Prevention [AUCD RTOI 2004-03-03] FX The authors thank the individuals with DMD and their families who participated in the survey. We thank Shawnell Damon for her assistance in conducting the interviews. Finally, we thank Rachele Peterson and Cecilia Lopez for their expert technical assistance in the preparation and submission of the manuscript. This work was done by the authors on behalf of the Association of University Centers on Disabilities through a cooperative agreement with the Centers for Disease Control and Prevention (Contract No. AUCD RTOI 2004-03-03). NR 22 TC 11 Z9 11 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0148-639X J9 MUSCLE NERVE JI Muscle Nerve PD JUL PY 2011 VL 44 IS 1 BP 93 EP 101 DI 10.1002/mus.22005 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 778HH UT WOS:000291694000016 PM 21674523 ER PT J AU Carver, S Kuenzi, A Bagamian, KH Mills, JN Rollin, PE Zanto, SN Douglass, R AF Carver, Scott Kuenzi, Amy Bagamian, Karoun H. Mills, James N. Rollin, Pierre E. Zanto, Susanne N. Douglass, Richard TI A temporal dilution effect: hantavirus infection in deer mice and the intermittent presence of voles in Montana SO OECOLOGIA LA English DT Article DE Sin Nombre virus; Dilution effect; Transmission; Temporal; Density independence ID SIN-NOMBRE-VIRUS; SOUTHWESTERN UNITED-STATES; SMALL MAMMALS; LYME-DISEASE; POPULATION-DYNAMICS; SPECIES-DIVERSITY; PULMONARY SYNDROME; MALLEE WHEATLANDS; HOST DYNAMICS; LONG-TERM AB The effect of intermittently occurring, non-reservoir host species on pathogen transmission and prevalence in a reservoir population is poorly understood. We investigated whether voles, Microtus spp., which occur intermittently, influenced estimated standing antibody prevalence (ESAP) to Sin Nombre hantavirus (SNV, Bunyaviridae: Hantavirus) among deer mice, Peromyscus maniculatus, whose populations are persistent. We used 14 years of data from central Montana to investigate whether ESAP among deer mice was related to vole presence or abundance while controlling for the relationship between deer mouse abundance and ESAP. We found a reduction in deer mouse ESAP associated with the presence of voles, independent of vole abundance. A number of studies have documented that geographic locations which support a higher host diversity can be associated with reductions in pathogen prevalence by a hypothesized dilution effect. We suggest a dilution effect may also occur in a temporal dimension at sites where host richness fluctuates. Preservation of host diversity and optimization of environmental conditions which promote occurrence of ephemeral species, such as voles, may result in a decreased ESAP to hantaviruses among reservoir hosts. Our results may extend to other zoonotic infectious diseases. C1 [Carver, Scott; Kuenzi, Amy; Douglass, Richard] Montana Tech Univ Montana, Dept Biol, Butte, MT 59701 USA. [Carver, Scott] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. [Bagamian, Karoun H.] Emory Univ, Populat Biol Ecol & Evolut Program, Atlanta, GA 30322 USA. [Mills, James N.; Rollin, Pierre E.] Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Special Pathogens Branch, Atlanta, GA 30333 USA. [Zanto, Susanne N.] Montana Dept Publ Hlth & Human Serv, Publ Hlth Lab, Helena, MT 59604 USA. RP Carver, S (reprint author), Montana Tech Univ Montana, Dept Biol, 1300 Pk St, Butte, MT 59701 USA. EM scott.carver@colostate.edu RI Carver, Scott/J-7654-2014 OI Carver, Scott/0000-0002-3579-7588 FU National Center for Research Resources [P20 RR16455-06-07, 08]; U.S. Centers for Disease Control and Prevention, Atlanta, GA FX We thank the private ranch owner at Cascade for allowing us access to his property. Numerous individuals provided valuable assistance in the field including K. Coffin, R. Van Horn, C. Rognli, T. Wilson, W. Semmens, K. Hughes, A. Skypala, D. Waltee, B. Lonner, J. Wilson, A. Leary, A. Alvarado, J. Bertoglio and F. Arneson. K. Wagoner provided database support, encouragement and general advice. R. Ostfeld and two anonymous reviewers provided constructive feedback, which greatly improved this paper. Financial support was provided by NIH grant P20 RR16455-06-07,08 from the INBRE-BRIN program of the National Center for Research Resources and the U.S. Centers for Disease Control and Prevention, Atlanta, GA, through cooperative agreement. The authors declare that the study described herein complies with the laws of the United States of America. The findings and conclusions presented here are those of the author(s) and do not necessarily represent the views of the funding agencies. NR 59 TC 11 Z9 11 U1 1 U2 28 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0029-8549 J9 OECOLOGIA JI Oecologia PD JUL PY 2011 VL 166 IS 3 BP 713 EP 721 DI 10.1007/s00442-010-1882-z PG 9 WC Ecology SC Environmental Sciences & Ecology GA 777HI UT WOS:000291606100014 PM 21170746 ER PT J AU Din, ES Wasley, A Jacques-Carroll, L Sirotkin, B Wang, S AF Din, Erica S. Wasley, Annemarie Jacques-Carroll, Lisa Sirotkin, Barry Wang, Susan TI Estimating the Number of Births to Hepatitis B Virus-infected Women in 22 States, 2006 SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE perinatal hepatitis B; hepatitis B virus; number of births; select United States; hepatitis B vaccine ID CARRIER STATE; PERINATAL TRANSMISSION; UNITED-STATES; PREVALENCE; CALIFORNIA; TAIWAN; AGE AB Background: Estimating the annual number of births to hepatitis B virus (HBV)-infected women is essential for monitoring efforts to prevent perinatal HBV transmission. We describe a method for estimating births to HBV-infected women in 22 states during 2006. Methods: The number of births to HBV-infected women was calculated by (1) multiplying the number of US/Canadian-born mothers stratified by US race/ethnicity-specific HBV prevalence estimates, and (2) adding the number of foreign-born mothers stratified by their region of birth and multiplied by region-specific HBV prevalence estimates. Results: Of 2,359,912 births, an estimated 16,608 (0.7%) were to HBV-infected women. Foreign-born women, who represented 25.3% of all mothers, accounted for 80.6% of estimated HBV-infected mothers. Estimated foreign-born HBV-infected mothers were from Southeast Asia (31.2%), East Asia (21.2%), and Africa (13.8%). Non-Hispanic blacks represented 55.1% of US/Canadian-born HBV-infected mothers. Compared with a previous estimate, which considers foreign-born status only for Asian/Pacific Islander mothers, this method estimated an additional 3000 births to HBV-infected women. Conclusions: Incorporating maternal country of birth and region-specific HBV infection prevalence likely enhances estimation of births to HBV-infected women in the United States. According to our estimate, approximately 10,000 births to HBV-infected women were not identified by state and local health departments in 22 states. C1 [Din, Erica S.; Wasley, Annemarie; Wang, Susan] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Jacques-Carroll, Lisa; Sirotkin, Barry] Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA 30333 USA. RP Din, ES (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd NE,MS G-32, Atlanta, GA 30333 USA. EM edin@emory.edu FU Centers for Disease Control and Prevention FX Supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the CDC. NR 26 TC 7 Z9 8 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD JUL PY 2011 VL 30 IS 7 BP 575 EP 579 DI 10.1097/INF.0b013e31820cd65c PG 5 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 778BV UT WOS:000291675100011 PM 21266937 ER PT J AU Tai, E Richardson, LC Townsend, J Howard, E Mcdonald, LC AF Tai, Eric Richardson, Lisa C. Townsend, Julie Howard, Elizabeth Mcdonald, L. Clifford TI CLOSTRIDIUM DIFFICILE INFECTION AMONG CHILDREN WITH CANCER SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE Clostridium difficile; children; cancer; epidemiology ID DISEASE; SURVEILLANCE; EPIDEMIOLOGY AB We used data from the Kids' Inpatient Database to examine Clostridium difficile infection (CDI) among children with cancer. The CDI rate was 15 times greater among children with cancer compared with those without cancer. Children with cancer accounted for 21% of all pediatric CDI cases. Increased adherence to infection control recommendations is needed to address CDI in children with cancer. C1 [Tai, Eric; Richardson, Lisa C.; Townsend, Julie; Mcdonald, L. Clifford] Ctr Dis Control & Prevent, Atlanta, GA USA. [Howard, Elizabeth] Univ Texas SW Austin, Dept Pediat, Austin, TX USA. RP Tai, E (reprint author), 4770 Buford Hwy NE,MS-K57, Atlanta, GA 30341 USA. EM Cvn5@cdc.gov FU Centers for Disease Control and Prevention FX Supported by the Centers for Disease Control and Prevention. NR 10 TC 26 Z9 27 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD JUL PY 2011 VL 30 IS 7 BP 610 EP 612 DI 10.1097/INF.0b013e31820970d1 PG 3 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 778BV UT WOS:000291675100021 PM 21206395 ER PT J AU Top, KA Esquilin, JM Yen, C Esona, MD Gentsch, JR Bhatia, M LaRussa, P AF Top, Karina A. Esquilin, Jose M. Yen, Catherine Esona, Mathew D. Gentsch, Jon R. Bhatia, Monica LaRussa, Philip TI Detection of Mutations in Antigenic Regions of Rotavirus Viral Proteins 4 and 7 in a Child With Chronic Shedding of Rotavirus Vaccine-type Strain SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Letter ID IDENTIFICATION C1 [Top, Karina A.; Esquilin, Jose M.; Bhatia, Monica; LaRussa, Philip] Columbia Univ, Dept Pediat, New York, NY 10027 USA. [Yen, Catherine; Esona, Mathew D.; Gentsch, Jon R.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. RP Top, KA (reprint author), Columbia Univ, Dept Pediat, New York, NY 10027 USA. EM plarussa@columbia.edu NR 5 TC 1 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD JUL PY 2011 VL 30 IS 7 BP 630 EP 630 DI 10.1097/INF.0b013e31821c38f2 PG 1 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 778BV UT WOS:000291675100030 PM 21673551 ER PT J AU Smith, PJ Wood, D Darden, PM AF Smith, Philip J. Wood, David Darden, Paul M. TI Highlights of Historical Events Leading to National Surveillance of Vaccination Coverage in the United States SO PUBLIC HEALTH REPORTS LA English DT Editorial Material ID IMMUNIZATION INFORMATION-SYSTEMS; AUGUST 2009-JANUARY 2010; AGED 19-35 MONTHS; A H1N1 2009; SEASONAL INFLUENZA; POLIOMYELITIS VACCINATION; ADVISORY-COMMITTEE; MEASLES OUTBREAK; CUTTER INCIDENT; POLIO VACCINE C1 [Smith, Philip J.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Wood, David] Univ Florida, Coll Med, Jacksonville, FL USA. [Darden, Paul M.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. RP Smith, PJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, MS E-62,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM pzs6@cdc.gov NR 155 TC 0 Z9 0 U1 0 U2 6 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JUL-AUG PY 2011 VL 126 SU 2 BP 3 EP 12 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 777ZT UT WOS:000291665800002 PM 21815302 ER PT J AU McElligott, JT Roberts, JR O'Brien, ES Freeland, KD Kolasa, MS Stevenson, J Darden, PM AF McElligott, James T. Roberts, James R. O'Brien, Etizabeth S. Freeland, Katherine D. Kolasa, Maureen S. Stevenson, John Darden, Paul M. TI Improving Immunization Rates at 18 Months of Age: Implications for Individual Practices SO PUBLIC HEALTH REPORTS LA English DT Article ID WELL-CHILD VISIT; AREA VACCINATION COVERAGE; UNITED-STATES AB Objective. We sought to model the effect that a targeted immunization visit at 18 months of age could have on immunization rates of preschool-aged children in a sample of pediatric practices. Methods. We conducted retrospective chart reviews in six practices of all active patients aged 18-30 months. Up-to-date (UTD) status was defined as receipt of four diphtheria-tetanus-acellular pertussis, three polio, one measles-mumps-rubella, three hepatitis B, and one varicella vaccines. Haemophilus influenza tybe b vaccine was not included due to a shortage in vaccine supply during the time of the study. Practice vaccination rates were determined at 17 months, 18 months, and the age at assessment. Of those not UTD at 17 months, the percentage of children who could be brought UTD with one visit was calculated for each practice. This calculated rate was compared with the measured rate at 18 months of age and at the age of assessment. Results. At each practice, we reviewed 183-616 charts (median = 382). Observed UTD immunization rates at 17 months ranged from 26% to 64% (median = 38%) and increased 3 to 27 percentage points (median = 6) from age 17 months to 18 months and 9 to 39 percentage points (median = 17) from age 17 months to the age at assessment. A simulated vaccination visit at 18 months of age could improve the UTD rates from 27 to 61 percentage points (median = 44). Conclusion. Practice-based interventions aimed at encouraging an 18-month well-child visit that emphasizes delivery of vaccines have the potential to substantially increase timely vaccination rates among individual practices. C1 [McElligott, James T.; Roberts, James R.; O'Brien, Etizabeth S.; Freeland, Katherine D.] Med Univ S Carolina, Charleston, SC 29425 USA. [Kolasa, Maureen S.; Stevenson, John] Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA USA. [Darden, Paul M.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. RP McElligott, JT (reprint author), Med Univ S Carolina, 135 Rutledge Ave, Charleston, SC 29425 USA. EM mcellig@musc.edu FU Centers for Disease Control and Prevention (CDC) [U011P0001146] FX This study was funded by Centers for Disease Control and Prevention (CDC) grant #U011P0001146. This study was originally presented in February 2009 at the South Eastern Regional Meeting of the Academic Pediatric Society in New Orleans, Louisiana. Paul Darden has acted as a consultant to Pfizer in 2010 and Sanofi Pasteur in 2009; he has no ongoing relationship with either company. NR 22 TC 3 Z9 3 U1 0 U2 1 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JUL-AUG PY 2011 VL 126 SU 2 BP 33 EP 38 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 777ZT UT WOS:000291665800005 PM 21812167 ER PT J AU Dorell, CG Jain, N Yankey, D AF Dorell, Christina G. Jain, Nidhi Yankey, David TI Validity of Parent-Reported Vaccination Status for Adolescents Aged 13-17 Years: National Immunization Survey-Teen, 2008 SO PUBLIC HEALTH REPORTS LA English DT Article ID ADVISORY-COMMITTEE; PRACTICES ACIP; HUMAN-PAPILLOMAVIRUS; STATISTICAL-METHODS; RECORD SCATTERING; COVERAGE RATES; UNITED-STATES; HPV VACCINE; RECOMMENDATIONS; CHILDREN AB Objective. The validity of parent-reported adolescent vaccination histories has not been assessed. This study evaluated the validity of parent-reported adolescent vaccination histories by a combination of immunization card and recall, and by recall only, compared with medical provider records. Methods. We analyzed data from the 2008 National Immunization Survey-Teen. Parents of adolescents aged 13-17 years reported their child's vaccination history either by immunization card and recall (n=3,661) or by recall only (n=12,822) for the hepatitis B (Hep B), measles-mumps-rubella (MMR), varicella (VAR), tetanus-diphtheria/tetanus-diphtheria-acellular pertussis (Td/Tdap), meningococcal conjugate (MCV4), and quadrivalent human papillomavirus (HPV4) (for girls only) vaccines. We validated parental report with medical records. Results. Among the immunization card/recall group, vaccines with >20% false-positive reports included MMR (32.3%) and Td/Tdap (36.9%); vaccines with >20% false-negative reports included VAR (35.2%), MCV4 (36.0%), and Tdap (41.9%). Net bias ranged from -25.0 to -0.1 percentage points. Kappa values ranged from 0.22 to 0.92. Among the recall-only group, vaccines with >20% false-positive reports included Hep B (33.9%), MMR (61.4%), VAR (26.2%), and Td/Tdap (60.6%); vaccines with >20% false-negative reports included Hep B (58.9%), MMR (33.7%), VAR (51.6%), Td/Tdap (25.5%), Tdap (50.3%) MCV4 (63.0%), and HPV4 (20.5%). Net bias ranged from -46.0 to 0.5 percentage points. Kappa values ranged from 0.03 to 0.76. Conclusions. Validity of parent-reported vaccination histories varies by type of report and vaccine. For recently recommended vaccines, false-negative rates were substantial and higher than false-positive rates, resulting in net under-reporting of vaccination rates by both the immunization card/recall and recall-only groups. Provider validation of parent-reported vaccinations is needed for valid surveillance of adolescent vaccination coverage. C1 [Dorell, Christina G.; Yankey, David] Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA 30333 USA. [Jain, Nidhi] US Hlth Resources & Serv Adm, Off Reg Operat, San Francisco, CA USA. RP Dorell, CG (reprint author), Ctr Dis Control & Prevent, Immunizat Serv Div, 1600 Clifton Rd NE,MS E-62, Atlanta, GA 30333 USA. EM cdorell@cdc.gov NR 36 TC 31 Z9 31 U1 1 U2 4 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JUL-AUG PY 2011 VL 126 SU 2 BP 60 EP 69 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 777ZT UT WOS:000291665800008 PM 21812170 ER PT J AU Smith, PJ Lindley, MC Rodewald, LE AF Smith, Philip J. Lindley, Megan C. Rodewald, Lance E. TI Vaccination Coverage Among U.S. Children Aged 19-35 Months Entitled by the Vaccines for Children Program, 2009 SO PUBLIC HEALTH REPORTS LA English DT Article ID UNITED-STATES; MEASLES; BIAS AB Objectives. Following the measles outbreaks of the late 1980s and early 1990s, vaccination coverage was found to be low nationally, and there were pockets of underimmunized children primarily in inner cities. We described the percentage and demographics of children who were entitled to the Vaccines for Children (VFC) program in 2009 and evaluated whether Healthy People 2010 (HP 2010) vaccination coverage objectives of 90% were achieved among these children. Methods. We analyzed data from 16,967 children aged 19-35 months sampled by the National Immunization Survey in 2009. VFC-entitled children included children who were (1) on Medicaid, (2) not covered by health insurance, (3) of American Indian/Alaska Native race/ethnicity, or (4) covered by private health insurance that did not pay all of the costs of vaccines, but who were vaccinated at a Federally Qualified Health Center or a Rural Health Center. Results. An estimated 49.7% of all children aged 19-35 months were entitled to VFC vaccines. Compared with children who did not qualify for VFC, the VFC-entitled children were significantly more likely to be Hispanic or non-Hispanic black; to have a mother who was widowed, divorced, separated, or never married; and to live in a household with an annual income below the federal poverty level. Mothers of VFC-entitled children were significantly less likely to have some college experience or to be college graduates. Of nine vaccines analyzed, two vaccines-polio at 91.7% and hepatitis B at 92.2%-achieved the HP 2010 90% coverage objective for VFC-entitled children, and four others, including measles-mumps-rubella at 88.8%, achieved greater than 80% coverage. Conclusions. Today, children with demographic characteristics like those of children who were at the epicenter of the measles outbreaks two decades ago are entitled to VFC vaccines at no cost, and have achieved high vaccination coverage levels. C1 [Smith, Philip J.; Lindley, Megan C.; Rodewald, Lance E.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Smith, PJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS E-62, Atlanta, GA 30333 USA. EM pzs6@cdc.gov NR 30 TC 12 Z9 12 U1 0 U2 3 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JUL-AUG PY 2011 VL 126 SU 2 BP 109 EP 123 PG 15 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 777ZT UT WOS:000291665800013 PM 21812175 ER PT J AU Smith, PJ Humiston, SC Marcuse, EK Zhao, Z Dorell, CG Howes, C Hibbs, B AF Smith, Philip J. Humiston, Sharon C. Marcuse, Edgar K. Zhao, Zhen Dorell, Christina G. Howes, Cynthia Hibbs, Beth TI Parental Delay or Refusal of Vaccine Doses, Childhood Vaccanation Coverage at 24 Months of Age, and the Health Belief Model SO PUBLIC HEALTH REPORTS LA English DT Article ID SAFETY CONCERNS; POLIOMYELITIS VACCINATION; POLIO VACCINE; UNITED-STATES; CHILDREN; IMMUNIZATION; ATTITUDES; MEASLES; ADULTS; PARTICIPATION AB Objective. We evaluated the association between parents' beliefs about vaccines, their decision to delay or refuse vaccines for their children, and vaccination coverage of children at aged 24 months. Methods. We used data from 11,206 parents of children aged 24-35 months at the time of the 2009 National Immunization Survey interview and determined their vaccination status at aged 24 months. Data included parents' reports of delay and/or refusal of vaccine doses, psychosocial factors suggested by the Health Belief Model, and provider-reported up-to-date vaccination status. Results. In 2009, approximately 60.2% of parents with children aged 24-35 months neither delayed nor refused vaccines, 25.8% only delayed, 8.2% only refused, and 5.8% both delayed and refused vaccines. Compared with parents who neither delayed nor refused vaccines, parents who delayed and refused vaccines were significantly less likely to believe that vaccines are necessary to protect the health of children (70.1% vs. 96.2%), that their child might get a disease if they aren't vaccinated (71.0% vs. 90.0%), and that vaccines are safe (50.4% vs. 84.9%). Children of parents who delayed and refused also had significantly lower vaccination coverage for nine of the 10 recommended childhood vaccines including diphtheria-tetanus-acellular pertussis (65.3% vs. 85.2%), polio (76.9% vs. 93.8%), and measles-mumps-rubella (68.4% vs. 92.5%). After adjusting for sociodemographic differences, we found that parents who were less likely to agree that vaccines are necessary to protect the health of children, to believe that their child might get a disease if they aren't vaccinated, or to believe that vaccines are safe had significantly lower coverage for all 10 childhood vaccines. Conclusions. Parents who delayed and refused vaccine doses were more likely to have vaccine safety concerns and perceive fewer benefits associated with vaccines. Guidelines published by the American Academy of Pediatrics may assist providers in responding to parents who may delay or refuse vaccines. C1 [Smith, Philip J.; Zhao, Zhen; Dorell, Christina G.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Humiston, Sharon C.] Childrens Mercy Hosp & Clin, Kansas City, MO USA. [Marcuse, Edgar K.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA. [Howes, Cynthia] Univ Chicago, Natl Opin Res Ctr, Chicago, IL 60637 USA. [Hibbs, Beth] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA 30333 USA. RP Smith, PJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS E-62, Atlanta, GA 30333 USA. EM pzs6@cdc.gov NR 54 TC 95 Z9 96 U1 3 U2 25 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JUL-AUG PY 2011 VL 126 SU 2 BP 135 EP 146 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 777ZT UT WOS:000291665800015 PM 21812176 ER PT J AU Parekh, AK Goodman, RA Gordon, C Koh, HK AF Parekh, Anand K. Goodman, Richard A. Gordon, Catherine Koh, Howard K. CA HHS Interagcy Workgrp Multiple TI Managing Multiple Chronic Conditions: A Strategic Framework for Improving Health Outcomes and Quality of Life SO PUBLIC HEALTH REPORTS LA English DT Article ID SELF-MANAGEMENT PROGRAM; CHRONIC DISEASE; CHRONIC ILLNESS; PRIMARY-CARE; PREVALENCE; HOSPITALIZATION; EXPENDITURES; GUIDELINES; DISORDERS; PEOPLE AB The escalating problem of multiple chronic conditions (MCC) among Americans is now a major public health and medical challenge, associated with suboptimal health outcomes and rising health-care expenses. Despite this problem's growth, the delivery of health services has continued to employ outmoded "siloed" approaches that focus on individual chronic diseases. We describe an action-oriented framework developed by the U.S. Department of Health and Human Services with additional input provided by stakeholder organizations-that outlines national strategies for maximizing care coordination and for improving health and quality of life for individuals with MCC. We note how the framework's potential can be optimized through some of the provisions of the new Patient Protection and Affordable Care Act, and through public-private partnerships. C1 [Parekh, Anand K.; Goodman, Richard A.; Koh, Howard K.] US Dept HHS, Off Assistant Secretary Hlth, Washington, DC 20201 USA. [Goodman, Richard A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Hlth Aging Program, Atlanta, GA USA. [Gordon, Catherine] Ctr Dis Control & Prevent, Off Associate Director Policy, Washington, DC USA. RP Parekh, AK (reprint author), US Dept HHS, Off Assistant Secretary Hlth, 200 Independence Ave SW, Washington, DC 20201 USA. EM anand.parekh@hhs.gov NR 41 TC 102 Z9 104 U1 2 U2 20 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JUL-AUG PY 2011 VL 126 IS 4 BP 460 EP 471 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 777ZS UT WOS:000291665600003 PM 21800741 ER PT J AU Grossman, CI Forsyth, A Purcell, DW Allison, S Toledo, C Gordon, CM AF Grossman, Cynthia I. Forsyth, Andrew Purcell, David W. Allison, Susannah Toledo, Carlos Gordon, Christopher M. TI Advancing Novel HIV Prevention Intervention Research with MSM-Meeting Report SO PUBLIC HEALTH REPORTS LA English DT Article ID UNITED-STATES; PUBLIC-HEALTH; MEN; SEX; HIV/AIDS; RISK; BEHAVIORS; EPIDEMIC; AMERICA; IMPACT AB HIV continues to exact an enormous toll on society and to disproportionately affect gay and bisexual men and other men who have sex with men (MSM). Innovative prevention interventions are needed to reverse this trend. In August 2009, the U.S. National Institute of Mental Health and the Centers for Disease Control and Prevention convened a meeting of scientists, community representatives, advocates, and federal partners to discuss innovative prevention-intervention science. The meeting was structured to maximize discussion of (1) healthy sex interventions, (2) community and structural interventions, (3) integrated biomedical and behavioral interventions, and (4) interventions to improve uptake of HIV testing. Presentations and discussion focused on research gaps in designing risk-reducing and sexual health-promoting interventions for MSM, including interventions to address mental health, substance use, disclosure, and stigma. This article summarizes the meeting proceedings, highlights key points, and outlines future directions. C1 [Grossman, Cynthia I.; Forsyth, Andrew; Allison, Susannah; Gordon, Christopher M.] NIMH, NIH, Bethesda, MD 20892 USA. [Purcell, David W.; Toledo, Carlos] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Grossman, CI (reprint author), NIMH, NIH, 6001 Execut Blvd,Room 6201, Bethesda, MD 20892 USA. EM grossmanc@mail.nih.gov OI Purcell, David/0000-0001-8125-5168 NR 30 TC 16 Z9 16 U1 1 U2 2 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JUL-AUG PY 2011 VL 126 IS 4 BP 472 EP 479 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 777ZS UT WOS:000291665600004 PM 21800742 ER PT J AU Kanwal, R Kullman, G Fedan, KB Kreiss, K AF Kanwal, Richard Kullman, Greg Fedan, Kathleen B. Kreiss, Kathleen TI Occupational Lung Disease Risk and Exposure to Butter-Flavoring Chemicals After Implementation of Controls at a Microwave Popcorn Plant SO PUBLIC HEALTH REPORTS LA English DT Article ID BRONCHIOLITIS OBLITERANS; DIACETYL; WORKERS; RATS AB Objectives. After an outbreak of severe lung disease among workers exposed to butter-flavoring chemicals at a microwave popcorn plant, we determined whether or not lung disease risk declined after implementation of exposure controls. Methods. National Institute for Occupational Safety and Health staff performed eight serial cross-sectional medical and industrial hygiene surveys at the plant from November 2000 through August 2003. Medical surveys included standardized questionnaires and spirometry testing. Industrial hygiene surveys measured levels of production-related air contaminants, including butter-flavoring chemicals such as diacetyl. All diacetyl concentrations above detectable limits were corrected for the effects of absolute humidity and days to sample extraction. Results. Ventilation and isolation of the production process resulted in one to three orders of magnitude reductions in diacetyl air concentrations in different areas of the plant. Workers with past high exposures had stable chest symptoms over time; nasal, eye, and skin irritation symptoms declined. New workers had lower symptom prevalences and higher lung function than workers with past high exposures, and they did not worsen over time. In workers who had at least three spirometry tests, those with past high exposures were more likely to experience rapid declines in lung function than new workers. Conclusions. Implemented controls lowered exposures to butter-flavoring chemicals and decreased lung disease risk for much of the plant workforce. Some workers with continuing potential for intermittent, short-term peak and measurable time-weighted exposures remain at risk and should use respiratory protection and have regularly scheduled spirometry to detect rapid lung function declines that may be work-related. Close follow-up of such workers is likely to yield additional information on risks due to peak and time-weighted exposure levels. C1 [Kanwal, Richard; Kullman, Greg; Fedan, Kathleen B.; Kreiss, Kathleen] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Kreiss, K (reprint author), NIOSH, Ctr Dis Control & Prevent, 1095 Willowdale Rd,MS H-2800, Morgantown, WV 26505 USA. EM kxk2@cdc.gov FU National Institute for Occupational Safety and Health (NIOSH) FX Funding for this work was provided by the National Institute for Occupational Safety and Health (NIOSH). The findings and conclusions in this article are those of the authors and do not necessarily represent the views of NIOSH. NR 17 TC 13 Z9 14 U1 2 U2 12 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JUL-AUG PY 2011 VL 126 IS 4 BP 480 EP 494 PG 15 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 777ZS UT WOS:000291665600005 PM 21800743 ER PT J AU Holman, RC Folkema, AM Singleton, RJ Redd, JT Christensen, KY Steiner, CA Schonberger, LB Hennessy, TW Cheek, JE AF Holman, Robert C. Folkema, Arianne M. Singleton, Rosalyn J. Redd, John T. Christensen, Krista Y. Steiner, Claudia A. Schonberger, Lawrence B. Hennessy, Thomas W. Cheek, James E. TI Disparities in Infectious Disease Hospitalizations for American Indian/Alaska Native People SO PUBLIC HEALTH REPORTS LA English DT Article ID UNITED-STATES; GENERAL-POPULATION; RESPIRATORY-TRACT; ALASKA NATIVES; CHILDREN; TRENDS; INFANTS; MORTALITY; ADULTS; RISK AB Objectives. We described disparities in infectious disease (ID) hospitalizations for American Indian/Alaska Native (Al/AN) people. Methods. We analyzed hospitalizations with an ID listed as the first discharge diagnosis in 1998-2006 for Al/AN people from the Indian Health Service National Patient Information Reporting System and compared them with records for the general U.S. population from the Nationwide Inpatient Survey. Results. The ID hospitalization rate for Al/AN people declined during the study period. The 2004-2006 mean annual age-adjusted ID hospitalization rate for Al/AN people (1,708 per 100,000 populiation) was slightly higher than that for the U.S. population (1,610 per 100,000 population). The rate for Al/AN people was highest in the Southwest (2,314 per 100,000 population), Alaska (2,063 per 100,000 population), and Northern Plains West (1,957 per 100,000 population) regions, and among infants (9,315 per 100,000 population). ID hospitalizations accounted for approximately 22% of all Al/AN hospitalizations. Lower-respiratory-tract infections accounted for the largest proportion of ID hospitalizations among Al/AN people (35%) followed by skin and soft tissue infections (19%), and infections of the kidney, urinary tract, and bladder (11%). Conclusions. Although the ID hospitalization rate for Al/AN people has declined, it remains higher than that for the U.S. general population, and is highest in the Southwest, Northern Plains West, and Alaska regions. Lower-respiratory-tract infections; skin and soft tissue infections; and kidney, urinary tract, and bladder infections contributed most to these health disparities. Future prevention strategies should focus on high-risk regions and age groups, along with illnesses contributing to health disparities. C1 [Holman, Robert C.; Folkema, Arianne M.; Christensen, Krista Y.; Schonberger, Lawrence B.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Singleton, Rosalyn J.] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. [Singleton, Rosalyn J.; Hennessy, Thomas W.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Arctic Invest Program, Anchorage, AK USA. [Redd, John T.; Cheek, James E.] Indian Hlth Serv, Div Epidemiol & Dis Prevent, Off Publ Hlth Support, Albuquerque, NM USA. [Steiner, Claudia A.] Agcy Healthcare Res & Qual, Ctr Delivery Org & Markets, Healthcare Cost & Utilizat Project, Rockville, MD USA. RP Holman, RC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, 1600 Clifton Rd NE,MS A-39, Atlanta, GA 30333 USA. EM RHolman@cdc.gov NR 35 TC 17 Z9 17 U1 0 U2 3 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JUL-AUG PY 2011 VL 126 IS 4 BP 508 EP 521 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 777ZS UT WOS:000291665600007 PM 21800745 ER PT J AU Estes, CR Marsh, SM Castillo, DN AF Estes, Chris R. Marsh, Suzanne M. Castillo, Dawn N. TI Surveillance of Traumatic Firefighter Fatalities: An Assessment of Four Systems SO PUBLIC HEALTH REPORTS LA English DT Article ID PUBLIC-HEALTH SURVEILLANCE AB Objectives. Firefighters regularly respond to hazardous situations that put them at risk for fatal occupational injuries. Traumatic occupational fatality surveillance is a foundation for understanding the problem and developing prevention strategies. We assessed four surveillance systems for their utility in characterizing firefighter fatalities and informing prevention measures. Methods. We examined three population-based systems (the Bureau of Labor Statistics' Census of Fatal Occupational Injuries and systems maintained by the United States Fire Administration and the National Fire Protection Association) and one case-based system (data collected through the National Institute for Occupational Safety and Health Fire Fighter Fatality Investigation and Prevention Program). From each system, we selected traumatic fatalities among firefighters for 2003-2006. Then we compared case definitions, methods for case ascertainment, variables collected, and rate calculation methods. Results. Overall magnitude of fatalities differed among systems. The population-based systems were effective in characterizing the circumstances of traumatic firefighter fatalities. The case-based surveillance system was effective in formulating detailed prevention recommendations, which could not be made based on the population-based data alone. Methods for estimating risk were disparate and limited fatality rate comparisons between firefighters and other workers. Conclusions. The systems included in this study contribute toward a greater understanding of firefighter fatalities. Areas of improvement for these systems should continue to be identified as they are used to direct research and prevention efforts. C1 [Estes, Chris R.; Marsh, Suzanne M.; Castillo, Dawn N.] NIOSH, Ctr Dis Control & Prevent, Div Safety Res, Surveillance & Field Invest Branch, Morgantown, WV 26505 USA. RP Estes, CR (reprint author), NIOSH, Ctr Dis Control & Prevent, Div Safety Res, Surveillance & Field Invest Branch, 1095 Willowdale Rd,MS-1808, Morgantown, WV 26505 USA. EM cestes@cdc.gov RI Alkhalawi, Mohammed/C-6111-2012 NR 25 TC 6 Z9 6 U1 0 U2 2 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JUL-AUG PY 2011 VL 126 IS 4 BP 540 EP 551 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 777ZS UT WOS:000291665600010 PM 21800748 ER PT J AU Rein, DB Lesesne, SB Smith, BD Weinbaum, CM AF Rein, David B. Lesesne, Sarah B. Smith, Bryce D. Weinbaum, Cindy M. TI Models of Community-Based Hepatitis B Surface Antigen Screening Programs in the US and Their Estimated Outcomes and Costs SO PUBLIC HEALTH REPORTS LA English DT Article ID VIRUS INFECTION; UNITED-STATES AB Objectives. Information on the process and method of service delivery is sparse for hepatitis B surface antigen (HBsAg) testing, and no systematic study has evaluated the relative effectiveness or cost-effectiveness of different HBsAg screening models. To address this need, we compared five specific community-based screening programs. Methods. We funded five HBsAg screening programs to collect information on their design, costs, and outcomes of participants during a six-month observation period. We categorized programs into four types of models. For each model, we calculated the number screened, the number screened as per Centers for Disease Control and Prevention (CDC) recommendations, and the cost per screening. Results. The models varied by cost per person screened and total number of people screened, but they did not differ meaningfully in the proportion of people screened following CDC recommendations, the proportion of those screened who tested positive, or the proportion of those who newly tested positive. Conclusions. Integrating screening into outpatient service settings is the most cost-effective method but may not reach all people needing to be screened. Future research should examine cost-effective methods that expand the reach of screening into communities in outpatient settings. C1 [Smith, Bryce D.; Weinbaum, Cindy M.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Rein, David B.; Lesesne, Sarah B.] RTI Int, Atlanta, GA 30341 USA. RP Rein, DB (reprint author), RTI Int, 2951 Flowers Rd,Ste 119, Atlanta, GA 30341 USA. EM drein@rti.org FU Centers for Disease Control and Prevention's (CDC's) Division of Viral Hepatitis (DVH) under Public Health Service [200-2009-E-30515] FX This study was funded by the Centers for Disease Control and Prevention's (CDC's) Division of Viral Hepatitis (DVH) under Public Health Service contract #200-2009-E-30515. The views expressed in this article are those of the authors and do not necessarily represent the official positions of CDC and the DVH. NR 12 TC 11 Z9 11 U1 1 U2 3 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JUL-AUG PY 2011 VL 126 IS 4 BP 560 EP 567 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 777ZS UT WOS:000291665600012 PM 21800750 ER PT J AU Romero, LM Galbraith, JS Wilson-Williams, L Gloppen, KM AF Romero, Lisa M. Galbraith, Jennifer S. Wilson-Williams, Lyndsey Gloppen, Kari M. TI HIV Prevention Among African American Youth: How Well Have Evidence-Based Interventions Addressed Key Theoretical Constructs? SO AIDS AND BEHAVIOR LA English DT Article DE Adolescents; African American; HIV prevention; Sexual risk behaviors; Interventions ID SEXUALLY-TRANSMITTED-DISEASES; RANDOMIZED CONTROLLED-TRIAL; ADOLESCENT RISK BEHAVIOR; CONDOM USE; FEMALE ADOLESCENTS; PSYCHOSOCIAL FACTORS; SUPPORTIVE FAMILIES; SCHOOL-STUDENTS; SELF-EFFICACY; HEALTH AB Certain constructs are demonstrated in the research literature to be related to HIV risk behaviors among African American adolescents. This study examines how well these constructs are addressed in evidence-based interventions (EBIs) developed for this population. A literature review on variables for sexual risk behaviors among African American adolescents was undertaken. Simultaneously, a review was conducted of the contents of HIV-prevention EBIs. To facilitate comparison, findings from both were organized into constructs from prominent behavior change theories. Analysis showed that environmental conditions and perceived norms were frequently associated with sexual risk behaviors in the literature, while EBIs devoted considerable time to knowledge, skills, and self-efficacy. Findings imply that (a) EBIs might be complemented with activities that focus on important constructs identified in the literature and (b) researchers should better assess the relationship between skill development and HIV risk behaviors. Implications for practice and research are discussed. C1 [Romero, Lisa M.; Wilson-Williams, Lyndsey; Gloppen, Kari M.] CDC, Res Applicat Branch, Div Adolescent, Atlanta, GA 30341 USA. [Romero, Lisa M.; Wilson-Williams, Lyndsey; Gloppen, Kari M.] CDC, Sch Hlth, Atlanta, GA 30341 USA. [Galbraith, Jennifer S.] CDC, Prevent Res Branch, Div HIV AIDS Prevent, Atlanta, GA 30341 USA. RP Romero, LM (reprint author), CDC, Res Applicat Branch, Div Adolescent, 4770 Buford Highway NE,Mailstop K-12, Atlanta, GA 30341 USA. EM lmromero@cdc.gov NR 110 TC 10 Z9 10 U1 0 U2 7 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS behav. PD JUL PY 2011 VL 15 IS 5 BP 976 EP 991 DI 10.1007/s10461-010-9745-5 PG 16 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 785YE UT WOS:000292268300011 PM 20635131 ER PT J AU Mosby, LG Rasmussen, SA Jamieson, DJ AF Mosby, Laura G. Rasmussen, Sonja A. Jamieson, Denise J. TI 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Review DE H1N1; influenza; pregnancy ID CRITICALLY-ILL PATIENTS; RESPIRATORY-DISTRESS-SYNDROME; EXTRACORPOREAL MEMBRANE-OXYGENATION; NEW-YORK-CITY; VIRUS-INFECTION; HOSPITALIZED-PATIENTS; SWINE FLU; A(H1N1) INFECTION; ADULT PATIENTS; UNITED-STATES AB To summarize the literature regarding 2009 H1N1 influenza A during pregnancy, we conducted a systematic literature review using a PubMed search and other strategies. Studies were included if they reported 2009 H1N1 influenza in pregnant women as original data. In all, 2153 abstracts were reviewed, and a total of 120 studies were included. Data were extracted regarding number of cases, additional risk factors for influenza-associated complications, treatment, and maternal and pregnancy outcomes. Authors were contacted to determine the extent of overlap when it was suspected. Pregnancy was associated with increased risk of hospital and intensive care unit admission and of death. Pregnant women who received delayed treatment with neuraminidase inhibitors or who had additional risk factors were more likely to develop severe disease. Preterm and emergency cesarean deliveries were frequently reported. These results reinforce the importance of early identification and treatment of suspected influenza in this high-risk population. C1 [Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Mosby, Laura G.] Emory Univ, Sch Med, Atlanta, GA USA. [Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA. RP Jamieson, DJ (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mail Stop K-34, Atlanta, GA 30341 USA. OI Rasmussen, Sonja/0000-0002-0574-4928; Carlson, Laura/0000-0001-8119-9143 NR 143 TC 90 Z9 95 U1 1 U2 13 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD JUL PY 2011 VL 205 IS 1 BP 10 EP 18 DI 10.1016/j.ajog.2010.12.033 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 783KX UT WOS:000292082400017 PM 21345415 ER PT J AU Mitchell, AA Gilboa, SM Werler, MM Kelley, KE Louik, C Hernandez-Diaz, S AF Mitchell, Allen A. Gilboa, Suzanne M. Werler, Martha M. Kelley, Katherine E. Louik, Carol Hernandez-Diaz, Sonia CA Natl Birth Defects Prevention Stud TI Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008 SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE epidemiology; medications; over-the-counter medications; pregnancy; prescription medications ID BIRTH-DEFECTS; POPULATION; EXPOSURE AB OBJECTIVE: The objective of the study was to provide information on overall medication use throughout pregnancy, with particular focus on the first trimester and specific prescription medications. STUDY DESIGN: The study design included the Slone Epidemiology Center Birth Defects Study, 1976-2008, and the National Birth Defects Prevention Study, 1997-2003, which together interviewed more than 30,000 women about their antenatal medication use. RESULTS: Over the last 3 decades, first-trimester use of prescription medication increased by more than 60%, and the use of 4 or more medications more than tripled. By 2008, approximately 50% of women reported taking at least 1 medication. Use of some specific medications markedly decreased or increased. Prescription medication use increased with maternal age and education, was highest for non-Hispanic whites, and varied by state. CONCLUSION: These data reflect the widespread and growing use of medications by pregnant women and reinforce the need to study their respective fetal risks and safety. C1 [Mitchell, Allen A.; Werler, Martha M.; Kelley, Katherine E.; Louik, Carol] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. [Hernandez-Diaz, Sonia] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Gilboa, Suzanne M.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Mitchell, AA (reprint author), Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. RI Publications, NBDPS/B-7692-2013; OI Werler, Martha/0000-0003-3392-6814; Louik, Carol/0000-0001-5429-5084; Mitchell, Allen/0000-0003-0950-6799 FU Centers for Disease Control and Prevention through the Massachusetts Department of Public Health [U50/CCU113247]; Centers for Disease Control and Prevention [02081]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [R01 HD 046595] FX This study was supported in part by Cooperative Agreement no. U50/CCU113247 with the Centers for Disease Control and Prevention through the Massachusetts Department of Public Health, Cooperative agreements under program announcement no. 02081 from the Centers for Disease Control and Prevention to the centers participating in the National Birth Defects Prevention Study, and Grant R01 HD 046595 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. NR 19 TC 67 Z9 67 U1 1 U2 15 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD JUL PY 2011 VL 205 IS 1 AR 51.e1 DI 10.1016/j.ajog.2011.02.029 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 783KX UT WOS:000292082400029 PM 21514558 ER PT J AU Knust, BM Wolf, PC Wells, SJ AF Knust, Barbara M. Wolf, Paul C. Wells, Scott J. TI Characterization of the risk of deer-cattle interactions in Minnesota by use of an on-farm environmental assessment tool SO AMERICAN JOURNAL OF VETERINARY RESEARCH LA English DT Article ID WHITE-TAILED DEER; MYCOBACTERIUM-BOVIS; ODOCOILEUS-VIRGINIANUS; DAIRY HERDS; TUBERCULOSIS; MICHIGAN; TRANSMISSION; SURVIVAL; WILDLIFE AB Objective-To characterize the risk of interactions that may lead to the transmission of Mycobacterium bovis between cattle and white-tailed deer (Odocoileus virginianus) on farms in northern Minnesota. Sample-53 cattle farms in northwestern Minnesota adjacent to an area where bovine tuberculosis-infected cattle and deer were detected. Procedures-A semiquantitative deer-cattle interaction assessment tool was used for the 53 cattle herds. Farm risk scores were analyzed on the basis of deer damage to stored feed. Results-27 (51%) farms reported deer damage to stored cattle feeds within the year previous to the farm visit. A strong association was found between increases in the percentage of land that could serve as deer cover and deer damage to stored feeds on a farm. The total risk score was significantly associated with the probability of a farm having deer damage. By use of a logistic regression model, the total risk score and proportion of nonagricultural land around a farm could be used to predict the likelihood of deer damage to stored feeds. Conclusions and Clinical Relevance-Management practices on many farms in northwestern Minnesota allowed potential deer-cattle interactions. The on-farm risk assessment tool served as a valuable tool for prioritizing the biosecurity risks for farms. Continued development of biosecurity is needed to prevent potential transmission of bovine tuberculosis between deer and cattle, especially on farms that have a higher risk of deer damage. (Am J Vet Res 201172:924-931) C1 [Knust, Barbara M.; Wells, Scott J.] Univ Minnesota, Coll Vet Med, Ctr Anim Hlth & Food Safety, St Paul, MN 55108 USA. [Wolf, Paul C.] Wildlife Serv, APHIS, USDA, St Paul, MN 55107 USA. RP Knust, BM (reprint author), CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM bknust@cdc.gov FU 2007 Minnesota Rapid Agricultural Response Fund FX Supported by the 2007 Minnesota Rapid Agricultural Response Fund. NR 21 TC 7 Z9 7 U1 0 U2 10 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA SN 0002-9645 J9 AM J VET RES JI Am. J. Vet. Res. PD JUL PY 2011 VL 72 IS 7 BP 924 EP 931 PG 8 WC Veterinary Sciences SC Veterinary Sciences GA 785IL UT WOS:000292222600009 PM 21728853 ER PT J AU Kecojevic, A Lindsell, CJ Lyons, MS Holtgrave, D Torres, G Heffelfinger, J Brown, J Couture, E Jung, J Connell, S Rothman, RE AF Kecojevic, Aleksandar Lindsell, Christopher J. Lyons, Michael S. Holtgrave, David Torres, Gretchen Heffelfinger, James Brown, Jeremy Couture, Eileen Jung, Julianna Connell, Samantha Rothman, Richard E. CA Natl Emergency Dept HIV Testing TI Public Health and Clinical Impact of Increasing Emergency Department-Based HIV Testing: Perspectives From the 2007 Conference of the National Emergency Department HIV Testing Consortium SO ANNALS OF EMERGENCY MEDICINE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; FOR-DISEASE-CONTROL; PREVENTIVE SERVICES; CARE SETTINGS; MISSED OPPORTUNITIES; SCREENING-PROGRAM; INFECTION; MEDICINE; RECOMMENDATIONS; PHYSICIANS AB Objective: Understanding perceived benefits and disadvantages of HIV testing in emergency departments (EDs) is imperative to overcoming barriers to implementation. We codify those domains of public health and clinical care most affected by implementing HIV testing in EDs, as determined by expert opinion. Methods: Opinions were systematically collected from attendees of the 2007 National ED HIV Testing Consortium meeting. Structured evaluation of strengths, weaknesses, opportunities, and threats analysis was conducted to assess the impact of ED-based HIV testing on public health. A modified Delphi method was used to assess the impact of ED-based HIV testing on clinical care from both individual patient and individual provider perspectives. Results: Opinions were provided by 98 experts representing 42 academic and nonacademic institutions. Factors most frequently perceived to affect public health were (strengths) high volume of ED visits and high prevalence of HIV, (weaknesses) undue burden on EDs, (opportunities) reduction of HIV stigma, and (threats) lack of resources in EDs. Diagnostic testing and screening for HIV were considered to have a favorable impact on ED clinical care from both individual patient and individual provider perspectives; however, negative test results were not perceived to have any benefit from the provider's perspective. The need for HIV counseling in the ED was considered to have a negative impact on clinical care from the provider's perspective. Conclusion: Experts in ED-based HIV testing perceived expanded ED HIV testing to have beneficial impacts for both the public health and individual clinical care; however, limited resources were frequently cited as a possible impediment. Many issues must be resolved through further study, education, and policy changes if the full potential of HIV testing in EDs is to be realized. [Ann Emerg Med. 2011;58:S151-S159.] C1 [Kecojevic, Aleksandar; Jung, Julianna; Connell, Samantha; Rothman, Richard E.] Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD 21209 USA. [Lindsell, Christopher J.; Lyons, Michael S.] Univ Cincinnati, Dept Emergency Med, Cincinnati, OH USA. [Holtgrave, David] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA. [Torres, Gretchen] Hlth Educ & Res Trust, Amer Hosp Assoc, Chicago, IL USA. [Heffelfinger, James] George Washington Univ, Dept Emergency Med, Sch Med, Washington, DC USA. [Brown, Jeremy] Ctr Dis Control & Prevent, Atlanta, GA USA. [Couture, Eileen] Stroger Hosp, Rush Med Sch, Dept Emergency Med, Chicago, IL USA. RP Kecojevic, A (reprint author), Johns Hopkins Univ, Sch Med, Dept Emergency Med, 5801 Smith Ave,Davis Bldg 3220, Baltimore, MD 21209 USA. EM ak955@drexel.edu RI Pollack, Harold/A-1166-2007; OI Rothman, Richard/0000-0002-1017-9505; Lindsell, Christopher/0000-0002-3297-2811; Kelen, Gabor/0000-0002-3236-8286 FU Gilead Sciences, Inc.; Health Research and Educational Trust of the American Hospital Association; Maryland Department of Health and Mental Hygiene; Centers for Disease Control and Prevention, Atlanta, GA FX By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see icmje.org). The meeting of the National ED HIV Testing Consortium was funded by an unrestricted grant from Gilead Sciences, Inc., with organizational support from the Health Research and Educational Trust of the American Hospital Association. Dr. Rothman was funded in part by a grant from the Maryland Department of Health and Mental Hygiene.; Publication of this article was supported by Centers for Disease Control and Prevention, Atlanta, GA. NR 48 TC 9 Z9 9 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD JUL PY 2011 VL 58 IS 1 SU S BP S151 EP S159 DI 10.1016/j.annemergmed.2011.03.040 PG 9 WC Emergency Medicine SC Emergency Medicine GA 786XM UT WOS:000292341200027 PM 21684395 ER PT J AU Torres, GW Heffelfinger, JD Pollack, HA Barrera, SG Rothman, RE AF Torres, Gretchen Williams Heffelfinger, James D. Pollack, Harold A. Barrera, Susan Gregory Rothman, Richard E. TI HIV Screening Programs in US Emergency Departments: A Cross-Site Comparison of Structure, Process, and Outcomes SO ANNALS OF EMERGENCY MEDICINE LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASE; MISSED OPPORTUNITIES; NATIONAL-SURVEY; CARE; IMPLEMENTATION; IDENTIFICATION; PERCEPTIONS; EXPERIENCE; PHYSICIANS; INFECTION AB Objective: We present findings from a multisite evaluation that systematically compares HIV screening programs in 6 emergency departments (EDs). Methods: From 2007 to 2008, we collected previous-year data on structural factors, process attributes, testing outcomes, and cost-effectiveness from 6 ED HIV testing programs operating for 6 months or longer. We administered questionnaires to program directors, conducted site visits, and interviewed key informants. Results: HIV care providers (n=3 sites), emergency physicians (n=2), or health departments (n=1) initiated the testing programs. ED leadership and providers helped design and implement the programs (n=5), and emergency physicians or administrators provided daily oversight (n=5). Testing strategies included targeted (patients selected from at-risk populations; n=2), nontargeted (patients selected without regard to risk or intention of testing all; n=3), and universal (all patients selected; n=1) screening. Testing was conducted by supplemental staff (n=4) and existing hospital staff (n=2). ED testing programs were funded by grants (n=3), city HIV prevention/care budgets (n=2), or the hospital (n=1). The median percentage of census tested was 4.7% (range 2.1% to 8.4%). The median rate of preliminary positive test results was 1.2% (range 1.0% to 7.3%). The median confirmed new HIV diagnosis rate was 0.9% (range 0.8% to 6.4%). The median linkage to care rate was 92.0% (range 50% to 100%). The median cost per patient receiving a new diagnosis and linked to care was $10,200 (range $3,400 to $12,300). Conclusion: Although structure and process of screening programs varied across EDs, outcomes were similar, which suggests that with current ED environments, testing methods, and resources available, the capacity and structure to increase testing in EDs has limits. These ED HIV screening programs were cost-effective according to standard thresholds. [Ann Emerg Med. 2011;58:S104-S113.] C1 [Torres, Gretchen Williams; Barrera, Susan Gregory] Univ Chicago, Harris Sch Publ Policy Studies, Chicago, IL 60637 USA. [Heffelfinger, James D.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Pollack, Harold A.] Univ Chicago, Sch Social Serv Adm, Ctr Hlth Adm Studies, Chicago, IL 60637 USA. [Rothman, Richard E.] Johns Hopkins Univ, Dept Emergency Med, Baltimore, MD USA. RP Torres, GW (reprint author), Amer Hosp Assoc, Hlth Res & Educ Trust, 1 N Franklin St,30th Floor, Chicago, IL 60606 USA. EM gwtorres@uchicago.edu RI Pollack, Harold/A-1166-2007; OI Rothman, Richard/0000-0002-1017-9505 FU Centers for Disease Control and Prevention through Agency for Healthcare Research; Quality's Accelerating Change and Transformation in Organizations and Networks; Health Research and Educational Trust of the American Hospital Association [HHSA2902006000221] FX By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist. This project was funded by the Centers for Disease Control and Prevention through a contract with the Agency for Healthcare Research and Quality's Accelerating Change and Transformation in Organizations and Networks program and the Health Research and Educational Trust of the American Hospital Association (HHSA2902006000221, Task Order 1). NR 36 TC 14 Z9 15 U1 1 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD JUL PY 2011 VL 58 IS 1 SU S BP S104 EP S113 DI 10.1016/j.annemergmed.2011.03.034 PG 10 WC Emergency Medicine SC Emergency Medicine GA 786XM UT WOS:000292341200020 PM 21684388 ER PT J AU White, DAE Scribner, AN Vahidnia, F Dideum, PJ Gordon, DM Frazee, BW Voetsch, AC Heffelfinger, JD AF White, Douglas A. E. Scribner, Alicia N. Vahidnia, Farnaz Dideum, Patrick J. Gordon, Danielle M. Frazee, Bradley W. Voetsch, Andrew C. Heffelfinger, James D. TI HIV Screening in an Urban Emergency Department: Comparison of Screening Using an Opt-In Versus an Opt-Out Approach SO ANNALS OF EMERGENCY MEDICINE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE SETTINGS; GENITOURINARY MEDICINE; RECOMMENDATIONS; INFECTION; CDC AB Objective: We compare outcomes of opt-in and opt-out HIV screening approaches in an urban emergency department. Methods: This was a 1-year prospective observational study comparing 2 6-month screening approaches. Eligibility for opt-in and opt-out screening was identical: aged 15 years or older, medically stable, and able to complete general consent. During the opt-in phase, triage nurses referred patients to HIV testers stationed at triage, who obtained separate opt-in written consent and performed rapid oral fluid tests. During the opt-out phase, registration staff conducted integrated opt-out consent and then referred patients to HIV testers. We assessed the proportion of potentially eligible patients who were offered screening (screening offer rate), the proportion offered screening who accepted (screening acceptance rate), the proportion who accepted screening and subsequently completed testing (test completion rate), and the proportion of potentially eligible patients who completed testing (overall screening rate) during each phase. Results: For the opt-in versus the opt-out phases, respectively, there were 23,236 potentially eligible patients versus 26,757, screening offer rate was 27.9% versus 75.8% (P<.001), screening acceptance rate was 62.7% versus 30.9% (P<.001), test completion rate was 99.8% versus 74.6% (P<.001), and overall screening rate was 17.4% versus 17.5% (P=.90). Conclusion: A significantly higher proportion of patients were offered HIV screening with an opt-out approach at registration. However, this was offset by much higher screening acceptance and test completion rates with the opt-in approach at triage. Overall screening rates with the 2 approaches were nearly identical. [Ann Emerg Med. 2011;58:S89-S95.] C1 [White, Douglas A. E.; Scribner, Alicia N.; Vahidnia, Farnaz; Dideum, Patrick J.; Gordon, Danielle M.; Frazee, Bradley W.] Highland Hosp, Alameda Cty Med Ctr, Dept Emergency Med, Oakland, CA 94602 USA. [Vahidnia, Farnaz] Univ Calif Berkeley, Sch Publ Hlth, Dept Epidemiol & Biostat, Berkeley, CA 94720 USA. [Voetsch, Andrew C.; Heffelfinger, James D.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP White, DAE (reprint author), Highland Hosp, Alameda Cty Med Ctr, Dept Emergency Med, 1411 E 31st St, Oakland, CA 94602 USA. EM daewhite@gmail.com OI Vahidnia, Farnaz/0000-0003-1130-4643 FU Centers for Disease Control and Prevention [U18 PS000321] FX By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). This study was funded by cooperative agreements from the Centers for Disease Control and Prevention to Dr. White (U18 PS000321). NR 19 TC 26 Z9 26 U1 2 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD JUL PY 2011 VL 58 IS 1 SU S BP S89 EP S95 DI 10.1016/j.annemergmed.2011.03.032 PG 7 WC Emergency Medicine SC Emergency Medicine GA 786XM UT WOS:000292341200018 PM 21684416 ER PT J AU Rudolf, M Belay, B Dahly, D AF Rudolf, Mary Belay, Brook Dahly, Darren TI Development of a tool to identify babies' risk of later obesity SO ANNALS OF HUMAN BIOLOGY LA English DT Meeting Abstract C1 [Rudolf, Mary] Univ Leeds, Acad Unit Paediat, Leeds LS2 9JT, W Yorkshire, England. [Belay, Brook] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Dahly, Darren] Univ Leeds, Ctr Biostat & Epidemiol, Leeds LS2 9JT, W Yorkshire, England. NR 0 TC 0 Z9 0 U1 0 U2 3 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0301-4460 J9 ANN HUM BIOL JI Ann. Hum. Biol. PD JUL PY 2011 VL 38 IS 4 BP 462 EP 462 PG 1 WC Anthropology; Biology; Public, Environmental & Occupational Health SC Anthropology; Life Sciences & Biomedicine - Other Topics; Public, Environmental & Occupational Health GA 781OU UT WOS:000291944100013 ER PT J AU Liu, FY Kariyawasam, S Jayarao, BM Barrangou, R Gerner-Smidt, P Ribot, EM Knabel, SJ Dudley, EG AF Liu, Fenyun Kariyawasam, Subhashinie Jayarao, Bhushan M. Barrangou, Rodolphe Gerner-Smidt, Peter Ribot, Efrain M. Knabel, Stephen J. Dudley, Edward G. TI Subtyping Salmonella enterica Serovar Enteritidis Isolates from Different Sources by Using Sequence Typing Based on Virulence Genes and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs) SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID FRAGMENT LENGTH POLYMORPHISM; FIELD GEL-ELECTROPHORESIS; SEROTYPE ENTERITIDIS; UNITED-STATES; AFLP TECHNIQUE; FOODNET SITES; INFECTIONS; RESISTANCE; EGGS; EPIDEMIC AB Salmonella enterica subsp. enterica serovar Enteritidis is a major cause of food-borne salmonellosis in the United States. Two major food vehicles for S. Enteritidis are contaminated eggs and chicken meat. Improved subtyping methods are needed to accurately track specific strains of S. Enteritidis related to human salmonellosis throughout the chicken and egg food system. A sequence typing scheme based on virulence genes (fimH and sseL) and clustered regularly interspaced short palindromic repeats (CRISPRs)-CRISPR-including multi-virulence-locus sequence typing (designated CRISPR-MVLST)-was used to characterize 35 human clinical isolates, 46 chicken isolates, 24 egg isolates, and 63 hen house environment isolates of S. Enteritidis. A total of 27 sequence types (STs) were identified among the 167 isolates. CRISPR-MVLST identified three persistent and predominate STs circulating among U. S. human clinical isolates and chicken, egg, and hen house environmental isolates in Pennsylvania, and an ST that was found only in eggs and humans. It also identified a potential environment-specific sequence type. Moreover, cluster analysis based on fimH and sseL identified a number of clusters, of which several were found in more than one outbreak, as well as 11 singletons. Further research is needed to determine if CRISPR-MVLST might help identify the ecological origins of S. Enteritidis strains that contaminate chickens and eggs. C1 [Liu, Fenyun; Barrangou, Rodolphe; Knabel, Stephen J.; Dudley, Edward G.] Penn State Univ, Dept Food Sci, University Pk, PA 16802 USA. [Kariyawasam, Subhashinie; Jayarao, Bhushan M.] Penn State Univ, Anim Diagnost Lab, University Pk, PA 16802 USA. [Kariyawasam, Subhashinie; Jayarao, Bhushan M.] Penn State Univ, Dept Vet & Biomed Sci, University Pk, PA 16802 USA. [Barrangou, Rodolphe] Danisco USA Inc, Madison, WI 53716 USA. [Gerner-Smidt, Peter; Ribot, Efrain M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Dudley, EG (reprint author), Penn State Univ, Dept Food Sci, 326 Food Sci Bldg, University Pk, PA 16802 USA. EM egd100@psu.edu RI Barrangou, Rodolphe/I-2878-2014 OI Barrangou, Rodolphe/0000-0002-0648-3504 FU U.S. Department of Agriculture Special Milk Safety [2009-34163-20132] FX This study was partially supported by a U.S. Department of Agriculture Special Milk Safety grant to the Pennsylvania State University (contract 2009-34163-20132). NR 43 TC 37 Z9 39 U1 0 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD JUL PY 2011 VL 77 IS 13 BP 4520 EP 4526 DI 10.1128/AEM.00468-11 PG 7 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA 782CR UT WOS:000291985700030 PM 21571881 ER PT J AU Blackmore, S Pfeiffer, CM Lee, A Fazili, Z Hamilton, MS AF Blackmore, Sheena Pfeiffer, Christine M. Lee, Anne Fazili, Zia Hamilton, Malcolm S. TI Isotope Dilution-LC-MS/MS Reference Method Assessment of Serum Folate Assay Accuracy and Proficiency Testing Consensus Mean SO CLINICAL CHEMISTRY LA English DT Article ID TANDEM MASS-SPECTROMETRY; FOLIC-ACID; MICROBIOLOGIC ASSAY; LABORATORY MEDICINE; CLINICAL-CHEMISTRY; QUALITY-CONTROL; TRACEABILITY; RADIOASSAY; FORTIFICATION; UNCERTAINTY AB BACKGROUND: Current methods for measuring folates in clinical laboratories are competitive folate binding protein assays. These assays show a considerable lack of agreement that has implications for the comparability of data across studies as well as for long-term population studies. The development of isotope dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) reference methods permitted the evaluation of method accuracy and consistency over time. METHODS: We measured 3 pools of human serum by ID-LC-MS/MS, calculated values for total folate, and distributed the same pools to participants in a national External Quality Assessment scheme. We used linear regression to compare the all-laboratory and method data with reference method values. The exercise was repeated after 18 months to assess the stability of the all-laboratory and method data. RESULTS: The distributed serum pools had mass spectrometry values for folate species typical of those found in healthy individuals from populations not receiving dietary folic acid fortification. There was good agreement of the all-laboratory data set with the reference method (y = 0.86x + 0.91 mu g/L) at both time points. Linear regression demonstrated that the Abbott Architect showed the closest agreement with the reference method. The Roche Elecsys method was nonlinear and showed a calibration offset of 2.6 mu g/L (4.57 nmol/L). CONCLUSIONS: Calibration of serum folate assays traceable to higher-order reference methods increases method accuracy and improves consistency. The all-laboratory consensus mean proved sufficiently accurate and stable to be used as the target for monitoring laboratory performance. (C) 2011 American Association for Clinical Chemistry C1 [Blackmore, Sheena; Lee, Anne; Hamilton, Malcolm S.] Good Hope Hosp, UK NEQAS Haematin Scheme Haematin, Sutton Coldfield, England. [Pfeiffer, Christine M.; Fazili, Zia] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Blackmore, S (reprint author), Heart England Fdn Trust, Good Hope Hosp, UK NEQAS Haematin, Dept Haematol, Sutton Coldfield B75 7RR, England. EM blackmore@heartofengland.nhs.uk NR 29 TC 6 Z9 7 U1 1 U2 13 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 J9 CLIN CHEM JI Clin. Chem. PD JUL PY 2011 VL 57 IS 7 BP 986 EP 994 DI 10.1373/clinchem.2010.160135 PG 9 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 784DL UT WOS:000292134400013 PM 21561849 ER PT J AU Ritchey, MD Sucosky, MS Jefferies, T McCormick, D Hesting, A Blanton, C Duwve, J Bruner, R Daley, WR Jarrett, J Brown, MJ AF Ritchey, Matthew D. Sucosky, Marissa Scalia Jefferies, Taran McCormick, David Hesting, Amy Blanton, Curtis Duwve, Joan Bruner, Robin Daley, W. Randolph Jarrett, Jeffery Brown, Mary Jean TI Lead Poisoning Among Burmese Refugee Children-Indiana, 2009 SO CLINICAL PEDIATRICS LA English DT Article DE refugee; lead poisoning; traditional medicine; childhood; screening ID SKIN ABSORPTION; BLOOD; MEDICINES; HEALTH; RISK; INTELLIGENCE; TOXICITY; EXPOSURE AB Recent routine screening revealed multiple cases of unexplained lead poisoning among children of Burmese refugees living in Fort Wayne, Indiana. A cross-sectional study was conducted to determine (a) the prevalence of elevated blood lead levels (BLLs) among Burmese children and (b) potential sources of lead exposure. A case was defined as an elevated venous BLL (>= 10 mu g/dL); prevalence was compared with all Indiana children screened during 2008. Environmental and product samples were tested for lead. In all, 14 of 197 (7.1%) children had elevated BLLs (prevalence ratio: 10.7) that ranged from 10.2 to 29.0 mu g/dL. Six cases were newly identified; 4 were among US-born children. Laboratory testing identified a traditional ethnic digestive remedy, Daw Tway, containing a median 520 ppm lead. A multilevel linear regression model identified daily use of thanakha, an ethnic cosmetic, and Daw Tway use were related to elevated BLLs (P < .05). Routine monitoring of BLLs among this population should remain a priority. C1 [Ritchey, Matthew D.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Ritchey, Matthew D.; McCormick, David; Duwve, Joan; Bruner, Robin] Indiana State Dept Hlth, Indianapolis, IN USA. [Sucosky, Marissa Scalia; Jefferies, Taran; Blanton, Curtis; Jarrett, Jeffery; Brown, Mary Jean] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Hesting, Amy] Ft Wayne Allen Cty Dept Hlth, Ft Wayne, IN USA. [Daley, W. Randolph] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA USA. RP Ritchey, MD (reprint author), 2 N Meridian Ave,5K99, Indianapolis, IN 46204 USA. EM mritchey@isdh.in.gov OI Jarrett, Jeffery/0000-0001-5755-3552 FU National Center for Environmental Health, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; Lead and Healthy Homes Division, Indiana State Department of Health; Fort Wayne -Allen County Department of Health FX This study was supported in part through a cooperative agreement with the National Center for Environmental Health, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; the Lead and Healthy Homes Division, Indiana State Department of Health; and the Fort Wayne -Allen County Department of Health. NR 38 TC 3 Z9 4 U1 0 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0009-9228 J9 CLIN PEDIATR JI Clin. Pediatr. PD JUL PY 2011 VL 50 IS 7 BP 648 EP 656 DI 10.1177/0009922811398958 PG 9 WC Pediatrics SC Pediatrics GA 784PG UT WOS:000292168600011 PM 21398347 ER PT J AU Tepper, NK Paulen, ME Marchbanks, PA Curtis, KM AF Tepper, Naomi K. Paulen, Melissa E. Marchbanks, Polly A. Curtis, Kathryn M. TI Family planning methods in peripartum cardiomyopathy Reply SO CONTRACEPTION LA English DT Letter C1 [Tepper, Naomi K.; Marchbanks, Polly A.; Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Paulen, Melissa E.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. RP Tepper, NK (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. EM ntepper@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD JUL PY 2011 VL 84 IS 1 BP 109 EP 110 DI 10.1016/j.contraception.2010.10.017 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 783HF UT WOS:000292071400018 ER PT J AU McCanlies, EC Araia, SK Joseph, PN Mnatsakanova, A Andrew, ME Burchfiel, CM Violanti, JM AF McCanlies, Erin C. Araia, Sewit Kesete Joseph, Parveen Nedra Mnatsakanova, Anna Andrew, Michael E. Burchfiel, Cecil M. Violanti, John M. TI C-reactive protein, Interleukin-6, and posttraumatic stress disorder symptomology in urban police officers SO CYTOKINE LA English DT Article DE Police; Posttraumatic stress disorder (PTSD); C-reactive protein (CRP); Interleukin-6 (IL-6); Inflammatory markers ID EXPOSURE; MARKERS; EVENT; PTSD AB Our aim was to examine the relationship between the level of the inflammatory markers, C-reactive protein (CRP) and interleukin-6 (IL-6), and posttraumatic stress disorder (PTSD) symptomology in a random sample of 115 police officers. CRP was measured in citrated plasma using a particle enhanced immunone-pholometric assay and IL-6 was measured in serum with a solid-phase quantitative sandwich ELISA. The presence of high PTSD symptomology was defined as having an Impact of Event Scale score (IES) of >= 26 compared to <26 (low PTSD symptomology). 28% of the officers had high PTSD symptomology. Mean levels of CRP and IL-6 did not differ significantly between officers with high PTSD symptomology and those with low symptomology (CRP: 0.76 mg/l vs. 0.97 mg/l; IL-6: 2.03 pg/ml vs. 1.74 pg/ml). We found no association of CRP and IL-6 levels with PTSD symptomology. This study was limited by sample size and its cross-sectional study design. A lack of association may occur if either CRP or IL-6 is elevated only at the onset of PTSD symptomology, or if inflammation is related to specific key components that define PTSD. Further research examining these relationships in a larger population may be worthwhile. Published by Elsevier Ltd. C1 [Araia, Sewit Kesete] W Virginia Univ, Sch Med, Dept Community Med, Morgantown, WV 26506 USA. [McCanlies, Erin C.; Araia, Sewit Kesete; Joseph, Parveen Nedra; Mnatsakanova, Anna; Andrew, Michael E.; Burchfiel, Cecil M.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Violanti, John M.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Social & Prevent Med, Buffalo, NY 14260 USA. RP McCanlies, EC (reprint author), NIOSH, CDC, 1095 Willowdale Rd,M-S 4050, Morgantown, WV 26505 USA. EM eim4@cdc.gov FU National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention [1R03OH003772-01] FX The Buffalo Police Health Study was funded by the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (Contract No.: 1R03OH003772-01). The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the National Institute for Occupational Safety and Health. NR 29 TC 19 Z9 19 U1 1 U2 6 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1043-4666 J9 CYTOKINE JI Cytokine PD JUL PY 2011 VL 55 IS 1 BP 74 EP 78 DI 10.1016/j.cyto.2011.03.025 PG 5 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA 781FP UT WOS:000291916300012 PM 21493089 ER PT J AU Dowell, SF Braden, CR AF Dowell, Scott F. Braden, Christopher R. TI Implications of the Introduction of Cholera to Haiti SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 [Dowell, Scott F.; Braden, Christopher R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Dowell, SF (reprint author), Ctr Dis Control & Prevent, Mailstop D69,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM sfd2@cdc.gov NR 7 TC 18 Z9 18 U1 0 U2 11 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUL PY 2011 VL 17 IS 7 BP 1299 EP 1300 DI 10.3201/eid1707.110625 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 790IL UT WOS:000292581600027 PM 21762593 ER PT J AU Casas, L Fernandez, MF Llop, S Guxens, M Ballester, F Olea, N Irurzun, MB Rodriguez, LS Riano, I Tardon, A Vrijheid, M Calafat, AM Sunyer, J AF Casas, Lidia Fernandez, Mariana F. Llop, Sabrina Guxens, Monica Ballester, Ferran Olea, Nicolas Basterrechea Irurzun, Mikel Santa Marina Rodriguez, Loreto Riano, Isolina Tardon, Adonina Vrijheid, Martine Calafat, Antonia M. Sunyer, Jordi CA INMA Project TI Urinary concentrations of phthalates and phenols in a population of Spanish pregnant women and children SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Phthalate; Phenol; Pregnancy; Children; Social class; Exposure ID BISPHENOL-A CONCENTRATIONS; DI-N-BUTYLPHTHALATE; ENVIRONMENTAL PHENOLS; OXIDATIVE METABOLITES; TESTICULAR TOXICITY; HUMAN SPERM; DNA-DAMAGE; IN-UTERO; EXPOSURE; HEALTH AB Background: Phthalate and phenol exposure is prevalent among the general population and of potential concern for pregnant women and children because of their suspected susceptibility to endocrine effects. Objectives: To evaluate the extent of exposure to several phthalates and phenols in a sample of Spanish pregnant women - according to their individual characteristics (age, social class, education, and body mass index) - and children who participated in the INMA - Infancia y Medio Ambiente (Environment and Childhood) project. Methods: One spot urine sample was taken during the third trimester of pregnancy from 120 pregnant women and from 30 4-year old children belonging to 5 Spanish birth cohorts, and analyzed for 11 phthalate metabolites and 9 phenols. Results: Three metabolites of di(2-ethylhexyl) phthalate, mono-2-ethyl-5-carboxypentyl phthalate, mono-2-ethyl-5-hydroxyhexyl phthalate, and mono-2-ethyl-5-oxohexyl phthalate; two metabolites of dibutyl phthalates, mono-isobutyl phthalate and mono-n-butyl phthalate; monoethyl phthalate (MEP), the main metabolite of diethyl phthalate; and two phenols, methyl paraben (M-PB) and 2,5-dichlorophenol were detected in the urine samples of all women. The highest urinary concentrations were for MEP and M-PB. Urinary concentrations of all phthalate metabolites and of 2,4-dichlorophenol, 2,5-dichlorophenol, and bisphenol A were lower in the pregnant women than in the children. Among women, a positive relationship with social class and education was shown for most of the phthalate metabolites and phenols. Almost all phthalate metabolites varied by region even after adjusting for social class and education. Conclusions: Phthalate and phenol exposures are prevalent in a group of pregnant women and young children, two susceptible populations, and these exposures might be positively related to social class. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Casas, Lidia; Guxens, Monica; Vrijheid, Martine; Sunyer, Jordi] Ctr Res Environm Epidemiol, Barcelona 08003, Catalonia, Spain. [Casas, Lidia; Guxens, Monica; Vrijheid, Martine; Sunyer, Jordi] Hosp del Mar Res Inst IMIM, Barcelona 08003, Catalonia, Spain. [Fernandez, Mariana F.; Olea, Nicolas] Univ Granada, San Cecilio Univ Hosp, Lab Med Invest, Granada, Spain. [Llop, Sabrina; Ballester, Ferran] Inst Salud Carlos III, Madrid, Spain. [Llop, Sabrina] Ctr Publ Hlth Res CSISP, Valencia, Spain. [Ballester, Ferran] Univ Valencia, Valencia, Spain. [Basterrechea Irurzun, Mikel; Santa Marina Rodriguez, Loreto] Dept Sanidad, Subdirecc Salud Publ Gipuzkoa, San Sebastian, Spain. [Basterrechea Irurzun, Mikel; Santa Marina Rodriguez, Loreto] Inst Invest Sanitaria BIODONOSTIA, San Sebastian, Spain. [Riano, Isolina] Hosp San Agustin, Aviles, Spain. [Tardon, Adonina] Univ Oviedo, Oviedo, Spain. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Sunyer, Jordi] Pompeu Fabra Univ, Barcelona, Catalonia, Spain. RP Casas, L (reprint author), Ctr Res Environm Epidemiol, Dr Aiguader 88, Barcelona 08003, Catalonia, Spain. EM lcasas@creal.cat RI Fernandez, Mariana/C-9877-2012; Olea, Nicolas/H-3198-2014; Llop, Sabrina/L-2122-2015; Osborne, Nicholas/N-4915-2015; Vrijheid, M/H-2702-2014; Sunyer, J/G-6909-2014 OI Fernandez, Mariana/0000-0001-6417-8914; Olea, Nicolas/0000-0002-8938-3743; Osborne, Nicholas/0000-0002-6700-2284; Vrijheid, M/0000-0002-7090-1758; Sunyer, J/0000-0002-2602-4110 FU Instituto de Salud Carlos III [Red INMA G03/176 CB06/02/0041, FIS-FEDER 03/1615, 04/1509, 04/1112, 04/1931, 05/1079, 05/1052, 06/1213, 07/0314, 09/02647]; Spanish Ministry of Health [FIS-PI041436, FIS-PI081151, FIS-PI06/0867, FIS-PS09/00090, FISS-PI042018, FISS-PI09/02311]; Generalitat de Catalunya-CIRIT [1999SGR 00241]; Obra Social Cajastur; Universidad de Oviedo; Department of Health of the Basque Government [2005111093, 2009111069]; Provincial Government of Gipuzkoa [DFG06/004, DFG08/001]; Conselleria de Sanitat Generalitat Valenciana, and Fundacion Roger Tome FX This study was funded by grants from Instituto de Salud Carlos III (Red INMA G03/176 CB06/02/0041, FIS-FEDER 03/1615, 04/1509, 04/1112, 04/1931, 05/1079, 05/1052, 06/1213, 07/0314 and 09/02647), Spanish Ministry of Health (FIS-PI041436, FIS-PI081151, FIS-PI06/0867, FIS-PS09/00090 FISS-PI042018, FISS-PI09/02311), Generalitat de Catalunya-CIRIT 1999SGR 00241, Obra Social Cajastur, Universidad de Oviedo, Department of Health of the Basque Government (2005111093 and 2009111069), the Provincial Government of Gipuzkoa (DFG06/004 and DFG08/001), Conselleria de Sanitat Generalitat Valenciana, and Fundacion Roger Tome. NR 52 TC 142 Z9 148 U1 2 U2 58 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 J9 ENVIRON INT JI Environ. Int. PD JUL PY 2011 VL 37 IS 5 BP 858 EP 866 DI 10.1016/j.envint.2011.02.012 PG 9 WC Environmental Sciences SC Environmental Sciences & Ecology GA 782LV UT WOS:000292012100004 PM 21440302 ER PT J AU Romero-Franco, M Hernandez-Ramirez, RU Calafat, AM Cebrian, ME Needham, LL Teitelbaum, S Wolff, MS Lopez-Carrillo, L AF Romero-Franco, Michelle Hernandez-Ramirez, Raill U. Calafat, Antonia M. Cebrian, Mariano E. Needham, Larry L. Teitelbaum, Susan Wolff, Mary S. Lopez-Carrillo, Lizbeth TI Personal care product use and urinary levels of phthalate metabolites in Mexican women SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Phthalates; Personal care products; Mexican women ID ASSESSING HUMAN EXPOSURE; PREGNANT-WOMEN; COSMETIC PRODUCTS; INTERNAL EXPOSURE; MONOESTERS; PERFORMANCE; POPULATION; BIOMARKERS; CHEMICALS; HUMANS AB Sources of phthalates other than Polyvinyl chloride (PVC) related products are scarcely documented in Mexico. The objective of our study was to explore the association between urinary levels of nine phthalate metabolites and the use of personal care products. Subjects included 108 women who participated as controls in an ongoing population-based case-control study of environmental factors and genetic susceptibility to breast cancer in northern Mexico. Direct interviews were performed to inquire about sociodemographic characteristics, reproductive history, use of personal care products, and diet. Phthalate metabolites measured in urine by high performance liquid chromatography-isotope dilution tandem mass spectrometry were monoethyl phthalate (MEP), monobenzyl phthalate (MBzP), mono-n-butyl phthalate (MBP), mono-isobutyl phthalate (MiBP), mono-3-carboxypropyl phthalate (MCPP) as well as mono-2-ethylhexyl phthalate (MEHP), mono-2-ethyl-5-oxohexyl phthalate (MEOHP), mono-2-ethyl-5-hydroxyhexyl phthalate (MEHHP), mono-2-ethyl-5-carboxypentyl phthalate (MECPP) that are metabolites of di-ethylhexyl phthalate (DEHP). Detectable urinary concentrations of phthalate metabolites varied from 75% (MEHP) to 100% (MEP, MBP, MEOHP, MEHHP and MECPP). Medians of urinary concentrations of some phthalate metabolites were significantly higher among users of the following personal care products compared to nonusers: body lotion (MEHHP, MECPP and sum of DEHP metabolites (Sigma DEHP)), deodorant (MEHP and Sigma DEHP), perfume (MiBP), anti-aging facial cream (MEP, MBP and MCPP) and bottled water (MCPP, MEHHP and MEOHP). Urinary concentrations of MEP showed a positive relationship with the number of personal care products used. Our results suggest that the use of some personal care products contributes to phthalate body burden that deserves attention due to its potential health impact. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Romero-Franco, Michelle; Hernandez-Ramirez, Raill U.; Lopez-Carrillo, Lizbeth] Natl Inst Publ Hlth, Ctr Populat Hlth Res, Cuernavaca 62100, Morelos, Mexico. [Calafat, Antonia M.; Needham, Larry L.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Cebrian, Mariano E.] CINVESTAV, Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Toxicol, San Pedro Zacatenco 07360, DF, Mexico. [Teitelbaum, Susan; Wolff, Mary S.] Mt Sinai Sch Med, Ctr Childrens Environm Hlth & Dis Prevent Res, New York, NY 10029 USA. RP Lopez-Carrillo, L (reprint author), Natl Inst Publ Hlth, Ctr Populat Hlth Res, Ave Univ 655,Col Santa Maria Ahuacatitlan,Cerrada, Cuernavaca 62100, Morelos, Mexico. EM michelle.romerof@gmail.com; ruhernandez@gmail.com; aic7@cdc.gov; mcebrian@cinvestav.mx; LNeedham@cdc.gov; susan.teitelbaum@mssm.edu; mary.wolff@mssm.edu; lizbeth@insp.mx RI Needham, Larry/E-4930-2011 FU CONACYT [2005-C02-14373, FOSISS 2009-01-111384]; SEP-CONACYT [2008-79912]; Fogarty International Center [D43TW000640] FX Authors gratefully acknowledge B.Sc. Veronica Lopez for the overall coordination of field work, and Manori Silva, Tao Jia, Ella Samandar and Jim Preau for their technical assistance in measuring the urinary concentrations of phthalate metabolites. The study was supported by CONACYT Fondo Sectorial de Investigacion en Salud y Seguridad Social (FOSISS) 2005-C02-14373, FOSISS 2009-01-111384 and SEP-CONACYT 2008-79912. Michelle Romero-Franco is an Irving J. Selikoff International Scholar of the Mount Sinai School of Medicine. Her work was supported in part by Award Number D43TW000640 from the Fogarty International Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Fogarty International Center or the National Institutes of Health. The findings expressed in this paper are the opinions of the authors and do not necessarily reflect the official opinion of the Centers for Disease Control and Prevention. NR 45 TC 65 Z9 66 U1 3 U2 40 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 J9 ENVIRON INT JI Environ. Int. PD JUL PY 2011 VL 37 IS 5 BP 867 EP 871 DI 10.1016/j.envint.2011.02.014 PG 5 WC Environmental Sciences SC Environmental Sciences & Ecology GA 782LV UT WOS:000292012100005 PM 21429583 ER PT J AU Ye, XY Wong, LY Bishop, AM Calafat, AM AF Ye, Xiaoyun Wong, Lee-Yang Bishop, Amber M. Calafat, Antonia M. TI Variability of Urinary Concentrations of Bisphenol A in Spot Samples, First Morning Voids, and 24-Hour Collections SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE biomonitoring; bisphenol A; BPA; exposure; human; urine; variability ID TEMPORAL VARIABILITY; EXPOSURE; POPULATION; CHILDREN; PHENOLS; PHYTOESTROGENS; METABOLITES; PREDICTORS; BIOMARKERS; PHTHALATE AB BACKGROUND: Human exposure to bisphenol A (BPA) is widespread. After exposure, BPA is rapidly metabolized and eliminated in urine. Therefore, there is considerable within-person and between-person variability of BPA concentrations in spot urine samples. However, no information exists on the within-day variability of urinary BPA concentrations. OBJECTIVES: We examined the between-person and within-person and between-day and within-day variability in the urinary BPA concentrations of eight adults who collected all voids for 1 week to investigate the impact of sampling strategy in the exposure assessment of BPA using spot, first morning, or 24-hr urine collections. METHODS: We determined the urinary concentrations of BPA using on-line solid-phase extraction coupled to isotope dilution high-performance liquid chromatography/tandem mass spectrometry. RESULTS: The between-day and within-person variability was the primary contributor to the total variance both for first morning voids (77%) and 24-hr urine collections (88%). For the spot collections, we observed considerable within-day variance (70%), which outweighed the between-person (9%) and between-day and within-person (21%) variances. CONCLUSIONS: Regardless of the type of void (spot, first morning, 24-hr collection), urinary BPA concentrations for a given adult changed considerably-both within a day and for the 7 days of the study period. Single 24-hr urine collections accurately reflect daily exposure but can misrepresent variability in daily exposures over time. Of interest, when the population investigated is sufficiently large and samples are randomly collected relative to meal ingestion times and bladder emptying times, the single spot-sampling approach may adequately reflect the average exposure of the population to BPA. C1 [Ye, Xiaoyun; Wong, Lee-Yang; Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Bishop, Amber M.] Battelle Mem Inst, Atlanta, GA USA. RP Ye, XY (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Hwy,Mailstop F53, Atlanta, GA 30341 USA. EM xay5@cdc.gov NR 37 TC 115 Z9 116 U1 3 U2 19 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD JUL PY 2011 VL 119 IS 7 BP 983 EP 988 DI 10.1289/ehp.1002701 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 786IT UT WOS:000292299300032 PM 21406337 ER PT J AU Parker, JD Rich, DQ Glinianaia, SV Leem, JH Wartenberg, D Bell, ML Bonzini, M Brauer, M Darrow, L Gehring, U Gouveia, N Grillo, P Ha, E van den Hooven, EH Jalaludin, B Jesdale, BM Lepeule, J Morello-Frosch, R Morgan, GG Slama, R Pierik, FH Pesatori, AC Sathyanarayana, S Seo, J Strickland, M Tamburic, L Woodruff, TJ AF Parker, Jennifer D. Rich, David Q. Glinianaia, Svetlana V. Leem, Jong Han Wartenberg, Daniel Bell, Michelle L. Bonzini, Matteo Brauer, Michael Darrow, Lyndsey Gehring, Ulrike Gouveia, Nelson Grillo, Paolo Ha, Eunhee van den Hooven, Edith H. Jalaludin, Bin Jesdale, Bill M. Lepeule, Johanna Morello-Frosch, Rachel Morgan, Geoffrey G. Slama, Remy Pierik, Frank H. Pesatori, Angela Cecilia Sathyanarayana, Sheela Seo, Juhee Strickland, Matthew Tamburic, Lillian Woodruff, Tracey J. TI The International Collaboration on Air Pollution and Pregnancy Outcomes: Initial Results SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE air pollution; birth weight; ICAPPO; low birth weight; particulate matter; pregnancy ID ADVERSE BIRTH OUTCOMES; PRETERM BIRTH; TIME-SERIES; PARTICULATE MATTER; LOS-ANGELES; EXPOSURE; WEIGHT; HEALTH; CALIFORNIA; MORTALITY AB BACKGROUND: The findings of prior studies of air pollution effects on adverse birth outcomes are difficult to synthesize because of differences in study design. OBJECTIVES: The International Collaboration on Air Pollution and Pregnancy Outcomes was formed to understand how differences in research methods contribute to variations in findings. We initiated a feasibility study to a) assess the ability of geographically diverse research groups to analyze their data sets using a common protocol and b) perform location-specific analyses of air pollution effects on birth weight using a standardized statistical approach. METHODS: Fourteen research groups from nine countries participated. We developed a protocol to estimate odds ratios (ORs) for the association between particulate matter <= 10 mu m in aerodynamic diameter (PM(10)) and low birth weight (LBW) among term births, adjusted first for socioeconomic status (SES) and second for additional location-specific variables. RESULTS: Among locations with data for the PM(10) analysis, ORs estimating the relative risk of term LBW associated with a 10-mu g/m(3) increase in average PM(10) concentration during pregnancy, adjusted for SES, ranged from 0.63 [95% confidence interval (CI), 0.30-1.35] for the Netherlands to 1.15 (95% CI, 0.61-2.18) for Vancouver, with six research groups reporting statistically significant adverse associations. We found evidence of statistically significant heterogeneity in estimated effects among locations. CONCLUSIONS: Variability in PM(10)-LBW relationships among study locations remained despite use of a common statistical approach. A more detailed meta-analysis and use of more complex protocols for future analysis may uncover reasons for heterogeneity across locations. However, our findings confirm the potential for a diverse group of researchers to analyze their data in a standardized way to improve understanding of air pollution effects on birth outcomes. C1 [Parker, Jennifer D.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Rich, David Q.] Univ Rochester, Sch Med & Dent, Dept Community & Prevent Med, Rochester, NY USA. [Glinianaia, Svetlana V.] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Leem, Jong Han] Inha Univ, Dept Occupat & Environm Med, Inchon, South Korea. [Wartenberg, Daniel] UMDNJ, Robert Wood Johnson Med Sch, Piscataway, NJ USA. [Bell, Michelle L.] Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USA. [Bonzini, Matteo] Univ Insubria, Dept Expt Med, Varese, Italy. [Brauer, Michael] Univ British Columbia, Dept Med, Vancouver, BC, Canada. [Darrow, Lyndsey; Strickland, Matthew] Emory Univ, Dept Environm Hlth, Atlanta, GA 30322 USA. [Gehring, Ulrike] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands. [Gouveia, Nelson] Univ Sao Paulo, Sch Med, Dept Prevent Med, Sao Paulo, Brazil. [Grillo, Paolo] Fdn IRCCS CaGranda Osped Maggiore Policlin, Epidemiol Unite, Milan, Italy. [Ha, Eunhee; Seo, Juhee] Ewha Womans Univ, Dept Prevent Med, Seoul, South Korea. [van den Hooven, Edith H.] Erasmus MC, Generat Study Grp R, Rotterdam, Netherlands. [van den Hooven, Edith H.; Pierik, Frank H.] Netherlands Org Appl Sci Res TNO, Dept Urban Environm, Delft, Netherlands. [Jalaludin, Bin] Univ New S Wales, Ctr Res Evidence Management & Surveillance, Sydney SW Area Hlth Serv, Sydney, NSW, Australia. [Jalaludin, Bin] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia. [Jesdale, Bill M.; Morello-Frosch, Rachel] Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA. [Lepeule, Johanna; Slama, Remy] Inst Albert Bonniot, INSERM, Team Environm Epidemiol Appl Reprod & Resp Hlth, U823, Grenoble, France. [Lepeule, Johanna; Slama, Remy] Univ J Fourier Grenoble, Grenoble, France. [Morello-Frosch, Rachel] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Morgan, Geoffrey G.] N Coast Area Hlth Serv, Lismore, NSW, Australia. [Morgan, Geoffrey G.] Univ Sydney, Univ Ctr Rural Health N Coast, Sydney, NSW 2006, Australia. [Pesatori, Angela Cecilia] Univ Milan, Dept Environm & Occupat Hlth, Milan, Italy. [Sathyanarayana, Sheela] Univ Washington, Seattle Childrens Res Inst, Seattle, WA 98195 USA. [Tamburic, Lillian] Univ British Columbia, Ctr Hlth Serv & Policy Res, Vancouver, BC V5Z 1M9, Canada. [Woodruff, Tracey J.] Univ Calif San Francisco, Ctr Reprod Hlth & Environment, San Francisco, CA 94143 USA. RP Parker, JD (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 6107, Hyattsville, MD 20782 USA. EM jdparker@cdc.gov RI LEPEULE, Johanna/K-1085-2016; Slama, Remy/M-1755-2013; Bonzini, Matteo/K-7540-2016; Gouveia, Nelson/C-4580-2013; lepeule, johanna/N-2579-2013 OI Slama, Remy/0000-0002-8980-8529; Bonzini, Matteo/0000-0002-6405-7554; Gouveia, Nelson/0000-0003-0625-0265; Gehring, Ulrike/0000-0003-3612-5780; pesatori, angela/0000-0002-0261-3252; Morello-Frosch, Rachel/0000-0003-1153-7287; Brauer, Michael/0000-0002-9103-9343; FU National Institutes of Health [1R01ES016317]; Institut national de la sante et de la recherche medicale (INSERM); Netherlands Organization for Scientific Research (NWO) FX M.L.B. was supported in part by National Institutes of Health grant 1R01ES016317. J.L. was supported by a postdoctoral grant from Institut national de la sante et de la recherche medicale (INSERM). U.G. was supported by a research fellowship of the Netherlands Organization for Scientific Research (NWO). NR 47 TC 22 Z9 23 U1 2 U2 18 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD JUL PY 2011 VL 119 IS 7 BP 1023 EP 1028 DI 10.1289/ehp.1002725 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 786IT UT WOS:000292299300038 PM 21306972 ER PT J AU Byams, VR Kouides, PA Kulkarni, R Baker, JR Brown, DL Gill, JC Grant, AM James, AH Konkle, BA Maahs, J Dumas, MM McAlister, S Nance, D Nugent, D Philipp, CS Soucie, JM Stang, E AF Byams, V. R. Kouides, P. A. Kulkarni, R. Baker, J. R. Brown, D. L. Gill, J. C. Grant, A. M. James, A. H. Konkle, B. A. Maahs, J. Dumas, M. M. McAlister, S. Nance, D. Nugent, D. Philipp, C. S. Soucie, J. M. Stang, E. CA Haemophilia Treatment Ctr Network TI Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres SO HAEMOPHILIA LA English DT Article DE gynaecology; heavy menstrual bleeding; inherited bleeding disorders; obstetrics; von Willebrand disease; women ID VON-WILLEBRAND-DISEASE; QUALITY-OF-LIFE; INTRANASAL DESMOPRESSIN; INTRAUTERINE SYSTEM; TRANEXAMIC ACID; WOMEN; MENORRHAGIA; COMPLICATIONS; HYSTERECTOMY; MULTICENTER AB Inherited bleeding disorders are especially problematic for affected girls and women due to the monthly occurrence of menstrual periods and the effects on reproductive health. Although heavy menstrual bleeding (HMB) is the most common manifestation, females with inherited bleeding disorders (FBD) experience other bleeding symptoms throughout the lifespan that can lead to increased morbidity and impairment of daily activities. The purpose of this article is to describe the utility of a female-focused surveillance effort [ female Universal Data Collection (UDC) project] in the United States Haemophilia Treatment Centres (HTCs) and to describe the baseline frequency and spectrum of diagnoses and outcomes. All FBD aged 2 years and older receiving care at selected HTCs were eligible for enrolment. Demographic data, diagnoses and historical data regarding bleeding symptoms, treatments, gynaecological abnormalities and obstetrical outcomes were analysed. Analyses represent data collected from 2009 to 2010. The most frequent diagnoses were type 1 von Willebrand's disease (VWD) (195/319; 61.1%), VWD type unknown (49/319; 15.4%) and factor VIII deficiency (40/319; 12.5%). HMB was the most common bleeding symptom (198/253; 78.3%); however, 157 (49.2%) participants reported greater than four symptoms. Oral contraceptives were used most frequently to treat HMB (90/165; 54.5%), followed by desmopressin [1-8 deamino-D-arginine vasopressin (DDAVP)] (56/165; 33.9%). Various pregnancy and childbirth complications were reported, including bleeding during miscarriage (33/43; 76.7%) and postpartum haemorrhage (PPH) (41/109; 37.6%). FBD experience multiple bleeding symptoms and obstetrical-gynaecological morbidity. The female UDC is the first prospective, longitudinal surveillance in the US focusing on FBD and has the potential to further identify complications and reduce adverse outcomes in this population. C1 [Byams, V. R.; Grant, A. M.; McAlister, S.; Soucie, J. M.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Kouides, P. A.] Mary M Gooley Hemophilia Treatment Ctr, Rochester, NY USA. [Kulkarni, R.] Michigan State Univ, E Lansing, MI 48824 USA. [Baker, J. R.] Univ Calif Los Angeles, Div Pediat Hematol Oncol, Los Angeles, CA USA. [Brown, D. L.] Gulf States Hemophilia & Thrombophilia Ctr, Houston, TX USA. [Gill, J. C.] Blood Ctr Wisconsin, Milwaukee, WI USA. [James, A. H.] Duke Univ, Med Ctr, Durham, NC USA. [Konkle, B. A.; Nance, D.] Puget Sound Comprehens Hemophilia Ctr, Seattle, WA USA. [Maahs, J.] Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN USA. [Dumas, M. M.] Dartmouth Hitchcock Hemophilia Ctr, Lebanon, NH USA. [Nugent, D.] Childrens Hosp Orange Cty, Orange, CA 92668 USA. [Philipp, C. S.] UMDNJ Robert Wood Johnson Med Sch, New Brunswick, NJ USA. [Stang, E.] Mt States Reg Hemophilia & Thrombosis Ctr, Aurora, CO USA. RP Byams, VR (reprint author), Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd NE,MS E64, Atlanta, GA 30333 USA. EM vbyams@cdc.gov RI Kerlin, Bryce/E-3369-2011 OI Kerlin, Bryce/0000-0002-1756-8271 FU cooperative agreement with the Centers for Disease Control and Prevention, USA FX This work was supported by a cooperative agreement with the Centers for Disease Control and Prevention, USA. NR 31 TC 14 Z9 15 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1351-8216 J9 HAEMOPHILIA JI Haemophilia PD JUL PY 2011 VL 17 SU 1 SI SI BP 6 EP 13 DI 10.1111/j.1365-2516.2011.02558.x PG 8 WC Hematology SC Hematology GA 783SG UT WOS:000292103700003 PM 21692922 ER PT J AU Sharathkumar, AA Soucie, JM Trawinski, B Greist, A Shapiro, AD AF Sharathkumar, A. A. Soucie, J. M. Trawinski, B. Greist, A. Shapiro, A. D. TI Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US) SO HAEMOPHILIA LA English DT Article DE cardiovascular disease; haemophilia A; haemophilia B ID AMERICAN-HEART-ASSOCIATION; BODY-MASS INDEX; MYOCARDIAL-INFARCTION; PRIMARY PREVENTION; METABOLIC SYNDROME; MORTALITY; DEATH; HIV; ATHEROGENESIS; INDIVIDUALS AB The primary objective of the study was to examine the prevalence of cardiovascular disease (CVD) events and their known risk factors among persons with haemophilia (PWH). This cross-sectional study, covering a 5-year period, included PWH aged >= 35 years who were cared for at a single haemophilia treatment centre in the United States. Medical records were extensively reviewed to collect the information about CVD events and their risk factors such as obesity, hypertension, diabetes, hypercholesterolemia and smoking. Prevalence rates were compared with national population estimates and associations between risk factors and CVD events were examined using logistic regression. The study cohort comprised 185 PWH (102 haemophilia A and 83 haemophilia B). Lifetime prevalence of a CVD event was 19.5% (36/185, 95% confidence interval [CI] 13.8-25.2%). CVD mortality was 5.4% (10/185, 95% CI 2.7-8.1). Compared with US non-Hispanic White males (NHWH), PWH had about twice the prevalence of coronary artery disease, stroke and myocardial infarction. The prevalence of CVD risk factors for PWH was similar to that for US NHWM with 39.5% of PWH exposed to two or more of these risk factors. Both hypertension and smoking were associated significantly with CVD events, with odds ratios of 4.9 and 6.3, respectively. In conclusion, this study revealed that both CVD events and its risk factors were at least equally prevalent among PWH and might have been even higher than among the US NHWM in the United States. Therefore, it is imperative to implement strategies for CVD prevention among PWH. C1 [Sharathkumar, A. A.; Trawinski, B.; Greist, A.; Shapiro, A. D.] Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN 46260 USA. [Sharathkumar, A. A.] Indiana Univ Sch Med, Dept Pediat, James Whitcomb Riley Hosp Children, Indianapolis, IN USA. [Soucie, J. M.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Blood Disorders, MS, Atlanta, GA USA. RP Shapiro, AD (reprint author), Indiana Hemophilia & Thrombosis Ctr, 8402 Harcourt Rd,Ste 500, Indianapolis, IN 46260 USA. EM ashapiro@ihtc.org FU Bayer Hemophilia Awards Foundation FX This project was supported by a 2003 grant from The Bayer Hemophilia Awards Foundation. The authors thank the Data Analysis Team, Epidemiology Resource Center, Public Health and Preparedness Commission, Indiana State Department of Health for providing information regarding cause of death in deceased patients. The authors thank Roshni Kulkarni, MD, Professor and Director, Pediatric & Adolescent Hematology/Oncology, Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI for her critical reading of this manuscript. NR 42 TC 26 Z9 26 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1351-8216 J9 HAEMOPHILIA JI Haemophilia PD JUL PY 2011 VL 17 IS 4 BP 597 EP 604 DI 10.1111/j.1365-2516.2010.02463.x PG 8 WC Hematology SC Hematology GA 784JZ UT WOS:000292154700004 PM 21323799 ER PT J AU Christman, MC Kedwaii, A Xu, JP Donis, RO Lu, GQ AF Christman, Mary C. Kedwaii, Ambreen Xu, Jianpeng Donis, Ruben O. Lu, Guoqing TI Pandemic (H1N1) 2009 virus revisited: An evolutionary retrospective SO INFECTION GENETICS AND EVOLUTION LA English DT Review DE Influenza; Pandemic H1N1; Evolution; Genetic mutation; Genome reassortment; Phylodynamics ID INFLUENZA-A VIRUS; RNA VIRUSES; SWINE; REASSORTMENT; HEMAGGLUTININ; NEURAMINIDASE; REPLICATION; EMERGENCE; HUMANS; RECOMBINATION AB The pandemic (H1N1) 2009 virus is unique in many aspects, especially in its genetics and evolution. In this paper, we examine the molecular mechanisms underlying the evolution of this novel virus through a comprehensive bioinformatics analysis, and present results in the context of a review of the literature. The pandemic virus was found to arise from a reassortment of two swine viruses, each of which ultimately arose from interspecies transmission. It experienced fast evolutionary rates and strong selection pressures, diverging into two different clusters at the early pandemic stage. Cluster I became extinct at the end of 2009 whereas Cluster II continued to circulate at much lower rates in 2010. Therefore, on August 10 of 2010 the WHO declared the end of the pandemic. Important mutations associated with host specificity, virulence, and drug resistance were detected in the pandemic virus, indicating effective transmission and increased severity in humans. Much has been learned about the evolutionary dynamics of this pandemic virus; however, it is still impossible to predict when the next pandemic will occur and which virus will be responsible. Improved surveillance at different levels (both national and international) and in different hosts (especially in swine) appears to be crucial for early detection and prevention of future influenza pandemics. (C) 2011 Elsevier B.V. All rights reserved. C1 [Christman, Mary C.; Kedwaii, Ambreen; Xu, Jianpeng; Lu, Guoqing] Univ Nebraska, Dept Biol, Omaha, NE 68182 USA. [Donis, Ruben O.] Ctr Dis Control & Prevent, Influenza Div, Mol Virol & Vaccines Branch, Atlanta, GA USA. RP Lu, GQ (reprint author), Univ Nebraska, Dept Biol, Omaha, NE 68182 USA. EM rvd6@CDC.GOV; glu3@unomaha.edu FU NIH [R01 LM009985-01A1]; UCRCA; University of Nebraska at Omaha FX This publication was made possible by NIH grant number R01 LM009985-01A1. The authors also acknowledge the UCRCA, the University of Nebraska at Omaha, for continuous funding support to this research program. The authors are grateful to Andy Zhong and Todd Herpy for their help with structural analysis. We would also like to thank Thaine Rowley for a Perl script to concatenate the eight segments of the viral sequences for phylogenetic analysis. NR 77 TC 28 Z9 28 U1 5 U2 26 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD JUL PY 2011 VL 11 IS 5 BP 803 EP 811 DI 10.1016/j.meegid.2011.02.021 PG 9 WC Infectious Diseases SC Infectious Diseases GA 785UP UT WOS:000292256800003 PM 21382522 ER PT J AU Piccinali, RV Marcet, PL Ceballos, LA Kitron, U Gurtler, RE Dotson, EM AF Piccinali, R. V. Marcet, P. L. Ceballos, L. A. Kitron, U. Guertler, R. E. Dotson, E. M. TI Genetic variability, phylogenetic relationships and gene flow in Triatoma infestans dark morphs from the Argentinean Chaco SO INFECTION GENETICS AND EVOLUTION LA English DT Article DE Triatoma infestans; Dark morphs; Evolutionary history; Gene flow; Epidemiological relevance ID CHAGAS-DISEASE VECTOR; MITOCHONDRIAL-DNA; HEMIPTERA-REDUVIIDAE; POPULATION-STRUCTURE; STATISTICAL TESTS; BOLIVIAN CHACO; SOUTH-AMERICA; SYLVATIC FOCI; WILD; SOFTWARE AB The recent discovery of sylvatic populations of Triatoma infestans outside the Andean Valleys of Bolivia prompted an evolutionary question about the putative ancestral area of origin and dispersal of the species, and an epidemiological question regarding the possible role of these sylvatic populations in the recolonization process of insecticide-treated houses. The finding of a population of sylvatic melanic T. infestans (dark morphs) in the Argentinean dry Chaco at 7 km from a peridomestic bug population of typical coloration gave us the opportunity to test both questions simultaneously by employing phylogenetic and population genetic approaches. For this purpose we analyzed sylvatic and peridomestic bugs using sequence-based mitochondrial and nuclear markers (mtCOI and ITS-1) and microsatellites. Sylvatic bugs were confirmed to be T. infestans and not hybrids, and showed high levels of genetic variability and departures from neutral expectations for mtCOI variation. New ITS-1 and mtCOI haplotypes were recorded, as well as haplotypes shared with peridomestic and/or domestic bugs from previous records. The peridomestic population was invariant for ITS-1 and mtCOI, but showed variability for microsatellites and signatures of a population bottleneck, probably due to a limited number of founders. Phylogenetic analyses were consistent with the presence of ancestral haplotypes in sylvatic bugs. According to F-statistics and assignment methods there was a significant differentiation between sylvatic and peridomestic bugs and gene flow was low and asymmetric, with more bugs moving from the peridomicile to the sylvatic environment. These results support the hypothesis of the Chaco region as the area of origin of T. infestans, and a limited role of sylvatic melanic T. infestans in peridomestic infestation in the Argentinean Chaco. (C) 2011 Elsevier B.V. All rights reserved. C1 [Piccinali, R. V.; Ceballos, L. A.; Guertler, R. E.] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Lab Ecoepidemiol, Dept Ecol Genet & Evoluc, Buenos Aires, DF, Argentina. [Marcet, P. L.; Dotson, E. M.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Entomol Branch, Atlanta, GA USA. [Kitron, U.] Emory Univ, Dept Environm Studies, Atlanta, GA 30322 USA. RP Piccinali, RV (reprint author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, Lab Ecoepidemiol, Dept Ecol Genet & Evoluc, 2Do Piso,Pabellon 2,Ciudad Univ,Int Guiraldes 216, Buenos Aires, DF, Argentina. EM rpicci@ege.fcen.uba.ar OI Marcet, Paula/0000-0002-0676-3020 FU Microsoft Corporation; National Institutes of Health [R01 TW05836]; Fogarty International Center; National Institute of Environmental Health Sciences; TDR/WHO; Universidad de Buenos Aires; Agencia Nacional de Promocion Cientifica y Tecnica FX LAMARC 2.1.3, MRBAYES 3.1 and part of the STRUCTURE 2.3.3 runs were carried out by using the resources of the Computational Biology Service Unit from Cornell University which is partially funded by Microsoft Corporation. Many thanks to the CDC core facilities for providing the microsatellite and mtCO1 oligonucleotides. M.S. Rodriguero and J.M. Gurevitz are greatly acknowledged for many helpful discussions and ideas that improved this manuscript. This work was founded by grants from National Institutes of Health Research Grant #R01 TW05836 funded by the Fogarty International Center and the National Institute of Environmental Health Sciences (U.K. and R.E.G.), TDR/WHO, Universidad de Buenos Aires and Agencia Nacional de Promocion Cientifica y Tecnica (R.E.G). R.V.P. and R.E.G. are members of CONICET Carrera de Investigador Cientifico (Argentina). The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 68 TC 15 Z9 15 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD JUL PY 2011 VL 11 IS 5 BP 895 EP 903 DI 10.1016/j.meegid.2011.02.013 PG 9 WC Infectious Diseases SC Infectious Diseases GA 785UP UT WOS:000292256800013 PM 21352954 ER PT J AU Yadav, PD Vincent, MJ Khristova, M Kale, C Nichol, ST Mishra, AC Mourya, DT AF Yadav, Pragya D. Vincent, Martin J. Khristova, Marina Kale, Charuta Nichol, Stuart T. Mishra, Akhilesh C. Mourya, Devendra T. TI Genomic analysis reveals Nairobi sheep disease virus to be highly diverse and present in both Africa, and in India in the form of the Ganjam virus variant SO INFECTION GENETICS AND EVOLUTION LA English DT Article DE Nairoviruses; Ganjam virus; Hazara virus; Nairobi sheep disease; Dugbe virus; Polymerase gene; Nucleocapsid gene ID HEMORRHAGIC-FEVER-VIRUS; TICKS HAEMAPHYSALIS INTERMEDIA; GENUS NAIROVIRUS; ANDHRA-PRADESH; REASSORTMENT; BUNYAVIRUSES; INFECTIONS; GENERATION; WARBURTON; NUTTALL AB Nairobi sheep disease (NSD) virus, the prototype tick-borne virus of the genus Nairovirus, family Bunyaviridae is associated with acute hemorrhagic gastroenteritis in sheep and goats in East and Central Africa. The closely related Ganjam virus found in India is associated with febrile illness in humans and disease in livestock. The complete S, M and L segment sequences of Ganjam and NSD virus and partial sequence analysis of Ganjam viral RNA genome S, M and L segments encoding regions (396 bp, 701 bp and 425 bp) of the viral nucleocapsid (N), glycoprotein precursor (GPC) and L polymerase (L) proteins, respectively, was carried out for multiple Ganjam virus isolates obtained from 1954 to 2002 and from various regions of India. M segments of NSD and Ganjam virus encode a large ORF for the glycoprotein precursor (GPC), (1627 and 1624 amino acids in length, respectively) and their L segments encode a very large L polymerase (3991 amino acids). The complete S, M and L segments of NSD and Ganjam viruses were more closely related to one another than to other characterized nairoviruses, and no evidence of reassortment was found. However, the NSD and Ganjam virus complete M segment differed by 22.90% and 14.70%, for nucleotide and amino acid respectively, and the complete L segment nucleotide and protein differing by 9.90% and 2.70%, respectively among themselves. Ganjam and NSD virus, completes segment differed by 9.40-10.40% and 3.2-4.10 for nucleotide and proteins while among Ganjam viruses 0.0-6.20% and 0.0-1.4%, variation was found for nucleotide and amino acids. Ganjam virus isolates differed by up to 17% and 11% at the nucleotide level for the partial sand L gene fragments, respectively, with less variation observed at the deduced amino acid level (10.5 and 2%, sand L, respectively). However, the virus partial M gene fragment (which encodes the hypervariable mucin-like domain) of these viruses differed by as much as 56% at the nucleotide level. Phylogenetic analysis of partial sequence differences suggests considerable mixing and movement of Ganjam virus strains within India, with no clear relationship between genetic lineages and virus geographic origin or year of isolation. Surprisingly, NSD virus does not represent a distinct lineage, but appears as a variant with other Ganjam virus among NSD virus group. (C) 2011 Elsevier BM. All rights reserved. C1 [Yadav, Pragya D.; Kale, Charuta; Mishra, Akhilesh C.; Mourya, Devendra T.] Natl Inst Virol, Pune 410021, Maharashtra, India. [Yadav, Pragya D.; Vincent, Martin J.; Khristova, Marina; Nichol, Stuart T.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. RP Mourya, DT (reprint author), Natl Inst Virol, Microbial Containement Complex,Sus Rd, Pune 410021, Maharashtra, India. EM dtmourya@gmail.com NR 44 TC 11 Z9 11 U1 3 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD JUL PY 2011 VL 11 IS 5 BP 1111 EP 1120 DI 10.1016/j.meegid.2011.04.001 PG 10 WC Infectious Diseases SC Infectious Diseases GA 785UP UT WOS:000292256800040 PM 21511058 ER PT J AU Dubey, JP Rajendran, C Ferreira, LR Martins, J Kwok, OCH Hill, DE Villena, I Zhou, H Su, C Jones, JL AF Dubey, J. P. Rajendran, C. Ferreira, L. R. Martins, J. Kwok, O. C. H. Hill, D. E. Villena, I. Zhou, H. Su, C. Jones, J. L. TI High prevalence and genotypes of Toxoplasma gondii isolated from goats, from a retail meat store, destined for human consumption in the USA SO INTERNATIONAL JOURNAL FOR PARASITOLOGY LA English DT Article DE Toxoplasma gondii; Goats; Retail meat; Capra hircus; Genotype; Bioassay; PCR-RFLP; USA ID UNITED-STATES; GENETIC-CHARACTERIZATION; CONGENITAL TOXOPLASMOSIS; RISK-FACTORS; DIRECT AGGLUTINATION; POPULATION-STRUCTURE; ATYPICAL GENOTYPES; INFECTION; BRAZIL; DIVERSITY AB Little information is available concerning the presence of viable Toxoplasma gondii in tissues of goats worldwide. In the present study, hearts of 234 goats obtained from a local USA grocery store were examined for T. gondii infection. Blood clot or fluid removed from each heart was tested for antibodies to T. gondii by using the modified agglutination test (MAT). Antibodies to T. gondii were found in 125 (53.4%) of 234 goats, with titers of 1:5 in 20, 1:10 in 44, 1:20 in 16, 1:40 in five, 1:160 in five, 1:320 in five, and 1:640 or higher in 30 goats. Hearts of 112 goats (46 goats <1:5, and 66 goats 1:10 or higher) were used for isolation of viable T. gondii by bioassays in mice. For bioassays, 50 g of the myocardium were digested in an acid pepsin solution and the digest inoculated into mice; the recipient mice were examined for T. gondii infection. Toxoplasma gondii was isolated from 29 goats; from hearts of one of 46 with titers of <1:5, one of nine with titers of 1:10, one of three with titers of 1:40, and 26 of 40 with titers of 1:160 or higher. Two isolates were highly virulent to outbred Swiss Webster mice; all infected mice died of toxoplasmosis, irrespective of the dose. All T. gondii isolates were subsequently grown in cell cultures. Genotyping of the 29 T. gondii isolates using 10 PCR-restriction fragment length polymorphism markers (SAG1, SAG2, SAG3, BTUB, GRA6, c22-8, c29-2, L358, PK1 and Apico) from DNA obtained from cell culture grown tachyzoites revealed 12 genotypes. Nine isolates were clonal Type II lineage, four isolates had type II alleles at all loci except a type I allele at the Apico locus, and four isolates were clonal Type Ill. The remaining 12 strains were divided into nine atypical genotypes, including five new and four previously identified genotypes. DNA sequences of four introns (EF1, HP2, UPRT1 and UPRT7) and two genes (GRA6 and GRA7) were generated for the five new genotypes. Comparing these sequences with previously published data revealed no unique sequences in these goat strains. Taken together, these results indicate high parasite prevalence and moderate genetic diversity of T. gondii in goats, which have important implications in public health. We believe this is the first genetic analysis of T. gondii isolates from goats in the USA. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. C1 [Dubey, J. P.; Rajendran, C.; Ferreira, L. R.; Martins, J.; Kwok, O. C. H.; Hill, D. E.] ARS, USDA, Anim & Nat Resources Inst, Anim Parasit Dis Lab, Beltsville, MD 20705 USA. [Villena, I.] Hosp Maison Blanche, Lab Parasitol Mycol, Natl Reference Ctr Toxoplasmosis, Biol Resources Ctr Toxoplasma, F-51092 Reims, France. [Zhou, H.] Shandong Univ, Sch Med, Dept Parasitol, Jinan 250012, Shandong, Peoples R China. [Su, C.] Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA. [Jones, J. L.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Chamblee, GA 30341 USA. RP Dubey, JP (reprint author), ARS, USDA, Anim & Nat Resources Inst, Anim Parasit Dis Lab, Bldg 1001, Beltsville, MD 20705 USA. EM jitender.dubey@ars.usda.gov RI Su, Chunlei/M-1892-2013 OI Su, Chunlei/0000-0001-8392-7108 NR 54 TC 57 Z9 59 U1 0 U2 15 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0020-7519 J9 INT J PARASITOL JI Int. J. Parasit. PD JUL PY 2011 VL 41 IS 8 BP 827 EP 833 DI 10.1016/j.ijpara.2011.03.006 PG 7 WC Parasitology SC Parasitology GA 785NC UT WOS:000292234700003 PM 21515278 ER PT J AU Cain, KP Varma, JK AF Cain, Kevin P. Varma, Jay K. TI You have to find TB to treat TB SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Editorial Material ID TUBERCULOSIS C1 [Cain, Kevin P.; Varma, Jay K.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Cain, KP (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM kcain@cdc.gov NR 9 TC 1 Z9 1 U1 0 U2 0 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD JUL PY 2011 VL 15 IS 7 BP 854 EP 854 DI 10.5588/ijtld.11.0247 PG 1 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 785MV UT WOS:000292234000002 PM 21682958 ER PT J AU Marks, SM AF Marks, S. M. TI Diabetes and tuberculosis, US National Health Interview Survey, 2000-2005 SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE tuberculosis; diabetes AB Blacks and Hispanics are disproportionately affected by diabetes, which may confound ethnic association with tuberculosis (TB). We analyzed 2000-2005 National Health Interview Survey data. We present adjusted odds ratios (aORs) and 99% confidence intervals (CIs) for the association of diabetes with history of TB disease, controlling for race/ethnicity and age. Diabetics had an aOR of 1.4 (99%CI 1.0-2.0) for history of TB, controlling for being foreign-born non-Hispanic (aOR 2.2, 99 A,CI 1.6-3.2), US-born Hispanic (aOR 2.1, 99%CI 1.4-3.2), age >= 65 years (aOR 2.0, 99%CI 1.5-2.6), and being Black (aOR 1.6, 99%CI 1.1-2.4). After controlling for race/ethnicity, self-identified diabetics had an increased aOR for history of TB. C1 [Marks, S. M.] US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. RP Marks, SM (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div TB Eliminat, Mailstop E-10,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM Smarks@cdc.gov NR 10 TC 2 Z9 2 U1 1 U2 2 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD JUL PY 2011 VL 15 IS 7 BP 982 EP 984 DI 10.5588/ijtld.10.0637 PG 3 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 785MV UT WOS:000292234000022 PM 21682976 ER PT J AU Yasinskaya, Y Plikaytis, B Sizemore, C Sacks, L AF Yasinskaya, Y. Plikaytis, B. Sizemore, C. Sacks, L. TI Advancing the development of diagnostic tests and biomarkers for tuberculosis SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE TB; tuberculosis; biomarkers AB High costs and limited returns on investment have hampered progress in developing new diagnostic tests and treatments for tuberculosis (TB). We need new biomarkers to develop assays that can rapidly, efficiently and reliably detect Mycobacterium tuberculosis infection and disease, identify drug resistance and expedite drug and vaccine development. This can only be accomplished through cross-disciplinary collaborations to facilitate access to human specimens. The Food and Drug Administration, Centers for Disease Control and Prevention, National Institutes of Health, the industry and academia experts came together in a June 2010 workshop to examine the field of TB diagnostic test development and biomarker discovery, identify areas of most urgent need and formulate strategies to address those needs. C1 [Yasinskaya, Y.; Sacks, L.] US FDA, Off Crit Path Programs, Silver Spring, MD 20903 USA. [Plikaytis, B.] Ctr Dis Control & Prevent, Mycobacteriol Lab Branch, Atlanta, GA USA. [Sizemore, C.] NIAID, TB & Other Mycobacterial Dis Sect, NIH, Bethesda, MD 20892 USA. RP Yasinskaya, Y (reprint author), US FDA, Off Crit Path Programs, Rm 4110,Bldg 32,10903 New Hampshire Ave, Silver Spring, MD 20903 USA. EM Yuliya.Yasinskaya@fda.hhs.gov NR 4 TC 5 Z9 5 U1 0 U2 1 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD JUL PY 2011 VL 15 IS 7 BP 985 EP 987 DI 10.5588/ijtld.10.0712 PG 3 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 785MV UT WOS:000292234000023 PM 21682977 ER PT J AU Katz, LS Sharma, NV Harcourt, BH Thomas, JD Wang, X Mayer, LW Jordan, IK AF Katz, Lee S. Sharma, Nitya V. Harcourt, Brian H. Thomas, Jennifer Dolan Wang, Xin Mayer, Leonard W. Jordan, I. King TI Using Single-Nucleotide Polymorphisms To Discriminate Disease-Associated from Carried Genomes of Neisseria meningitidis SO JOURNAL OF BACTERIOLOGY LA English DT Article ID PATHOGEN-SPECIFIC GENES; MENINGOCOCCAL-DISEASE; POPULATION-STRUCTURE; DNA-SEQUENCE; VIRULENCE; SEROGROUP; DATABASE; STRAIN; IDENTIFICATION; EVOLUTION AB Neisseria meningitidis is one of the main agents of bacterial meningitis, causing substantial morbidity and mortality worldwide. However, most of the time N. meningitidis is carried as a commensal not associated with invasive disease. The genomic basis of the difference between disease-associated and carried isolates of N. meningitidis may provide critical insight into mechanisms of virulence, yet it has remained elusive. Here, we have taken a comparative genomics approach to interrogate the difference between disease-associated and carried isolates of N. meningitidis at the level of individual nucleotide variations (i.e., single nucleotide polymorphisms [SNPs]). We aligned complete genome sequences of 8 disease-associated and 4 carried isolates of N. meningitidis to search for SNPs that show mutually exclusive patterns of variation between the two groups. We found 63 SNPs that distinguish the 8 disease-associated genomes from the 4 carried genomes of N. meningitidis, which is far more than can be expected by chance alone given the level of nucleotide variation among the genomes. The putative list of SNPs that discriminate between disease-associated and carriage genomes may be expected to change with increased sampling or changes in the identities of the isolates being compared. Nevertheless, we show that these discriminating SNPs are more likely to reflect phenotypic differences than shared evolutionary history. Discriminating SNPs were mapped to genes, and the functions of the genes were evaluated for possible connections to virulence mechanisms. A number of overrepresented functional categories related to virulence were uncovered among SNP-associated genes, including genes related to the category "symbiosis, encompassing mutualism through parasitism." C1 [Katz, Lee S.; Sharma, Nitya V.; Jordan, I. King] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA. [Katz, Lee S.; Harcourt, Brian H.; Thomas, Jennifer Dolan; Wang, Xin; Mayer, Leonard W.] Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Atlanta, GA 30333 USA. [Jordan, I. King] PanAmer Bioinformat Inst, Santa Marta, Magdalena, Colombia. RP Jordan, IK (reprint author), Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA. EM king.jordan@biology.gatech.edu FU Centers for Disease Control and Prevention [1 R36 GD 000075-1]; Georgia Institute of Technology; Georgia Research Alliance (GRA) [VAC09.O]; Alfred P. Sloan Foundation [BR-4839] FX This work was supported in part by the Centers for Disease Control and Prevention (1 R36 GD 000075-1) (L.S.K.), the Bioinformatics Program of the Georgia Institute of Technology (N.V.S.), the Georgia Research Alliance (GRA. VAC09.O) (B.H.H., I.K.J., and L.W.M.), and the Alfred P. Sloan Foundation (BR-4839) (I.K.J.). NR 51 TC 2 Z9 2 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD JUL PY 2011 VL 193 IS 14 BP 3633 EP 3641 DI 10.1128/JB.01198-10 PG 9 WC Microbiology SC Microbiology GA 784DQ UT WOS:000292134900023 PM 21622743 ER PT J AU Lockhart, SR Wagner, D Iqbal, N Pappas, PG Andes, DR Kauffman, CA Brumble, LM Hadley, S Walker, R Ito, JI Baddley, JW Chiller, T Park, BJ AF Lockhart, Shawn R. Wagner, Debra Iqbal, Naureen Pappas, Peter G. Andes, David R. Kauffman, Carol A. Brumble, Lisa M. Hadley, Susan Walker, Randall Ito, James I. Baddley, John W. Chiller, Tom Park, Benjamin J. TI Comparison of In Vitro Susceptibility Characteristics of Candida Species from Cases of Invasive Candidiasis in Solid Organ and Stem Cell Transplant Recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006 SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID GLOBAL ANTIFUNGAL SURVEILLANCE; BONE-MARROW-TRANSPLANTATION; STANDARDIZED DISK DIFFUSION; FUNGAL-INFECTIONS; IMMUNOCOMPROMISED PATIENTS; FLUCONAZOLE PROPHYLAXIS; ACTIVE SURVEILLANCE; UNITED-STATES; EPIDEMIOLOGY; KRUSEI AB Invasive fungal infections (IFI) are a major cause of morbidity and mortality among both solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients. Candida is the most common cause of IFI in SOT recipients and the second most common cause of IFI in HSCT recipients. We determined susceptibilities to fluconazole, voriconazole, itraconazole, posaconazole, amphotericin B, and caspofungin for 383 invasive Candida sp. isolates from SOT and HSCT recipients enrolled in the Transplant-Associated Infection Surveillance Network and correlated these results to clinical data. Fluconazole resistance in C. albicans, C. tropicalis, and C. parapsilosis isolates was low (1%), but the high percentage of C. glabrata and C. krusei isolates within this group of patients increased the overall percentage of fluconazole resistance to 16%. Voriconazole resistance was 3% overall but was 8% among C. glabrata isolates. On multivariable analysis, among HSCT recipients fluconazole nonsusceptibility was independently associated with C. glabrata, non-Hodgkin's lymphoma, cytomegalovirus (CMV) antigenemia, diabetes active at the time of the IFI, and any prior amphotericin B use; among SOT recipients, fluconazole nonsusceptibility was independently associated with any fluconazole use in the 3 months prior to the IFI, C. glabrata, ganciclovir use in the 3 months prior to the IFI, diabetes acquired since the transplant, and gender. C1 [Lockhart, Shawn R.; Wagner, Debra; Iqbal, Naureen; Chiller, Tom; Park, Benjamin J.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA. [Pappas, Peter G.; Baddley, John W.] Univ Alabama, Dept Med, Div Infect Dis & Prevent Med, Birmingham, AL 35294 USA. [Andes, David R.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Kauffman, Carol A.] Univ Michigan, Ann Arbor, MI 48109 USA. [Kauffman, Carol A.] Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Brumble, Lisa M.] Mayo Clin, Jacksonville, FL 32224 USA. [Hadley, Susan] Tufts Med Ctr, Boston, MA USA. [Walker, Randall] Mayo Clin, Coll Med, Rochester, MN USA. [Ito, James I.] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Baddley, John W.] Birmingham Vet Affairs Med Ctr, Dept Med, Div Infect Dis, Birmingham, AL USA. RP Lockhart, SR (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, 1600 Clifton Rd NE,Mailstop G-11, Atlanta, GA 30333 USA. EM gyi2@cdc.gov FU Astellas; Pfizer; Merck; Schering-Plough FX TRANSNET was sponsored by Astellas, Pfizer, Merck, and Schering-Plough.; Potential conflicts of interest are as follows: P.G.P. receives research support from and is an ad hoc advisor for Merck, Pfizer, and Astellas; J.W.B. received research support from Pfizer and is a consultant/advisor for Merck and Pfizer; J.I.I. received honoraria for speaker activities from Astellas, Cubist, and Pfizer; D.R.A. has received grants from and is a consultant for Merck, Astellas, and Pfizer; and C.A.K. receives research support from Merck and chairs a data adjudication committee for Pfizer. All other authors have no conflicts. NR 34 TC 17 Z9 17 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JUL PY 2011 VL 49 IS 7 BP 2404 EP 2410 DI 10.1128/JCM.02474-10 PG 7 WC Microbiology SC Microbiology GA 786BC UT WOS:000292276200004 PM 21562099 ER PT J AU Demas, A Oberstaller, J DeBarry, J Lucchi, NW Srinivasamoorthy, G Sumari, D Kabanywanyi, AM Villegas, L Escalante, AA Kachur, SP Barnwell, JW Peterson, DS Udhayakumar, V Kissinger, JC AF Demas, Allison Oberstaller, Jenna DeBarry, Jeremy Lucchi, Naomi W. Srinivasamoorthy, Ganesh Sumari, Deborah Kabanywanyi, Abdunoor M. Villegas, Leopoldo Escalante, Ananias A. Kachur, S. Patrick Barnwell, John W. Peterson, David S. Udhayakumar, Venkatachalam Kissinger, Jessica C. TI Applied Genomics: Data Mining Reveals Species-Specific Malaria Diagnostic Targets More Sensitive than 18S rRNA SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID POLYMERASE-CHAIN-REACTION; PARASITE PLASMODIUM-FALCIPARUM; MIXED INFECTIONS; VIVAX MALARIA; PCR; IDENTIFICATION; GENES; PAPUA; AMPLIFICATION; CHALLENGES AB Accurate and rapid diagnosis of malaria infections is crucial for implementing species-appropriate treatment and saving lives. Molecular diagnostic tools are the most accurate and sensitive method of detecting Plasmodium, differentiating between Plasmodium species, and detecting subclinical infections. Despite available whole-genome sequence data for Plasmodium falciparum and P. vivax, the majority of PCR-based methods still rely on the 18S rRNA gene targets. Historically, this gene has served as the best target for diagnostic assays. However, it is limited in its ability to detect mixed infections in multiplex assay platforms without the use of nested PCR. New diagnostic targets are needed. Ideal targets will be species specific, highly sensitive, and amenable to both single-step and multiplex PCRs. We have mined the genomes of P. falciparum and P. vivax to identify species-specific, repetitive sequences that serve as new PCR targets for the detection of malaria. We show that these targets (Pvr47 and Pfr364) exist in 14 to 41 copies and are more sensitive than 18S rRNA when utilized in a single-step PCR. Parasites are routinely detected at levels of 1 to 10 parasites/mu l. The reaction can be multiplexed to detect both species in a single reaction. We have examined 7 P. falciparum strains and 91 P. falciparum clinical isolates from Tanzania and 10 P. vivax strains and 96 P. vivax clinical isolates from Venezuela, and we have verified a sensitivity and specificity of similar to 100% for both targets compared with a nested 18S rRNA approach. We show that bioinformatics approaches can be successfully applied to identify novel diagnostic targets and improve molecular methods for pathogen detection. These novel targets provide a powerful alternative molecular diagnostic method for the detection of P. falciparum and P. vivax in conventional or multiplex PCR platforms. C1 [Kissinger, Jessica C.] Univ Georgia, Ctr Trop & Emerging Global Dis, Paul Coverdell Ctr, Athens, GA 30602 USA. [Oberstaller, Jenna; Kissinger, Jessica C.] Univ Georgia, Dept Genet, Athens, GA 30602 USA. [Demas, Allison] Assoc Publ Hlth Labs, Silver Spring, MD USA. [Demas, Allison; Lucchi, Naomi W.] VA Med Ctr, Atlanta Res & Educ Foundation, Decatur, GA USA. [Demas, Allison; Lucchi, Naomi W.; Kachur, S. Patrick; Barnwell, John W.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Villegas, Leopoldo] Asociac Civil Impacto Social, Tumeremo, Venezuela. [Sumari, Deborah; Kabanywanyi, Abdunoor M.] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. [Escalante, Ananias A.] Arizona State Univ, Tempe, AZ USA. [Peterson, David S.] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA. [Kissinger, Jessica C.] Univ Georgia, Inst Bioinformat, Athens, GA 30602 USA. RP Kissinger, JC (reprint author), Univ Georgia, Ctr Trop & Emerging Global Dis, Paul Coverdell Ctr, Rm 370,500 DW Brooks Dr, Athens, GA 30602 USA. EM jkissing@uga.edu RI Kissinger, Jessica/E-9610-2010; OI Kissinger, Jessica/0000-0002-6413-1101; DeBarry, Jeremy/0000-0001-5718-2675 FU CDC-UGA [8212]; University of Georgia Research Computing Center; Association of Public Health Laboratories; CDC; Atlanta Research and Education Foundation, Atlanta, GA; NIH [R01 AI068908] FX This work was supported in part by a CDC-UGA seed grant (OPHR no. 8212) awarded to J.C.K. and V.U. This study was supported in part by resources and technical expertise from the University of Georgia Research Computing Center, a partnership between the Office of the Vice President for Research and the Office of the Chief Information Officer. A.D. was supported by an EID Fellowship from the Association of Public Health Laboratories and the CDC. N.W.L. and A.D. (after the EID Fellowship) were supported by the Atlanta Research and Education Foundation, Atlanta, GA. J.D. was supported by NIH grant R01 AI068908 awarded to J.C.K. NR 40 TC 27 Z9 27 U1 1 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JUL PY 2011 VL 49 IS 7 BP 2411 EP 2418 DI 10.1128/JCM.02603-10 PG 8 WC Microbiology SC Microbiology GA 786BC UT WOS:000292276200005 PM 21525225 ER PT J AU Shu, B Wu, KH Emery, S Villanueva, J Johnson, R Guthrie, E Berman, L Warnes, C Barnes, N Klimov, A Lindstrom, S AF Shu, Bo Wu, Kai-Hui Emery, Shannon Villanueva, Julie Johnson, Roy Guthrie, Erica Berman, LaShondra Warnes, Christine Barnes, Nathelia Klimov, Alexander Lindstrom, Stephen TI Design and Performance of the CDC Real-Time Reverse Transcriptase PCR Swine Flu Panel for Detection of 2009 A (H1N1) Pandemic Influenza Virus SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID UNITED-STATES; A VIRUSES; HUMANS; EMERGENCE; INFECTION; PIGS; IDENTIFICATION; TRANSMISSION; REASSORTMENT AB Swine influenza viruses (SIV) have been shown to sporadically infect humans and are infrequently identified by the Influenza Division of the Centers for Disease Control and Prevention (CDC) after being received as unsubtypeable influenza A virus samples. Real-time reverse transcriptase PCR (rRT-PCR) procedures for detection and characterization of North American lineage (N. Am) SIV were developed and implemented at CDC for rapid identification of specimens from cases of suspected infections with SIV. These procedures were utilized in April 2009 for detection of human cases of 2009 A (H1N1) pandemic (pdm) influenza virus infection. Based on genetic sequence data derived from the first two viruses investigated, the previously developed rRT-PCR procedures were optimized to create the CDC rRT-PCR Swine Flu Panel for detection of the 2009 A (H1N1) pdm influenza virus. The analytical sensitivity of the CDC rRT-PCR Swine Flu Panel was shown to be 5 copies of RNA per reaction and 10(-1.3 similar to-0.7) 50% infectious doses (ID(50)) per reaction for cultured viruses. Cross-reactivity was not observed when testing human clinical specimens or cultured viruses that were positive for human seasonal A (H1N1, H3N2) and B influenza viruses. The CDC rRT-PCR Swine Flu Panel was distributed to public health laboratories in the United States and internationally from April 2009 until June 2010. The CDC rRT-PCR Swine Flu Panel served as an effective tool for timely and specific detection of 2009 A (H1N1) pdm influenza viruses and facilitated subsequent public health response implementation. C1 [Shu, Bo; Wu, Kai-Hui; Emery, Shannon; Villanueva, Julie; Johnson, Roy; Guthrie, Erica; Berman, LaShondra; Warnes, Christine; Barnes, Nathelia; Klimov, Alexander; Lindstrom, Stephen] Ctr Dis Control & Prevent, Virus Surveillance & Diagnost Branch, Influenza Div, Atlanta, GA 30329 USA. [Johnson, Roy; Barnes, Nathelia] Battelle Mem Inst, Atlanta, GA USA. RP Lindstrom, S (reprint author), Ctr Dis Control & Prevent, Virus Surveillance & Diagnost Branch, Influenza Div, 1600 Clifton Rd,MS-G16, Atlanta, GA 30329 USA. EM SLindstrom@cdc.gov NR 33 TC 50 Z9 54 U1 1 U2 9 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JUL PY 2011 VL 49 IS 7 BP 2614 EP 2619 DI 10.1128/JCM.02636-10 PG 6 WC Microbiology SC Microbiology GA 786BC UT WOS:000292276200037 PM 21593260 ER PT J AU Shewmaker, PL Steigerwalt, AG Nicholson, AC Carvalho, MDS Facklam, RR Whitney, AM Teixeira, LM AF Shewmaker, Patricia Lynn Steigerwalt, Arnold G. Nicholson, Ainsley C. Carvalho, Maria da Gloria S. Facklam, Richard R. Whitney, Anne M. Teixeira, Lucia M. TI Reevaluation of the Taxonomic Status of Recently Described Species of Enterococcus: Evidence that E. thailandicus Is a Senior Subjective Synonym of "E. sanguinicola" and Confirmation of E. caccae as a Species Distinct from E. silesiacus SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID SP-NOV.; SEQUENCE ALIGNMENT; IDENTIFICATION AB Several of the more recently proposed new species of Enterococcus are nearly identical based on 16S rRNA gene sequence analysis and phenotypic traits. In the present study, DNA-DNA reassociation experiments, in conjunction with sequencing of the 16S rRNA and rpoB genes, provided evidence that "Enterococcus sanguinicola" and Enterococcus thailandicus actually represent the same species. In contrast, Enterococcus caccae and Enterococcus silesiacus, two other species with nearly identical 16S rRNA gene sequences, were confirmed to be separate species. C1 [Shewmaker, Patricia Lynn; Steigerwalt, Arnold G.; Nicholson, Ainsley C.; Carvalho, Maria da Gloria S.; Facklam, Richard R.; Whitney, Anne M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Teixeira, Lucia M.] Univ Fed Rio de Janeiro, Inst Microbiol, BR-21941590 Rio De Janeiro, Brazil. RP Shewmaker, PL (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop C0-2, Atlanta, GA 30333 USA. EM paw3@cdc.gov FU FAPERJ; CNPq FX L.M.T. was supported in part by grants from the Brazilian government agencies (FAPERJ and CNPq). NR 15 TC 5 Z9 5 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JUL PY 2011 VL 49 IS 7 BP 2676 EP 2679 DI 10.1128/JCM.00399-11 PG 4 WC Microbiology SC Microbiology GA 786BC UT WOS:000292276200048 PM 21543565 ER PT J AU Pfeiffer, CM Zhang, M Lacher, DA Molloy, AM Tamura, T Yetley, EA Picciano, MF Johnson, CL AF Pfeiffer, Christine M. Zhang, Mindy Lacher, David A. Molloy, Anne M. Tamura, Tsunenobu Yetley, Elizabeth A. Picciano, Mary-Frances Johnson, Clifford L. TI Comparison of Serum and Red Blood Cell Folate Microbiologic Assays for National Population Surveys SO JOURNAL OF NUTRITION LA English DT Article ID TANDEM MASS-SPECTROMETRY; BIO-RAD RADIOASSAY; WHOLE-BLOOD; INTERNATIONAL STANDARD; LC-MS/MS; VITAMIN-B-12; PLASMA AB Three laboratories participated with their laboratory-specific microbiologic growth assays (MA) in the NHANES 2007-2008 to assess whether the distributions of serum (n = 2645) and RBC folate (n = 2613) for the same one-third sample of participants were comparable among laboratories. Laboratory (L) 2 produced the highest and L1 the lowest serum and RBC folate geometric means (nmol/L) in the NHANES sample (serum: L1, 39.5; L2, 59.2; L3, 47.7; and RBC: L1, 1120; L2, 1380; L3, 1380). Each laboratory produced different reference intervals for the central 95% of the population. Pearson correlation coefficients were highest between L3 and L1 (serum, r = 0.95; RBC, r = 0.92) and lowest between L2 and L1 (serum, r = 0.81; RBC, r = 0.65). Notable procedural differences among the laboratories were the Lactobacillus rhamnosus microorganism (L1 and L3: chloramphenicol resistant, L2: wild type) and the calibrator [L1: [6S]5-methyltetrahydrofolate (5-methylTHF), L2: [6R,S] 5-formyltetrahydrofolate ([6R,S] 5-formyITHF), L3: folic acid (FA)]. Compared with 5-methylTHF as calibrator, the folate results were 22-32% higher with FA as calibrator and 8% higher with 5-formyITHF as calibrator, regardless of the matrix (n = 30 serum, n = 28 RBC). The use of different calibrators explained most of the differences in results between L3 and L1 but not between L2 and L1. The use of the wild-type L. rhamnosus by L2 appeared to be the main reason for the differences in results between L2 and the other 2 laboratories. These findings indicate how assay variations influence MA folate results and how those variations can affect population data. To ensure data comparability, better assay harmonization is needed. J. Nutr. 141: 1402-1409, 2011. C1 [Pfeiffer, Christine M.; Zhang, Mindy] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Lacher, David A.; Johnson, Clifford L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Molloy, Anne M.] Trinity Coll Dublin, Inst Mol Med, Dublin, Ireland. [Tamura, Tsunenobu] Univ Alabama, Birmingham, AL 35294 USA. [Yetley, Elizabeth A.; Picciano, Mary-Frances] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. RP Pfeiffer, CM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. EM CPfeiffer@cdc.gov OI Molloy, Anne/0000-0002-1688-9049 FU Office of Dietary Supplements, NIH FX Supported by the Office of Dietary Supplements, NIH. The findings and conclusions in this report are those of the authors and do not necessarily represent the official views or positions of the CDC/Agency for Toxic Substances and Disease Registry, the NIH, or the Department of Health and Human Services. NR 23 TC 24 Z9 24 U1 0 U2 0 PU AMER SOC NUTRITIONAL SCIENCE PI BETHESDA PA 9650 ROCKVILLE PIKE, RM L-2407A, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD JUL PY 2011 VL 141 IS 7 BP 1402 EP 1409 DI 10.3945/jn.111.141515 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 783DL UT WOS:000292061600028 PM 21613453 ER PT J AU Eaton, DK Brener, ND Kann, L Roberts, AM Kyle, TM Flint, KH Ross, ALR AF Eaton, Danice K. Brener, Nancy D. Kann, Laura Roberts, Alice M. Kyle, Tonja M. Flint, Katherine H. Ross, Alexander L. R. TI Computer Availability and Principals' Perceptions of Online Surveys SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE instruments; research; risk behaviors; adolescents; online surveys ID HEALTH-RISK BEHAVIORS; PAPER-AND-PENCIL; DRUG-USE; PREVALENCE; PARTICIPATION; CHALLENGES; PREVENTION; TOBACCO AB BACKGROUND: School-based risk behavior surveys traditionally have been administered via paper-and-pencil. This study assessed the feasibility of conducting in-class online surveys in US high schools. METHODS: A paper-and-pencil questionnaire assessing computer availability and perceptions of online surveys was mailed to a nationally representative sample of public and private high school principals in fall 2008. Completed surveys were returned by principals from 580 of 704 selected schools. Prevalence and 95% confidence intervals were computed. RESULTS: Most high schools have at least 1 computer lab, most computers in computer labs are connected to the Internet, and just under half of schools with a stationary computer lab had a sufficient number of computers to accommodate an in-class online survey administration. The 2 most common problems associated with online surveys were logistics of providing enough computers for an entire class and rotating classes into computer labs. Nearly two thirds of principals preferred online to paper-and-pencil surveys when administered to 4 randomly selected classes that met at different times during the school day, but less than half reported this preference when administered to 4 randomly selected classes that met at the same time during the school day. CONCLUSION: Many schools do not have sufficient computer capacity to participate in a voluntary in-class online survey. An online survey could impose significant perceived and actual burden on schools and therefore could result in unacceptably low school participation rates. Online administration for in-class surveys of students in US high schools are not recommended. C1 [Eaton, Danice K.; Kann, Laura] Ctr Dis Control & Prevent, Surveillance & Evaluat Res Branch, Div Adolescent & Sch Hlth, Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Roberts, Alice M.; Kyle, Tonja M.; Flint, Katherine H.; Ross, Alexander L. R.] ICF Macro, Beltsville, MD 20705 USA. RP Eaton, DK (reprint author), Ctr Dis Control & Prevent, Surveillance & Evaluat Res Branch, Div Adolescent & Sch Hlth, Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS K-33, Atlanta, GA 30341 USA. EM dhe0@cdc.gov; nad1@cdc.gov; lkk1@cdc.gov; ARoberts@icfi.com; TKyle@icfi.com; KFlint@icfi.com; AlexanderLRoss@gmail.com NR 20 TC 1 Z9 1 U1 1 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-4391 J9 J SCHOOL HEALTH JI J. Sch. Health PD JUL PY 2011 VL 81 IS 7 BP 365 EP 373 DI 10.1111/j.1746-1561.2011.00604.x PG 9 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA 782WM UT WOS:000292043400001 PM 21668876 ER PT J AU Gouw, SC van den Berg, HM Astermark, J Oldenburg, J Margaglione, M Thompson, AR Boekhorst, J Miller, CH de Groot, PG van der Bom, JG AF Gouw, S. C. van den Berg, H. M. Astermark, J. Oldenburg, J. Margaglione, M. Thompson, A. R. Boekhorst, J. Miller, C. H. de Groot, P. G. van der Bom, J. G. TI F8 gene mutation type and inhibitor development in patients with severe hemophilia A: preliminary results of a systematic review and meta-analysis SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Gouw, S. C.] Univ Med Ctr Utrecht, Dept Paediat, Utrecht, Netherlands. [Gouw, S. C.; de Groot, P. G.] Univ Med Ctr Utrecht, Dept Clin Chem & Hematol, Utrecht, Netherlands. [van den Berg, H. M.] Univ Med Ctr, Dept Clin Chem & Hematol, Utrecht, Netherlands. [van den Berg, H. M.] Meander Med Ctr, Board Directors, Amersfoort, Netherlands. [Astermark, J.] Malmo Univ Hosp, Dept Coagulat Disorders, Malmo, Sweden. [Oldenburg, J.] Univ Clin Bonn, Inst Expt Hematol & Transfus Med, Bonn, Germany. [Margaglione, M.] Univ Foggia, Foggia, Italy. [Thompson, A. R.] Puget Sound Blood Ctr, Seattle, WA 98104 USA. [Thompson, A. R.] Univ Washington, Seattle, WA 98195 USA. [Boekhorst, J.] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, NL-6525 ED Nijmegen, Netherlands. [Miller, C. H.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [van der Bom, J. G.] Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RA Leiden, Netherlands. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUL PY 2011 VL 9 SU 2 SI SI MA O-TU-123 BP 300 EP 300 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA V33AX UT WOS:000208992800154 ER PT J AU Mili, FD Hooper, WC Lally, C Austin, H AF Mili, F. D. Hooper, W. C. Lally, C. Austin, H. TI Family history of myocardial infarction as a risk factor for venous thromboembolism among whites and blacks SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Mili, F. D.; Hooper, W. C.] Ctr Dis Control & Prevent, Res Lab Branch, Div Blood Disorders, Atlanta, GA USA. [Lally, C.; Austin, H.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUL PY 2011 VL 9 SU 2 SI SI MA P-TU-342 BP 416 EP 416 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA V33AX UT WOS:000208992801130 ER PT J AU Miller, CH Payne, A Kelly, F Soucie, JM Hooper, WC AF Miller, C. H. Payne, A. Kelly, F. Soucie, J. M. Hooper, W. C. TI Establishment of the CDC hemophilia A mutation project (CHAMP) to provide standardized F8 mutation databases SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Miller, C. H.; Payne, A.; Kelly, F.; Soucie, J. M.; Hooper, W. C.] Ctr Dis Control & Prevent, Div Blood Disorders, NCBDDD, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUL PY 2011 VL 9 SU 2 SI SI MA P-TU-485 BP 460 EP 460 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA V33AX UT WOS:000208992801266 ER PT J AU Mili, FD Hooper, WC Lally, C Austin, H AF Mili, F. D. Hooper, W. C. Lally, C. Austin, H. TI The impact of family history of venous thromboembolism, factor V Leiden and prothrombin 20210G > A mutations, and acquired risk factors on the risk of venous thromboembolism SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Mili, F. D.; Hooper, W. C.] Ctr Dis Control & Prevent, Div Blood Disorders, Res Lab Branch, Atlanta, GA USA. [Lally, C.; Austin, H.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUL PY 2011 VL 9 SU 2 SI SI MA P-WE-328 BP 623 EP 623 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA V33AX UT WOS:000208992802231 ER PT J AU Philipp, CS Khan, I Faiz, A Beckman, MG Kenney, KM Bockenstedt, P Heit, JA Kulkarni, R Manco-Johnson, M Moll, S Ortel, TL AF Philipp, C. S. Khan, I Faiz, A. Beckman, M. G. Kenney, K. M. Bockenstedt, P. Heit, J. A. Kulkarni, R. Manco-Johnson, M. Moll, S. Ortel, T. L. TI Characteristics of cancer associated and non-cancer associated venous thromboembolism (VTE) among adults obtaining care at us thrombosis and hemostasis centers SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Philipp, C. S.; Khan, I; Faiz, A.] Univ Med & Dent New Jersey, New Brunswick, NJ USA. [Beckman, M. G.; Kenney, K. M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bockenstedt, P.] Univ Michigan, Ann Arbor, MI 48109 USA. [Heit, J. A.] Mayo Clin, Rochester, MN USA. [Kulkarni, R.] Michigan State Univ, E Lansing, MI 48824 USA. [Manco-Johnson, M.] Univ Colorado, Boulder, CO 80309 USA. [Moll, S.] Univ N Carolina, Chapel Hill, NC 27515 USA. [Ortel, T. L.] Duke Univ, Durham, NC 27706 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUL PY 2011 VL 9 SU 2 SI SI MA P-WE-376 BP 638 EP 638 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA V33AX UT WOS:000208992802278 ER PT J AU Kempton, CL Allen, G Gauger, C Hord, J Kruse-Jarres, R Pruthi, R Walsh, C Young, G Soucie, JM AF Kempton, C. L. Allen, G. Gauger, C. Hord, J. Kruse-Jarres, R. Pruthi, R. Walsh, C. Young, G. Soucie, J. M. TI Inhibitors in mild and moderate hemophilia A: a heterogeneous problem SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Kempton, C. L.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA. [Kempton, C. L.] Emory Univ, Dept Med Hematol Oncol, Atlanta, GA 30322 USA. [Allen, G.] Brown Univ, Dept Pediat, Providence, RI 02912 USA. [Gauger, C.] Nemours Childrens Clin, Dept Pediat, Jacksonville, FL USA. [Hord, J.] Akron Childrens Hosp, Dept Pediat, Akron, OH USA. [Kruse-Jarres, R.] Tulane Univ, Dept Pediat, New Orleans, LA 70118 USA. [Pruthi, R.] Mayo Clin, Dept Med, Rochester, MN USA. [Walsh, C.] Mt Sinai Med Ctr, Dept Med, Miami Beach, FL USA. [Young, G.] Childrens Hosp Los Angeles, Dept Pediat, Los Angeles, CA USA. [Soucie, J. M.] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA 30333 USA. RI Allen, Geoffrey/S-3535-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUL PY 2011 VL 9 SU 2 SI SI MA P-TH-525 BP 932 EP 932 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA V33AX UT WOS:000208992804299 ER EF